DESCRIPTION

CYANOTRIAZOLE COMPOUNDS

Technical Field

[0001]

This invention relates to cyanotriazole compounds which stimulate the citric acid cycle acitivity and/or improve hyperglycemia. The citric acid cycle activators are useful for treating and/or preventing diseases or disorders related to energy imbalance which comes from less energy output than calorie intake. Besides, the hypoglycemic agents are helpful for treating diabetes and impaired glucose tolerance accompanied by postprandial hyperglycemia. The compounds of this invention possessing activities of promoting the citric acid cycle and/or reducing blood glucose are applicable to, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

Background Art

[0002]

Overweight, obesity and insulin resistance associated with them are major risk factors for a number of chronic diseases including diabetes and cardiovascular diseases (non-patent documents 1-4), especially, the global pandemic of diabetes is serious problem for public health and puts a huge burden on healthcare system in the world (non-patent document 5). Although various oral and injectable hypoglycemic drugs have been developed and launched, the efforts to stop or to slow down the growth rate of diabetes-related mortality and morbidity are not still going well. Postprandial hyperglycemia (PPH) which is one of phenomenon of blood glucose dysregulation seen in diabetes and impaired glucose tolerance (IGT) is cautioned as an independent risk factor for

cardiovascular disease (non-patent documents 6-7). Close relation between PPH and carotid intima-media thickness suggested that PPH was associated with atherosclerosis (non-patent documents 8-9). Some recent studies imply that PPH causes vascular inflammation and endothelial dysfunction through oxidative stress during PPH (non-patent documents 10-11). Three types of oral anti-diabetics, α-glucosidase inhibitors, glinides and DPP4 inhibitors, were developed aiming to lower PPH. Acarbose, a member of the α-glucosidase inhibitors class, showed a promising result that its treatment reduce both the risk of diabetes progression in patients with IGT and the incidence of cardiovascular disease in its clinical trial "STOP-NIDDM" (non-patent documents 12-13), however, another drug, a member of the glinides class, nateglinide failed to show its benefits in the trial "NAVIGATOR" (non-patent document 14). In addition, two DPP4 inhibitors, saxagliptin and alogliptin, did not have benefits for cardiovascular disease risk reduction in their clinical outcome trials, "SAVOR-TIMI 53" (non-patent document 15) and "EXAMIN" (non-patent document 16), respectively. Considering such a wavering situation, more efficacious and safer anti-diabetic agents having potency to lower PPH should be desirable for suppressing diabetes epidemic and also relieving diabetic vascular complications. Screening for new compounds with lowering PPH resulted in finding newly synthesized cyanotriazol compounds which reduced PPH after meal loading in Zucker Diabetic Fatty rats, one of type 2 diabetes model rats which show severe hyperglycemia and insulin resistance. This result demonstrated that the cyanotriazol compounds would be applicable to treating diabetes and preventing diabetic various complications.

[0003]

When metabolic disorders including diabetes, obesity and so on are considered, they are highly involved in energy imbalance between energy expenditure and calorie intake.

Although proper dietary restriction and exercise are best means for improving the metabolic disorders (non-patent document 17), it has been proved that the efficacy by themselves was insufficient (non-patent document 18) and drug intervention facilitated raising the probability of achieving clinical treatment target. Thus, modulation, particularly augmentation, of cellular energy expenditure is an attractive drug target to correct such energy imbalance-related disorders. The citric acid cycle has pivotal and mandatory roles in the aerobic metabolism, which mainly reduces NAD^+ to NADH and discharges carbon dioxide from metabolizing various energy substrates. We conceived that this cycle activation may lead to promote energy metabolism and expenditure, therefore we has conducted drug discovery screening to find synthetic chemical compounds with promoting citric acid cycle activity. Consequently, we found newly synthesized cyanotriazol compounds with strong efficacy on stimulating cellular citric acid cycle substrate consumption by measuring intracellular radiolabeled content derived from [^{14}C]-citrate. For further certification, we employed an extracellular flux analyzer (XF24-3; Seahorse Bioscience) to measure actual carbon dioxide evolution rate (CDER) in cultured cells treated by several screened compounds (non-patent document 19). The analysis proved that the tested compounds accelerated not only CDER and but also oxygen consumption rate (OCR), which indicates energy expenditure is highly stimulated by the compounds.

[0004]

In this invention, we found that newly synthesized cyanotriazole compounds have strong efficacy to improve hyperglycemia and/or to stimulate the citric acid cycle activity. Not limiting the usage as an anti-obesity and/or diabetic drug, expected profits by a cyanotriazol compound are curative or preventive effects on diseases or disorders related to energy imbalance which comes from less energy output than calorie intake, for example, impaired glucose

tolerance, insulin resistance, diabetic complication, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

[0005]

Patent Document 1 discloses a production method of cyanotriazole compounds.

Patent Document 2 and Non-Patent Documents 20-21 disclose a cyanotriazole compound as a human epidermis growth factor receptor 2 tyrosinase inhibitor.

Patent Document 3 discloses a production method of cyanotriazole compounds.

Patent Document 4 discloses a cyanotriazole compound as an inhibitor of fatty acid syhthase.

Document List

Patent Documents

[0006]

[Patent Document 1] JP-A-51-53529

[Patent Document 2] CN 1651418 A

[Patent Document 3] US 4039531

[Patent Document 4] WO 2011/140296

Non-Patent Documents

[0007]

[Non-Patent Document 1] Diabetes Care, 2011, *34*, e115-120

[Non-Patent Document 2] Diabetes Care, 2011, *34*, e126-131

[Non-Patent Document 3] Diabetes Care, 2011, *34*, e140-145

[Non-Patent Document 4] Diabetes Care, 2011, *34*, e152-157

[Non-Patent Document 5] IDF DIABETES ATLAS Fifth edition, 2011, 5th Ed, International Diabetes Federation

[Non-Patent Document 6] Arch Intern Med *164*, 2090-2095

[Non-Patent Document 7] J Clin Endocrinol Metab *91*, 813-819

[Non-Patent Document 8] Diabetes Care *23*, 1830-1834

[Non-Patent Document 9] Atherosclerosis *210*, 302-306

[Non-Patent Document 10] Am J Cardiol *100*, 899-904

[Non-Patent Document 11] Nutr Res *32*, 727-740

[Non-Patent Document 12] Lancet *359*, 2072-2077
[Non-Patent Document 13] JAMA *290*, 486-494
[Non-Patent Document 14] N Engl J Med *362*, 1463-1476
[Non-Patent Document 15] N Engl J Med *369*, 1317-1326
[Non-Patent Document 16] N Engl J Med *369*, 1327-1335
[Non-Patent Document 17] Circulation *122*, 406-441
[Non-Patent Document 18] Eat Weight Disord *14*, e56-65
[Non-Patent Document 19] Biochimica et Biophysica Acta - Bioenergetics 1817, S123
[Non-Patent Document 20] Bioorganic Medicinal Chemistry, vol.15, 2007, 1533-1538
[Non-Patent Document 21] Tetrahydron Letters, *53*, 2012, 59-63

Summary of the Invention

Problems to be Solved by the Invention

[0008]

An object of the present invention is therefore to provide a compound which stimulates the citric acid cycle acitivity and/or improves hyperglycemia with less side effects, and excellent safety, and is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

Means of Solving the Problems

[0009]


The present inventors intensively conducted studies with the view to attaining the aforementioned object. As a result, they found that a cyanotriazole compound represented by the general formula (1) below and a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and is useful for

treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure. The present invention has been achieved based on the finding.

[0010]

The present invention provides a cyanotriazole compound represented by the formula (1):

[0011]



(1)

[0012]

wherein

R^1 is a phenyl group, a thiazolyl group, a thienyl group, a pyridyl group or a quinolyl group, each of which is substituted (provided that the phenyl group is substituted with a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halogen atom, a phenoxy group or a carboxy group, then the the phenyl group is substituted with additional one or more substituents); or

an oxazolyl group, a furyl group, a pyrrolyl group, a piperidyl group, an indolyl group, a benzofuryl group, a benzothienyl group, a phenyl lower alkyl group, a pyrimidinyl group, a 2,3-dihydroindolyl group, an imidazolyl group, a benzothiazolyl group, an isoxazolyl group, a 2,3-dihydrobenzofuryl group, an isothiazolyl group, a dibenzofuryl group, a benzo[1,3]dioxolyl group, a carbazolyl group, a naphthyl group, a 2-oxo-1,2,3,4-tetrahydroquinolyl group, a 6-

oxo-1,6-dihydropyrimidinyl group, an imidazo[1,2-a]pyridyl group, an oxadiazolyl group, a thiadiazolyl group, a benzoxazolyl group, a styryl group, a benzoyl group, a cycloalkyl group, a higher alkyl group, a 2-oxo-1,2-dihydroquinolyl group, a benzimidazolyl group, a 2,3-dihydro[1,4]benzodioxinyl group, a fluorenyl group, a bicyclo[2,2,1]hept-2-enyl group, a thieno[3,2-b]pyridyl group, an imidazo[1,2-a]benzimidazolyl group, a 3,4-dihydro-2H-[1,4]benzoxazinyl group, a 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl group or an amino group, each of which is optionally substituted.; and

R^2 is

(1) a hydrogen atom,

(2) a lower alkyl group optionally substituted with one or more substituents excluding an oxo group, or

(3) a heterocyclyl group optionally substituted with one or more substituents;

provided that

5-(4-styrylphenyl)-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3,4,5-trimethoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

methyl 4-[4-(4-cyano-1,2,3-triazol-5-yl)styryl]benzoate;

5-[4-(4-cyanostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-{4-[4-(*N*,*N*-dimethylamino)styryl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(biphenyl-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[4-(2-oxo-2*H*-chromen-3-yl)styryl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[4-(benzo[d]oxazol-2-yl)styryl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(2-methoxynaphthalen-1-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(4-methoxynaphthalen-1-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(pyridin-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(thiophen-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(benzofuran-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-[4-(4-formylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(4'-formylbiphenyl-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
4-(2,3-dimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3,4-dimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3,4,5-trimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3-fluoro-4-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(4-fluoro-3-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(4-fluoro-3-methoxyphenyl)-1,2,3-triazole-5-carbonitrile;
(5-(5-cyano-1,2,3-triazol-4-yl)furan-2-yl)methyl acetate;
2-[4-(4'-benzoxazole-2-yl-stilbene-4-yl)-5-cyano-1,2,3-triazole-N-yl]acetic acid methyl ester;
4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-N-trityl-1,2,3-triazole-5-carbonitrile;
2-(4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-5-cyano-1,2,3-triazol-N-yl)acetamide;
2-(4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-5-cyano-1,2,3-triazol-N-yl)acetic acid;
4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-N-(2-oxo-2-phenylethyl)-1,2,3-triazole-5-carbonitrile; and
4-(4'-benzoxazole-2-yl-stilbene-4-yl)-5-cyano-N-acetamide-1,2,3-triazole;
are excluded,
or a salt thereof (hereinafter to be referred to as Compound (1)).

[0013]

In this embodiment, R^1 is preferably a group represented by formula:

-A-L1-B

wherein

A is a divalent group selected from (A1) to (A45):

(A1) a phenylene group,

(A2) a thiazolediyl group,

(A3) an oxazolediyl group,

(A4) a thiophenediyl group,

(A5) a furandiyl group,

(A6) a pyrrolediyl group,

(A7) a pyridinediyl group,

(A8) a piperidinediyl group,

(A9) an indolediyl group,

(A10) a benzofurandiyl group,

(A11) a benzothiophenediyl group,

(A12) -lower alkylene-phenylene-,

(A13) a pyrimidinediyl group,

(A14) a quinolinediyl group,

(A15) a 2,3-dihydroindolediyl group,

(A16) an imidazolediyl group,

(A17) a benzothiazolediyl group,

(A18) an isoxazolediyl group,

(A19) a 2,3-dihydrobenzofurandiyl group,

(A20) an isothiazolediyl group,

(A21) a dibenzofurandiyl group,

(A22) a benzo[1,3]dioxolediyl group,

(A23) a carbazolediyl group,

(A24) a naphthalenediyl group,

(A25) a 2-oxo-1,2,3,4-tetrahydroquinolinediyl group,

(A26) a 6-oxo-1,6-dihydropyrimidinediyl group,

(A27) an imidazo[1,2-a]pyridinediyl group,

(A28) a [1,3,4]oxadiazolediyl group,

(A29) a [1,2,4]thiadiazolediyl group,

(A30) a benzoxazolediyl group,
(A31) a [1,3,4]thiadiazolediyl group,
(A32) a styrenediyl group,
(A33) -CO-phenylene-,
(A24) a cycloalkanediyl group,
(A35) a higher alkylene group,
(A36) a 2-oxo-1,2-dihydroquinolinediyl group,
(A37) a benzimidazolediyl group,
(A38) a 2,3-dihydro[1,4]benzodioxinediyl group,
(A39) a fluorenediyl group,
(A40) a bicyclo[2,2,1]hept-2-enediyl group,
(A41) a thieno[3,2-b]pyridinediyl group,
(A42) an imidazo[1,2-a]benzimidazolediyl group,
(A43) a 3,4-dihydro-2H-[1,4]benzoxazinediyl group,
(A44) a 3,4-dihydro-2H-benzo[b][1,4]dioxepinediyl group, and
(A45) -NH-,

each of (A1) to (A45) is optionally substituted with one or more members selected from the group consisting of

a halogen atom;
a lower alkyl group optionally substituted with one or more halogen atoms;
a lower alkenyl group;
a hydroxy group;
a lower alkoxy group optionally substituted with one or more halogen atoms;
a lower alkenyloxy group;
a lower alkynyloxy group;
a cyano group;
an amino group optionally mono- or di-substituted with members selected from the group consisting of a lower alkyl group, a lower alkyl-carbonyl group, a lower alkoxy-carbonyl group, and a lower alkylsulfonyl group;
a N,N-di-lower alkylamino lower alkyl group;
a N,N-di-lower alkylamino lower alkoxy group;
a cycloalkyl group optionally substituted with one or more

halogen atoms;
a cycloalkoxy group optionally substituted with one or more halogen atoms;
a cycloalkyl lower alkyl group optionally substituted with one or more halogen atoms;
a cycloalkyl lower alkoxy group optionally substituted with one or more halogen atoms;
a lower alkoxy lower alkyl group optionally substituted with one or more halogen atoms;
a lower alkoxy lower alkoxy group optionally substituted with one or more halogen atoms;
a lower alkylthio group;
a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally

substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenoxy lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a thienyl group;
an oxetanyl lower alkoxy group optionally substituted with one or more lower alkyl groups;
a furyl group;
a piperidyl group;
a pyrrolidinyl group; and
a morpholinyl group;

L1 is
a bond,
lower alkylene, lower alkenylene,
-O-, -O-lower alkylene, lower alkylene-O-, -O-lower alkenylene, lower alkenylene-O-,
-O-lower alkylene-CO-, -CO-lower alkylene-O-,
-O-lower alkylene-O-, -O-lower alkenylene-O-, lower alkylene-O-lower alkylene, lower alkylene-C(OH)-lower alkylene,
-CO-, -CO-lower alkylene, lower alkylene-CO-,
-NH-, -NH-lower alkylene, lower alkylene-NH-, -N(phenyl)-, -N(lower alkyl)-, -N(lower alkyl)-lower alkylene, lower alkylene-N(lower alkyl)-,
-CONH-, -CONH-lower alkylene, lower alkylene-CONH-, -CO-N(lower alkyl)-, -CO-N(lower alkyl)-lower alkylene, lower alkylene-CO-N(lower alkyl)-,
-NHCO-, -N(lower alkyl)-CO-, -NHCO-lower alkylene, lower

alkylene-NHCO-, -N(lower alkyl)-CO-lower alkylene, lower alkylene -N(lower alkyl)-CO-,
$-CO_2-$, $-CO_2$-lower alkylene, lower alkylene-CO_2-,
-OCO-, -OCO-lower alkylene, lower alkylene-OCO-,
$-NHCO_2$-lower alkylene, lower alkylene-$NHCO_2-$, -N(lower alkyl)-CO_2-lower alkylene, lower alkylene-N(lower alkyl)-CO_2-,
-OCONH-lower alkylene, lower alkylene-OCONH-, -OCO-N(lower alkyl)-lower alkylene, lower alkylene-OCO-N(lower alkyl)-,
-S-, lower alkylene-S-, -S-lower alkylene, lower alkylene-S-lower alkylene,
$-SO_2-$, lower alkylene-SO_2-, $-SO_2$-lower alkylene, lower alkylene-SO_2-lower alkylene,
$-NHSO_2$-lower alkylene, lower alkylene-$NHSO_2-$, -N(lower alkyl)-SO_2-lower alkylene, lower alkylene-N(lower alkyl)-SO_2-,
$-SO_2NH$-lower alkylene, lower alkylene-SO_2NH-, $-SO_2$-N(lower alkyl) -lower alkylene, or lower alkylene-SO_2-N(lower alkyl)-; and

B is a group or an atom selected from (B1) to (B65):

(B1) a phenyl group,
(B2) a naphthyl group,
(B3) a tetrahydronaphthyl group,
(B4) an imidazolyl group,
(B5) a [1,2,3]triazolyl group,
(B6) a thiazolyl group,
(B7) a pyrazolyl group,
(B8) a thienyl group,
(B9) a furyl group,
(B10) a tetrahydrofuryl group,
(B11) a pyrrolyl group,
(B12) a pyridyl group,
(B13) an imidazo[1,2-a]pyridyl group,
(B14) a pyrimidinyl group,
(B15) a pyridazyl group,
(B16) a pyrazyl group,
(B17) a pyrrolo[2,3-b]pyridyl group,

(B18) a pyrazolo[3,4-b]pyridyl group,
(B19) a piperidyl group,
(B20) a piperazinyl group,
(B21) a morpholinyl group,
(B22) a pyrrolidinyl group,
(B23) a quinolyl group,
(B24) an isoquinolyl group,
(B25) a 1,2,3,4-tetrahydroquinolyl group,
(B26) a 1,2,3,4-tetrahydroisoquinolyl group,
(B27) a 2-oxo-1,2,3,4-tetrahydroquinolyl group,
(B28) an indolyl group,
(B29) a 2,3-dihydroindolyl group,
(B30) an indanyl group,
(B31) a benzofuryl group,
(B32) a 2,3-dihydrobenzofuryl group,
(B33) a benzothienyl group,
(B34) a benzothiazolyl group,
(B35) a benzo[1,3]dioxolyl group,
(B36) a cycloalkyl group,
(B37) a cycloalkenyl group,
(B38) a tetrahydropyranyl group,
(B39) an oxetanyl group,
(B40) an oxiranyl group,
(B41) a 2,3-dihydro[1,4]benzodioxinyl group,
(B42) a 3,4-dihydro-2H-benzo[1,4]oxazinyl group,
(B43) a dibenzofuryl group,
(B44) a 4H-benzo[1,3]dioxinyl group,
(B45) a 1,2,4-oxadiazolyl group,
(B46) a 1,3,4-oxadiazolyl group,
(B47) an indazolyl group,
(B48) an isoxazolyl group,
(B49) a benzoisoxazolyl group,
(B50) a 2-oxo-1,2-dihydro-1H-benzimidazolyl group,
(B51) a 2-oxo-2,3-dihydro-3H-benzothiazolyl group,
(B52) a 2,3,4,5-tetrahydrobenzo[1,4]oxazepinyl group,

(B53) an isoindolinyl group,
(B54) a 2,4-dihydro-1H-benzo[1,3]oxazinyl group,
(B55) a 1,2,3,4-tetrahydrobenzo[1,4]oxazepinyl group,
(B56) a 2,3,4,5-tetrahydro-1H-benzoazepinyl group,
(B57) a tetrazolyl group,
(B58) a 2-oxo-1,2-dihydroquinolyl group,
(B59) a 3,4-dihydro-2H-benzodioxepinyl group,
(B60) a 3,6-dihydropyranyl group,
(B61) a 2-oxo-benzoxazolyl group,
(B62) an oxazolyl group,
(B63) a benzoxazolyl group,
(B64) a triphenylphosphonium group, and
(B65) a hydrogen atom,
each of (B1) to (B64) is optionally substituted on the ring(s) with one or more members selected from the group consisting of
a halogen atom;
an oxo group;
a lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, and a hydroxy group;
a higher alkyl group;
a hydroxy group;
a lower alkoxy group optionally substituted with one or more halogen atoms;
a cyano group;
a nitro group;
an amino group optionally mono- or di-substituted with lower alkyl groups;
a lower alkylsulfonylamino group;
a N,N-di-lower alkylamino-carbonyl group;
a N,N-di-lower alkylamino lower alkoxy group;
an acetylamino lower alkyl group;
a formyl group;
a lower alkyl-carbonyl group;
a lower alkylsulfonyl group;


a lower alkoxy-carbonyl group optionally substituted with one or more halogen atoms;
a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, a lower alkoxy group optionally substituted with one or more halogen atoms, and a phenoxy group;
a phenoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenoxy lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally

substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a benzoyl group;
a lower alkylthio group optionally substituted with one or more halogen atoms;
a morpholinyl group;
a piperazinyl group optionally substituted with one or more lower alkyl groups;
a thienyl group;
a pyrrolyl group;
a pyrimidinyl group;
a pyrazolyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms;
a thiazolyl group optionally substituted with one or more lower alkyl groups;
a tetrahydropyranyloxy group;
a furyl group;
a pyrazinyl group optionally substituted with one or more lower alkyl groups;
a [1,2,4]oxadiazolyl group optionally substituted with one or more lower alkyl groups;
a [1,3,4]oxadiazolyl group optionally substituted with one or more lower alkyl groups;
a pyrrolidinyl group;
a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms;
an isoxazolyl group;
an imidazolyl group;
a cycloalkyl group;
a 2-oxo-pyrrolidinyl group; and
a [1,2,3]triazolyl group optionally substituted with one or more cyano groups.

[0014]

The present invention also provides a cyanotriazole compound represented by the formula (1aa):

[0015]



(1aa)

[0016]

wherein

R^{1a} is one of the following (1-1) to (1-34):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-108):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-3) a lower alkoxy lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atoms; and a cycloalkyl group,

(1-1-4) a cycloalkyl group,

(1-1-5) a cycloalkoxy group optionally substituted with one or more halogen atoms,

(1-1-6) a cycloalkyl lower alkyl group,

(1-1-7) a cycloalkyl lower alkoxy group optionally substituted on the cycloalkyl group with one or more members selected from the group consisting of a halogen

atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group optionally substituted with one or more halogen atoms,

(1-1-8) a cycloalkyl lower alkoxy lower alkyl group optionally substituted on the cycloalkyl group with one or more members selected from the group consisting of a hydroxy; and a lower alkoxy group,

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-10) a cyano group,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkoxy-carbonyl group; a lower alkylsulfonyl group; a phenyl group; a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom and a lower alkyl group optionally substituted with one or more halogen atoms; a phenoxy group; and a cyano group,

(1-1-12) a phenyl lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; and a hydroxy group,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen

atoms; a cyano group; a halogen atom; and a 5-cyano-1H-1,2,3-triazol-4-yl group (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; and a cyano group,

(1-1-17) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atoms; and a lower alkyl group,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; and

a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a cyano group,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group,

(1-1-28) a benzoxazolyl group optionally substituted with one or more halogen atoms,

(1-1-29) a benzofuryl group optionally substituted with one or more halogen atoms,

(1-1-30) a benzofuryl lower alkoxy group optionally substituted on the benzofuran ring with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkyl-carbonyl group; and a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-32) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-34) an indolinyl lower alkyl group,

(1-1-35) a benzothienylvinyl group,

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-1-37) a lower alkoxy lower alkoxy group,

(1-1-38) a cycloalkoxy lower alkyl group optionally substituted on the cycloalkyl group with one or more lower

alkyl groups,
(1-1-39) a cycloalkyl lower alkenyl group,
(1-1-40) a cycloalkenyloxy group,
(1-1-41) a cycloalkenylvinyl group,
(1-1-42) an oxiranyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-43) an oxetanyl lower alkoxy group optionally substituted on the oxetane ring with one or more lower alkyl groups,
(1-1-44) a tetrahydropyranyl lower alkoxy group,
(1-1-45) a hydroxy group,
(1-1-46) a phenyl lower alkoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkylthio group optionally substituted with one or more halogen atoms,
(1-1-47) a phenyl lower alkenyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-48) a benzoyl group optionally substituted with one or more halogen atoms,
(1-1-49) a phenylthio lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atoms; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-50) a phenylsulfonyl group optionally substituted with one or more lower alkyl groups,
(1-1-51) a phenylsulfonyl lower alkyl group optionally substituted on the phenyl ring with one or more halogen

atoms,
(1-1-52) a naphthyl group optionally substituted with one or more halogen atoms,
(1-1-53) a naphthylvinyl group optionally substituted on the naphthyl ring with one or more halogen atoms,
(1-1-54) a tetrahydronaphthyloxy group,
(1-1-55) an indanyloxy group,
(1-1-56) an amino group optionally mono- or di-substituted with members selected from the group consisting of a lower alkyl group; a lower alkyl-carbonyl group; a lower alkoxy-carbonyl group; and a lower alkylsulfonyl group;
(1-1-57) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-58) an aminocarbonyl group optionally substituted with one or more members selected from the group consisting of a lower alkyl group; a cycloalkyl group; a cycloalkyl lower alkyl group; and a phenyl group optionally substituted with one or more halogen atoms,
(1-1-59) a pyridyl lower alkoxy group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-60) a pyridyloxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-61) a pyrrolo[2,3-b]pyridyl group optionally substituted with one or more lower alkyl groups,
(1-1-62) a pyrazolo[3,4-b]pyridyl group optionally substituted with one or more lower alkyl groups,
(1-1-63) an imidazo[1,2-a]pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-64) a pyrimidinyl lower alkyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-65) a pyrimidinyl lower alkoxy group optionally substituted on the pyrimidine ring with one or more members selected from the group consisting of a lower alkoxy group; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group,

(1-1-66) a pyrimidinyloxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-67) a pyrimidinyloxy lower alkyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-68) a pyrazinyl group optionally substituted with one or more lower alkyl groups,

(1-1-69) a pyridazinyl group optionally substituted with one or more members selected from the group consisting of a lower alkyl group; and a lower alkoxy group,

(1-1-70) a piperidyl lower alkyl group,

(1-1-71) a piperidylcarbonyl group,

(1-1-72) a piperazinyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-1-73) an imidazolyl group,

(1-1-74) a pyrazolyl group optionally substituted with one or more lower alkyl groups,

(1-1-75) a pyrrolyl lower alkyl group,

(1-1-76) a thiazolyl group,

(1-1-77) a thiazolyl lower alkoxy group optionally substituted on the thiazole ring with one or more lower alkyl groups,

(1-1-78) a benzothiazolyl group optionally substituted with

one or more halogen atoms,

(1-1-79) a furyl group,

(1-1-80) a furylvinyl group optionally substituted on the furan ring with one or more lower alkyl groups,

(1-1-81) a benzofurylvinyl group (preferably the benzofurylvinyl group is bonded to the o- or m-position on the phenyl ring of (1-1)),

(1-1-82) a 2,3-dihydrobenzofuryl group,

(1-1-83) a thienyl lower alkoxy group,

(1-1-84) a thienylvinyl group optionally substituted on the thiophene ring with one or more halogen atoms (preferably the thienylvinyl group is bonded to the o- or m-position on the phenyl ring of (1-1)),

(1-1-85) a benzothienyl lower alkyl group optionally substituted on the benzothiophene ring with one or more halogen atoms,

(1-1-86) a benzothienyl lower alkoxy group optionally substituted on the benzothiophene ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-87) a benzo[1,3]dioxolyl lower alkyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-1-88) a benzo[1,3]dioxolyl lower alkoxy group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-1-89) a 4H-benzo[1,3]dioxinyl group optionally substituted with one or more halogen atoms,

(1-1-90) a 4H-benzo[1,3]dioxinylvinyl group optionally substituted on the benzo[1,3]dioxine ring with one or more halogen atoms,

(1-1-91) a quinolyl group,

(1-1-92) a quinolyl lower alkoxy group,

(1-1-93) a quinolylvinyl group,

(1-1-94) a 3,4-dihydro-2H-quinolyl group,
(1-1-95) a 3,4-dihydro-2H-quinolyl lower alkyl group,
(1-1-96) a 2-oxo-1,2,3,4-tetrahydroquinolyl group,
(1-1-97) a 2-oxo-1,2,3,4-tetrahydroquinolyl lower alkoxy group,
(1-1-98) a 2-oxo-1,2,3,4-tetrahydroquinolyloxy group optionally substituted with one or more lower alkyl groups,
(1-1-99) an isoquinolyl group,
(1-1-100) a 3,4-dihydro-1H-isoquinolyl group,
(1-1-101) a 3,4-dihydro-1H-isoquinolyl lower alkyl group,
(1-1-102) an indolyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group; and a lower alkoxy-carbonyl group,
(1-1-103) an indolyl lower alkyl group,
(1-1-104) an indolylvinyl group optionally substituted on the indole ring with one or more lower alkyl groups,
(1-1-105) an indolinyl group,
(1-1-106) an indolinylcarbonyl group,
(1-1-107) a 1H-1,2,3-triazolyl group optionally substituted with one or more cyano groups, and
(1-1-108) a triphenylphosphonium lower alkyl group,

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-26):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,
(1-2-2) a lower alkoxy group,
(1-2-3) a cycloalkyl group,
(1-2-4) a halogen atom,
(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a

hydroxy group; and a cyano group,
(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,
(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-2-10) an amino group optionally mono- or di-substituted with members selected from the group consisting of a lower alkyl group; a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms; a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms; and a benzoyl group optionally substituted with one or more halogen atoms,
(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-2-12) a lower alkenyl group,
(1-2-13) a cycloalkyl lower alkyl group,
(1-2-14) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from

the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a hydroxy group,

(1-2-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-16) a phenyl lower alkoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group optionally substituted with one or more halogen atoms; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-17) a phenyl lower alkylsulfonyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-18) a mono- or di-N-lower alkyl amino lower alkyl group;

(1-2-19) a piperidyl group optionally substituted with one or more members selected from the group consisting of a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-20) a piperazinyl group optionally substituted with one or more phenyl groups optionally substituted with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally

substituted with one or more halogen atoms,

(1-2-21) an indolyl group,

(1-2-22) a morpholinyl group,

(1-2-23) a thienyl group,

(1-2-24) a benzothienyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-25) a furyl group, and

(1-2-26) a cyano group,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-12):

(1-3-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3-2) a cycloalkyl group,

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-3-4) a lower alkoxy lower alkyl group,

(1-3-5) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-3-6) a naphthyl group,

(1-3-7) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-3-8) a furyl group,

(1-3-9) a dihydrobenzofuryl group,

(1-3-10) a thienyl group,

(1-3-11) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group

optionally substituted with one or more halogen atoms, and

(1-3-12) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-14):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atom and a hydroxy group; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl-carbonyl group; a lower alkoxy-carbonyl group; and a benzyloxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms, and a halogen atom,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a halogen atom,

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-6) a cycloalkyl lower alkenyl group,

(1-4-7) a halogen atom,

(1-4-8) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-9) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-10) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-11) a thienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a phenyl group optionally substituted with one or more halogen atoms,

(1-4-12) a thienylvinyl group,

(1-4-13) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-4-14) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-8):

(1-5-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group,

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,

(1-5-3) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-5-4) a naphthyl group,

(1-5-5) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5-6) a quinolyl group,

(1-5-7) a benzothienyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-5-8) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-5):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a phenoxy group; a benzyl group; and a benzoyl group,

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a phenyl group; and a phenyl lower alkoxy group,

(1-6-4) an indanyl group, and

(1-6-5) a benzo[1,3]dioxolyl lower alkyl group,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-9):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7-2) a phenyl group optionally substituted with one or

more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7-3) a benzofuryl group,

(1-7-4) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7-5) a naphthyl group,

(1-7-6) a halogen atom,

(1-7-7) a pyridyl group,

(1-7-8) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-7-9) a [1,2,3]triazolyl group optionally substituted with one or more cyano groups,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-8):

(1-8-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-8-3) a lower alkoxy-carbonyl group,

(1-8-4) a benzoyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-8-5) a phenyl lower alkyl-carbonyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-8-6) a phenyl lower alkoxy-carbonyl group,

(1-8-7) a phenoxycarbonyl group, and

(1-8-8) a phenylsulfonyl group optionally substituted with one or more lower alkyl groups,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-8):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-9-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,

(1-9-3) a cycloalkyl lower alkyl group,

(1-9-4) a halogen atom,

(1-9-5) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-9-6) a thienyl lower alkyl group,

(1-9-7) a tetrahydrofuryl lower alkyl group, and

(1-9-8) a benzo[1,3]dioxolyl group,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of the following (1-10-1) to (1-10-7):

(1-10-1) a halogen atom,

(1-10-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-10-3) a lower alkyl group,

(1-10-4) a benzyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-10-5) a styryl group optionally substituted on the

phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-10-6) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms, and

(1-10-7) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more members selected from the group consisting of the following (1-11-1) to (1-11-7):

(1-11-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-11-2) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-11-3) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-11-4) a halogen atom,

(1-11-5) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-11-6) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-11-7) a thienyl group,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-4):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally

substituted with one or more halogen atoms,

(1-12-3) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-12-4) a phenoxy group,

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-7):

(1-13-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-13-2) a pyrrolidyl group,

(1-13-3) a piperidyl group,

(1-13-4) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-13-5) a lower alkoxy group,

(1-13-6) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-13-7) a morpholinyl group,

(1-14) a quinolyl group substituted with one or more members selected from the group consisting of the following (1-14-1) to (1-14-5):

(1-14-1) a lower alkoxy group,

(1-14-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-14-3) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-14-4) a pyrrolidyl group, and

(1-14-5) a thienyl group,

(1-15) a 2,3-dihydro-1H-indolyl group optionally substituted with one or more members selected from the group consisting of

the following (1-15-1) to (1-15-2):

(1-15-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-15-2) a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-16) an imidazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-16-1) to (1-16-4):

(1-16-1) a lower alkyl group,

(1-16-2) a halogen atom,

(1-16-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-16-4) a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-17) a benzothiazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-17-1) to (1-17-6):

(1-17-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-17-2) a lower alkoxy group,

(1-17-3) a halogen atom,

(1-17-4) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-17-5) a phenoxy group optionally substituted with one or more members selected from the group consisting of a

halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-17-6) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-18) an isoxazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-19) a 2,3-dihydrobenzofuryl group optionally substituted with one or more members selected from the group consisting of the following (1-19-1) to (1-19-3):

(1-19-1) a halogen atom,

(1-19-2) a phenyl group optionally substituted with one or more halogen atoms, and

(1-19-3) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-20) an isothiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-21) a dibenzofuryl group,

(1-22) a benzo[1,3]dioxolyl group optionally substituted with one or more members selected from the group consisting of the following (1-22-1) to (1-22-2):

(1-22-1) a halogen atom, and

(1-22-2) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-23) a carbazolyl group optionally substituted with one or more lower alkyl groups,

(1-24) a naphthyl group optionally substituted with one or more benzyloxy groups optionally substituted on the phenyl

ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-25) a 2-oxo-1,2,3,4-tetrahydroquinolyl group optionally substituted with one or more benzyl groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-26) a 6-oxo-1,6-dihydropyrimidinyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-27) an imidazo[1,2-a]pyridyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-28) a [1,3,4]oxadiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-29) a [1,2,4]thiadiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,
(1-30) a benzoxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-30-1) to (1-30-4):
(1-30-1) a lower alkyl group,
(1-30-2) a lower alkoxy group,
(1-30-3) a halogen atom, and
(1-30-4) a phenyl group,
(1-31) a [1,3,4]thiadiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms;
(1-32) a styryl group optionally substituted on the phenyl ring with one or more benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-33) a benzoyl group optionally substituted with one or more benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

and

(1-34) a cycloalkyl group optionally substituted with one or more members selected from the group consisting of a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and a benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms;

provided that

5-(4-styrylphenyl)-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3,4,5-trimethoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-cyanostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(pyridin-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(thiophen-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(benzofuran-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

4-(4-methylphenyl)-5-cyano-1,2,3-triazole;

4-(4-isopropylphenyl)-5-cyano-1,2,3-triazole;

4-(4-methoxyphenyl)-5-cyano-1,2,3-triazole;

4-(2,3-dimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3,4-dimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3,4,5-trimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(4-fluorophenyl)-5-cyano-1,2,3-triazole;
4-(4-chlorophenyl)-5-cyano-1,2,3-triazole;
4-(4-bromophenyl)-5-cyano-1,2,3-triazole;
4-(4-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3-fluoro-4-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3-phenoxyphenyl)-5-cyano-1,2,3-triazole; and
4-(4-fluoro-3-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(2-fluorophenyl)-1,2,3-triazole-5-carbonitrile; and
4-(4-fluoro-3-methoxyphenyl)-1,2,3-triazole-5-carbonitrile;
are excluded,
or a salt thereof (hereinafter to be referred to as Compound (1aa)).

[0017]

As preferable embodiment, R^{1a} is one of the following (1-1) to (1-13):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-36):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-3) a lower alkoxy lower alkyl group,

(1-1-4) a cycloalkyl group,

(1-1-5) a cycloalkoxy group,

(1-1-6) a cycloalkyl lower alkyl group,

(1-1-7) a cycloalkyl lower alkoxy group,

(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-10) a cyano group,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the

pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-29) a benzofuryl group,

(1-1-30) a benzofuryl lower alkoxy group,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-34) an indolinyl lower alkyl group,

(1-1-35) a benzothienylvinyl group, and

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a

halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-3):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-3) a benzofuryl group,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or

more members selected from the group consisting of the following (1-10-1) to (1-10-2):

(1-10-1) a halogen atom, and

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidinyl group, and

(1-13-3) a piperidyl group.

[0018]

As another preferable embodiment, R^{1a} is the following (1-1):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-36):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with

one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),
(1-1-3) a lower alkoxy lower alkyl group,
(1-1-4) a cycloalkyl group,
(1-1-5) a cycloalkoxy group,
(1-1-6) a cycloalkyl lower alkyl group,
(1-1-7) a cycloalkyl lower alkoxy group,
(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,
(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),
(1-1-10) a cyano group,
(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members

selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-29) a benzofuryl group,

(1-1-30) a benzofuryl lower alkoxy group,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-34) an indolinyl lower alkyl group,

(1-1-35) a benzothienylvinyl group, and

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms.

[0019]

As another preferable embodiment, R^{1a} is one of the following (1-2) to (1-13):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members

selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl

ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-3):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-3) a benzofuryl group,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the

following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of the following (1-10-1) to (1-10-2):

(1-10-1) a halogen atom, and

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidinyl group, and

(1-13-3) a piperidyl group.

[0020]

As another preferable embodiment, R^{1a} is the following (1-2):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a

lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0021]

As another preferable embodiment, R^{1a} is the following (1-3):

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms.

[0022]

As another preferable embodiment, R^{1a} is the following (1-5):

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0023]

As another preferable embodiment, R^{1a} is the following (1-13):

(1-13) a pyrimidinyl group optionally substituted with one or

more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidinyl group, and

(1-13-3) a piperidyl group.

[0024]

As another preferable embodiment, R^{1a} is one of the following (1-1) to (1-7), (1-9), (1-10), (1-12) and (1-13):

(1-1) a phenyl group substituted with one or more (preferably 1 to 3) members selected from the group consisting of

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),
(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-31) a thienyl group,
(1-1-32) a benzothienyl group,
(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,
(1-1-35) a benzothienylvinyl group, and
(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of
(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,
(1-2-4) a halogen atom,
(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and
(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a

halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of

(1-4-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of

(1-6-1) a lower alkyl group, and

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of

(1-7-3) a benzofuryl group,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group.

[0025]

As another preferable embodiment, R^{1a} is the following (1-1):

(1-1) a phenyl group substituted with one or more (preferably 1 to 3) members selected from the group consisting of

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen

atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more

halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-35) a benzothienylvinyl group, and

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms.

[0026]

As another preferable embodiment, R^{1a} is one of the following (1-2) to (1-7), (1-9), (1-10), (1-12) and (1-13):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of

(1-4-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl

ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of

(1-6-1) a lower alkyl group, and

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of

(1-7-3) a benzofuryl group,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group.

[0027]

As another preferable embodiment, R^{1a} is the following (1-2):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0028]

As another preferable embodiment, R^{1a} is the following (1-3):

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0029]

As another preferable embodiment, R^{1a} is the following (1-5):

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group

optionally substituted with one or more halogen atoms.

[0030]

As another preferable embodiment, R^{1a} is the following (1-13):

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of

(1-13-1) a phenyl group,


(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group.

[0031]

The present invention also provides a cyanotriazole compound represented by the formula (1bb):

[0032]



(1bb)

[0033]

wherein

R^{1b} is one of the following (1-1) to (1-13):

(1-1) a phenyl group optionally substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-34):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-3) a lower alkoxy lower alkyl group,

(1-1-4) a cycloalkyl group,

(1-1-5) a cycloalkoxy group,

(1-1-6) a cycloalkyl lower alkyl group,

(1-1-7) a cycloalkyl lower alkoxy group,

(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,

(1-1-9) a halogen atom,

(1-1-10) a cyano group,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom,

(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-29) a benzofuryl group,

(1-1-30) a benzofuryl lower alkoxy group,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms, and

(1-1-34) an indolinyl lower alkyl group,

(1-2) a thiazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group optionally substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more

members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group optionally substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-2):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group; and

R^{2a} is one of the following (2-1) to (2-3):


(2-1) a lower alkyl group optionally substituted with one or more members selected from the group consisting of a hydroxy group; and a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or

more halogen atoms,

(2-2) a 2-oxo-1,3-dioxolanyl group, and

(2-3) a group represented by the formula:

[0034]



[0035]

wherein

* is a bonding site;

R^{2A} is one of the following (2A-1) to (2A-2):

(2A-1) a hydrogen atom, or

(2A-2) a lower alkyl group; and

R^{2B} is one of the following (2B-1) to (2B-6):

(2B-1) a lower alkoxy group optionally substituted with one or more members selected from the group consisting of a lower alkoxy group; a carboxy group; a lower alkoxy-carbonyl group; a hydroxy group; a phenyl lower alkoxy-carbonyl group; a lower alkenyloxy-carbonyl group; a morpholinyl group; a benzyloxycarbonyl group; and a tetrahydropyran-2-yloxy group,

(2B-2) a lower alkyl group;

(2B-3) a lower alkylamino group optionally substituted with one or more lower alkoxy-carbonyl groups;

(2B-4) a cycloalkyl group;

(2B-5) a cycloalkoxy group; and


(2B-6) a phenyl group;

or a salt thereof (hereinafter to be referred to as Compound (1bb)).

[0036]

As preferable embodiment, the cyanotriazole compound or salt is a compound represented by the formula (1bbA):

[0037]



(1bbA)

[0038]

wherein each symbol is as defined in Compound (1bb), or a salt thereof (hereinafter to be referred to as Compound (1bbA)).

[0039]

As another preferable embodiment, R^{1b} is one of the following (1-1) to (1-5):

(1-1) a phenyl group optionally substituted with one or more members selected from:

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-9) a halogen atom,

(1-1-11) a phenyl group optionally substituted with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower

alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group, and

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-2) a thiazolyl group optionally substituted with one or more members selected from:

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from:

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group optionally substituted with one or more members selected from:

(1-4-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-5) a furyl group optionally substituted with one or more members selected from:

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms; and

R^{2a} is one of the following groups:

a 1-(((2-carboxy-2,2-dimethylethoxy)carbonyl)oxy)ethyl group;

a 1-(((2-carboxy-1,1-dimethylethoxy)carbonyl)oxy)ethyl group;

a 1-(((2-hydroxyethoxy)carbonyl)oxy)ethyl group;

a 1-(butyryloxy)ethyl group;

a 1-(isobutyryloxy)ethyl group;

an acetoxymethyl group; and

a butyryloxymethyl group.

[0040]

The present invention also provides a cyanotriazole compound selected from the group consisting of following compounds:

5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 11),

5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,

5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,

5-[3-trifluoromethyl-5-(6-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 14),

5-[3-trifluoromethyl-5-(6-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,

5-[3-trifluoromethyl-5-(6-trifluoromethyl-pyridin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,

5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 15),

5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 21),
5-[3-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 22),
5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 23),
5-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile (Example 29),
5-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-cyano-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 41),
5-{3-[(E)-2-(4-cyano-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-cyano-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-

phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 47),
5-{3-chloro-5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(5-trifluoromethyl-pyridin-3-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 49),
5-{3-[(*E*)-2-(5-trifluoromethyl-pyridin-3-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(5-trifluoromethyl-pyridin-3-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 50),
5-{3-[(*E*)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(*E*)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 51),
5-{3-trifluoromethyl-5-[(*E*)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(*E*)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 52),
5-{3-[(*E*)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 55),
5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-1H-

[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 60),
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 70),
5-[4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 75),
5-[2-(4-chloro-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 77),
5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 78),
5-[2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 79),
5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,

5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 90),
5-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 92),
5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-ethyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 98),
5-[2-(4-chloro-phenyl)-5-ethyl-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-ethyl-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 100),
5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 108),
5-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 120),
5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-2H-

[1,2,3]triazole-4-carbonitrile,
5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 122),
5-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-yl}-3H-[1,2,3]triazole-4-carbonitrile (Example 137),
5-{5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-yl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-yl}-1H-[1,2,3]triazole-4-carbonitrile,
5-[1-(4,4,4-trifluoro-butyl)-1H-indol-6-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 146),
5-[1-(4,4,4-trifluoro-butyl)-1H-indol-6-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[1-(4,4,4-trifluoro-butyl)-1H-indol-6-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[6-(4-fluoro-phenyl)-benzofuran-2-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 147),
5-[6-(4-fluoro-phenyl)-benzofuran-2-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[6-(4-fluoro-phenyl)-benzofuran-2-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-(5'-fluoro-3'-trifluoromethyl-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile (Example 220),
5-(5'-fluoro-3'-trifluoromethyl-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(5'-fluoro-3'-trifluoromethyl-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3',5'-bis-trifluoromethyl-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile (Example 275),

5-(5-chloro-3',5'-bis-trifluoromethyl-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3',5'-bis-trifluoromethyl-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3'-fluoro-4'-trifluoromethoxy-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile (Example 276),
5-(5-chloro-3'-fluoro-4'-trifluoromethoxy-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3'-fluoro-4'-trifluoromethoxy-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(3'-fluoro-5,4'-bis-trifluoromethoxy-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile (Example 298),
5-(3'-fluoro-5,4'-bis-trifluoromethoxy-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(3'-fluoro-5,4'-bis-trifluoromethoxy-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(3,4-bis-trifluoromethyl-benzyloxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 423),
5-[3-(3,4-bis-trifluoromethyl-benzyloxy)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(3,4-bis-trifluoromethyl-benzyloxy)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethoxy-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 504),
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethoxy-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethoxy-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 600),
5-{3-[(E)-2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-methyl-phenyl)-vinyl]-phenyl}-3H-

[1,2,3]triazole-4-carbonitrile (Example 607),
5-{3-[(E)-2-(4-fluoro-3-methyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-methyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-5-chloro-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 610),
5-{3-[(E)-2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-5-chloro-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-5-chloro-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 613),
5-{3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 617),
5-{3-[(E)-2-(4-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 620),
5-{3-trifluoromethyl-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 623),
5-{3-chloro-5-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,

5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-methyl-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 627),
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-methyl-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-methyl-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-trifluoromethoxy-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 639),
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-trifluoromethoxy-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-trifluoromethoxy-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 640),
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-ethoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 644),
5-{3-ethoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-ethoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-5-trifluoromethyl-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 645),
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-5-trifluoromethyl-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-5-trifluoromethyl-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 646),
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-phenyl}-1H-

[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(3-trifluoromethoxy-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 649),
5-{3-chloro-5-[(E)-2-(3-trifluoromethoxy-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(3-trifluoromethoxy-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-methoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 657),
5-{3-methoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-methoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 659),
5-{3-[(E)-2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 663),
5-{3-[(E)-2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-(3-benzo[b]thiophen-2-yl-5-chloro-phenyl)-3H-[1,2,3]triazole-4-carbonitrile (Example 718),
5-(3-benzo[b]thiophen-2-yl-5-chloro-phenyl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(3-benzo[b]thiophen-2-yl-5-chloro-phenyl)-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 790),
5-[3-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,

5-[3-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 807),
5-[3-methyl-5-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 931),
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-5-trifluoromethoxy-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 934),
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-5-trifluoromethoxy-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-5-trifluoromethoxy-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-ethoxy-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 944),
5-[3-ethoxy-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-ethoxy-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 989),
5-[3-methyl-4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-((E)-2-benzo[b]thiophen-2-yl-vinyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (Example 1004),
5-[3-((E)-2-benzo[b]thiophen-2-yl-vinyl)-phenyl]-2H-

[1,2,3]triazole-4-carbonitrile,
5-[3-((E)-2-benzo[b]thiophen-2-yl-vinyl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 1017),
5-{3-[(E)-2-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (Example 1018),
5-{3-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-2-fluoro-phenyl)-5-ethyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (Example 1248),
5-[2-(4-chloro-2-fluoro-phenyl)-5-ethyl-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-2-fluoro-phenyl)-5-ethyl-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(E)-2-(4-fluoro-phenyl)-vinyl]-furan-2-yl}-3H-[1,2,3]triazole-4-carbonitrile (Example 1505),
5-{5-[(E)-2-(4-fluoro-phenyl)-vinyl]-furan-2-yl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(E)-2-(4-fluoro-phenyl)-vinyl]-furan-2-yl}-1H-[1,2,3]triazole-4-carbonitrile,
5-(6-(benzofuran-2-yl)-pyridin-2-yl)-3H-[1,2,3]triazole-4-carbonitrile (Example 1573),
5-(6-(benzofuran-2-yl)-pyridin-2-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(6-(benzofuran-2-yl)-pyridin-2-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(piperidin-1-yl)-pyrimidin-4-yl)-3H-[1,2,3]triazole-4-carbonitrile (Example 1672),

5-(2-phenyl-6-(piperidin-1-yl)-pyrimidin-4-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(piperidin-1-yl)-pyrimidin-4-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(pyrrolidin-1-yl)-pyrimidin-4-yl)-3H-[1,2,3]triazole-4-carbonitrile (Example 1676),
5-(2-phenyl-6-(pyrrolidin-1-yl)-pyrimidin-4-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(pyrrolidin-1-yl)-pyrimidin-4-yl)-1H-[1,2,3]triazole-4-carbonitrile,
3-(1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1806),
3-(1-{4-[3-chloro-5-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1808),
3-(1-{4-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1810),
3-[1-(4-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-5-cyano-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid (Example 1811),
3-(1-{4-cyano-5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1812),
3-[1-(4-cyano-5-{3-trifluoromethyl-5-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid (Example 1813),
3-(1-{4-[2-(4-chloro-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1814),
3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid (Example 1815),

3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid (Example 1816),

3-(1-{4-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1817),

3-(1-{4-cyano-5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1818),

3-(1-{4-cyano-5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1819),

3-(1-{4-cyano-5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1820),

3-(1-{4-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1822),

3-(1-{4-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1823),

3-(1-{4-cyano-5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1824),

3-(1-{4-cyano-5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1825),

3-(1-{4-cyano-5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid (Example 1826),

3-(1-{4-[3-(2,5-bis-trifluoromethylbenzyloxy)phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}ethoxycarbonyloxy)-3-methylbutyric acid (Example 1827),


carbonic acid 1-{4-[3-(2,5-bis-trifluoromethylbenzyloxy) phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}ethyl ester -2-

hydroxyethyl ester (Example 1828),
acetic acid 4-cyano-5-[3-methyl-5- (4-trifluoromethylpyrimidin-2-yl)phenyl]-2H-[1,2,3]triazol-2-ylmethyl ester (Example 1829),
acetic acid 4-{3-chloro-5-[(E)-2-(3-trifluoromethylphenyl) vinyl]phenyl}-5-cyano-2H-[1,2,3]triazol-2-ylmethyl ester (Example 1830), and
butyric acid 4-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-5-cyano-2H-[1,2,3]triazol-2-ylmethyl ester (Example 1831),
or a salt thereof.

[0041]

The present invention also provides a cyanotriazole compound represented by the formula (1'a):

[0042]



(1'a)

[0043]

wherein

$R^{1'}$ is one of the following (1-1) to (1-12):

(1-1) a phenyl group optionally substituted with one or more (preferably 1 to 3) members selected from the group consisting of the following (1-1-1) to (1-1-34):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is

substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-3) a lower alkoxy lower alkyl group,

(1-1-4) a cycloalkyl group,

(1-1-5) a cycloalkoxy group,

(1-1-6) a cycloalkyl lower alkyl group,

(1-1-7) a cycloalkyl lower alkoxy group,

(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-10) a cyano group,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and halogen atoms (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group optionally substituted with one or

more lower alkyl groups optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups

optionally substituted with one or more halogen atoms,
(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),
(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,
(1-1-29) a benzofuryl group,
(1-1-30) a benzofuryl lower alkoxy group,
(1-1-31) a thienyl group,
(1-1-32) a benzothienyl group,
(1-1-33) a 2,2-difluorobenzo[1,3]dioxolyl group, and
(1-1-34) an indolinyl lower alkyl group,

(1-2) a thiazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):
(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,
(1-2-2) a lower alkoxy group,
(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or

more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group optionally substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a benzyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group optionally substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-2):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more phenyl groups optionally substituted with one or more

halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms, and

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms;

provided that

5-(4-styrylphenyl)-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3,4,5-trimethoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-cyanostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(pyridin-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

4-phenyl-5-cyano-1,2,3-triazole;

4-(4-methylphenyl)-5-cyano-1,2,3-triazole;

4-(4-isopropylphenyl)-5-cyano-1,2,3-triazole;

4-(4-methoxyphenyl)-5-cyano-1,2,3-triazole;

4-(2,3-dimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3,4-dimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3,4,5-trimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(4-fluorophenyl)-5-cyano-1,2,3-triazole;

4-(4-chlorophenyl)-5-cyano-1,2,3-triazole;

4-(4-bromophenyl)-5-cyano-1,2,3-triazole;


4-(4-phenoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3-fluoro-4-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3-phenoxyphenyl)-5-cyano-1,2,3-triazole; and
4-(4-fluoro-3-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(2-fluorophenyl)-1,2,3-triazole-5-carbonitrile; and
4-(4-fluoro-3-methoxyphenyl)-1,2,3-triazole-5-carbonitrile;
are excluded,
or a salt thereof (hereinafter to be referred to as Compound (1'a)).

[0044]

The present invention also provides a cyanotriazole compound represented by the formula (1'b):

[0045]



(1'b)


[0046]

wherein

$R^{1'}$ is as defined in Compound (1'a); and

$R^{2'}$ is a group represented by the formula:

[0047]



[0048]

wherein

* is a bonding site;

$R^{2A'}$ is

(2A-1) a hydrogen atom, or

(2A-2) a lower alkyl group; and

$R^{2B'}$ is

(2B-1) a lower alkoxy group optionally substituted with one or more members selected from the group consisting of a

carboxy group; a lower alkoxy-carbonyl group; a hydroxy group; a phenyl lower alkoxy-carbonyl group; a lower alkenyloxy-carbonyl group; and a tetrahydropyran-2-yloxy group, or


(2B-2) a lower alkyl group;

or a salt thereof (hereinafter to be referred to as Compound (1'b)).

[0049]

The present invention also provides a cyanotriazole compound represented by the formula (1'bA):

[0050]



(1'bA)

[0051]

wherein

$R^{1'}$ is as defined in Compound (1'a); and

$R^{2'}$ is as defined in Compound (1'b),

or a salt thereof (hereinafter to be referred to as Compound (1'bA)).

[0052]

Compound (1) encompasses Compound (1a) (mentioned below), Compound (1b) (mentioned below), Compound (1aa), Compound (1bb), Compound (1bbA), Compound (1'a), Compound (1'b), Compound (1'bA) and Compounds (1A)-(IC) (mentioned below).

[0053]

In one embodiment, Compound (1) is used as a prophylactic and/or therapeutic agent for a disease or a disorder on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect.

[0054]

The present invention also provides a citric acid cycle activator comprising, as an active ingredient, Compound (1).

[0055]

The present invention also provides a hypoglycemic agent comprising, as an active ingredient, Compound (1).

[0056]

The present invention also provides a prophylactic and/or therapeutic agent for a disease or a disorder on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, comprising Compound (1) as an active ingredient. In one embodiment, the disease or disorder on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect is selected from the group consisting of diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and cardiovascular disease.

[0057]

The present invention also provides use of Compound (1) for manufacturing a prophylactic and/or therapeutic agent for a disease or a disorder on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect.

[0058]

The present invention also provides a method for preventing and/or treating a disease or a disorder on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, comprising administering an effective amount of Compound (1) to a patient.

Effect of the Invention

[0059]

Since Compound (1) stimulates the citric acid cycle activity and/or improves hyperglycemia, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect,

for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

Brief Description of the Drawings

[0060]

Figure 1 shows carbon dioxide evolution rate (CDER) of the compound of Example 60.

Figure 2 shows oxygen consumption rate (OCR) of the compound of Example 60.

Description of Embodiments

[0061]

Suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof and which appear in the above and following description in the present specification are explained in detail as follows.

[0062]

The term "lower" is intended to mean 1 to 6 carbon atom(s) unless otherwise indicated.

The term "higher" is intended to mean 7 to 20 carbon atom(s) unless otherwise indicated.

Examples of the "lower alkyl" include straight or branched ones such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *tert*-butyl, *sec*-butyl, n-pentyl, neopentyl, n-hexyl, isohexyl, 3-methylpentyl and the like.

Examples of the "higher alkyl" include straight or branched ones such as n-heptyl, n-octyl, n-nonyl, n-decyl and the like.

Examples of the "lower alkyl group optionally substituted with one or more halogen atoms" include trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 2,2-difluoropropyl, 2,2-dichloropropyl, 4,4,4-trifluorobutyl, 2,3-difluorobutyl, 2-chloro-3-fluorobutyl and the like, in which

preferred is trifluoromethyl or 4,4,4-trifluorobutyl.

[0063]

Examples of the "lower alkoxy" include straight or branched ones such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, *tert*-butoxy, *sec*-butoxy, n-pentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, 3-methylpentyloxy and the like, in which preferred is methoxy, ethoxy or isopropoxy.

Examples of the "lower alkoxy group optionally substituted with one or more halogen atoms" include difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 3,3,3-trifluoropropoxy, 2,2-difluoropropoxy, 2,2-dichloropropoxy, 4,4,4-trifluorobutoxy, 2,3-difluorobutoxy, 2-chloro-3-fluorobutoxy and the like, in which preferred is trifluoromethoxy or 4,4,4-trifluorobutoxy.

[0064]

Examples of the "lower alkoxy lower alkyl" include methoxymethyl, ethoxymethyl, propoxymethyl, methoxyethyl, ethoxyethyl, methoxypropyl and the like, in which preferred is ethoxymethyl.

Examples of the "lower alkoxy lower alkoxy" include methoxymethoxy, ethoxymethoxy, propoxymethoxy, methoxyethoxy, ethoxyethoxy, methoxypropoxy and the like, in which preferred is methoxymethoxy or ethoxymethoxy.

[0065]

Examples of the "lower alkenyl" include linear or branched ones that have 1 to 3 double bonds such as vinyl (ethenyl), 1-methyetheyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3-hexenyl, 5-hexenyl and the like, in which preferred is vinyl or 1-methyetheyl.

Examples of the "lower alkenyloxy" include linear or branched ones that have 1 to 3 double bonds such as vinyloxy (ethenyloxy), 1-propenyloxy, 2-propenyloxy, 2-methyl-1-propenyloxy, 1-butenyloxy, 2-butenyloxy, 3-butenyloxy, 3-

methyl-2-butenyoxyl, 1-pentenyloxy, 2-pentenyloxy, 3-pentenyloxy, 4-pentenyloxy, 4-methyl-3-pentenyloxy, 1-hexenyloxy, 3-hexenyloxy, 5-hexenyloxy and the like, in which preferred is vinyloxy, 3-butenyloxy or 3-methyl-2-butenyoxyl.

[0066]

Examples of the "lower alkynyloxy" include linear or branched ones that have 1 to 3 triple bonds such as ethynyloxy, 1-propynyloxy, 2-propynyloxy, 1-butynyloxy, 2-butynyloxy, 3-butynyloxy, 1-pentynyloxy, 2-pentynyloxy, 3-pentynyloxy, 4-pentynyloxy, 1,1-dimethylprop-2-yn-1-yloxy, 1-hexynyloxy, 2-hexynyloxy, 3-hexynyloxy, 4-hexynyloxy, 5-hexynyloxy and the like, in which preferred is 2-butynyloxy.

Examples of the "lower alkylthio" include straight or branched ones such as methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, *tert*-butylthio, *sec*-butylthio, n-pentylthio, neopentylthio, n-hexylthio, isohexylthio, 3-methylpentylthio and the like in which preferred is methylthio or ethylthio.

[0067]

Examples of the "lower alkyl-carbonyl" include straight or branched ones such as acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl, tert-butylcarbonyl, pentylcarbonyl, hexylcarbonyl and the like, in which preferred is acetyl or ethylcarbonyl.

Examples of the "lower alkoxy-carbonyl" include straight or branched ones such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl and the like, in which preferred is methoxycarbonyl or ethoxycarbonyl.

[0068]

Examples of the "lower alkenyloxy-carbonyl" include linear or branched ones that have 1 to 3 double bonds such as vinyloxycarbonyl (ethenyloxycarbonyl), 1-propenyloxycarbonyl, 2-propenyloxycarbonyl, 2-methyl-1-propenyloxycarbonyl, 1-butenyloxycarbonyl, 2-butenyloxycarbonyl, 3-butenyloxycarbonyl,

3-methyl-2-butenyoxylcarbonyl, 1-pentenyloxycarbonyl, 2-pentenyloxycarbonyl, 3-pentenyloxycarbonyl, 4-pentenyloxycarbonyl, 4-methyl-3-pentenyloxycarbonyl, 1-hexenyloxycarbonyl, 3-hexenyloxycarbonyl, 5-hexenyloxycarbonyl and the like, in which preferred is vinyloxycarbonyl, 2-propenyloxycarbonyl or 3-methyl-2-butenyoxylcarbonyl.

Examples of the "lower alkylsulfonyl" include straight or branched ones such as methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, hexylsulfonyl and the like, in which preferred is methylsulfonyl.

[0069]

Examples of the "cycloalkyl" include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, bicyclo[2.2.1]heptanyl and the like, in which preferred is cyclopropyl, adamantyl or bicyclo[2.2.1]heptanyl.

Examples of the "cycloalkoxy" include cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, adamantyloxy, bicyclo[2.2.1]heptanyloxy and the like, in which preferred is cyclobutoxy.

[0070]

Examples of the "cycloalkyl lower alkyl" include cyclopropylmethyl, cyclopropylethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, adamantylmethyl, bicyclo[2.2.1]heptanylmethyl and the like, in which preferred is cyclopropylmethyl.

Examples of the "cycloalkyl lower alkoxy" include cyclopropylmethoxy, 1-cyclopropylethoxy, 2-cyclopropylethoxy, cyclopentylmethoxy, cyclohexylmethoxy, cycloheptylmethoxy, cyclooctylmethoxy, 2-cyclohexylethoxy, adamantylmethoxy, bicyclo[2.2.1]heptanylmethoxy and the like, in which preferred is cyclopropylmethoxy.

Examples of the "cycloalkyl lower alkoxy lower alkyl" include cyclopropylmethoxymethyl, cyclopropylmethoxyethyl, cyclopentylmethoxymethyl, cyclohexylmethoxymethyl,

cycloheptylmethoxymethyl, cyclooctylmethoxymethyl, cyclohexylmethoxyethyl, cyclohexylethoxymethyl, adamantylmethoxymethyl, bicyclo[2.2.1]heptanylmethoxymethyl and the like, in which preferred is cyclohexylmethoxymethyl.

[0071]

Examples of the "cycloalkoxy lower alkyl" include cyclopropoxymethyl, cyclopropoxyethyl, cyclopentoxymethyl, cyclohexyloxymethyl, cycloheptoxymethyl, cyclooctoxymethyl, cyclohexyloxyethyl, adamantyloxymethyl, bicyclo[2.2.1]heptanyloxymethyl and the like, in which preferred is cyclopropoxymethyl or cyclopentoxymethyl.

Examples of the "cycloalkoxy lower alkoxy" include cyclopropoxymethoxy, cyclopropoxyethoxy, cyclopentoxymethoxy, cyclohexyloxymethoxy, adamantyloxymethoxy, bicyclo[2.2.1]heptanyloxymethoxy and the like, in which preferred is cyclopropoxymethoxy.

[0072]

Examples of the "cycloalkyl lower alkenyl" include 2-cyclopropylvinyl, 3-cyclopropyl-1-propen-1-yl, 3-cyclopropyl-2-propen-1-yl, 3-cyclopropyl-2-methyl-1-propen-1-yl, 3-cyclopropyl-2-methyl-2-propen-1-yl, 4-cyclopropyl-1-buten-1-yl, 4-cyclopropyl-2-buten-1-yl, 4-cyclopropyl-3-buten-1-yl, 2-cyclobutylvinyl, 2-cyclopentylvinyl, 2-cyclohexylvinyl and the like, in which preferred is 2-cyclopropylvinyl.

Examples of the "cycloalkylvinyl" include 2-cyclopropylvinyl, 2-cyclobutylvinyl, 2-cyclopentylvinyl, 2-cyclohexylvinyl and the like, in which preferred is 2-cyclopropylvinyl.

[0073]

Examples of the "cycloalkenyl" include 1-cyclopropenyl, 1-cyclobutenyl, 1-cyclopentenyl, 1-cyclohexenyl, bicyclo[2,2,1]hept-2-enyl and the like, in which preferred is 1-cyclopropenyl or bicyclo[2,2,1]hept-2-enyl.

Examples of the "cycloalkenyloxy" include 1-cyclopropenyloxy, 1-cyclobutenyloxy, 1-cyclopentenyloxy, 1-

cyclohexenyloxy, bicyclo[2,2,1]hept-2-enyloxy and the like, in which preferred is 1-cyclopropenyloxy or 1-cyclohexenyloxy.

[0074]

Examples of the "halogen" include fluoro, chloro, bromo and iodo, in which preferred is fluoro or chloro.

Examples of the "phenyl lower alkyl" include benzyl, 1-phenylethyl, phenethyl (2-phenylethyl), 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 6-phenylhexyl and the like, in which preferred is benzyl or phenethyl.

Examples of the "phenoxy lower alkyl" include phenoxymethyl, 1-phenoxyethyl, 2-phenoxyethyl, 3-phenoxypropyl, 4-phenoxybutyl, 5-phenoxypentyl, 6-phenoxyhexyl and the like, in which preferred is phenoxymethyl.

[0075]

Examples of the "phenyl lower alkoxy" include benzyloxy, 1-phenylethoxy, 2-phenylethoxy, 1-methyl-2-phenylethoxy, 3-phenylpropyloxy, 1-phenylbutyloxy, 4-phenylbutyloxy, 5-phenylpentyloxy, 6-phenylhexyloxy and the like, in which preferred is benzyloxy, 1-phenylethoxy or 1-methyl-2-phenylethoxy.

Examples of the "phenoxy lower alkoxy" include phenoxymethoxy, 1-phenoxyethoxy, 2-phenoxyethoxy, 3-phenoxypropoxy, 4-phenoxybutoxy, 5-phenoxypentoxy, 6-phenoxyhexoxy and the like, in which preferred is phenoxymethoxy or 2-phenoxyethoxy.

[0076]

Examples of the "phenyl lower alkoxy lower alkyl" include benzyloxymethyl, 1-phenylethoxymethyl, 2-phenylethoxymethyl, 3-phenylpropoxymethyl, 4-phenylbutoxymethyl, 5-phenylpentoxymethyl, 6-phenylhexoxymethyl and the like, in which preferred is benzyloxymethyl.

Examples of the "phenyl lower alkenyl" include styryl, 3-phenyl-1-propen-1-yl, 3-phenyl-2-propen-1-yl, 3-phenyl-2-methyl-1-propen-1-yl, 3-phenyl-2-methyl-2-propen-1-yl, 4-phenyl-1-buten-1-yl, 4-phenyl-2-buten-1-yl, 4-phenyl-3-buten-

1-yl and the like, in which preferred is styryl.

[0077]

Examples of the "phenyl lower alkenyloxy" include styryloxy, 3-phenyl-1-propen-1-yloxy, 3-phenyl-2-propen-1-yloxy, 3-phenyl-2-methyl-1-propen-1-yloxy, 3-phenyl-2-methyl-2-propen-1-yloxy, 4-phenyl-1-buten-1-yloxy, 4-phenyl-2-buten-1-yloxy, 4-phenyl-3-buten-1-yloxy and the like, in which preferred is styryloxy.

Examples of the "phenylthio lower alkyl" include phenylthiomethyl, 1-phenylthioethyl, 2-phenylthioethyl, 3-phenylthiopropyl, 4-phenylthiobutyl, 5-phenylthiopentyl, 6-phenylthiohexyl and the like, in which preferred is phenylthiomethyl or 2-phenylthioethyl.

[0078]

Examples of the "phenylsulfonyl lower alkyl" include phenylsulfonylmethyl, 1-phenylsulfonylethyl, 2-phenylsulfonylethyl, 3-phenylsulfonylpropyl, 4-phenylsulfonylbutyl, 5-phenylsulfonylpentyl, 6-phenylsulfonylhexyl and the like, in which preferred is phenylsulfonylmethyl or 2-phenylsulfonylethyl.

Examples of the "phenyl lower alkylsulfonyl lower alkyl" include benzylsulfonylmethyl, (1-phenylethylsulfonyl)methyl, (2-phenylethylsulfonyl)methyl, (3-phenylpropylsulfonyl)methyl and the like, in which preferred is benzylsulfonylmethyl.

[0079]

Examples of the "phenyl lower alkyl-carbonyl" include benzylcarbonyl, 1-phenylethylcarbonyl, 2-phenylethylcarbonyl, 3-phenylpropylcarbonyl, 4-phenylbutylcarbonyl, 5-phenylpentylcarbonyl, 6-phenylhexylcarbonyl and the like, in which preferred is benzylcarbonyl or 2-phenylethylcarbonyl.

Examples of the "phenyl lower alkoxy-carbonyl" include benzyloxycarbonyl, 1-phenylethoxycarbonyl, 2-phenylethoxycarbonyl, 1-methyl-2-phenylethoxycarbonyl, 3-phenylpropyloxycarbonyl, 4-phenylbutyloxycarbonyl, 5-phenylpentyloxycarbonyl, 6-phenylhexyloxycarbonyl and the like,

in which preferred is benzyloxycarbonyl, 1-phenylethoxycarbonyl or 1-methyl-2-phenylethoxycarbonyl.

[0080]

Examples of the "benzyloxy lower alkyl" include benzyloxymethyl, 1-benzyloxyethyl, 2-benzyloxyethyl, 1-benzyloxypropyl, 3-benzyloxypropyl and the like, in which preferred is 1-benzyloxypropyl.

Examples of the "benzylthio lower alkyl" include benzylthiomethyl, 1-benzylthioethyl, 2-benzylthioethyl, 3-benzylthiopropyl and the like, in which preferred is benzylthiomethyl.

[0081]

Examples of the "lower alkylamino" include straight or branched ones such as methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, *tert*-butylamino, *sec*-butylamino, n-pentylamino, neopentylamino, n-hexylamino, isohexylamino, 3-methylpentylamino and the like, in which preferred is methylamino or ethylamino.

Examples of the "N-lower alkyl-N-phenyl amino" include N-methyl-N-phenyl amino, N-ethyl-N-phenyl amino, N-propyl-N-phenyl amino, N-isopropyl-N-phenyl amino and the like, in which preferred is N-methyl-N-phenyl amino or N-ethyl-N-phenyl amino.

Examples of the "N-lower alkyl-N-phenyl amino lower alkyl" include N-methyl-N-phenyl amino methyl, N-ethyl-N-phenyl amino methyl, N-methyl-N-phenyl amino ethyl, N-methyl-N-phenyl amino propyl and the like, in which preferred is N-methyl-N-phenyl amino methyl.

Examples of the "N-benzyl-N-lower alkyl amino" include N-benzyl-N-methylamino, N-benzyl-N-ethylamino, N-benzyl-N-propylamino and the like, in which preferred is N-benzyl-N-methylamino.

[0082]

Examples of the "mono- or di-N-lower alkyl amino lower alkyl" include mono- or di-N-methylaminomethyl, mono- or di-N-

ethylaminomethyl, mono- or di-N-propylaminomethyl, mono- or di-N-methylaminoethyl, mono- or di-N-methylaminopropyl and the like, in which preferred is mono- or di-N-methylaminomethyl.

Examples of the "N,N-di-lower alkylamino lower alkyl" include N,N-di-methylaminomethyl, N,N-di-ethylaminomethyl, N,N-di-propylaminomethyl, N,N-di-methylaminoethyl, N,N-di-methylaminopropyl, N-ethyl-N-methylaminomethyl, N-ethyl-N-methylaminoethyl and the like, in which preferred is N,N-di-methylaminomethyl or N,N-di-ethylaminomethyl.

Examples of the "N,N-di-lower alkylamino lower alkoxy" include N,N-di-methylaminomethoxy, N,N-di-ethylaminomethoxy, N,N-di-propylaminomethoxy, N,N-di-methylaminoethoxy, N,N-di-methylaminopropoxy, N-ethyl-N-methylaminomethoxy, N-ethyl-N-methylaminoethoxy and the like, in which preferred is N,N-di-methylaminomethoxy, N,N-dimethylaminopropoxy or N,N-di-ethylaminomethoxy.

[0083]

Examples of the "N,N-di-lower alkylamino-carbonyl" include N,N-di-methylaminocarbonyl, N,N-di-ethylaminocarbonyl, N,N-di-propylaminocarbonyl, N,N-di-butylaminocarbonyl, N,N-di-methylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, N-ethyl-N-methylaminocarbonyl and the like, in which preferred is N,N-di-methylaminocarbonyl or N,N-di-ethylaminocarbonyl.

Examples of the "lower alkylsulfonylamino" include methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, butylsulfonylamino, isobutylsulfonylamino and the like, in which preferred is methylsulfonylamino or ethylsulfonylamino.

Examples of the "acetylamino lower alkyl" include acetylaminomethyl, 2-acetylaminoethyl, 3-acetylaminopropyl, 2-acetylamino-1-methylethyl, 4-acetylaminobutyl, 5-acetylaminopentyl, 6-acetylamino hexyl and the like, in which preferred is acetylaminomethyl or 2-acetylaminoethyl.

[0084]

Examples of the "pyridyl lower alkyl" include (pyridin-2-

yl)methyl, (pyridin-3-yl)methyl, 1-(pyridin-2-yl)ethyl, 2-(pyridin-2-yl)ethyl, 2-(pyridin-3-yl)ethyl, 3-(pyridin-2-yl)propyl and the like, in which preferred is 2-(pyridin-2-yl)ethyl.

Examples of the "pyridyl lower alkoxy" include (pyridin-2-yl)methoxy, (pyridin-3-yl)methoxy, 1-(pyridin-2-yl)ethoxy, 2-(pyridin-2-yl)ethoxy, 2-(pyridin-3-yl)ethoxy, 3-(pyridin-2-yl)propoxy and the like, in which preferred is (pyridin-2-yl)methoxy or 2-(pyridin-2-yl)ethoxy.

Examples of the "pyridyloxy lower alkyl" include (pyridin-2-yloxy)methyl, 1-(pyridin-2-yloxy)ethyl, 2-(pyridin-2-yloxy)ethyl, 3-(pyridin-2-yloxy)propyl and the like, in which preferred is (pyridin-2-yloxy)methyl or 2-(pyridin-2-yloxy)ethyl.

[0085]

Examples of the "pyrimidinyl lower alkyl" include (pyrimidin-2-yl)methyl, (pyrimidin-4-yl)methyl, (pyrimidin-5-yl)methyl, 1-(pyrimidin-2-yl)ethyl, 2-(pyrimidin-2-yl)ethyl, 2-(pyrimidin-4-yl)ethyl, 3-(pyrimidin-2-yl)propyl and the like, in which preferred is (pyrimidin-2-yl)methyl or 2-(pyrimidin-2-yl)ethyl.

Examples of the "pyrimidinyl lower alkoxy" include (pyrimidin-2-yl)methoxy, (pyrimidin-4-yl)methoxy, (pyrimidin-5-yl)methoxy, 1-(pyrimidin-2-yl)ethoxy, 2-(pyrimidin-2-yl)ethoxy, 2-(pyrimidin-4-yl)ethoxy, 3-(pyrimidin-2-yl)propoxy and the like, in which preferred is (pyrimidin-2-yl)methoxy.

Examples of the "pyrimidinyloxy lower alkyl" include (pyrimidin-2-yloxy)methyl, (pyrimidin-4-yloxy)methyl, (pyrimidin-5-yloxy)methyl, 1-(pyrimidin-2-yloxy)ethyl, 2-(pyrimidin-2-yloxy)ethyl, 2-(pyrimidin-4-yloxy)ethyl, 3-(pyrimidin-2-yloxy)propyl and the like, in which preferred is (pyrimidin-2-yloxy)methyl.

[0086]

Examples of the "benzofuryl lower alkoxy" include (benzofuran-2-yl)methoxy, (benzofuran-3-yl)methoxy, 1-

(benzofuran-2-yl)ethoxy, 2-(benzofuran-2-yl)ethoxy, 3-(benzofuran-2-yl)propoxy and the like, in which preferred is (benzofuran-2-yl)methoxy.

Examples of the "indolinyl lower alkyl" include (indolin-1-yl)methyl, (indolin-2-yl)methyl, (indolin-3-yl)methyl, 1-(indolin-1-yl)ethyl, 2-(indolin-1-yl)ethyl, 3-(indolin-2-yl)propyl and the like, in which preferred is (indolin-1-yl)methyl.

[0087]

Examples of the "oxetanyl lower alkoxy" include (oxetan-2-yl)methoxy, (oxetan-3-yl)methoxy, 1-(oxetan-2-yl)ethoxy, 2-(oxetan-2-yl)ethoxy, 1-(oxetan-3-yl)ethoxy, 2-(oxetan-3-yl)ethoxy, 3-(oxetan-2-yl)propoxy, 3-(oxetan-3-yl)propoxy and the like, in which preferred is (oxetan-2-yl)methoxy or (oxetan-3-yl)methoxy.

Examples of the "tetrahydrofuryl lower alkyl" include (tetrahydrofuran-2-yl)methyl, (tetrahydrofuran-3-yl)methyl, 1-(tetrahydrofuran-2-yl)ethyl, 2-(tetrahydrofuran-2-yl)ethyl, 3-(tetrahydrofuran-2-yl)propyl and the like, in which preferred is (tetrahydrofuran-2-yl)methyl.

Examples of the "tetrahydropyranyl lower alkoxy" include (tetrahydropyran-2-yl)methoxy, 1-(tetrahydropyran-2-yl)ethoxy, 2-(tetrahydropyran-2-yl)ethoxy, 3-(tetrahydropyran-2-yl)propyloxy and the like, in which preferred is (tetrahydropyran-2-yl)methoxy.

[0088]

Examples of the "piperidyl lower alkyl" include (piperidin-1-yl)methyl, (piperidin-2-yl)methyl, (piperidin-3-yl)methyl, (piperidin-4-yl)methyl, 1-(piperidin-1-yl)ethyl, 2-(piperidin-1-yl)ethyl, 3-(piperidin-1-yl)propyl and the like, in which preferred is (piperidin-1-yl)methyl.

Examples of the "pyrrolyl lower alkyl" include (pyrrol-1-yl)methyl, (pyrrol-2-yl)methyl, (pyrrol-3-y)methyl, 1-(pyrrol-1-yl)ethyl, 2-(pyrrol-1-yl)ethyl, 1-(pyrrol-2-yl)ethyl, 2-(pyrrol-2-yl)ethyl, 3-(pyrrol-1-yl)propyl and the like, in

which preferred is (pyrrol-1-yl)methyl or (pyrrol-2-yl)methyl.

Examples of the "thiazolyl lower alkoxy" include (thiazol-2-yl)methoxy, (thiazol-4-yl)methoxy, (thiazol-5-yl)methoxy, 1-(thiazol-2-yl)ethoxy, 2-(thiazol-2-yl)ethoxy, 3-(thiazol-2-yl)propoxy and the like, in which preferred is (thiazol-2-yl)methoxy.

[0089]

Examples of the "thienyl lower alkyl" include (thiophen-2-yl)methyl, (thiophen-3-yl)methyl, 1-(thiophen-2-yl)ethyl, 2-(thiophen-2-yl)ethyl, 3-(thiophen-2-yl)propyl and the like, in which preferred is (thiophen-2-yl)methyl or (thiophen-3-yl)methyl.

Examples of the "thienyl lower alkoxy" include (thiophen-2-yl)methoxy, (thiophen-3-yl)methoxy, 1-(thiophen-2-yl)ethoxy, 2-(thiophen-2-yl)ethoxy, 3-(thiophen-2-yl)propoxy and the like, in which preferred is (thiophen-2-yl)methoxy or (thiophen-3-yl)methoxy.

Examples of the "benzothienyl lower alkyl" include (benzothiophen-2-yl)methyl, (benzothiophen-3-yl)methyl, 1-(benzothiophen-2-yl)ethyl, 2-(benzothiophen-2-yl)ethyl, 3-(benzothiophen-2-yl)propyl and the like, in which preferred is (benzothiophen-2-yl)methyl or (benzothiophen-3-yl)methyl.

Examples of the "benzothienyl lower alkoxy" include (benzothiophen-2-yl)methoxy, (benzothiophen-3-yl)methoxy, 1-(benzothiophen-2-yl)ethoxy, 2-(benzothiophen-2-yl)ethoxy, 3-(benzothiophen-2-yl)propoxy and the like, in which preferred is (benzothiophen-2-yl)methoxy or (benzothiophen-3-yl)methoxy.

[0090]

Examples of the "benzo[1,3]dioxolyl lower alkyl" include (benzo[1,3]dioxol-2-yl)methyl, (benzo[1,3]dioxol-4-yl)methyl, (benzo[1,3]dioxol-5-yl)methyl, 1-(benzo[1,3]dioxol-4-yl)ethyl, 2-(benzo[1,3]dioxol-4-yl)ethyl, 1-(benzo[1,3]dioxol-5-yl)ethyl, 2-(benzo[1,3]dioxol-5-yl)ethyl, 3-(benzo[1,3]dioxol-4-yl)propyl and the like, in which preferred is (benzo[1,3]dioxol-4-yl)methyl or (benzo[1,3]dioxol-5-yl)methyl.

Examples of the "benzo[1,3]dioxolyl lower alkoxy" include (benzo[1,3]dioxol-2-yl)methoxy, (benzo[1,3]dioxol-4-yl)methoxy, (benzo[1,3]dioxol-5-yl)methoxy, 1-(benzo[1,3]dioxol-4-yl)ethoxy, 2-(benzo[1,3]dioxol-4-yl)ethoxy, 1-(benzo[1,3]dioxol-5-yl)ethoxy, 2-(benzo[1,3]dioxol-5-yl)ethoxy, 3-(benzo[1,3]dioxol-4-yl)propoxy and the like, in which preferred is (benzo[1,3]dioxol-4-yl)methoxy or (benzo[1,3]dioxol-5-yl)methoxy.

[0091]

Examples of the "quinolyl lower alkoxy" include (quinolin-2-yl)methoxy, (quinolin-3-yl)methoxy, (quinolin-4-yl)methoxy, (quinolin-5-yl)methoxy, (quinolin-6-yl)methoxy, (quinolin-7-yl)methoxy, (quinolin-8-yl)methoxy, 1-(quinolin-2-yl)ethoxy, 2-(quinolin-2-yl)ethoxy, 3-(quinolin-2-yl)propoxy and the like, in which preferred is (quinolin-2-yl)methoxy or 2-(quinolin-2-yl)ethoxy.

Examples of the "3,4-dihydro-2H-quinolyl lower alkyl" include (3,4-dihydro-2H-quinolin-1-yl)methyl, (3,4-dihydro-2H-quinolin-2-yl)methyl, (3,4-dihydro-2H-quinolin-3-yl)methyl, (3,4-dihydro-2H-quinolin-4-yl)methyl, (3,4-dihydro-2H-quinolin-5-yl)methyl, (3,4-dihydro-2H-quinolin-6-yl)methyl, (3,4-dihydro-2H-quinolin-7-yl)methyl, (3,4-dihydro-2H-quinolin-8-yl)methyl, 1-(3,4-dihydro-2H-quinolin-2-yl)ethyl, 2-(3,4-dihydro-2H-quinolin-2-yl)ethyl, 3-(3,4-dihydro-2H-quinolin-2-yl)propyl and the like, in which preferred is (3,4-dihydro-2H-quinolin-1-yl)methyl, (3,4-dihydro-2H-quinolin-2-yl)methyl or 2-(3,4-dihydro-2H-quinolin-2-yl)ethyl.

Examples of the "2-oxo-1,2,3,4-tetrahydroquinolyl lower alkoxy" include (2-oxo-1,2,3,4-tetrahydroquinolin-1-yl)methoxy, (2-oxo-1,2,3,4-tetrahydroquinolin-2-yl)methoxy, (2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)methoxy, (2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)methoxy, (2-oxo-1,2,3,4-tetrahydroquinolin-5-yl)methoxy, (2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)methoxy, (2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)methoxy, (2-oxo-1,2,3,4-

tetrahydroquinolin-8-yl)methoxy, 1-(2-oxo-1,2,3,4-tetrahydroquinolin-2-yl)ethoxy, 2-(2-oxo-1,2,3,4-tetrahydroquinolin-2-yl)ethoxy, 3-(2-oxo-1,2,3,4-tetrahydroquinolin-2-yl)propoxy, 3-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)propoxy and the like, in which preferred is (2-oxo-1,2,3,4-tetrahydroquinolin-2-yl)methoxy, 2-(2-oxo-1,2,3,4-tetrahydroquinolin-2-yl)ethoxy or 3-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)propoxy.

[0092]

Examples of the "3,4-dihydro-1H-isoquinolyl lower alkyl" include (3,4-dihydro-1H-isoquinolin-1-yl)methyl, (3,4-dihydro-1H-isoquinolin-2-yl)methyl, (3,4-dihydro-1H-isoquinolin-3-yl)methyl, (3,4-dihydro-1H-isoquinolin-4-yl)methyl, (3,4-dihydro-1H-isoquinolin-5-yl)methyl, (3,4-dihydro-1H-isoquinolin-6-yl)methyl, (3,4-dihydro-1H-isoquinolin-7-yl)methyl, (3,4-dihydro-1H-isoquinolin-8-yl)methyl, 1-(3,4-dihydro-1H-isoquinolin-1-yl)ethyl, 2-(3,4-dihydro-1H-isoquinolin-1-yl)ethyl, 3-(3,4-dihydro-1H-isoquinolin-1-yl)propyl and the like, in which preferred is (3,4-dihydro-1H-isoquinolin-1-yl)methyl, (3,4-dihydro-1H-isoquinolin-2-yl)methyl or 2-(3,4-dihydro-1H-isoquinolin-1-yl)ethyl.

[0093]

Examples of the "indolyl lower alkyl" include (indol-1-yl)methyl, (indol-2-yl)methyl, (indol-3-yl)methyl, 1-(indol-1-yl)ethyl, 2-(indol-1-yl)ethyl, 3-(indol-2-yl)propyl and the like, in which preferred is (indol-1-yl)methyl.

Examples of the "triphenylphosphonium lower alkyl" include triphenylphosphonium methyl, 1-(triphenylphosphonium)ethyl, 2-(triphenylphosphonium)ethyl, 3-(triphenylphosphonium)propyl and the like, in which preferred is triphenylphosphonium methyl.

[0094]

Examples of the "alkyl" include straight or branched ones having 1 to 10 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *tert*-butyl, *sec*-butyl, n-pentyl,

neopentyl, n-hexyl, isohexyl, 3-methylpentyl and the like.

[0095]

Examples of the "aryl" include phenyl, 1-naphthyl, 2-naphthyl and the like.

Examples of the "aryl lower alkyl" include benzyl, 1-phenylethyl, phenethyl (2-phenylethyl), 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 6-phenylhexyl, 1-naphthylmethyl, 2-naphthylmethyl, 1-(1-naphthyl)ethyl, 1-(2-naphthyl)ethyl, 2-(1-naphthyl)ethyl, 2-(2-naphthyl)ethyl, 3-(1-naphthyl)propyl, 3-(2-naphthyl)propyl, 4-(1-naphthyl)butyl, 4-(2-naphthyl)butyl and the like, in which preferred is benzyl or phenethyl.

Examples of the "aryl lower alkenyl" include styryl, 3-phenyl-1-propen-1-yl, 3-phenyl-2-propen-1-yl, 3-phenyl-2-methyl-1-propen-1-yl, 3-phenyl-2-methyl-2-propen-1-yl, 4-phenyl-1-buten-1-yl, 4-phenyl-2-buten-1-yl, 4-phenyl-3-buten-1-yl and the like, in which preferred is styryl.

[0096]

Examples of the "acyl" include straight or branched alkylcarbonyl having 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, such as formyl, acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl, isobutylcarbonyl, sec-butylcarbonyl, tert-butylcarbonyl, pentylcarbonyl, hexylcarbonyl and the like.

Examples of the "aroyl" include benzoyl, 1-naphthoyl, 2-naphthoyl and the like, in which preferred is benzoyl.

[0097]

Examples of the "lower alkylene" include linear or branched ones such as methylene, ethylene, 1-methylethylene, 2-methylethylene, trimethylene, 2-methyltrimethylene, 2,2 dimethyltrimethylene, 1-methyltrimethylene, methylmethylene, ethylmethylene, dimethylmethylene, tetramethylene, pentamethylene, hexamethylene and the like.

Examples of the "higher alkylene" include linear or branched ones such as heptamethylene, octamethylene, nonamethylene, decamethylene, dodecamethylene,

tetradecamethylene, hexadecamethylene, octadecamethylene and the like.

[0098]

Examples of the "lower alkenylene" include linear or branched ones that have 1 to 3 double bonds such as vinylene, 1-methylvinylene, 2-methylvinylene, 1,2-dimethylvinylene, 1-propenylene, 1-methyl-1-propenylene, 2-methyl-1-propenylene, 2-propenylene, 2-butenylene, 1-butenylene, 3-butenylene, 2-pentenylene, 1-pentenylene, 3-pentenylene, 4-pentenylene, 1,3-butadienylene, 1,3-pentadienylene, 2-penten-4-ynylene, 2-hexenylene, 1-hexenylene, 5-hexenylene, 3-hexenylene, 4-hexenylene, 3,3-dimethyl-1-propenylene, 2-ethyl-1-propenylene, 1,3,5-hexatrienylene, 1,3-hexadienylene, 1,4-hexadienylene and the like.

Examples of the "phenylene" include 1,2-phenylene, 1,3-phenylene and 1,4-phenylene.

[0099]

Examples of "heterocyclyl" include saturated or unsaturated monocyclic or polycyclic heterocyclyl containing at least one hetero atom selected from the group consisting of oxygen, sulfur and nitrogen. Examples of preferable heterocyclyl include the following (a) to (n):

(a) unsaturated 3 to 8-membered, preferably 5 or 6-membered heteromonocyclyl containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, and its N-oxide, tetrahydropyridyl (e.g., 1,2,3,6-tetrahydropyridyl), pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), dihydrotriazinyl (e.g., 4,5-dihydro-1,2,4-triazinyl, 2,5-dihydro-1,2,4-triazinyl, etc.), dihydropyrimidinyl (e.g., 1,6-dihydrodihydropyrimidinyl), tetrahydropyrimidinyl (e.g., 1,2,3,6-tetrahydropyrimidiny) etc.;

(b) saturated 3 to 8-membered, preferably 5 or 7-

membered heteromonocyclyl containing 1 to 4 nitrogen atoms, for example, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidyl, pyrazolidinyl, piperazinyl, azepanyl, 1,4-diazepanyl, etc.;

(c) saturated or unsaturated condensed 7 to 12-membered heterocyclyl containing 1 to 5 nitrogen atoms, for example, decahydroquinolyl, indolyl, dihydroindolyl (e.g., 2,3-dihydroindolyl, etc.), isoindolyl, indolizinyl, benzimidazolyl, dihydrobenzimidazolyl (e.g., 2,3-dihydro-1H-benzo[d]imidazolyl, etc.), quinolyl, dihydroquinolyl (e.g. 1,4-dihydroquinolyl, 1,2-dihydroquinolyl, etc.), tetrahydroquinolyl (1,2,3,4-tetrahydroquinolyl, etc.), isoquinolyl, dihydroisoquinolyl (e.g., 3,4-dihydro-1H-isoquinolyl, 1,2-dihydroisoquinolyl, etc.), tetrahydroisoquinolyl (e.g., 1,2,3,4-tetrahydro-1H-isoquinolyl, 5,6,7,8-tetrahydroisoquinolyl, etc.), carbostyril, dihydrocarbostyril (e.g., 3,4-dihydrocarbostyril, etc.), indazolyl, benzotriazolyl (e.g. benzo[d][1,2,3]triazolyl, etc.), tetrazolopyridyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), dihydrotriazolopyridazinyl, imidazopyridyl (e.g., imidazo[1,2-a]pyridyl, imidazo[4,5-c]pyridyl, imidazo[1,5-a]pyridyl, etc.), imidazobenzimidazolyl (e.g., imidazo[1,2-a]benzimidazolyl), naphthyridinyl, cinnolinyl, quinoxalinyl, quinazolinyl, pyrazolopyridyl (e.g., pyrazolo[2,3-a]pyridyl, etc.), tetrahydropyridoindolyl (e.g., 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indolyl, etc.), azabicyclooctanyl (e.g., (1R,5S)-8-azabicyclo[3.2.1]octanyl), carbazolyl etc.;

(d) saturated or unsaturated 3 to 8-membered, preferably 5 or 6- membered heteromonocyclyl containing 1 to 2 oxygen atoms, for example, furyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl, etc.), tetrahydrofuryl, etc.;

(e) unsaturated condensed 7 to 12-membered heterocyclyl containing 1 to 3 oxygen atoms, for example, benzofuryl, dihydrobenzofuryl (e.g. 2,3-dihydrobenzo[b]furyl, etc.), chromanyl, benzodioxanyl (e.g., 1,4-benzodioxanyl, etc.),

benzodioxolyl (benzo[1,3]dioxolyl, etc.), dibenzofuryl, dihydrobenzodioxanyl (e.g., 2,3-dihydro[1,4]benzodioxanyl), dihydrobenzodioxinyl (e.g., 2,3-dihydro[1,4]benzodioxinyl), dihydrobenzodioxepinyl (e.g., 3,4-dihydro-benzo[b][1,4]dioxepinyl) etc.;

(f) unsaturated 3 to 8-membered, preferably 5 or 6-membered heteromonocyclyl containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

(g) saturated 3 to 8-membered, preferably 5 or 6-membered heteromonocyclyl containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, morpholinyl, etc.;

(h) unsaturated condensed 7 to 12-membered heterocyclyl containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, benzoxazolyl, benzoxadiazolyl, benzisoxazolyl, dihydrobenzoxazinyl (e.g., 2,3-dihydrobenz-1,4-oxazinyl, etc.), furopyridyl (e.g., furo[2,3-c]pyridyl, 6,7-dihydrofuro[2,3-c]pyridyl, furo[3,2-c]pyridyl, 4,5-dihydrofuro[3,2-c]pyridyl, furo[2,3-b]pyridyl, 6,7-dihydrofuro[2,3-b]pyridyl, etc.), furopyrrolyl (e.g., furo[3,2-b]pyrrolyl etc.), etc.;

(i) unsaturated 3 to 8-membered, preferably 5 or 6-membered heteromonocyclyl containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiazolinyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5- thiadiazolyl, 1,2,3-thiadiazolyl, etc.), isothiazolyl , etc.;

(j) saturated 3 to 8-membered, preferably 5 or 6-membered heteromonocyclyl containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolidinyl, etc.;

(k) unsaturated 3 to 8-membered, preferably 5 or 6-membered heteromonocyclyl containing a sulfur atom, for example, thienyl, etc.;

(l) unsaturated condensed 7 to 12-membered heterocyclyl containing 1 to 3 sulfur atoms, for example, benzothienyl (e.g.

benzo[b]thienyl, etc.);

(m) unsaturated condensed 7 to 12-membered heterocyclyl containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, benzothiazolyl, benzothiadiazolyl, thienopyridyl (e.g., thieno[2,3-c]pyridyl, 6,7-dihydrothieno[2,3-c]pyridyl, thieno[3,2-c]pyridyl, 4,5-dihydrothieno[3,2-c]pyridyl, thieno[2,3-b]pyridyl, 6,7-dihydrothieno[2,3-b]pyridyl, thieno[3,2-b]pyridyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridyl, etc.), imidazothiazolyl (e.g., imidazo[2,1-b]thiazolyl, etc.), dihydroimidazothiazolyl (e.g., 2,3-dihydroimidazo[2,1-b]thiazolyl, etc.), thienopyrazinyl (e.g., thieno[2,3-b]pyrazinyl, etc.), etc.; and

(n) saturated or unsaturated 7-to 12-membered heterocyclic spiro groups containing 1 to 2 nitrogen atoms, for example, azaspiroundecanyl (e.g., 3-azaspiro[5.5]undecanyl), etc.

[0100]

R^1 is preferably a group represented by formula:

-A-L1-B

wherein each symbol is as defined above.

[0101]

R^1 is more preferably one of the following (1-1) to (1-34):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-108):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is

substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),
(1-1-3) a lower alkoxy lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atoms; and a cycloalkyl group,
(1-1-4) a cycloalkyl group,
(1-1-5) a cycloalkoxy group optionally substituted with one or more halogen atoms,
(1-1-6) a cycloalkyl lower alkyl group,
(1-1-7) a cycloalkyl lower alkoxy group optionally substituted on the cycloalkyl group with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group optionally substituted with one or more halogen atoms,
(1-1-8) a cycloalkyl lower alkoxy lower alkyl group optionally substituted on the cycloalkyl group with one or more members selected from the group consisting of a hydroxy; and a lower alkoxy group,
(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),
(1-1-10) a cyano group,
(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkoxy-carbonyl group; a lower alkylsulfonyl group; a phenyl group; a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom and a lower alkyl group optionally substituted with one or more

halogen atoms; a phenoxy group; and a cyano group,
(1-1-12) a phenyl lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; and a hydroxy group,
(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; a halogen atom; and a 5-cyano-1H-1,2,3-triazol-4-yl group (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),
(1-1-14) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),
(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-16) a phenyl lower alkoxy group optionally substituted

on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; and a cyano group,

(1-1-17) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atoms; and a lower alkyl group,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a cyano group,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the

pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group,

(1-1-28) a benzoxazolyl group optionally substituted with one or more halogen atoms,

(1-1-29) a benzofuryl group optionally substituted with one or more halogen atoms,

(1-1-30) a benzofuryl lower alkoxy group optionally substituted on the benzofuran ring with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkyl-carbonyl group; and a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-32) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted

with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-34) an indolinyl lower alkyl group,

(1-1-35) a benzothienylvinyl group,

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-1-37) a lower alkoxy lower alkoxy group,

(1-1-38) a cycloalkoxy lower alkyl group optionally substituted on the cycloalkyl group with one or more lower alkyl groups,

(1-1-39) a cycloalkyl lower alkenyl group,

(1-1-40) a cycloalkenyloxy group,

(1-1-41) a cycloalkenylvinyl group,

(1-1-42) an oxiranyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-43) an oxetanyl lower alkoxy group optionally substituted on the oxetane ring with one or more lower alkyl groups,

(1-1-44) a tetrahydropyranyl lower alkoxy group,

(1-1-45) a hydroxy group,

(1-1-46) a phenyl lower alkoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkylthio group optionally substituted with one or more halogen atoms,

(1-1-47) a phenyl lower alkenyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen

atoms,

(1-1-48) a benzoyl group optionally substituted with one or more halogen atoms,

(1-1-49) a phenylthio lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atoms; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-50) a phenylsulfonyl group optionally substituted with one or more lower alkyl groups,

(1-1-51) a phenylsulfonyl lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-52) a naphthyl group optionally substituted with one or more halogen atoms,

(1-1-53) a naphthylvinyl group optionally substituted on the naphthyl ring with one or more halogen atoms,

(1-1-54) a tetrahydronaphthyloxy group,

(1-1-55) an indanyloxy group,

(1-1-56) an amino group optionally mono- or di-substituted with members selected from the group consisting of a lower alkyl group; a lower alkyl-carbonyl group; a lower alkoxy-carbonyl group; and a lower alkylsulfonyl group;

(1-1-57) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-58) an aminocarbonyl group optionally substituted with one or more members selected from the group consisting of a lower alkyl group; a cycloalkyl group; a cycloalkyl lower alkyl group; and a phenyl group optionally substituted with one or more halogen atoms,

(1-1-59) a pyridyl lower alkoxy group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more

halogen atoms,

(1-1-60) a pyridyloxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-61) a pyrrolo[2,3-b]pyridyl group optionally substituted with one or more lower alkyl groups,

(1-1-62) a pyrazolo[3,4-b]pyridyl group optionally substituted with one or more lower alkyl groups,

(1-1-63) an imidazo[1,2-a]pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-64) a pyrimidinyl lower alkyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-65) a pyrimidinyl lower alkoxy group optionally substituted on the pyrimidine ring with one or more members selected from the group consisting of a lower alkoxy group; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group,

(1-1-66) a pyrimidinyloxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-67) a pyrimidinyloxy lower alkyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-68) a pyrazinyl group optionally substituted with one or more lower alkyl groups,

(1-1-69) a pyridazinyl group optionally substituted with one or more members selected from the group consisting of a lower alkyl group; and a lower alkoxy group,

(1-1-70) a piperidyl lower alkyl group,

(1-1-71) a piperidylcarbonyl group,

(1-1-72) a piperazinyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-1-73) an imidazolyl group,

(1-1-74) a pyrazolyl group optionally substituted with one or more lower alkyl groups,

(1-1-75) a pyrrolyl lower alkyl group,

(1-1-76) a thiazolyl group,

(1-1-77) a thiazolyl lower alkoxy group optionally substituted on the thiazole ring with one or more lower alkyl groups,

(1-1-78) a benzothiazolyl group optionally substituted with one or more halogen atoms,

(1-1-79) a furyl group,

(1-1-80) a furylvinyl group optionally substituted on the furan ring with one or more lower alkyl groups,

(1-1-81) a benzofurylvinyl group (preferably the benzofurylvinyl group is bonded to the o- or m-position on the phenyl ring of (1-1)),

(1-1-82) a 2,3-dihydrobenzofuryl group,

(1-1-83) a thienyl lower alkoxy group,

(1-1-84) a thienylvinyl group optionally substituted on the thiophene ring with one or more halogen atoms (preferably the thienylvinyl group is bonded to the o- or m-position on the phenyl ring of (1-1)),

(1-1-85) a benzothienyl lower alkyl group optionally substituted on the benzothiophene ring with one or more halogen atoms,

(1-1-86) a benzothienyl lower alkoxy group optionally substituted on the benzothiophene ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-87) a benzo[1,3]dioxolyl lower alkyl group optionally substituted on the benzo[1,3]dioxole ring with one or more

halogen atoms,

(1-1-88) a benzo[1,3]dioxolyl lower alkoxy group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-1-89) a 4H-benzo[1,3]dioxinyl group optionally substituted with one or more halogen atoms,

(1-1-90) a 4H-benzo[1,3]dioxinylvinyl group optionally substituted on the benzo[1,3]dioxine ring with one or more halogen atoms,

(1-1-91) a quinolyl group,

(1-1-92) a quinolyl lower alkoxy group,

(1-1-93) a quinolylvinyl group,

(1-1-94) a 3,4-dihydro-2H-quinolyl group,

(1-1-95) a 3,4-dihydro-2H-quinolyl lower alkyl group,

(1-1-96) a 2-oxo-1,2,3,4-tetrahydroquinolyl group,

(1-1-97) a 2-oxo-1,2,3,4-tetrahydroquinolyl lower alkoxy group,

(1-1-98) a 2-oxo-1,2,3,4-tetrahydroquinolyloxy group optionally substituted with one or more lower alkyl groups,

(1-1-99) an isoquinolyl group,

(1-1-100) a 3,4-dihydro-1H-isoquinolyl group,

(1-1-101) a 3,4-dihydro-1H-isoquinolyl lower alkyl group,

(1-1-102) an indolyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group; and a lower alkoxy-carbonyl group,

(1-1-103) an indolyl lower alkyl group,

(1-1-104) an indolylvinyl group optionally substituted on the indole ring with one or more lower alkyl groups,

(1-1-105) an indolinyl group,

(1-1-106) an indolinylcarbonyl group,

(1-1-107) a 1H-1,2,3-triazolyl group optionally substituted with one or more cyano groups, and

(1-1-108) a triphenylphosphonium lower alkyl group,

(1-2) a thiazolyl group substituted with one or more members

selected from the group consisting of the following (1-2-1) to (1-2-26):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a hydroxy group; and a cyano group,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an amino group optionally mono- or di-substituted with members selected from the group consisting of a lower alkyl group; a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms; a benzyl group optionally substituted on the phenyl ring with

one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms; and a benzoyl group optionally substituted with one or more halogen atoms,

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-12) a lower alkenyl group,

(1-2-13) a cycloalkyl lower alkyl group,

(1-2-14) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a hydroxy group,

(1-2-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-16) a phenyl lower alkoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group optionally substituted with one or more halogen atoms; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-17) a phenyl lower alkylsulfonyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-18) a mono- or di-N-lower alkyl amino lower alkyl group;

(1-2-19) a piperidyl group optionally substituted with one or more members selected from the group consisting of a

phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-20) a piperazinyl group optionally substituted with one or more phenyl groups optionally substituted with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-21) an indolyl group,

(1-2-22) a morpholinyl group,

(1-2-23) a thienyl group,

(1-2-24) a benzothienyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-25) a furyl group, and

(1-2-26) a cyano group,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-12):

(1-3-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3-2) a cycloalkyl group,

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-3-4) a lower alkoxy lower alkyl group,

(1-3-5) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups

optionally substituted with one or more halogen atoms,

(1-3-6) a naphthyl group,

(1-3-7) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-3-8) a furyl group,

(1-3-9) a dihydrobenzofuryl group,

(1-3-10) a thienyl group,

(1-3-11) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-3-12) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-14):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atom and a hydroxy group; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl-carbonyl group; a lower alkoxy-carbonyl group; and a benzyloxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms, and a halogen atom,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more members selected from the group consisting of a lower

alkyl group optionally substituted with one or more halogen atoms; and a halogen atom,

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-6) a cycloalkyl lower alkenyl group,

(1-4-7) a halogen atom,

(1-4-8) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-9) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-10) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-11) a thienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a phenyl group optionally substituted with one or more halogen atoms,

(1-4-12) a thienylvinyl group,

(1-4-13) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-4-14) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-8):

(1-5-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted

with one or more halogen atoms; and a phenyl group,

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,

(1-5-3) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-5-4) a naphthyl group,

(1-5-5) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5-6) a quinolyl group,

(1-5-7) a benzothienyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-5-8) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-5):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a phenoxy group; a benzyl group; and a benzoyl group,

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a phenyl group; and a phenyl lower alkoxy

group,

(1-6-4) an indanyl group, and

(1-6-5) a benzo[1,3]dioxolyl lower alkyl group,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-9):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7-3) a benzofuryl group,

(1-7-4) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7-5) a naphthyl group,

(1-7-6) a halogen atom,

(1-7-7) a pyridyl group,

(1-7-8) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-7-9) a [1,2,3]triazolyl group optionally substituted with one or more cyano groups,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-8):

(1-8-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-8-3) a lower alkoxy-carbonyl group,

(1-8-4) a benzoyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-8-5) a phenyl lower alkyl-carbonyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-8-6) a phenyl lower alkoxy-carbonyl group,

(1-8-7) a phenoxycarbonyl group, and

(1-8-8) a phenylsulfonyl group optionally substituted with one or more lower alkyl groups,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-8):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-9-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,

(1-9-3) a cycloalkyl lower alkyl group,

(1-9-4) a halogen atom,

(1-9-5) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-9-6) a thienyl lower alkyl group,

(1-9-7) a tetrahydrofuryl lower alkyl group, and

(1-9-8) a benzo[1,3]dioxolyl group,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of the

following (1-10-1) to (1-10-7):

(1-10-1) a halogen atom,

(1-10-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-10-3) a lower alkyl group,

(1-10-4) a benzyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-10-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-10-6) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms, and

(1-10-7) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more members selected from the group consisting of the following (1-11-1) to (1-11-7):

(1-11-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-11-2) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-11-3) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-11-4) a halogen atom,

(1-11-5) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-11-6) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-11-7) a thienyl group,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-4):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-12-3) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-12-4) a phenoxy group,

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-7):

(1-13-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-13-2) a pyrrolidyl group,

(1-13-3) a piperidyl group,

(1-13-4) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-13-5) a lower alkoxy group,

(1-13-6) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-13-7) a morpholinyl group,

(1-14) a quinolyl group substituted with one or more members selected from the group consisting of the following (1-14-1) to (1-14-5):

(1-14-1) a lower alkoxy group,

(1-14-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-14-3) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-14-4) a pyrrolidyl group, and

(1-14-5) a thienyl group,

(1-15) a 2,3-dihydro-1H-indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-15-1) to (1-15-2):

(1-15-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-15-2) a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-16) an imidazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-16-1) to (1-16-4):

(1-16-1) a lower alkyl group,

(1-16-2) a halogen atom,

(1-16-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-16-4) a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-17) a benzothiazolyl group optionally substituted with one

or more members selected from the group consisting of the following (1-17-1) to (1-17-6):

(1-17-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-17-2) a lower alkoxy group,

(1-17-3) a halogen atom,

(1-17-4) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-17-5) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-17-6) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-18) an isoxazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-19) a 2,3-dihydrobenzofuryl group optionally substituted with one or more members selected from the group consisting of the following (1-19-1) to (1-19-3):

(1-19-1) a halogen atom,

(1-19-2) a phenyl group optionally substituted with one or more halogen atoms, and

(1-19-3) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-20) an isothiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-21) a dibenzofuryl group,

(1-22) a benzo[1,3]dioxolyl group optionally substituted with one or more members selected from the group consisting of the following (1-22-1) to (1-22-2):

(1-22-1) a halogen atom, and

(1-22-2) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-23) a carbazolyl group optionally substituted with one or more lower alkyl groups,

(1-24) a naphthyl group optionally substituted with one or more benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-25) a 2-oxo-1,2,3,4-tetrahydroquinolyl group optionally substituted with one or more benzyl groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-26) a 6-oxo-1,6-dihydropyrimidinyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-27) an imidazo[1,2-a]pyridyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-28) a [1,3,4]oxadiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-29) a [1,2,4]thiadiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-30) a benzoxazolyl group optionally substituted with one or more members selected from the group consisting of the

following (1-30-1) to (1-30-4):

(1-30-1) a lower alkyl group,

(1-30-2) a lower alkoxy group,

(1-30-3) a halogen atom, and

(1-30-4) a phenyl group,

(1-31) a [1,3,4]thiadiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms;

(1-32) a styryl group optionally substituted on the phenyl ring with one or more benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-33) a benzoyl group optionally substituted with one or more benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

and

(1-34) a cycloalkyl group optionally substituted with one or more members selected from the group consisting of a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and a benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms.

[0102]

R^1 is further more preferably one of the following (1-1) to (1-13):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-36):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl

groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-3) a lower alkoxy lower alkyl group,

(1-1-4) a cycloalkyl group,

(1-1-5) a cycloalkoxy group,

(1-1-6) a cycloalkyl lower alkyl group,

(1-1-7) a cycloalkyl lower alkoxy group,

(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-10) a cyano group,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom (preferably

provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally

substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-29) a benzofuryl group,

(1-1-30) a benzofuryl lower alkoxy group,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted

with one or more halogen atoms,

(1-1-34) an indolinyl lower alkyl group,

(1-1-35) a benzothienylvinyl group, and

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members

selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl

ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-3):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-3) a benzofuryl group,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the

following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of the following (1-10-1) to (1-10-2):

(1-10-1) a halogen atom, and

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidinyl group, and

(1-13-3) a piperidyl group.

[0103]

In another embodiment, R^1 is further more preferably the following (1-1):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-36):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-3) a lower alkoxy lower alkyl group,

(1-1-4) a cycloalkyl group,

(1-1-5) a cycloalkoxy group,

(1-1-6) a cycloalkyl lower alkyl group,

(1-1-7) a cycloalkyl lower alkoxy group,

(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-10) a cyano group,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group

optionally substituted with one or more halogen atoms,
(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),
(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),
(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with

one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups

optionally substituted with one or more halogen atoms,
(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,
(1-1-29) a benzofuryl group,
(1-1-30) a benzofuryl lower alkoxy group,
(1-1-31) a thienyl group,
(1-1-32) a benzothienyl group,
(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,
(1-1-34) an indolinyl lower alkyl group,
(1-1-35) a benzothienylvinyl group, and
(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms.

[0104]

In another embodiment, R^1 is further more preferably one of the following (1-2) to (1-13):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):
(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,
(1-2-2) a lower alkoxy group,
(1-2-3) a cycloalkyl group,
(1-2-4) a halogen atom,
(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally

substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one

or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups

optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-3):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-3) a benzofuryl group,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of the following (1-10-1) to (1-10-2):

(1-10-1) a halogen atom, and

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more

halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidinyl group, and

(1-13-3) a piperidyl group.

[0105]

In another embodiment, R^1 is further more preferably the following (1-2):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0106]

In another embodiment, R^1 is further more preferably the following (1-3):

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms.

[0107]

In another embodiment, R^1 is further more preferably the

following (1-5):

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0108]

In another embodiment, R^1 is further more preferably the following (1-13):

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidinyl group, and

(1-13-3) a piperidyl group.

[0109]

R^1 is still more preferably one of the following (1-1) to (1-7), (1-9), (1-10), (1-12) and (1-13):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-35) a benzothienylvinyl group, and

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally

substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of

(1-4-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group

consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of

(1-6-1) a lower alkyl group, and

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of

(1-7-3) a benzofuryl group,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group.

[0110]

In another embodiment, R^1 is still more preferably the following (1-1):

(1-1) a phenyl group substituted with one or more members

selected from the group consisting of

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members

selected from the group consisting of a lower alkoxy group substituted with one or more halogen atoms; a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-35) a benzothienylvinyl group, and

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms.

[0111]

In another embodiment, R^1 is still more preferably one of the following (1-2) to (1-7), (1-9), (1-10), (1-12) and (1-13):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of

(1-4-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of

(1-6-1) a lower alkyl group, and

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of

(1-7-3) a benzofuryl group,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of

(1-10-2) a phenyl group optionally substituted with one or

more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group.

[0112]

In another embodiment, R^1 is still more preferably the following (1-2):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0113]

In another embodiment, R^1 is still more preferably the following (1-3):

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0114]

In another embodiment, R^1 is still more preferably the following (1-5):

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0115]

In another embodiment, R^1 is still more preferably the following (1-13):

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group.

[0116]

In another embodiment, R^1 is preferably is one of the following (1-1) to (1-13):

(1-1) a phenyl group optionally substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-34):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),
(1-1-3) a lower alkoxy lower alkyl group,
(1-1-4) a cycloalkyl group,
(1-1-5) a cycloalkoxy group,
(1-1-6) a cycloalkyl lower alkyl group,
(1-1-7) a cycloalkyl lower alkoxy group,
(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,
(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),
(1-1-10) a cyano group,
(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members

selected from the group consisting of a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or

more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-29) a benzofuryl group,

(1-1-30) a benzofuryl lower alkoxy group,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms, and

(1-1-34) an indolinyl lower alkyl group,

(1-2) a thiazolyl group optionally substituted with one or more members selected from the group consisting of the

following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or

more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group optionally substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl

ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group optionally substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-2):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group.

[0117]

In the above-mentioned embodiment, R^1 is more preferably one of the following (1-1) to (1-5):

(1-1) a phenyl group optionally substituted with one or more members selected from:

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),
(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),
(1-1-11) a phenyl group optionally substituted with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,
(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,
(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more lower alkyl groups substituted with one or more halogen atoms),
(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups

optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group, and

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-2) a thiazolyl group optionally substituted with one or more members selected from:

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from:

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group optionally substituted with one or more

members selected from:

(1-4-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-5) a furyl group optionally substituted with one or more members selected from:

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms.

[0118]

In another embodiment, R^1 is preferably one of the following (1-1) to (1-12):

(1-1) a phenyl group optionally substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-34):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-3) a lower alkoxy lower alkyl group,

(1-1-4) a cycloalkyl group,

(1-1-5) a cycloalkoxy group,

(1-1-6) a cycloalkyl lower alkyl group,

(1-1-7) a cycloalkyl lower alkoxy group,

(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy

group),

(1-1-10) a cyano group,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and halogen atoms (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group substituted with one or more halogen atoms; and a fluoro atom),

(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with

one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-29) a benzofuryl group,

(1-1-30) a benzofuryl lower alkoxy group,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a 2,2-difluorobenzo[1,3]dioxolyl group, and

(1-1-34) an indolinyl lower alkyl group,

(1-2) a thiazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted

with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group optionally substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted

with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a benzyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group optionally substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-2):

(1-7-1) a benzyloxy lower alkyl group optionally

substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms, and

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally

substituted with one or more halogen atoms.

[0119]

In another embodiment, R^1 is preferably one of the following (1-1) to (1-6), (1-9) and (1-12):

(1-1) a phenyl group optionally substituted with one or more members selected from the group consisting of

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group (preferably benzyl, 2-phenylethyl) optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally

substituted with one or more halogen atoms; and a cyano group (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more lower alkyl groups substituted with one or more halogen atoms),

(1-1-14) a phenoxy group (preferably provided that the phenyl group of (1-1) is substituted with one or more phenoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a halogen atom),

(1-1-16) a phenyl lower alkoxy group (preferably benzyloxy) optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group, and

(1-1-33) a 2,2-difluorobenzo[1,3]dioxolyl group,

(1-2) a thiazolyl group optionally substituted with one or more members selected from the group consisting of

(1-2-1) a lower alkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group optionally substituted with one or more members selected from the group consisting of

(1-4-2) a phenyl group optionally substituted with one or

more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of

(1-6-1) a lower alkyl group, and

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms.

[0120]

In another embodiment, R^1 is preferably one of the following (1-1) to (1-3):

(1-1) a phenyl group optionally substituted with one or more members selected from the group consisting of

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms (preferably provided that the phenyl group of (1-1) is substituted with one or more lower alkyl groups, then the phenyl group of (1-1) is substituted with additional one or more substituents),

(1-1-2) a lower alkoxy group (preferably provided that the phenyl group of (1-1) is substituted with one or more lower

alkoxy groups, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a lower alkoxy group and a halogen atom),

(1-1-9) a halogen atom (preferably provided that the phenyl group of (1-1) is substituted with one or more halogen atoms, then the phenyl group of (1-1) is substituted with additional one or more substituents excluding a phenoxy group),

(1-1-11) a phenyl group optionally substituted with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably provided that when the styryl group is bonded to the p-position on the phenyl ring of (1-1), then the styryl group is substituted on the phenyl ring with one or more lower alkyl groups substituted with one or more halogen atoms),

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms (preferably a pyridylvinyl group substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms),

(1-1-25) a pyrimidinyl group optionally substituted with

one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-1-33) a 2,2-difluorobenzo[1,3]dioxolyl group,

(1-2) a thiazolyl group optionally substituted with one or more members selected from the group consisting of

(1-2-1) a lower alkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms.

[0121]


R^2 is preferably one of the following (2-1) to (2-4):

(2-1) a lower alkyl group optionally substituted with one or more members selected from the group consisting of a hydroxy group; and a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(2-2) a 2-oxo-1,3-dioxolanyl group, and

(2-3) a group represented by the formula:

[0122]



[0123]

wherein

* is a bonding site;

R^{2A} is one of the following (2A-1) to (2A-2):

(2A-1) a hydrogen atom, or

(2A-2) a lower alkyl group; and

R^{2B} is one of the following (2B-1) to (2B-6):

(2B-1) a lower alkoxy group optionally substituted with one or more members selected from the group consisting of a lower alkoxy group; a carboxy group; a lower alkoxy-carbonyl group; a hydroxy group; a phenyl lower alkoxy-carbonyl group; a lower alkenyloxy-carbonyl group; a morpholinyl group; a benzyloxycarbonyl group; and a tetrahydropyran-2-yloxy group,

(2B-2) a lower alkyl group;

(2B-3) a lower alkylamino group optionally substituted with one or more lower alkoxy-carbonyl groups;

(2B-4) a cycloalkyl group;

(2B-5) a cycloalkoxy group;

(2B-6) a phenyl group, and

(2-4) a hydrogen atom.

[0124]

R^2 is more preferably one of the following groups:

a hydrogen atom;

a 1-(((2-carboxy-2,2-dimethylethoxy)carbonyl)oxy)ethyl group;

a 1-(((2-carboxy-1,1-dimethylethoxy)carbonyl)oxy)ethyl group;

a 1-(((2-hydroxyethoxy)carbonyl)oxy)ethyl group;

a 1-(butyryloxy)ethyl group;

a 1-(isobutyryloxy)ethyl group;


an acetoxymethyl group; and

a butyryloxymethyl group.

[0125]

In another embodiment, R^2 is preferably a hydrogen atom, or a group represented by the formula:

[0126]



[0127]

wherein

* is a bonding site;

R^{2A} is one of the following (2A-1) to (2A-2):

(2A-1) a hydrogen atom, and

(2A-2) a lower alkyl group; and

R^{2B} is one of the following (2B-1) to (2B-2):

(2B-1) a lower alkoxy group optionally substituted with one or more members selected from the group consisting of a carboxy group; a lower alkoxy-carbonyl group; a hydroxy group; a phenyl lower alkoxy-carbonyl group; a lower alkenyloxy-carbonyl group; and a tetrahydropyran-2-yloxy group, and

(2B-2) a lower alkyl group.

[0128]

Compound (1) excludes the following compounds:

5-(4-styrylphenyl)-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3,4,5-trimethoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

methyl 4-[4-(4-cyano-1,2,3-triazol-5-yl)styryl]benzoate;

5-[4-(4-cyanostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-{4-[4-(*N*,*N*-dimethylamino)styryl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(biphenyl-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[4-(2-oxo-2*H*-chromen-3-yl)styryl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[4-(benzo[d]oxazol-2-yl)styryl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(2-methoxynaphthalen-1-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(4-methoxynaphthalen-1-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(pyridin-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(thiophen-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(benzofuran-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-[4-(4-formylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(4'-formylbiphenyl-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
4-(2,3-dimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3,4-dimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3,4,5-trimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3-fluoro-4-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(4-fluoro-3-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(4-fluoro-3-methoxyphenyl)-1,2,3-triazole-5-carbonitrile;
(5-(5-cyano-1,2,3-triazol-4-yl)furan-2-yl)methyl acetate;
2-[4-(4'-benzoxazole-2-yl-stilbene-4-yl)-5-cyano-1,2,3-triazole-N-yl]acetic acid methyl ester;
4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-N-trityl-1,2,3-triazole-5-carbonitrile;
2-(4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-5-cyano-1,2,3-triazol-N-yl)acetamide;
2-(4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-5-cyano-

1,2,3-triazol-N-yl)acetic acid;
4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-N-(2-oxo-2-phenylethyl)-1,2,3-triazole-5-carbonitrile; and
4-(4'-benzoxazole-2-yl-stilbene-4-yl)-5-cyano-N-acetamide-1,2,3-triazole;
and salts thereof.

[0129]

Compound (1) is preferably Compound (1aa) or Compound (1bb).

Compound (1aa) excludes the following compounds:
5-(4-styrylphenyl)-1,2,3-triazole-4-carbonitrile;
5-[4-(4-methylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(4-methoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(3,4,5-trimethoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(4-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(3-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(4-cyanostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(pyridin-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(thiophen-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(benzofuran-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
4-(4-methylphenyl)-5-cyano-1,2,3-triazole;
4-(4-isopropylphenyl)-5-cyano-1,2,3-triazole;
4-(4-methoxyphenyl)-5-cyano-1,2,3-triazole;
4-(2,3-dimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3,4-dimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3,4,5-trimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(4-fluorophenyl)-5-cyano-1,2,3-triazole;
4-(4-chlorophenyl)-5-cyano-1,2,3-triazole;
4-(4-bromophenyl)-5-cyano-1,2,3-triazole;
4-(4-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3-fluoro-4-phenoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3-phenoxyphenyl)-5-cyano-1,2,3-triazole; and
4-(4-fluoro-3-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(2-fluorophenyl)-1,2,3-triazole-5-carbonitrile; and
4-(4-fluoro-3-methoxyphenyl)-1,2,3-triazole-5-carbonitrile;
and salts thereof.

[0130]

Table 1 lists abbreviations, symbols and terms used in the preparations, Reference Examples, Examples, and Formulae in the above and subsequent descriptions of the present specification (including the tables) have the following meanings.

Table 1 List of Abbreviation

[0131]

Abbreviation	Description
AcOEt	ethyl acetate
AcOK	potassium acetate
AcOH	acetic acid
BF_3	boron trifluoride
BINAP	2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
DEAD	diethyl azodicarboxylate
DMF	*N*,*N*-dimethylformamide
DIPEA	*N*,*N*-diisopropylethylamine
DMA	dimethylacetamide
DME	1,2-dimethoxyethane
DMSO	dimethyl sulfoxide
Et_2O	diethyl ether
Et_3N	triethylamine
EtOH	ethyl alcohol
IBX	2-iodoxybenzoic acid
MeOH	methyl alcohol
MsCl	methanesulfonyl chloride
MeI	iodomethane
n-BuLi	*n*-butyllithium
NBS	*N*-bromosuccinimide
NCS	*N*-chlorosuccinimide
NMP	*N*-methylpyrrolidone
$Pd(OAc)_2$	palladium(II) acetate
$Pd(PPh_3)_4$	tetrakis(triphenylphosphine)palladium(0)
Pd/C	palladium on carbon
PPh_3	triphenylphosphine
SO_3Py	sulfur trioxide pyridine complex
TBME	tert-butyl methyl ether
TFA	trifluoroacetic acid
THF	tetrahydrofuran
tert-BuONa	sodium tert-butoxide

Ref. Ex. No.	Reference Example Number
Ex. No.	Example Number
STR	structure
m. p.	melting point
MS(M+H)	Mass spectrum data

[0132]


Compound (1) can be produced according to, for example, Reaction Schemes 1 to 7. However these reaction schemes are given for just example, and those skilled in the art will readily understand that these reaction schemes are not limited to the disclosed embodiment and that known variations and modifications can be used for these reaction schemes without departing from the scope and spirit of the present invention. All the starting materials and target compounds shown in Reaction Schemes 1 to 7 may be in the form of suitable salts. Examples of such salts are as described for Compound (1) below.

[0133]

Compound (1a), which is Compound (1) wherein R^2 is a hydrogen atom, can be produced according to the following Reaction Scheme 1.

[0134]

Reaction Scheme 1



[0135]

wherein R^1 is as defined above; R^3 is benzenesulfonyl, nitro, etc; and MN_3 is sodium azide, lithium azide, potassium azide, trimethylsilyl azide, etc.

Compound (1a) can be produced by subjecting Compound (2) and Compound (3) to the Knoevenagel condensation in a suitable solvent, in the presence of a catalyst, and then subjecting

the resulting compound to 1,3-dipolar addition with Compound (4), or by reacting Compound (2), Compound (3) and Compound (4) in a suitable solvent without catalyst.

Examples of the solvent include water, methanol, ethanol, *N*,*N*-dimethylformamide, *N*-methylpyrrolidone, acetonitrile, acetone, ethyl acetate, diethyl ether, tetrahydrofuran, hexane, benzene, toluene, mixed solvents thereof, etc.

Examples of the catalyst include piperidine, pyridine, acetic acid, benzoic acid, *p*-toluene sulfonic acid, sodium hydroxide, aluminum oxide, potassium fluoride, potassium acetate, *N*-benzyl-*N*,*N*,*N*-triethylammonium chloride, tetrabutylammonium fluoride, mixed catalysts thereof, etc.

Compound (3) is usually used in an amount of at least about 1 mol, preferably about 1 to 2 mol, per 1 mol of Compound (2).

Compound (4) is usually used in an amount of at least 1 mol, preferably about 1 to 2 mol, per 1 mol of Compound (2).

The catalyst is usually used in an amount of about 0.1 to 2 mol, preferably about 0.5 to 1 mol, per 1 mol of Compound (2).


The reaction is usually carried out at about room temperature to 150°C, preferably about 80 to 110°C. The reaction is usually finished in about 1 to 12 hours.

[0136]

Compound (1b), which is Compound (1) wherein R^2 is not a hydrogen atom, can be produced according to the following Reaction Scheme 2.

[0137]

Reaction Scheme 2



[0138]

wherein R^1 is as defined above; R^{2a} is a lower alkyl group or a heterocyclyl group, each of which is optionally substituted; and X^1 is a leaving group.

Examples of the leaving group for X^1 include a halogen atom, a lower alkanesulfonyloxy group optionally substituted with one or more halogen atoms (e.g., methanesulfonyloxy, trifluoromethanesulfonyloxy), an arenesulfonyloxy group (e.g., benzenesulfonyloxy) and the like, in which preferred is a halogen atom.

Compound (1b) can be produced by reacting Compound (1a) with Compound (5) in a suitable solvent, in the presence of a base.

Examples of the solvent include *N*,*N*-dimethylformamide, *N*-methylpyrrolidone, acetonitrile, acetone, ethyl acetate, diethyl ether, tetrahydrofuran, hexane, benzene, toluene, mixed solvents thereof, etc.

Examples of the base include sodium carbonate, sodium bicarbonate, sodium hydride, potassium *tert*-butoxide, triethylamine, diisopropylethylamine, 4-dimethylaminopyridine, etc.

Compound (5) is usually used in an amount of at least about 1 mol, preferably about 1 to 2 mol, per 1 mol of Compound (1a).

The base is usually used in an amount of at least about 1 mol, preferably about 1 to 2 mol, per 1 mol of Compound (1a).

The reaction is usually carried out at about room temperature to 150°C, preferably about 40 to 100°C. The reaction is usually finished in about 1 to 24 hours.

When R^{2a} has carboxy group(s) and/or hydroxy group(s), a protecting group generally used in peptide chemistry and the like may be introduced into these groups. After the reaction, the objective compound can be obtained by removing the protecting group according to a method known per se.

Examples of the carboxy-protecting group include a benzyl

group, an allyl group, a *tert*-butyl group, etc.


Examples of the hydroxy-protecting group include a tetrahydropyran-2-yl group, etc.

[0139]

Compound (2) can be produced according to one of the following non-limiting Reaction Schemes 3 to 7, or the like.

[0140]

Reaction Scheme 3



[0141]

wherein R^1 is as defined above; and R^4 is a hydrogen atom, an alkyl group, an aryl group or an acyl group.

The reaction for producing Compound (2) or Compound (7) from Compound (6) can be carried out in a suitable solvent, in the presence of a suitable reducing agent.

Examples of the solvent include diethyl ether, dimethoxyethane, dioxane, methanol, ethanol, tetrahydrofuran, hexane, toluene, dichloromethane, 1,2-dichloroethane, mixed solvents thereof, etc.

Examples of the reducing agent include hydride reducing agents such as borane, sodium borohydride, lithium aluminium hydride, diisobutylaluminum hydride sodium, bis(2-methoxyethoxy)aluminum hydride, etc.

The reducing agent is usually used in an amount of at least 0.25 to 10 mol, preferably about 1 to 5 mol, per 1 mol of Compound (6).

The reaction is usually carried out at about -78 to 100°C, preferably about -78 to 70°C. The reaction is usually finished in about 1 to about 12 hours.

The reaction for producing Compound (2) from Compound (7) can be carried out in a suitable solvent, in the presence of an oxidizing agent.

Examples of the solvent include *N*,*N*-dimethylformamide,

dimethyl sulfoxide, ethyl acetate, dioxane, acetonitrile, acetone, dichloromethane, 1,2-dichloroethane, chloroform, mixed solvents thereof, etc.


Examples of the oxidizing agent include pyridinium dichlorochlomate, mangange(IV) oxide, 2,2,6,6-tetramethylpiperidine 1-oxy (TEMPO) - oxidizing agents (sodium hypochlorite - potassium bromide, bromine, iodine, sodium nitrite, oxygen, etc.), 2-iodoxybenzoic acid, Dess-Martin reagent, dimethylsulfoxide (Swern oxidation, etc.), etc.

The oxidizing agent is usually used in an amount of at least 1 mol, preferably about 1 to 2 mol, per 1 mol of Compound (7).

The reaction is usually carried out at about -100 to 100°C, preferably about -80 to 70°C. The reaction is usually finished in about 1 to about 12 hours.

[0142]

Reaction Scheme 4



[0143]

wherein R^1 is as defined above; and X^2 is a halogen atom.

The reaction for producing Compound (2) from Compound (8) can be carried out by subjecting Compound (8) to a formylation reaction.

This formylation reaction can be carried out in a suitable solvent, in the presence of an organometal reagent and a formylating reagent.

Examples of the solvent include diethyl ether, tetrahydrofuran, toluene, hexane, pentane, mixed solvents thereof, etc.

Examples of the organometal reagent include organolithium reagents (n-butyllithium, etc), organo magnesium reagents (ethymagnesium bromide, isopropylmagnesium chloride, etc.), etc.

Examples of the formylating reagent include *N,N*-

dimethylformamide, 1-formylpiperidine, 4-formylmorpholine, etc.


The organometal reagent is usually used in an amount of 1 mol per 1 mol of Compound (8).

The formylating reagent is usually used in an amount of at least 1 mol, preferably about 5 to 20 mol, per 1 mol of Compound (8).

The reaction is usually carried out at about -150 to 0 °C, preferably about -90 to -40°C. The reaction is usually finished in about 1 to about 6 hours.

[0144]

Reaction Scheme 5



[0145]

wherein R^1 is as defined above.

The reaction for producing Compound (2) from Compound (9) can be carried out in a suitable solvent, in the presence of a catalytic hydrogenation reducing agent.

Examples of the solvent include tetrahydrofuran, acetic acid, formic acid, water, mixed solvents thereof, etc.

Examples of the catalytic hydrogenation reducing agent include Raney nickel, etc.

The catalytic hydrogenation reducing agent is usually used in an amount of 0.3 to 5 mol per 1 mol of Compound (9).

The reaction is usually carried out at about 60 to 150°C, preferably about 90 to 110°C. The reaction is usually finished in about 1 to about 5 hours.

The reaction for producing Compound (2) from Compound (9) can also be carried out in a suitable solvent in the presence of a reducing agent.

Examples of solvent include tetrahydrofuran, toluene, dichloromethane, 1,2-dichloroethane, mixed solvents thereof, etc.


Examples of the reducing agent include diisobutylaluminium hydride, etc.

The reducing agent is usually used in an amount of at least 0.25 mol to 5 mol, preferably about 0.25 to 2 mol, per 1 mol of Compound (9).

The reaction is usually carried out at about -150 to 0 °C, preferably about -90 to -40°C. The reaction is usually finished in about 1 to about 5 hours.

[0146]

Reaction Scheme 6



(10) (2)

[0147]

wherein R^1 is as defined above; and R^5 is a lower alkyl group.

The reaction for producing Compound (2) from Compound (10) can be carried out in a suitable solvent, in the presence of an acid.

Examples of the solvent include water, diethyl ether, dioxane, tetrahydrofuran, acetonitrile, ethyl acetate, acetone, N,N-dimethylformamide, metanol, ethanol, dichloromethane, toluene, etc.


Examples of the acid include inorganic acids such as hydrochloric acid, sulfuric acid, acetic acid, methanesulfonic acid, *p*-toluenesulfonic acid, trifluoroacetic acid, hydrochloric acid, etc.

The acid is usually used in an amount of 0.1 to 100 mol, preferably about 1 to 30 mol, per 1 mol of Compound (10).

The reaction is usually carried out at about 0 to 100°C. The reaction is usually finished in about 0.5 to about 12 hours.

[0148]

Reaction Scheme 7



(11) (2)

[0149]

wherein R^1 is as defined above.

Compound (2) can be produced by subjecting Compound (11) to the Vilsmeier-Haack reaction in a suitable solvent, in the presence of the Vilsmeier reagent produced by a *N,N*-dimethylformamide and phosphorus oxychloride, etc.

Examples of the solvent include dichloromethane, chloroform, tetrachloromethane, 1,2-dichloroethane, N,N-dimethylformamide, toluene, etc.

The Vilsmeier reagent is usually used in an amount of 1-5 mol, preferably about 1 to 2 mol, per 1 mol of Compound (11).

The reaction is usually carried out at about 0 to 100 °C. The reaction is usually finished in about 0.5 to about 12 hours.

[0150]

Compound (1), intermediate compounds therefor and starting compounds therefor can be produced according to the above-mentioned reaction schemes. They can also be produced according to the synthesis methods described in the Reference Examples and Examples of the present specification and in consideration of the techniques known at the time of filing of the present application or known techniques.

The starting compounds and intermediate compounds shown in the above-mentioned reaction schemes can be subjected, where necessary before being applied to reactions, to protection of a functional group with a suitable protecting group by a known method, and to deprotection of the protecting group by a known method after completion of the reaction.


In addition, compounds in the form in which a solvate (for example, hydrate, ethanolate, etc.) was added to the starting material compounds and object compounds shown in each of the reaction formula are included in each of the formula.

Compound (1) encompasses isomers such as optical isomers, stereoisomers, positional isomers, rotational isomers and the like.

[0151]

Compound (1) encompasses the following compounds: a compound represented by the formula (1A):

[0152]




(1A)

,

[0153]

a compound represented by the formula (1B):

[0154]




(1B)

,

[0155]

and a compound represented by the formula (1C):

[0156]



(1C)

.

[0157]

That is, Compound (1) encompasses 2H-[1,2,3]triazole-4-carbonitrile compound (2H-[1,2,3]triazole-5-carbonitrile compound) (Compound (1A)), 3H-[1,2,3]triazole-4-carbonitrile compound (1H-[1,2,3]triazole-5-carbonitrile compound) (Compound (1B)) and 1H-[1,2,3]triazole-4-carbonitrile compound (3H-[1,2,3]triazole-5-carbonitrile compound) (Compound (1C)).

When R^2 is not a hydrogen atom, Compound (1A) is preferable from among Compound (1).

[0158]

The starting material compounds and object compounds shown in the above-mentioned reaction schemes can be used in an appropriate salt form.

Each of the object compounds obtained according to the above-mentioned reaction schemes can be isolated and purified from the reaction mixture by, for example, after cooling the reaction mixture, performing an isolation procedure such as filtration, concentration, extraction, etc., to separate a crude reaction product, and then subjecting the crude reaction product to a general purification procedure such as column chromatography, recrystallization, etc.

[0159]

Among Compound (1), those having a basic group or groups can easily form salts with common pharmaceutically acceptable acids. Examples of such acids include hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and other inorganic acids, methansulfonic acid, *p*-toluenesulfonic acid, AcOH, citric acid, tartaric acid, maleic acid, fumaric acid, malic acid, lactic acid and other organic acids, etc.

Among Compound (1), those having an acidic group or groups can easily form salts by reacting with pharmaceutically acceptable basic compounds. Examples of such basic compounds include sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, etc.

[0160]

In Compound (1), one or more atoms can be substituted with one or more isotopic atoms. Examples of the isotopic atoms include deuterium (^2H), tritium (^3H), ^{13}C, ^{14}N, ^{18}O, etc.

[0161]

The following is an explanation of pharmaceutical

preparations comprising Compound (1) as an active ingredient. Such pharmaceutical preparations are obtained by formulating Compound (1) into general pharmaceutical preparations, using typically employed diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, etc.

[0162]

The form of such pharmaceutical preparations can be selected from various forms according to the purpose of therapy. Typical examples include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injections (solutions, suspensions, etc.) and the like.

[0163]

To form tablets, any of various known carriers can be used, including, for example, lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose and other excipients; water, EtOH, propanol, simple syrup, glucose solutions, starch solutions, gelatin solutions, carboxymethyl cellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone and other binders; dry starch, sodium alginate, agar powder, laminaran powder, sodium hydrogencarbonate, calcium carbonate, aliphatic acid esters of polyoxyethylenesorbitan, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose and other disintegrants; white sugar, stearin, cacao butter, hydrogenated oils and other disintegration inhibitors; quaternary ammonium base, sodium lauryl sulfate and other absorption promoters; glycerin, starch and other wetting agents; starch, lactose, kaolin, bentonite, colloidal silicic acid and other adsorbents; purified talc, stearates, boric acid powder, polyethylene glycol and other lubricants; etc.

Such tablets may be coated with general coating materials as required, to prepare, for example, sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated

tablets, double- or multi-layered tablets, etc.

To form pills, any of various known carriers can be used, including, for example, glucose, lactose, starch, cacao butter, hydrogenated vegetable oils, kaolin, talc and other excipients; gum arabic powder, tragacanth powder, gelatin, EtOH and other binders; laminaran, agar and other disintegrants; etc.

[0164]

To form suppositories, any of various known carriers can be used, including, for example, polyethylene glycol, cacao butter, higher alcohols, esters of higher alcohols, gelatin, semisynthetic glycerides, etc.

[0165]

To form an injection, a solution, emulsion or suspension is sterilized and preferably made isotonic with blood. Any of various known widely used diluents can be employed to prepare the solution, emulsion or suspension. Examples of such diluents include water, EtOH, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, aliphatic acid esters of polyoxyethylene sorbitan, etc. In this case, the pharmaceutical preparation may contain sodium chloride, glucose or glycerin in an amount sufficient to prepare an isotonic solution, and may contain general solubilizers, buffers, analgesic agents, etc., and further, if necessary, coloring agents, preservatives, flavors, sweetening agents, etc., and/or other medicines.

[0166]

The proportion of Compound (1) in the pharmaceutical preparation is not limited and can be suitably selected from a wide range. It is typically preferable that the pharmaceutical preparation contain Compound (1) in a proportion of 1 to 70 wt%.

[0167]

The route of administration of the pharmaceutical preparation according to the present invention is not limited,

and the preparation can be administered by a route suitable for the form of the preparation, the patient's age and sex, the conditions of the disease, and other conditions.

For example, tablets, pills, solutions, suspensions, emulsions, granules and capsules are administered orally.

[0168]

Injections are intravenously administered singly or as mixed with general injection transfusions such as glucose solutions, amino acid solutions or the like, or singly administered intramuscularly, intracutaneously, subcutaneously or intraperitoneally, as required. Suppositories are administered intrarectally.

[0169]

The dosage of the pharmaceutical preparation is suitably selected according to the method of use, the patient's age and sex, the severity of the disease, and other conditions, and is typically about 0.001 to about 100 mg/kg body weight/day, preferably 0.001 to 50 mg/kg body weight/day, in single or divided doses.

[0170]

Hydrophobic penetrating cations, e.g. triphenylphosphonium derivatives and rodamine 123 derivatives, are known as carriers which lead various molecules toward mitochondria (non-patent documents: Trends Biotechnol 15, 326-330; PLoS One 8, e61902). Because the citric cycle exists within the mitochondria, the citric acid activators are likely to be more potent by means of binding covalently to the hydrophobic penetrating cation or mixing with it.

Examples




[0171]

Working examples of compounds used in the invention are shown below, being followed by the Pharmacological Test results of these compounds.

The following compounds of Reference Examples and Examples are shown as one tautomer, which are not limited, and

the other two tautomers are also encompassed therein. For example, the compound of Example 1 encompasses the three tautomers:

[0172]



and


[0173]

Reference Example 1

Synthesis of 3-bromo-2-oxo-pentanoic acid methyl ester

To a suspension of copper(II) bromide (13.12 g, 58.7 mmol) in AcOEt (80 ml) was added 2-oxo-pentanoic acid methyl ester (2.55 g, 19.6 mmol) in chloroform (40 ml). The reaction mixture was refluxed for 8 hr. After cooling to room temperature, the reaction mixture was filtered through a pad of Celite. The filtrate was concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt = 1/0 to 3/1) to give the title compound (3.30 g, 81%) as a colorless oil

^{1}H-NMR ($CDCl_3$) δ: 1.08 (3H, t, J = 7.3 Hz), 1.95-2.20 (2H, m), 3.93 (3H, s), 4.98 (1H, dd, J = 6.2, 8.1 Hz).

[0174]

Reference Example 2

Synthesis of 2-(6-trifluoromethyl-pyridin-2-yl)-thiazole-4-carboxylic acid ethyl ester

To a solution of 6-trifluoromethyl-pyridine-2-carbothioic acid amide (884 mg, 4.29 mmol) in EtOH (10 ml) was added ethyl bromopyruvate (0.656 ml, 5.23 mmol), and the reaction mixture was reflux for 4 hr. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt = 9/1 to 2/1) to give the title compound (1.13 g, 88%) as a pale yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 1.44 (3H, t, J = 7.1 Hz), 4.47 (2H, q, J =

7.1 Hz), 7.73 (1H, d, J = 7.9 Hz), 8.01 (1H, t, J = 7.9 Hz), 8.31 (1H, s), 8.52 (1H, d, J = 7.9 Hz).

[0175]

Reference Example 3

Synthesis of 2-hexyl-thiazole-4-carboxylic acid ethyl ester

The title compound was obtained using heptanethioic acid amide and ethyl bromopyruvate in the same manner as in Reference Example 2.

^{1}H-NMR ($CDCl_3$) δ: 0.86-0.91 (3H, m), 1.26-1.46 (9H, m), 1.75-1.85 (2H, m), 3.06 (2H, t, J = 7.8 Hz), 4.42 (2H, q, J = 7.1 Hz), 8.05 (1H, s).

[0176]

Reference Example 4

Synthesis of 5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazole-4-carboxylic acid methyl ester

The title compound was obtained using 5-trifluoromethyl-pyridine-2-carbothioic acid amide and 3-bromo-2-oxo-pentanoic acid methyl ester in the same manner as in Reference Example 2.

^{1}H-NMR ($CDCl_3$) δ: 1.42 (3H, t, J = 7.5 Hz), 3.34 (2H, q, J = 7.5 Hz), 3.99 (3H, s), 8.03 (1H, dd, J = 1.9, 8.4 Hz), 8.38 (1H, d, J = 8.4 Hz), 8.84 (1H, d, J = 1.9 Hz).

[0177]

Reference Example 5

Synthesis of 5-ethyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester

The title compound was obtained using 3-trifluoromethyl-thiobenzamide and 3-bromo-2-oxo-pentanoic acid methyl ester in the same manner as in Reference Example 2.

^{1}H-NMR ($CDCl_3$) δ: 1.40 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 3.98 (3H, s), 7.57 (1H, t, J = 7.8 Hz), 7.68 (1H, d, J = 7.8 Hz), 8.11 (1H, d, J = 7.8 Hz), 8.19 (1H, s).

[0178]

Reference Example 6

Synthesis of 5-ethyl-2-(6-trifluoromethyl-pyridin-3-yl)-thiazole-4-carboxylic acid methyl ester

The title compound was obtained using 6-trifluoromethyl-thionicotinamide and 3-bromo-2-oxo-pentanoic acid methyl ester in the same manner as in Reference Example 2.

^{1}H-NMR ($CDCl_3$) δ: 1.42 (3H, t, J = 7.5 Hz), 3.35 (2H, q, J = 7.5 Hz), 3.99 (3H, s), 7.77 (1H, dd, J = 0.4, 8.2 Hz), 8.45-8.48 (1H, m), 9.19 (1H, d, J = 2.0 Hz).

[0179]

Reference Example 7

Synthesis of 5-methyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazole-4-carboxylic acid methyl ester

The title compound was obtained using 5-trifluoromethyl-pyridine-2-carbothioic acid amide and 3-bromo-2-oxo-butyric acid methyl ester in the same manner as in Reference Example 2.

^{1}H-NMR ($CDCl_3$) δ: 2.86 (3H,s), 3.99 (3H, s), 8.03 (1H, dd, J = 1.7, 8.3 Hz), 8.37 (1H, d, J = 8.3 Hz), 8.84-8.85 (1H, m).

[0180]

Reference Example 8

Synthesis of 2-(5-chloro-pyridin-2-yl)-5-methyl-thiazole-4-carboxylic acid methyl ester

The title compound was obtained using 5-chloro-pyridine-2-carbothioic acid amide and 3-bromo-2-oxo-butyric acid methyl ester in the same manner as in Reference Example 2.

^{1}H-NMR ($CDCl_3$) δ: 2.83 (3H, s), 3.97 (3H, s), 7.77 (1H, dd, J = 2.4, 8.5 Hz), 8.20 (1H, dd, J = 0.7, 8.5 Hz), 8.53 (1H, dd, J = 0.7, 2.4 Hz).

[0181]

Reference Example 9

Synthesis of 2-(3-trifluoromethyl-phenoxy)-thiazole-4-carboxylic acid ethyl ester

To a solution of 2-bromo-thiazole-4-carboxylic acid ethyl ester (300 mg, 1.27 mmol) in DMF (6 ml) were added *m*-hydroxybenzotrifluoride (227 mg, 1.398 mmol) and K_2CO_3 (527 mg, 3.81 mmol). The reaction mixture was stirred at 100°C for 5 hr. After cooling to room temperature, the reaction was quenched by addition of water, and the mixture was extracted with AcOEt.

The combined organic layers were washed with water and brine, dried over $MgSO_4$, and concentrated *in vacuo* to give the title compound (395 mg, 98%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 1.38 (3H, t, J = 7.1 Hz), 4.38 (2H, q, J = 7.1 Hz), 7.54-7.58 (4H, m), 7.78 (1H, s).

[0182]

Reference Example 10

Synthesis of 2-(4-chloro-phenylsulfanyl)-thiazole-4-carboxylic acid ethyl ester

To a solution of 2-bromo-thiazole-4-carboxylic acid ethyl ester (250 mg, 1.27 mmol) in DMF (6 ml) were added *p*-chlorobenzenethiol (168 mg, 1.165 mmol) and K_2CO_3 (439 mg, 3.18 mmol). The reaction mixture was stirred at 100°C for 1 hr. After cooling to room temperature, the reaction was quenched by addition of water, and the mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/AcOEt = 1/0 to 3/1) to give the title compound (259 mg, 82%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 1.40 (3H, t, J = 7.1 Hz), 4.42 (2H, q, J = 7.1 Hz), 7.41-7.45 (2H, m), 7.58-7.62 (2H, m), 8.02 (1H, s).

[0183]

Reference Example 11

Synthesis of 5-methyl-2-(3-trifluoromethyl-phenylsulfanyl)-thiazole-4-carboxylic acid methyl ester

The title compound was obtained using 2-bromo-5-methyl-thiazole-4-carboxylic acid methyl ester and 3-(trifluoromethyl)thiophenol in the same manner as in Reference Example 10.

^{1}H-NMR ($CDCl_3$) δ: 2.70 (3H, s), 3.94(3H, s), 7.54 (1H, t, J = 7.8 Hz), 7.67 (1H, d, J = 7.8 Hz), 7.77 (1H, d, J = 7.8 Hz), 7.86 (1H, s).

[0184]

Reference Example 12

Synthesis of 2-[N-(4-chloro-phenyl)-N-methyl-amino]-thiazole-4-carboxylic acid ethyl ester

To a solution of 2-(4-chloro-phenylamino)-thiazole-4-carboxylic acid ethyl ester (116 mg, 0.41 mmol) in DMF (3 ml) was added NaH (21 mg, 0.533 mmol), and the reaction mixture was stirred at room temperature for 30 min, and then MeI (31 µl, 0.49 mmol) was added to the solution. The reaction mixture was stirred at room temperature overnight. After addition of water, the reaction mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/AcOEt = 9/1 to 3/1) to give the title compound (49 mg, 40%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 1.38 (3H, t, J = 7.1 Hz), 3.57 (3H, s), 4.37 (2H, q, J = 7.1 Hz), 7.30-7.36 (2H, m), 7.38-7.42 (3H, m).

[0185]

Reference Example 13

Synthesis of 2-[N-ethyl-N-(3-trifluoromethyl-phenyl)-amino]-thiazole-4-carboxylic acid ethyl ester

The title compound was obtained using 2-(3-trifluoromethyl-phenylamino)-thiazole-4-carboxylic acid ethyl ester and iodoethane in the same manner as in Reference Example 12.

^{1}H-NMR ($CDCl_3$) δ: 1.27 (3H, t, J = 7.1 Hz), 1.38 (3H, t, J = 7.1 Hz), 4.12 (2H, q, J = 7.1 Hz), 4.36 (2H, q, J = 7.1 Hz), 7.38 (1H, s), 7.56-7.57 (3H, m), 7.63 (1H, m).

[0186]

Reference Example 14

Synthesis of 2-(3-chloro-4-fluoro-phenyl)-thiazole-4-carboxylic acid ethyl ester

To a solution of 2-bromo-thiazole-4-carboxylic acid ethyl ester (150 mg, 0.635 mmol) in 1,4-dioxane (3 ml), were added 3-chloro-4-fluorophenylboronic acid (111 mg, 0.635 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride

(51.9 mg, 0.064 mmol) and potassium triphosphate (405 mg, 1.906 mmol). The reaction mixture was refluxed for 8 hr under nitrogen. 1 mol/l HCl was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by flash column chromatography (hexane/AcOEt = 9/1 to 2/1) to give the title compound (113 mg, 62%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 1.44 (3H, t, J = 7.1 Hz), 4.46 (2H, q, J = 7.1 Hz), 7.23 (1H, t, J = 8.6 Hz), 7.87 (1H, ddd, J = 2.3, 4.5, 8.6 Hz), 8.12 (1H, dd, J = 2.3, 6.9 Hz), 8.17 (1H, s).

[0187]

Reference Example 15

Synthesis of 2-(3-trifluoromethoxy-phenyl)-thiazole-4-carboxylic acid ethyl ester

The title compound was obtained using 2-bromo-thiazole-4-carboxylic acid ethyl ester and 3-(trifluoromethoxy)phenylboronic acid in the same manner as in Reference Example 14.

^{1}H-NMR ($CDCl_3$) δ: 1.44 (3H, t, J = 7.1 Hz), 4.46 (2H, q, J = 7.1 Hz), 7.30-7.34 (1H, m), 7.50 (1H, t, J = 8.0 Hz), 7.90-7.94 (2H, m), 8.20 (1H, s).

[0188]

Reference Example 16

Synthesis of 2-(4-chloro-phenyl)-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid ethyl ester

To a solution of p-bromo-alpha,alpha,alpha-trifluorotoluene (168 mg, 0.747 mmol) in toluene (5 ml) were added 2-(4-chloro-phenyl)-thiazole-4-carboxylic acid ethyl ester (200 mg, 0.747 mmol), cesium carbonate (608 mg, 1.868 mmol), *rac*-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (46.5 mg, 0.075 mmol) and $Pd(OAc)_2$ (16.77 mg, 0.075 mmol). The reaction mixture was refluxed for 7 hr under nitrogen. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed

with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by flash column chromatography (hexane/AcOEt = 1/0 to 3/1) to give the title compound (169 mg, 55%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 1.26 (3H, t, J = 7.1 Hz), 4.32 (2H, q, J = 7.1 Hz), 7.43-7.48 (2H, m), 7.65 (2H, d, J = 8.3 Hz), 7.71 (2H, d, J = 8.3 Hz), 7.92-7.97 (2H, m).

[0189]

Reference Example 17

Synthesis of 2-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazole-4-carboxylic acid ethyl ester

To a solution of 2-formyl-thiazole-4-carboxylic acid ethyl ester (130 mg, 0.702 mmol) and (3-trifluoromethyl-benzyl)-phosphonic acid diethyl ester (239 mg, 0.807 mmol) in THF (3 ml) was added *tert*-BuONa (108 mg, 1.123 mmol) at 0°C. The reaction mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by flash column chromatography (hexane/AcOEt = 1/0 to 3/1) to give the title compound (34 mg, 15%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 1.43 (3H, t, J = 7.1 Hz), 4.46 (2H, q, J = 7.1 Hz), 7.45-7.61 (4H, m), 7.72 (1H, d, J = 7.5 Hz), 7.77 (1H, s), 8.13 (1H, s).

[0190]

Reference Example 18

Synthesis of 2-(3-trifluoromethyl-phenylamino)-thiazole-4-carboxylic acid ethyl ester

A mixture of 2-bromo-thiazole-4-carboxylic acid ethyl ester (300 mg, 1.271 mmol) and *m*-aminobenzotrifluoride (1 ml) was stirred for 6 hr at 140°C. 1 N HCl was added to the reaction mixture, and the mixture was extracted with Et_2O. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by

flash column chromatography (hexane/AcOEt = 4/1 to 3/2) to give the title compound (342 mg, 85%) as a pale yellow solid.
^{1}H-NMR ($CDCl_3$) δ: 1.39 (3H, t, J = 7.1 Hz), 4.38 (2H, q, J = 7.1 Hz), 7.35 (1H, d, J = 7.5 Hz), 7.49 (1H, t, J = 7.8 Hz), 7.53-7.62 (3H, m), 7.81 (1H, s).

[0191]

Reference Example 19

Synthesis of [2-(6-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-methanol

To a suspension of 2-(6-trifluoromethyl-pyridin-2-yl)-thiazole-4-carboxylic acid ethyl ester (500 mg, 1.65 mmol) and $NaBH_4$ (313 mg, 8.27 mmol) in DME (6 ml) was added dropwise MeOH (2.68 ml) at 50°C. The reaction mixture was stirred for 1.5 hr at 65°C. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo* to give the title compound (442 mg, quant.) as a white solid.
^{1}H-NMR ($CDCl_3$) δ: 2.22 (1H, t, J = 5.9 Hz), 4.86 (2H, d, J = 5.9 Hz), 7.37 (1H, t, J = 0.8 Hz), 7.69 (1H, dd, J = 0.8, 7.8 Hz), 7.97 (1H, t, J = 7.8 Hz), 8.35 (1H, d, J = 7.8 Hz).

[0192]

Reference Example 20

Synthesis of [2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol

The title compound was obtained using 2-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 19.
^{1}H-NMR ($CDCl_3$) δ: 2.52 (1H, br), 4.85(2H, s), 7.25 (1H, s), 7.56 (1H, t, J = 7.8 Hz), 7.68 (1H, d, J = 7.8 Hz), 8.10 (1H, d, J = 7.8 Hz), 8.22 (1H, s).

[0193]

Reference Example 21

Synthesis of [2-(3-chloro-4-fluoro-phenyl)-thiazol-4-yl]-methanol

The title compound was obtained using 2-(3-chloro-4-fluoro-phenyl)-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 19.

^{1}H-NMR ($CDCl_3$) δ: 2.10-2.61(1H, br), 4.83(2H, s), 7.18-7.24 (2H, m), 7.79 (1H, ddd, J = 2.3, 4.5, 8.6 Hz), 8.01 (1H, dd, J = 2.3, 6.9 Hz).

[0194]

Reference Example 22

Synthesis of [2-(4-chloro-phenylsulfanyl)-thiazol-4-yl]-methanol

The title compound was obtained using 2-(4-chloro-phenylsulfanyl)-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 19.

^{1}H-NMR ($CDCl_3$) δ: 2.13-2.19 (1H, br), 4.73 (2H, d, J = 5.1 Hz), 7.11 (1H, s), 7.38-7.41(2H, m), 7.54-7.57 (2H, m).

[0195]

Reference Example 23

Synthesis of [5-ethyl-2-(6-trifluoromethyl-pyridin-3-yl)-thiazol-4-yl]-methanol

The title compound was obtained using 5-ethyl-2-(6-trifluoromethyl-pyridin-3-yl)-thiazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 19.

^{1}H-NMR ($CDCl_3$) δ: 1.36 (3H, t, J = 7.5 Hz), 2.34 (1H, t, J = 5.7 Hz), 2.92 (2H, q, J = 7.5 Hz), 4.76 (2H, d, J = 5.7 Hz), 7.75 (1H, d, J = 8.2 Hz), 8.37 (1H, dd, J = 1.8, 8.2 Hz), 9.19 (1H, d, J = 1.8 Hz).

[0196]

Reference Example 24

Synthesis of [5-methyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-methanol

The title compound was obtained using 5-methyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 19.

^{1}H-NMR ($CDCl_3$) δ: 2.33 (1H, brs), 2.53 (3H, s), 4.75 (2H, d, J = 4.7 Hz), 7.99-8.01 (1H, m), 8.25 (1H, d, J = 8.3 Hz), 8.82-

8.83 (1H, m).

[0197]

Reference Example 25

Synthesis of [2-(5-chloro-pyridin-2-yl)-5-methyl-thiazol-4-yl]-methanol

The title compound was obtained using 2-(5-chloro-pyridin-2-yl)-5-methyl-thiazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 19.

^{1}H-NMR ($CDCl_3$) δ: 2.30 (1H, t, J = 5.8 Hz), 2.50 (3H, s), 4.73 (2H, d, J = 5.8 Hz), 7.74 (1H, dd, J = 2.4, 8.5 Hz), 8.08 (1H, dd, J = 0.6, 8.5 Hz), 8.52 (1H, dd, J = 0.6, 2.4 Hz).

[0198]

Reference Example 26

Synthesis of [2-(4-chloro-benzyloxy)-thiazol-4-yl]-methanol

To a solution of 4-chlorobenzyl alcohol (302 mg, 2.12 mmol) in THF (3 ml) was added NaH (119 mg, 2.97 mmol), and the reaction mixture was stirred at room temperature for 30 min. Then 2-bromo-thiazole-4-carboxylic acid ethyl ester (200 mg, 0.847 mmol) was added to the solution. The mixture was refluxed for 2 hr. The reaction was quenched by addition of water, and then the mixture was washed with AcOEt. The aqueous solution was acidified with HCl and extracted with AcOEt. The combined organic layers was washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. Triethylamine (0.142 ml, 1.02 mmol) and THF (20 ml) were added to the residue and then ethyl chlorocarbonate (0.089 ml, 0.932 mmol) was added to the solution at 0°C, and the mixture was stirred for 30 min. After filtration of precipitate, $NaBH_4$ (96 mg, 2.54 mmol) in water (1 ml) was added to the filtrate at 0°C. The mixture was stirred for 1 hr at same temperature. The reaction was quenched by addition of water, and the mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/AcOEt = 9/1 to 3/1) to give the title compound (118 mg, 54%) as a

colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 2.02-2.06 (1H, m), 4.58 (2H, d, J = 5.4 Hz), 5.40 (2H, s), 6.56-6.58 (1H, m), 7.34-7.41 (4H, m).

[0199]

Reference Example 27

Synthesis of [5-bromo-2-(4-chloro-phenyl)-thiazol-4-yl]-methanol

To a solution of [2-(4-chloro-phenyl)-thiazol-4-yl]-methanol (462 mg, 2.05 mmol) in DMF (4 ml) was added NBS (383 mg, 2.15 mmol). The reaction mixture was stirred overnight at room temperature. Water was added to the reaction mixture and the precipitate was filtered. The obtained solid was dissolved in AcOEt, and the solution was washed with water and brine, dried over $MgSO_4$, and concentrated *in vacuo* to give the title compound (560 mg, 90%) as a pale yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 2.33-2.38 (1H, m), 4.75 (2H, d, J = 6.1 Hz), 7.40-7.44 (2H, m), 7.78-7.82(2H, m).

[0200]

Reference Example 28

Synthesis of [5-bromo-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol

The title compound was obtained using [2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 27.

^{1}H-NMR ($CDCl_3$) δ: 2.43 (1H, t, J = 6.1 Hz), 4.77 (2H, d, J = 6.1 Hz), 7.70 (2H, d, J = 8.2 Hz), 7.98 (2H, d, J = 8.2 Hz).

[0201]

Reference Example 29

Synthesis of [5-bromo-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol

The title compound was obtained using [2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 27.

^{1}H-NMR ($CDCl_3$) δ: 2.41 (1H, t, J = 6.1 Hz), 4.77 (2H, d, J = 6.1 Hz), 7.58 (1H, t, J = 7.8 Hz), 7.70 (1H, d, J = 7.8 Hz),

8.02 (1H, d, J = 7.8 Hz), 8.15 (1H, s).

[0202]

Reference Example 30

Synthesis of [5-bromo-2-(4-chloro-phenoxy)-thiazol-4-yl]-methanol

The title compound was obtained using [2-(4-chloro-phenoxy)-thiazol-4-yl]-methanol in the same manner as in Reference Example 27.

^{1}H-NMR ($CDCl_3$) δ: 2.07 (1H, t, J = 6.3 Hz), 4.54 (2H, d, J = 6.3 Hz), 7.19-7.24 (2H, m), 7.36-7.41 (2H, m).

[0203]

Reference Example 31

Synthesis of [5-bromo-2-(3-chloro-4-fluoro-phenyl)-thiazol-4-yl]-methanol

The title compound was obtained using [2-(3-chloro-4-fluoro-phenyl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 27.

^{1}H-NMR ($CDCl_3$) δ: 2.48 (1H, brs), 4.75 (2H, s), 7.21 (1H, t, J = 8.6 Hz), 7.71 (1H, ddd, J = 2.3, 4.4, 8.6 Hz), 7.96 (1H, dd, J = 2.3, 6.9 Hz).

[0204]

Reference Example 32

Synthesis of [5-bromo-2-(6-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-methanol

The title compound was obtained using [2-(6-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 27.

^{1}H-NMR ($CDCl_3$) δ: 2.35 (1H, t, J = 6.0 Hz), 4.78 (2H, d, J = 6.0 Hz), 7.70 (1H, dd, J = 0.7, 7.9 Hz), 7.99 (1H, t, J = 7.9 Hz), 8.31 (1H, d, J = 7.9 Hz).

[0205]

Reference Example 33

Synthesis of [5-propyl-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol

To a solution of [5-((E)-1-propen-1-yl)-2-(3-

trifluoromethyl-phenyl)-thiazol-4-yl]-methanol (127 mg, 0.424 mmol) in EtOH (4 ml) was added 5% *Pd/C*-ethylenediamine complex (20 mg). The reaction mixture was stirred at room temperature for 1 hr under hydrogen. After filtration, the filtrate was concentrated to give the title compound (126 mg, 99%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 1.01 (3H, t, J = 7.3 Hz), 1.66-1.75 (2H, m), 2.40 (1H, t, J = 5.9 Hz), 2.83 (2H, t, J = 7.5 Hz), 4.73 (2H, d, J = 5.9 Hz), 7.55 (1H, t, J = 7.8 Hz), 7.65 (1H, d, J = 7.8 Hz), 8.05 (1H, d, J = 7.8 Hz), 8.17 (1H, s).

[0206]

Reference Example 34

Synthesis of [2-(4-chloro-phenyl)-5-ethyl-thiazol-4-yl]-methanol

To a solution of [2-(4-chloro-phenyl)-5-vinyl-thiazol-4-yl]-methanol (72 mg, 0.286 mmol) in EtOH (4 ml) was added 5% *Pd/C*-ethylenediamine complex (20 mg). The reaction mixture was stirred at room temperature for 3 hr under hydrogen. After filtration, the filtrate was concentrated to give the title compound (60 mg, 83%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 1.32 (3H, t, J = 7.5 Hz), 2.44-2.68 (1H, br), 2.86 (2H, q, J = 7.5 Hz), 4.71 (2H, s), 7.37-7.40 (2H, m), 7.80-7.84 (2H, m).

[0207]

Reference Example 35

Synthesis of [2-(4-chloro-phenyl)-5-propyl-thiazol-4-yl]-methanol

The title compound was obtained using [2-(4-chloro-phenyl)-5-((E)-1-propen-1-yl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 34.

^{1}H-NMR ($CDCl_3$) δ: 1.00 (3H, t, J = 7.3 Hz), 1.64-1.74 (2H, m), 2.43-2.49 (1H, br), 2.80 (2H, t, J = 7.5 Hz), 4.70 (2H, d, J = 4.0 Hz), 7.37-7.40 (2H, m), 7.80-7.84 (2H, m).

[0208]

Reference Example 36

Synthesis of [2-(4-chloro-phenoxy)-5-ethyl-thiazol-4-yl]-methanol

The title compound was obtained using [2-(4-chloro-phenoxy)-5-vinyl-thiazol-4-yl]-methanol in the same manner as in Reference Example 34.

^{1}H-NMR ($CDCl_3$) δ: 1.24 (3H, t, J = 7.6 Hz), 2.09-2.13 (1H, m), 2.73 (2H, q, J = 7.6 Hz), 4.50 (2H, d, J = 5.4 Hz), 7.19-7.23 (2H, m), 7.35-7.37 (2H, m).

[0209]

Reference Example 37

Synthesis of [2-(4-chloro-phenyl)-5-isobutyl-thiazol-4-yl]-methanol

The title compound was obtained using [2-(4-chloro-phenyl)-5-(2-methyl-1-propen-1-yl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 34.

^{1}H-NMR ($CDCl_3$) δ: 0.98 (6H, d, J = 6.6 Hz), 1.84-1.91 (1H, m), 2.29-2.60 (1H, br), 2.69 (2H, d, J = 7.2 Hz), 4.69 (2H, s), 7.38-7.41 (2H, m), 7.82-7.85 (2H, m).

[0210]

Reference Example 38

Synthesis of [2-(4-chloro-phenyl)-5-methyl-thiazol-4-yl]-methanol

To the solution of [5-bromo-2-(4-chloro-phenyl)-thiazol-4-yl]-methanol (200 mg, 0.657 mmol) in 1,4-dioxane (4 ml) were added methylboronic acid (59.0 mg, 0.985 mmol), $Pd(Ph_3P)_4$ (76 mg, 0.066 mmol) and K_2CO_3 (272 mg, 1.970 mmol). The reaction mixture was refluxed for 16 hr under nitrogen. After evaporation, water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue obtained was purified by flash column chromatography (hexane/AcOEt = 4/1 to 1/2) to give the title compound (130 mg, 83%) as a pale yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 2.42 (1H, t, J = 5.8 Hz), 2.47 (3H, s), 4.71 (2H, d, J = 5.8 Hz), 7.36-7.41 (2H, m), 7.80-7.83 (2H, m).

[0211]

Reference Example 39

Synthesis of [5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 38.

^{1}H-NMR ($CDCl_3$) δ: 2.45-2.50 (4H, m), 4.73 (2H, d, J = 5.8 Hz), 7.67 (2H, d, J = 8.2 Hz), 7.99 (2H, d, J = 8.2 Hz).

[0212]

Reference Example 40

Synthesis of [5-methyl-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 38.

^{1}H-NMR ($CDCl_3$) δ: 2.49 (3H, s), 2.56 (1H, t, J = 5.9 Hz), 4.73 (2H, d, J = 5.9 Hz), 7.54 (1H, t, J = 7.8 Hz), 7.64 (1H, d, J = 7.8 Hz), 8.03 (1H, d, J = 7.8 Hz), 8.15 (1H, s).

[0213]

Reference Example 41

Synthesis of [2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(3-chloro-4-fluoro-phenyl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 38.

^{1}H-NMR ($CDCl_3$) δ: 2.38 (1H, t, J = 5.8 Hz), 2.48 (3H, s), 4.71 (2H, d, J = 5.8 Hz), 7.18 (1H, t, J = 8.6 Hz), 7.73 (1H, ddd, J = 2.3, 4.5, 8.6 Hz), 7.97 (1H, dd, J = 2.3, 7.0 Hz).

[0214]

Reference Example 42

Synthesis of [5-methyl-2-(6-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(6-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-methanol in the

same manner as in Reference Example 38.

^{1}H-NMR ($CDCl_3$) δ: 2.30 (1H, t, J = 5.8 Hz), 2.51 (3H, s), 4.74 (2H, d, J = 5.8 Hz), 7.65 (1H, dd, J = 0.8, 7.8 Hz), 7.94 (1H, t, J = 7.8 Hz), 8.30 (1H, d, J = 7.8 Hz).

[0215]

Reference Example 43

Synthesis of [2-(4-chloro-phenyl)-5-vinyl-thiazol-4-yl]-methanol

To a solution of [5-bromo-2-(4-chloro-phenyl)-thiazol-4-yl]-methanol (200 mg, 0.657 mmol) in DME/H_2O= 3/1 (4 ml) were added 1,1'-bis(diphenylphosphino)ferrocene-palladium dichloride (16.21 mg, 0.020 mmol), sodium phosphate, tribasic (374 mg, 0.985 mmol) and vinylboronic acid pinacol cyclic ester (0.148 ml, 0.854 mmol). The reaction mixture was refluxed for 8 hr under nitrogen. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by flash column chromatography (hexane/AcOEt = 4/1 to 1/2) to give the title compound (104 mg, 63%) as a pale yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 2.52 (1H, t, J = 5.9 Hz), 4.79 (2H, d, J = 5.9 Hz), 5.35 (1H, d, J = 10.9 Hz), 5.56 (1H, d, J = 17.2 Hz), 6.87 (1H, dd, J = 10.9, 17.2 Hz), 7.40-7.43 (2H, m), 7.83-7.88 (2H, m).

[0216]

Reference Example 44

Synthesis of [2-(4-chloro-phenyl)-5-((E)-1-propen-1-yl)-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(4-chloro-phenyl)-thiazol-4-yl]-methanol and trans-1-propen-1-ylboronic acid in the same manner as in Reference Example 43.

^{1}H-NMR ($CDCl_3$) δ: 1.92 (3H, dd, J = 1.7, 6.7 Hz), 2.19-2.66 (1H, br), 4.76 (2H, s), 6.07 (1H, dq, J = 15.4, 6.7 Hz), 6.55 (1H, dq, J = 15.4, 1.7 Hz), 7.37-7.42 (2H, m), 7.81-7.86 (2H, m).

[0217]

Reference Example 45

Synthesis of [5-((E)-1-propen-1-yl)-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol and trans-1-propen-1-ylboronic acid in the same manner as in Reference Example 43.

^{1}H-NMR ($CDCl_3$) δ: 1.93 (3H, dd, J = 1.7, 6.7 Hz), 2.39 (1H, brs), 4.76-4.81 (2H, m), 6.11 (1H, dq, J = 15.4, 6.7 Hz), 6.57 (1H, dq, J = 15.4, 1.7 Hz), 7.55 (1H, t, J = 7.8 Hz), 7.66 (1H, d, J = 7.8 Hz), 8.06 (1H, d, 7.8 Hz), 8.18 (1H, s).

[0218]

Reference Example 46

Synthesis of [2-(4-chloro-phenoxy)-5-vinyl-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(4-chloro-phenoxy)-thiazol-4-yl]-methanol and vinylboronic acid pinacol ester in the same manner as in Reference Example 43.

^{1}H-NMR ($CDCl_3$) δ: 2.14 (1H, t, J = 6.2 Hz), 4.58 (2H, q, J = 6.2 Hz), 5.19 (1H, d, J = 10.9 Hz), 5.31 (1H, d, J = 17.1 Hz), 6.77 (1H, dd, J = 10.9, 17.1 Hz), 7.22-7.25 (2H, m), 7.37-7.40 (2H, m).

[0219]

Reference Example 47

Synthesis of [2-(4-chloro-phenyl)-5-(2-methyl-1-propen-1-yl)-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(4-chloro-phenyl)-thiazol-4-yl]-methanol and 2,2-dimethylethenylboronic acid pinacol ester in the same manner as in Reference Example 43.

^{1}H-NMR ($CDCl_3$) δ: 1.93 (3H, s), 1.97 (3H, s), 2.65 (1H, t, J = 5.8 Hz), 4.73 (2H, d, J = 5.8 Hz), 6.32 (1H, s), 7.38-7.41 (2H, m), 7.83-7.86 (2H, s).

[0220]

Reference Example 48

Synthesis of 2-(4-chloro-phenylsulfanyl)-thiazole-4-carbaldehyde

To a solution of [2-(4-chloro-phenylsulfanyl)-thiazol-4-yl]-methanol (80 mg, 0.310 mmol) in DMSO (2 ml) was added IBX (104 mg, 0.372 mmol). The reaction mixture was stirred for 2 hr at room temperature. Water and AcOEt were added to the reaction mixture, and the precipitate was filtered. The filtrate was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by flash column chromatography (hexane/AcOEt = 1/0 to 3/1) to give the title compound (62 mg, 78%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 7.43-7.47 (2H, m), 7.60-7.64 (2H, m), 8.02 (1H, s), 9.95 (1H, s).

[0221]

Reference Example 49

Synthesis of 2-(4-chloro-phenyl)-5-propyl-thiazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-phenyl)-5-propyl-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 1.04 (3H, t, J = 7.3 Hz), 1.71-1.83 (2H, m), 3.26 (2H, t, J = 7.6 Hz), 7.41-7.46 (2H, m), 7.85-7.90 (2H, m), 10.19 (1H, s).

[0222]

Reference Example 50

Synthesis of 5-propyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde

The title compound was obtained using [5-propyl-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 1.05 (3H, t, J = 7.3 Hz), 1.76-1.83 (2H, m), 3.28 (2H, t, J = 7.6 Hz), 7.60 (1H, t, J = 7.8 Hz), 7.71 (1H, d, J = 7.8 Hz), 8.11 (1H, d, J = 7.8 Hz), 8.21 (1H, s), 10.22 (1H, s).

[0223]

Reference Example 51

Synthesis of 2-(4-chloro-phenoxy)-5-ethyl-thiazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-phenoxy)-5-ethyl-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 1.31 (3H, t, J = 7.5 Hz), 3.20 (2H, q, J = 7.5 Hz), 7.25-7.28 (2H, m), 7.37-7.40 (2H, m), 9.98 (1H, s).

[0224]

Reference Example 52

Synthesis of 2-(4-chloro-phenyl)-5-isobutyl-thiazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-phenyl)-5-isobutyl-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 1.02 (6H, d, J = 6.6 Hz), 1.95-2.03 (1H, m), 3.17 (2H, d, J = 7.2 Hz), 7.42-7.45 (2H, m), 7.86-7.89 (2H, m), 10.18 (1H, s).

[0225]

Reference Example 53

Synthesis of 5-ethyl-2-(6-trifluoromethyl-pyridin-3-yl)-thiazole-4-carbaldehyde

The title compound was obtained using [5-ethyl-2-(6-trifluoromethyl-pyridin-3-yl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 1.42 (3H, t, J = 7.5 Hz), 3.37 (2H, q, J = 7.5 Hz), 7.80 (1H, d, J = 8.2 Hz), 8.44 (1H, dd, J = 1.8, 8.2 Hz), 9.23 (1H, d, J = 1.8 Hz), 10.24 (1H, s).

[0226]

Reference Example 54

Synthesis of 5-methyl-2-(6-trifluoromethyl-pyridin-2-yl)-thiazole-4-carbaldehyde

The title compound was obtained using [5-methyl-2-(6-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-methanol in the

same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 2.87 (3H, s), 7.72 (1H, dd, J = 0.7, 7.9 Hz), 8.01 (1H, t, J = 7.9 Hz), 8.40 (1H, d, J = 7.9 Hz), 10.21 (1H, s).

[0227]

Reference Example 55

Synthesis of 5-methyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazole-4-carbaldehyde

The title compound was obtained using [5-methyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 2.89 (3H, s), 8.05-8.08 (1H, m), 8.35 (1H, d, J = 8.3 Hz), 8.85-8.86 (1H, m), 10.22 (1H, s).

[0228]

Reference Example 56

Synthesis of 2-(5-chloro-pyridin-2-yl)-5-methyl-thiazole-4-carbaldehyde

The title compound was obtained using [2-(5-chloro-pyridin-2-yl)-5-methyl-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 2.86 (3H, s), 7.80 (1H, dd, J = 2.3, 8.5 Hz), 8.17 (1H, dd, J = 0.7, 8.5 Hz), 8.55 (1H, dd, J = 0.7, 2.3 Hz), 10.19 (1H, s).

[0229]

Reference Example 57

Synthesis of 5-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde

The title compound was obtained using [5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 2.87 (3H, s), 7.72 (2H, d, J = 8.2 Hz), 8.05 (2H, d, J = 8.2 Hz), 10.22 (1H, s).

[0230]

Reference Example 58

Synthesis of 5-methyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-

carbaldehyde

The title compound was obtained using [5-methyl-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 2.87 (3H, s), 7.60 (1H, t, J = 7.8 Hz), 7.71 (1H, d, J = 7.8 Hz), 8.09 (1H, d, J = 7.8 Hz), 8.20 (1H, s), 10.22 (1H, s).

[0231]

Reference Example 59

Synthesis of 2-(4-chloro-phenyl)-5-methyl-thiazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-phenyl)-5-methyl-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 2.84 (3H, s), 7.41-7.46 (2H, m), 7.84-7.89 (2H, m), 10.20 (1H, s).

[0232]

Reference Example 60

Synthesis of 2-(4-chloro-benzyloxy)-thiazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-benzyloxy)-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 5.52 (2H, s), 7.36-7.43 (4H, m), 7.64 (1H, s), 9.74 (1H, s).

[0233]

Reference Example 61

Synthesis of 2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazole-4-carbaldehyde

The title compound was obtained using [2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 2.85 (3H, s), 7.23 (1H, t, J = 8.6 Hz), 7.78 (1H, ddd, J = 2.3, 4.4, 8.6 Hz), 8.03 (1H, dd, J = 2.3, 6.9 Hz), 10.19 (1H, s).

[0234]

Reference Example 62

Synthesis of 2-(4-chloro-phenyl)-5-ethyl-thiazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-phenyl)-5-ethyl-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 7.41-7.46 (2H, m), 7.85-7.90 (2H, m), 10.19 (1H, s).

[0235]

Reference Example 63

Synthesis of 5-methyl-2-(3-trifluoromethyl-phenylsulfanyl)-thiazole-4-carbaldehyde

To a suspension of 5-methyl-2-(3-trifluoromethyl-phenylsulfanyl)-thiazole-4-carboxylic acid methyl ester (122 mg, 0.366 mmol) and $NaBH_4$ (69 mg, 8.27 mmol) in DME (4 ml) was added dropwise MeOH (0.38 ml) at 60°C. The reaction mixture was stirred for 1.5 hr at 60°C. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over Na_2SO_4, and concentrated *in vacuo*.

To a solution of the residue in DMSO (2 ml) was added IBX (123 mg, 0.439 mmol). The reaction mixture was stirred overnight at room temperature. Water and AcOEt were added to the reaction mixture, and the precipitate was filtered. The filtrate was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by flash column chromatography (hexane/AcOEt = 1/0 to 4/1) to give the title compound (86 mg, 77%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 2.73 (3H, s), 7.56 (1H, t, J = 7.8 Hz), 7.68 (1H, d, J = 7.8 Hz), 7.80 (1H, d, J = 7.8 Hz), 7.88 (1H, s), 10.08 (1H, s).

[0236]

Reference Example 64

Synthesis of 2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-

thiazole-4-carbaldehyde

The title compound was obtained using 2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 7.38(1H, d, J = 16.2 Hz), 7.51-7.63 (3H, m), 7.74 (1H, d, J = 7.6 Hz), 7.80 (1H, s), 8.13 (1H, s), 10.06 (1H, s).

[0237]

Reference Example 65

Synthesis of 2-(3-trifluoromethoxy-phenyl)-thiazole-4-carbaldehyde

The title compound was obtained using 2-(3-trifluoromethoxy-phenyl)-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 7.34-7.37 (1H, m), 7.53 (1H, t, J = 8.3 Hz), 7.90-7.93 (2H, m), 8.21 (1H, s), 10.12 (1H, s).

[0238]

Reference Example 66

Synthesis of 2-(3-trifluoromethyl-phenoxy)-thiazole-4-carbaldehyde

The title compound was obtained using 2-(3-trifluoromethyl-phenoxy)-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 7.56-7.61 (4H, m), 7.78 (1H, s), 9.79 (1H, s).

[0239]

Reference Example 67

Synthesis of 2-[N-(4-chloro-phenyl)-N-methyl-amino]-thiazole-4-carbaldehyde

The title compound was obtained using 2-[N-(4-chloro-phenyl)-N-methyl-amino]-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 3.57 (3H, s), 7.31-7.36 (2H, m), 7.40-7.44 (3H, m), 9.74 (1H, s).

[0240]

Reference Example 68

Synthesis of 2-(4-chloro-phenyl)-5-(4-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde

The title compound was obtained using 2-(4-chloro-phenyl)-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 7.46-7.50 (2H, m), 7.72-7.79 (4H, m), 7.95-7.99 (2H, m), 10.07 (1H, s).

[0241]

Reference Example 69

Synthesis of 2-[N-ethyl-N-(3-trifluoromethyl-phenyl)-amino]-thiazole-4-carbaldehyde

The title compound was obtained using 2-[N-ethyl-N-(3-trifluoromethyl-phenyl)-amino]-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 1.29(3H, t, J = 7.1 Hz), 4.10 (2H, q, J = 7.1 Hz), 7.39 (1H, s), 7.57-7.63 (4H, m), 9.75 (1H, s).

[0242]

Reference Example 70

Synthesis of 2-hexyl-thiazole-4-carbaldehyde

The title compound was obtained using 2-hexyl-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 0.87-0.92 (3H, m), 1.29-1.44 (6H, m), 1.78-1.88 (2H, m), 3.06 (2H, t, J = 7.8 Hz), 8.07 (1H, s), 10.00 (1H, s).

[0243]

Reference Example 71

Synthesis of 5-ethyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde

The title compound was obtained using 5-ethyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 1.40 (3H, t, J = 7.5 Hz), 3.34 (2H, q, J = 7.5 Hz), 7.59 (1H, t, J = 7.8 Hz), 7.71 (1H, d, J = 7.8 Hz), 8.11 (1H, d, J = 7.8 Hz), 8.21 (1H, s), 10.22 (1H, s).

[0244]

Reference Example 72

Synthesis of 5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazole-4-carbaldehyde

The title compound was obtained using 5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 1.42 (3H, t, J = 7.5 Hz), 3.36 (2H, q, J = 7.5 Hz), 8.07 (1H, dd, J = 2.1, 8.3 Hz), 8.35 (1H, d, J = 8.3 Hz), 8.86 (1H, d, J = 2.1 Hz), 10.21 (1H, s).

[0245]

Reference Example 73

Synthesis of 5-bromo-2-(4-chloro-phenyl)-thiazole-4-carbaldehyde

To a solution of 2-(4-chloro-phenyl)-thiazole-4-carbaldehyde (600 mg, 2.68 mmol) in CH_3CN (10 ml) was added NBS (1.196 g, 6.44 mmol). The reaction mixture was stirred for 1 hr at 50°C. Additional NBS (645 mg, 3.62 mmol) was added to solution, and the mixture was refluxed for 1 hr. After concentration, the residue was purified by flash column chromatography (hexane/AcOEt = 9/1 to 2/1) to give the title compound (89 mg, 11%) as pale yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 7.44-7.48 (2H, m), 7.85-7.89 (2H, m), 10.10 (1H, s).

[0246]

Reference Example 74

Synthesis of 2-(4-chloro-phenyl)-5-methoxy-thiazole-4-carbaldehyde

To a solution of 5-bromo-2-(4-chloro-phenyl)-thiazole-4-carbaldehyde (89 mg, 0.294 mmol) in MeOH (4 ml) was added sodium methoxide (284 mg, 1.471 mmol). The reaction mixture was stirred overnight at room temperature. Water was added to the reaction mixture and the precipitate was filtered. The obtained solid was dissolved in AcOEt, and the solution was dried over $MgSO_4$, and concentrated *in vacuo*. The residue was

purified by flash column chromatography (hexane/AcOEt = 2/1 to 1/1) to give the title compound (42 mg, 56%) as a white solid. ^{1}H-NMR ($CDCl_3$) δ: 4.21 (3H, s), 7.41-7.43 (2H, m), 7.80-7.83 (2H, m), 10.01 (1H, s).

[0247]

Reference Example 75

Synthesis of 2-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazole-5-carboxylic acid ethyl ester

To a solution of ethyl 2-bromothiazole-5-carboxylate (500 mg, 2.118 mmol) in DME (10 ml) were added trans-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester (663 mg, 2.224 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium dichloride (86 mg, 0.106 mmol) and 2M sodium carbonate solution (3.18 ml, 6.35 mmol). The reaction mixture was stirred for 4 hr at 80°C under nitrogen. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by flash column chromatography (hexane/AcOEt = 1/0 to 3/1) to give the title compound (512 mg, 74%) as a white solid. ^{1}H-NMR ($CDCl_3$) δ: 1.40 (3H, t, J = 7.1 Hz), 4.39 (2H, q, J = 7.1 Hz), 7.32 (1H, d, J = 16.1 Hz), 7.53-7.62 (3H, m), 7.72-7.80 (2H, m), 8.39 (1H, s).

[0248]

Reference Example 76

Synthesis of {2-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazol-5-yl}-methanol

To a suspension of $LiAlH_4$ (59 mg, 1.564 mmol) in THF (10 ml) was added dropwise 2-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazole-5-carboxylic acid ethyl ester (512 mg, 1.564 mmol) in THF (4 ml) at 0°C. 59 µl of water, 59 µl of 15% aqueous NaOH solution and 177 µl of water were added to the reaction mixture at 0°C. After filtration of the precipitate, the filtrate was concentrated *in vacuo* to give the title compound (410 mg, 92%) as a yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 2.13-2.17 (1H, m), 4.90 (2H, d, J = 5.3 Hz), 7.30 (1H, d, J = 16.3 Hz), 7.41 (1H, d, J = 16.3 Hz), 7.47-7.59 (2H, m), 7.68-7.76 (2H, m), 7.76 (1H, s).

[0249]

Reference Example 77

Synthesis of 2-trifluoromethyl-6-vinyl-pyridine

To a solution of 545 mg of 2-chloro-6-trifluoromethylpyridine and 554 mg of vinylboronic acid pinacol cyclic ester in 12 mL of 1,2-dimethoxyethane/water (3/1) were added 122 mg of 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride CH_2Cl_2 complex and 1.71 g of sodium phosphate tribasic dodecahydrate. The reaction mixture was stirred at 80°C under argon for 6 hr. The reaction was quenched by addition of water (15 mL), and extracted with AcOEt. The organic solution was dried over Na_2SO_4. After concentration, the dark red oil was purified by silica gel column (hexane -> hexane/AcOEt 10%) to give the title compound (336 mg, 65%) as colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 5.60 (1H, d, J = 10.8 Hz), 6.31 (1H, d, J = 17.4 Hz), 6.87 (1H, dd, J = 10.8, 17.4 Hz), 7.53 (1H, d, J = 7.9 Hz), 7.54 (1H, d, J = 7.9 Hz), 7.82 (1H, t, J = 7.9 Hz).

[0250]

Reference Example 78

Synthesis of 4-trifluoromethyl-2-vinyl-pyridine

The title compound was obtained using 2-chloro-4-(trifluoromethyl)pyridine in the same manner as in Reference Example 77.

^{1}H-NMR ($CDCl_3$) δ: 5.61 (1H, d, J = 10.8 Hz), 6.31 (1H, d, J = 17.4 Hz), 6.87 (1H, dd, J = 10.8, 17.4 Hz), 7.37 (1H, d, J = 5.1 Hz), 7.53 (1H, s), 8.75 (1H, d, J = 5.1 Hz).

[0251]

Reference Example 79

Synthesis of 4-trifluoromethyl-2-vinyl-pyrimidine

The title compound was obtained using 2-chloro-4-(trifluoromethyl)pyrimidine in the same manner as in Reference

Example 77.

^{1}H-NMR ($CDCl_3$) δ: 5.86 (1H, d, J = 10.4 Hz), 6.77 (1H, d, J = 17.3 Hz), 6.94 (1H, dd, J = 10.4, 17.3 Hz), 7.45 (1H, d, J = 5.0 Hz), 8.94 (1H, d, J = 5.0 Hz).

[0252]

Reference Example 80

Synthesis of 3-(1-methyl-2-phenyl-ethoxy)-5-trifluoromethyl-benzonitrile

To a solution of 187 mg of 3-hydroxy-5-trifluoromethyl-benzonitrile in 4 ml of tetrahydrofuran were added 289 mg of PPh_3, 136 mg of 1-phenyl-2-propanol and 0.58 ml of DEAD at 0°C. The reaction mixture was stirred at 0°C for 1 hr and at room temperature for 24 hr. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (hexane/AcOEt 2% -> hexane/AcOEt 20%) to give the title compound (205 mg, 67%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.36 (3H, d, J = 6.1 Hz), 2.91 (1H, dd, J = 5.8, 13.9 Hz), 3.07 (1H, dd, J = 6.7, 13.9 Hz), 4.60-4.66 (1H, m), 7.20-7.33 (7H, m), 7.42 (1H, s).

[0253]

Reference Example 81

Synthesis of 3-methoxymethoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzonitrile

To a solution of 360 mg of 3-methoxymethoxy-benzonitrile in 8 ml of tetrahydrofuran were added 29 mg of (1,5-cyclooctadiene)(methoxy)iridium(I) dimer, 24 mg of 4,4'-di-tert-butyl-2,2'-dipyridyl and 560 mg of bis(pinacolato)diboron. The resulting mixture was stirred under reflux for 16 hr. The dark red solution was concentrated to give the crude product (638 mg) as a wine red oil. This crude product was used for the next step without further purification.

^{1}H-NMR ($CDCl_3$) δ: 1.35 (12H, s), 3.48 (3H, s), 5.21 (2H, s), 7.38 (1H, s), 7.64 (1H, s), 7.72 (1H, s).

[0254]

Reference Example 82

Synthesis of 3-(2,5-bis(trifluoromethyl)benzyloxy)-5-trifluoromethyl-benzonitrile

To a suspension of 200 mg of 3-hydroxy-5-trifluoromethyl-benzonitrile and 265 mg of K_2CO_3 in 4 ml of CH_3CN was added 0.235 ml of 2,5-bis(trifluoromethyl)benzyl bromide. The reaction mixture was stirred at 80°C for 2 hr. The mixture was filtered and the filtrate was concentrated to give the title compound (440 mg, quant.) as a white solid.

^{1}H NMR ($CDCl_3$) δ: 5.34 (2H, s), 7.43 (1H, s), 7.48 (1H, s), 7.59 (1H, s), 7.78 (1H, d, J = 8.0 Hz), 7.90 (1H, d, J = 8.0 Hz), 8.01 (1H, s).

[0255]

Reference Example 83

Synthesis of 3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-benzonitrile

To a solution of 218 mg of 2-chloro-4-(trifluoromethyl)pyridine and 373 mg of 3-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzonitrile in 5 ml of dimethoxyethane were added 49 mg of 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride CH_2Cl_2 complex and 2 molar sodium carbonate aqueous solution, and the mixture was degassed. The reaction mixture was stirred at 80°C under argon for 3 hr. The reaction was quenched by addition of water, and the mixture was extracted twice with TBME. The organic solution was concentrated and the residue was purified by silica gel column chromatography (hexane/AcOEt 5% -> hexane/AcOEt 30%) to give the title compound (274 mg, 82%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 3.94 (3H, s), 7.25 (1H, s), 7.53 (1H, d, J = 5.0 Hz), 7.84 (1H, s), 7.91 (2H, s), 8.99 (1H, d, J = 5.0 Hz).

[0256]

Reference Example 84

Synthesis of 3-methoxymethoxy-5-(5-trifluoromethyl-pyridin-2-yl)-benzonitrile

The title compound was obtained using 3-methoxymethoxy-5-

(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzonitrile and 2-chloro-5-trifluoromethyl-pyridine in the same manner as in Reference Example 83.

^{1}H-NMR ($CDCl_3$) δ: 3.52 (3H, s), 5.28 (2H, s), 7.43 (1H, s), 7.84 (1H, d, J = 8.4 Hz), 7.97 (2H, s), 8.04 (1H, dd, J = 2.2, 8.4 Hz), 8.97 (1H, s).

[0257]

Reference Example 85

Synthesis of 1-methoxy-3-phenoxy-5-trifluoromethyl-benzene

A suspension of 1-methoxy-3-iodo-5-trifluoromethyl-benzene (600 mg, 2.0 mmol), cesium carbonate (1.4 g, 4.30 mmol), cuprous bromide (30 mg, 0.21 mmol), ethyl 2-cyclohexanonecarboxylate 70 mg (4.38 mmol) and phenol (240 mg, 4.38 mmol) in DMSO (1.5 ml) was heated to 80°C for 8 hr under argon. The reaction mixture was allowed to cool to room temperature. After water was added to the reaction mixture, the mixture was extracted by hexane. After silica gel chromatography was charged with the resulting organic layers, it was eluted with AcOEt:hexane (1:10) to give the title compound (471 mg, 89%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 3.81 (3H, s), 6.69 (1H, s), 6.82 (1H, s), 6.85 (1H, s), 7.03-7.05 (2H, m), 7.16-7.19 (1H, m), 7.36-7.39 (2H, m).

[0258]

Reference Example 86

Synthesis of 3-(3-methoxy-5-trifluoromethyl-phenyl)-thiophene

The title compound was obtained using 1-iodo-3-methoxy-5-trifluoromethyl-benzene and thiophene-3-boronic acid in the same manner as in Reference Example 83.

^{1}H-NMR ($CDCl_3$) δ: 3.89 (3H, s), 7.05 (1H, s), 7.27 (1H, m), 7.36-7.44 (3H, m), 7.51 (1H, dd, J = 1.4, 3.0 Hz).

[0259]

Reference Example 87

Synthesis of trifluoromethanesulfonic acid 3-phenoxy-5-trifluoromethylphenyl ester

To a solution of 1-methoxy-3-phenoxy-5-trifluoromethyl benzene (471.2 mg, 1.76 mmol) in CH_2Cl_2 (2 ml) was added 1M boron tribromide in CH_2Cl_2 (6 ml, 6 mmol) at room temperature. The reaction mixture was stirred for 3 hr. Then water was added dropwise to the reaction mixture. After it was stirred for 0.5 hr, the organic layer was separated. After silica gel chromatography was charged with the resulting organic layer, it was eluted with AcOEt:hexane (1:10) to give 475.6 mg of 3-phenoxy-5-trifluoromethyl-phenol as a pale pink oil.

To a solution of 3-phenoxy-5-trifluoromethyl-phenol (475.6 mg) and DIPEA (0.60 ml) in CH_2Cl_2 (10 ml) was added trifluoromethanesulfonic anhydride (0.36 ml, 2.14 mmol) at 0°C. The reaction mixture was stirred at room temperature for 3 hr. Then water was added dropwise. After it was stirred for 10 min, the organic layer was separated. After silica gel chromatography was charged with the resulting organic layer, it was eluted with AcOEt:hexane (1:10) to give the title compound (639 mg, 94%) as a pale brown oil.

^{1}H-NMR ($CDCl_3$) δ: 7.04 (1H, s), 7.06-7.10 (2H, m), 7.21 (1H, s), 7.23 (1H, s), 7.25-7.29 (1H, m), 7.42-7.47 (2H, m).

[0260]

Reference Example 88

Synthesis of trifluoromethanesulfonic acid 3-(thiophen-3-yl)-5-trifluoromethylphenyl ester

The title compound was obtained using 3-(3-methoxy-5-trifluoromethyl-phenyl)-thiophene in the same manner as in Reference Example 87.

^{1}H-NMR ($CDCl_3$) δ: 7.38 (1H, dd, J = 1.3, 5.0 Hz), 7.43 (1H, s), 7.48 (1H, dd, J = 3.0, 5.0 Hz), 7.60 (1H, dd, J = 1.3, 3.0 Hz), 7.65 (1H, s), 7.85 (1H, s).

[0261]

Reference Example 89

Synthesis of 3-phenoxy-5-trifluoromethyl-benzonitrile

A suspension of trifluoromethanesulfonic acid 3-phenoxy-5-trifluoromethylphenyl ester (638.7 mg, 1.65 mmol), zinc

cyanide (300 mg, 2.56 mmol) and $Pd(PPh_3)_4$ (190 mg, 0.164 mmol) in DMF (6 ml) was heated to 80°C for 8 hr under argon. The reaction mixture was allowed to cool to room temperature. The reaction mixture was filtered through a layer of Celite with AcOEt. The filtrate was washed twice with water and filtered through a column of silica gel. The eluate was concentrated *in vacuo* and the crude product was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 10% gradient)) to give the title compound (348 mg, 80%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 7.04-7.08 (2H, m), 7.26-7.30 (1H, m), 7.34 (1H, s), 7.42-7.48 (3H, m), 7.58 (1H, s).

[0262]

Reference Example 90

Synthesis of 3-(thiophen-3-yl)-5-trifluoromethyl-benzonitrile

The title compound was obtained using trifluoromethanesulfonic acid 3-(thiophen-3-yl)-5-trifluoromethylphenyl ester in the same manner as in Reference Example 89.

^{1}H-NMR ($CDCl_3$) δ: 7.39 (1H, dd, J = 1.3, 5.1 Hz), 7.49 (1H, dd, J = 2.8, 5.1 Hz), 7.61 (1H, dd, J = 1.3, 2.8 Hz), 7.82 (1H, s), 8.03 (2H, s).

[0263]

Reference Example 91

Synthesis of 2-chloro-3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzonitrile

To a suspension of 19 mg of 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride CH_2Cl_2 complex and 263 mg of sodium phosphate tribasic dodecahydrate in 1.5 ml of dimethoxyethane were added 100 mg of 3-bromo-2-chloro-benzonitrile and 165 mg of trans-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester and 0.5 ml of water.

The reaction mixture was stirred at 80°C under nitrogen for 7 hr. The reaction was quenched by addition of water and

then AcOEt was added thereto. After separation the aqueous phase was extracted with AcOEt. The organic solution was filtered through a Na_2SO_4 and silica gel pad and concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 5% -> hexane/AcOEt 20%) to give the title compound (111 mg, 78%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 7.15 (1H, d, J = 16.5 Hz), 7.41 (1H, t, J = 8.1 Hz), 7.50-7.64 (4H, m), 7.74-7.77 (2H, m), 7.90 (1H, dd, J = 1.5, 8.1 Hz).

[0264]

Reference Example 92

Synthesis of 3-cyclohexylmethoxymethyl-benzaldehyde

To a solution of cyclohexanemethanol (350 mg, 3.07 mmol) in DMF (5 ml) was added 60% NaH (120 mg, 3.0 mmol) at 0°C under argon and the reaction mixture was stirred at 0°C for 15 min. To the reaction mixture was added α-bromo-m-tolunitrile (590 mg, 3.0 mmol) at 0°C, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The organic layers were washed twice with water, and then dried over anhydrous $MgSO_4$. The solvents were removed under reduced pressure to give crude product as a pale yellow oil. The crude material was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 7% gradient)) to give 295.7 mg of 3-((cyclohexylmethoxy)methyl)benzonitrile as a colorless oil.

A suspension of 3-((cyclohexylmethoxy)methyl)benzonitrile (295.7 mg) and Raney Ni (1.0 g) in 88% formic acid (10 ml) was heated to 100°C for 1.5 hr. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with diisopropyl ether and filtered through a layer of Celite. The filtrate was washed three times with water, and then dried over anhydrous $MgSO_4$. The solvents were removed under reduced pressure, and the resulting crude product was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 7% gradient)) to give the title compound (262 mg, 38%) as a

colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 0.85-1.00 (2H, m), 1.00-1.40 (3H, m), 1.60-1.95 (6H, m), 3.30 (2H, d, J = 6.5 Hz), 4.56 (2H, s), 7.51 (1H, t, J = 7.5 Hz), 7.62 (1H, d, J = 7.5 Hz), 7.80 (1H, d, J = 7.5 Hz), 7.85 (1H, s), 10.03 (1H, s).

[0265]

Reference Example 93

Synthesis of 3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethyl-benzaldehyde

To a solution of 440 mg of 3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethyl-benzonitrile in 1 ml of THF were added 2 ml of formic acid (90%) and 250 mg of Raney Ni. The reaction mixture was stirred at 100°C for 2 hr. After cooling to room temperature the mixture was diluted with AcOEt and filtered. The filtrate was concentrated. The residue was diluted with water and the mixture was extracted with CH_2Cl_2 twice. The organic solution was washed with water and brine, dried over $MgSO_4$, and concentrated to give the title compound (440 mg, quant.) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 5.38 (2H, s), 7.53 (1H, s), 7.67 (1H, s), 7.80-7.75 (2H, m), 7.89 (1H, d, J = 8.2 Hz), 8.05 (1H, s), 10.05 (1H, s).

[0266]

Reference Example 94

Synthesis of 3-(1-methyl-2-phenyl-ethoxy)-5-trifluoromethyl-benzaldehyde

The title compound was obtained using 3-(1-methyl-2-phenyl-ethoxy)-5-trifluoromethyl-benzonitrile in the same manner as in Reference Example 93.

^{1}H-NMR ($CDCl_3$) δ: 1.36 (3H, d, J = 6.0 Hz), 2.90 (1H, dd, J = 6.0, 13.8 Hz), 3.09 (1H, dd, J = 6.5, 13.8 Hz), 4.67-4.73 (1H, m), 7.20-7.33 (6H, m), 7.49 (1H, s), 7.65 (1H, s), 9.97 (1H, s).

[0267]

Reference Example 95

Synthesis of 3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-benzaldehyde

The title compound was obtained using 3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-benzonitrile in the same manner as in Reference Example 93.

^{1}H-NMR ($CDCl_3$) δ: 3.96 (3H, s), 7.50-7.53 (2H, m), 7.90 (1H, s), 7.99 (1H, s), 8.12 (1H, s), 8.90 (1H, d, J = 5.0 Hz), 10.08 (1H, s).

[0268]

Reference Example 96

Synthesis of 3-hydroxy-5-(5-trifluoromethyl-pyridin-2-yl)-benzaldehyde

The title compound was obtained using 3-methoxymethoxy-5-(5-trifluoromethyl-pyridin-2-yl)-benzonitrile in the same manner as in Reference Example 93.

^{1}H-NMR (DMSO-d_6) δ: 7.39 (1H, s), 7.90 (1H, s), 8.17 (1H, s), 8.25 (1H, d, J = 8.5 Hz), 8.33 (1H, dd, J = 2.2, 8.5 Hz), 9.08 (1H, s), 10.04 (1H, s).

[0269]

Reference Example 97

Synthesis of 2-chloro-3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde

The title compound was obtained using 2-chloro-3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzonitrile in the same manner as in Reference Example 93.

^{1}H-NMR ($CDCl_3$) δ: 7.13 (1H, d, J = 16.2 Hz), 7.43 (1H, t, J = 7.7 Hz), 7.53-7.65 (3H, m), 7.74-7.79 (2H, m), 7.87-7.93 (2H, m), 10.59 (1H, s).

[0270]

Reference Example 98

Synthesis of 6-(tert-butyl-dimethyl-silyloxymethyl)-pyridine-2-carbaldehyde

To a solution of 610 mg of [6-(tert-butyl-dimethyl-silyloxymethyl)-pyridin-2-yl]-methanol in 8 ml of CH_3CN was added 876 mg of IBX. The reaction mixture was stirred at 70°C

for 1 hr. The reaction was diluted with isopropyl ether and the resulting suspension was filtered. The filtrate was concentrated to give the title compound (567 mg, 94%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 0.16 (6H, s), 0.98 (9H, s), 4.93 (2H, s), 7.75-7.92 (3H, m), 10.03 (1H, s).

[0271]

Reference Example 99

Synthesis of 1-[6-(tert-butyl-dimethyl-silyloxymethyl)-pyridin-2-yl]-propan-1-ol

To a solution of 563 mg of 6-(tert-butyl-dimethyl-silyloxymethyl)-pyridine-2-carbaldehyde in 8 ml of THF was added 1.46 ml of 2 molar ethylmagnesium chloride at -20°C. The reaction mixture was stirred at same temperature for 2 hr and warmed to room temperature. The reaction was quenched by addition of saturated ammonium chloride aqueous solution, and the mixture was extracted twice with AcOEt. The organic solution was washed with water and brine, and concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 5% -> hexane/AcOEt 20%) to give the title compound (296 mg, 47%) as a pale pink solid.

^{1}H-NMR ($CDCl_3$) δ: 0.12 (6H, s), 0.92-0.98 (12H, m), 1.66-1.73 (1H, m), 1.83-1.89 (1H, m), 4.32 (1H, d, J = 5.4 Hz), 4.64-4.68 (1H, m), 4.83 (2H, s), 7.09 (1H, d, J = 7.8 Hz), 7.40 (1H, d, J = 7.8 Hz), 7.69 (1H, t, J = 7.8 Hz).

[0272]

Reference Example 100

Synthesis of {6-[1-(4-trifluoromethyl-benzyloxy)-propyl]-pyridin-2-yl}-methanol

To a solution of 290 mg of 1-[6-(tert-butyl-dimethyl-silyloxymethyl)-pyridin-2-yl]-propan-1-ol and 0.175 ml of alpha'-bromo-alpha,alpha,alpha-trifluoro-p-xylene in 4 ml of DMF was added 50 mg of NaH (60 wt%) at 0°C. The reaction mixture was stirred at room temperature for 15 hr. The reaction was quenched by addition of 1 molar HCl, and the

mixture was extracted twice with AcOEt. The organic solution was washed with water and brine, and concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 20% -> hexane/AcOEt 40%) to give the title compound (255 mg, 76%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 0.96 (3H, t, J = 7.4 Hz), 1.84-1.91 (2H, m), 3.86 (1H, t, J = 5.0 Hz), 4.43-4.57 (3H, m), 4.76 (2H, d, J = 5.0 Hz), 7.14 (1H, d, J = 7.8 Hz), 7.35 (1H, d, J = 7.8 Hz), 7.45 (2H, d, J = 8.1 Hz), 7.60 (2H, d, J = 8.1 Hz), 7.71 (1H, t, J = 7.8 Hz).

[0273]

Reference Example 101

Synthesis of 6-[1-(4-trifluoromethyl-benzyloxy)-propyl]-pyridine-2-carbaldehyde

To a solution of 250 mg of {6-[1-(4-trifluoromethyl-benzyloxy)-propyl]-pyridin-2-yl}-methanol in 4 ml of DMSO was added 280 mg of IBX. The reaction mixture was stirred at room temperature for 3 hr. The reaction was quenched by addition of water, and the mixture was extracted twice with AcOEt. The organic solution was washed with water and brine, and concentrated. The residue was filtered through a silica gel short column to give the title compound (249 mg, quant.) as a pale blue oil.

^{1}H-NMR ($CDCl_3$) δ: 0.99 (3H, t, J = 7.5 Hz), 1.88-1.97 (2H, m), 4.49-4.59 (3H, m), 7.46 (2H, d, J = 8.1 Hz), 7.60 (2H, d, J = 8.1 Hz), 7.67-7.70 (1H, m), 7.89-7.90 (2H, m), 10.08 (1H, s).

[0274]

Reference Example 102

Synthesis of (3-diethoxymethyl-phenyl)-methanol

To a solution of 3-(diethoxymethyl)benzaldehyde (2.51 g, 12.1 mmol) in EtOH (40 ml) was added $NaBH_4$ (0.68 g, 18.1 mmol) at 0°C. The reaction mixture was stirred overnight at room temperature. Water was added to the reaction mixture at 0°C, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water and brine, dried over

Na_2SO_4, and concentrated *in vacuo* to give the title compound (2.45 g, 96%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.22-1.27 (6H, m), 1.64 (1H, t, J = 6.1 Hz), 3.51-3.66 (4H, m), 4.72 (2H, d, J = 6.1 Hz), 5.50 (1H, s), 7.33-7.41 (3H, m), 7.48 (1H, s).

[0275]

Reference Example 103

Synthesis of methanesulfonic acid 2,5-bis-trifluoromethyl-benzyl ester

To a solution of 2,5-bis(trifluoromethyl)benzyl alcohol (1.50 g, 6.15 mmol) in AcOEt (30 ml) were added Et_3N (1.72 ml, 12.3 mmol) and MsCl (0.57 ml, 7.38 mmol) at 0°C. The reaction mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo* to give the title compound (2.00 g, 100%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 3.11 (3H, s), 5.45 (2H, s), 7.78 (1H, d, J = 8.2 Hz), 7.87 (1H, d, J = 8.2 Hz), 7.93 (1H, s).

[0276]

Reference Example 104

Synthesis of methanesulfonic acid 3-fluoro-5-trifluoromethyl-benzyl ester

The title compound was obtained using 3-fluoro-5-(trifluoromethyl)benzyl alcohol in the same manner as in Reference Example 103.

^{1}H-NMR ($CDCl_3$) δ: 3.06 (3H, s), 5.26 (2H, s), 7.32-7.39 (2H, m), 7.47 (1H, s).

[0277]

Reference Example 105

Synthesis of methanesulfonic acid 3-diethoxymethyl-benzyl ester

The title compound was obtained using 3-diethoxymethyl-benzyl alcohol in the same manner as in Reference Example 103.

^{1}H-NMR ($CDCl_3$) δ: 1.23-1.27 (6H, m), 2.93 (3H, s), 3.51-3.65

(4H, m), 5.26 (2H, s), 5.51 (1H, s), 7.34-7.40 (2H, m), 7.42-7.53 (2H, m).

[0278]

Reference Example 106

Synthesis of methanesulfonic acid 2,4-bis-trifluoromethyl-benzyl ester

To solution of 2,4-bistrifluoromethylbenzaldehyde (1.5 g, 6.20 mmol) in EtOH (20 ml) was added $NaBH_4$ (100 mg, 2.74 mmol) at room temperature, and the reaction mixture was stirred for 2 hr. The solvents were removed under reduced pressure. The residue that was diluted with AcOEt was washed with dilute HCl and water (3 times), and the organic layer was dried over anhydrous $MgSO_4$. The solvents were removed under reduced pressure to give 1.54 g of a crude (2,4-bis(trifluoromethyl)phenyl)methanol as a colorless oil.

To a solution of (2,4-bis(trifluoromethyl)phenyl)methanol (1.54 g) and Et_3N (1.2 ml, 8.63 mmol) in CH_2Cl_2 (50 ml) was added dropwise MsCl (0.55 ml, 7.11 mmol) at 0°C. The reaction mixture was stirred at 0°C for 2 hr. Then water was added. The organic layers were separated and washed with diluted HCl and water (3 times), and then dried over anhydrous Na_2SO_4. The solvents were removed under reduced pressure to give the title compound (1.91 g, 96%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 3.10 (3H, s), 5.46 (2H, s), 7.83-7.92 (2H, m), 7.97 (1H, s).

[0279]

Reference Example 107

Synthesis of 3-trifluoromethyloxy-5-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-benzaldehyde

To a solution of 3-bromo-5-trifluoromethoxy-benzaldehyde (1.20 g, 4.46 mmol) in DMSO (20 mL) were added bis(neopentylglycolato)diboron (1.11 g, 4.91 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.11 g, 0.134 mmol) and AcOK (1.31, 13.4 mmol). The reaction mixture was stirred for 2.5 hr at 80°C under nitrogen. Water

was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water (twice) and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=100:0-70:30) to give the title compound (0.72 g, 53%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.04 (6H, s), 3.80 (4H, s), 7.77 (1H, s), 7.87 (1H, s), 8.22 (1H, s), 10.04 (1H, s).

[0280]

Reference Example 108

Synthesis of 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-5-trifluoromethyl-benzaldehyde

The title compound was obtained using 3-bromo-5-trifluoromethylbenzaldehyde and bis(pinacolato)diboron in the same manner as in Reference Example 107.

^{1}H-NMR ($CDCl_3$) δ: 1.40 (12H, s), 8.24 (1H, s), 8.31 (1H, s), 8.49 (1H, s), 10.11 (1H, s).

[0281]

Reference Example 109

Synthesis of 3-chloro-5-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-benzaldehyde

The title compound was obtained using 3-bromo-5-chloro-benzaldehyde and bis(neopentyl glycolato)diboron in the same manner as in Reference Example 107.

^{1}H-NMR ($CDCl_3$) δ: 1.04 (6H, s), 3.80 (4H, s), 7.90 (1H, s), 8.01 (1H, s), 8.16 (1H, s), 10.00 (1H, s).

[0282]

Reference Example 110

Synthesis of 4-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-3-methyl-benzaldehyde

The title compound was obtained using 4-bromo-3-methyl-benzaldehyde and bis(neopentyl glycolato)diboron in the same manner as in Reference Example 107.

^{1}H-NMR ($CDCl_3$) δ: 1.05 (6H, s), 2.58 (3H, s), 3.80 (4H, s),

7.61-7.66 (2H, m), 7.85-7.89 (1H, m), 9.99 (1H, s).

[0283]

Reference Example 111

Synthesis of 3-tert-butyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzaldehyde

The title compound was obtained using 3-bromo-5-tert-butyl-benzaldehyde and bis(pinacolato)diboron in the same manner as in Reference Example 107.

^{1}H-NMR ($CDCl_3$) δ: 1.39 (12H, s), 1.40 (9H, s), 8.02-8.04 (1H, m), 8.10-8.12 (1H, m), 8.13-8.15 (1H, m), 10.06 (1H, s).

[0284]

Reference Example 112

Synthesis of 3-(3-hydroxy-phenyl)-thiophene-2-carbaldehyde

To a solution of 3-bromothiophene-2-carboxaldehyde (1.30 g, 6.81 mmol) in DME (26 ml) were added 3-hydroxyphenylboronic acid (1.03 g, 7.49 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.17 g, 0.204 mmol) and 2M sodium carbonate solution (7.49 ml, 15.0 mmol). The reaction mixture was stirred for 2 hr at 80°C under nitrogen. Water was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=65:35-50:50) to give the title compound (1.32 g, 95%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 5.31 (1H, s), 6.92-6.96 (2H, m), 7.03-7.05 (1H, m), 7.22 (1H, d, J = 5.0 Hz), 7.35 (1H, t, J = 7.8 Hz), 7.74-7.75 (1H, m), 9.91 (1H, s).

[0285]

Reference Example 113

Synthesis of 1-(3-diethoxymethyl-benzyloxy)-3,5-bis-trifluoromethyl-benzene

To a solution of 3-diethoxymethyl-benzyl bromide (0.50 g, 1.74 mmol) in DMF (8 ml) were added 3,5-

bis(trifluoromethyl)phenol (0.42 g, 1.82 mmol) and K_2CO_3 (0.36 g, 2.60 mmol). The reaction mixture was stirred for 2 hr at 80°C. After cooling to room temperature, water was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=100:0-90:10) to give the title compound (0.25 g, 34%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.24 (6H, t, J = 7.0 Hz), 3.49-3.67 (4H, m), 5.16 (2H, s), 5.53 (1H, s), 7.38-7.49 (6H, m), 7.55 (1H, s).

[0286]

Reference Example 114

Synthesis of (3,5-bis-trifluoromethyl-benzyl)-(3-([1,3]dioxolan-2-yl)-phenyl)-amine

To a solution of 2-(3-bromophenyl)-1,3-dioxolane (2.00 g, 8.73 mmol) in toluene (40 ml) were added 3,5-bis(trifluoromethyl)benzylamine (2.12 g, 8.73 mmol), $Pd(OAc)_2$ (98 mg, 0.437 mmol), rac-BINAP (0.54g 0.873 mmol) and tert-BuONa (0.92 g, 9.61 mmol). The reaction mixture was stirred for 2.5 hr at 100°C under argon atmosphere. After cooling to room temperature, the mixture was filtered through a pad of Celite and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=100:0-75:25) to give the title compound (2.74 g, 80%) as an orange solid.

^{1}H-NMR ($CDCl_3$) δ: 3.98-4.18 (4H, m), 4.19-4.32 (1H, m), 4.48 (2H, d, J = 5.9 Hz), 5.74 (1H, s), 6.53-6.62 (1H, m), 6.77 (1H, s), 6.88 (1H, d, J = 7.8 Hz), 7.19 (1H, t, J = 7.8 Hz), 7.79 (1H, s), 7.84 (2H, s).

[0287]

Reference Example 115

Synthesis of (3,5-bis-trifluoromethyl-benzyl)-(3-([1,3]dioxolan-2-yl)-phenyl)-methyl-amine

To a solution of (3,5-bis-trifluoromethyl-benzyl)-(3-

([1,3]dioxolan-2-yl)-phenyl)-amine (0.50 g, 1.28 mmol) in DMF (10 ml) was added NaH (61 mg, 1.53 mmol, 60 wt% in mineral oil) at 0°C. After the resulting suspension was stirred for 15 min, MeI (0.16 ml, 2.56 mmol) was added. The reaction mixture was stirred overnight at room temperature. Saturated aqueous NH_4Cl solution was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=100:0-85:15) to give the title compound (0.22 g, 42%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 3.04 (3H, s), 4.01-4.16 (4H, m), 4.61 (2H, s), 5.78 (1H, s), 6.69-6.72 (1H, m), 6.89-6.91 (2H, m), 7.23-7.28 (1H, m), 7.71 (2H, s), 7.98 (1H, s).

[0288]

Reference Example 116

Synthesis of 2-(3-bromo-5-chloro-phenyl)-[1,3]dioxolane

To a solution of 3-bromo-5-chloro-benzaldehyde (2.00 g, 9.13 mmol) in toluene (15 ml) were added ethylene glycol (0.76 ml, 9.13 mmol) and p-toluenesulfonic acid (87 mg, 0.457 mmol). The reaction mixture was refluxed for 6 hr using Dean-Stark apparatus. After cooling to room temperature, saturated aqueous $NaHCO_3$ solution was added to the reaction mixture at 0°C, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=100:0-90:10) to give the title compound (1.49 g, 62%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 4.00-4.13 (4H, m), 5.76 (1H, s), 7.40 (1H, s), 7.50-7.51 (2H, m).

[0289]

Reference Example 117

Synthesis of 1-(3-chloro-5-([1,3]dioxolan-2-yl)-phenyl)-4-

trifluoromethyl-piperidine

The title compound was obtained using 4-trifluoromethyl-piperidine and 2-(3-bromo-5-chloro-phenyl)-1,3-dioxolane in the same manner as in Reference Example 114.

^{1}H-NMR ($CDCl_3$) δ: 1.67-1.76 (2H, m), 1.94-1.98 (2H, m), 2.09-2.24 (1H, m), 2.70-2.77 (2H, m), 3.74-3.80 (2H, m), 4.00-4.15 (4H, m), 5.73 (1H, s), 6.85-6.87 (1H, m), 6.89-6.91 (1H, m), 6.95-6.96 (1H, m).

[0290]

Reference Example 118

Synthesis of (3,5-bis-trifluoromethyl-benzyl)-triphenyl-phosphonium iodide

A suspension of 3,5-bis(trifluoromethyl)benzyl bromide (1.0 g, 3.26 mmol) and sodium iodide (1.0 g, 6.67 mmol) in acetone (10 ml) was stirred under reflux for 0.5 hr. The reaction mixture was filtered and the solvents were removed under reduced pressure. The residue was diluted with CH_2Cl_2 and was filtered. The solvents were removed under reduced pressure. To a solution of the resulting residue in CH_3CN was added PPh_3 (1.0 g, 3.81 mmol). The mixture was stirred under reflux for 1 hr. The reaction mixture was allowed to cool to room temperature. The solvents were removed under reduced pressure. To the residue was added AcOEt and hexane to give a suspension. The suspension was filtrated to give the title compound (1.89 g, 94%) as pale yellow prisms.

^{1}H-NMR ($CDCl_3$) δ: 5.84 (2H, d, J = 14.9 Hz), 7.57 -7.75 (9H, m), 7.75-7.90 (9H, m).

[0291]

Reference Example 119

Synthesis of (3-trifluoromethyl-benzyl)-phosphonic acid diethyl ester

A solution of 3-trifluoromethylbenzyl bromide (2.53 g, 10.6 mmol) and triethyl phosphite (3 ml, 17.5 mmol) was heated at 140°C at 10 hr. The excess of reagents were removed *in vacuo*. The residue was purified by silica gel column chromatography

(AcOEt:hexane = 1:2) to give the title compound (2.82 g, 90%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.22-1.29 (6H, m), 3.19 (2H, d, J = 21.8 Hz), 3.98-4.14 (4H, m), 7.26-7.55 (4H, m).

[0292]

Reference Example 120

Synthesis of (3-diethoxymethyl-benzyl)-phosphonic acid diethyl ester

To a solution of potassium *t*-butoxide (1 g, 8.91 mmol) in tetrahydrofuran (8 ml) was added diethyl phosphite (1.1 ml, 8.54 mmol) at 0°C under argon. The mixture was stirred at 0°C for 45 min. To the reaction mixture was added a solution of 3-(diethoxymethyl)benzyl methanesulfonate (1.2 g, 4.2 mmol) in tetrahydrofuran (5 ml) at 0°C, and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with AcOEt-hexane (1:4). The organic layers were washed with brine, and dried over anhydrous Na_2SO_4. The solvents were removed under reduced pressure to give crude product as a colorless oil. The crude material was purified by silica gel (neutral) column chromatography (AcOEt/hexane = 1:2) to give the title compound (977 mg, 70%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.15-1.3 (12H, m), 3.16 (2H, d, J = 21.5 Hz), 3.5-3.7 (4H, m), 3.9-4.05 (4H, m), 5.49 (1H, s), 7.25-7.4 (4H, m).

[0293]

Reference Example 121

Synthesis of (6-bromo-benzofuran-2-yl)-methanol

The title compound was obtained using 6-bromo-benzofuran-2-carboxylic acid ethyl ester in the same manner as in Reference Example 19.

^{1}H-NMR ($CDCl_3$) δ: 4.76 (2H, s), 6.64 (1H, s), 7.33-7.43 (2H, m), 7.63 (1H, s).

[0294]

Reference Example 122

Synthesis of 6-bromo-benzofuran-2-carbaldehyde

The title compound was obtained using (6-bromo-benzofuran-2-yl)-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 7.47-7.54 (2H, m), 7.63 (1H, d, J = 8.4 Hz), 7.80 (1H, s), 9.88 (1H, s).

[0295]

Reference Example 123

Synthesis of 2-(3'-trifluoromethyl-biphenyl-3-yl)-ethanol

The title compound was obtained using 3-bromophenethyl alcohol and 3-(trifluoromethyl)phenylboronic acid in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 1.44 (1H, t, J = 6.0 Hz), 2.96 (2H, t, J = 6.0 Hz), 3.93 (2H, q, J = 6.0 Hz), 7.27-7.62 (6H, m), 7.75-7.83 (2H, m).

[0296]

Reference Example 124

Synthesis of 4-hydroxy-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde

The title compound was obtained using 3-bromo-4-hydroxybenzaldehyde and (*E*)-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester in the same manner as in Reference Example 91.

^{1}H-NMR (DMSO-d_6) δ: 7.07 (1H, d, J = 8.4 Hz), 7.48 (1H, d, J = 16.6 Hz), 7.57 (1H, d, J = 16.6 Hz), 7.62-7.63 (2H, m), 7.72 (1H, dd, J = 2.0, 8.4 Hz), 7.93 (2H, s), 8.19 (1H, d, J = 2.0 Hz), 9.85 (1H, s).

[0297]

Reference Example 125

Synthesis of trifluoromethanesulfonic acid 4-formyl-2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl ester

To a solution of 200 mg of 4-hydroxy-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde in CH_2Cl_2 were added 0.179 ml of DIPEA and 0.139 ml of trifluoromethanesulfonic anhydride at 0°C, and the mixture was

stirred at room temperature for 18 hr. The reaction was quenched by addition of water. The aqueous phase was extracted twice with AcOEt. The organic layer were washed with water and brine, and concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 5% => hexane/AcOEt 20%) to give the title compound (74 mg, 26%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 7.33 (1H, d, J = 16.4 Hz), 7.38 (1H, d, J = 16.4 Hz), 7.51-7.62 (3H, m), 7.74-7.78 (2H, m), 7.90 (1H, dd, J = 2.0, 8.5 Hz), 8.30 (1H, d, J = 2.0 Hz), 10.09 (1H, s).

[0298]

Reference Example 126

Synthesis of {4-trifluoromethyl-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-methanol

The title compound was obtained using (3-bromo-4-trifluoromethyl-phenyl)-methanol and (*E*)-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 1.95 (1H, s), 4.82 (2H, s), 7.13 (1H, d, J = 16.1 Hz), 7.38 (1H, d, J = 8.1 Hz), 7.48-7.57 (3H, m), 7.67-7.79 (4H, m).

[0299]

Reference Example 127

Synthesis of 2-(3-chloro-4-fluoro-phenyl)-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester

The title compound was obtained using 2-bromo-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester and 3-chloro-4-fluorophenylboronic acid in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 1.41 (3H, t, J = 7.1 Hz), 4.42 (2H, q, J = 7.1 Hz), 7.23-7.29 (1H, m), 7.86 (1H, ddd, J = 2.3, 4.4, 8.6 Hz), 8.09 (1H, dd, J = 2.3, 6.8 Hz).

[0300]

Reference Example 128

Synthesis of 2-(4-trifluoromethoxy-phenyl)-oxazole-4-

carboxylic acid ethyl ester

To the solution of 4-(trifluoromethoxy)benzamide (500 mg, 2.437 mmol) in EtOH (4 ml) was added ethyl bromopyruvate (0.918 ml, 7.31 mmol). The reaction mixture was stirred at 150°C for 20 min by using a microwave reactor. After concentration, the residue was purified by flash column chromatography (hexane/AcOEt = 9/1 to 2/1) to give the title compound (180 mg, crude) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 1.42 (3H, t, J = 7.1 Hz), 4.44 (2H, q, J = 7.1 Hz), 7.29-7.35 (2H, m), 8.14-8.19 (2H, m), 8.29 (1H, s).

[0301]

Reference Example 129

Synthesis of 3-(5-fluoro-benzoxazol-2-yl)-benzoic acid methyl ester

To a solution of methyl hydrogen isophthalate (1.5 g, 8.33 mmol) and 2-amino-4-fluorophenol (1.058 g, 8.33 mmol) in methanesulfonic acid (15 ml, 231 mmol) was added slowly phosphoric anhydride (5.91 g, 41.6 mmol). The reaction mixture was stirred for 2 hr at 80°C. After the reaction mixture was cooled to 0°C, saturated aqueous $NaHCO_3$ solution was added to the reaction mixture. The precipitate was collected by filtration, washed with water and CH_3CN:water (1:1) and air-dried at 60°C to give the title compound (1.08 g, 48%) as a brown solid.

^{1}H-NMR (DMSO-d_6) δ: 3.94 (3H, s), 7.30-7.38 (1H, m), 7.72-7.92 (3H, m), 8.20-8.24 (1H, m), 8.43-8.48 (1H, m), 8.72-8.74 (1H, m).

[0302]

Reference Example 130

Synthesis of [3-(5-fluoro-benzoxazol-2-yl)-phenyl]-methanol

To a solution of 3-(5-fluoro-benzoxazol-2-yl)-benzoic acid methyl ester (0.50 g, 1.84 mmol) in THF (10 ml) was added $LiAlH_4$ (0.07 g, 1.84 mmol) at 0°C. The reaction mixture was stirred for 3.5 hr at the same temperature. Water, 15% NaOH aqueous solution and water were added successively to the

reaction mixture. The suspension was filtered through a pad of Celite. Water was added to the filtrate, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with brine, dried over Na_2SO_4, and concentrated *in vacuo* to give the title compound (332 mg, 74%) as an orange solid.
^{1}H-NMR (DMSO-d_6) δ: 1.81 (1H, t, J = 5.6 Hz), 4.82 (2H, d, J = 5.6 Hz), 7.05-7.13 (1H, m), 7.43-7.60 (4H, m), 8.14-8.19 (1H, m), 8.25 (1H, s).

[0303]

Reference Example 131

Synthesis of 3-[2-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-propionic acid methyl ester

The title compound was obtained using methyl 3-(2-hydroxyphenyl)propionate and 2,5-bis(trifluoromethyl)benzyl bromide in the same manner as in Reference Example 82.
^{1}H-NMR ($CDCl_3$) δ: 2.65-2.70 (2H, m), 3.06 (2H, t, J = 7.9 Hz), 3.67 (3H, s), 5.32 (2H, s), 6.88 (1H, d, J = 8.3 Hz), 6.93 (1H, t, J = 6.5 Hz), 7.19-7.26 (2H, m), 7.71 (1H, d, J = 8.3 Hz), 7.65 (1H, d, J = 8.3 Hz), 8.11 (1H, s).

[0304]

Reference Example 132

Synthesis of 3-[2-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-propan-1-ol

The title compound was obtained using 3-[2-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-propionic acid methyl ester in the same manner as in Reference Example 19.
^{1}H-NMR ($CDCl_3$) δ: 1.38 (1H, t, J = 5.6 Hz), 1.88-1.97 (2H, m), 2.83 (2H, t, J = 7.3 Hz), 3.66-3.72 (2H, m), 5.32 (2H, s), 6.89 (1H, d, J = 8.2 Hz), 6.98 (1H, t, J = 7.4 Hz), 7.18-7.24 (2H, m), 7.71 (1H, d, J = 8.2 Hz), 7.85 (1H, d, J = 8.2 Hz), 8.14 (1H, s).

[0305]

Reference Example 133

Synthesis of 2-(4-chloro-phenyl)-5-methyl-oxazole-4-carboxylic acid methyl ester

To a solution of methyl acetoacetate (0.108 ml, 1 mmol) in DMF (3 ml) were added 4-chlorobenzylamine (1.5 mmol), iodine (305 mg, 1.200 mmol), copper(II) acetate hydrate (19.96 mg, 0.100 mmol) and tert-butyl hydroperoxide (0.333 ml, 2.000 mmol). After the reaction mixture was stirred for 4 hr at room temperature, additional 4-chlorobenzylamine (0.5 mmol) was added to the reaction again. The reaction mixture was stirred for 14 hr at rt. The reaction was quenched by addition of water, and the mixture was extracted three times with AcOEt. The organic solution was washed with water, 10% sodium thiosulfate aqueous solution, and brine and concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 5% -> hexane/AcOEt 20%) to give the title compound (67 mg, 27%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 2.71 (3H, s), 3.95 (3H, s), 7.42-7.45 (2H, m), 7.99-8.02 (2H, m).

[0306]

Reference Example 134

Synthesis of [2-(4-chloro-phenyl)-5-methyl-oxazol-4-yl]-methanol

The title compound was obtained using 2-(4-chloro-phenyl)-5-methyl-oxazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 19.

^{1}H-NMR ($CDCl_3$) δ: 2.40 (3H, s), 4.59 (2H, s), 7.39-7.42 (2H, m), 7.91-7.94 (2H, m).

[0307]

Reference Example 135

Synthesis of 5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazole-4-carboxylic acid methyl ester

The title compound was obtained using 3-cyclopropyl-3-oxopropionic acid methyl ester and 3-(trifluoromethyl)benzylamine in the same manner as in Reference Example 133.

^{1}H-NMR ($CDCl_3$) δ: 1.21-1.28 (4H, m), 2.81-2.90 (1H, m), 3.98 (3H, s), 7.58 (1H, t, J = 7.8 Hz), 7.71 (1H, d, J = 7.8 Hz),

8.18 (1H, d, J = 7.8 Hz), 8.25 (1H, s).

[0308]

Reference Example 136

Synthesis of 2-(3-chloro-phenyl)-5-cyclopropyl-oxazole-4-carboxylic acid methyl ester

The title compound was obtained using methyl 3-cyclopropyl-3-oxopropionate and 3-chlorobenzylamine in the same manner as in Reference Example 133.

^{1}H-NMR ($CDCl_3$) δ: 1.19-1.23 (4H, m), 2.80-2.87 (1H, m), 3.97 (3H, s), 7.35-7.43 (2H, m), 7.88 (1H, dt, J = 1.5, 7.5 Hz), 7.98 (1H, t, J = 1.5 Hz).

[0309]

Reference Example 137

Synthesis of [5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-methanol

The title compound was obtained using 5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 19.

^{1}H-NMR ($CDCl_3$) δ: 0.99-1.10 (4H, m), 1.96-2.05 (1H, m), 2.20 (1H, s), 4.68 (2H, s), 7.56 (1H, t, J = 7.7 Hz), 7.66 (1H, d, J = 7.7 Hz), 8.13 (1H, d, J = 7.7 Hz), 8.20 (1H, s).

[0310]

Reference Example 138

Synthesis of 3-bromo-5-ethoxymethyl-benzaldehyde

To a solution of 1,3-dibromo-5-ethoxymethyl-benzene (1.42 g, 4.83 mmol) in dry Et_2O (28 ml) was added dropwise *n*-BuLi (1.907 ml, 5.07 mmol, 2.66 M solution in hexane) at -78°C under nitrogen. The reaction mixture was stirred for 1 hr at the same temperature. DMF (3.72 ml, 48.3 mmol) was added to the reaction mixture, and stirring was continued for 1 hr. Saturated aqueous NH_4Cl solution was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column

chromatography (Hexane:AcOEt=100:0-80:20) to give the title compound (978 mg, 83%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.28 (3H, t, J = 7.0 Hz), 3.59 (2H, q, J = 7.0 Hz), 4.55 (2H, s), 7.76 (1H, s), 7.78 (1H, s), 7.92 (1H, s), 9.96 (1H, s).

[0311]

Reference Example 139

Synthesis of (3-bromo-5-chloro-phenyl)-cyclopropyl-methanol

To a solution of 3-bromo-5-chloro-benzaldehyde (1.5 g, 6.83 mmol) in THF (20 mL) was added dropwise cyclopropylmagnesium bromide (11.7 mL, 8.20 mmol, 0.7 M solution in THF) at 0°C. The reaction mixture was stirred for 5 hr at the same temperature. Saturated aqueous NH_4Cl solution was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=100:0-85:15) to give the title compound (807 mg, 45%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 0.40-0.52 (2H, m), 0.61-0.70 (2H, m), 1.11-1.19 (1H, m), 1.97 (1H, d, J = 3.0 Hz), 3.94 (1H, dd, J = 3.0, 8.5 Hz), 7.37 (1H, s), 7.42-7.43 (1H, m), 7.48 (1H, s).

[0312]

Reference Example 140

Synthesis of 1-bromo-3-chloro-5-cyclopropylmethyl-benzene

To a solution of (3-bromo-5-chloro-phenyl)-cyclopropyl-methanol (493 mg, 1.89 mmol) in CH_2Cl_2 (15 ml) were added triethylsilane (0.90 ml, 5.65 mmol), BF_3-Et_2O complex (0.465 ml, 3.77 mmol) at 0°C. The reaction mixture was stirred for 2 hr at the same temperature. Saturated aqueous $NaHCO_3$ solution was added to the reaction mixture, and the mixture was extracted twice with CH_2Cl_2. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column

chromatography (Hexane/AcOEt=100:0-95:5) to give the title compound (430 mg, 93%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 0.18-0.22 (2H, m), 0.55-0.59 (2H, m), 0.91-0.98 (1H, m), 2.49 (2H, d, J = 7.0 Hz), 7.19 (1H, s), 7.29 (1H, s), 7.34-7.35 (1H, m).

[0313]

Reference Example 141

Synthesis of 1,3-dibromo-5-cyclopropyl-benzene

To a solution of diethyl zinc (12.6 ml, 13.8 mmol, 1.1 M solution in hexane) in 1,2-dichloroethane (25 ml) was added TFA (1.03 ml, 13.8 mmol) at 0°C under nitrogen. After the reaction mixture was stirred for 20 min at the same temperature, diiodomethane (1.12 ml, 13.8 mmol) was added, and stirring was continued for 20 min. 1,3-Dibromo-5-vinyl-benzene (1.45 g, 5.54 mmol) in 1,2-dichloroethane (10 ml) was added dropwise to the resulting mixture, and stirring was continued for 4 hr at 80°C under nitrogen. The reaction mixture was concentrated *in vacuo*. 1N NaOH aqueous solution was added to the residue, and the mixture was extracted twice with CH_2Cl_2. The combined organic layers were washed with brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography(Hexane:AcOEt=100:0-95:5) to give the title compound (1.13 g, 74%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 0.67-0.71 (2H, m), 0.96-1.02 (2H, m), 1.79-1.85 (1H, m), 7.12 (1H, s), 7.13 (1H, s), 7.46-7.47 (1H, m).

[0314]

Reference Example 142

Synthesis of 3-bromo-5-cyclopropyl-benzaldehyde

The title compound was obtained using 1,3-dibromo-5-cyclopropyl-benzene in the same manner as in Reference Example 138.

^{1}H-NMR ($CDCl_3$) δ: 0.74-0.79 (2H, m), 1.04-1.10 (2H, m), 1.91-1.98 (1H, m), 7.45-7.50 (2H, m), 7.75-7.78 (1H, m), 9.91 (1H, s).

[0315]

Reference Example 143

Synthesis of 1,3-dibromo-5-cyclobutoxy-benzene

The title compound was obtained using 3,5-dibromo-phenol and cyclobutanol in the same manner as in Reference Example 80.

^{1}H-NMR ($CDCl_3$) δ: 1.64-1.74 (1H, m), 1.83-1.91 (1H, m), 2.10-2.19 (2H, m), 2.41-2.47 (2H, m), 4.55-4.62 (1H, m), 6.88 (1H, s), 6.89 (1H, s), 7.21-7.22 (1H, m).

[0316]

Reference Example 144

Synthesis of 3-bromo-5-cyclobutoxy-benzaldehyde

The title compound was obtained using 1,3-dibromo-5-cyclobutoxy-benzene in the same manner as in Reference Example 138.

^{1}H-NMR ($CDCl_3$) δ: 1.67-1.77 (1H, m), 1.85-1.93 (1H, m), 2.12-2.22 (2H, m), 2.44-2.52 (2H, m), 4.68 (1H, quint, J = 7.2 Hz), 7.20 (1H, s), 7.22 (1H, s), 7.56 (1H, s), 9.88 (1H, s).

[0317]

Reference Example 145

Synthesis of 2-(4-chloro-phenyl)-4-ethyl-thiazole-5-carboxylic acid methyl ester

The title compound was obtained using 4-chloro-thiobenzamide and methyl 2-chloro-3-oxopentanoate in the same manner as in Reference Example 2.

^{1}H-NMR ($CDCl_3$) δ: 1.34 (3H, t, J = 7.5 Hz), 3.19 (2H, q, J = 7.5 Hz), 3.90 (3H, s), 7.41-7.44 (2H, m), 7.90-7.93 (2H, m).

[0318]

Reference Example 146

Synthesis of 3-[(*Z*)-2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-benzaldehyde

To solution of 3-(diethoxymethyl)benzaldehyde (0.18 ml, 0.885 mmol), 18-crown-6-ether (20 mg, 0.076 mmol) and (3,5-bis-trifluoromethyl-benzyl)triphenyl phosphonium iodide (500 mg, 0.812 mmol) in CH_2Cl_2 was slowly added potassium *t*-butoxide (200 mg, 1.78 mmol) at -78°C. After the reaction mixture was

stirred at same temperature for 7 hr, water was added, and the mixture was acidified with 5N HCl. The layer of CH_2Cl_2 was separated. After silica gel chromatography was charged with the layer, the elution from AcOEt:hexane (1:10) gave a crude product. The crude product was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 5% gradient)) to give the title compound (159 mg, 54%) as a colorless oil.
^{1}H-NMR ($CDCl_3$) δ: 6.72 (1H, d, J = 12.2 Hz), 6.87 (1H, d, J = 12.2 Hz), 7.40-7.47 (2H, m), 7.62 (2H, s), 7.71 (1H, s), 7.73 (1H, m), 7.76-7.81 (1H, m), 9.94 (1H, s).

[0319]

Reference Example 147

Synthesis of 3-(5-fluoro-benzoxazol-2-yl)-benzaldehyde

To a solution of [3-(5-fluoro-benzoxazol-2-yl)-phenyl]-methanol (332 mg, 1.37 mmol) in DMSO (3.5 mL) was added IBX (573 mg, 2.05 mmol) at room temperature. The reaction mixture was stirred for 1.5 hr at the same temperature. Water and AcOEt were added to the reaction mixture, and the precipitate was filtered through a pad of Celite. The filtrate was extracted twice with AcOEt. The combined organic layers were washed with water, saturated aqueous sodium bicarbonate solution and brine, dried over Na_2SO_4, and concentrated *in vacuo* to give the title compound (268 mg, 81%) as a brown solid.
^{1}H-NMR ($CDCl_3$) δ: 7.10-7.17 (1H, m), 7.45-7.58 (2H, m), 7.73 (1H, t, J = 8.0 Hz), 8.08 (1H, d, J = 7.5 Hz), 8.50 (1H, d, J = 7.5 Hz), 8.74 (1H, s), 10.14 (1H, s).

[0320]

Reference Example 148

Synthesis of 3-[2-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-propionaldehyde

The title compound was obtained using 3-[2-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-propan-1-ol in the same manner as in Reference Example 147.
^{1}H-NMR ($CDCl_3$) δ: 2.78-2.83 (2H, m), 3.05 (2H, t, J = 7.5 Hz),

5.32 (2H, s), 6.88 (1H, d, J = 8.3 Hz), 6.97 (1H, t, J = 7.5 Hz), 7.20-7.24 (2H, m), 7.72 (1H, d, J = 8.3 Hz), 7.86 (1H, d, J = 8.3 Hz), 8.05 (1H, s), 9.82 (1H, s).

[0321]

Reference Example 149

Synthesis of 5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazole-4-carbaldehyde

The title compound was obtained using [5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-methanol in the same manner as in Reference Example 147.

^{1}H-NMR ($CDCl_3$) δ: 1.28-1.33 (4H, m), 2.68-2.77 (1H, m), 7.61 (1H, t, J = 7.8 Hz), 7.73 (1H, d, J = 7.8 Hz), 8.17 (1H, d, J = 7.8 Hz), 8.23 (1H, s), 10.06 (1H, s).

[0322]

Reference Example 150

Synthesis of 3-trifluoromethyl-5-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-benzaldehyde

To a solution of 116 mg of 3-trifluoromethyl-5-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-benzaldehyde in 4 mL of EtOH was added 30 mg of 5% Pd/C-ethylenediamine complex, and the reaction mixture was stirred at 30°C for 3 hr. After filtration, the filtrate was concentrated to give a mixture of the title compound and benzyl alcohol (109 mg) as a brown oil. To a solution of the mixture in 2 mL of DMSO was added IBX (141 mg, 0.504 mmol). The reaction mixture was stirred at room temperature for 2 hr. The reaction was quenched by addition of water, and then the mixture was extracted twice with TBME. The organic solution was washed with water and brine, and concentrated to give the title compound (100 mg, 86%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 3.22-3.31 (4H, m), 7.26 (1H, d, J = 7.6 Hz), 7.53 (1H, d, J = 7.6 Hz), 7.70 (1H, s), 7.75 (1H, t, J = 7.6 Hz), 7.92 (1H, s), 7.96 (1H, s), 10.02 (1H, s).

[0323]

Reference Example 151

Synthesis of 3-(3,5-bis-trifluoromethyl-phenoxymethyl)-benzaldehyde

To a solution of 1-(3-diethoxymethyl-benzyloxy)-3,5-bis-trifluoromethyl-benzene (0.25 g, 0.592 mmol) in THF (7.5 mL) was added 2N HCl (7.5 ml). The reaction mixture was stirred for 2.5 hr at room temperature. Saturated aqueous $NaHCO_3$ solution was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with brine, dried over Na_2SO_4, and concentrated *in vacuo* to give the title compound (0.23 g, 100%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 5.22 (2H, s), 7.41 (2H, s), 7.51 (1H, s), 7.61 (1H, t, J = 7.6 Hz), 7.72 (1H, d, J = 7.6 Hz), 7.90 (1H, d, J = 7.6 Hz), 7.98 (1H, s), 10.07 (1H, s).

[0324]

Reference Example 152

Synthesis of 3-[N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-amino]-benzaldehyde

The title compound was obtained using (3,5-bis-trifluoromethyl-benzyl)-(3-([1,3]dioxolan-2-yl)-phenyl)-methyl-amine in the same manner as in Reference Example 151.

^{1}H-NMR ($CDCl_3$) δ: 3.12 (3H, s), 4.68 (2H, s), 6.95-6.98 (1H, m), 7.23-7.29 (2H, m), 7.40 (1H, t, J = 7.6 Hz), 7.68 (2H, s), 7.80 (1H, s), 9.95 (1H, s).

[0325]

Reference Example 153

Synthesis of 5-(3-trifluoromethyl-phenoxy)-thiophene-2-carbaldehyde

To a solution of 5-bromothiophene-2-carboxaldehyde (0.85 g, 4.45 mmol) in NMP (10 ml) were added 3-hydroxybenzotrifluoride (0.80 ml, 6.68 mmol) and cesium carbonate (2.18 g, 6.68 mmol). The reaction mixture was stirred for 5 hr at 110°C. Water was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water and brine,

dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt= 90:10-80:20) to give the title compound (0.89 g, 74%) as an orange oil.

^{1}H-NMR ($CDCl_3$) δ: 6.58 (1H, d, J = 6.6 Hz), 7.35-7.38 (1H, m), 7.44 (1H, s), 7.49-7.57 (3H, m), 9.75 (1H, s).

[0326]

Reference Example 154

Synthesis of 1-(3,4-difluoro-phenyl)-1H-indole-6-carbaldehyde

A suspension of indole-6-carbaldehyde (145 mg, 1.00 mmol), 1,2-difluoro-4-iodobenzene (200 µl, 1.66 mmol), copper(I) iodide (40 mg, 0.21 mmol), potassium phosphate (450 mg, 2.12 mmol) and N,N'-dimethylethylenediamine (40 µl, 0.37 mmol) in toluene 2 ml was stirring at 110°C for 10 hr under argon. The reaction mixture was cooled to room temperature, diluted with hexane, and then purified by silica gel chromatography (AcOEt:hexane = 1 : 10) to give the title compound (134 mg, 52%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 6.77 (1H, dd, J = 0.9, 3.3 Hz), 7.25-7.33 (1H, m), 7.33-7.43 (2H, m), 7.48 (1H, d, J = 3.3 Hz), 7.72 (1H, dd, J = 1.2, 8.4 Hz), 7.80 (1H, d, J = 8.4 Hz), 7.99 (1H, m), 10.05 (1H, s).

[0327]

Reference Example 155

Synthesis of 3-chloro-5-(4-trifluoromethyl-piperidin-1-yl)-benzaldehyde

The title compound was obtained using 1-(3-chloro-5-diethoxymethyl-phenyl)-4-trifluoromethyl-piperidinein the same manner as in Reference Example 151.

^{1}H-NMR ($CDCl_3$) δ: 1.67-1.78 (2H, m), 1.97-2.04 (2H, m), 2.16-2.31 (1H, m), 2.79-2.84 (2H, m), 3.82-3.88 (2H, m), 7.11-7.12 (1H, m), 7.26-7.29 (2H, m), 9.89 (1H, s).

[0328]

Reference Example 156

Synthesis of (3'-trifluoromethyl-biphenyl-3-yl)-acetaldehyde

To a solution of 2-(3'-trifluoromethyl-biphenyl-3-yl)-ethanol (533 mg, 2 mmol) in CH_3CN (6 ml) was added IBX (728 mg, 2.60 mmol). The reaction mixture was stirred at 60°C for 4 hr. The reaction was diluted with IPE and the resulting suspension was filtered. The filtrate was concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 5% -> 20%) to give the title compound (354 mg, 67%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 3.80 (2H, s), 7.26 (1H, d, J = 7.2 Hz), 7.44 (1H, s), 7.48 (1H, t, J = 7.6 Hz), 7.53-7.58 (2H, m), 7.62 (1H, d, J = 7.6 Hz), 7.76 (1H, d, J = 7.6 Hz), 7.82 (1H, s), 9.82 (1H, s).

[0329]

Reference Example 157

Synthesis of 4-trifluoromethyl-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde

The title compound was obtained using {4-trifluoromethyl-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 7.23 (1H, d, J = 16.1 Hz), 7.48-7.60 (3H, m), 7.73-7.88 (4H, m), 8.28 (1H, s), 10.14 (1H, s).

[0330]

Reference Example 158

Synthesis of 2-(4-chloro-phenyl)-5-methyl-oxazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-phenyl)-5-methyl-oxazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H-NMR ($CDCl_3$) δ: 2.72 (3H, s), 7.44-7.48 (2H, m), 7.97-8.01 (2H, m), 10.02 (1H, s).

[0331]

Reference Example 159

Synthesis of 2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazole-5-carbaldehyde

To the solution of {2-[(*E*)-2-(3-trifluoromethyl-phenyl)-

vinyl]-thiazol-5-yl}-methanol (410 mg, 1.437 mmol) in AcOEt (16 ml) was added IBX (1.207 g, 4.31 mmol). The reaction mixture was refluxed for 1 hr. After filtration, the filtrate was concentrated. The residue was purified by flash column chromatography (hexane/AcOEt = 9/1 to 3/2) to give the title compound (350 mg, 86%) as a yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 7.37 (1H, d, J = 16.1 Hz), 7.56-7.83 (5H, m), 8.42 (1H, s), 10.05 (1H, s).

[0332]

Reference Example 160

Synthesis of 3-(2,3-dihydro-indol-1-ylmethyl)-benzaldehyde

A solution of indole (140 mg, 1.23 mmol), methanesulfonic acid 3-diethoxymethyl-benzyl ester (300 mg, 1.04 mmol) and DIPEA (0.35 ml) in CH_3CN (5 ml) was stirred at room temperature overnight and then heated to 80°C for 8 hr. The solvents were removed under reduced pressure. The residue was purified by silica gel chromatography (AcOEt-hexane = 1:4) to give a pale yellow oil.

To solution of the pale yellow oil in CH_3CN (2 ml) was added 1N HCl (1 ml) and the mixture was stirred at room temperature for 1 hr. The reaction mixture was basified with saturated $NaHCO_3$ aqueous solution and extracted with AcOEt, and the organic layer was dried over anhydrous Na_2SO_4. The solvents were removed under reduced pressure to give crude product as a pale brown oil. The crude material was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 15% gradient)) to give the title compound (224 mg, 95%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 3.00 (2H, t, J = 8.2 Hz), 3.34 (2H, t, J = 8.2 Hz), 4.32 (2H, s), 6.46 (1H, d, J = 7.8 Hz), 6.70 (1H, dt, J = 0.9, 7.4 Hz), 7.03-7.13 (2H, m), 7.51 (1H, t, J = 7.6 Hz), 7.66 (1H, d, J = 7.6 Hz), 7.80 (1H, d, J = 7.6 Hz), 7.90 (1H, s), 10.02 (1H, s).

[0333]

Reference Example 161

Synthesis of 3-(1-phenyl-ethoxy)-5-trifluoromethyl-benzaldehyde

The title compound was obtained using 3-hydroxy-5-trifluoromethyl-benzaldehyde and (1-bromoethyl)benzene in the same manner as in Reference Example 82.

^{1}H-NMR ($CDCl_3$) δ: 1.72 (3H, d, J = 6.4 Hz), 5.45 (1H, q, J = 6.4 Hz), 7.29-7.42 (6H, m), 7.51 (1H, s), 7.65 (1H, s), 9.94 (1H, s).

[0334]

Reference Example 162

Synthesis of 3-(2,5-bis-trifluoromethyl-benzyloxy)-5-methoxy-benzaldehyde

The title compound was obtained using 3-hydroxy-5-methoxy-benzaldehyde and 2,5-bis(trifluoromethyl)benzyl bromide in the same manner as in Reference Example 82.

^{1}H-NMR ($CDCl_3$) δ: 3.87 (3H, s), 5.32 (2H, s), 6.81 (1H, s), 7.08-7.11 (2H, m), 7.72 (1H, d, J = 8.1 Hz), 7.85 (1H, d, J = 8.1 Hz), 8.06 (1H, s), 9.93 (1H, s).

[0335]

Reference Example 163

Synthesis of 3-cyclopropylmethoxy-5-(5-trifluoromethyl-pyridin-2-yl)-benzaldehyde

The title compound was obtained using 3-hydroxy-5-(5-trifluoromethyl-pyridin-2-yl)-benzaldehyde and cyclopropylmethyl bromide in the same manner as in Reference Example 82.

^{1}H-NMR ($CDCl_3$) δ: 0.37-0.43 (2H, m), 0.67-0.73 (2H, m), 1.26-1.33 (1H, m), 3.97 (2H, d, J = 6.9 Hz), 7.50 (1H, s), 7.90-7.93 (2H, m), 7.99-8.02 (1H, m), 8.13 (1H, s), 8.97 (1H, s), 10.07 (1H, s).

[0336]

Reference Example 164

Synthesis of 3-(3-trifluoromethyl-benzyloxy)-5-(5-trifluoromethyl-pyridin-2-yl)-benzaldehyde

The title compound was obtained using 3-hydroxy-5-(5-

trifluoromethyl-pyridin-2-yl)-benzaldehyde and 3-(trifluoromethyl)benzyl bromide in the same manner as in Reference Example 82.

^{1}H-NMR ($CDCl_3$) δ: 5.27 (2H, s), 7.48-7.68 (5H, m), 7.77 (1H, s), 7.93 (1H, d, J = 8.3 Hz), 8.03-8.06 (2H, m), 8.18 (1H, s), 10.09 (1H, s).

[0337]

Reference Example 165

Synthesis of 2-ethoxy-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde

The title compound was obtained using 2-hydroxy-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde and iodoethane in the same manner as in Reference Example 82.

^{1}H-NMR ($CDCl_3$) δ: 1.49 (3H, t, J = 7.0 Hz), 4.08 (2H, q, J = 7.0 Hz), 7.19 (1H, d, J = 16.5 Hz), 7.27 (1H, t, J = 7.7 Hz), 7.45 (1H, d, J = 16.5 Hz), 7.50-7.57 (2H, m), 7.72 (1H, d, J = 7.4 Hz), 7.76 (1H, s), 7.81 (1H, dd, J = 1.7, 7.7 Hz), 7.88 (1H, dd, J = 1.7, 7.7 Hz), 10.44 (1H, s).

[0338]

Reference Example 166

Synthesis of 3-{[N-(4-fluoro-phenyl)-N-methyl-amino]-methyl}-benzaldehyde

To a suspension of 155 mg of 3-chloromethyl-benzaldehyde and 207 mg of K_2CO_3 in 4 ml of CH_3CN was added 150 mg of 4-fluoro-N-methylaniline. The reaction mixture was stirred at 80°C for 2 hr and room temperature for 3 days. The mixture was filtered and then concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 10% -> 20%) to give the title compound (240 mg, 99%) as a light yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 2.99 (3H, s), 4.53 (2H, s), 6.66-6.70 (2H, m), 6.87-6.96 (2H, m), 7.49-7.51 (2H, m), 7.76-7.79 (2H, m), 10.00 (1H, s).

[0339]

Reference Example 167

Synthesis of 3-(benzofuran-2-ylmethoxy)-benzaldehyde

The title compound was obtained using 2-bromomethyl-benzofuran and 3-hydroxybenzaldehyde in the same manner as in Reference Example 82.

^{1}H-NMR ($CDCl_3$) δ: 5.24 (2H, s), 6.83 (1H, s), 7.21-7.35 (3H, m), 7.45-7.59 (5H, m), 9.99 (1H, s).

[0340]

Reference Example 168

Synthesis of 3-(2,5-bis-trifluoromethyl-benzyloxy)-benzaldehyde

The title compound was obtained using 3-hydroxybenzaldehyde and 2,5-bis(trifluoromethyl)benzyl bromide in the same manner as in Reference Example 82.

^{1}H-NMR ($CDCl_3$) δ: 5.35 (2H, s), 7.28-7.31 (1H, m), 7.49-7.56 (3H, m), 7.73 (1H, d, J = 8.1 Hz), 7.86 (1H, d, J = 8.1 Hz), 8.08 (1H, s), 10.01 (1H, s).

[0341]

Reference Example 169

Synthesis of 3-fluoro-4-(3-trifluoromethyl-phenoxy)-benzaldehyde

To a solution of 3,4-difluorobenzaldehyde (0.45 g, 3.17 mmol) in NMP (5 ml) were added 3-hydroxybenzotrifluoride (0.45 ml, 3.80 mmol) and potassium carbonate (0.66 g, 4.75 mmol). The reaction mixture was stirred for 5 hr at 100°C. Water was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water (twice) and brine, dried over Na_2SO_4, and concentrated *in vacuo* to give the title compound (0.90 g, 100%) as a brown oil.

^{1}H-NMR ($CDCl_3$) δ: 7.13-7.40 (3H, m), 7.43-7.57 (2H, m), 7.64-7.77 (2H, m), 9.94 (1H, s).

[0342]

Reference Example 170

Synthesis of 3-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-thiophene-2-carbaldehyde

The title compound was obtained using 3-(3-hydroxy-phenyl)-thiophene-2-carbaldehyde and methanesulfonic acid 2,5-

bis-trifluoromethyl-benzyl ester in the same manner as in Reference Example 82.

^{1}H-NMR ($CDCl_3$) δ: 5.35 (2H, s), 7.08-7.14 (3H, m), 7.23 (1H, d, J = 5.0 Hz), 7.44 (1H, t, J = 8.0 Hz), 7.74-7.76 (2H, m), 7.85 (1H, d, J = 8.0 Hz), 8.09 (1H, s), 9.88 (1H, s).

[0343]

Reference Example 171

Synthesis of 5-fluoro-2-(3-fluoro-5-trifluoromethyl-benzyloxy)-3-methyl-benzaldehyde

The title compound was obtained using methanesulfonic acid 3-fluoro-5-trifluoromethyl-benzyl ester and 5-fluoro-2-hydroxy-3-methyl-benzaldehyde in the same manner as in Reference Example 82.

^{1}H-NMR (DMSO-d_6) δ: 2.34 (3H, s), 5.12 (2H, s), 7.31-7.37 (1H, m), 7.51-7.58 (1H, m), 7.69-7.78 (3H, m), 10.16 (1H, s).

[0344]

Reference Example 172

Synthesis of 3-(4,4,4-trifluoro-butoxy)-5-trifluoromethyl-benzaldehyde

The title compound was obtained using 3-hydroxy-5-trifluoromethyl-benzaldehyde and 1-bromo-4,4,4-trifluorobutane in the same manner as in Reference Example 82.

^{1}H-NMR ($CDCl_3$) δ: 2.07-2.16 (2H, m), 2.27-2.39 (2H, m), 4.14 (2H, t, J = 6.0 Hz), 7.41 (1H, s), 7.55 (1H, s), 7.73 (1H, s), 10.02 (1H, s).

[0345]

Reference Example 173

Synthesis of 3-(4-trifluoromethoxy-benzylsulfanylmethyl)-benzaldehyde

To a solution of 3-chloromethyl-benzaldehyde (155 mg, 1 mmol) in THF (6 ml) were added potassium carbonate (166 mg, 1.200 mmol) and 4-(trifluoromethoxy)benzyl mercaptan (219 mg, 1.050 mmol). The reaction mixture was stirred at 70°C for 5 hr. The mixture was filtered, and then the filtrate was concentrated. The residue was purified by silica gel column

chromatography (hexane -> hexane/AcOEt 20%) to give the title compound (188 mg, 58%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 3.61 (2H, s), 3.68 (2H, s), 7.15 (2H, d, J = 8.0 Hz), 7.26-7.30 (2H, m), 7.48-7.56 (2H, m), 7.76-7.78 (2H, m), 10.01 (1H, s).

[0346]

Reference Example 174

Synthesis of 1-(2,4,5-trifluoro-benzyl)-piperidine-4-carbaldehyde

A suspension of 4-piperidinemethanol (260 mg, 2.257 mmol), potassium carbonate (390 mg, 2.82 mmol) and 2,4,5-trifluorobenzyl bromide (423 mg, 1.881 mmol) in *N,N*-dimethylformamide (5 ml) was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The organic layers were washed with water (twice) and brine, and dried over anhydrous Na_2SO_4. The solvents were removed under reduced pressure to give a colorless oil. A solution of the colorless oil and IBX (632 mg, 2.26 mmol) was stirred at 40°C for 2 hr. To reaction mixture was added water and AcOEt. The mixture was filtrated through a layer of Celite with AcOEt. The filtrate was separated, and the organic layer was washed with water (twice), and dried over Na_2SO_4. The solvents were removed under reduced pressure to give a colorless oil. The crude product was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 50% gradient)) to give the title compound (241 mg, 50%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 1.61-1.80 (2H, m), 1.87-1.97 (2H, m), 2.14-2.31 (3H, m), 2.77-2.86 (2H, m), 3.50 (2H, s), 6.85-6.93 (1H, m), 7.20-7.29 (1H, m), 9.65 (1H, d, J =0.9 Hz).

[0347]

Reference Example 175

Synthesis of 3-(2-methoxy-benzyloxy)-5-trifluoromethyl-benzaldehyde

To a solution of 190 mg of 3-hydroxy-5-trifluoromethyl-

benzaldehyde in 4 ml of CH_3CN were added 166 mg of K_2CO_3 and 0.149 ml of 2-methoxybenzyl chloride. The reaction mixture was stirred at 80°C for 2 hr. 10 mg of NaI was added thereto, and the reaction was stirred at 80°C for 1 h. After cooling to room temperature, the reaction mixture was filtered, and the filtrate was concentrated to give the title compound (368 mg, quant.) as a brown solid.

^{1}H-NMR ($CDCl_3$) δ: 3.90 (3H, s), 5.22 (2H, s), 6.93-7.00 (2H, m), 7.34 (1H, t, J = 7.5 Hz), 7.44 (1H, d, J = 7.5 Hz), 7.52 (1H, s), 7.67 (1H, s), 7.70 (1H, s), 10.00 (1H, s).

[0348]

Reference Example 176

Synthesis of 3-(4-fluoro-phenyl)-benzo[b]thiophene-2-carbaldehyde

The title compound was obtained using 3-bromo-benzo[b]thiophene-2-carboxaldehyde and 4-fluorophenylboronic acid in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.24-7.32 (2H, m), 7.40-7.59 (4H, m), 7.75 (1H, d, J = 8.0 Hz), 7.95 (1H, d, J = 8.0 Hz), 9.93 (1H, s).

[0349]

Reference Example 177

Synthesis of 2-(3-chloro-phenyl)-5-cyclopropyl-oxazole-4-carbaldehyde

The title compound was obtained using 2-(3-chloro-phenyl)-5-cyclopropyl-oxazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 1.25-1.30 (4H, m), 2.67-2.74 (1H, m), 7.38-7.46 (2H, m), 7.87 (1H, dt, J = 1.5, 7.5 Hz), 7.96 (1H, t, J = 1.5 Hz), 10.04 (1H, s).

[0350]

Reference Example 178

Synthesis of 2-(4-chloro-phenyl)-4-methyl-thiazole-5-carbaldehyde

The title compound was obtained using 2-(4-chloro-phenyl)-4-methyl-thiazole-5-carboxylic acid ethyl ester in the

same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 2.79 (3H, s), 7.43-7.48 (2H, m), 7.93-7.97 (2H, m), 10.10 (1H, s).

[0351]

Reference Example 179

Synthesis of 4-methyl-2-(3-trifluoromethyl-phenyl)-thiazole-5-carbaldehyde

The title compound was obtained using 4-methyl-2-(3-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 2.81 (3H, s), 7.62 (1H, t, J = 7.8 Hz), 7.76 (1H, d, J = 7.8 Hz), 8.15 (1H, d, J = 7.8 Hz), 8.31 (1H, s), 10.13 (1H, s).

[0352]

Reference Example 180

Synthesis of 2-(3-chloro-4-fluoro-phenyl)-4-trifluoromethyl-thiazole-5-carbaldehyde

The title compound was obtained using 2-(3-chloro-4-fluoro-phenyl)-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 7.26-7.32 (1H, m), 7.91 (1H, ddd, J = 2.3, 4.4, 8.6 Hz), 8.15 (1H, dd, J = 2.3, 6.8 Hz), 10.23 (1H, d, J = 0.8 Hz).

[0353]

Reference Example 181

Synthesis of 2-(4-trifluoromethoxy-phenyl)-oxazole-4-carbaldehyde

The title compound was obtained using 2-(4-trifluoromethoxy-phenyl)-oxazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 7.33-7.37 (2H, m), 8.14-8.19 (2H, m), 8.34 (1H, s), 10.02 (1H, s).

[0354]

Reference Example 182

Synthesis of 2-(4-chloro-phenyl)-4-ethyl-thiazole-5-

carbaldehyde

The title compound was obtained using 2-(4-chloro-phenyl)-4-ethyl-thiazole-5-carboxylic acid methyl ester in the same manner as in Reference Example 63.

^{1}H-NMR ($CDCl_3$) δ: 1.44 (3H, t, J = 7.5 Hz), 3.13 (2H, q, J = 7.5 Hz), 7.43-7.47 (2H, m), 7.93-7.98 (2H, m), 10.11 (1H, s)

[0355]

Reference Example 183

Synthesis of 3-(4-fluoro-benzyl)-5-trifluoromethoxy-benzaldehyde

To a solution of 3-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-5-trifluoromethoxy-benzaldehyde (0.33 g, 1.09 mmol) in DME (10 mL) were added 4-fluorobenzyl bromide (0.136 ml, 1.09 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.027 g, 0.033 mmol) and 2 M aqueous sodium carbonate solution (0.820 mL, 1.64 mmol). The reaction mixture was stirred for 1.5 hr at 80°C under nitrogen. Water was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=100:0-85:15) to give the title compound (228 mg, 70%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 4.14 (2H, s), 7.27-7.33 (3H, m), 7.56-7.64 (4H, m), 9.97 (1H, s).

[0356]

Reference Example 184

Synthesis of 1-(4,4,4-trifluoro-butyl)-1H-indole-6-carbaldehyde

To a solution of indole-6-carbaldehyde (145 mg, 1.00 mmol) in DMF (1.5 ml) was added 60% NaH (50 mg, 3.5 mmol) at 0°C under argon, and the reaction mixture was stirred at 0°C for 0.5 hr. To the reaction mixture was added 1-bromo-4,4,4-trifluorobutane (191.9 mg, 1.00 mmol) at 0°C, and stirred at room temperature overnight. Water was added to the reaction

mixture, and the mixture was extracted with AcOEt. The organic layer was washed twice with water, and then dried over anhydrous Na_2SO_4. The solvents were removed under reduced pressure to give crude product as a pale orange oil. The crude material was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 15% gradient)) to give the title compound (195 mg, 76%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 2.0-2.3 (4H, m), 4.32 (2H, t, J = 6.8 Hz), 6.61 (1H, dd, J = 0.8, 3.1 Hz), 7.32 (1H, d, J = 3.1 Hz), 7.65 (1H, dd, J = 1.3, 8.2 Hz), 7.74 (1H, d, J = 8.2 Hz), 7.9 (1H, s), 10.08 (1H, s).

[0357]

Reference Example 185

Synthesis of 1-(2,4-bis-trifluoromethyl-benzyl)-1H-pyrrole-2-carbaldehyde

The title compound was obtained using pyrrole-2-carboxaldehyde and methanesulfonic acid 2,4-bis-trifluoromethyl-benzyl ester in the same manner as in Reference Example 184.

^{1}H-NMR ($CDCl_3$) δ: 5.82 (2H, s), 6.39 (1H, dd, J = 2.6, 4.0 Hz), 6.65 (1H, d, J = 8.2 Hz), 6.96 (1H, m), 7.07 (1H, dd, J = 1.7, 4.0 Hz), 7.65 (1H, d, J = 8.2 Hz), 7.95 (1H, s), 9.58 (1H, d, J = 0.9 Hz).

[0358]

Reference Example 186

Synthesis of 3-(5-trifluoromethyl-pyridin-2-yloxymethyl)-benzaldehyde

To a solution of (3-diethoxymethyl-phenyl)-methanol (210 mg, 1 mmol) and 2-chloro-5-(trifluoromethyl)pyridine (0.154 ml, 1.200 mmol) in DMF (4 ml) was added NaH (60.0 mg, 1.500 mmol) at 0°C and the mixture was stirred at room temperature for 20 hr. The reaction was quenched by addition of 1 molar HCl (2 ml) and THF (1 ml) at 0°C. The mixture was stirred for 30 min and extracted twice with AcOEt after diluted with water (5 ml). The organic solution was washed with water and brine, filtered

through a Na_2SO_4 short column, and concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 5% -> hexane/AcOEt 20%) to give the title compound (277 mg, 98%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 5.53 (2H, s), 6.92 (1H, d, J = 8.7 Hz), 7.56 (1H, t, J = 7.5 Hz), 7.71-7.87 (3H, m), 7.99 (1H, s), 8.46 (1H, s), 10.05 (1H, s).

[0359]

Reference Example 187

Synthesis of 3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-benzaldehyde

The title compound was obtained using (3-diethoxymethyl-phenyl)-methanol and 2-chloro-4-(trifluoromethyl)pyridine in the same manner as in Reference Example 186.

^{1}H-NMR ($CDCl_3$) δ: 5.52 (2H, s), 7.07 (1H, s), 7.11 (1H, d, J = 5.3 Hz), 7.56 (1H, t, J = 7.5 Hz), 7.73 (1H, d, J = 7.5 Hz), 7.85 (1H, d, J = 7.5 Hz), 7.99 (1H, s), 8.33 (1H, d, J = 5.3 Hz), 10.05 (1H, s).

[0360]

Reference Example 188

Synthesis of 4-[(*E*)-2-(3-formyl-phenyl)-vinyl]-benzonitrile

To a solution of (3-diethoxymethyl-benzyl)-phosphonic acid diethyl ester (367.6 mg, 1.11 mmol) and 4-cyanobenzaldehyde (170 mg, 1.30 mmol) in tetrahydorofuran (5 ml) was added 60% NaH (50 mg, 3.5 mmol) at 0°C under argon, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was acidified by 5N HCl at 0°C, and water was added. The reaction mixture was stirred overnight. The resulting suspension was filtered, and the white powder was washed with water. The resulting powder was purified by silica gel chromatography (CH_2Cl_2) to give the title compound (142 mg, 49%) as a colorless solid.

^{1}H-NMR ($CDCl_3$) δ: 7.19 (1H, d, J = 16.3 Hz), 7.27 (H, d, J = 16.3 Hz), 7.55-7.69(5H, m), 7.76-7.84 (2H, m), 8.06 (1H, t, J = 1.7 Hz), 10.07 (1H, s).

[0361]

Reference Example 189

Synthesis of 3-[2-(5-trifluoromethyl-pyridin-2-yloxy)-ethyl]-benzaldehyde

To a solution of 2-chloro-5-(trifluoromethyl)pyridine (0.119 ml, 0.927 mmol) and 2-(3-[1,3]dioxolan-2-yl-phenyl)-ethanol (150 mg, 0.772 mmol) in 3 ml of DMF was added 46 mg of NaH (60wt%) at 0°C and the mixture was stirred at room temperature for 18 hr. The reaction was quenched by addition of 1N HCl and THF (1 ml) at 0°C. The mixture was stirred for 2 hr and extracted twice with TBME. The organic solution was washed with water and brine, filtered through a Na_2SO_4 short column, and concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 5% -> hexane/AcOEt 20%) to give the title compound (188 mg, 82%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 3.19 (2H, t, J = 6.6 Hz), 4.60 (2H, t, J = 6.6 Hz), 6.95 (1H, s), 7.07 (1H, d, J = 5.4 Hz), 7.50 (1H, t, J = 7.5 Hz), 7.57-7.59 (1H, m), 7.75-7.78 (1H, m), 7.82 (1H, s), 8.29 (1H, d, J = 5.4 Hz), 10.02 (1H, s).

[0362]

Reference Example 190

Synthesis of 3-[(*E*)-2-(4-ethoxy-phenyl)-vinyl]-benzaldehyde

To a solution of (3-diethoxymethyl-benzyl)-phosphonic acid diethyl ester (150 mg, 0.45 mmol) and 4-ethoxybenzaldehyde (80 mg, 1.30 mmol) in tetrahydrofuran (5 ml) was added *tert*-BuONa (100 mg, 1.04 mmol) at 0°C, and the reaction mixture was stirred at room temperature for 3 days. The reaction was worked up and treated in the same manner as in Reference Example 188 to give the title compound (99 mg, 87%) as a yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 1.43 (3H, t, J = 7.0 Hz), 4.07 (2H, q, J = 7.0 Hz), 6.90 (2H, d, J = 8.8 Hz), 7.03 (1H, d, J = 16.2 Hz), 7.16 (1H, d, J = 16.2 Hz), 7.45-7.6 (3H, m), 7.7-7.8 (2H, m), 8.00 (1H, m), 10.05 (1H, s).

[0363]

Reference Example 191

Synthesis of 3-chloro-5-cyclopropylmethyl-benzaldehyde

The title compound was obtained using 1-bromo-3-chloro-5-cyclopropylmethyl-benzene in the same manner as in Reference Example 138.

^{1}H-NMR ($CDCl_3$) δ: 0.22-0.25 (2H, m), 0.58-0.62 (2H, m), 0.96-1.01 (1H, m), 2.61 (2H, d, J = 7.0 Hz), 7.52 (1H, s), 7.66 (1H, s), 7.69-7.70 (1H, m), 9.96 (1H, s).

[0364]

Reference Example 192

Synthesis of 4-formyl-2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzonitrile

The title compound was obtained using trifluoro-methanesulfonic acid 4-formyl-2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl ester in the same manner as in Reference Example 89.

^{1}H-NMR ($CDCl_3$) δ: 7.41-7.63 (4H, m), 7.80-7.82 (3H, m), 7.86 (1H, d, J = 1.0 Hz), 8.30 (1H, s), 10.14 (1H, s).

[0365]

Reference Example 193

Synthesis of 3-[2-(2,4-difluoro-phenyl)-ethyl]-benzaldehyde

The title compound was obtained using 3-[(*E*)-2-(2,4-difluoro-phenyl)-vinyl]-benzaldehyde in the same manner as in Reference Example 150.

^{1}H-NMR ($CDCl_3$) δ: 2.89-3.00 (4H, m), 6.73-6.82 (2H, m), 6.99-7.07 (1H, m), 7.39-7.47 (2H, m), 7.69-7.74 (2H, m), 9.99 (1H, s).

[0366]

Reference Example 194

Synthesis of 3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde

The title compound was obtained using 3-formyl-5-methylphenylboronic acid and 5-bromo-2-(trifluoromethyl)pyridine in the same manner as in Reference

Example 112.

^{1}H-NMR ($CDCl_3$) δ: 2.55 (3H, s), 7.68 (1H, s), 7.77-7.81 (2H, m), 7.92 (1H, s), 8.06-8.12 (1H, m), 8.96-8.97 (1H, m), 10.08 (1H, s).

[0367]

Reference Example 195

Synthesis of 5-ethoxymethyl-4'-fluoro-biphenyl-3-carbaldehyde

The title compound was obtained using 3-bromo-5-ethoxymethyl-benzaldehyde and 4-fluorophenylboronic acid in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 1.30 (3H, t, J = 7.1 Hz), 3.62 (2H, q, J = 7.1 Hz), 4.64 (2H, s), 7.14-7.18 (2H, m), 7.58-7.61 (2H, m), 7.80 (1H, s), 7.84 (1H, s), 7.96-7.97 (1H, m), 10.09 (1H, s).

[0368]

Reference Example 196

Synthesis of 3-cyclopropyl-5-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde

The title compound was obtained using 3-bromo-5-cyclopropyl-benzaldehyde and 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-trifluoromethyl-pyridine in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 0.82-0.86 (2H, m), 1.00-1.16 (2H, m), 2.05-2.11 (1H, m), 7.58 (1H, s), 7.63 (1H, s), 7.79 (1H, d, J = 8.2 Hz), 7.86-7.88 (2H, m), 8.06-8.09 (1H, m), 1.07 (1H, s).

[0369]

Reference Example 197

Synthesis of 3-cyclobutoxy-5-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde

The title compound was obtained using 3-bromo-5-cyclobutoxy-benzaldehyde and 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-trifluoromethyl-pyridine in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 1.71-1.81 (1H, m), 1.90-1.97 (1H, m), 2.19-2.28 (2H, m), 2.50-2.58 (2H, m), 4.75-4.81 (1H, m), 7.31-7.33 (1H, m), 7.35-7.36 (1H, m), 7.66 (1H, t, J = 1.5 Hz), 7.79 (1H,

d, J = 8.0 Hz), 8.07 (1H, dd, J = 2.1, 8.2 Hz), 8.96 (1H, d, J = 2.1 Hz), 10.04 (1H, s).

[0370]

Reference Example 198

Synthesis of 2-ethoxy-5-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde

The title compound was obtained using 5-bromo-2-ethoxy-benzaldehyde and 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-trifluoromethyl-pyridine in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 1.54 (3H, t, J = 7.0 Hz), 4.25 (2H, q, J = 7.0 Hz), 7.14 (1H, d, J = 8.8 Hz), 7.75 (1H, d, J = 8.2 Hz), 7.80 (1H, dd, J = 2.5, 8.8 Hz), 8.04 (1H, dd, J = 2.1, 8.2 Hz), 8.09 (1H, d, J = 2.5 Hz), 8.92-8.94 (1H, m), 10.56 (1H, s).

[0371]

Reference Example 199

Synthesis of 4-isopropoxy-3-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde

The title compound was obtained using 3-bromo-4-isopropoxy-benzaldehyde and 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-trifluoromethyl-pyridine in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 1.37 (6H, d, J = 6.0 Hz), 4.74-4.80 (1H, m), 7.13 (1H, d, J = 8.6 Hz), 7.75 (1H, d, J = 8.1 Hz), 7.87 (1H, d, J = 2.1 Hz), 7.93 (1H, dd, J = 2.1, 8.6 Hz), 8.03 (1H, dd, J = 2.1, 8.1 Hz), 8.92-8.93 (1H, m), 8.95 (1H, s).

[0372]

Reference Example 200

Synthesis of 5-(3-fluoro-5-trifluoromethyl-phenyl)-thiophene-2-carbaldehyde

The title compound was obtained using 5-formyl-2-thiopheneboronic acid and 3-bromo-5-fluorobenzotrifluoride in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 7.36 (1H, d, J = 8.1 Hz), 7.47 (1H, d, J = 4.0 Hz), 7.54 (1H, d, J = 9.1 Hz), 7.70 (1H, s), 7.78 (1H, d,

J = 4.0 Hz), 9.93 (1H, s).

[0373]

Reference Example 201

Synthesis of 4-(4-trifluoromethyl-pyrimidin-2-yl)-benzaldehyde

The title compound was obtained using 4-formylphenylboronic acid and 2-chloro-4-(trifluoromethyl)pyrimidine in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 7.59 (1H, d, J = 5.0 Hz), 8.03 (2H, d, J = 8.1 Hz), 8.70 (2H, d, J = 8.1 Hz), 9.11 (1H, d, J = 5.0 Hz), 10.13 (1H, s).

[0374]

Reference Example 202

Synthesis of 5'-fluoro-5-methyl-3'-trifluoromethyl-biphenyl-3-carbaldehyde

The title compound was obtained using 3-formyl-5-methylphenylboronic acid and 3-bromo-5-fluorobenzotrifluoride in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 2.53 (3H, s), 7.35 (1H, d, J = 8.3 Hz), 7.50 (1H, d, J = 9.3 Hz), 7.65 (2H, s), 7.75 (1H, s), 7.89 (1H, s), 10.07 (1H, s).

[0375]

Reference Example 203

Synthesis of 2-(3,5-bis-trifluoromethyl-benzyl)-benzaldehyde

The title compound was obtained using 2-formylphenylboronic acid and 3,5-bis(trifluoromethyl)benzyl bromide in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 4.57 (2H, s), 7.29 (1H, d, J = 7.4 Hz), 7.52-7.62 (4H, m), 7.70 (1H, s), 7.85-7.87 (1H, m), 10.11 (1H, s).

[0376]

Reference Example 204

Synthesis of 3-(2,5-bis-trifluoromethyl-benzyl)-5-chloro-benzaldehyde

The title compound was obtained using 3-chloro-5-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-benzaldehyde and 2,5-

bis(trifluoromethyl)benzyl bromide in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 4.30 (2H, s), 7.36 (1H, s), 7.44 (1H, s), 7.52 (1H, s), 7.67 (1H, d, J = 8.2 Hz), 7.76 (1H, s), 7.86 (1H, d, J = 8.2 Hz), 9.94 (1H, s).

[0377]

Reference Example 205

Synthesis of 6-(4-fluoro-phenyl)-benzofuran-2-carbaldehyde

The title compound was obtained using 6-bromo-benzofuran-2-carbaldehyde and 4-fluorophenylboronic acid in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 7.18 (2H, t, J = 8.7 Hz), 7.49-7.63 (4H, m), 7.75 (1H, s), 7.80 (1H, d, J = 8.1 Hz), 9.88 (1H, s).

[0378]

Reference Example 206

Synthesis of 2-((*E*)-styryl)-5-trifluoromethyl-benzaldehyde

The title compound was obtained using 2-bromo-5-(trifluoromethyl)benzaldehyde and trans-2-phenylvinylboronic acid in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 7.17 (1H, d, J = 16 Hz), 7.37-7.46 (3H, m), 7.60-7.63 (2H, m), 7.84-7.87 (2H, m), 8.04 (1H, d, J = 16 Hz), 8.13 (1H, s), 10.38 (1H, s).

[0379]

Reference Example 207

Synthesis of 3-trifluoromethyl-5-(6-trifluoromethyl-pyridin-2-yl)-benzaldehyde

The title compound was obtained using 2-chloro-6-(trifluoromethyl)pyridine and 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-5-trifluoromethyl-benzaldehyde in the same manner as in Reference Example 112.

^{1}H-NMR ($CDCl_3$) δ: 7.73-7.76 (1H, m), 8.04-8.06 (2H, m), 8.23 (1H, s), 8.61 (1H, s), 8.77 (1H, s), 10.20 (1H, s).

[0380]

Reference Example 208

Synthesis of 4-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-

2-carbaldehyde

The title compound was obtained using 4-bromo-2-furaldehyde and (*E*)-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 6.92-7.07 (2H, m), 7.47-7.53 (3H, m), 7.63 (1H, d, J = 7.8 Hz), 7.71 (1H, s), 7.80 (1H, s), 9.70 (1H, s).

[0381]

Reference Example 209

Synthesis of 3-[(*E*)-2-(2,4-difluoro-phenyl)-vinyl]-benzaldehyde

The title compound was obtained using 3-bromobenzaldehyde and 2-((*E*)-2-(2,4-difluorophenyl)vinyl)-4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 6.83-6.94 (2H, m), 7.16 (1H, d, J = 16.5 Hz), 7.29 (1H, d, J = 16.5 Hz), 7.53-7.61 (2H, m), 7.76-7.80 (2H, m), 8.02 (1H, s), 10.06 (1H, s).

[0382]

Reference Example 210

Synthesis of 2-hydroxy-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde

The title compound was obtained using 3-bromo-2-hydroxybenzaldehyde and (*E*)-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.07 (1H, t, J = 7.7 Hz), 7.27 (1H, d, J = 16.5 Hz), 7.47-7.53 (4H, m), 7.72 (1H, d, J = 7.4 Hz), 7.77 (1H, s), 7.83 (1H, dd, J = 1.6, 7.7 Hz), 9.93 (1H, s), 11.6 (1H, s).

[0383]

Reference Example 211

Synthesis of 5-chloro-2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde

The title compound was obtained using 2-bromo-5-chloro-

benzaldehyde and (*E*)-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.05 (1H, d, J = 16.2 Hz), 7.49-7.58 (3H, m), 7.67 (1H, d, J = 8.4 Hz), 7.74 (1H, s), 7.76 (1H, s), 7.82 (1H, d, J = 2.3 Hz), 8.03 (1H, d, J = 16.2 Hz), 10.26 (1H, s).

[0384]

Reference Example 212

Synthesis of 3-chloro-5-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-benzaldehyde

The title compound was obtained using 3-chloro-5-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-benzaldehyde and 5-bromo-2,2-difluoro-1,3-benzodioxole in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.15-7.18 (1H, m), 7.30-7.33 (2H, m), 7.75 (1H, s), 7.84 (1H, s), 7.90 (1H, s), 10.04 (1H, s).

[0385]

Reference Example 213

Synthesis of 3-(4-trifluoromethyl-pyrimidin-2-yl)-benzaldehyde

The title compound was obtained using 3-formylphenylboronic acid and 2-chloro-4-(trifluoromethyl)pyrimidine in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.58-7.61 (1H, m), 7.70 (1H, t, J = 7.7 Hz), 8.07-8.09 (1H, m), 8.79-8.82 (1H, m), 9.02 (1H, s), 9.10 (1H, d, J = 5.0 Hz), 10.16 (1H, s).

[0386]

Reference Example 214

Synthesis of 4-(3,5-bis-trifluoromethyl-phenyl)-thiophene-3-carbaldehyde

The title compound was obtained using 3-bromo-4-formylthiophene and 3,5-bis(trifluoromethyl)phenylboronic acid in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.41 (1H, d, J = 3.2 Hz), 7.88-7.90 (3H, m), 7.31 (1H, d, J = 3.2 Hz), 9.92 (1H, s).

[0387]

Reference Example 215

Synthesis of 5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiophene-2-carbaldehyde

The title compound was obtained using 5-bromothiophene-2-carboxaldehyde and (*E*)-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.13-7.21 (3H, m), 7.50-7.58 (2H, m), 7.66-7.70 (2H, m), 7.76 (1H, s), 9.88 (1H, s).

[0388]

Reference Example 216

Synthesis of 3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-benzaldehyde

The title compound was obtained using 3-chloro-5-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-benzaldehyde and 2-chloro-4-(trifluoromethyl)pyrimidine in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.62 (1H, d, J = 4.9 Hz), 8.00-8.04 (1H, m), 8.77-8.78 (1H, m), 8.91-8.92 (1H, m), 9.11 (1H, d, J = 4.9 Hz), 10.12 (1H, s).

[0389]

Reference Example 217

Synthesis of 3-chloro-5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde

The title compound was obtained using 3-bromo-5-chloro-benzaldehyde and (*E*)-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.15 (1H, d, J = 16.4 Hz), 7.23 (1H, d, J = 16.4 Hz), 7.49-7.56 (2H, m), 7.59-7.78 (4H, m), 7.91 (1H, s), 10.01 (1H, s).

[0390]

Reference Example 218

Synthesis of 3-(benzo[*b*]thiophen-3-yl)-5-chloro-benzaldehyde

The title compound was obtained using 3-bromo-5-chloro-benzaldehyde and benzothiophene-3-boronic acid in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.43-7.46 (2H, m), 7.52 (1H, s), 7.84-7.99 (5H, m), 10.06 (1H, s).

[0391]

Reference Example 219

Synthesis of 5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-carbaldehyde

The title compound was obtained using 5-bromo-2-furaldehyde and (*E*)-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 6.59 (1H, d, J = 3.6 Hz), 7.00 (1H, d, J = 16.4 Hz), 7.27 (1H, d, J = 3.6 Hz), 7.41 (1H, d, J = 16.4 Hz), 7.48-7.58 (2H, m), 7.66 (1H, d, J = 7.6 Hz), 7.76 (1H, s), 9.63 (1H, s).

[0392]

Reference Example 220

Synthesis of 3-(3,5-bis-trifluoromethyl-phenyl)-thiophene-2-carbaldehyde

The title compound was obtained using 3-bromothiophene-2-carboxaldehyde and 3,5-bis(trifluoromethyl)phenylboronic acid in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.27 (1H, d, J = 5.0 Hz), 7.84 (1H, d, J = 5.0 Hz), 7.93 (2H, s), 7.98 (1H, s), 9.84 (1H, s).

[0393]

Reference Example 221

Synthesis of 2-fluoro-4-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde

The title compound was obtained using 4-bromo-2-fluorobenzaldehyde and (*E*)-2-(3-trifluoromethylphenyl)vinylboronic acid pinacol ester in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 6.90-7.33 (4H, m), 7.52-7.54 (1H, m), 7.55

(1H, d, J = 7.8 Hz), 7.71 (1H, d, J = 7.5 Hz), 7.79 (1H, s), 7.89 (1H, t, J = 7.8 Hz), 10.35 (1H, s).

[0394]

Reference Example 222

Synthesis of 1-(2,5-bis-trifluoromethyl-phenyl)-piperidine-4-carbaldehyde

A suspension of 4-((tetrahydro-2H-pyran-2-yloxy)methyl)piperidine (300 mg, 1.51 mmol), 2,5-bis(trifluoromethyl)bromobenzene (0.261 ml, 1.51 mmol), $Pd(OAc)_2$ (33.8 mg, 0.151 mmol), *rac*-BINAP (94 mg, 0.151 mmol) and *tert*-BuONa (730 mg, 7.60 mmol) in toluene (10 ml) was heated to 100°C for 10 hr under argon. After the reaction mixture was allowed to cool to room temperature, the reaction mixture was filtered through a layer of Celite with AcOEt. The filtrate was concentrated *in vacuo* and the crude product was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 7% gradient)) to give 1-(2,5-bis(trifluoromethyl)phenyl)-4-((tetrahydro-2H-pyran-2-yloxy)methyl)piperidine(251 mg, 50%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) 1.4-1.9 (11H, m), 2.7-2.8 (2H, m), 3.1-3.2 (2H, m), 3.30 (1H, dd, J = 6.3, 9.5 Hz), 3.5-3.6 (1H, m), 3.68 (1H, dd, J = 6.8, 9.5 Hz), 3.85-3.95 (1H, m), 4.60 (1H, m), 7.43 (1H, d, J =8.3 Hz), 7.54 (1H, s), 7.73 (1H, d, J = 8.3 Hz).

To a solution of 1-(2,5-bis(trifluoromethyl)phenyl)-4-((tetrahydro-2H-pyran-2-yloxy)methyl)piperidine (250.5 mg, 0.765 mmol) in THF (4 ml) was added 5N HCl, and the reaction mixture was stirred at room temperature for 3 hr. The reaction mixture was diluted with AcOEt and basified with 5N aqueous NaOH and saturated aqueous $NaHCO_3$ solution. The organic layer was washed twice with water, dried over anhydrous Na_2SO_4. The solvents were removed under reduced pressure to give a pale brown oil.

To a solution of the pale brown oil in DMSO (2 ml) was added IBX (210 mg, 0.498 mmol) and the reaction mixture was stirred at room temperature overnight. To the resulting

suspension were added AcOEt and water, and the mixture was filtered through a layer of Celite with AcOEt. The organic layers were separated, and washed twice with water, dried over anhydrous $MgSO_4$. The solvents were removed under reduced pressure to give crude product as a pale brown oil. The crude material was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 10% gradient)) to give the title compound (132 mg, 58%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.8-1.95 (2H, m), 1.95-2.1 (2H, m), 2.3-2.5 (1H, m), 2.75-2.85 (2H, m), 3.1-3.2 (2H, m), 7.47 (1H, d, J =8.4 Hz), 7.54 (1H, s), 7.76 (1H, d, J = 8.4 Hz), 9.73 (1H d, J = 0.9 Hz).

[0395]

Reference Example 223

Synthesis of 3-[(*E*)-2-(5-trifluoromethyl-pyridin-3-yl)-vinyl]-benzaldehyde

A reaction vessel was charged with $Pd(OAc)_2$ (0.024 g, 0.109 mmol), 3-dimethylaminopropionic acid hydrochloride (0.020 g, 0.131 mmol), K_2CO_3 (0.301 g, 2.179 mmol), 3-vinyl-benzaldehyde (0.144 g, 1.090 mmol), 3-bromo-5-(trifluoromethyl)pyridine (0.295 g, 1.308 mmol) and NMP (4 ml). The reaction mixture was stirred at 120°C under argon for 9 hr. The reaction was quenched by addition of water, and then extracted with TBME (6 ml x2). The organic layer was washed with water and brine, and concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 10% -> 30%) to give the title compound (250 mg, 80%) as a light yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 7.22 (1H, d, J = 16.4 Hz), 7.31 (1H, d, J = 16.4 Hz), 7.59 (1H, t, J = 7.6 Hz), 7.79-7.86 (2H, m), 8.08 (2H, s), 8.79 (1H, s), 8.93 (1H, s), 10.08 (1H, s).

[0396]

Reference Example 224

Synthesis of 3-trifluoromethyl-5-[(*E*)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-benzaldehyde

The title compound was obtained using 2-trifluoromethyl-6-vinyl-pyridine and 3-bromo-5-(trifluoromethyl)benzaldehyde in the same manner as in Reference Example 223.

^{1}H-NMR ($CDCl_3$) δ: 7.36 (1H, d, J = 16.1 Hz), 7.60 (2H, d, J = 7.7 Hz), 7.83-7.90 (2H, m), 8.08 (2H, s), 8.28 (1H, s), 10.11 (1H, s).

[0397]

Reference Example 225

Synthesis of 3-[(*E*)-2-(5-trifluoromethyl-pyridin-2-yl)-vinyl]-benzaldehyde

The title compound was obtained using 5-trifluoromethyl-2-vinyl-pyridine and 3-bromobenzaldehyde in the same manner as in Reference Example 223.

^{1}H-NMR ($CDCl_3$) δ: 7.29 (1H, d, J = 16.1 Hz), 7.59 (1H, d, J = 8.3 Hz), 7.58 (1H, t, J = 7.6 Hz), 7.81-7.93 (4H, m), 8.12 (1H, s), 8.87 (1H, s), 10.07 (1H, s).

[0398]

Reference Example 226

Synthesis of 3-[(*E*)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-benzaldehyde

The title compound was obtained using 4-trifluoromethyl-2-vinyl-pyridine and 3-bromobenzaldehyde in the same manner as in Reference Example 223.

^{1}H-NMR ($CDCl_3$) δ: 7.30 (1H, d, J = 16.1 Hz), 7.40 (1H, d, J = 5.0 Hz), 7.55-7.60 (2H, m), 7.78-7.86 (3H, m), 8.11 (1H, s), 8.80 (1H, d, J = 5.0 Hz), 10.07 (1H, s).

[0399]

Reference Example 227

Synthesis of 3-[(*E*)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-benzaldehyde

The title compound was obtained using 3-bromobenzaldehyde and 4-trifluoromethyl-2-vinyl-pyrimidine in the same manner as in Reference Example 223.

^{1}H-NMR ($CDCl_3$) δ: 7.39 (1H, d, J = 16.0 Hz), 7.46 (1H, d, J = 5.0 Hz), 7.60 (1H, t, J = 7.6 Hz), 7.88-7.91 (2H, m), 8.14-

8.18 (2H, m), 8.98 (1H, d, J = 5.0 Hz), 10.07 (1H, s).

[0400]

Reference Example 228

Synthesis of 5-(3-fluoro-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrrole-2-carbaldehyde

A reaction vessel was charged with 3-bromo-5-fluorobenzotrifluoride (243 mg, 1 mmol), N-methylpyrrole-2-carboxaldehyde (218 mg, 2 mmol), AcOK (196 mg, 2 mmol), $Pd(OAc)_2$ (23 mg, 0.1 mmol) and DMA (3 ml). The reaction was carried out under microwave irradiation at 180°C for 10 min and quenched by addition of water. The reaction mixture was extracted twice with AcOEt and the combined organic phase was washed with water, and concentrated. The residue was purified by silica gel column chromatography (hexane/AcOEt 10% -> 20%) to give the title compound (76 mg, 28%) as a brown oil.

^{1}H-NMR ($CDCl_3$) δ: 3.95 (3H, s), 6.37 (1H, d, J = 4.1 Hz), 7.00 (1H, d, J = 4.1 Hz), 7.32-7.40 (2H, m), 7.49 (1H, s), 9.63 (1H, s).

[0401]

Reference Example 229

Synthesis of 3-phenoxy-5-trifluoromethyl-benzaldehyde

A suspension of 3-phenoxy-5-trifluoromethylbenzonitrile (347.8 mg, 1.32 mmol), Raney Ni (0.4 g) in 90% formic acid (3 ml) was heated to 100°C for 1.5 hr. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with AcOEt and filtered through a layer of Celite. The filtrate was washed three times with water, and then dried over anhydrous Na_2SO_4. The solvents were removed under reduced pressure, and the resulting crude product was purified by flash chromatography on silica gel (AcOEt/hexane (0 to 30% gradient)) to give the title compound (307 mg, 87%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 7.05-7.09 (2H, m), 7.22-7.26 (1H, m), 7.40-7.45 (2H, m), 7.50 (1H, s), 7.60 (1H, s), 7.83 (1H, s), 9.99 (1H, s).

[0402]

Reference Example 230

Synthesis of 3-(thiophen-3-yl)-5-trifluoromethyl-benzaldehyde

The title compound was obtained using 3-(thiophen-3-yl)-5-trifluoromethyl-benzonitrile in the same manner as in Reference Example 229.

^{1}H-NMR ($CDCl_3$) δ: 7.46 (1H, dd, J = 1.5, 5.0 Hz), 7.48 (1H, dd, J = 3.0, 5.0 Hz), 7.64 (1H, dd, J = 1.5, 3.0 Hz), 8.05 (1H, s), 8.08 (1H, s), 8.27 (1H, s), 10.12 (1H, s).

[0403]

Reference Example 231

Synthesis of 3-(benzofuran-2-yl)-4-fluoro-benzaldehyde

The title compound was obtained using 3-bromo-4-fluorobenzaldehyde and benzo[b]furan-2-boronic acid in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 7.27-7.40 (4H, m), 7.57 (1H, d, J = 7.7 Hz), 7.65 (1H, d, J = 7.2 Hz), 7.86-7.91 (1H, m), 8.60 (1H, dd, J = 2.1, 7.2 Hz), 10.08 (1H, s).

[0404]

Reference Example 232

Synthesis of 3-methyl-4-(3-trifluoromethyl-benzyl)-benzaldehyde

The title compound was obtained using 4-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-3-methyl-benzaldehyde and 3-(trifluoromethyl)benzyl bromide in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 2.32 (3H, s), 4.11 (2H, s), 7.23-7.30 (2H, m), 7.37-7.44 (2H, m), 7.46-7.52 (1H, m), 7.66-7.73 (2H, m), 9.98 (1H, s).

[0405]

Reference Example 233

Synthesis of 3-tert-butyl-5-(5-trifluoromethyl-pyridin-2-yl)-benzaldehyde

The title compound was obtained using 3-tert-butyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzaldehyde

and 2-chloro-5-(trifluoromethyl)pyridine in the same manner as in Reference Example 91.

^{1}H-NMR ($CDCl_3$) δ: 1.45 (9H, s), 7.93 (1H, d, J = 8.1 Hz), 8.02-8.04 (2H, m), 8.32 (1H, s), 8.40-8.42 (1H, m), 8.99 (1H, s), 10.12 (1H, s).

[0406]

Reference Example 234

Synthesis of 1-(2,5-bis-trifluoromethyl-phenyl)-1H-pyrrole-3-carbaldehyde

To a solution of 241 mg of 2,5-bis(trifluoromethyl)aniline in 1 ml of AcOH was added 160 mg of 2,5-dimethoxy-3-tetrahydrofurancarboxaldehyde and the reaction mixture was stirred at 90°C for 2 hr. The reaction was quenched by addition of water, and the mixture was extracted with AcOEt. The organic solution was washed with water and 5wt% $NaHCO_3$ aqueous solution, and concentrated to give the title compound (318 mg, quant.) as a brown oil.

^{1}H-NMR ($CDCl_3$) δ: 6.82-6.88 (2H, m), 7.46 (1H, s), 7.72 (1H, s), 7.89 (1H, d, J = 8.2 Hz), 8.00 (1H, d, J = 8.2 Hz), 9.87 (1H, s).

[0407]

Reference Example 235

Synthesis of 3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-benzaldehyde

The title compound was obtained using 3-formyl-5-methylphenylboronic acid and 2-chloro-4-(trifluoromethyl)pyrimidine in the same manner as in Reference Example 91

^{1}H-NMR ($CDCl_3$) δ: 2.56 (3H, s), 7.58 (1H, d, J = 5.0 Hz), 7.89 (1H, s), 8.61 (1H, s), 8.82 (1H, s), 9.09 (1H, d, J = 5.0 Hz), 10.13 (1H, s).

[0408]

Reference Example 236

Synthesis of 2-(4-chloro-phenyl)-5-propyl-oxazole-4-carboxylic acid methyl ester

The title compound was obtained using methyl 3-oxohexanoate and 4-chlorobenzylamine in the same manner as in Reference Example 133.

^{1}H NMR ($CDCl_3$) δ: 1.03 (3H, t, J = 7.5 Hz), 1.76-1.83 (2H, m), 3.09 (2H, t, J = 7.6 Hz), 3.94 (3H, s), 7.43-7.46 (2H, m), 8.00-8.03 (2H, m).

[0409]

Reference Example 237

Synthesis of [2-(4-chloro-phenyl)-5-propyl-oxazol-4-yl]-methanol

The title compound was obtained using 2-(4-chloro-phenyl)-5-propyl-oxazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 19.

^{1}H NMR ($CDCl_3$) δ: 0.99 (3H, t, J = 7.4 Hz), 1.66-1.78 (2H, m), 2.71 (2H, t, J = 7.4 Hz), 3.00 (1H, t, J = 6.0 Hz), 4.59 (2H, d, J = 6.0 Hz), 7.39-7.42 (2H, m), 7.91-7.94 (2H, m).

[0410]

Reference Example 238

Synthesis of 2-(4-chloro-phenyl)-5-propyl-oxazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-phenyl)-5-propyl-oxazol-4-yl]-methanol in the same manner as in Reference Example 147.

^{1}H NMR ($CDCl_3$) δ: 1.04 (3H, t, J = 7.4 Hz), 1.77-1.87 (2H, m), 3.07 (2H, t, J = 7.5 Hz), 7.45-7.47 (2H, m), 7.99-8.01 (2H, m), 10.02 (1H, s).

[0411]

Reference Example 239

Synthesis of [2-(4-chloro-phenyl)-5-cyclopropyl-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(4-chloro-phenyl)-thiazol-4-yl]-methanol and cyclopropylboronic acid in the same manner as in Reference Example 38.

^{1}H NMR ($CDCl_3$) δ: 0.72-0.77 (2H, m), 1.08-1.15 (2H, m), 2.00-2.07 (1H, m), 2.44 (1H, t, J = 5.8 Hz), 4.81 (2H, d, J = 5.8

Hz), 7.36-7.40 (2H, m), 7.77-7.80 (2H, m).

[0412]

Reference Example 240

Synthesis of 2-(4-chloro-phenyl)-5-cyclopropyl-thiazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-phenyl)-5-cyclopropyl-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H NMR ($CDCl_3$) δ: 0.85-0.90 (2H, m), 1.34-1.45 (2H, m), 3.07-3.15 (1H, m), 7.40-7.43 (2H, m), 7.80-7.40 (2H, m), 10.22 (1H, s).

[0413]

Reference Example 241

Synthesis of [5-methyl-2-(4-trifluoromethoxy-phenoxy)-thiazol-4-yl]-methanol

The title compound was obtained using [5-bromo-2-(4-chloro-phenyl)-thiazol-4-yl]-methanol and methylboronic acid in the same manner as in Reference Example 38.

^{1}H NMR ($CDCl_3$) δ: 2.01 (1H, t, J = 6.1 Hz), 2.34 (3H, s), 4.51 (2H, d, J = 6.1 Hz), 7.28-7.36 (4H, m).

[0414]

Reference Example 242

Synthesis of 5-methyl-2-(4-trifluoromethoxy-phenoxy)-thiazole-4-carbaldehyde

The title compound was obtained using [5-methyl-2-(4-trifluoromethoxy-phenoxy)-thiazol-4-yl]-methanol in the same manner as in Reference Example 48.

^{1}H NMR ($CDCl_3$) δ: 2.72 (3H, s), 7.26-7.38 (4H, m), 9.90 (1H, s).

[0415]

Reference Example 243

Synthesis of 2-(4-chloro-phenyl)-5-isopropyl-oxazole-4-carboxylic acid methyl ester

The title compound was obtained using methyl isobutyrylacetate and 4-chlorobenzylamine in the same manner as in Reference Example 133.

^{1}H NMR ($CDCl_3$) δ: 1.36 (6H, d, J = 7.2 Hz), 3.80-3.89 (1H, m), 3.94 (3H, s), 7.42-7.44 (2H, m), 7.99-8.02 (2H, m).

[0416]

Reference Example 244

Synthesis of [2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-methanol

The title compound was obtained using 2-(4-chloro-phenyl)-5-isopropyl-oxazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 19.

^{1}H NMR ($CDCl_3$) δ: 1.34 (6H, d, J = 7.2 Hz), 2.65 (1H, t, J = 6.0 Hz), 3.13-3.22 (1H, m), 4.61 (2H, d, J = 6.0 Hz), 7.40-7.43 (2H, m), 7.92-7.95 (2H, m).

[0417]

Reference Example 245

Synthesis of 2-(4-chloro-phenyl)-5-isopropyl-oxazole-4-carbaldehyde

The title compound was obtained using [2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-methanol in the same manner as in Reference Example 147.

^{1}H NMR ($CDCl_3$) δ: 1.41 (6H, d, J = 6.9 Hz), 3.65-3.74 (1H, m), 7.44-7.49 (2H, m), 7.98-8.02 (2H, m), 10.04 (1H, s).

[0418]

Reference Example 246

Synthesis of 5-ethyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester

The title compound was obtained using 3-trifluoromethyl-thiobenzamide and 3-bromo-2-oxo-pentanoic acid methyl ester in the same manner as in Reference Example 2.

^{1}H NMR ($CDCl_3$) δ: 1.40 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 3.98 (3H, s), 7.57 (1H, t, J = 7.8 Hz), 7.68 (1H, d, J = 7.8 Hz), 8.11 (1H, d, J = 7.8 Hz), 8.19 (1H, s).

[0419]

Reference Example 247

Synthesis of 5-ethyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde

The title compound was obtained using 5-ethyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 63.

^{1}H NMR ($CDCl_3$) δ: 1.40 (3H, t, J = 7.5 Hz), 3.34 (2H, q, J = 7.5 Hz), 7.59 (1H, t, J = 7.8 Hz), 7.71 (1H, d, J = 7.8 Hz), 8.11 (1H, d, J = 7.8 Hz), 8.21 (1H, s), 10.22 (1H, s).

[0420]

Reference Example 248

Synthesis of 2-(3,4-difluoro-phenyl)-5-isobutyl-oxazole-4-carboxylic acid methyl ester

The title compound was obtained using 5-methyl-3-oxo-hexanoic acid methyl ester and 3,4-difluorobenzylamine in the same manner as in Reference Example 133.

^{1}H NMR ($CDCl_3$) δ: 1.00 (3H, s), 1.02 (3H, s), 2.10-2.19 (1H, m), 3.00 (2H, d, J = 7.2 Hz), 3.95 (3H, s), 7.22-7.29 (1H, m), 7.81-7.86 (1H, m), 7.87-7.92 (1H, m).

[0421]

Reference Example 249

Synthesis of 2-(3,4-difluoro-phenyl)-5-isobutyl-oxazole-4-carbaldehyde

The title compound was obtained using 2-(3,4-difluoro-phenyl)-5-isobutyl-oxazole-4-carboxylic acid methyl ester in the same manner as in Reference Example 63.

^{1}H NMR ($CDCl_3$) δ: 1.02 (3H, s), 1.03 (3H, s), 2.13-2.20 (1H, m), 2.97 (2H, d, J = 7.1 Hz), 7.27-7.31 (1H, m), 7.81-7.91 (2H, m), 10.00 (1H, s).

[0422]

Reference Example 250

Synthesis of 2-(4-trifluoromethoxy-phenoxy)-thiazole-4-carboxylic acid ethyl ester

The title compound was obtained using 2-bromo-thiazole-4-carboxylic acid ethyl ester and 4-(trifluoromethoxy)phenol in the same manner as in Reference Example 9.

^{1}H NMR ($CDCl_3$) δ: 1.38 (3H, t, J = 7.1 Hz), 4.38 (2H, q, J = 7.1 Hz), 7.26-7.29 (2H, m), 7.35-7.38 (2H, m), 7.75 (1H, s).

[0423]

Reference Example 251

Synthesis of [2-(4-trifluoromethoxy-phenoxy)-thiazol-4-yl]-methanol

The title compound was obtained using 2-(4-trifluoromethoxy-phenoxy)-thiazole-4-carboxylic acid ethyl ester in the same manner as in Reference Example 19.

^{1}H NMR ($CDCl_3$) δ: 2.00 (1H, t, J = 6.2 Hz), 4.59 (2H, d, J = 6.2 Hz), 6.73 (1H, s), 7.23-7.34 (4H, m).

[0424]

Reference Example 252

Synthesis of [5-bromo-2-(4-trifluoromethoxy-phenoxy)-thiazol-4-yl]-methanol

The title compound was obtained using [2-(4-trifluoromethoxy-phenoxy)-thiazol-4-yl]-methanol in the same manner as in Reference Example 27.

^{1}H NMR ($CDCl_3$) δ: 2.06 (1H, t, J = 6.3 Hz), 4.55 (2H, d, J = 6.3 Hz), 7.24-7.33 (4H, m).

[0425]

Reference Example 318

Synthesis of (E)-3-[2,5-bis(trifluoromethyl)-phenyl]-prop-2-en-1-ol

To a solution of (E)-3-(2,5-bis-trifluoromethyl-phenyl)-acrylic acid ethyl ester (1.79 g, 5.74 mmol) in CH_2Cl_2 (35 ml) was added diisobutylaluminium hydride (0.94M in hexane) (13.4 ml, 12.6 mmol) at -30°C under argon. After the reaction mixture was stirred at the same temperature for 45 min, methanol was added thereto in order to decompose the excess diisobutylaluminium hydride. Water, CH_2Cl_2 and Celite were added to the reaction mixture, and the mixture was filtered through a pad of Celite. The filtrate was extracted twice with CH_2Cl_2. The organic layer was washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo* to give the title compound (1.56 g, 100%).

^{1}H-NMR ($CDCl_3$) δ: 4.40-4.42 (2H, m), 6.41-6.47 (1H, m), 7.00-

7.05 (1H, m), 7.61 (1H, d, J = 8.2 Hz), 7.77 (1H, d, J = 8.2 Hz), 7.87 (1H, s).

[0426]

Reference Example 323

Synthesis of 5-phenoxy-2-phenyl-benzaldehyde

To a solution of 2-methyl-4-phenoxy-biphenyl (105.4 mg, 0.405 mmol) in CCl_4 (2 ml) were added NBS (180 mg, 1.0 mmol) and 2,2'-azodiisobutyronitrile (catalytic amount). After being stirred for 2 hr under reflux, the reaction mixture was cooled and filtrated. The filtrate was concentrated *in vacuo* to give a colorless oil. To a solution of the oil in 2-butanone (4 ml) and water (2 ml) was added silver nitrate (200 mg, 1.18 mmol). After being stirred for 1 hr under reflux, the reaction mixture was cooled, and extracted with AcOEt. The organic layer was washed with water, dried over anhydrous Na_2SO_4, and then concentrated *in vacuo*. The obtained residue was purified by TLC (AcOEt/hexane = 1/20) to give the title compound (94.2 mg, 85%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 7.06-7.10 (2H, m), 7.15-7.20 (1H, m), 7.30 (1H, dd, J = 2.8, 8.4 Hz), 7.35-7.50 (8H, m), 7.59 (1H, d, J = 2.7 Hz), 9.93 (1H, s).

[0427]

Reference Example 342

Synthesis of 4-[2,5-bis(trifluoromethyl)-phenyl]-but-3-yn-1-ol

To a solution of 2,5-bis(trifluoromethyl)bromobenzene (2.0g, 6.83 mmol) in THF (20 ml) were added 3-butyn-1-ol (0.62 ml, 8.19 mmol), $PdCl_2(PPh_3)_2$ (0.19 g, 0.273 mmol), Et_3N (1.90 ml, 13.7 mmol) and CuI (26 mg, 0.137 mmol). After the reaction mixture was refluxed for 2.5 hr, it was filtered through a pad of Celite. The filtrate was concentrated *in vacuo* and the residue was purified by silica gel column chromatography (hexane/AcOEt = 9:1-4:1) to give the title compound (1.49 g, 77%).

^{1}H-NMR ($CDCl_3$) δ: 1.80 (1H, t, J = 6.4 Hz), 2.75 (2H, t, J = 6.2 Hz), 3.84-3.88 (2H, m), 7.63 (1H, d, J = 8.2 Hz), 7.77 (1H,

d, J = 8.2 Hz), 7.82 (1H, s).

[0428]

Reference Example 484

Synthesis of (E)-3-[3-[[2,5-bis(trifluoromethyl)-phenyl]-methoxy]-phenyl]-acrylaldehyde

To a solution of 3-(2,5-bis-trifluoromethyl-benzyloxy)-benzaldehyde (1.00 g, 2.87 mmol) in toluene (20 ml) was added (triphenylphosphoranylidene)acetaldehyde (1.05 g, 3.45 mmol) and the reaction mixture was stirred at 100°C overnight. The reaction mixture was concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/AcOEt = 10:1-9:1) to give the title compound (0.49 g, 45%).

^{1}H-NMR ($CDCl_3$) δ: 5.33 (2H, s), 6.67-7.08 (1H, m), 7.09-7.23 (3H, m), 7.37-7.49 (2H, m), 7.73 (1H, d, J = 8.3 Hz), 7.86 (1H, d, J = 8.3 Hz), 8.08 (1H, s), 9.72 (1H, d, J = 7.7 Hz).

[0429]

Reference Example 597

Synthesis of 3-bromo-5-fluoro-phenol

To a solution of 3-bromo-5-fluoroanisole (7.0 g, 36.6 mmol) in AcOH (35 ml) was added 47% HBr aq. (35 ml). The reaction mixture was stirred at 120°C for 23.5 hr. The reaction was quenched by addition of water and AcOEt. After neutralized with saturated aqueous $NaHCO_3$ solution, the reaction mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The obtained residue was purified by silica gel column chromatography (hexane/AcOEt = 9/1) to give the title compound (7.69 g, quant.) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 6.11 (1H, brs), 6.53 (1H, dt, J = 2.2, 10.0 Hz), 6.79-6.84 (2H, m).

[0430]

Reference Example 600

Synthesis of [3,4-bis(trifluoromethyl)-phenyl]-methanol

To a solution of 3,4-bis(trifluoromethyl)benzoic acid

(1.00 g, 3.87 mmol) in THF (20 ml) at 0°C was added BH_3 THF complex (1.0M THF solution, 8.44 ml, 8.44 mmol). The reaction mixture was stirred at room temperature for 3 hr. The reaction was quenched by addition of 1N HCl aq. at 0°C, and the reaction mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The obtained residue was purified by silica gel column chromatography (hexane/AcOEt = 3/1) to give the title compound (820 mg, 87%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 1.99 (1H, brs), 4.85 (2H, s), 7.67-7.69 (1H, m), 7.83-7.86 (2H, m).

[0431]

Reference Example 618

Synthesis of 3-(difluoro-methoxy)-5-([1,3]dioxolan-2-yl)-phenol

To a solution of 2-(3-difluoromethoxy-5-[1,3]dioxolan-2-yl-phenyl)-5,5-dimethyl-[1,3,2]dioxaborinane (3.84 g, 11.7 mmol) in THF (40 ml) were added 3N NaOH (11.7 ml, 35.1 mmol) and 30% H_2O_2 (11.7 ml) at 0°C. After the reaction mixture was stirred at 0°C for 30 min, it was warmed to room temperature and stirring was continued for 1 hr. The reaction mixture was acidified with 5N HCl, and extracted twice with AcOEt. The organic layer was washed with brine, dried over $MgSO_4$, and concentrated *in vacuo* to give the crude product of the title compound (3.73 g). This product was used in the next step without purification.

[0432]

Reference Example 643

Synthesis of 3-(tetrahydro-pyran-2-yloxy)-adamantane-1-carboxylic acid ethyl ester

To a solution of 3-hydroxy-adamantane-1-carboxylic acid (1.0 g, 5.10 mmol) in DMF (10 ml) were added K_2CO_3 (1.0 g, 6.25 mmol) and iodoethane (0.6 ml, 6.58 mmol). After being stirred at room temperature for 3 days and at 60 °C for 1 hr, the reaction mixture was cooled and filtrated. The filtrate was

concentrated *in vacuo* to give a colorless oil. To a solution of the oil in CH_2Cl_2 (20 ml) were added 3,4-dihydro-2H-pyran (0.6 ml, 6.58 mmol) and pyridinium *p*-toluensulfonate (catalytic amount). After the reaction mixture was stirred at room temperature for 5 hr, Et_3N (0.1 ml) was added to the reaction mixture. The reaction mixture was concentrated *in vacuo*. The obtained residue was purified by silica gel column chromatography (AcOEt/hexane = 1/20) to give the title compound (1.26 g, 80%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.24 (3H, t, J = 7.1 Hz), 1.45-2.04 (18H, m), 2.21-2.28 (2H, m), 3.38-3.51 (1H, m), 3.89-4.01 (1H, m), 4.11 (2H, q, J = 7.1 Hz), 4.82-4.93 (1H, m).

[0433]

Reference Example 742

Synthesis of 2-phenyl-4-(phenylmethoxy-methyl)-pyrimidine

A mixture of 4-(benzyloxymethyl)-6-chloro-2-phenylpyrimidine (1.61 g, 5.18 mmol), AcONa (0.85 g, 10.36 mmol) and 10% Pd on carbon (160 mg) in DMF (20 ml) under hydrogen was stirred at room temperature for 45 min. The reaction mixture was filtered through a celite pad. To the filtrate was added water and the reaction mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The obtained residue was triturated with hexane/EtOH to give the title compound (0.91g, 64%) as a pale yellow powder.

^{1}H-NMR ($CDCl_3$) δ: 4.71 (2H, s), 4.73 (2H, s), 7.30-7.45 (6H, m), 7.46-7.53 (3H, m), 8.39-8.45 (2H, m), 8.79 (1H, d, J = 5.1 Hz).

[0434]

Reference Example 750

Synthesis of (2-phenyl-pyrimidin-4-yl)-methanol

To a solution of 2-phenyl-4-(phenylmethoxy-methyl)-pyrimidine (0.90 g, 3.26 mmol) in CH_2Cl_2 (18 ml) at -10°C was added BBr_3 (1.0M CH_2Cl_2 solution, 3.91 ml, 3.91 mmol). The reaction mixture was stirred at -10°C for 0.5 hr. The reaction was quenched by addition of saturated aqueous $NaHCO_3$ solution

and the reaction mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, and dried over Na_2SO_4. The solution was purified by silica gel column chromatography ($MeOH/CH_2Cl_2$ = 0% to 5%) to give the title compound (0.38 g, 63%) as a yellow powder.

^{1}H-NMR ($CDCl_3$) δ: 3.72 (1H, t, J = 5.1 Hz), 4.82 (2H, d, J = 5.1 Hz), 7.18 (1H, dd, J = 0.7, 5.1 Hz), 7.49-7.53 (3H, m), 8.43-8.49 (2H, m), 8.76 (1H, d, J = 5.1 Hz).

[0435]

Reference Example 760

Synthesis of 6-(phenylmethoxy-methyl)-2-[4-(trifluoromethyl)-phenyl]-3H-pyrimidin-4-one

A mixture of 4-(trifluoromethyl)benzamidine hydrochloride (1.20 g, 4.60 mmol), ethyl 4-(benzyloxy)-3-oxobutanoate (1.09 g, 4.60 mmol) and 28% sodium methoxide (1.83 ml, 9.21 mmol) in MeOH (10 ml) was heated under reflux for 18 hr. After cooling to room temperature, the reaction mixture was concentrated *in vacuo*. To the residue was added water, and then the mixture was acidified with AcOH (pH = 4). The resulting precipitate was filtered, and washed with water. The solid was triturated with isopropyl ether to give the title compound (1.21 g, 73%) as a beige powder.

^{1}H-NMR ($CDCl_3$) δ: 4.54 (2H, d, J = 1.2 Hz), 4.72 (2H, s), 6.75 (1H, t, J = 1.2 Hz), 7.31-7.45 (5H, m), 7.80-7.82 (2H, m), 8.33-8.36 (2H, m), 13.24 (1H, brs).

[0436]

Reference Example 825

Synthesis of 3-[(E)-2-(2,2-difluoro-1,3-benzodioxol-5-yl)-vinyl]-benzaldehyde

To a solution of 3-vinyl-benzaldehyde (0.35 g, 2.65 mmol) in NMP (5.3 ml) were added 5-bromo-2,2-difluoro-1,3-benzodioxole (0.63 g, 2.65 mmol), $Pd(OAc)_2$ (30 mg, 0.133 mmol), K_2CO_3 (0.73 g, 5.30 mmol) and N, N-dimethylglycine (14 mg, 0.133 mmol). After the reaction mixture was stirred at 100°C overnight under argon, it was quenched by the addition of

water and extracted with AcOEt. The organic layer was washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/AcOEt = 10:0-9:1) to give the title compound (563 mg, 74%).

^{1}H-NMR ($CDCl_3$) δ: 7.05 (1H, t, J = 8.1 Hz), 7.13-7.22 (3H, m), 7.28 (1H, s), 7.54 (1H, t, J = 7.6 Hz), 7.73-7.80 (2H, m), 8.02 (1H, s), 10.06 (1H, s).

[0437]

Reference Example 831

Synthesis of 4-chloro-6-(phenylmethoxy-methyl)-2-[4-(trifluoromethyl)-phenyl]-pyrimidine

A mixture of 6-(phenylmethoxy-methyl)-2-[4-(trifluoromethyl)-phenyl]-3H-pyrimidin-4-one (0.90 g, 2.50 mmol) and $POCl_3$ (0.70 ml, 7.49 mmol) in CH_3CN (18 ml) was stirred at 80°C for 3 hr. After cooling to room temperature, the reaction mixture was poured into water, and extracted with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo* to give the title compound (0.79 g, 84%) as a yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 4.68-4.72 (4H, m), 7.09-7.23 (2H, m), 7.29-7.43 (3H, m), 7.53-7.54 (1H, m), 7.71-7.76 (2H, m), 8.52-8.59 (2H, m).

[0438]

Reference Example 916

Synthesis of methyl 4-[bis(tert-butoxycarbonyl)amino]-3-bromobenzoate

To a solution of methyl 4-amino-3-bromobenzoate (1.00 g, 4.35 mmol) in THF (20 ml) were added di-*tert*-butyl dicarbonate (7.27 ml, 31.3 mmol) and *N,N*-dimethyl-4-aminopyridine (0.053 g, 0.435 mmol). After being stirred at room temperature for 8 hr, the reaction mixture was concentrated *in vacuo*. The residue was purified by flash column chromatography (AcOEt/hexane = 20% to 50%) to give a white solid. The suspension of the obtained residue in hexane was filtrated to give the title

compound (1.45 g, 78%) as a white powder.

^{1}H-NMR ($CDCl_3$) δ: 1.39 (18H, s), 3.94 (3H, s), 7.29 (1H, d, J = 8.2 Hz), 7.99 (1H, dd, J = 1.9, 8.2 Hz), 8.29 (1H, d, J = 1.9 Hz).

[0439]

Reference Example 924

Synthesis of 3-bromo-4-(tert-butoxycarbonylamino)-benzoic acid

To a solution of methyl 4-(bis(tert-butoxycarbonyl)amino)-3-bromobenzoate (1.451 g, 3.37 mmol) in MeOH (30 ml) was added 1N NaOH (10.12 ml, 10.12 mmol). The reaction mixture was stirred at room temperature overnight, then at 50°C for 1 hr. After acidified with 1N HCl, the reaction mixture was extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous $MgSO_4$ and then concentrated *in vacuo* to give the title compound (927 mg, 87%) as a pale yellow solid.

^{1}H-NMR (DMSO-d_6) δ: 1.48 (9H, s), 7.78 (1H, d, J = 8.5 Hz), 7.89 (1H, dd, J = 1.9, 8.5 Hz), 8.08 (1H, d, J = 1.9 Hz), 8.66 (1H, s), 13.14 (1H, brs).

[0440]

Reference Example 934

Synthesis of (2-bromo-4-hydroxymethyl-phenyl)-carbamic acid tert-butyl ester

To a solution of 3-bromo-4-(tert-butoxycarbonylamino)benzoic acid (927 mg, 2.93 mmol) in THF (20 ml) were added Et_3N (0.49 ml, 3.52 mmol) and ethyl chlorocarbonate (0.308 ml, 3.23 mmol) at 0°C. After being stirred at 0°C for 30 min, the precipitate was filtrated off. To the filtrate was added a solution of $NaBH_4$ (333 mg, 8.80 mmol) in H_2O (4 ml) at 0°C. After being stirred at 0°C for 1 hr, the reaction mixture was concentrated *in vacuo*. Water was added to the reaction mixture. The reaction mixture was extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous $MgSO_4$, and then concentrated *in vacuo* to give the title compound (937 mg, quant.) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 1.53 (9H, s), 1.53-1.56 (1H, m), 4.62 (2H, s), 6.99 (1H, brs), 7.24-7.28 (1H, m), 7.55 (1H, d, J = 2.0 Hz), 8.13 (1H, d, J = 8.5 Hz).

[0441]

Reference Example 935

Synthesis of N-[4-formyl-2-[3-(trifluoromethyl)phenyl]-phenyl]-N-methyl-acetamide

To a solution of 6-(methylamino)-3'-(trifluoromethyl)biphenyl-3-carbaldehyde (46 mg, 0.165 mmol) in CH_2Cl_2 (4 ml) were added pyridine (0.054 ml, 0.658 mmol) and acetyl chloride (0.128 ml, 1.79 mmol) at room temperature overnight. Water was added to the reaction mixture. The reaction mixture was extracted with CH_2Cl_2. The organic layer was washed with 1N HCl and brine, dried over anhydrous $MgSO_4$, and then concentrated *in vacuo*. The residue was purified by flash column chromatography (AcOEt/hexane = 40% to 75%) to give the title compound (21 mg, 39%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.82 (3H, s), 3.04 (3H, s), 7.49-8.01 (7H, m), 10.11 (1H, s).

[0442]

Reference Example 1014

Synthesis of 1-(3,4-difluoro-phenyl)-2,3-dihydro-1H-indole-4-carboxylic acid methyl ester

To a solution of 1-(3,4-difluoro-phenyl)-1H-indole-4-carboxylic acid methyl ester (0.20 g, 0.696 mmol) in TFA (2 ml) was added triethylsilane (0.1 ml, 0.63 mmol). The reaction mixture was stirred at room temperature for 3 days. To a reaction mixture was added triethylsilane (0.2 ml). After being stirred for 3 hr at 50°C, the reaction mixture was cooled, washed with water and saturated aqueous $NaHCO_3$ solution, dried over anhydrous Na_2SO_4, and then concentrated *in vacuo*. The obtained residue was purified by cystallization (hexane) to give the title compound (176 mg, 88%) as a white solid.

^{1}H-NMR ($CDCl_3$) δ: 3.51 (2H, t, J = 8.5 Hz), 3.91 (3H, s), 3.94 (2H, t, J = 8.5 Hz), 6.87-6.96 (1H, m), 7.05 (1H, ddd, J = 2.8,

6.8, 12.4 Hz), 7.09-7.12 (3H, m), 7.40 (1H, dd, J = 2.2, 6.8 Hz).

[0443]

Reference Example 1123

Synthesis of 2-(4-chlorophenyl)-4-(trifluoromethyl)-thiazole-5-carboxylic acid ethyl ester

To a solution of ethyl 2-chloro-3-keto-4,4,4-trifluorobutyrate (200 mg, 0.915 mmol) in EtOH (4 ml) was added 4-chlorothiobenzamide (157 mg, 0.915 mmol). After being stirred at reflux temperature for 8 hr, the reaction mixture was concentrated *in vacuo*. The residue was purified by flash column chromatography (AcOEt/hexane = 10% to 33%). To the obtained residue in EtOH (4 ml) was added *p*-toluenesulfonic acid monohydrate (17 mg, 0.092 mmol). After being stirred at reflux temperature for 16 hr, the reaction mixture was concentrated *in vacuo*. The residue was purified by flash column chromatography (AcOEt/hexane = 10% to 33%) to give the title compound (101 mg, 33%) as a white powder.

^{1}H-NMR ($CDCl_3$) δ: 1.41 (3H, t, J = 7.1 Hz), 4.42 (2H, q, J = 7.2 Hz), 7.44-7.49 (2H, m), 7.91-7.96 (2H, m).

[0444]

Reference Example 1173

Synthesis of 2-(morpholin-4-yl)-thiazole-4-carboxylic acid ethyl ester

To a solution of ethyl 2-bromothiazole-4-carboxylate (200 mg, 0.847 mmol) in DMF (3 ml) was added morpholine (369 mg, 4.24 mmol). After the reaction mixture was stirred at 100°C for 4 hr, water was added thereto. The reaction mixture was extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous $MgSO_4$, and then concentrated *in vacuo* to give the title compound (186 mg, 91%) as a pale yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 1.37 (3H, t, J = 7.1 Hz), 3.51-3.54 (4H, m), 3.79-3.83 (4H, m), 4.36 (2H, q, J = 7.1 Hz), 7.48 (1H, s).

[0445]

Reference Example 1319

Synthesis of 5-fluoro-2-iodo-3-methyl-benzo[b]thiophene

To a solution of 5-fluoro-3-methylbenzo[b]thiophene (942 mg, 5.67 mmol) in THF (35 ml) was added *n*-butyllithium (3.97 ml, 6.23 mmol, 1.57 M in *n*-hexane) at -78°C under argon. After the solution was stirred at -78°C for 2 hr, iodine (1582 mg, 6.23 mmol) in THF (10 ml) was added to the reaction mixture. The resulting solution was stirred at 0°C for 1h. The reaction mixture was quenched with saturated aqueous solution of $Na_2S_2O_4$ and extracted with AcOEt. The organic layer was washed with saturated aqueous solution of $Na_2S_2O_4$ and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The crude product was purified by silica gel chromatography (hexane/AcOEt = 100:0-95:5) to give the title compound (1.41 g, 85%).

^{1}H-NMR ($CDCl_3$) δ: 2.37 (3H, s), 7.03-7.10 (1H, m), 7.33 (1H, dd, J = 2.5, 9.6 Hz), 7.67 (1H, dd, J = 4.9, 8.8 Hz).

[0446]

Reference Example 1377

Synthesis of 2-[4-(trifluoromethyl)-phenyl]-imidazo[1,2-a]pyridine-7-carboxylic acid methyl ester

4-Trifluoromethylphenacyl bromide (801 mg, 3 mmol), methyl 2-aminopyridine-4-carboxylate (456 mg, 3.00 mmol) and 2-butanone (7 mL) were charged into a reaction tube equipped with a condenser, and the mixture was heated to reflux and stirred for 14 hr. The formed precipitate was collected by filtration. The solid was then dissolved in saturated aqueous $NaHCO_3$ solution. The aqueous solution was extracted with AcOEt and the combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (504 mg, 52%) as a pale purple solid.

^{1}H-NMR ($CDCl_3$) δ: 3.98 (3H, s), 7.43 (1H, dd, J = 1.8, 7.2 Hz), 7.72 (2H, d, J = 8.1 Hz), 8.04 (1H, s), 8.10 (2H, d, J = 8.1 Hz), 8.17-8.20 (1H, m), 8.39 (1H, s).

[0447]

Reference Example 1415

Synthesis of 7-(trifluoromethyl)-benzo[b]thiophene-2-

carboxylic acid ethyl ester

To a solution of 2-fluoro-3-trifluoromethyl benzaldehyde (3.53 g, 18.37 mmol) in DMSO (35 ml) were added Et_3N (7.64 ml, 55.1 mmol) and ethyl mercaptoacetate (2.208 ml, 20.21 mmol). After the resulting solution was stirred at 80°C for 2 hr, it was quenched with water, and extracted twice with AcOEt. The organic layer was washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The crude product was purified by silica gel column chromatography (hexane/AcOEt = 100:0-75:25) to give the title compound (4.58 g, 91%).

^{1}H-NMR ($CDCl_3$) δ: 1.43 (3H, t, J = 7.1 Hz), 4.43 (2H, q, J = 7.1 Hz), 7.47-7.55 (1H, m), 7.76 (1H, d, J = 7.5 Hz), 8.05 (1H, d, J = 8.0 Hz), 8.12 (1H, s).

[0448]

Reference Example 1477

Synthesis of 3-chloro-4-fluoro-thiobenzamide

To a solution of 3-chloro-4-fluorobenzonitrile (3.00 g, 19.3 mmol) in DMF (30 ml) was added 22% ammonium sulfide solution (11.95 g, 38.6 mmol). After the reaction mixture was stirred at 60-65°C for 2 hr, and water was added thereto. After being filtered the precipitate, the obtained precipitate was dissolved in AcOEt. The solution was washed with water and brine, dried over anhydrous $MgSO_4$, and then concentrated *in vacuo* to give the title compound (2.24 g, 61%) as a pale yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 7.01-7.24 (1H, br), 7.18 (1H, t, J = 8.5 Hz), 7.54-7.88 (1H, br), 7.74-7.79 (1H, m), 7.98 (1H, dd, J = 2.4, 6.9 Hz).

[0449]

Reference Example 1494

Synthesis of 2-bromo-5-methyl-3H-imidazole-4-carboxylic acid ethyl ester

To a solution of ethyl 4-methyl-5-imidazolecarboxylate (1 g, 6.49 mmol) in $CHCl_3$ (10 ml) and CH_3CN (10 ml) was added NBS (1.27 g, 7.14 mmol). The reaction mixture was stirred at room

temperature for 19 hr. The reaction was quenched by addition of water and the reaction mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The obtained residue was purified by silica gel column chromatography (CH_2Cl_2/MeOH = 10/1) to give an orange powder. The powder was triturated with isopropyl ether/AcOEt to afford the title compound (0.47 g, 31%) as a pale orange powder.

^{1}H-NMR ($CDCl_3$) δ: 1.36 (3H, t, J = 7.1 Hz), 2.51 (3H, brs), 4.35 (2H, q, J = 7.1 Hz), 10.29-10.87 (1H, br).

[0450]

Reference Example 1497

Synthesis of 6-[1-[[4-(trifluoromethyl)-phenyl]-methoxy]-ethyl]-pyridine-2-carboxylic acid ethyl ester

The mixture of 6-(1-(4-(trifluoromethyl)benzyloxy)ethyl)picolinonitrile (480 mg, 1.57 mmol) and 1N HCl/EtOH (6 ml, 6.00 mmol) was stirred under reflux for 18 hr. The reaction was quenched by addition of saturated aqueous $NaHCO_3$ solution and extracted with AcOEt. The combined organic layers were washed with water and brine, and concentrated *in vacuo* to give the title compound (420 mg, 76%) as a brown oil.

^{1}H-NMR ($CDCl_3$) δ: 1.44 (3H, t, J = 6.9 Hz), 1.57 (3H, d, J = 6.6 Hz), 4.45-4.54 (4H, m), 4.81 (1H, q, J = 6.6 Hz), 7.45 (2H, d, J = 8.3 Hz), 7.59 (2H, d, J = 8.3 Hz), 7.70-7.73 (1H, m), 7.87 (1H, t, J = 7.8 Hz), 8.02-8.05 (1H, m).

[0451]

Reference Example 1643

Synthesis of 5-bromo-[1,3,4]oxadiazole-2-carboxylic acid ethyl ester

The mixture of ethyl 5-amino-1,3,4-oxadiazole-2-carboxylate (1.00 g, 6.36 mmol) and cupric bromide (2.13 g, 9.55 mmol) in CH_3CN (20 ml) was stirred at room temperature for 15 min. To the reaction mixture was added tert-butyl nitrite (1.51 ml, 12.73 mmol) and the mixture was stirred at room

temperature for 2 hr and at 50°C for 0.5 hr. After concentration *in vacuo*, the reaction was quenched by addition of water and AcOEt. The resulting suspension was filtered. The filtrate was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The obtained residue was purified by silica gel column chromatography (hexane/AcOEt = 4/1 to 1/1) to give the title compound (0.66 g, 47%) as a colorless oil.
^{1}H-NMR ($CDCl_3$) δ: 1.46 (3H, t, J = 7.1 Hz), 4.53 (2H, q, J = 7.1 Hz).

[0452]

Reference Example 1666

Synthesis of acetic acid [2-(4-chlorophenyl)-5-[(4-chlorophenyl)-methyl]-thiazol-4-yl]-methyl ester

To a solution of (2-(4-chlorophenyl)thiazol-4-yl)methyl acetate (200 mg, 0.747 mmol) in toluene (2 ml) were added p-chlorobenzyl chloride (0.191 ml, 1.494 mmol), palladium acetate (8 mg, 0.037 mmol), 2-(diphenylphosphino)-2'-(*N*,*N*-dimethylamino)biphenyl (28 mg, 0.075 mmol), Cs_2CO_3 (365 mg, 1.12 mmol) and pivalic acid (0.017 ml, 0.149 mmol). After the reaction mixture was stirred at 110°C for 8 hr under nitrogen, water was added thereto. The reaction mixture was extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous $MgSO_4$, and then concentrated *in vacuo*. The residue was purified by flash column chromatography (AcOEt /hexane = 0% to 30%) to give the title compound (162 mg, 55%) as a white powder.
^{1}H-NMR ($CDCl_3$) δ: 2.08 (3H, s), 4.21 (2H, s), 5.22 (2H, s), 7.15-7.18 (2H, m), 7.27-7.31 (2H, m), 7.36-7.40 (2H, m), 7.79-7.82 (2H, m).

[0453]

Reference Example 1668

Synthesis of 4-formyl-piperidine-1-carboxylic acid phenyl ester

To a solution of 4-piperidinemethanol (173 mg, 1.5 mmol)

in saturated aqueous $NaHCO_3$ solution (5 ml) and CH_2Cl_2 (5 ml) was added phenyl chloroformate (0.188 ml, 1.500 mmol) by portions at 0 °C for 10 min. The reaction mixture was stirred at 0°C for 1 hr. 2,2,6,6-Tetramethylpiperidine 1-oxyl (10 mg, 0.064 mmol), KBr (15 mg, 0.126 mmol) and tetrabutylammonium bromide (20 mg, 0.062 mmol) were added to the reaction mixture, and then sodium hypochlorite (5% for Cl) (4 ml) were added dropwise thereto at 0°C for 0.5 hr. After the reaction mixture was stirred for 10 min, the reaction was quenched by $Na_2S_2O_3$. The organic layer was seprated, washed with water, dried over anhydrous Na_2SO_4, and then concentrated *in vacuo*. The obtained residue was purified by flash column chromatography (AcOEt/hexane = 30% to 70%) to give the title compound (218 mg, 52%) as a pale yellow oil.

^{1}H-NMR ($CDCl_3$) δ: 1.61-1.79 (2H, m), 1.94-2.08 (2H, m), 2.46-2.58 (1H, m), 3.02-3.30 (2H, m), 4.05-4.25 (2H, m), 7.06-7.14 (2H, m), 7.16-7.27 (1H, m), 7.32-7.40 (2H, m), 9.72 (1H, s).

[0454]

Reference Example 1729

Synthesis of [[[4-(trifluoromethyl)-benzoyl]amino]-carbamoyl]-formic acid ethyl ester

To a solution of 4-(trifluoromethyl)benzoic acid hydrazide (1.50 g, 7.35 mmol) in CH_2Cl_2 (30 ml) at 0°C were added ethyl oxalyl chloride (0.90 ml, 8.08 mmol) and Et_3N (1.23 ml, 8.82 mmol). The reaction mixture was stirred at room temperature for 17 hr. The reaction was quenched by addition of water and the reaction mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The obtained residue was triturated with isopropyl ether to give the title compound (1.85 g, 83%) as a white powder.

^{1}H-NMR ($CDCl_3$) δ: 1.41 (3H, t, J = 7.2 Hz), 4.42 (2H, q, J = 7.2 Hz), 7.71 (2H, d, J = 8.2 Hz), 7.96 (2H, d, J = 8.2 Hz), 9.70 (2H, brs).

[0455]

Reference Example 1730

Synthesis of 5-[4-(trifluoromethyl)-phenyl]-[1,3,4]oxadiazole-2-carboxylic acid ethyl ester

To a solution of ethyl [[[4-(trifluoromethyl)-benzoyl]amino]-carbamoyl]-formic acid ethyl ester (1.60 g, 5.26 mmol) in CH_2Cl_2 (48 ml) were added a solution of 2-chloro-1,3-dimethylimidazolinium chloride (0.89 g, 5.26 mmol) in CH_2Cl_2 and Et_3N (1.47 ml, 10.52 mmol). The reaction mixture was stirred at room temperature for 22 hr. The reaction was quenched by addition of 0.5N HCl and the reaction mixture was extracted with CH_2Cl_2. The combined organic layers were washed with saturated aqueous $NaHCO_3$ solution and brine, dried over $MgSO_4$, and concentrated *in vacuo*. The obtained residue was purified by silica gel column chromatography (hexane/AcOEt = 3/1) to give the title compound (0.78 g, 52%) as a white powder.

^{1}H-NMR ($CDCl_3$) δ: 1.50 (3H, t, J = 7.2 Hz), 4.58 (2H, q, J = 7.2 Hz), 7.83 (2H, d, J = 8.3 Hz), 8.31 (2H, d, J = 8.3 Hz).

[0456]

Reference Example 1737

Synthesis of 1-(3,5-dibromo-phenyl)-3-methyl-butan-1-ol

To a stirred solution of 3,5-dibromobenzaldehyde (2.20 g, 8.34 mmol) in THF (44 ml) was added isobutyl magnesium bromide (10.0 ml, 10.0 mmol, 1M THF solution) at 0°C. The reaction mixture was gradually warmed to room temperature and stirred overnight. The reaction mixture was poured into saturated aqeous NH_4Cl solution and extracted twice with AcOEt. The organic layer was washed with brine, dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane:AcOEt = 100 : 0—75 : 25) to give the title compound (711 mg, 26%).

^{1}H-NMR ($CDCl_3$) δ: 0.95-0.98 (6H, m), 1.41-1.47 (1H, m), 1.64-1.78 (2H, m), 1.81 (1H, d, J = 3.6 Hz), 4.67-4.72 (1H, m), 7.43-7.44 (2H, m), 7.56 (1H, s).

[0457]

Reference Example 1752

Synthesis of 1,3-dibromo-5-(3-methyl-butyl)-benzene

To a solution of 1-(3,5-dibromophenyl)-3-methylbutan-1-one (1.24 g, 3.87 mmol) in diethylene glycol (15 ml) were added hydrazine hydrate (0.752 ml, 15.50 mmol) and potassium hydroxide (0.522 g, 9.30 mmol). After the reaction mixture was stirred at 150°C for 5 hr, it was neutralized with 6N HCl and extracted twice with AcOEt. The organic layer was washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane:AcOEt = 100 : 0—85 : 15) to give the title compound (917 mg, 77%).

^{1}H-NMR ($CDCl_3$) δ: 0.93 (6H, d, J = 6.7 Hz), 1.45-1.51 (2H, m), 1.56-1.61 (1H, m), 2.53-2.57 (2H, m), 2.61 (2H, s), 7.46-7.49 (1H, m).

[0458]

Reference Example 1863

Synthesis of 2-(4-chlorophenyl)-4-cyclopropyl-thiazole-5-carboxylic acid methyl ester

A solution of bromine (0.168 ml, 3.26 mmol) in CCl_4 (3 ml) was added dropwise to a suspension of methyl 3-cyclopropyl-3-oxopropionate (0.463 g, 3.26 mmol) and $NaHCO_3$ (0.821 g, 9.77 mmol) in CCl_4 (7 ml) at -10 °C for 1 hr. After being stirred for 20 min, to the reaction mixture were added 4-chloro-benzenecarbothiamide (0.559 g, 3.26 mmol) and EtOH (20 ml). The reaction mixture was stirred at room temperature for 0.5 h and then under reflux for 5 hr. After being cooled, the reaction mixture was filtrated. The obtained filtrate was concentrated *in vacuo*. The residue was purified by flash column chromatography (AcOEt/hexane = 0% to 10%) to give the title compound (218 mg, 52%) as a pale yellow solid.

^{1}H-NMR ($CDCl_3$) δ: 1.09-1.14 (2H, m), 1.18-1.24 (2H, m), 3.02-3.08 (1H, m), 3.90 (3H, s), 7.38-7.42 (2H, m), 7.84-7.87 (2H, m).

[0459]

Reference Example 1891

Synthesis of 2-amino-3-cyclopropyl-3-oxo-propionic acid methyl ester HCl

To a solution of methyl 3-cyclopropyl-3-oxopropanoate (1.0 g, 7.03 mmol) in AcOH (1 ml) was added slowly sodium nitrite (0.485 g, 7.03 mmol) in water (1.5 ml) at 0°C. After the reaction mixture was stirred at room temperature overnight, water was added thereto, and the mixture was extracted with AcOEt. The combined organic layers were washed with water, saturated aqueous $NaHCO_3$ solution, and brine, dried over Na_2SO_4, and concentrated *in vacuo* to give the crude product of 3-cyclopropyl-2-[(Z)-hydroxyimino]-3-oxo-propionic acid methyl ester (1.15 g). This product was used in the next step without purification.

The crude product of 3-cyclopropyl-2-[(Z)-hydroxyimino]-3-oxo-propionic acid methyl ester (1.15 g) was dissolved in EtOH (10 ml) and 4N HCl (AcOEt solution) (5.0 ml) was added thereto. The reaction mixture was stirred at room temperature for 10 hr under hydrogen (balloon) in the presence of 10% Pd-C (wet). The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated *in vacuo* to give the title compound (1.17 g, 90%).

^{1}H-NMR ($CDCl_3$) δ: 0.96-1.09 (2H, m), 1.12-1.19 (2H, m), 2.42-2.47 (1H, m), 3.85 (3H, s), 5.60 (1H, s), 8.68 (3H, brs).

[0460]

Reference Example 1892

Synthesis of 3-cyclopropyl-2-[(3,4-difluoro-benzoyl)amino]-3-oxo-propionic acid methyl ester

To a solution of 2-amino-3-cyclopropyl-3-oxo-propionic acid methyl ester HCl (480 mg, 2.479 mmol) in CH_2Cl_2 (15 ml) were added DIPEA (705 mg, 5.45 mmol) and 3,4-difluorobenzoyl chloride (0.348 ml, 2.97 mmol) at 0°C. After the reaction mixture was stirred at room temperature overnight, it was quenched by water and extracted with AcOEt. The organic layer was washed with brine, dried over Na_2SO_4 and concentrated *in*

vacuo. The residue was purified by silica gel chromatography (hexane/AcOEt = 100:0-75:25) to give the title compound (514 mg, 69%).

^{1}H-NMR ($CDCl_3$) δ: 1.07-1.30 (4H, m), 2.39-2.45 (1H, m), 3.87 (3H, s), 5.58 (1H, d, J = 6.3 Hz), 7.22-7.33 (1H, m), 7.58-7.64 (1H, m), 7.69-7.75 (1H, m).

[0461]

Reference Example 1899

Synthesis of 5-cyclopropyl-2-(3,4-difluoro-phenyl)-oxazole-4-carboxylic acid methyl ester

To a solution of triphenylphosphine (907 mg, 3.46 mmol) and iodine (878 mg, 3.46 mmol) in CH_2Cl_2 (10 ml) were added Et_3N (0.964 ml, 6.92 mmol) and 3-cyclopropyl-2-(3,4-difluoro-benzoylamino)-3-oxo-propionic acid methyl ester (514 mg, 1.729 mmol) in CH_2Cl_2 (10 ml). After the reaction mixture was stirred at room temperature overnight, it was quenched by saturated aqueous solution of $Na_2S_2O_3$ and extracted with CH_2Cl_2. The organic layer was washed with brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/AcOEt = 100:0-75:25) to give the title compound (478 mg, 99%).

^{1}H-NMR ($CDCl_3$) δ: 1.16-1.25 (4H, m), 2.80-2.86 (1H, m), 3.97 (3H, s), 7.21-7.25 (1H, m), 7.73-7.78 (1H, m), 7.79-7.84 (1H, m).

[0462]

Reference Example 2069

Synthesis of 3-[4-(trifluoromethyloxy)-phenyl]-isothiazole-5-carboxylic acid ethyl ester

To a solution of 5-(4-trifluoromethoxy-phenyl)-[1,3,4]oxathiazol-2-one (500 mg, 1.900 mmol) in xylene (7.5ml) was added ethyl propiolate (0.578 ml, 5.70 mmol). After the reaction mixture was stirred at 120°C for 3 days, it was concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane/AcOEt = 100:0-75:25) to give the title compound (132 mg, 21%) and 3-[4=(trifluoromethyloxy)-phenyl]-

isothiazole-4-carboxylic acid ethyl ester (136 mg, 22%).
^{1}H-NMR ($CDCl_3$) δ: 1.27 (3H, t, J = 7.1 Hz), 4.28 (2H, q, J = 7.1 Hz), 7.28 (2H, d, J = 8.2 Hz), 7.66-7.70 (2H, m), 9.38 (1H, s).

[0463]

Reference Example 2079

Synthesis of 2-[(4-chloro-benzoyl)amino]-5-methyl-thiazole-4-carboxylic acid methyl ester

To a suspension of 2-amino-5-methylthiazole-4-carboxylic acid methyl ester (200 mg, 1.161 mmol) in CH_2Cl_2 at room temperature were added Et_3N (0.194 ml, 1.394 mmol) and 4-chlorobenzoyl chloride (0.162 ml, 1.278 mmol). The reaction mixture was stirred for 3 hr. Water and CH_2Cl_2 were added to the reaction mixture. The resulting precipitate was collected by filtration and dried to give the title compound (218 mg, 60%) as a colorless powder.
^{1}H-NMR (DMSO-d_6) δ: 2.66 (3H, s), 3.81 (3H, s), 7.60-7.64 (2H, m), 8.10-8.14 (2H, m), 12.94 (1H, brs).

[0464]

Reference Example 2080

Synthesis of 5-cyclobutyl-2-[5-(trifluoromethyl)-pyridin-3-yl]-oxazole-4-carboxylic acid ethyl ester

To a solution of 5-cyclobutyl-oxazole-4-carboxylic acid ethyl ester (214 mg, 1.096 mmol) in diethylcarbonate (5 ml) were added 3-bromo-5-trifluoromethylpyridine (322 mg, 1.425 mmol), tri-*o*-tolylphosphine (66.7 mg, 0.219 mmol), cesium carbonate (714 mg, 2.192 mmol) and $Pd(OAc)_2$ (24.61 mg, 0.110 mmol). After the resulting suspension was stirred at 110°C for 24 hr, it was filtered through a pad of Celite. The filtrate was concentrated *in vacuo* and the residue was purified by silica gel column chromatography (hexane/AcOEt = 100:0-85:15) to give the title compound (165 mg, 44%).
^{1}H-NMR ($CDCl_3$) δ: 1.44 (3H, t, J = 7.1 Hz), 1.99-2.07 (1H, m), 2.09-2.20 (1H, m), 2.40-2.52 (4H, m), 4.31-4.38 (1H, m), 4.44 (2H, q, J = 7.1 Hz), 8.63 (1H, s), 8.97 (1H, s), 9.49 (1H, d,

J = 1.8 Hz).

[0465]

Reference Example 2083

Synthesis of 5-Methyl-2-(4-trifluoromethyl-benzylamino)-thiazole-4-carboxylic acid methyl ester

To a suspension of 2-amino-5-methylthiazole-4-carboxylic acid methyl ester (200 mg, 1.161 mmol) in CH_2Cl_2 were added alpha,alpha,alpha-trifluoro-*p*-tolualdehyde (0.174 ml, 1.278 mmol) and AcOH (6.65 µl, 0.116 mmol) and the reaction mixture was stirred for 1 hr. After sodium triacetoxyborohydride (492 mg, 2.323 mmol) was added thereto, the reaction mixture was stirred for 3 days. The reaction was quenched by addition of saturated aqueous $NaHCO_3$ solution and organic layer was washed with water and brine, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/AcOEt = 1/1) to give the title compound (87 mg, 22%) as a colorless powder.

^{1}H-NMR ($CDCl_3$) δ: 2.60 (3H, s), 3.88 (3H, s), 4.52 (2H, d, J = 5.7 Hz), 5.66 (1H, brs), 7.47 (2H, d, J = 8.0 Hz), 7.61 (2H, J = 8.0 Hz).

[0466]

Reference Example 2094

Synthesis of 2-amino-5-[4-(trifluoromethyl)-phenyl]-thiazole-4-carboxylic acid methyl ester

To a solution of alpha,alpha,alpha-trifluoro-*p*-tolualdehyde (2.87 ml, 20.98 mmol) and methyl dichloroacetate (2.17 ml, 20.98 mmol) in Et_2O was dropwise added sodium methoxide (3.88 ml, 19.51 mmol) for 20 min at 0°C, and the reaction mixture was stirred for 1 hr. The reaction was quenched by addition of brine and water. The organic layer was concentrated. To the obtained residue were added MeOH and thiourea (1.60 g, 20.98 mmol), the reaction mixture was refluxed overnight. The reaction mixture was concentrated. The residue was dissolved with AcOEt and washed with water and brine, and concentrated. The obtained solid was washed with

EtOH and dried to give the title compound (4.74 g, 74%) as a pale brown powder.

^{1}H-NMR (DMSO-d_6) δ: 3.65 (3H, s), 7.42 (2H, s), 7.61 (2H, d, J = 8.2 Hz), 7.73 (2H, d, J = 8.2 Hz).

[0467]

Reference Example 2143

Synthesis of 2-(2,2-difluoro-1,3-benzodioxol-5-yl)-oxazole-4-carboxylic acid ethyl ester

To a solution of ethyl oxazole-4-carboxylate (0.297 ml, 2.480 mmol) in dioxane (5 ml) were added 5-bromo-2,2-difluorobenzodioxole (588 mg, 2.480 mmol), 2-(dicylohexylphosphino)biphenyl (87 mg, 0.248 mmol), cesium carbonate (1616 mg, 4.96 mmol) and $Pd(OAc)_2$ (27.8 mg, 0.124 mmol). After the resulting suspension was stirred at 110°C for 12 hr, it was filtered through a pad of Celite. The filtrate was concentrated *in vacuo* and the residue was purified by silica gel column chromatography (hexane/AcOEt = 100:0-85:15) to give the title compound (350 mg, 47%).

^{1}H-NMR ($CDCl_3$) δ: 1.41 (3H, t, J = 7.1 Hz), 4.44 (2H, q, J = 7.1 Hz), 7.17 (1H, d, J = 8.3 Hz), 7.83 (1H, d, J = 1.5 Hz), 7.91 (1H, dd, J = 1.5, 8.3 Hz), 8.27 (1H, s).

[0468]

Reference Example 2160

Synthesis of [6-[4-(trifluoromethyl)-phenyl]-benzothiazol-2-yl]-amine

4'-Trifluoromethyl-biphenyl-4-ylamine (3.46 g, 14.57 mmol) and potassium thiocyanate (4.96 g, 51.0 mmol) were dissolved in acetic acid. To this solution was dropwise added a solution of bromine (0.826 ml, 16.03 mmol) in acetic acid, maintaining a reaction temperature below 25°C. After being stirred overnight, the reaction mixture was neutralized with 25% NH_4OH aq., and extracted with AcOEt. The combined organic layers were washed with brine and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/AcOEt = 3/2) to give the title compound (3.65 g, 85%)

as a pale yellow powder.

^{1}H-NMR (DMSO-d_6) δ: 7.43 (1H, d, J = 8.4 Hz), 7.60 (1H, dd, J = 2.0, 8.4 Hz), 7.63 (2H, s), 7.78 (2H, d, J = 8.2 Hz), 7.89 (2H, d, J = 8.2 Hz), 8.09 (1H, d, J = 2.0 Hz).

[0469]

Reference Example 2161

Synthesis of 6-phenoxy-benzothiazole

6-Phenoxy-benzothiazol-2-ylamine (2.90 g, 11.97 mmol) was dissolved in hot 85% H_3PO_4, and the solution was cooled to -8°C. A solution of sodium nitrate (4.95 g, 71.8 mmol) in water was added slowly below -4°C. Then 50% hypophosphorous acid (29 ml) was added slowly thereto and the reaction mixture was stirred overnight. After cold water was added thereto, the reaction mixture was neutralized with 25% NH_4OH aq. and extracted with AcOEt. The combined organic layers were washed with brine and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/AcOEt = 6/1) was to give the title compound (1.03 g, 37%) as a red oil.

^{1}H-NMR ($CDCl_3$) δ: 7.04-7.07 (2H, m), 7.13-7.17 (1H, m), 7.24 (1H, dd, J = 2.4, 8.8 Hz), 7.35-7.40 (2H, m), 7.51 (1H, d, J = 2.4 Hz), 8.08 (1H, d, J = 8.8 Hz), 8.91 (1H, s).

[0470]

Reference Example 2162

Synthesis of 6-phenoxy-benzothiazole-2-carboxylic acid methyl ester

A solution of 6-phenoxy-benzothiazole (1.03 g, 4.53 mmol) and Cs_2CO_3 (1.77 g, 5.44 mmol) in DMF was degassed and flushed with CO_2 twice. The reaction mixture was stirred for 21 hr at 125°C under CO_2 gas. Then the reaction mixture was cooled to room temperature. Methyl iodide (0.850 ml, 13.60 mmol) was added to the mixture and stirred at 50°C for 3 hr. Water was added to the reaction mixture and extracted with AcOEt. The combined organic layers were washed with water and brine and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/AcOEt = 4/1) to give the title

compound (0.74 g, 57%) as a yellow powder.
^{1}H-NMR ($CDCl_3$) δ: 4.08 (3H, s), 7.08-7.11 (2H, m), 7.19-7.23 (1H, m), 7.30 (1H, dd, J = 2.4, 9.0 Hz), 7.39-7.43 (3H, m), 8.17 (1H, d, J = 9.0 Hz).

[0471]

Reference Example 2192

Synthesis of 5-[4-(chloromethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

To a solution of 5-[4-(hydroxymethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (98.7 mg, 0.493 mmol) and pyridine (0.077 ml, 0.952 mmol) in CH_2Cl_2 (2 ml) was added thionyl chloride (0.072 ml, 0.986 mmol) at 0°C. After being stirred at room temperature, the reaction mixture was diluted with AcOEt, washed with HCl aq. and water, dried over anhydrous Na_2SO_4, and then concentrated *in vacuo*. The obtained residue was purified by flash column chromatography (AcOEt/hexane = 0% to 30%) to give the title compound (65 mg, 63%) as a pale yellow solid.
^{1}H-NMR ($CDCl_3$) δ: 4.65 (2H, s), 7.56 (2H, d, J = 8.3 Hz), 8.00 (2H, d, J = 8.3 Hz), 12.06 (1H, br.).

[0472]

Reference Example 2213

Synthesis of 2-(3-chlorophenyl)-4-([1,3]dioxolan-2-yl)-5-iodo-thiazole

To a solution of 2-(3-chloro-phenyl)-4-[1,3]dioxolan-2-yl-thiazole (317 mg, 1.184 mmol) in THF (9 ml) was added *n*-BuLi (0.814 ml, 1.302 mmol, 1.6 M in *n*-hexane). After the reaction mixture was stirred for 1 hr, iodine (601 mg, 2.368 mmol) was added thereto, and stirring was continued for 3 hr. The reaction mixture was quenched with saturated aqueous solution of $Na_2S_2O_4$, and extracted twice with AcOEt. The organic layer was washed with water and brine, dried over Na_2SO_4 and concentrated *in vacuo*. The crude product was purified by silica gel column chromatography (hexane:AcOEt = 100 : 0-75 : 25) to give the title compound (287 mg, 62%).

^{1}H-NMR ($CDCl_3$) δ: 4.07-4.15 (2H, m), 4.34-4.42 (2H, m), 6.11 (1H, s), 7.36 (1H, t, J = 7.7 Hz), 7.38-7.42 (1H, m), 7.71-7.74 (1H, m), 7.91-7.92 (1H, m).

[0473]

Reference Example 2214

Synthesis of 2-(3-chlorophenyl)-4-([1,3]dioxolan-2-yl)-5-(trifluoromethyl)-thiazole

To a solution of 2-(3-chloro-phenyl)-4-[1,3]dioxolan-2-yl-5-iodo-thiazole (287 mg, 0.729 mmol) in DMF (4 ml) were added slowly methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (0.650 ml, 5.10 mmol) and copper(I) iodide (167 mg, 0.875 mmol). The resulting suspension was stirred at 100°C for 5 hr. After water was added to the reaction mixture, the resulting insoluble material was filtered through a pad of Celite. The filtrate was extracted with AcOEt. The organic layer was washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane:AcOEt = 100 : 0—75 : 25) to give the title compound (223 mg, 91%).

^{1}H-NMR ($CDCl_3$) δ: 4.09-4.16 (2H, m), 4.32-4.39 (2H, m), 6.23 (1H, s), 7.40 (1H, t, J = 7.9 Hz), 7.46-7.48 (1H, m), 7.78-7.80 (1H, m), 7.98 (1H, t, J = 1.8 Hz).









[0474]







The following compounds were synthesized in the same manner as in the above-mentioned Reference Examples or the below-mentioned Examples. The structures and ^{1}H-NMR data thereof are shown in the following Table 2. The "ref." in Table 2 means "Reference Example No." or "Example No." which the compound was synthesized in reference to.






[0475]

Table 2


[0476]


Ref. Ex. No.	STR	1H-NMR	ref.
255		1H-NMR (DMSO-d6) δ: 1.44 (3H, t, J = 7.1 Hz), 4.46 (2H, q, J = 7.1 Hz), 7.25-7.29 (1H, m), 7.55-7.57 (2H, m), 7.75 (1H, d, J = 8.7 Hz).	Ref. Ex. 125
256		1H-NMR (DMSO-d6) δ: 1.45 (3H, t, J = 7.1 Hz), 2.60 (3H, s), 4.47 (2H, q, J = 7.1 Hz), 7.24-7.28 (1H, m), 7.51 (1H, d, J = 2.1 Hz), 7.70 (1H, d, J = 8.6 Hz).	Ref. Ex. 125
257		1H-NMR (CDCl3) δ: 1.96-2.01 (4H, m), 3.61-3.69 (4H, m), 7.21-7.25 (1H, m), 7.61-7.65 (1H, m), 7.71-7.73 (2H, m), 8.40 (1H, s), 10.21 (1H, s).	Ref. Ex. 1173
258		1H-NMR (CDCl3) δ: 7.63 (1H, s), 7.69-7.78 (6H, m), 7.95-7.96 (1H, m), 9.92 (1H, s).	Ref. Ex. 112
259		1H-NMR (CDCl3) δ: 7.04-7.10 (6H, m), 7.38-7.41 (9H, m), 7.54 (1H, t, J = 7.9 Hz), 7.74-7.76 (1H, m), 7.81 (1H, d, J = 7.9 Hz), 7.92 (1H, s).	Ref. Ex. 184
260		1H-NMR (CDCl3) δ: 4.03 (2H, s), 7.12 (2H, d, J = 8.2 Hz), 7.26-7.28 (2H, m), 7.43-7.48 (2H, m), 7.69 (1H, s), 7.74 (1H, d, J = 7.2 Hz), 9.98 (1H, s).	Ref. Ex. 38
261		1H-NMR (CDCl3) δ: 4.12 (2H, s), 7.35-7.52 (6H, m), 7.71-7.77 (2H, m), 10.0 (1H, s).	Ref. Ex. 38
262		1H-NMR (CDCl3) δ: 4.12 (2H, s), 7.28-7.37 (3H, m), 7.48-7.49 (2H, m), 7.73 (1H, s), 7.75-7.77 (1H, m), 9.99 (1H, s).	Ref. Ex. 38


Ref. Ex. No.	STR	1H-NMR	ref.
263		1H-NMR (CDCl3) δ: 5.38 (2H, s), 7.24-7.25 (1H, m), 7.26-7.55 (3H, m), 7.85-7.97 (3H, m), 9.99 (1H, s).	Ref. Ex. 82
264		1H-NMR (DMSO-d6) δ: 2.01 (2H, t, J = 8.2 Hz), 2.40-2.43 (2H, m), 2.67 (2H, t, J = 7.5 Hz), 2.82 (2H, t, J = 7.5 Hz), 4.04 (2H, t, J = 6.2 Hz), 6.76 (1H, d, J = 8.2 Hz), 6.99 (1H, d, J = 8.2 Hz), 7.03 (1H, s), 7.28, (1H, d, J = 7.5 Hz), 7.41 (1H, s), 7.50-7.53 (2H, m), 9.97 (1H, s), 9.98 (1H, s).	Ref. Ex. 82
265		1H-NMR (CDCl3) δ: 2.00-2.22 (4H, m), 4.26 (2H, t, J = 6.6 Hz), 6.70 (1H, d, J = 3.2 Hz), 7.18 (1H, d, J = 3.2 Hz), 7.40 (1H, d, J = 8.6 Hz), 7.80 (1H, dd, J = 1.5, 8.6 Hz), 8.16 (1H, d, J = 1.4 Hz), 10.04 (1H, s).	Ref. Ex. 184
266		1H-NMR (CDCl3) δ: 5.29 (2H, s), 7.09 (1H, d, J = 8.5 Hz), 7.54-7.96 (5H, m), 7.96 (1H, s), 9.87 (1H, s).	Ref. Ex. 82
267		1H-NMR (CDCl3) δ: 5.17 (2H, s), 6.66 (1H, t, J = 74.0 Hz), 7.35 (1H, d, J = 8.1 Hz), 7.38 (4H, s), 7.48-7.54 (1H, m), 7.55 (1H, s), 9.93 (1H, s).	Ref. Ex. 82
268		1H-NMR (CDCl3) δ: 5.25 (2H, s), 6.66 (1H, t, J = 73.7 Hz), 7.37 (1H, d, J = 8.2 Hz), 7.50-7.65 (5H, m), 7.73 (1H, s), 9.94 (1H, s).	Ref. Ex. 82








Ref. Ex. No.	STR	1H-NMR	ref.
270		1H-NMR (CDCl3) δ: 3.18 (2H, t, J = 6.6 Hz), 4.25-4.27 (2H, m), 7.15-7.18 (1H, m), 7.37 (1H, s), 7.43-7.56 (6H, m), 9.96 (1H, s).	Ref. Ex. 80
271		1H-NMR (CDCl3) δ: 7.17 (1H, d, J = 8.2 Hz), 7.33-7.36 (2H, m), 7.68 (2H, d, J = 8.2 Hz), 7.95-7.97 (2H, m), 10.07 (1H, s).	Ref. Ex. 75
273		1H-NMR (CDCl3) δ: 7.38-7.39 (1H, m), 7.51-7.53 (1H, m), 7.68 (1H, s), 7.74-7.76 (2H, m), 7.99-8.02 (2H, m), 10.09 (1H, s).	Ref. Ex. 75
274		1H-NMR (CDCl3) δ: 5.84-6.06 (1H, m), 7.27-7.29 (1H, m), 7.47-7.56 (3H, m), 7.74-7.75 (2H, m), 7.96-7.98 (2H, m), 10.08 (1H, s).	Ref. Ex. 75
275		1H-NMR (CDCl3) δ: 7.58-7.60 (4H, m), 7.91-7.93 (4H, m), 8.20 (2H, s), 8.27 (1H, s), 10.17 (1H, s).	Ref. Ex. 75







[0477]







Ref. Ex. No.	STR	1H-NMR	ref.
276		1H-NMR (CDCl3) δ: 7.38-7.51 (4H, m), 7.75-7.76 (2H, m), 7.93-8.02 (3H, m), 10.10 (1H, s).	Ref. Ex. 75
277		1H-NMR (CDCl3) δ: 7.39 (1H, d, J = 5.4 Hz), 7.52 (1H, d, J = 5.4 Hz), 7.64-7.68 (1H, m), 7.84-8.15 (5H, m), 8.15 (1H, s), 10.07 (1H, s).	Ref. Ex. 75
278		1H-NMR (CDCl3) δ: 7.52 (2H, d, J = 8.1 Hz), 7.61 (1H, s), 7.81 (1H, d, J = 8.1 Hz), 7.91-8.01 (3H, m), 10.10 (1H, s).	Ref. Ex. 75
279		1H-NMR (CDCl3) δ: 7.36 (1H, t, J = 7.7 Hz), 7.66-7.73 (4H, m), 7.98-8.01 (2H, m), 10.09 (1H, s).	Ref. Ex. 75
280		1H-NMR (DMSO-d6) δ: 7.51 (2H, d, J = 8.5 Hz), 7.58 (1H, d, J = 4.0 Hz), 7.64 (2H, s), 7.75 (2H, d, J = 8.5 Hz), 8.02 (1H, d, J = 4.0 Hz), 9.90 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
281		1H-NMR (CDCl3) δ: 7.60-7.65 (3H, m), 7.80 (1H, d, J = 8.3 Hz), 7.85 (1H, s), 7.94-7.98 (2H, m), 10.08 (1H, s).	Ref. Ex. 75
282		1H-NMR (CDCl3) δ: 7.77-7.87 (1H, m), 7.86-8.10 (4H, m), 10.10 (1H, s).	Ref. Ex. 75
283		1H-NMR (CDCl3) δ: 4.19 (2H, s), 7.35 (2H, d, J = 8.0 Hz), 7.62 (2H, s), 7.77 (1H, s), 7.87 (2H, d, J = 8.0 Hz), 10.01 (1H, s).	Ref. Ex. 75
284		1H-NMR (CDCl3) δ: 4.32 (2H, s), 7.28-7.31 (2H, m), 7.44 (1H, s), 7.63-7.66 (1H, m), 7.83-7.86 (3H, m), 10.01 (1H, s).	Ref. Ex. 75
285		1H-NMR (CDCl3) δ: 7.30-7.33 (2H, m), 7.47-7.51 (3H, m), 7.93 (2H, d, J = 8.4 Hz), 10.09 (1H, s).	Ref. Ex. 75







Ref. Ex. No.	STR	1H-NMR	ref.
286		1H-NMR (CDCl3) δ: 2.40-2.43 (2H, m), 2.69-2.72 (2H, m), 6.71 (1H, d, J = 8.1 Hz), 6.81 (1H, d, J = 8.1 Hz), 7.05-7.07 (2H, m), 7.24 (1H, t, J = 8.1 Hz), 7.89-7.92 (2H, m), 9.91 (1H, s), 10.29 (1H, s).	Ref. Ex. 169
287		1H-NMR (CDCl3) δ: 2.67-2.70 (2H, m), 2.89-2.96 (2H, m), 3.40 (3H, s), 6.91-7.06 (5H, m), 7.84-7.86 (2H, m), 9.93 (1H, s).	Ref. Ex. 12
288		1H-NMR (CDCl3) δ: 2.59-2.62 (2H, m), 2.81-2.84 (2H, m), 3.40 (3H, s), 6.78 (1H, d, J = 8.1 Hz), 6, 90 (1H, d, J = 8.1 Hz), 6.98-7.01 (2H, m), 7.28-7.32 (1H, m), 7.84-7.86 (2H, m), 9.92 (1H, s).	Ref. Ex. 12
289		1H-NMR (CDCl3) δ: 7.27-7.33 (1H, m), 7.82-8.02 (5H, m), 10.15 (1H, s).	Ref. Ex. 75
290		1H-NMR (CDCl3) δ: 7.37 (1H, d, J = 8.2 Hz), 7.52 (1H, d, J = 8.2 Hz), 7.66-7.69 (2H, m), 7.85-7.87 (1H, m), 7.94-7.96 (1H, m), 8.10 (1H, s), 10.12 (1H, s).	Ref. Ex. 75
291		1H-NMR (CDCl3) δ: 4.19 (2H, s), 7.45 (1H, d, J = 7.6 Hz), 7.53 (1H, t, J = 7.6 Hz), 7.63 (2H, s), 7.76 (1H, s), 7.79 (1H, s), 7.80 (1H, d, J = 7.6 Hz), 10.01 (1H, s).	Ref. Ex. 75







Ref. Ex. No.	STR	1H-NMR	ref.
292		1H-NMR (CDCl3) δ: 7.18-7.25 (2H, m), 7.61 (1H, s), 7.82-7.84 (1H, m), 7.93-7.98 (2H, m), 10.43 (1H, s).	Ref. Ex. 75
293		1H-NMR (CDCl3) δ: 7.45-7.87 (6H, m), 7.87 (1H, s), 10.05 (1H, s).	Ref. Ex. 75
294		1H-NMR (CDCl3) δ: 5.19 (2H, s), 7.02-7.04 (1H, m), 7.26-7.27 (2H, m), 7.42 (1H, t, J = 8.0 Hz), 7.51-7.67 (4H, m), 7.74 (2H, d, J = 8.0 Hz), 7.96 (2H, d, J = 8.0 Hz), 10.06 (1H, s).	Ref. Ex. 82
295		1H-NMR (CDCl3) δ: 5.11 (2H, s), 7.00-7.02 (1H, m), 7.22-7.26 (1H, m), 7.37-7.42 (6H, m), 7.73 (2H, d, J = 8.3 Hz), 7.94-7.96 (2H, m), 10.06 (1H, s).	Ref. Ex. 82
296		1H-NMR (CDCl3) δ: 7.43-7.63 (7H, m), 7.91 (1H, s), 10.06 (1H, s).	Ref. Ex. 75
297		1H-NMR (CDCl3) δ: 7.40-7.58 (5H, m), 7.90 (1H, s), 10.03 (1H, s).	Ref. Ex. 75
298		1H-NMR (CDCl3) δ: 7.30-7.50 (1H, m), 7.61-7.63 (2H, m), 7.66-7.67 (1H, m), 7.80-7.85 (2H, m), 10.46 (1H, s).	Ref. Ex. 75








Ref. Ex. No.	STR	1H-NMR	ref.
299		1H-NMR (CDCl3) δ: 7.41-7.42 (1H, m), 7.45-7.46 (1H, m), 7.58 (1H, s), 7.76 (1H, s), 7.82 (1H, s), 7.97 (1H, s), 10.02 (1H, s).	Ref. Ex. 75
300		1H-NMR (CDCl3) δ: 7.45-7.52 (3H, m), 7.61-7.71 (4H, m), 8.04 (1H, s), 10.08 (1H, s).	Ref. Ex. 75
301		1H-NMR (CDCl3) δ: 7.42-7.43 (1H, m), 7.46-7.48 (1H, m), 7.60 (1H, s), 7.64 (1H, s), 7.67 (1H, s), 8.03 (1H, s), 10.06 (1H, s).	Ref. Ex. 75
302		1H-NMR (CDCl3) δ: 7.47-7.49 (2H, m), 7.54-7.56 (2H, m), 7.65 (1H, s), 7.72 (1H, s), 8.00 (1H, s), 10.08 (1H, s).	Ref. Ex. 75
303		1H-NMR (CDCl3) δ: 3.91 (3H, s), 7.12-7.21 (2H, m), 7.24-7.43 (4H, m).	Ref. Ex. 75
304		1H-NMR (CDCl3) δ: 7.31-7.35 (2H, m), 7.35-7.42 (1H, m), 7.54 (1H, s), 7.62 (1H, s), 7.81 (1H, s).	Ref. Ex. 125

Ref. Ex. No.	STR	1H-NMR	ref.
305		1H-NMR (CDCl3) δ: 6.94-7.05 (2H, m), 7.40-7.46 (1H, m), 7.55 (1H, s), 7.63 (1H, s), 7.80 (1H, s).	Ref. Ex. 75, Ref. Ex. 750, Ref. Ex. 125
306		1H-NMR (CDCl3) δ: 7.31-7.44 (3H, m), 7.92 (1H, s), 7.98 (2H, s).	Ref. Ex. 89
307		1H-NMR (CDCl3) δ: 7.30-7.47 (3H, m), 8.02 (1H, s), 8.13 (1H, s), 8.22 (1H, s), 10.14 (1H, s).	Ref. Ex. 93
308		1H-NMR (CDCl3) δ: 6.96-7.05 (2H, m), 7.26-7.45 (1H, m), 7.92 (1H, s), 7.99 (2H, s).	Ref. Ex. 89
309		1H-NMR (CDCl3) δ: 7.79 (1H, s), 8.00 (1H, s), 8.20 (1H, s), 10.09 (1H, s).	Ref. Ex. 125
310		1H-NMR (CDCl3) δ: 6.80-6.81 (1H, m), 7.55-7.56 (1H, m), 7.91 (1H, s), 7.98 (1H, s), 8.04 (1H, s), 8.18 (1H, s), 10.13 (1H, s).	Ref. Ex. 75







[0479]







Ref. Ex. No.	STR	1H-NMR	ref.
311		1H-NMR (CDCl3) δ: 6.96-7.06 (2H, m), 7.44-7.48 (1H, m), 8.01 (1H, s), 8.15 (1H, s), 8.20 (1H, s), 10.13 (1H, s).	Ref. Ex. 93
312		1H-NMR (CDCl3) δ: 7.45-7.48 (2H, m), 7.53-7.56 (2H, m), 7.79 (1H, s), 7.84 (1H, s), 7.94 (1H, s), 10.03 (1H, s).	Ref. Ex. 75
313		1H-NMR (CDCl3) δ: 7.27-7.34 (2H, m), 7.40-7.44 (1H, m), 7.76 (1H, s), 7.85 (1H, s), 7.91 (1H, s), 10.04 (1H, s).	Ref. Ex. 75
314		1H-NMR (CDCl3) δ: 4.34 (2H, s), 7.40-7.43 (2H, m), 7.51-7.57 (1H, m), 7.64-7.67 (2H, m), 7.79-7.87 (2H, m), 10.01 (1H, s).	Ref. Ex. 75
315		1H-NMR (CDCl3) δ: 4.02 (2H, s), 6.85-7.11 (3H, m), 7.42-7.51 (2H, m), 7.69-7.77 (2H, m), 9.99 (1H, s).	Ref. Ex. 75
316		1H-NMR (CDCl3) δ: 1.36 (3H, t, J = 7.2 Hz), 4.30 (2H, q, J = 7.2 Hz), 6.48 (1H, d, J = 15.8 Hz), 7.74 (1H, d, J = 8.2 Hz), 7.94 (1H, d, J = 8.2 Hz), 7.94 (1H, s), 8.04 (1H, dd, J = 2.1, 15.8 Hz).	Ref. Ex. 188






Ref. Ex. No.	STR	1H-NMR	ref.
317		1H-NMR (CDCl3) δ: 5.42 (2H, s), 7.03-7.15 (2H, m), 7.55-7.60 (1H, m), 7.75-7.77 (1H, m), 7.88-7.92 (2H, m), 8.11 (1H, s), 10.55 (1H, s).	Ref. Ex. 82
319		1H-NMR (CDCl3) δ: 4.80-4.84 (2H, m), 6.46-6.51 (1H, m), 7.13-7.16 (1H, m), 7.24-7.26 (1H, m), 7.45-7.52 (3H, m), 7.63 (1H, d, J = 8.2 Hz), 7.78 (1H, d, J = 8.2 Hz), 7.90 (1H, s), 9.99 (1H, s).	Ref. Ex. 80
320		1H-NMR (CDCl3) δ: 2.14-2.20 (2H, m), 3.06-3.09 (2H, m), 4.12 (2H, s), 7.18-7.22 (1H, m), 7.39 (1H, s), 7.45-7.49 (2H, m), 7.59 (1H, d, J = 8.2 Hz), 7.64 (1H, s), 7.78 (1H, d, J = 8.2 Hz), 9.98 (1H, s).	Ref. Ex. 80
321		1H-NMR (CDCl3) δ: 2.24 (3H, s), 6.87 (1H, dd, J = 2.5, 8.3 Hz), 6.92 (1H, d, J = 2.5 Hz), 7.05-7.08 (2H, m), 7.09-7.13 (1H, m), 7.18 (1H, d, J = 8.3 Hz), 7.30-7.43 (7H, m).	Ref. Ex. 75
322		1H-NMR (CDCl3) δ: 7.02 (1H, d, J = 5.0 Hz), 7.40-7.43 (2H, m), 7.45-7.48 (2H, m), 7.75 (1H, dd, J = 1.2, 5.0 Hz), 9.86 (1H, d, J = 1.2 Hz).	Ref. Ex. 75
324		1H-NMR (CDCl3) δ: 7.41-7.45 (1H, m), 7.46-7.51 (2H, m), 7.58-7.61 (2H, m), 7.97-7.99 (2H, m), 8.02 (1H, t, J = 1.5 Hz), 10.03 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
325		1H-NMR (CDCl3) δ: 3.82 (3H, m), 6.66-6.68 (1H, m), 6.80 (1H, s), 6.88 (1H, s), 6.94-7.01 (2H, m), 7.30-7.37 (2H, m).	Ref. Ex. 85
326		1H-NMR (CDCl3) δ: 7.00-7.04 (2H, m), 7.05 (1H, t, J = 2.2 Hz), 7.22 (1H, s), 7.24 (1H, s), 7.39-7.43 (2H, m).	Ref. Ex. 87
327		1H-NMR (CDCl3) δ: 7.00-7.04 (2H, m), 7.35 (1H, s), 7.40-7.44 (3H, m), 7.61 (1H, s).	Ref. Ex. 89
328		1H-NMR (CDCl3) δ: 7.00-7.04 (2H, m), 7.37-7.41 (2H, m), 7.50 (1H, s), 7.59 (1H, s), 7.85 (1H, s), 10.00 (1H, s).	Ref. Ex. 229
329		1H-NMR (CDCl3) δ: 6.95 (1H, dd, J = 2.2, 8.5 Hz), 7.07-7.08 (1H, m), 7.21-7.24 (1H, m), 7.32-7.35 (1H, m), 7.47 (1H, s), 7.62 (1H, s), 7.89 (1H, s), 10.01 (1H, s).	Ref. Ex. 229
330		1H-NMR (CDCl3) δ: 3.90 (3H, s), 7.12 (1H, s), 7.23 (1H, s), 7.38 (1H, s), 7.41-7.45 (2H, m), 7.49-7.53 (2H, m).	Ref. Ex. 75
331		1H-NMR (CDCl3) δ: 3.87 (3H, s), 7.11 (1H, s), 7.15 (1H, s), 7.24 (1H, s), 7.27 (1H, d, J = 8.4 Hz), 7.33 (1H, dd, J = 2.0, 8.4 Hz), 7.51 (1H, d, J = 2.0 Hz).	Ref. Ex. 75







[0480]








Ref. Ex. No.	STR	1H-NMR	ref.
332		1H-NMR (CDCl3) δ: 7.47-7.53 (5H, m), 7.63 (1H, s), 7.83 (1H, s).	Ref. Ex. 87
333		1H-NMR (CDCl3) δ: 7.29 (1H, d, J = 8.2 Hz), 7.39 (1H, dd, J = 2.1, 8.2 Hz), 7.56-7.57 (3H, m), 7.71 (1H, s).	Ref. Ex. 87
334		1H-NMR (CDCl3) δ: 7.46-7.54 (4H, m), 7.90 (1H, s), 8.01 (2H, s).	Ref. Ex. 89
335		1H-NMR (CDCl3) δ: 7.27 (1H, d, J = 8.3 Hz), 7.39 (1H, dd, J = 2.0, 8.3 Hz), 7.56 (1H, d, J = 2.0 Hz), 7.91 (2H, s), 7.95 (1H, s).	Ref. Ex. 89
336		1H-NMR (CDCl3) δ: 7.47-7.51 (2H, m), 7.57-7.60 (2H, m), 8.05 (1H, s), 8.12 (1H, s), 8.25 (1H, s), 10.14 (1H, s).	Ref. Ex. 229
337		1H-NMR (CDCl3) δ: 7.33 (1H, d, J = 8.2 Hz), 7.38 (1H, dd, J = 2.1, 8.2 Hz), 7.56 (1H, d, J = 2.1 Hz), 7.94 (1H, s), 8.12 (1H, s), 8.17 (1H, s), 10.12 (1H, s)	Ref. Ex. 229






Ref. Ex. No.	STR	1H-NMR	ref.
338		1H-NMR (CDCl3) δ: 3.89 (3H, s), 7.15 (2H, s), 7.28 (1H, s), 7.32-7.35 (3H, m), 7.46-7.49 (1H, m).	Ref. Ex. 75
339		1H-NMR (CDCl3) δ: 7.34-7.41 (3H, m), 7.51-7.56 (2H, m), 7.60 (1H, s), 7.75 (1H, s).	Ref. Ex. 87
340		1H-NMR (CDCl3) δ: 7.32-7.53 (3H, m), 7.53-7.56 (1H, m), 7.94 (3H, s).	Ref. Ex. 89
341		1H-NMR (CDCl3) δ: 7.36-7.41 (3H, m), 7.52-7.56 (1H, m), 7.98 (1H, s), 8.15-8.18 (2H, m), 10.13 (1H, s).	Ref. Ex. 229
343		1H-NMR (CDCl3) δ: 1.23-1.28 (1H, m), 1.68-1.76 (4H, m), 2.86-2.89 (2H, m), 3.68-3.75 (2H, m), 7.55 (1H, d, J = 8.2 Hz), 7.61 (1H, s), 7.75 (1H, d, J = 8.2 Hz).	Ref. Ex. 33
344		1H-NMR (CDCl3) δ: 1.84-1.95 (4H, m), 2.92-2.95 (2H, m), 4.06-4.11 (2H, m), 7.16-7.19 (1H, m), 7.38 (1H, s), 7.43-7.47 (2H, m), 7.56 (1H, d, J = 8.3 Hz), 7.63 (1H, s), 7.76 (1H, d, J = 8.3 Hz), 9.98 (1H, s).	Ref. Ex. 80







Ref. Ex. No.	STR	1H-NMR	ref.
345		1H-NMR (CDCl3) δ: 3.38 (2H, t, J = 6.5 Hz), 4.27 (2H, t, J = 6.5 Hz), 7.15-7.17 (1H, m), 7.36 (1H, s), 7.43-7.48 (2H, m), 7.63 (1H, d, J = 8.2 Hz), 7.78 (1H, s), 7.80 (1H, d, J = 8.2 Hz), 9.97 (1H, s).	Ref. Ex. 80
346		1H-NMR (CDCl3) δ: 5.25 (2H, s), 7.53 (1H, s), 7.68 (1H, s), 7.80 (1H, s), 7.91-7.94 (3H, m), 10.04 (1H, s).	Ref. Ex. 82, Ref. Ex. 93
347		1H-NMR (CDCl3) δ: 4.00 (3H, s), 5.39 (2H, s), 7.05 (1H, d, J = 8.3 Hz), 7.47 (1H, s), 7.54-7.56 (1H, m), 7.71 (1H, d, J = 8.3 Hz), 7.84 (1H, d, J = 8.3 Hz), 8.18 (1H, s), 9.85 (1H, s).	Ref. Ex. 82
348		1H-NMR (CDCl3) δ: 5.39 (2H, s), 6.98-6.99 (1H, m), 7.51-7.54 (1H, m), 7.76-7.90 (3H, m), 8.05 (1H, s), 10.47 (1H, s).	Ref. Ex. 82
349		1H-NMR (CDCl3) δ: 3.83 (3H, s), 5.37 (2H, s), 6.95-6.99 (1H, m), 7.13-7.16 (1H, m), 7.39 (1H, s), 7.75 (1H, d, J = 8.2 Hz), 7.87 (1H, d, J = 8.2 Hz), 8.07 (1H, s), 10.52 (1H, s).	Ref. Ex. 82







[0481]







Ref. Ex. No.	STR	1H-NMR	ref.
350		1H-NMR (CDCl3) δ: 4.72 (2H, s), 7.05 (1H, d, J = 7.3 Hz), 7.16 (1H, s), 7.50-7.61 (3H, m), 7.84-7.91 (2H, m), 10.15 (1H, s).	Ref. Ex. 75
351		1H-NMR (CDCl3) δ: 5.55 (2H, s), 7.28-7.34 (1H, m), 7.46-7.49 (1H, m), 7.65-7.70 (1H, m), 7.77-7.89 (3H, m), 8.08-8.10 (2H, m), 9.29 (1H, d, J = 8.7 Hz), 11.00 (1H, s)	Ref. Ex. 82
352		1H-NMR (CDCl3) δ: 5.39 (2H, s), 6.99-7.05 (1H, m), 7.27-7.31 (1H, m), 7.57-7.59 (1H, m), 7.76-7.78 (1H, m), 7.88-7.90 (1H, m), 8.05 (1H, s), 10.49 (1H, s).	Ref. Ex. 82
353		1H-NMR (CDCl3) δ: 1.45-1.50 (3H, m), 4.12-4.17 (2H, m), 7.31 (1H, s), 7.39-7.44 (3H, m), 7.54 (1H, s), 7.68 (1H, s), 10.04 (1H, s).	Ref. Ex. 75
354		1H-NMR (CDCl3) δ: 2.48 (3H, s), 7.39-7.68 (5H, m), 7.90 (1H, s), 10.03 (1H, s).	Ref. Ex. 75
355		1H-NMR (CDCl3) δ: 3.62 (3H, s), 7.42-7.48 (4H, m), 7.68 (1H, s), 10.42 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
356		1H-NMR (CDCl3) δ: 7.39-7.43 (2H, m), 7.73 (1H, s), 7.83-7.89 (2H, m), 8.09 (1H, s), 8.18 (1H, s), 8.37 (1H, s), 10.14 (1H, s).	Ref. Ex. 75
357		1H-NMR (CDCl3) δ: 1.58 (3H, s), 7.48-7.49 (1H, m), 7.71-7.72 (1H, m), 8.12 (2H, s), 8.31 (1H, s), 10.12 (1H, s).	Ref. Ex. 75
358		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.32-7.42 (6H, m), 7.52 (1H, s).	Ref. Ex. 82
359		1H-NMR (CDCl3) δ: 5.15 (2H, s), 7.37-7.41 (2H, m), 7.45 (1H, s), 7.54 (1H, s), 7.76-7.79 (1H, s), 8.64-8.70 (2H, m).	Ref. Ex. 82
360		1H-NMR (CDCl3) δ: 5.27 (2H, s), 7.28-7.27 (1H, m), 7.42-7.51 (4H, m), 7.73-7.76 (1H, m), 8.62-8.64 (1H, s).	Ref. Ex. 82
361		1H-NMR (CDCl3) δ: 5.14 (2H, s), 7.36-7.39 (4H, m), 7.48 (1H, s), 7.62 (1H, s), 7.74 (1H, s), 10.01 (1H, s).	Ref. Ex. 93
362		1H-NMR (CDCl3) δ: 5.19 (2H, s), 7.38-7.39 (1H, m), 7.49 (1H, s), 7.66 (1H, s), 7.76-7.78 (2H, m), 8.63-8.65 (1H, m), 8.72 (1H, s), 10.02 (1H, s).	Ref. Ex. 93








Ref. Ex. No.	STR	1H-NMR	ref.
363		1H-NMR (CDCl3) δ: 5.30 (2H, s), 7.24-7.27 (1H, m), 7.49-7.53 (2H, m), 7.67 (1H, s), 7.73-7.76 (2H, m), 8.63-8.65 (1H, m), 10.01 (1H, s).	Ref. Ex. 93
364		1H-NMR (CDCl3) δ: 7.14-7.19 (1H, m), 7.31-7.44 (4H, m), 7.54-7.57 (2H, m), 7.98 (1H, s), 8.00 (1H, s), 8.19 (1H, s), 10.10 (1H, s).	Ref. Ex. 112
365		1H-NMR (CDCl3) δ: 6.44 (1H, t, J = 54.7 Hz), 7.05-7.07 (1H, m), 7.23-7.28 (1H, m), 7.63-7.66 (2H, m), 7.79-7.80 (1H, m), 7.87 (1H, s), 7.97-7.99 (1H, m), 10.09 (1H, s).	Ref. Ex. 75
366		1H-NMR (CDCl3) δ: 6.70 (1H, t, J = 56.3 Hz), 7.26-7.31 (1H, m), 7.54 (1H, m), 7.63-7.67 (2H, m), 7.83-7.84 (1H, m), 7.93-7.95 (1H, m), 8.07 (1H, s), 10.10 (1H, s).	Ref. Ex. 75
367		1H-NMR (CDCl3) δ: 2.50 (3H, s), 7.41 (1H, s), 7.61 (1H, s), 7.65 (1H, s), 7.78 (1H, s), 7.79 (1H, d, J = 8.3 Hz), 7.92 (1H, d, J = 8.3 Hz), 10.04 (1H, s).	Ref. Ex. 75
368		1H-NMR (CDCl3) δ: 1.39-1.40 (6H, m), 4.66-4.71 (1H, m), 7.31 (1H, s), 7.38 (1H, s), 7.40-7.43 (2H, m), 7.53 (1H, s), 7.66 (1H, s), 10.01 (1H, s).	Ref. Ex. 75







Ref. Ex. No.	STR	1H-NMR	ref.
369		1H-NMR (CDCl3) δ: 7.59 (1H, d, J = 8.8 Hz), 7.66-7.68 (1H, m), 7.93-7.95 (2H, m), 8.04 (2H, s), 10.09 (1H, s).	Ref. Ex. 75
370		1H-NMR (CDCl3) δ: 7.63-7.81 (5H, m), 7.85 (1H, s), 8.05 (1H, s), 10.10 (1H, s).	Ref. Ex. 75
371		1H-NMR (CDCl3) δ: 7.29-7.35 (2H, m), 7.41-7.45 (1H, m), 7.61 (1H, s), 7.73 (1H, s), 7.98 (1H, s), 10.08 (1H, s).	Ref. Ex. 75
372		1H-NMR (CDCl3) δ: 7.05-7.13 (1H, m), 7.28-7.35 (1H, m), 7.62 (1H, s), 7.77 (1H, s), 7.95 (1H, s), 10.07 (1H, s).	Ref. Ex. 75
373		1H-NMR (CDCl3) δ: 7.41 (1H, dd, J = 1.3, 5.0 Hz), 7.45 (1H, dd, J = 2.9, 5.0 Hz), 7.57 (1H, dd, J = 1.3, 3.9 Hz), 7.92 (1H, t, J = 1.6 Hz), 7.98 (1H, t, J = 1.7 Hz), 8.01 (1H, t, J = 1.5 Hz), 10.00 (1H, s).	Ref. Ex. 75
374		1H-NMR (CDCl3) δ: 7.45-7.49 (4H, m), 7.59-7.61 (2H, m), 8.01 (2H, d, J = 1.7 Hz), 8.06 (1H, t, J = 1.7 Hz), 10.12 (1H, s).	Ref. Ex. 75








Ref. Ex. No.	STR	1H-NMR	ref.
375		1H-NMR (CDCl3) δ: 7.41-7.45 (1H, m), 7.46 (1H, dd, J = 2.9, 5.0 Hz), 7.48-7.53 (3H, m), 7.61 (1H, dd, J = 1.4, 2.9 Hz), 7.65-7.69 (2H, m), 8.01 (1H, t, J = 1.6 Hz), 8.06 (1H, t, J = 1.7 Hz), 8.08 (1H, t, J = 1.6 Hz), 10.14 (1H, s).	Ref. Ex. 75
376		1H-NMR (CDCl3) δ: 7.11-7.13 (2H, m), 7.19-7.23 (3H, m), 7.33-7.36 (2H, m), 7.44-7.48 (4H, m), 7.69-7.73 (2H, m), 9.90 (1H, s).	Ref. Ex. 75
377		1H-NMR (CDCl3) δ: 7.10-7.15 (2H, m), 7.20-7.24 (3H, m), 7.31 (2H, d, J = 8.1 Hz), 7.42-7.49 (4H, m), 7.73 (2H, d, J = 8.1 Hz), 9.97 (1H, s).	Ref. Ex. 75
378		1H-NMR (CDCl3) δ: 7.70 (1H, s), 7.83 (1H, s), 7.97 (1H, s), 8.04 (2H, s), 8.07 (1H, s), 10.12 (1H, s).	Ref. Ex. 75
379		1H-NMR (CDCl3) δ: 7.42-7.49 (2H, m), 7.57 (1H, s), 7.80-7.86 (1H, m), 7.94-7.99 (1H, m), 8.10 (1H, s), 8.17 (1H, s), 8.28 (1H, s), 10.15 (1H, s).	Ref. Ex. 75
380		1H-NMR (CDCl3) δ: 7.17 (1H, dd, J = 3.7, 5.1 Hz), 7.44 (1H, dd, J = 1.1, 5.1 Hz), 7.49 (1H, dd, J = 1.1, 3.7 Hz), 8.04 (1H, s), 8.09 (1H, s), 8.28 (1H, s), 10.12 (1H, s).	Ref. Ex. 112

Ref. Ex. No.	STR	1H-NMR	ref.
381		1H-NMR (CDCl3) δ: 4.01 (3H, s), 7.78 (1H, s), 7.88 (1H, s), 7.95 (1H, s), 7.98 (1H, s), 8.15 (1H, s), 10.10 (1H, s).	Ref. Ex. 75
382		1H-NMR (CDCl3) δ: 7.41-7.52 (2H, m), 7.67 (2H, d, J = 7.5 Hz), 7.79 (1H, s), 8.04 (1H, s), 10.13 (1H, s).	Ref. Ex. 75
383		1H-NMR (CDCl3) δ: 7.31-7.32 (1H, m), 7.46 (1H, s), 7.54-7.55 (2H, m), 7.67 (1H, s), 7.75 (1H, s), 8.02 (1H, s), 10.09 (1H, s).	Ref. Ex. 75
384		1H-NMR (CDCl3) δ: 7.37-7.39 (3H, m), 7.52-7.54 (1H, m), 7.60 (1H, s), 7.76 (1H, s), 7.90 (1H, s), 10.06 (1H, s).	Ref. Ex. 75
385		1H-NMR (CDCl3) δ: 5.34 (2H, s), 7.61 (1H, s), 7.70-7.87 (3H, m), 8.25 (1H, s), 10.18 (1H, s).	Ref. Ex. 82
386		1H-NMR (CDCl3) δ: 5.49 (2H, s), 7.20-7.23 (1H, m), 7.39-7.44 (1H, m), 7.66-7.68 (1H, m), 7.76 (1H, d, J = 8.2 Hz), 7.86 (1H, d, J = 8.2 Hz), 8.16 (1H, s), 10.33 (1H, s).	Ref. Ex. 82








[0483]







Ref. Ex. No.	STR	1H-NMR	ref.
387		1H-NMR (CDCl3) δ: 5.17 (2H, s), 7.27-7.28 (1H, m), 7.31 (1H, d, J = 8.5 Hz), 7.38 (1H, d, J = 8.5 Hz), 7.47-7.54 (4H, m), 10.00 (1H, s).	Ref. Ex. 80
388		1H-NMR (CDCl3) δ: 5.22 (2H, s), 6.96 (1H, d, J = 8.9 Hz), 7.34-7.38 (2H, m), 7.50-7.52 (2H, m), 7.85 (1H, s), 10.48 (1H, s).	Ref. Ex. 82
389		1H-NMR (CDCl3) δ: 5.22 (2H, s), 6.97-6.99 (1H, m), 7.27-7.29 (1H, m), 7.33-7.38 (2H, m), 7.49 (1H, s), 7.56-7.58 (1H, m), 10.50 (1H, s).	Ref. Ex. 82
390		1H-NMR (CDCl3) δ: 2.27 (3H, s), 6.95-7.04 (2H, m), 7.18-7.21 (1H, m), 7.42 (1H, s), 7.72 (1H, s), 7.75 (1H, s), 10.05 (1H, s).	Ref. Ex. 75
391		1H-NMR (CDCl3) δ: 6.07 (2H, s), 6.61 (1H, s), 7.17-7.20 (1H, m), 7.22-7.25 (1H, m), 7.37-7.42 (1H, m), 7.45-7.47 (1H, m), 7.60 (1H, d, J = 8.1 Hz), 7.83 (1H, d, J = 8.1 Hz), 7.87 (1H, d, J = 8.2 Hz), 9.93 (1H, s).	Ref. Ex. 113
392		1H-NMR (CDCl3) δ: 5.88 (2H, s), 7.09 (1H, d, J = 7.7 Hz), 7.19-7.24 (1H, m), 7.33-7.38 (3H, m), 7.39-7.43 (2H, m), 7.48 (1H, d, J = 7.7 Hz), 7.79 (1H, d, J = 8.0 Hz), 9.91 (1H, s).	Ref. Ex. 113
393		1H-NMR (CDCl3) δ: 5.13 (2H, s), 7.19-7.24 (2H, m), 7.27-7.33 (1H, m), 7.49 (1H, s), 7.63 (1H, s), 7.77 (1H, s), 10.04 (1H, s).	Ref. Ex. 82







Ref. Ex. No.	STR	1H-NMR	ref.
394		1H-NMR (CDCl3) δ: 7.34-7.37 (2H, m), 7.51-7.60 (3H, m), 7.89-7.92 (1H, m), 8.32 (1H, s), 10.00 (1H, s).	Ref. Ex. 75
395		1H-NMR (CDCl3) δ: 3.91 (3H, s), 7.04-7.08 (2H, m), 7.32-7.37 (2H, m), 7.59-7.61 (1H, m), 7.86-7.89 (1H, m), 8.29 (1H, s), 10.03 (1H, s).	Ref. Ex. 75
396		1H-NMR (CDCl3) δ: 7.40-7.41 (1H, m), 7.50-7.51 (1H, m), 7.65 (1H, s), 7.82 (1H, s), 7.91 (1H, s), 7.97 (1H, s), 10.06 (1H, s).	Ref. Ex. 75
397		1H-NMR (CDCl3) δ: 7.36-7.40 (1H, m), 7.65-7.70 (2H, m), 7.80 (1H, s), 7.91-7.95 (2H, m), 10.04 (1H, s).	Ref. Ex. 75
398		1H-NMR (CDCl3) δ: 5.84 (2H, s), 6.40 (1H, dd, J = 2.6, 4.1 Hz), 6.73 (1H, s), 6.97 (1H, s), 7.09 (1H, dd, J = 1.7, 4.1 Hz), 7.62 (1H, d, J = 8.2 Hz), 7.83 (1H, d, J = 8.2 Hz), 9.58 (1H, s).	Ref. Ex. 184
399		1H-NMR (CDCl3) δ: 5.79 (2H, s), 7.02 (2H, d, J = 8.3 Hz), 7.18-7.23 (3H, m), 7.34-7.42 (3H, m), 7.76-7.78 (1H, m), 9.89 (1H, s).	Ref. Ex. 113

Ref. Ex. No.	STR	1H-NMR	ref.
400		1H-NMR (CDCl3) δ: 7.59-7.71 (2H, m), 7.73 (1H, s), 7.82-7.84 (1H, m), 7.91-7.98 (2H, m), 10.03 (1H, s).	Ref. Ex. 75
401		1H-NMR (CDCl3) δ: 3.86 (2H, s), 6.89-6.99 (2H, m), 7.09-7.14 (1H, m), 7.40 (1H, s), 7.56 (1H, s), 7.72 (1H, s), 9.94 (1H, s).	Ref. Ex. 75
402		1H-NMR (CDCl3) δ: 7.61-7.63 (1H, m), 7.87 (2H, s), 7.98-8.00 (1H, m), 8.05 (1H, s), 8.36 (1H, s), 9.99 (1H, s).	Ref. Ex. 75
403		1H-NMR (CDCl3) δ: 7.23 (1H, dd, J = 1.4, 5.0 Hz), 7.39 (1H, dd, J = 1.4, 3.0 Hz), 7.53 (1H, dd, J = 3.0, 5.0 Hz), 7.63-7.66 (1H, m), 7.86-7.89 (1H, m), 8.29 (1H, s), 10.15 (1H, s).	Ref. Ex. 112
404		1H-NMR (CDCl3) δ: 6.63 (1H, s), 7.61-7.63 (3H, m), 7.85-7.89 (1H, m), 8.28 (1H, s), 10.10 (1H, s).	Ref. Ex. 112
405		1H-NMR (CDCl3) δ: 7.11-7.16 (4H, m), 7.18-7.24 (1H, m), 7.34-7.45 (4H, m), 7.62 (1H, d, J = 8.1 Hz), 7.87-7.91 (1H, m), 8.31 (1H, s), 10.06 (1H, s).	Ref. Ex. 112
406		1H-NMR (DMSO-d6) δ: 5.33 (2H, s), 7.36-7.39 (1H, m), 7.71-7.84 (4H, m), 10.16 (1H, s).	Ref. Ex. 82








[0484]








Ref. Ex. No.	STR	1H-NMR	ref.
407		1H-NMR (DMSO-d6) δ: 5.37 (2H, s), 7.29-7.34 (1H, m), 7.58 (1H, d, J = 7.8 Hz), 7.66-7.75 (4H, m), 10.23 (1H, s).	Ref. Ex. 82
408		1H-NMR (DMSO-d6) δ: 5.25 (2H, s), 7.53-7.55 (1H, m), 7.73-7.77 (3H, m), 7.98-7.99 (1H, m), 10.12 (1H, s).	Ref. Ex. 82
409		1H-NMR (CDCl3) δ: 5.22 (2H, s), 7.13-7.28 (4H, m), 7.35-7.40 (1H, m), 7.60-7.62 (1H, m), 10.29 (1H, s).	Ref. Ex. 82
410		1H-NMR (CDCl3) δ: 5.37 (2H, s), 7.19-7.23 (1H, m), 7.39-7.43 (1H, m), 7.65-7.66 (1H, m), 7.90 (1H, s), 7.94 (2H, s), 10.35 (1H, s).	Ref. Ex. 82
411		1H-NMR (CDCl3) δ: 5.21 (2H, s), 7.17-7.19 (1H, m), 7.39-7.42 (2H, m), 7.49 (1H, s), 7.65 (1H, s), 7.75 (1H, s), 10.03 (1H, s).	Ref. Ex. 82
412		1H-NMR (CDCl3) δ: 5.22 (2H, s), 6.91 (1H, d, J = 8.9 Hz), 7.34-7.38 (2H, m), 7.49 (1H, s), 7.64-7.66 (1H, m), 7.98 (1H, s), 10.46 (1H, s).	Ref. Ex. 82
413		1H-NMR (CDCl3) δ: 5.15 (2H, s), 7.36 (1H, d, J = 8.2 Hz), 7.43 (1H, d, J = 8.2 Hz), 7.52 (1H, s), 7.70 (1H, s), 7.74 (1H, s), 10.18 (1H, s).	Ref. Ex. 82








Ref. Ex. No.	STR	1H-NMR	ref.
414		1H-NMR (CDCl3) δ: 1.06 (6H, s), 3.80 (4H, s), 7.60-7.62 (1H, m), 7.72-7.74 (1H, m), 8.08 (1H, s), 10.02 (1H, s).	Ref. Ex. 107
415		1H-NMR (CDCl3) δ: 5.32 (2H, s), 7.13-7.18 (1H, m), 7.36-7.41 (1H, m), 7.51-7.55 (1H, m), 7.61-7.64 (3H, m), 7.69 (1H, s), 10.31 (1H, s).	Ref. Ex. 82
416		1H-NMR (CDCl3) δ: 5.29 (2H, s), 7.12-7.28 (3H, m), 7.34-7.44 (3H, m), 7.60 (1H, d, J = 7.8 Hz), 10.29 (1H, s).	Ref. Ex. 82
417		1H-NMR (CDCl3) δ: 2.73-2.77 (2H, m), 3.44-3.47 (2H, m), 5.37 (2H, s), 7.26 (1H, d, J = 8.0 Hz), 7.39 (1H, t, J = 8.0 Hz), 7.56 (1H, d, J = 8.0 Hz), 7.92 (2H, s), 8.01 (1H, s), 10.46 (1H, s).	Ref. Ex. 184
418		1H-NMR (CDCl3) δ: 5.67 (2H, s), 6.37 (1H, dd, J = 2.8, 3.9 Hz), 7.03-7.06 (2H, m), 7.53 (2H, s), 7.78 (1H, s), 9.54 (1H, d, J = 0.8 Hz).	Ref. Ex. 184
419		1H-NMR (CDCl3) δ: 5.51 (2H, s), 6.33 (1H, dd, J = 2.7, 4.0 Hz), 6.98 (2H, s), 7.01 (1H, d, J = 1.5, 4.0 Hz), 7.17 (1H, d, J = 1.3 Hz), 7.56 (1H, t, J = 1.5 Hz), 9.55 (1H, d, J = 0.8 Hz).	Ref. Ex. 184

Ref. Ex. No.	STR	1H-NMR	ref.
420		1H-NMR (CDCl3) δ: 5.69 (2H, s), 6.33 (1H, dd, J = 2.5, 4.0 Hz), 6.52-6.55 (1H, m), 6.99 (1H, s), 7.03 (1H, dd, J = 1.5, 4.0 Hz), 7.09 (1H, t, J = 7.9 Hz), 7.36-7.39 (1H, m), 9.57 (1H, s).	Ref. Ex. 184
421		1H-NMR (CDCl3) δ: 7.44-7.47 (1H, m), 7.54-7.59 (1H, m), 7.71 (1H, s), 8.09 (1H, s), 8.22 (1H, s), 8.30 (1H, s), 10.19 (1H, s).	Ref. Ex. 81, Ref. Ex. 75
422		1H-NMR (CDCl3) δ: 7.40-7.41 (1H, m), 7.50-7.57 (2H, m), 7.62-7.66 (2H, m), 7.90 (1H, s), 10.07 (1H, s).	Ref. Ex. 75
423		1H-NMR (CDCl3) δ: 7.34 (1H, d, J = 8.5 Hz), 7.62-7.70 (3H, m), 7.83 (1H, d, J = 8.1 Hz), 7.95 (1H, d, J = 8.1 Hz), 10.04 (1H, s).	Ref. Ex. 75
424		1H-NMR (CDCl3) δ: 7.08-7.10 (1H, m), 7.29-7.34 (1H, m), 7.48-7.51 (1H, m), 7.60-7.62 (1H, m), 7.81 (1H, s), 10.05 (1H, s).	Ref. Ex. 75
425		1H-NMR (CDCl3) δ: 3.03 (3H, s), 5.24 (2H, s), 7.24-7.28 (1H, m), 7.62-7.67 (2H, m).	Ref. Ex. 103






[0485]






Ref. Ex. No.	STR	1H-NMR	ref.
426		1H-NMR (CDCl3) δ: 5.17 (2H, s), 6.99-7.01 (1H, m), 7.25-7.29 (2H, m), 7.55-7.57 (1H, m), 7.63-7.65 (1H, m), 7.68-7.69 (1H, m), 10.46 (1H, s).	Ref. Ex. 82
427		1H-NMR (CDCl3) δ: 5.40 (2H, s), 7.22-7.31 (1H, m), 7.38 (1H, t, J = 8.0 Hz), 7.62-7.63 (1H, m), 7.75 (1H, d, J = 8.0 Hz), 7.87 (1H, d, J = 8.0 Hz), 8.28 (1H, s), 10.57 (1H, s).	Ref. Ex. 82
428		1H-NMR (CDCl3) δ: 5.77-6.13 (1H, m), 7.30-7.45 (1H, m), 7.51-7.60 (5H, m), 7.89 (1H, s), 10.06 (1H, s).	Ref. Ex. 75
429		1H-NMR (CDCl3) δ: 4.32 (2H, s), 7.06-7.09 (1H, m), 7.45-7.48 (2H, m), 7.60-7.88 (3H, m), 9.96 (1H, s).	Ref. Ex. 75
430		1H-NMR (CDCl3) δ: 5.13 (2H, s), 6.92-7.05 (1H, m), 7.23-7.40 (2H, m), 7.47-7.52 (3H, m), 9.99 (1H, s).	Ref. Ex. 82
431		1H-NMR (CDCl3) δ: 5.15 (2H, s), 7.16-7.25 (2H, m), 7.47-7.61 (3H, m), 10.00 (1H, s).	Ref. Ex. 82
432		1H-NMR (CDCl3) δ: 5.27 (2H, s), 6.90-7.01 (1H, m), 7.10-7.19 (1H, m), 7.35-7.39 (2H, m), 7.60-7.63 (1H, m), 10.29 (1H, s).	Ref. Ex. 82






Ref. Ex. No.	STR	1H-NMR	ref.
433		1H-NMR (CDCl3) δ: 4.28 (2H, s), 7.66 (2H, s), 7.73 (1H, s), 7.82 (1H, s), 7.90 (1H, s), 8.08 (1H, s), 10.07 (1H, s).	Ref. Ex. 75
434		1H-NMR (CDCl3) δ: 7.69-7.79 (6H, m), 8.05 (1H, s), 10.10 (1H, s).	Ref. Ex. 75
435		1H-NMR (CDCl3) δ: 4.08 (2H, s), 7.17-7.34 (6H, m), 7.57 (1H, s), 7.64 (1H, s), 9.96 (1H, s).	Ref. Ex. 75
436		1H-NMR (CDCl3) δ: 6.58 (1H, t, J = 73.4 Hz), 7.24-7.27 (2H, m), 7.59-7.72 (4H, m), 8.01 (1H, s), 10.10 (1H, s).	Ref. Ex. 75
437		1H-NMR (CDCl3) δ: 2.99 (3H, s), 5.25 (2H, s), 7.25-7.29 (2H, m), 7.36 (1H, d, J = 7.8 Hz), 7.46 (1H, t, J = 7.9 Hz).	Ref. Ex. 106
438		1H-NMR (CDCl3) δ: 2.97 (3H, s), 5.25 (2H, s), 5.92 (1H, tt, J = 2.8, 53.0 Hz), 7.24-7.28 (2H, m), 7.34 (1H, d, J = 7.7 Hz), 7.44 (1H, t, J = 7.7 Hz).	Ref. Ex. 106
439		1H-NMR (CDCl3) δ: 5.82 (2H, s), 7.04-7.07 (2H, m), 7.20-7.28 (4H, m), 7.31-7.32 (2H, m), 7.74 (1H, t, J = 1.3 Hz), 9.91 (1H, s).	Ref. Ex. 113







Ref. Ex. No.	STR	1H-NMR	ref.
440		1H-NMR (CDCl3) δ: 5.58 (2H, s), 6.31 (1H, dd, J = 2.9, 3.7 Hz), 6.95 (1H, s), 6.98-7.02 (2H, m), 7.03-7.08 (1H, m), 7.08-7.14 (1H, m), 7.33 (1H, t, J = 8.0 Hz), 9.55 (1H, d, J = 0.8 Hz).	Ref. Ex. 184
441		1H-NMR (CDCl3) δ: 5.58 (2H, s), 5.88 (1H, tt, J = 2.9, 53.0 Hz), 6.30 (1H, t, J = 3.3 Hz), 6.96 (1H, s), 6.98 (2H, d, J = 3.5 Hz), 7.02-7.07 (1H, m), 7.09-7.15 (1H, m), 7.32 (1H, t, J = 8.0 Hz), 9.55 (1H, s).	Ref. Ex. 184
442		1H-NMR (CDCl3) δ: 5.03 (2H, s), 5.49 (2H, s), 6.24 (1H, t, J = 3.3 Hz), 6.88-6.94 (2H, m), 6.95 (2H, d, J = 3.5 Hz), 7.09-7.16 (2H, m), 7.29-7.44 (5H, m), 9.56 (1H, s).	Ref. Ex. 184
443		1H-NMR (CDCl3) δ: 5.61 (2H, s), 6.29 (1H, dd, J = 2.5, 4.0 Hz), 6.99 (1H, dd, J = 1.7, 4.0 Hz), 7.01-7.04 (1H, m), 7.20-7.25 (2H, m), 7.30-7.37 (1H, m), 7.38-7.46 (2H, m), 7.51-7.58 (4H, m), 9.58 (1H, d, J = 1.0 Hz).	Ref. Ex. 184
444		1H-NMR (CDCl3) δ: 7.38 (1H, d, J = 16.3 Hz), 7.65-7.72 (4H, m), 7.84-7.91 (2H, m), 8.12-8.21 (2H, m), 10.34 (1H, s).	Ref. Ex. 112
445		1H-NMR (CDCl3) δ: 4.12 (2H, s), 7.12-7.16 (2H, m), 7.29-7.35 (2H, m), 7.71 (1H, s), 7.88 (1H, s), 8.02 (1H, s), 10.05 (1H, s).	Ref. Ex. 81, Ref. Ex. 75
446		1H-NMR (CDCl3) δ: 7.35 (2H, d, J = 8.0 Hz), 7.63-7.66 (3H, m), 7.73 (1H, s), 8.02 (1H, s), 10.08 (1H, s).	Ref. Ex. 75








[0486]







Ref. Ex. No.	STR	1H-NMR	ref.
447		1H-NMR (CDCl3) δ: 1.24 (6H, t, J = 7.1 Hz), 3.51-3.65 (4H, m), 5.10 (2H, s), 5.52 (1H, s), 6.83-6.95 (2H, m), 7.03 (1H, s), 7.38-7.48 (3H, m), 7.53 (1H, s).	Ref. Ex. 82
448		1H-NMR (CDCl3) δ: 5.16 (2H, s), 6.84-6.89 (1H, m), 6.97 (1H, d, J = 7.8 Hz), 7.05 (1H, s), 7.60 (1H, t, J = 7.6 Hz), 7.70 (1H, d, J = 7.6 Hz), 7.89 (1H, d, J = 7.6 Hz), 7.96 (1H, s), 10.06 (1H, s).	Ref. Ex. 151
449		1H-NMR (CDCl3) δ: 6.65 (1H, t, J = 72.6 Hz), 7.61-7.72 (4H, m), 7.79-7.87 (2H, m), 7.97 (1H, s), 10.09 (1H, s).	Ref. Ex. 91
450		1H-NMR (CDCl3) δ: 6.64 (1H, t, J = 72.7 Hz), 7.11-7.31 (2H, m), 7.45-7.65 (4H, m), 7.94 (1H, s), 10.08 (1H, s).	Ref. Ex. 91
451		1H-NMR (CDCl3) δ: 6.64 (1H, t, J = 72.8 Hz), 7.33-7.36 (2H, m), 7.58-7.66 (4H, m), 7.93 (1H, s), 10.07 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
452		1H-NMR (CDCl3) δ: 1.04 (6H, s), 3.80 (4H, s), 6.58 (1H, t, J = 73.4 Hz), 7.68 (1H, s), 7.79 (1H, s), 8.14 (1H, s), 10.03 (1H, s).	Ref. Ex. 107
453		1H-NMR (CDCl3) δ: 6.63 (1H, t, J = 72.8 Hz), 7.45-7.63 (6H, m), 7.93 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
454		1H-NMR (CDCl3) δ: 6.67 (1H, t, J = 72.4 Hz), 7.63 (1H, s), 7.73 (1H, s), 7.96-8.10 (4H, m), 10.10 (1H, s).	Ref. Ex. 91
455		1H-NMR (CDCl3) δ: 6.66 (1H, t, J = 72.5 Hz), 7.40-7.43 (1H, m), 7.52-7.56 (1H, m), 7.60 (1H, s), 7.65 (1H, s), 7.70 (1H, s), 7.95 (1H, s), 10.09 (1H, s).	Ref. Ex. 91
456		1H-NMR (CDCl3) δ: 6.63 (1H, t, J = 72.6 Hz), 7.39 (1H, s), 7.60-7.73 (3H, m), 7.82-7.98 (2H, m), 10.05 (1H, s).	Ref. Ex. 91







Ref. Ex. No.	STR	1H-NMR	ref.
457		1H-NMR (CDCl3) δ: 7.85 (1H, s), 7.94-8.03 (5H, m), 10.08 (1H, s).	Ref. Ex. 91
458		1H-NMR (DMSO-d6) δ: 5.39 (2H, s), 7.18 (2H, d, J = 8.8 Hz), 7.66 (1H, d, J = 4.0 Hz), 7.79 (2H, d, J = 8.8 Hz), 8.01 (1H, d, J = 4.0 Hz), 8.11 (1H, s), 8.20 (2H, s), 9.88 (1H, s).	Ref. Ex. 82
459		1H-NMR (DMSO-d6) δ: 5.17 (2H, s), 7.12 (2H, d, J = 8.8 Hz), 7.30-7.59 (3H, m), 7.64 (1H, d, J = 4.0 Hz), 7.76 (2H, d, J = 8.8 Hz), 8.01 (1H, d, J = 4.0 Hz), 9.88 (1H, s).	Ref. Ex. 82
460		1H-NMR (DMSO-d6) δ: 5.40 (2H, s), 7.16 (2H, d, J = 8.7 Hz), 7.66 (1H, d, J = 4.0 Hz), 7.79 (2H, d, J = 8.7 Hz), 7.93-8.10 (3H, m), 8.19 (1H, s), 9.88 (1H, s).	Ref. Ex. 82
461		1H-NMR (DMSO-d6) δ: 5.42 (2H, s), 7.12-7.15 (1H, m), 7.43-7.48 (3H, m), 7.80 (1H, d, J = 4.0 Hz), 8.02-8.10 (3H, m), 8.22 (1H, s), 9.92 (1H, s).	Ref. Ex. 82







Ref. Ex. No.	STR	1H-NMR	ref.
462		1H-NMR (DMSO-d6) δ: 5.41 (2H, s), 7.13-7.17 (1H, m), 7.41-7.51 (3H, m), 7.79 (1H, d, J = 4.0 Hz), 8.06 (1H, d, J = 4.0 Hz), 8.11 (1H, s), 8.22 (2H, s), 9.92 (1H, s).	Ref. Ex. 82
463		1H-NMR (CDCl3) δ: 2.28 (3H, s), 7.10-7.15 (2H, m), 7.24-7.26 (1H, m), 7.55 (1H, s), 7.70 (1H, s), 7.87 (1H, s), 10.02 (1H, s).	Ref. Ex. 91
464		1H-NMR (CDCl3) δ: 7.37-7.48 (3H, m), 7.78 (1H, s), 7.88 (1H, s), 7.93 (1H, s), 10.04 (1H, s).	Ref. Ex. 91
465		1H-NMR (DMSO-d6) δ: 7.88 (1H, d, J = 8.4 Hz), 7.98 (1H, s), 8.11-8.19 (1H, m), 8.22-8.25 (2H, m), 8.29 (1H, s), 10.08 (1H, s).	Ref. Ex. 91
466		1H-NMR (CDCl3) δ: 5.76-6.13 (1H, m), 7.32-7.35 (2H, m), 7.60-7.64 (2H, m), 7.80-7.85 (2H, m), 7.95 (1H, s), 10.04 (1H, s).	Ref. Ex. 91
467		1H-NMR (CDCl3) δ: 7.31-7.37 (1H, m), 7.76-7.83 (3H, m), 7.88 (1H, s), 7.94 (1H, s), 10.05 (1H, s).	Ref. Ex. 91






Ref. Ex. No.	STR	1H-NMR	ref.
468		1H-NMR (DMSO-d6) δ: 4.04 (2H, s), 7.16-7.21 (4H, m), 7.42 (1H, s), 7.58 (1H, s), 7.72 (1H, s), 9.94 (1H, s).	Ref. Ex. 112
469		1H-NMR (CDCl3) δ: 6.57 (1H, t, J = 73.5 Hz), 7.23-7.24 (2H, m), 7.59-7.63 (2H, m), 7.79-7.84 (2H, m), 7.94 (1H, s), 10.04 (1H, s).	Ref. Ex. 91
470		1H-NMR (CDCl3) δ: 4.39 (2H, s), 7.45 (1H, s), 7.65-7.70 (2H, m), 7.80 (1H, s), 7.88 (1H, d, J = 8.2 Hz), 8.04 (1H, s), 10.3 (1H, s).	Ref. Ex. 81, Ref. Ex. 75
471		1H-NMR (CDCl3) δ: 4.33 (2H, s), 7.19 (1H, d, J = 7.6 Hz), 7.44 (1H, t, J = 7.6 Hz), 7.51 (1H, t, J = 7.56 Hz), 7.66 (1H, s), 7.72 (1H, d, J = 7.6 Hz), 7.81 (1H, s), 8.01 (1H, s), 10.02 (1H, s).	Ref. Ex. 81, Ref. Ex. 75
472		1H-NMR (CDCl3) δ: 5.22 (2H, s), 7.51-7.55 (2H, m), 7.63-7.65 (3H, m), 7.73 (1H, s), 7.76 (1H, s), 10.02 (1H, s).	Ref. Ex. 82
473		1H-NMR (CDCl3) δ: 5.25 (2H, s), 7.23-7.28 (1H, m), 7.52 (1H, s), 7.64-7.69 (2H, m), 7.78 (1H, s), 7.83-7.85 (1H, m), 10.04 (1H, s).	Ref. Ex. 82
474		1H-NMR (CDCl3) δ: 5.21 (2H, s), 7.33-7.39 (2H, m), 7.51 (2H, s), 7.64 (1H, s), 7.78 (1H, s), 10.03 (1H, s).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
475		1H-NMR (CDCl3) δ: 5.44 (2H, s), 7.53 (1H, s), 7.66 (1H, s), 7.82 (1H, s), 7.90-7.97 (2H, m), 8.02 (1H, s), 10.06 (1H, s).	Ref. Ex. 82
476		1H-NMR (CDCl3) δ: 2.39 (3H, s), 5.14 (2H, s), 7.19-7.31 (3H, m), 7.40 (1H, d, J = 7.3 Hz), 7.49 (1H, s), 7.66 (1H, s), 7.74 (1H, s), 10.02 (1H, s).	Ref. Ex. 82
477		1H-NMR (CDCl3) δ: 5.42 (2H, s), 7.31-7.36 (1H, m), 7.41-7.44 (2H, m), 7.53 (1H, s), 7.73 (1H, s), 7.79 (1H, s), 10.06 (1H, s).	Ref. Ex. 82
478		1H-NMR (DMSO-d6) δ: 5.41 (2H, s), 7.18-7.24 (2H, m), 7.33 (1H, s), 7.42-7.49 (2H, m), 8.11 (1H, s), 8.17-8.20 (3H, m), 9.80 (1H, s).	Ref. Ex. 82
479		1H-NMR (DMSO-d6) δ: 5.32 (2H, s), 7.16-7.23 (2H, m), 7.30 (1H, s), 7.43-7.46 (2H, m), 7.67-7.72 (3H, m), 8.17 (1H, s), 9.79 (1H, s).	Ref. Ex. 82
480		1H-NMR (CDCl3) δ: 5.29 (2H, s), 7.28-7.30 (1H, m), 7.49-7.53 (3H, m), 7.68 (1H, s), 7.80 (1H, s), 10.06 (1H, s).	Ref. Ex. 175


[0488]


Ref. Ex. No.	STR	1H-NMR	ref.
481		1H-NMR (CDCl3) δ: 5.24 (2H, s), 7.26-7.43 (3H, m), 7.48 (1H, s), 7.57-7.59 (1H, m), 7.64 (1H, s), 7.75 (1H, s), 10.02 (1H, s).	Ref. Ex. 82
482		1H-NMR (CDCl3) δ: 5.32 (2H, s), 7.38-7.44 (1H, m), 7.50 (1H, s), 7.54-7.63 (2H, m), 7.70 (1H, s), 7.80 (1H, s), 10.06 (1H, s).	Ref. Ex. 82
483		1H-NMR (CDCl3) δ: 5.30 (2H, s), 7.28-7.34 (1H, m), 7.44-7.47 (2H, m), 7.62 (1H, s), 7.68-7.73 (1H, m), 7.77 (1H, s), 10.02 (1H, s).	Ref. Ex. 82
485		1H-NMR (CDCl3) δ: 5.77-6.13 (1H, m), 7.61 (2H, d, J = 8.7 Hz), 7.61-7.77 (4H, m), 8.02 (1H, s), 10.08 (1H, s).	Ref. Ex. 91
486		1H-NMR (CDCl3) δ: 7.40-7.48 (3H, m), 7.64 (1H, s), 7.76 (1H, s), 8.00 (1H, s), 10.08 (1H, s).	Ref. Ex. 91
487		1H-NMR (CDCl3) δ: 7.55-7.58 (2H, m), 7.76-7.78 (1H, m), 7.89-7.99 (3H, m), 8.11-8.14 (2H, m), 8.22 (1H, s), 8.42 (1H, s), 10.18 (1H, s).	Ref. Ex. 75


Ref. Ex. No.	STR	1H-NMR	ref.
488		1H-NMR (CDCl3) δ: 4.31 (2H, q, J = 8.1 Hz), 5.51 (2H, s), 6.27 (1H, t, J = 3.3 Hz), 6.85-6.91 (2H, m), 6.97 (2H, d, J = 3.4 Hz), 7.11-7.17 (2H, m), 9.55 (1H, s).	Ref. Ex. 113
489		1H-NMR (CDCl3) δ: 1.97-2.09 (2H, m), 2.21-2.39 (2H, m), 3.98 (2H, t, J = 6.0 Hz), 5.49 (2H, s), 6.25 (1H, t, J = 3.3 Hz), 6.79-6.85 (2H, m), 6.96 (2H, d, J = 3.5 Hz), 7.10-7.15 (2H, m), 9.56 (1H, s).	Ref. Ex. 113
490		1H-NMR (CDCl3) δ: 7.47 (1H, s), 7.53 (1H, d J = 8.1 Hz), 7.78 (1H, s), 7.82 (1H, s), 7.85-7.92 (1H, m), 8.07 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
491		1H-NMR (CDCl3) δ: 7.50 (1H, d J = 8.0 Hz), 7.58 (1H, s), 7.72 (1H, s), 7.89 (1H, d J = 8.0 Hz), 7.95 (1H, s), 8.06 (1H, s), 10.02 (1H, s).	Ref. Ex. 91
492		1H-NMR (CDCl3) δ: 7.71-7.81 (2H, m), 7.92 (1H, s), 8.03 (1H, s), 8.07 (1H, s), 8.13 (1H, s), 8.35 (2H, s), 10.03 (1H, s).	Ref. Ex. 75
493		1H-NMR (CDCl3) δ: 7.74-7.84 (3H, m), 7.98 (1H, s), 8.04 (1H, s), 8.22 (1H, s), 8.36 (2H, s), 10.07 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
494		1H-NMR (CDCl3) δ: 4.00-4.13 (5H, m), 4.41-4.42 (2H, m), 5.75 (1H, s), 6.56-6.64 (1H, m), 6.76-6.78 (1H, m), 6.85 (1H, d, J = 7.6 Hz), 7.18 (1H, t, J = 7.6 Hz), 7.40-7.65 (4H, m).	Ref. Ex. 114
495		1H-NMR (CDCl3) δ: 3.02 (3H, s), 3.98-4.13 (4H, m), 4.54 (2H, s), 5.77 (1H, s), 6.68-6.75 (1H, m), 6.79-6.91 (2H, m), 7.18-7.37 (6H, m).	Ref. Ex. 12
496		1H-NMR (CDCl3) δ: 3.03 (3H, s), 3.98-4.12 (4H, m), 4.57 (2H, s), 5.77 (1H, s), 6.70-6.73 (1H, m), 6.85-6.88 (2H, m), 7.20-7.26 (1H, m), 7.40-7.51 (4H, m).	Ref. Ex. 12
497		1H-NMR (CDCl3) δ: 3.10 (3H, s), 4.60 (2H, s), 6.92-7.00 (1H, m), 7.18-7.35 (8H, m), 9.93 (1H, s).	Ref. Ex. 151
498		1H-NMR (CDCl3) δ: 3.10 (3H, s), 4.64 (2H, s), 6.97-6.99 (1H, m), 7.22-7.25 (2H, m), 7.35-7.61 (5H, m), 9.94 (1H, s).	Ref. Ex. 151







[0489]







Ref. Ex. No.	STR	1H-NMR	ref.
499		1H-NMR (CDCl3) δ: 5.18 (2H, s), 7.11-7.18 (1H, m), 7.20-7.26 (2H, m), 7.38-7.46 (1H, m), 7.59 (1H, t, J = 7.6 Hz), 7.70-7.75 (1H, m), 7.85-7.91 (1H, m), 7.97 (1H, s), 10.06 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
500		1H-NMR (CDCl3) δ: 5.19 (2H, s), 7.04 (2H, d, J = 8.5 Hz), 7.53-7.62 (3H, m), 7.68-7.75 (1H, m), 7.85-7.90 (1H, m), 7.96 (1H, s), 10.05 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
501		1H-NMR (CDCl3) δ: 5.23 (2H, s), 6.90-7.00 (2H, m), 7.17-7.24 (1H, m), 7.40 (1H, dd, J = 1.6, 7.8 Hz), 7.58 (1H, t, J = 7.7 Hz), 7.75-7.81 (1H, m), 7.84-7.88 (1H, m), 7.98 (1H, s), 10.05 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
502		1H-NMR (CDCl3) δ: 5.13 (2H, s), 6.84-6.89 (1H, m), 6.94-7.00 (2H, m), 7.22 (1H, t, J = 8.1 Hz), 7.58 (1H, t, J = 7.6 Hz), 7.69 (1H, d, J = 7.8 Hz), 7.88 (1H, d, J = 7.5 Hz), 7.95 (1H, s), 10.05 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
503		1H-NMR (CDCl3) δ: 5.23 (2H, s), 6.88 (1H, dd, J = 2.7, 6.9 Hz), 7.08-7.17 (2H, m), 7.59 (1H, t, J = 7.6 Hz), 7.76 (1H, d, J = 7.7 Hz), 7.87 (1H, d, J = 7.6 Hz), 7.97 (1H, s), 10.05 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
504		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.89 (2H, d, J = 1.8 Hz), 7.00 (1H, t, J = 1.8 Hz), 7.59 (1H, t, J = 7.6 Hz), 7.66-7.70 (1H, m), 7.85-7.90 (1H, m), 7.93 (1H, s), 10.05 (1H, s).	Ref. Ex. 113, Ref. Ex. 93








Ref. Ex. No.	STR	1H-NMR	ref.
505		1H-NMR (CDCl3) δ: 1.03-1.41 (5H, m), 1.77-1.89 (6H, m), 3.85 (2H, d, J = 6.0 Hz), 7.39 (1H, s), 7.55 (1H, s), 7.68 (1H, s), 10.00 (1H, s).	Ref. Ex. 175
506		1H-NMR (CDCl3) δ: 5.34 (2H, s), 7.11-7.17 (1H, m), 7.44-7.49 (2H, m), 7.62 (1H, s), 7.71-7.77 (2H, m), 10.02 (1H, s).	Ref. Ex. 82
507		1H-NMR (CDCl3) δ: 5.31 (2H, s), 7.44-7.50 (2H, m), 7.59-7.68 (2H, m), 7.74 (1H, s), 7.78 (1H, s), 10.02 (1H, s).	Ref. Ex. 82
508		1H-NMR (CDCl3) δ: 2.52 (3H, s), 7.23-7.24 (1H, m), 7.46-7.57 (3H, m), 7.65 (1H, s), 7.71 (1H, s), 7.88 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
509		1H-NMR (CDCl3) δ: 2.43 (3H, s), 4.14 (2H, s), 7.25-7.26 (1H, m), 7.50 (1H, s), 7.60-7.62 (3H, m), 7.78 (1H, s), 9.97 (1H, s).	Ref. Ex. 91
510		1H-NMR (CDCl3) δ: 2.51 (3H, s), 5.76-6.12 (1H, m), 7.24-7.33 (2H, m), 7.61-7.69 (4H, m), 7.87 (1H, s), 10.05 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
511		1H-NMR (CDCl3) δ: 5.17 (2H, s), 7.50 (1H, s), 7.55-7.57 (2H, m), 7.63 (1H, s), 7.76-7.79 (2H, m), 10.02 (1H, s).	Ref. Ex. 82
512		1H-NMR (CDCl3) δ: 2.52 (3H, s), 7.40-7.48 (3H, m), 7.62 (1H, s), 7.72 (1H, s), 7.88 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
513		1H-NMR (CDCl3) δ: 0.87-1.05 (2H, m), 1.16-1.33 (4H, m), 1.46-1.57 (1H, m), 1.68-1.79 (6H, m), 4.09 (2H, t, J = 6.6 Hz), 7.39 (1H, s), 7.54 (1H, s), 7.68 (1H, s), 10.00 (1H, s).	Ref. Ex. 82
514		1H-NMR (CDCl3) δ: 0.97 (3H, t, J = 7.3 Hz), 1.38-1.57 (2H, m), 1.83-1.89 (1H, m), 2.00-2.05 (1H, m), 5.18-5.23 (1H, m), 7.26-7.37 (6H, m), 7.46 (1H, s), 7.61 (1H, s), 9.89 (1H, s).	Ref. Ex. 82
515		1H-NMR (CDCl3) δ: 2.35 (6H, s), 5.10 (2H, s), 7.11-7.13 (2H, m), 7.22 (1H, s), 7.49 (1H, s), 7.66 (1H, s), 7.73 (1H, s), 10.02 (1H, s).	Ref. Ex. 82
516		1H-NMR (CDCl3) δ: 2.34 (3H, s), 2.36 (3H, s), 5.10 (2H, s), 7.03-7.07 (2H, m), 7.29 (1H, s), 7.48 (1H, s), 7.65 (1H, s), 7.72 (1H, s), 10.01 (1H, s).	Ref. Ex. 82
517		1H-NMR (CDCl3) δ: 3.98-4.18 (4H, m), 5.79 (1H, s), 5.84 (1H, brs), 7.07-7.38 (6H, m).	Ref. Ex. 114







[0490]







Ref. Ex. No.	STR	1H-NMR	ref.
518		1H-NMR (CDCl3) δ: 3.35 (3H, s), 4.00-4.13 (4H, m), 5.78 (1H, s), 7.07-7.35 (8H, m).	Ref. Ex. 12
519		1H-NMR (CDCl3) δ: 3.36 (3H, s), 7.12-7.15 (4H, m), 7.33-7.40 (5H, m), 9.93 (1H, s).	Ref. Ex. 151
520		1H-NMR (CDCl3) δ: 3.40 (3H, s), 7.24-7.30 (3H, m), 7.39-7.54 (5H, m), 9.97 (1H, s).	Ref. Ex. 151
521		1H-NMR (CDCl3) δ: 1.35-1.57 (2H, m), 1.57-1.68 (4H, m), 1.83-1.87 (2H, m), 2.36-2.41 (1H, m), 3.89 (2H, d, J = 6.9 Hz), 7.31 (1H, s), 7.35 (1H, s), 7.47 (1H, s).	Ref. Ex. 80
522		1H-NMR (CDCl3) δ: 2.51 (3H, s), 7.31 (2H, d J = 8.0 Hz), 7.61-7.64 (3H, m), 7.69 (1H, s), 7.87 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
523		1H-NMR (CDCl3) δ: 2.53 (3H, s), 7.67-7.72 (2H, m), 7.73 (4H, s), 7.91 (1H, s), 10.07 (1H, s).	Ref. Ex. 91







Ref. Ex. No.	STR	1H-NMR	ref.
524		1H-NMR (CDCl3) δ: 2.51 (3H, s), 6.57 (1H, t J = 73.7 Hz), 7.70-7.32 (2H, m), 7.59-7.63 (3H, m), 7.68 (1H, s), 7.86 (1H, s), 10.05 (1H, s).	Ref. Ex. 91
525		1H-NMR (CDCl3) δ: 2.52 (3H, s), 7.27-7.34 (1H, m), 7.62 (1H, s), 7.72 (1H, s), 7.76-7.86 (3H, m), 10.06 (1H, s).	Ref. Ex. 91
526		1H-NMR (CDCl3) δ: 1.35-1.41 (2H, m), 1.62-1.68 (4H, m), 1.84-1.88 (2H, m), 2.36-2.40 (1H, m), 3.94 (2H, t, J = 6.9 Hz), 7.40 (1H, s), 7.53 (1H, s), 7.69 (1H, s), 10.01 (1H, s).	Ref. Ex. 229
527		1H-NMR (CDCl3) δ: 1.66-1.75 (1H, m), 1.85-2.16 (5H, m), 4.92 (1H, bs), 5.83-5.87 (1H, m), 6.01-6.06 (1H, m), 7.40 (1H, s), 7.58 (1H, s), 7.68 (1H, s), 10.00 (1H, s).	Ref. Ex. 82
528		1H-NMR (CDCl3) δ: 5.34 (2H, s), 7.51-7.53 (2H, m), 7.66-7.68 (3H, m), 7.74-7.78 (2H, m), 10.03 (1H, s).	Ref. Ex. 82
529		1H-NMR (CDCl3) δ: 5.29 (2H, s), 7.33-7.36 (2H, m), 7.45-7.48 (1H, m), 7.53-7.57 (2H, m), 7.68 (1H, s), 7.78 (1H, s), 10.05 (1H, s).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
530		1H-NMR (CDCl3) δ: 5.20 (2H, s), 6.89 (1H, d, J = 8.8 Hz), 7.17 (1H, dd, J = 2.5, 8.8 Hz), 7.40 (1H, d, J = 2.5 Hz), 7.58 (1H, t, J = 7.6 Hz), 7.75 (1H, d, J = 7.7 Hz), 7.86 (1H, d, J = 7.6 Hz), 7.96 (1H, s), 10.05 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
531		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.83 (1H, dd, J = 2.9, 8.9 Hz), 7.09 (1H, d, J = 2.9 Hz), 7.35 (1H, d, J = 8.9 Hz), 7.58 (1H, d, J = 7.6 Hz), 7.68 (1H, d, J = 7.7 Hz), 7.87 (1H, d, J = 7.5 Hz), 7.94 (1H, s), 10.05 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
532		1H-NMR (CDCl3) δ: 5.20 (2H, s), 6.91-6.98 (2H, m), 7.32 (1H, d, J = 8.4 Hz), 7.60 (1H, t, J = 7.6 Hz), 7.74-7.78 (1H, m), 7.86-7.90 (1H, m), 7.98 (1H, s), 10.06 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
533		1H-NMR (CDCl3) δ: 5.13 (2H, s), 7.02-7.08 (1H, m), 7.33 (2H, d, J = 8.0 Hz), 7.57-7.62 (1H, m), 7.85-7.91 (2H, m), 8.07 (1H, s), 10.07 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
534		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.35 (2H, s), 7.59 (1H, t, J = 7.6 Hz), 7.81-7.86 (1H, m), 7.87-7.92 (1H, m), 8.04 (1H, s), 10.07 (1H, s).	Ref. Ex. 113, Ref. Ex. 93
535		1H-NMR (CDCl3) δ: 7.70-7.75 (1H, m), 8.00-8.05 (1H, m), 8.30-8.35 (1H, m), 8.51 (1H, s), 10.12 (1H, s).	Ex. 1, Ref. Ex. 151
536		1H-NMR (CDCl3) δ: 1.37-1.96 (14H, m), 3.50-3.60 (1H, m), 4.58 (2H, s), 7.50 (1H, t, J = 7.6 Hz), 7.60-7.65 (1H, m), 7.76-7.81 (1H, m), 7.86 (1H, s), 10.03 (1H, s).	Ref. Ex. 92






[04911]







Ref. Ex. No.	STR	1H-NMR	ref.
537		1H-NMR (CDCl3) δ: 1.15-1.37 (2H, m), 1.45-1.65 (4H, m), 1.65-1.90 (2H, m), 2.15-2.35 (1H, m), 3.37 (2H, d, J = 7.0 Hz), 4.58 (2H, s), 7.51 (1H, t, J = 7.6 Hz), 7.63 (1H, d, J = 7.6 Hz), 7.80 (1H, d, J = 7.6 Hz), 7.86 (1H, s), 10.03 (1H, s).	Ref. Ex. 92
538		1H-NMR (CDCl3) δ: 1.21-1.36 (2H, m), 1.40-1.75 (12H, m), 1.79-1.94 (1H, m), 3.27 (2H, d, J = 6.8 Hz), 4.57 (2H, s), 7.52 (1H, t, J = 7.6 Hz), 7.60-7.65 (1H, m), 7.77-7.82 (1H, m), 7.85 (1H, s), 10.03 (1H, s).	Ref. Ex. 92
539		1H-NMR (CDCl3) δ: 1.49-1.92 (10H, m), 2.06-2.19 (4H, m), 3.54-3.61 (1H, m), 4.61 (2H, s), 7.51 (1H, t, J = 7.6 Hz), 7.64-7.69 (1H, m), 7.77-7.82 (1H, m), 7.89 (1H, s), 10.03 (1H, s).	Ref. Ex. 92
540		1H-NMR (CDCl3) δ: 0.84 (3H, s), 0.86 (3H, s), 0.92 (3H, s), 1.10 (1H, dd, J = 3.3, 13.0 Hz), 1.20-1.34 (2H, m), 1.64-1.80 (2H, m), 2.01-2.23 (2H, m), 3.67-3.76 (1H, m), 4.51 (1H, d, J = 12.6 Hz), 4.64 (1H, d, J = 12.6 Hz), 7.51 (1H, t, J = 7.6 Hz), 7.60-7.66 (1H, m), 7.76-7.82 (1H, m), 7.85 (1H, s), 10.03 (1H, s).	Ref. Ex. 92
541		1H-NMR (CDCl3) δ: 1.52-1.78 (12H, m), 1.93-2.02 (3H, m), 3.05 (2H, s), 4.56 (2H, s), 7.51 (1H, t, J = 7.6 Hz), 7.59-7.65 (1H, m), 7.76-7.82 (1H, m), 7.83 (1H, s), 10.03 (1H, s).	Ref. Ex. 92
542		1H-NMR (CDCl3) δ: 0.72 (3H, d, J = 7.0 Hz), 0.91 (3H, d, J = 7.1 Hz), 0.95 (3H, d, J = 6.6 Hz), 0.79-1.06 (3H, m), 1.24-1.46 (2H, m), 1.60-1.71 (2H, m), 2.14-2.35 (2H, m), 3.15-3.25 (1H, m), 4.47 (1H, d, J = 11.8 Hz), 4.73 (1H, d, J = 11.8 Hz), 7.51 (1H, t, J = 7.6 Hz), 7.61-7.66 (1H, m), 7.77-7.82 (1H, m), 7.85 (1H, s), 10.03 (1H, s).	Ref. Ex. 92







Ref. Ex. No.	STR	1H-NMR	ref.
543		1H-NMR (CDCl3) δ: 0.73 (3H, d, J = 7.0 Hz), 0.91 (3H, d, J = 7.1 Hz), 0.95 (3H, d, J = 6.5 Hz), 0.78-1.06 (3H, m), 1.24-1.45 (2H, m), 1.60-1.73 (2H, m), 2.15-2.35 (2H, m), 3.15-3.26 (1H, m), 4.47 (1H, d, J = 11.8 Hz), 4.74 (1H, d, J = 11.8 Hz), 7.51 (1H, t, J = 7.6 Hz), 7.61-7.67 (1H, m), 7.76-7.82 (1H, m), 7.85 (1H, s), 10.03 (1H, s).	Ref. Ex. 92
544		1H-NMR (CDCl3) δ: 2.51 (3H, s), 7.42-7.46 (2H, m), 7.53-7.57 (2H, m), 7.63 (1H, s), 7.68 (1H, s), 7.86 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
545		1H-NMR (CDCl3) δ: 2.27 (3H, s), 2.49 (3H, s), 7.10-7.24 (3H, m), 3.78 (1H, s), 7.70 (1H, s), 7.90 (1H, s), 10.03 (1H, s).	Ref. Ex. 91
546		1H-NMR (CDCl3) δ: 2.53 (3H, s), 7.57-7.81 (5H, m), 7.86 (1H, s), 7.91 (1H, s), 10.07 (1H, s).	Ref. Ex. 91
547		1H-NMR (CDCl3) δ: 1.66-1.80 (12H, m), 2.04 (3H, bs), 3.55 (2H, s), 7.32 (1H, s), 7.35 (1H, s), 7.50 (1H, s).	Ref. Ex. 80
548		1H-NMR (CDCl3) δ: 1.38-1.44 (2H, m), 1.52-1.62 (8H, m), 1.60-1.76 (4H, m), 2.02-2.07 (1H, m), 3.77 (2H, d, J = 6.6 Hz), 7.30 (1H, s), 7.34 (1H, s), 7.46 (1H, s).	Ref. Ex. 80

Ref. Ex. No.	STR	1H-NMR	ref.
549		1H-NMR (CDCl3) δ: 2.53 (3H, s), 7.41-7.50 (2H, m), 7.66-7.75 (3H, m), 7.89 (1H, s), 10.07 (1H, s).	Ref. Ex. 91
550		1H-NMR (CDCl3) δ: 5.36 (2H, s), 7.42-7.44 (1H, m), 7.57-7.59 (3H, m), 8.01-8.02 (1H, m), 8.15-8.16 (1H, m), 10.00 (1H, s).	Ref. Ex. 82
551		1H-NMR (CDCl3) δ: 1.24-1.75 (14H, m), 2.02-2.08 (1H, m), 3.74-3.83 (2H, m), 7.39 (1H, s), 7.55 (1H, s), 7.69 (1H, s), 10.01 (1H, s).	Ref. Ex. 93
552		1H-NMR (CDCl3) δ: 1.67-1.80 (12H, m), 2.04-2.05 (3H, m), 4.16 (2H, s), 7.56 (1H, s), 7.68 (1H, s), 8.02 (1H, s), 10.01 (1H, s).	Ref. Ex. 93
553		1H-NMR (CDCl3) δ: 5.22 (2H, s), 7.28-7.31 (1H, m), 7.38 (1H, d, J = 8.5 Hz), 7.53 (1H, s), 7.57-7.58 (1H, m), 7.66 (1H, s), 7.78 (1H, s), 10.04 (1H, s).	Ref. Ex. 175
554		1H-NMR (CDCl3) δ: 3.98-4.13 (4H, m), 4.22-4.33 (1H, m), 4.40 (2H, d, J = 5.5 Hz), 5.72 (1H, s), 6.41 (1H, s), 6.67-6.70 (2H, m), 7.44-7.61 (4H, m).	Ref. Ex. 114








[0492]







Ref. Ex. No.	STR	1H-NMR	ref.
555		1H-NMR (CDCl3) δ: 7.87 (1H, s), 8.01-8.09 (4H, m), 10.01 (1H, s).	Ref. Ex. 91
556		1H-NMR (CDCl3) δ: 7.15-7.18 (1H, m), 7.32-7.35 (2H, m), 7.63 (1H, 1 J = 7.8 Hz), 7.79 (1H, d, J = 7.8 Hz), 7.88 (1H, d, J = 7.8 Hz), 8.03 (1H, s), 10.09 (1H, s).	Ref. Ex. 91
557		1H-NMR (CDCl3) δ: 3.05 (3H, s), 4.00-4.13 (4H, m), 4.58 (2H, s), 5.74 (1H, s), 6.50 (1H, s), 6.72 (1H, s), 6.76 (1H, s), 7.33-7.94 (4H, m).	Ref. Ex. 12
558		1H-NMR (CDCl3) δ: 3.13 (3H, s), 4.65 (2H, s), 6.73 (1H, s), 7.07 (1H, s), 7.13 (1H, s), 7.32-7.61 (4H, m), 9.89 (1H, s).	Ref. Ex. 151
559		1H-NMR (CDCl3) δ: 2.51 (3H, s), 6.95 (1H d, J = 9.0 Hz), 7.15 (1H, d, J = 9.0 Hz), 7.21-7.33 (1H, m), 7.58 (1H, s), 7.69 (1H, s), 7.82 (1H, s), 10.05 (1H, s).	Ref. Ex. 91



Ref. Ex. No.	STR	1H-NMR	ref.
560		1H-NMR (CDCl3) δ: 2.55 (3H, s), 7.68 (1H, s), 7.78 (1H, s), 7.91 (1H, s), 7.92 (1H, s), 8.04 (2H, s), 10.09 (1H, s).	Ref. Ex. 91
561		1H-NMR (CDCl3) δ: 2.53 (3H, s), 7.07-7.10 (1H, m), 7.18 (1H, t, J = 8.0 Hz), 7.30-7.33 (1H, m), 7.73 (1H, s), 7.77 (1H, s), 7.98 (1H, s), 10.07 (1H, s).	Ref. Ex. 91
562		1H-NMR (CDCl3) δ: 3.11 (2H, t, J = 6.7 Hz), 4.25 (2H, t, J = 6.7 Hz), 7.20-7.33 (4H, m), 7.36 (1H, s), 7.53 (1H, s), 7.69 (1H, s), 9.99 (1H, s).	Ref. Ex. 82
563		1H-NMR (CDCl3) δ: 3.15 (2H, t, J = 6.9 Hz), 4.30 (2H, t, J = 6.9 Hz), 7.26-7.39 (6H, m), 7.54 (1H, s), 7.69 (1H, s), 10.00 (1H, s).	Ref. Ex. 82
564		1H-NMR (CDCl3) δ: 1.02 (6H, s), 3.76 (4H, s), 7.02-7.04 (1H, m), 7.46 (1H, s), 7.54-7.57 (1H, m).	Ref. Ex. 107
565		1H-NMR (CDCl3) δ: 7.17-7.24 (1H, m), 7.28-7.35 (2H, m), 7.61 (1H, s), 7.72 (1H, s), 7.97 (1H, s), 10.07 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
566		1H-NMR (CDCl3) δ: 7.13 (1H, d, J = 8.3 Hz), 7.33 (1H, d, J = 4.0 Hz), 7.36-7.43 (2H, m), 7.74 (1H, d, J = 4.0 Hz), 9.90 (1H, s).	Ref. Ex. 91
567		1H-NMR (CDCl3) δ: 1.70 (3H, d, J = 6.4 Hz), 2.81 (3H, s), 6.05-6.12 (1H, m), 7.43-7.48 (1H, m), 7.61-7.68 (2H, m), 7.75 (1H, d, J = 7.8 Hz).	Ref. Ex. 103
568		1H-NMR (CDCl3) δ: 1.06 (3H, t, J = 7.4 Hz), 1.90-2.03 (2H, m), 2.76 (3H, s), 5.82-5.87 (1H, m), 7.46-7.49 (1H, m), 7.64-7.73 (3H, m).	Ref. Ex. 103
569		1H-NMR (CDCl3) δ: 2.49 (3H, s), 7.10-7.11 (1H, m), 7.51 (1H, s), 7.52 (1H, s), 7.73 (2H, s), 10.03 (1H, s).	Ref. Ex. 91
570		1H-NMR (CDCl3) δ: 2.41 (3H, s), 4.27 (2H, s), 7.21 (1H, s), 7.44-7.47 (2H, m), 7.59-7.64 (2H, m), 7.83-7.85 (1H, m), 9.95 (1H, s).	Ref. Ex. 91
571		1H-NMR (CDCl3) δ: 1.71 (3H, d, J = 6.2 Hz), 5.77-5.83 (1H, m), 7.37-7.42 (2H, m), 7.50-7.58 (2H, m), 7.68-7.71 (3H, m), 9.90 (1H, s).	Ref. Ex. 82







[0493]








Ref. Ex. No.	STR	1H-NMR	ref.
572		1H-NMR (CDCl3) δ: 1.15 (3H, t, J = 7.4 Hz), 1.91-2.00 (2H, m), 5.49-5.53 (1H, m), 7.36-7.41 (2H, m), 7.49-7.54 (2H, m), 7.82-7.71 (3H, m), 9.90 (1H, s).	Ref. Ex. 82
573		1H-NMR (CDCl3) δ: 1.07 (6H, d, J = 6.7 Hz), 2.05-2.18 (1H, m), 3.82 (2H, d, J = 6.5 Hz), 7.40 (1H, s), 7.55 (1H, s), 7.69 (1H, s), 10.01 (1H, s).	Ref. Ex. 82
574		1H-NMR (CDCl3) δ: 1.00 (6H, d, J = 6.6 Hz), 1.69-1.76 (2H, m), 1.84-1.88 (1H, m), 4.09 (2H, t, J = 6.5 Hz), 7.39 (1H, s), 7.55 (1H, s), 7.69 (1H , s), 10.01 (1H, s).	Ref. Ex. 82
575		1H-NMR (CDCl3) δ: 4.01-4.14 (4H, m), 5.27 (2H, s), 5.78 (1H, s), 6.99-7.03 (2H, m), 7.15 (1H, s), 7.72 (1H, d, J = 8.1 Hz), 7.85 (1H, d, J = 8.1 Hz), 8.05 (1H, s).	Ref. Ex. 82
576		1H-NMR (CDCl3) δ: 4.01-4.13 (4H, m), 5.16 (2H, s), 5.78 (1H, s), 6.99-7.02 (2H, m), 7.15 (1H, s), 7.87 (1H, s), 7.90 (2H, s).	Ref. Ex. 82
577		1H-NMR (CDCl3) δ: 5.22 (2H, s), 7.28-7.32 (1H, m), 7.39 (1H, s), 7.52 (1H, s), 7.89 (1H, s), 7.91 (2H, s), 9.94 (1H, s).	Ref. Ex. 151
578		1H-NMR (CDCl3) δ: 5.33 (2H, s), 7.28-7.30 (1H, m), 7.39 (1H, s), 7.53 (1H, s), 7.76 (1H, d, J = 8.4 Hz), 7.88 (1H, d, J = 8.4 Hz), 8.04 (1H, s), 9.94 (1H, s).	Ref. Ex. 151






Ref. Ex. No.	STR	1H-NMR	ref.
579		1H-NMR (CDCl3) δ: 7.17-7.22 (1H, m), 7.35-7.37 (2H, m), 8.01 (1H, s), 8.13 (1H, s), 8.21 (1H, s), 10.14 (1H, s).	Ref. Ex. 112
580		1H-NMR (CDCl3) δ: 7.14-7.17 (1H, m), 7.24-7.27 (1H, m), 7.33-7.37 (1H, m), 8.18 (2H, s), 8.38 (1H, s), 10.16 (1H, s).	Ref. Ex. 112
582		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.07 (1H, d, J = 8.2 Hz), 7.14-7.25 (3H, m), 7.45-7.49 (3H, m), 9.98 (1H, s).	Ref. Ex. 82
583		1H-NMR (CDCl3) δ: 2.12-2.21 (2H, m), 2.76-2.86 (2H, m), 4.00-4.09 (2H, m), 7.20-7.33 (5H, m), 7.39 (1H, s), 7.53 (1H, s), 7.70 (1H, s), 10.00 (1H, s).	Ref. Ex. 82
584		1H-NMR (CDCl3) δ: 2.35-2.42 (2H, m), 3.28-3.39 (1H, m), 4.21-4.25 (2H, m), 7.42 (1H, s), 7.57 (1H, s), 7.76 (1H, s), 10.02 (1H, s).	Ref. Ex. 82
585		1H-NMR (CDCl3) δ: 6.05 (2H, s), 6.91-6.94 (1H, m), 7.08-7.11 (2H, m), 7.61 (1H, s), 7.66 (1H, s), 7.96 (1H, s), 10.06 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
586		1H-NMR (CDCl3) δ: 4.04 (2H, s), 6.87-6.92 (2H, m), 6.99 (1H, d, J = 8.1 Hz), 7.45-7.48 (2H, m), 7.69 (1H, s), 7.75 (1H, d, J = 7.1 Hz), 9.99 (1H, s).	Ref. Ex. 91
587		1H-NMR (CDCl3) δ: 5.41 (2H, s), 6.59 (1H, dd, J = 0.7, 3.2 Hz), 7.08-7.24 (4H, m), 7.29-7.34 (1H, m), 7.46 (1H, t, J = 7.6 Hz), 7.63-7.69 (2H, m), 7.76-7.80 (1H, m), 9.96 (1H, s).	Ref. Ex. 189
588		1H-NMR (CDCl3) δ: 2.77 (2H, d, J = 5.9 Hz), 2.92 (2H, t, J = 5.8 Hz), 3.65 (2H, s), 3.76 (2H, s), 6.95-7.00 (1H, m), 7.07-7.14 (3H, m), 7.51 (1H, t, J = 7.8 Hz), 7.67-7.72 (1H, m), 7.78-7.83 (1H, m), 7.91 (1H, s), 10.03 (1H, s).	Ref. Ex. 160
589		1H-NMR (CDCl3) δ: 2.00-2.10 (2H, m), 2.84 (2H, t, J = 6.4 Hz), 3.39 (2H, t, J = 6.2 Hz), 4.54 (2H, s), 6.44 (1H, d, J = 8.0 Hz), 6.57-6.64 (1H, m), 6.93-7.02 (2H, m), 7.48 (1H, t, J = 7.5 Hz), 7.52-7.58 (1H, m), 7.74-7.81 (2H, m), 10.00 (1H, s).	Ref. Ex. 160
590		1H-NMR (CDCl3) δ: 5.35 (2H, s), 7.13 (1H, s), 7.41 (1H, s), 7.44 (1H, s), 7.67-7.69 (2H, m), 8.03 (1H, s), 9.97 (1H, s).	Ref. Ex. 82
591		1H-NMR (CDCl3) δ: 4.48 (2H, q, J = 7.8 Hz), 7.49 (1H, s), 7.62 (1H, s), 7.83 (1H, s), 10.04 (1H, s).	Ref. Ex. 82







[0494]






Ref. Ex. No.	STR	1H-NMR	ref.
592		1H-NMR (CDCl3) δ: 5.24 (2H, s), 7.14 (1H, s), 7.40 (1H, s), 7.45 (1H, s), 7.53-7.58 (2H, m), 7.87-7.92 (3H, m), 9.98 (1H, s).	Ref. Ex. 82
593		1H-NMR (CDCl3) δ: 5.20 (2H, s), 7.10 (1H, s), 7.36 (1H, s), 7.41 (1H, s), 7.53-7.58 (2H, m), 7.65-7.69 (2H, m), 9.95 (1H, s).	Ref. Ex. 82
594		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.07-7.18 (4H, m), 7.35-7.36 (1H, m), 7.39-7.40 (1H, m), 9.95 (1H, s).	Ref. Ex. 82
595		1H-NMR (CDCl3) δ: 5.18 (2H, s), 7.11 (1H, s), 7.33-7.36 (2H, m), 7.38 (1H, s), 7.42 (1H, s), 7.51 (1H, s), 9.96 (1H, s).	Ref. Ex. 82
596		1H-NMR (CDCl3) δ: 5.13 (2H, s), 7.09 (1H, s), 7.28-7.59 (7H, m), 9.94 (1H, s).	Ref. Ex. 82
598		1H-NMR (CDCl3) δ: 6.25 (1H, bns), 6.83 (1H, dt, J = 2.3, 9.8 Hz), 6.93-6.97 (2H, m).	Ref. Ex. 89

Ref. Ex. No.	STR	1H-NMR	ref.
599		1H-NMR (CDCl3) δ: 5.77 (1H, bns), 6.85 (1H, dt, J = 2.4, 9.5 Hz), 7.14-7.18 (2H, m), 9.90 (1H, d, J = 1.5 Hz).	Ref. Ex. 93
601		1H-NMR (CDCl3) δ: 6.05 (1H, bns), 7.05-7.11 (1H, m), 7.14 (1H, dt, J = 1.9, 6.8 Hz).	Ref. Ex. 89
602		1H-NMR (CDCl3) δ: 1.45-1.49 (2H, m), 1.73-2.00 (5H, m), 2.14-2.20 (2H, m), 3.92 (2H, d, J = 5.9 Hz), 7.39 (1H, s), 7.71 (1H, s), 7.85 (1H, s), 10.01 (1H, s).	Ref. Ex. 82
603		1H-NMR (CDCl3) δ: 1.48 (3H, t, J = 7.0 Hz), 4.16 (2H, t, J = 7.0 Hz), 7.38-7.42 (2H, m), 7.59-7.68 (3H, m), 7.78-7.85 (2H, m), 10.04 (1H, s).	Ref. Ex. 112
604		1H-NMR (CDCl3) δ: 1.41 (6H, d, J = 6.1 Hz), 4.67-4.76 (1H, m), 7.37-7.41 (2H, m), 7.59-7.68 (3H, m), 7.78-7.85 (2H, m), 10.04 (1H, m).	Ref. Ex. 112
605		1H-NMR (CDCl3) δ: 5.22 (2H, s), 7.00 (1H, dt, J = 2.4, 9.7 Hz), 7.24-7.27 (1H, m), 7.31-7.33 (1H, m), 7.89-7.91 (3H, m), 9.95 (1H, d, J = 1.4 Hz).	Ref. Ex. 82
606		1H-NMR (CDCl3) δ: 5.23 (2H, s), 6.96 (1H, dt, J = 2.4, 9.8 Hz), 7.21-7.26 (1H, m), 7.30-7.32 (1H, m), 7.38-7.42 (1H, m), 7.47-7.49 (1H, m), 7.63-7.69 (1H, m), 9.94 (1H, d, J = 1.5 Hz).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
607		1H-NMR (CDCl3) δ: 5.37 (2H, s), 6.96 (1H, dt, J = 2.4, 9.7 Hz), 7.23-7.26 (1H, m), 7.28-7.30 (1H, m), 7.85-7.92 (2H, m), 7.98-7.99 (1H, m), 9.94 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
608		1H-NMR (CDCl3) δ: 7.17-7.22 (2H, m), 7.40-7.72 (4H, m), 7.99 (1H, s), 10.07 (1H, s).	Ref. Ex. 91
609		1H-NMR (CDCl3) δ: 7.19-7.31 (1H, m), 7.45-7.73 (4H, m), 7.98 (1H, s), 10.08 (1H, s).	Ref. Ex. 91
610		1H-NMR (CDCl3) δ: 6.90-7.29 (2H, m), 7.43-7.78 (6H, m), 7.98 (1H, s), 10.05 (1H, s).	Ref. Ex. 75
611		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.08 (1H, s), 7.32-7.40 (6H, m), 9.44 (1H, s).	Ref. Ex. 82







[0495]







Ref. Ex. No.	STR	1H-NMR	ref.
612		1H-NMR (CDCl3) δ: 5.09 (2H, s), 7.05-7.12 (3H, m), 7.34-7.43 (4H, m), 9.95 (1H, s).	Ref. Ex. 82
613		1H-NMR (CDCl3) δ: 7.28-7.31 (3H, m), 4.44-4.48 (2H, m), 8.26-8.28 (1H, m), 9.86 (1H, s).	Ref. Ex. 91
614		1H-NMR (CDCl3) δ: 4.01-4.13 (4H, m), 5.78 (1H, s), 6.51 (1H, t, J = 73.1 Hz), 7.18 (1H, s), 7.29 (1H, s), 7.49 (1H, s).	Ref. Ex. 116
615		1H-NMR (CDCl3) δ: 5.26 (2H, s), 6.94 (1H, dt, J = 2.4, 9.8 Hz), 7.21-7.24 (1H, m), 7.27-7.33 (2H, m), 7.45 (1H, dd, J = 2.7, 8.8 Hz), 7.70 (1H, dd, J = 5.3, 8.5 Hz), 9.93 (1H, d, J = 1.6 Hz).	Ref. Ex. 82
616		1H-NMR (CDCl3) δ: 5.13 (2H, s), 6.96 (1H, dt, J = 2.4, 9.8 Hz), 7.21-7.25 (1H, m), 7.28-7.29 (1H, m), 7.55 (2H, d, J = 1.2 Hz), 7.76-7.78 (1H, m), 9.93 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
617		1H-NMR (CDCl3) δ: 1.02 (6H, s), 3.76 (4H, s), 4.01-4.16 (4H, m), 5.81 (1H, s), 6.53 (1H, t, J = 74.2 Hz), 7.30 (1H, s), 7.52 (1H, s), 7.75 (1H, s).	Ref. Ex. 107
619		1H-NMR (CDCl3) δ: 5.61 (1H, bs), 6.56 (1H, t, J = 73.0 Hz), 6.89-6.90 (1H, m), 7.19-7.21 (2H, m), 9.91 (1H, s).	Ref. Ex. 151








Ref. Ex. No.	STR	1H-NMR	ref.
620		1H-NMR (CDCl3) δ: 5.23 (2H, s), 6.59 (1H, t, J = 72.8 Hz), 7.05-7.06 (1H, m), 7.30 (1H, s), 7.36 (1H, s), 7.89 (1H, s), 7.92 (2H, s), 9.96 (1H, s).	Ref. Ex. 82
621		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.0 Hz), 4.15 (2H, t, J = 7.0 Hz), 7.37-7.47 (5H, m), 7.60-7.68 (3H, m), 10.03 (1H, s).	Ref. Ex. 112
622		1H-NMR (CDCl3) δ: 1.39 (6H, d, J = 6.1 Hz), 4.66-4.74 (1H, m), 7.36-7.47 (5H, m), 7.60-7.66 (3H, m), 10.03 (1H, s).	Ref. Ex. 112
623		1H-NMR (CDCl3) δ: 7.58-7.59 (1H, m), 8.05 (1H, s), 8.24 (1H, s), 8.63 (1H, s), 8.74 (1H, s), 8.95 (1H, d, J = 5.0 Hz), 10.19 (1H, s).	Ref. Ex. 112
624		1H-NMR (CDCl3) δ: 5.34 (2H, s), 6.59 (1H, t, J = 72.8 Hz), 7.05 (1H, m), 7.30 (1H, s), 7.36 (1H, s), 7.75 (1H, t, J = 8.4 Hz), 7.88 (1H, d J = 8.4 Hz), 8.04 (1H, s), 9.86 (1H, s).	Ref. Ex. 82
625		1H-NMR (CDCl3) δ: 5.13 (2H, s), 6.56 (1H, t, J = 73.1 Hz), 7.00-7.02 (1H, m), 7.23 (1H, s), 7.33-7.43 (6H, m), 9.93 (1H, s).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
626		1H-NMR (CDCl3) δ: 5.19 (2H, s), 6.57 (1H, t, J = 72.9 Hz), 7.01 (1H, s), 7.33 (1H, s), 7.53-7.65 (1H, m), 7.56 (2H, d, J = 8.2 Hz), 7.68 (2H, d, J = 8.2 Hz), 9.94 (1H, s).	Ref. Ex. 82
627		1H-NMR (CDCl3) δ: 5.09 (2H, s), 6.56 (1H, t, J = 72.9 Hz), 6.99 (1H, m), 7.24-7.38 (2H, m), 7.41 (4H, s), 9.93 (1H, s).	Ref. Ex. 82
628		1H-NMR (CDCl3) δ: 5.08 (2H, s), 6.56 (1H, t, J = 73.0 Hz), 7.00 (1H, s), 7.10 (2H, t, J = 8.6 Hz), 7.24 (1H, s), 7.33 (1H, s), 7.39-7.43 (2H, m), 9.93 (1H, s).	Ref. Ex. 82
629		1H-NMR (CDCl3) δ: 3.09 (3H, s), 5.33 (2H, s), 7.37-7.77 (1H, m), 7.88-7.93 (2H, m).	Ref. Ex. 103
630		1H-NMR (CDCl3) δ: 5.24 (2H, s), 7.27-7.30 (1H, m), 7.48-7.56 (3H, m), 7.75-7.80 (1H, m), 7.89-7.95 (2H, m), 10.00 (1H, s).	Ref. Ex. 82
631		1H-NMR (CDCl3) δ: 5.23 (2H, s), 6.99 (1H, dt, J = 2.4, 9.7 Hz), 7.21-7.28 (1H, m), 7.30-7.33 (1H, m), 7.75-7.78 (1H, m), 7.90-7.93 (2H, m), 9.94 (1H, d, J = 1.4 Hz).	Ref. Ex. 82
632		1H-NMR (CDCl3) δ: 5.82 (1H, s), 7.28-7.34 (1H, m), 7.36 (1H, dt, J = 1.8, 7.1 Hz), 9.86 (1H, d, J = 1.8 Hz).	Ref. Ex. 93














[0496]

Ref. Ex. No.	STR	1H-NMR	ref.
633		1H-NMR (CDCl3) δ: 2.38 (3H, s), 7.65 (1H, s), 7.92 (3H, s), 9.90 (1H, s).	Ref. Ex. 91
634		1H-NMR (CDCl3) δ: 7.99 (1H, d, J = 8.4 Hz), 8.08-8.11 (1H, m), 8.24 (1H, s), 8.63 (1H, s), 8.75 (1H, s), 9.01 (1H, s), 10.18 (1H, s).	Ref. Ex. 81, Ref. Ex. 75
635		1H-NMR (CDCl3) δ: 7.65 (1H, d, J = 5.1 Hz), 8.32 (1H, s), 9.05 (1H, s), 9.14 (1H, d, J = 5.1 Hz), 9.21 (1H, s), 10.21 (1H, s).	Ref. Ex. 81, Ref. Ex. 75
636		1H-NMR (CDCl3) δ: 3.80 (3H, s), 5.06 (2H, s), 6.73-6.74 (1H, m), 6.78 (1H, s), 6.84 (1H, s), 7.37-7.42 (5H, m).	Ref. Ex. 82
637		1H-NMR (CDCl3) δ: 3.84 (3H, s), 5.10 (2H, s), 6.78-6.80 (1H, m), 7.04 (1H, s), 7.10 (1H, s), 7.37-7.43 (5H, m), 9.90 (1H, s).	Ref. Ex. 93
638		1H-NMR (CDCl3) δ: 7.64 (1H, d, J = 5.0 Hz), 7.91 (1H, s), 8.65 (1H, s), 8.98 (1H, s), 9.12 (1H, d, J = 5.0 Hz), 10.16 (1H, s).	Ref. Ex. 91








Ref. Ex. No.	STR	1H-NMR	ref.
639		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.58 (1H, t, J = 72.9 Hz), 7.01 (1H, m), 7.21-7.37 (5H, m), 9.94 (1H, s).	Ref. Ex. 82
640		1H-NMR (CDCl3) δ: 5.14 (2H, s), 7.24-7.28 (1H, m), 7.47-7.48 (1H, m), 7.49-7.53 (2H, m), 7.55-7.57 (2H, m), 7.78-7.79 (1H, m), 10.00 (1H, s).	Ref. Ex. 82
641		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.95 (1H, dt, J = 2.4, 9.8 Hz), 7.21-7.25 (2H, m), 7.27-7.38 (3H, m), 9.93 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
642		1H-NMR (CDCl3) δ: 5.11 (2H, s), 7.21-7.26 (2H, m), 7.30-7.36 (2H, m), 7.45-7.51 (3H, m), 9.98 (1H, s).	Ref. Ex. 82
644		1H-NMR (CDCl3) δ: 1.30 (1H, t, J = 6.1 Hz), 1.40-1.88 (18H, m), 2.19-2.27 (2H, m), 3.28 (2H, d, J = 6.1 Hz), 3.38-3.51 (1H, m), 3.90-4.01 (1H, m), 4.83-4.88 (1H, m).	Ref. Ex. 76
645		1H-NMR (CDCl3) δ: 1.45-1.74 (13H, m), 2.18-2.27 (2H, m), 3.14 (2H, s), 4.56 (2H, s), 7.52 (1H, t, J = 7.5 Hz), 7.59-7.65 (1H, m), 7.77-7.85 (2H, m), 10.03 (1H, s).	Ref. Ex. 189








Ref. Ex. No.	STR	1H-NMR	ref.
646		1H-NMR (CDCl3) δ: 2.44 (3H, s), 5.21 (2H, s), 7.12 (1H, s), 7.29 (1H, s), 7.35 (1H, s), 7.87 (1H, s), 7.91 (2H, s), 9.96 (1H, s).	Ref. Ex. 82
647		1H-NMR (CDCl3) δ: 2.44 (3H, d, J = 0.3 Hz), 5.32 (2H, s), 7.12 (1H, s), 7.29 (1H, s), 7.36 (1H, s), 7.72 (1H, d, J = 8.2 Hz), 7.85 (1H, d, J = 8.2 Hz), 8.07 (1H, s), 9.95 (1H, s).	Ref. Ex. 82
648		1H-NMR (CDCl3) δ: 1.33 (1H, s), 1.45-1.70 (12H, m), 2.17-2.25 (2H, m), 3.09 (2H, s), 4.01-4.20 (4H, m), 4.51 (2H, s), 5.82 (1H, s), 7.25-7.42 (4H, m).	Ref. Ex. 116
649		1H-NMR (CDCl3) δ: 1.47-1.60 (8H, m), 1.68-1.72 (4H, m), 2.19-2.27 (2H, m), 3.14 (2H, s), 3.24 (3H, s), 4.57 (2H, s), 7.52 (1H, t, J = 7.6 Hz), 7.59-7.64 (1H, m), 7.77-7.85 (2H, m), 10.03 (1H, s).	Ref. Ex. 115, Ref. Ex. 151
650		1H-NMR (CDCl3) δ: 5.31 (2H, s), 7.38-7.44 (2H, m), 7.90-7.94 (3H, m), 9.88 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
651		1H-NMR (CDCl3) δ: 5.09 (2H, s), 6.57 (1H, t, J = 72.9 Hz), 6.99 (1H, m), 7.07-7.18 (4H, m), 7.31 (1H, s), 9.94 (1H, s).	Ref. Ex. 82
652		1H-NMR (CDCl3) δ: 7.59 (1H, d, J = 5.0 Hz), 7.70 (1H, t, J = 7.7 Hz), 8.06-8.09 (1H, m), 8.79-8.82 (1H, m), 9.02 (1H, s), 9.10 (1H, d, J = 5.0 Hz), 10.16 (1H, s).	Ref. Ex. 83







[0497]

Ref. Ex. No.	STR	1H-NMR	ref.
653		1H-NMR (CDCl3) δ: 7.48 (1H, d, J = 4.9 Hz), 7.78 (1H, s), 7.96 (1H, s), 8.07 (1H, s), 8.83 (1H, d, J = 4.9 Hz), 10.08 (1H, s).	Ref. Ex. 82
654		1H-NMR (CDCl3) δ: 3.85 (3H, s), 5.20 (2H, s), 6.80-6.82 (1H, m), 7.08-7.11 (2H, m), 7.87 (1H, s), 7.91 (2H, s), 9.93 (1H, s).	Ref. Ex. 82
655		1H-NMR (CDCl3) δ: 2.03-2.12 (2H, m), 2.28-2.37 (2H, m), 3.85 (3H, s), 4.06 (2H, t, J = 5.9 Hz), 6.69-6.79 (1H, s), 6.99-7.03 (2H, m), 9.91 (1H, s).	Ref. Ex. 82
656		1H-NMR (CDCl3) δ: 5.09 (2H, s), 6.95 (1H, dt, J = 2.4, 9.8 Hz), 7.20-7.24 (1H, m), 7.25-7.31 (2H, m), 7.34-7.38 (1H, m), 7.38-7.42 (1H, m), 9.93 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
657		1H-NMR (CDCl3) δ: 5.12 (2H, s), 6.95 (1H, dt, J = 2.4, 9.9 Hz), 7.01-7.08 (1H, m), 7.12-7.17 (1H, m), 7.18-7.22 (2H, m), 7.27-7.29 (1H, m), 7.34-7.41 (1H, m), 9.92 (1H, d, J = 1.6 Hz).	Ref. Ex. 82
658		1H-NMR (CDCl3) δ: 5.08 (2H, s), 6.94 (1H, dt, J = 2.4, 10.0 Hz), 7.07-7.14 (2H, m), 7.18-7.21 (1H, m), 7.28-7.29 (1H, m), 7.39-7.44 (2H, m), 9.92 (1H, d, J = 1.6 Hz).	Ref. Ex. 82
659		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.95 (1H, dt, J = 2.4, 9.8 Hz), 7.19-7.23 (1H, m), 7.24-7.29 (3H, m), 7.45-7.50 (2H, m), 9.92 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
660		1H-NMR (CDCl3) δ: 5.07 (2H, s), 6.97 (1H, dt, J = 2.4, 9.9 Hz), 7.20-7.24 (1H, m), 7.30-7.31 (1H, m), 7.52-7.71 (4H, m), 9.93 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
661		1H-NMR (CDCl3) δ: 5.19 (2H, s), 6.96 (1H, dt, J = 2.3, 9.8 Hz), 7.20-7.23 (1H, m), 7.28-7.30 (1H, m), 7.55-7.57 (2H, m), 7.66-7.69 (2H, m), 9.93 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
662		1H-NMR (CDCl3) δ: 7.30 (1H, s), 7.60 (2H, s), 7.64 (1H, s), 7.89 (1H, s), 7.95 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
663		1H-NMR (CDCl3) δ: 7.28-7.31 (1H, m), 7.99 (1H, s), 8.73 (1H, s), 8.85-8.87 (3H, m), 10.10 (1H, s).	Ref. Ex. 91
664		1H-NMR (CDCl3) δ: 7.97 (1H, s), 8.33 (1H, s), 8.43 (1H, s), 8.62 (1H, s), 8.69 (1H, s), 9.11 (1H, s), 10.09 (1H, s).	Ref. Ex. 91
665		1H-NMR (CDCl3) δ: 7.66-7.71 (2H, m), 7.97-8.01 (3H, m), 8.38-8.41 (1H, s), , 8.56 (1H, s), 10.14 (1H, s).	Ref. Ex. 83
666		1H-NMR (CDCl3) δ: 7.51-7.53 (1H, m), 7.70 (1H, t, J = 7.7 Hz), 7.99-8.01 (2H, m), 8.33-8.36 (1H, m), 8.56 (1H, s), 8.91 (1H, d, J = 5.0 Hz), 10.14 (1H, s).	Ref. Ex. 83
667		1H-NMR (CDCl3) δ: 7.26-7.28 (1H, m), 7.67 (1H, t, J = 7.7 Hz), 7.82-7.86 (3H, m), 7.91-7.94 (1H, m), 8.11 (1H, s), 10.11 (1H, s).	Ref. Ex. 83
668		1H-NMR (CDCl3) δ: 1.48 (3H, t, J = 7.0 Hz), 4.19 (2H, q, J = 7.0 Hz), 7.56-7.58 (2H, m), 8.34-8.35 (1H, m), 8.60 (1H, s), 9.08 (1H, d, J = 4.9 Hz), 10.10 (1H, s).	Ref. Ex. 83
669		1H-NMR (CDCl3) δ: 1.39 (6H, d, J = 6.0 Hz), 4.89-4.81 (1H, m), 7.55-7.58 (2H, m), 8.33-8.34 (1H, m), 8.57 (1H, s), 9.07 (1H, d, J = 4.9 Hz), 10.10 (1H, s).	Ref. Ex. 83
670		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.21-7.29 (2H, m), 7.34-7.40 (1H, m), 7.41-7.43 (1H, m), 7.46-7.47 (1H, m), 7.48-7.54 (2H, m), 9.99 (1H, s).	Ref. Ex. 82
671		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.23-7.27 (1H, m), 7.33-7.40 (2H, m), 7.46-7.47 (1H, m), 7.49-7.54 (2H, m), 7.58-7.59 (1H, m), 9.99 (1H, s).	Ref. Ex. 82
672		1H-NMR (CDCl3) δ: 5.10 (2H, s), 6.96 (1H, dt, J = 2.4, 9.8 Hz), 7.21-7.25 (1H, m), 7.27-7.29 (1H, m), 7.36-7.37 (2H, m), 7.57-7.58 (1H, m), 9.93 (1H, d, J = 1.5 Hz).	Ref. Ex. 82








[0498]








Ref. Ex. No.	STR	1H-NMR	ref.
673		1H-NMR (CDCl3) δ: 5.11 (2H, s), 7.23-7.28 (1H, m), 7.32-7.36 (1H, m), 7.40-7.44 (1H, m), 7.44-7.47 (1H, m), 7.53-7.54 (3H, m), 10.01 (1H, s).	Ref. Ex. 82
674		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.95 (1H, dt, J = 2.4, 9.8 Hz), 7.20-7.24 (1H, m), 7.27-7.28 (1H, m), 7.31-7.34 (1H, m), 7.40-7.42 (1H, m), 7.51-7.53 (1H, m), 9.93 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
675		1H-NMR (CDCl3) δ: 5.09 (2H, s), 6.94 (1H, dt, J = 2.4, 9.8 Hz), 7.14-7.17 (1H, m), 7.20-7.29 (3H, m), 7.41-7.46 (1H, m), 9.92 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
676		1H-NMR (CDCl3) δ: 7.17 (1H, d, J = 16.2 Hz), 7.25-7.27 (1H, m), 7.37 (1H, d, J = 16.2 Hz), 7.71 (1H, d, J = 4.0 Hz), 7.80 (1H, s), 7.92 (2H, s), 9.90 (1H, s).	Ref. Ex. 75
677		1H-NMR (DMSO-d6) δ: 3.28 (3H, s), 8.04-8.10 (2H, m), 8.13-8.17 (2H, m), 8.31 (1H, s), 8.44 (1H, s), 8.58 (1H, s), 10.20 (1H, s).	Ref. Ex. 91
678		1H-NMR (CDCl3) δ: 3.93 (3H, s), 7.23 (1H, s), 7.68-7.71 (1H, m), 7.87-7.91 (3H, m), 7.96-7.98 (1H, m).	Ref. Ex. 83
679		1H-NMR (CDCl3) δ: 3.95 (3H, s), 7.31 (1H, s), 7.59-7.60 (1H, m), 8.30 (1H, s), 8.49 (1H, s), 9.07-9.09 (1H, m).	Ref. Ex. 83








Ref. Ex. No.	STR	1H-NMR	ref.
680		1H-NMR (CDCl3) δ: 3.90 (3H, s), 7.16 (1H, s), 7.29-7.31 (2H, m), 7.39 (1H, s), 7.43-7.51 (3H, s).	Ref. Ex. 83
681		1H-NMR (CDCl3) δ: 1.34 (9H, s), 5.08 (2H, s), 6.95 (1H, dt, J = 2.4, 10.0 Hz), 7.16-7.20 (1H, m), 7.29-7.30 (1H, m), 7.35-7.39 (2H, m), 7.42-7.46 (2H, m), 9.92 (1H, d, J = 1.6 Hz).	Ref. Ex. 82
682		1H-NMR (CDCl3) δ: 3.96 (3H, s), 7.49 (1H, s), 7.66-7.69 (1H, m), 7.93-7.95 (1H, m), 7.98-7.99 (1H, m), 8.15 (1H, s), 10.09 (1H, s).	Ref. Ex. 93
683		1H-NMR (CDCl3) δ: 7.27-7.31 (1H, m), 7.51-7.63 (3H, m), 7.77-7.90 (5H, m), 10.12 (1H, s).	Ref. Ex. 75
684		1H-NMR (CDCl3) δ: 2.39 (3H, s), 7.11 (1H, d, J = 16.1 Hz), 7.28 (1H, d, J = 16.1 Hz), 7.50-7.66 (4H, m), 7.75 (1H, s), 9.83 (1H, s).	Ref. Ex. 75
685		1H-NMR (CDCl3) δ: 3.97 (3H, s), 7.57-7.59 (2H, m), 8.35-8.36 (1H, m), 8.62 (1H, s), 9.09 (1H, d, J = 4.9 Hz), 10.11 (1H, s).	Ref. Ex. 93
686		1H-NMR (CDCl3) δ: 3.94 (3H, s), 7.23-7.36 (1H, m), 7.37-7.54 (5H, m), 7.67 (1H, s), 10.05 (1H, s).	Ref. Ex. 93

Ref. Ex. No.	STR	1H-NMR	ref.
687		1H-NMR (CDCl3) δ: 3.94 (3H, s), 7.24-7.28 (1H, m), 7.83-7.91 (3H, m), 8.02-8.06 (1H, m), 8.97 (1H, s).	Ref. Ex. 83
688		1H-NMR (CDCl3) δ: 3.91 (3H, s), 7.20 (1H, s), 7.31 (1H, s), 7.37-7.45 (3H, m), 7.59 (1H, s).	Ref. Ex. 83
689		1H-NMR (CDCl3) δ: 3.96 (3H, s), 7.51-7.52 (1H, m), 7.91-7.93 (2H, m), 8.01-8.03 (1H, m), 8.13 (1H, s), 8.97 (1H, s), 10.08 (1H, s).	Ref. Ex. 93
690		1H-NMR (CDCl3) δ: 3.93 (3H, s), 7.36-7.38 (2H, m), 7.44-7.52 (2H, m), 7.67 (2H, s), 10.06 (1H, s).	Ref. Ex. 93
691		1H-NMR (CDCl3) δ: 7.24 (2H, d, J = 16.4 Hz), 7.49-7.58 (3H, m), 7.70 (1H, d, J = 7.8 Hz), 7.77-7.82 (3H, m), 8.05 (1H, s), 10.07 (1H, s).	Ref. Ex. 75
692		1H-NMR (CDCl3) δ: 6.62 (1H, t, J = 72.9 Hz), 7.17-7.26 (2H, m), 7.51-7.58 (4H, m), 7.70 (1H, d, J = 7.8 Hz), 7.79 (1H, s), 7.90 (1H, s), 10.04 (1H, s).	Ref. Ex. 75









[0499]









Ref. Ex. No.	STR	1H-NMR	ref.
693		1H-NMR (CDCl3) δ: 7.24-7.33 (2H, m), 7.59 (1H, t, J = 7.7 Hz), 7.79-7.86 (3H, m), 7.95 (2H, s), 8.08 (1H, s), 10.08 (1H, s).	Ref. Ex. 75
694		1H-NMR (CDCl3) δ: 7.16 (1H, d, J = 16.4 Hz), 7.23 (1H, d, J = 16.4 Hz), 7.60-7.67 (4H, m), 7.76 (2H, s), 7.91 (1H, s), 10.01 (1H, s).	Ref. Ex. 91
695		1H-NMR (CDCl3) δ: 5.44 (2H, s), 7.03 (1H, dt, J = 2.4, 9.9 Hz), 7.18-7.23 (1H, m), 7.38-7.37 (1H, m), 7.55-7.61 (1H, m), 7.64 (1H, d, J = 8.5 Hz), 7.74-7.79 (1H, m), 7.84-7.87 (1H, m), 8.09-8.11 (1H, m), 8.23 (1H, d, J = 8.5 Hz), 9.91 (1H, d, J = 1.8 Hz).	Ref. Ex. 82
696		1H-NMR (CDCl3) δ: 5.45 (2H, s), 7.29-7.36 (1H, m), 7.41-7.52 (2H, m), 7.54-7.61 (2H, m), 7.66 (1H, d, J = 8.5 Hz), 7.73-7.78 (1H, m), 7.84 (1H, dd, J = 1.1, 8.2 Hz), 8.09-8.12 (1H, m), 8.22 (1H, d, J = 8.5 Hz), 9.97 (1H, s).	Ref. Ex. 82
697		1H-NMR (CDCl3) δ: 2.60 (6H, s), 7.64-7.70 (1H, m), 7.84-7.88 (1H, m), 7.97 (1H, dt, J = 1.4, 7.7 Hz), 8.11-8.12 (1H, m), 8.39 (1H, s), 10.11 (1H, s).	Ref. Ex. 91
698		1H-NMR (CDCl3) δ: 4.08 (6H, s), 6.03 (1H, s), 7.64 (1H, t, J = 7.6 Hz), 8.00 (1H, dt, J = 1.5, 7.8 Hz), 8.72-8.76 (1H, m), 8.93-8.94 (1H, m), 10.14 (1H, s).	Ref. Ex. 91
699		1H-NMR (CDCl3) δ: 4.22 (3H, s), 7.11 (1H, d, J = 9.2 Hz), 7.69 (1H, t, J = 7.7 Hz), 7.88 (1H, d, J = 9.2 Hz), 7.98 (1H, dt, J = 1.4, 7.7 Hz), 8.35-8.40 (1H, m), 8.50-8.51 (1H, m), 10.12 (1H, s).	Ref. Ex. 91







Ref. Ex. No.	STR	1H-NMR	ref.
700		1H-NMR (CDCl3) δ: 1.10-1.42 (6H, m), 1.62-1.88 (4H, m), 2.09-2.28 (1H, m), 6.25-6.38 (2H, m), 7.55 (1H, s), 7.65 (1H, s), 7.71 (1H, s), 9.95 (1H, s).	Ref. Ex. 91
701		1H-NMR (CDCl3) δ: 7.63-7.65 (1H, m), 7.99-8.14 (2H, m), 8.41 (2H, s), 8.53 (1H, s), 10.13 (1H, s).	Ref. Ex. 91
702		1H-NMR (CDCl3) δ: 7.24-7.26 (2H, m), 7.56-7.63 (1H, m), 7.63 (4H, s), 7.77-7.82 (2H, m), 8.05 (1H, s), 10.07 (1H, s).	Ref. Ex. 91
703		1H-NMR (CDCl3) δ: 7.47 (1H, s), 7.85 (1H, s), 7.89 (1H, d, J = 8.2 Hz), 8.01-8.03 (2H, m), 8.95 (1H, s), 9.41 (1H, s), 10.03 (1H, s).	Ref. Ex. 83
704		1H-NMR (CDCl3) δ: 8.10 (1H, s), 8.17 (1H, s), 8.24 (1H, s), 8.31 (1H, s), 8.99 (1H, s), 9.10 (1H, s), 10.18 (1H, s).	Ref. Ex. 81, Ref. Ex. 75
705		1H-NMR (CDCl3) δ: 5.22 (2H, s), 7.38-7.47 (5H, m), 7.59-7.50 (1H, m), 7.90-7.92 (1H, m), 8.00-8.02 (2H, m), 8.15 (1H, s), 8.98 (1H, s), 10.07 (1H, s).	Ref. Ex. 82
706		1H-NMR (CDCl3) δ: 7.36 (1H, d, J = 16.0 Hz), 7.61-7.64 (1H, m), 7.82-7.94 (4H, m), 8.03 (2H, s), 10.12 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
707		1H-NMR (CDCl3) δ: 5.14 (2H, s), 6.97 (1H, dt, J = 2.4, 9.7 Hz), 7.22-7.26 (1H, m), 7.29-7.30 (1H, m), 7.59-7.60 (1H, m), 7.61-7.63 (2H, m), 9.94 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
708		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.96 (1H, dt, J = 2.4, 9.6 Hz), 7.20-7.26 (3H, m), 7.27-7.29 (1H, m), 7.38-7.39 (1H, m), 9.93 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
709		1H-NMR (CDCl3) δ: 5.09 (2H, s), 6.95 (1H, dt, J = 2.4, 9.8 Hz), 7.04-7.11 (2H, m), 7.20-7.25 (2H, m), 7.25-7.27 (1H, m), 9.93 (1H, d, J = 1.5 Hz).	Ref. Ex. 82
710		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.25-7.30 (1H, m), 7.47-7.55 (3H, m), 7.60-7.64 (3H, m), 9.97 (1H, s).	Ref. Ex. 82
711		1H-NMR (CDCl3) δ: 5.11 (2H, s), 7.21-7.22 (2H, m), 7.24-7.28 (1H, m), 7.39-7.40 (1H, m), 7.45-7.47 (1H, m), 7.49-7.54 (2H, m), 9.99 (1H, s).	Ref. Ex. 82
712		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.05-7.09 (2H, m), 7.23-7.30 (2H, m), 7.44-7.46 (1H, m), 7.49-7.54 (2H, m), 9.99 (1H, s).	Ref. Ex. 82
713		1H-NMR (DMSO-d6) δ: 2.68 (3H, s), 3.92 (3H, s), 7.60-7.61 (1H, m), 7.72 (1H, d, J = 8.8 Hz), 8.02-8.03 (1H, m), 8.14-8.15 (1H, m), 8.27 (1H, d, J = 8.8 Hz).	Ref. Ex. 83






[0500]






Ref. Ex. No.	STR	1H-NMR	ref.
714		1H-NMR (CDCl3) δ: 3.47 (3H, s), 5.16 (2H, s), 5.30 (1H, s), 6.77-6.78 (2H, m), 6.92 (1H, s).	Ref. Ex. 618
715		1H-NMR (CDCl3) δ: 5.25 (1H, d, J = 10.9 Hz), 5.66 (1H, d, J = 17.5 Hz), 6.63-6.69 (1H, m), 7.00 (1H, d, J = 8.3 Hz), 7.06-7.08 (1H, m), 7.15 (1H, s).	Ref. Ex. 77
716		1H-NMR (CDCl3) δ: 6.74-6.77 (1H, m), 7.02-7.05 (2H, m), 7.10 (2H, s), 7.73 (1H, s), 7.77 (1H, s), 7.89 (1H, s), 10.01 (1H, s).	Ref. Ex. 91
717		1H-NMR (CDCl3) δ: 7.98 (1H, s), 8.67 (1H, s), 8.71 (2H, s), 8.81 (1H, s), 10.09 (1H, s).	Ref. Ex. 91
718		1H-NMR (CDCl3) δ: 6.72-6.77 (1H, m), 7.03-7.17 (4H, m), 7.54-7.58 (1H, m), 7.75-7.82 (2H, m), 8.03 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
719		1H-NMR (CDCl3) δ: 7.42-7.45 (3H, m), 7.88-8.23 (5H, m), 10.07 (1H, s).	Ref. Ex. 91
720		1H-NMR (CDCl3) δ: 2.40 (3H, s), 5.10 (2H, s), 7.08 (1H, s), 7.27-7.47 (7H, m), 9.93 (1H, s).	Ref. Ex. 82
721		1H-NMR (CDCl3) δ: 2.41 (3H, s), 5.10 (2H, s), 6.98-7.08 (2H, m), 7.13-7.22 (2H, m), 7.25-7.26 (1H, m), 7.29-7.40 (2H, m), 9.93 (1H, s).	Ref. Ex. 82






Ref. Ex. No.	STR	1H-NMR	ref.
722		1H-NMR (CDCl3) δ: 2.41 (3H, s), 5.06 (2H, s), 7.04-7.12 (3H, m), 7.26-7.32 (2H, m), 7.38-7.44 (2H, m), 9.93 (1H, s).	Ref. Ex. 82
723		1H-NMR (CDCl3) δ: 2.42 (3H, d, J = 0.4 Hz), 5.15 (2H, s), 7.08-7.12 (1H, m), 7.27-7.30 (1H, m), 7.31-7.34 (1H, m), 7.52 (1H, t, J = 7.6 Hz), 7.58-7.66 (2H, m), 7.72 (1H, s), 9.94 (1H, s).	Ref. Ex. 82
724		1H-NMR (CDCl3) δ: 5.17 (2H, s), 6.61-6.75 (2H, m), 7.56 (1H, t, J = 7.6 Hz), 7.73 (1H, d, J = 7.6 Hz), 7.86 (1H, d, J = 7.6 Hz), 7.94 (1H, s), 10.04 (1H, s).	Ref. Ex. 113, Ref. Ex. 229
725		1H-NMR (CDCl3) δ: 2.40 (3H, s), 3.46 (3H, s), 3.74-3.79 (2H, m), 4.15-4.19 (2H, m), 7.04 (1H, s), 7.22 (1H, s), 7.28 (1H, s), 9.92 (1H, s).	Ref. Ex. 82
726		1H-NMR (CDCl3) δ: 2.41 (3H, s), 5.11 (2H, s), 6.82-6.96 (2H, m), 7.07 (1H, s), 7.29 (1H, s), 7.32 (1H, s), 7.43-7.52 (1H, m), 9.94 (1H, s).	Ref. Ex. 82
727		1H-NMR (CDCl3) δ: 2.43 (3H, d, J = 0.3 Hz), 5.15 (2H, s), 7.09 (1H, s), 7.26-7.38 (4H, m), 7.50 (1H, s), 9.94 (1H, s).	Ref. Ex. 82
728		1H-NMR (CDCl3) δ: 2.42 (3H, s), 5.09 (2H, s), 6.72-6.82 (1H, m), 6.90-7.00 (2H, m), 7.07 (1H, s), 7.24 (1H, s), 7.32 (1H, s), 9.93 (1H, s).	Ref. Ex. 82
729		1H-NMR (CDCl3) δ: 2.41 (3H, s), 5.05 (2H, s), 7.08 (1H, s), 7.11-7.22 (2H, m), 7.22-7.29 (2H, m), 7.31 (1H, s), 9.93 (1H, s).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
730		1H-NMR (CDCl3) δ: 2.42 (3H, s), 5.15 (2H, s), 6.90-7.09 (3H, m), 7.15-7.26 (1H, m), 7.28 (1H, s), 7.33 (1H, s), 9.94 (1H, s).	Ref. Ex. 82
731		1H-NMR (CDCl3) δ: 2.41 (3H, s), 3.83 (3H, s), 5.08 (2H, s), 6.87 (1H, dd, J = 2.2, 8.1 Hz), 6.97-7.03 (2H, m), 7.08 (1H, s), 7.26-7.35 (3H, m), 9.93 (1H, s).	Ref. Ex. 82
732		1H-NMR (CDCl3) δ: 7.34 (2H, s), 7.83 (1H, s), 7.98 (2H, s), 8.03 (1H, s), 8.08 (1H, s), 8.24 (1H, s), 10.12 (1H, s).	Ref. Ex. 75
733		1H-NMR (CDCl3) δ: 7.22-7.34 (2H, m), 7.51-7.60 (2H, m), 7.72 (1H, d, J = 8.0 Hz), 7.81 (1H, s), 8.00 (1H, s), 8.04 (1H, s), 8.22 (1H, s), 10.11 (1H, s).	Ref. Ex. 75
734		1H-NMR (CDCl3) δ: 3.48 (3H, s), 5.16 (2H, s), 5.19 (2H, s), 6.89-6.93 (2H, m), 7.01-7.02 (1H, m), 7.89 (3H, s).	Ref. Ex. 82
735		1H-NMR (CDCl3) δ: 2.74 (3H, s), 7.37 (1H, s), 7.68 (1H, t, J = 8.0 Hz), 7.80 (1H, s), 7.96-7.99 (1H, m), 8.31-8.34 (1H, m), 8.55 (1H, s), 10.12 (1H, s).	Ref. Ex. 83


[0501]


Ref. Ex. No.	STR	1H-NMR	ref.
736		1H-NMR (CDCl3) δ: 2.09-2.18 (2H, m), 2.29-2.43 (2H, m), 4.14-4.21 (2H, m), 7.50 (1H, s), 7.91-7.93 (2H, m), 8.03-8.06 (1H, m), 8.14 (1H, s), 8.97 (1H, s), 10.08 (1H, s).	Ref. Ex. 82
737		1H-NMR (CDCl3) δ: 1.87-2.02 (4H, m), 4.16-4.19 (2H, m), 4.46-4.50 (1H, m), 4.62-4.65 (1H, m), 7.50 (1H, s), 7.91-7.94 (2H, m), 8.02-8.06 (1H, m), 8.12 (1H, s), 8.97 (1H, s), 10.07 (1H, s).	Ref. Ex. 82
738		1H-NMR (CDCl3) δ: 7.18-7.31 (2H, m), 7.51-7.58 (2H, m), 7.67-7.73 (3H, m), 7.79 (1H, s), 7.90 (2H, d, J = 8.3 Hz), 10.02 (1H, s).	Ref. Ex. 75
739		1H-NMR (CDCl3) δ: 7.00 (1H, d, J = 16.4 Hz), 7.09 (2H, t, J = 8.6 Hz), 7.17 (1H, d, J = 16.4 Hz), 7.49-7.52 (2H, m), 7.71-7.73 (2H, m), 7.88 (1H, s), 10.00 (1H, s).	Ref. Ex. 91
740		1H-NMR (CDCl3) δ: 5.16 (2H, s), 6.97 (1H, dt, J = 2.4, 9.8 Hz), 7.22-7.25 (1H, m), 7.29-7.30 (1H, m), 7.32-7.38 (2H, m), 7.49-7.51 (1H, m), 9.94 (1H, d, J = 1.5 Hz).	Ref. Ex. 82


Ref. Ex. No.	STR	1H-NMR	ref.
741		1H-NMR (CDCl3) δ: 7.67 (1H, t, J = 7.7 Hz), 8.03 (1H, dt, J = 1.5, 7.7 Hz), 8.68 (1H, dt, J = 1.5, 7.7 Hz), 8.71 (2H, s), 8.91 (1H, t, J = 1.5 Hz), 10.14 (1H, s).	Ref. Ex. 91
743		1H-NMR (CDCl3) δ: 5.18 (2H, s), 6.70-6.71 (1H, m), 7.01-7.04 (2H, m), 7.85-7.90 (3H, m), 8.37 (1H, m), 9.88 (1H, s).	Ref. Ex. 93
744		1H-NMR (CDCl3) δ: 1.84-1.98 (4H, m), 4.06-4.10 (2H, m), 4.44-4.48 (1H, m), 4.60-4.64 (1H, m), 5.20 (2H, s), 6.80-6.82 (1H, m), 7.07-7.10 (2H, m), 7.87 (1H, s), 7.91 (2H, s), 9.92 (1H, s).	Ref. Ex. 82
745		1H-NMR (CDCl3) δ: 0.39-0.42 (2H, m), 0.67-0.73 (2H, m), 1.27-1.32 (1H, m), 3.89 (2H, d, J = 7.0 Hz), 5.22 (2H, s), 6.83-6.85 (1H, m), 7.09-7.12 (2H, m), 7.90 (1H, s), 7.93 (2H, s), 9.94 (1H, s).	Ref. Ex. 82
746		1H-NMR (CDCl3) δ: 2.67 (3H, s), 3.91 (3H, s), 7.54-7.59 (1H, m), 7.79 (1H, d, J = 8.8 Hz), 7.98-7.99 (1H, m), 8.23-8.29 (2H, m), 10.08 (1H, s).	Ref. Ex. 93
747		1H-NMR (CDCl3) δ: 0.55-0.58 (2H, m), 0.87-0.95 (2H, m), 1.58-1.61 (1H, m), 5.81-5.86 (1H, m), 6.46 (1H, d, J = 15.8 Hz), 7.50 (1H, s), 7.63 (1H, s), 7.66 (1H, s), 9.94 (1H, s).	Ref. Ex. 77









Ref. Ex. No.	STR	1H-NMR	ref.
748		1H-NMR (CDCl3) δ: 7.19-7.27 (2H, m), 7.60 (1H, s), 7.63-7.67 (5H, m), 7.98 (1H, s), 10.05 (1H, s).	Ref. Ex. 91
749		1H-NMR (CDCl3) δ: 6.62 (1H, t, J = 72.9 Hz), 7.21-7.25 (2H, m), 7.54 (2H, d, J = 11.0 Hz), 7.62-7.66 (4H, m), 7.90 (1H, s), 10.04 (1H, s).	Ref. Ex. 91
751		1H-NMR (CDCl3) δ: 0.57-0.60 (2H, m), 0.88-0.92 (2H, m), 1.55-1.63 (1H, m), 5.86 (1H, dd, J = 9.2, 15.7 Hz), 6.50 (1H, d, J = 15.7 Hz), 7.36 (1H, s), 7.51 (1H, s), 7.73 (1H, s), 9.98 (1H, s).	Ref. Ex. 75
752		1H-NMR (CDCl3) δ: 7.53-7.57 (3H, m), 7.69 (1H, d, J = 4.8 Hz), 8.53-8.57 (2H, m), 9.07 (1H, dd, J = 0.8, 4.8 Hz), 10.14 (1H, d, J = 0.8 Hz).	Ref. Ex. 159
753		1H-NMR (CDCl3) δ: 3.17 (3H, s), 5.37 (2H, s), 7.36-7.38 (1H, m), 7.49-7.52 (3H, m), 8.42-8.46 (2H, m), 8.87 (1H, d, J = 5.1 Hz).	Ref. Ex. 103
754		1H-NMR (CDCl3) δ: 4.42 (2H, q, J = 8.0 Hz), 5.22 (2H, s), 6.88-6.89 (1H, m), 7.11 (1H, s), 7.20 (1H, s), 7.89 (1H, s), 7.91 (2H, s), 9.94 (1H, s).	Ref. Ex. 82








[0502]









Ref. Ex. No.	STR	1H-NMR	ref.
755		1H-NMR (CDCl3) δ: 7.13-7.33 (3H, m), 7.58-7.70 (5H, m), 9.89 (1H, s).	Ref. Ex. 91
756		1H-NMR (CDCl3) δ: 7.04 (1H, d, J = 16.3 Hz), 7.16 (1H, d, J = 16.3 Hz), 7.58-7.66 (4H, m), 7.72 (1H, s), 8.00 (1H, s), 9.97 (1H, s).	Ref. Ex. 91
757		1H-NMR (CDCl3) δ: 5.31 (2H, s), 7.28-7.32 (1H, m), 7.43-7.45 (1H, m), 7.48-7.55 (6H, m), 8.45-8.49 (2H, m), 8.83 (1H, d, J = 5.1 Hz), 10.00 (1H, s).	Ref. Ex. 82
758		1H-NMR (CDCl3) δ: 7.70-7.73 (1H, m), 7.94-8.02 (3H, m), 8.37 (1H, s), 8.44 (1H, s), 10.09 (1H, s).	Ref. Ex. 91
759		1H-NMR (CDCl3) δ: 7.85 (1H, d, J = 5.0 Hz), 8.05 (1H, s), 8.57 (1H, s), 8.63 (1H, s), 8.75 (1H, s), 9.01 (1H, d, J = 5.0 Hz), 10.11 (1H, s).	Ref. Ex. 91
761		1H-NMR (CDCl3) δ: 1.49 (3H, t, J = 6.9 Hz), 4.20 (2H, q, J = 6.9 Hz), 7.49-7.50 (1H, m), 7.90-7.93 (2H, m), 8.02-8.05 (1H, m), 8.11-8.12 (1H, m), 8.97 (1H, s), 10.07 (1H, s).	Ref. Ex. 82
762		1H-NMR (CDCl3) δ: 4.52 (2H, q, J = 8.0 Hz), 7.54-7.55 (1H, m), 7.94 (1H, d, J = 8.4 Hz), 8.01-8.02 (1H, m), 8.05-8.07 (1H, m), 8.23-8.24 (1H, m), 8.98 (1H, s), 10.09 (1H, s).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
763		1H-NMR (CDCl3) δ: 0.92-1.05 (2H, m), 1.30-1.40 (2H, m), 1.43-1.56 (2H, m), 1.90-2.04 (5H, m), 3.48 (2H, d, J = 6.2 Hz).	Ref. Ex. 600
764		1H-NMR (CDCl3) δ: 0.96-1.18 (2H, m), 1.24-1.43 (2H, m), 1.70-1.83 (1H, m), 1.93-2.04 (5H, m), 3.02 (3H, s), 4.06 (2H, d, J = 6.3 Hz).	Ref. Ex. 103
765		1H-NMR (CDCl3) δ: 1.07-1.19 (2H, m), 1.33-1.47 (2H, m), 1.77-1.89 (1H, m), 1.96-2.11 (5H, m), 3.83 (2H, d, J = 6.2 Hz), 6.87 (1H, dt, J = 2.4, 10.1 Hz), 7.14-7.22 (2H, m), 9.92 (1H, d, J = 1.5 Hz).	Ref. Ex. 175
766		1H-NMR (CDCl3) δ: 1.08-1.20 (2H, m), 1.32-1.45 (2H, m), 1.77-1.88 (1H, m), 1.98-2.09 (5H, m), 3.84 (2H, d, J = 6.2 Hz), 7.15-7.20 (1H, m), 7.36-7.38 (1H, m), 7.44-7.48 (2H, m), 9.98 (1H, s).	Ref. Ex. 175
767		1H-NMR (CDCl3) δ: 1.32 (1H, t, J = 4.7 Hz), 1.48-1.62 (4H, m), 1.64-1.74 (4H, m), 1.78-1.82 (1H, m), 2.05-2.17 (1H, m), 3.62 (2H, dd, J = 4.5, 7.1 Hz).	Ref. Ex. 600
768		1H-NMR (CDCl3) δ: 1.55-1.77 (6H, m), 2.08-2.21 (2H, m), 3.03 (3H, s), 4.18 (2H, d, J = 7.5 Hz).	Ref. Ex. 103
769		1H-NMR (CDCl3) δ: 1.61-1.70 (4H, m), 1.72-1.82 (4H, m), 2.15-2.18 (2H, m), 3.96 (2H, d, J = 7.2 Hz), 6.88 (1H, dt, J = 2.4, 10.1 Hz), 7.15-7.19 (1H, m), 7.21 (1H, dd, J = 1.3, 2.4 Hz), 9.93 (1H, d, J = 1.3 Hz).	Ref. Ex. 175
770		1H-NMR (CDCl3) δ: 1.60-1.86 (6H, m), 2.14-2.18 (2H, m), 3.97 (2H, d, J = 7.3 Hz), 7.17-7.21 (1H, m), 7.39-7.40 (1H, m), 7.45-7.46 (1H, m), 7.47 (1H, d, J = 0.9 Hz), 9.99 (1H, s).	Ref. Ex. 175









Ref. Ex. No.	STR	1H-NMR	ref.
771		1H-NMR (CDCl3) δ: 0.58-0.60 (2H, m), 0.89-0.92 (2H, m), 1.52-1.65 (1H, m), 5.80-5.89 (1H, m), 6.60 (1H, d, J = 15.6 Hz), 6.92 (1H, d, J = 3.9 Hz), 7.59 (1H, d, J = 3.9 Hz), 9.80 (1H, s).	Ref. Ex. 77
772		1H-NMR (CDCl3) δ: 0.39-0.47 (2H, m), 0.68-0.73 (2H, m), 1.24-1.36 (1H, m), 3.92 (2H, d, J = 7.0 Hz), 7.21-7.22 (1H, m), 7.68-7.70 (1H, m), 7.88-7.91 (3H, m), 7.99 (1H, t, J = 7.8 Hz).	Ref. Ex. 83
773		1H-NMR (CDCl3) δ: 0.38-0.42 (2H, m), 0.66-0.72 (2H, m), 1.26-1.34 (1H, m), 3.93 (2H, d, J = 7.0 Hz), 7.23-7.24 (1H, m), 7.52-7.54 (1H, m), 7.44-7.45 (1H, m), 7.91 (2H, s), 8.89 (1H, d, J = 5.0 Hz).	Ref. Ex. 83
774		1H-NMR (CDCl3) δ: 0.38-0.42 (2H, m), 0.68-0.73 (2H, m), 1.27-1.34 (1H, m), 3.89 (2H, d, J = 6.9 Hz), 7.15-7.16 (1H, m), 7.34-7.35 (1H, m), 7.44-7.45 (1H, m), 7.59 (1H, t, J = 7.6 Hz), 7.73 (1H, d, J = 7.8 Hz), 7.80 (1H, d, J = 7.6 Hz), 7.78 (1H, s).	Ref. Ex. 83
775		1H-NMR (CDCl3) δ: 0.38-0.42 (2H, m), 0.68-0.73 (2H, m), 1.27-1.34 (1H, m), 3.91 (2H, d, J = 7.0 Hz), 7.20-7.21 (1H, m), 7.34-7.35 (1H, m), 7.45-7.46 (1H, m), 7.93 (1H, s), 7.97 (2H, s).	Ref. Ex. 83
776		1H-NMR (CDCl3) δ: 1.17-1.36 (6H, m), 1.64-1.88 (4H, m), 2.10-2.28 (1H, m), 6.28-6.41 (2H, m), 7.40 (1H, s), 7.53 (1H, s), 7.78 (1H, s), 9.99 (1H, s).	Ref. Ex. 77








Ref. Ex. No.	STR	1H-NMR	ref.
777		1H-NMR (CDCl3) δ: 6.92 (1H, d, J = 16.3 Hz), 7.23 (1H, d, J = 16.3 Hz), 7.35 (3H, s), 7.69-7.71 (2H, m), 7.85 (1H, s), 9.99 (1H, s).	Ref. Ex. 77
778		1H-NMR (CDCl3) δ: 7.04-7.17 (5H, m), 7.46-7.51 (2H, m), 7.66-7.71 (1H, m), 9.86 (1H, s).	Ref. Ex. 77
779		1H-NMR (CDCl3) δ: 0.39-0.43 (2H, m), 0.68-0.72 (2H, m), 1.28-1.37 (1H, m), 3.96 (2H, d, J = 7.1 Hz), 7.46-7.47 (1H, m), 7.66-7.68 (1H, m), 7.95-7.98 (3H, m), 8.12-8.13 (1H, m), 10.07 (1H, s).	Ref. Ex. 93
780		1H-NMR (CDCl3) δ: 0.39-0.43 (2H, m), 0.67-0.72 (2H, m), 1.30-1.36 (1H, m), 3.96 (2H, d, J = 6.9 Hz), 7.48-7.52 (2H, m), 7.90-7.91 (1H, m), 7.99 (1H, s), 8.12-8.13 (1H, m), 8.89 (1H, d, J = 5.0 Hz), 10.07 (1H, s).	Ref. Ex. 93
781		1H-NMR (CDCl3) δ: 0.39-0.42 (2H, m), 0.68-0.72 (2H, m), 1.28-1.36 (1H, m), 3.94 (2H, d, J = 7.0 Hz), 7.40-7.43 (2H, m), 7.59 (1H, t, J = 7.6 Hz), 7.65-7.68 (2H, m), 7.80 (1H, d, J = 7.6 Hz), 7.86 (1H, s), 10.04 (1H, s).	Ref. Ex. 93
782		1H-NMR (CDCl3) δ: 0.38-0.43 (2H, m), 0.68-0.73 (2H, m), 1.26-1.35 (1H, m), 3.95 (2H, d, J = 7.0 Hz), 7.42-7.43 (1H, m), 7.44-7.45 (1H, m), 7.68-7.69 (1H, m), 7.91 (1H, s), 8.04 (2H, s), 10.06 (1H, s).	Ref. Ex. 93
783		1H-NMR (CDCl3) δ: 7.19 (1H, d, J = 16.3 Hz), 7.48 (1H, d, J = 5.1 Hz), 7.65 (4H, s), 7.71 (1H, d, J = 5.1 Hz), 7.81 (1H, d, J = 16.3 Hz), 10.21 (1H, s).	Ref. Ex. 77
784		1H-NMR (CDCl3) δ: 7.04 (1H, d, J = 16.0 Hz), 7.12 (1H, d, J = 3.9 Hz), 7.18 (1H, d, J = 16.0 Hz), 7.31-7.37 (3H, m), 7.65 (1H, d, J = 3.9 Hz), 9.85 (1H, s).	Ref. Ex. 77








Ref. Ex. No.	STR	1H-NMR	ref.
785		1H-NMR (CDCl3) δ: 1.15-1.32 (3H, m), 1.54-2.06 (6H, m), 2.23-2.27 (2H, m), 6.35-6.38 (2H, m), 7.55 (1H, s), 7.66 (1H, s), 7.71 (1H, s), 9.96 (1H, s).	Ref. Ex. 77
786		1H-NMR (CDCl3) δ: 7.92-7.97 (2H, m), 8.01-8.10 (1H, m), 8.35-8.36 (1H, m), 8.43-8.44 (1H, m), 8.99 (1H, s), 10.09 (1H, s).	Ref. Ex. 91
787		1H-NMR (CDCl3) δ: 2.74 (3H, s), 4.63 (2H, s), 4.70 (2H, s), 7.20 (1H, d, J = 16.0 Hz), 7.26 (1H, s), 7.32-7.48 (5H, m), 7.83 (1H, s), 7.93 (1H, d, J = 16.0 Hz), 8.02 (2H, s).	Ref. Ex. 75
788		1H-NMR (CDCl3) δ: 2.74 (3H, s), 4.63 (2H, d, J = 0.5 Hz), 4.70 (2H, s), 7.15 (1H, d, J = 16.0 Hz), 7.32-7.43 (6H, m), 7.63-7.71 (4H, m), 7.87 (1H, d, J = 16.0 Hz).	Ref. Ex. 77
789		1H-NMR (CDCl3) δ: 2.72 (3H, s), 4.62 (2H, s), 4.69 (2H, s), 6.99 (1H, d, J = 16.1 Hz), 7.05-7.12 (2H, m), 7.31-7.43 (6H, m), 7.54-7.61 (2H, m), 7.81 (1H, d, J = 16.1 Hz).	Ref. Ex. 77
790		1H-NMR (CDCl3) δ: 2.42 (3H, s), 5.11 (2H, s), 7.08 (1H, s), 7.26 (1H, s), 7.33 (1H, s), 7.54 (2H, s), 7.78 (1H, s), 9.94 (1H, s).	Ref. Ex. 82
791		1H-NMR (CDCl3) δ: 1.33 (9H, s), 2.40 (3H, s), 5.06 (2H, s), 7.08 (1H, s), 7.28-7.31 (2H, m), 7.34-7.39 (2H, m), 7.40-7.45 (2H, m), 9.93 (1H, s).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
792		1H-NMR (CDCl3) δ: 2.43 (3H, s), 5.21 (2H, s), 7.09 (1H, s), 7.29 (1H, s), 7.34 (1H, s), 7.73 (1H, d, J = 8.0 Hz), 7.97 (1H, dd, J = 1.2, 8.0 Hz), 8.81 (1H, d, J = 1.2 Hz), 9.95 (1H, s).	Ref. Ex. 82
793		1H-NMR (CDCl3) δ: 5.06 (2H, s), 7.10-7.30 (4H, m), 7.34 (1H, dd, J = 1.3, 2.4 Hz), 7.47 (1H, dd, J = 1.3, 1.8 Hz), 9.92 (1H, s).	Ref. Ex. 82
794		1H-NMR (CDCl3) δ: 5.10 (2H, s), 6.74-6.84 (1H, m), 6.91-7.01 (2H, m), 7.21-7.24 (1H, m), 7.32-7.35 (1H, m), 7.47-7.50 (1H, m), 9.92 (1H, s).	Ref. Ex. 82
795		1H-NMR (CDCl3) δ: 5.11 (2H, s), 7.01-7.09 (1H, m), 7.12-7.25 (3H, m), 7.32-7.42 (2H, m), 7.46-7.48 (1H, m), 9.91 (1H, s).	Ref. Ex. 82
796		1H-NMR (CDCl3) δ: 5.07 (2H, s), 7.06-7.14 (2H, m), 7.21-7.24 (1H, m), 7.34-7.36 (1H, m), 7.37-7.44 (2H, m), 7.45-7.47 (1H, m), 9.91 (1H, s).	Ref. Ex. 82
797		1H-NMR (CDCl3) δ: 3.94 (3H, s), 5.11 (2H, s), 7.11-7.15 (1H, m), 7.21-7.28 (2H, m), 7.42 (1H, t, J = 8.0 Hz), 7.64 (1H, s), 7.99 (2H, s).	Ref. Ex. 100
798		1H-NMR (CDCl3) δ: 5.15 (2H, s), 7.14 (1H, d, J = 8.3 Hz), 7.23 (1H, s), 7.29 (1H, s), 7.43 (1H, t, J = 7.9 Hz), 7.98 (1H, s), 8.12 (2H, s), 10.00 (1H, s).	Ref. Ex. 130, Ref. Ex. 159
799		1H-NMR (CDCl3) δ: 5.10 (2H, s), 6.66-6.79 (3H, m), 7.21-7.30 (1H, m), 7.68-7.71 (1H, m), 7.81-7.84 (2H, m), 10.00 (1H, s).	Ref. Ex. 113, Ref. Ex. 130, Ref. Ex. 159









[0504]








Ref. Ex. No.	STR	1H-NMR	ref.
800		1H-NMR (CDCl3) δ: 5.14 (2H, s), 6.75-6.83 (1H, m), 6.85-7.00 (2H, m), 7.69-7.72 (1H, m), 7.81-7.83 (2H, m), 9.99 (1H, s).	Ref. Ex. 113, Ref. Ex. 130, Ref. Ex. 159
801		1H-NMR (CDCl3) δ: 5.14 (2H, s), 6.66-6.75 (2H, m), 7.72 (1H, s), 7.83 (2H, s), 9.99 (1H, s).	Ref. Ex. 113, Ref. Ex. 130, Ref. Ex. 159
802		1H-NMR (CDCl3) δ: 3.03 (3H, s), 3.94 (3H, s), 5.24 (2H, s), 7.61 (1H, s), 7.96 (1H, s), 8.04 (1H, s).	Ref. Ex. 103
803		1H-NMR (CDCl3) δ: 7.20-7.29 (2H, m), 7.81 (1H, s), 7.93-7.97 (5H, m), 10.00 (1H, s).	Ref. Ex. 77
804		1H-NMR (CDCl3) δ: 1.54-1.77 (4H, m), 2.18-2.31 (4H, m), 6.02 (1H, brs), 6.43 (1H, d, J = 16.1 Hz), 6.87 (1H, d, J = 16.1 Hz), 7.45 (1H, s), 7.52 (1H, s), 7.82 (1H, s), 10.00 (1H, s).	Ref. Ex. 77
805		1H-NMR (CDCl3) δ: 1.57-1.80 (4H, m), 2.15-2.30 (4H, m), 6.00 (1H, brs), 6.39 (1H, d, J = 16.1 Hz), 6.85 (1H, d, J = 16.1 Hz), 7.61 (1H, s), 7.65 (1H, s), 7.78 (1H, s), 9.96 (1H, s).	Ref. Ex. 77
806		1H-NMR (CDCl3) δ: 7.14 (1H, d, J = 16.5 Hz), 7.23 (1H, d, J = 16.5 Hz), 7.52 (1H, t, J = 7.8 Hz), 7.57 (1H, d, J = 7.8 Hz), 7.69 (1H, d, J = 7.8 Hz), 7.77 (1H, s), 7.91 (2H, s), 7.95 (1H, s), 9.99 (1H, s).	Ref. Ex. 77
807		1H-NMR (CDCl3) δ: 2.35 (3H, s), 7.03-7.11 (4H, m), 7.47-7.52 (3H, m), 9.81 (1H, s).	Ref. Ex. 77








Ref. Ex. No.	STR	1H-NMR	ref.
808		1H-NMR (CDCl3) δ: 1.47 (3H, t, J = 7.0 Hz), 4.14 (2H, q, J = 7.0 Hz), 7.23 (2H, s), 7.31-7.32 (1H, m), 7.34-7.35 (1H, m), 7.64 (1H, s), 7.78 (1H, s), 7.93 (2H, s), 10.00 (1H, s).	Ref. Ex. 77
809		1H-NMR (CDCl3) δ: 6.92-6.95 (1H, m), 7.04-7.07 (2H, m), 7.18 (2H, s), 7.98 (1H, s), 8.05 (1H, s), 8.19 (1H, s), 10.11 (1H, s).	Ref. Ex. 77
810		1H-NMR (CDCl3) δ: 0.57-0.61 (2H, m), 0.89-0.93 (2H, m), 1.59-1.64 (1H, m), 5.90 (1H, dd, J = 9.0, 15.3 Hz), 6.54 (1H, d, J = 15.3 Hz), 7.75 (1H, s), 7.91 (1H, s), 7.96 (1H, s), 10.04 (1H, s).	Ref. Ex. 77
811		1H-NMR (CDCl3) δ: 7.25 (1H, d, J = 16.3 Hz), 7.31 (1H, d, J = 16.3 Hz), 7.66 (4H, s), 8.00 (1H, s), 8.05 (1H, s), 8.22 (1H, s), 10.11 (1H, s).	Ref. Ex. 77
812		1H-NMR (CDCl3) δ: 2.70 (3H, s), 3.00-3.15 (4H, m), 4.56 (2H, d, J = 0.5 Hz), 4.63 (2H, s), 7.14 (1H, s), 7.31 (2H, d, J = 8.0 Hz), 7.30-7.39 (5H, m), 7.53 (2H, d, J = 8.0 Hz).	Ref. Ex. 33
813		1H-NMR (CDCl3) δ: 2.69 (3H, s), 3.03-3.09 (2H, m), 3.17-3.22 (2H, m), 4.57 (2H, s), 4.64 (2H, s), 7.15 (1H, brs), 7.32-7.38 (5H, m), 7.67 (2H, brs), 7.72 (1H, brs).	Ref. Ex. 33
814		1H-NMR (CDCl3) δ: 2.80 (3H, s), 3.37 (1H, brs), 4.79 (2H, s), 7.15 (1H, d, J = 16.0 Hz), 7.21 (1H, brs), 7.65-7.73 (4H, m), 7.94 (1H, d, J = 16.0 Hz).	Ref. Ex. 750

Ref. Ex. No.	STR	1H-NMR	ref.
815		1H-NMR (CDCl3) δ: 2.77 (3H, s), 3.45 (1H, t, J = 5.0 Hz), 4.75 (2H, d, J = 5.0 Hz), 6.99 (1H, d, J = 15.9 Hz), 7.09-7.14 (3H, m), 7.58-7.63 (2H, m), 7.85 (1H, d, J = 15.9 Hz).	Ref. Ex. 750
816		1H-NMR (CDCl3) δ: 2.88 (3H, s), 7.22 (1H, d, J = 16.1 Hz), 7.66-7.74 (5H, m), 7.96 (1H, d, J = 16.1 Hz), 10.04 (1H, s).	Ref. Ex. 159
817		1H-NMR (CDCl3) δ: 7.05-7.20 (2H, m), 7.27-7.38 (3H, m), 7.52 (1H, s), 7.72-7.76 (2H, m), 7.89 (1H, s), 10.01 (1H, s).	Ref. Ex. 91
818		1H-NMR (CDCl3) δ: 7.12 (1H, d, J = 16.3 Hz), 7.17 (1H, d, J = 16.3 Hz), 7.29-7.35 (2H, m), 7.40 (1H, d, J = 7.4 Hz), 7.54 (1H, s), 7.57 (1H, s), 7.63 (1H, s), 7.95 (1H, s), 10.04 (1H, s).	Ref. Ex. 91
819		1H-NMR (CDCl3) δ: 5.32 (2H, s), 7.42-7.45 (2H, m), 7.67 (1H, s), 7.75 (1H, d, J = 8.1 Hz), 7.87 (1H, d, J = 8.1 Hz), 8.03 (1H, s), 9.93 (1H, s).	Ref. Ex. 82
820		1H-NMR (CDCl3) δ: 5.24 (2H, s), 7.27-7.32 (1H, m), 7.38-7.39 (2H, m), 7.44 (1H, dd, J = 2.7, 8.8 Hz), 7.64 (1H, s), 7.67-7.70 (1H, m), 9.91 (1H, s).	Ref. Ex. 82
821		1H-NMR (CDCl3) δ: 0.36-0.40 (2H, m), 0.66-0.70 (2H, m), 1.26-1.31 (1H, m), 3.87 (2H, d, J = 7.2 Hz), 5.31 (2H, s), 6.83-6.84 (1H, m), 7.07-7.10 (2H, m), 7.73 (1H, d, J = 8.3 Hz), 7.85 (1H, d, J = 8.3 Hz), 8.07 (1H, s), 9.92 (1H, s).	Ref. Ex. 82


[0505]


Ref. Ex. No.	STR	1H-NMR	ref.
822		1H-NMR (CDCl3) δ: 0.35-0.38 (2H, m), 0.65-0.69 (2H, m), 1.24-1.33 (1H, m), 3.85 (2H, d, J = 7.1 Hz), 5.14 (2H, s), 6.80-6.81 (1H, m), 7.04-7.05 (1H, m), 7.08-7.09 (1H, m), 7.46-7.65 (3H, m), 7.71 (1H, s), 9.90 (1H, s).	Ref. Ex. 82
823		1H-NMR (CDCl3) δ: 2.86 (3H, s), 7.04-7.16 (3H, m), 7.57-7.63 (2H, m), 7.65 (1H, s), 7.90 (1H, d, J = 16.1 Hz), 10.03 (1H, s).	Ref. Ex. 159
824		1H-NMR (CDCl3) δ: 7.03-7.21 (4H, m), 7.48-7.56 (3H, m), 7.73-7.78 (2H, m), 8.02 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
826		1H-NMR (CDCl3) δ: 7.13 (2H, s), 7.29-7.39 (3H, m), 7.56 (1H, t, J = 7.6 Hz), 7.74-7.83 (2H, m), 8.03 (1H, s), 10.06 (1H, s).	Ref. Ex. 825
827		1H-NMR (CDCl3) δ: 7.05 (1H, d, J = 16.4 Hz), 7.17 (1H, d, J = 16.4 Hz), 7.35-7.38 (2H, m), 7.45-7.47 (2H, m), 7.71-7.74 (2H, m), 7.88 (1H, s), 10.00 (1H, s).	Ref. Ex. 825
828		1H-NMR (CDCl3) δ: 7.21 (1H, d, J = 16.1 Hz), 7.53-7.67 (3H, m), 7.81-7.87 (3H, m), 8.03 (2H, d, J = 5.4 Hz), 10.08 (1H, s).	Ref. Ex. 825
829		1H-NMR (CDCl3) δ: 5.44 (1H, d, J = 10.9 Hz), 5.87 (1H, d, J = 17.5 Hz), 6.72 (1H, dd, J = 10.9, 17.5 Hz), 7.63 (1H, s), 7.69 (1H, s), 7.74 (1H, s), 9.98 (1H, s).	Ref. Ex. 77
830		1H-NMR (CDCl3) δ: 5.47 (1H, d, J = 10.9 Hz), 5.90 (1H, d, J = 17.6 Hz), 6.76 (1H, dd, J = 10.9, 17.6 Hz), 7.48 (1H, s), 7.61 (1H, s), 7.85 (1H, s), 10.02 (1H, s).	Ref. Ex. 77


Ref. Ex. No.	STR	1H-NMR	ref.
832		1H-NMR (CDCl3) δ: 4.73 (2H, d, J = 0.5 Hz), 4.76 (2H, s), 7.31-7.45 (5H, m), 7.99-8.00 (1H, m), 8.02 (1H, brs), 8.58 (2H, s), 9.23 (1H, d, J = 1.3 Hz).	Ref. Ex. 91
833		1H-NMR (CDCl3) δ: 4.72 (2H, s), 4.73 (2H, s), 7.32-7.43 (5H, m), 7.76 (1H, d, J = 5.0 Hz), 8.88 (1H, d, J = 5.0 Hz).	Ref. Ex. 742
834		1H-NMR (CDCl3) δ: 3.13 (1H, t, J = 5.2 Hz), 4.91 (2H, dd, J = 0.6, 5.2 Hz), 7.88-7.89 (1H, m), 8.03-8.04 (1H, m), 8.59-8.60 (2H, m), 9.28 (1H, d, J = 1.3 Hz).	Ref. Ex. 750
835		1H-NMR (CDCl3) δ: 2.94 (1H, t, J = 5.2 Hz), 4.90 (2H, d, J = 5.2 Hz), 7.63 (1H, d, J = 5.2 Hz), 8.89 (1H, d, J = 5.2 Hz).	Ref. Ex. 750
836		1H-NMR (CDCl3) δ: 7.10 (1H, d, J = 16.4 Hz), 7.17 (1H, s), 7.19 (1H, d, J = 1.0 Hz), 7.37 (1H, s), 7.40-7.46 (2H, m), 7.74-7.76 (2H, m), 7.90 (1H, s), 10.01 (1H, s).	Ref. Ex. 825
837		1H-NMR (CDCl3) δ: 7.04 (1H, d, J = 17.2 Hz), 7.17-7.25 (3H, m), 7.55 (2H, d, J = 8.6 Hz), 7.73-7.74 (2H, m), 7.89 (1H, s), 10.00 (1H, s).	Ref. Ex. 825
838		1H-NMR (CDCl3) δ: 6.99-7.21 (4H, m), 7.27-7.37 (2H, m), 7.73-7.89 (2H, m), 7.89 (1H, s), 10.01 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
839		1H-NMR (CDCl3) δ: 7.00-7.22 (4H, m), 7.49-7.60 (4H, m), 7.94 (1H, s), 10.04 (1H, s).	Ref. Ex. 91
840		1H-NMR (CDCl3) δ: 1.47 (3H, t, J = 7.0 Hz), 4.14 (2H, q, J = 7.0 Hz), 7.18-7.23 (2H, m), 7.30-7.32 (2H, m), 7.48-7.57 (2H, m), 7.63 (1H, s), 7.69 (1H, d, J = 7.7 Hz), 7.77 (1H, s), 9.89 (1H, s).	Ref. Ex. 77
841		1H-NMR (CDCl3) δ: 8.08 (1H, brs), 8.32 (1H, d, J = 1.4 Hz), 8.66 (2H, brs), 9.57 (1H, d, J = 1.4 Hz), 10.15 (1H, s).	Ref. Ex. 159
842		1H-NMR (CDCl3) δ: 3.92 (3H, s), 7.22-7.27 (2H, m), 7.31-7.32 (1H, m), 7.36-7.37 (1H, m), 7.66-7.67 (1H, m), 7.78 (1H, s), 7.94 (2H, s), 10.02 (1H, s).	Ref. Ex. 77
843		1H-NMR (CDCl3) δ: 3.91 (3H, s), 7.14-7.23 (2H, m), 7.29-7.30 (1H, m), 7.32-7.33 (1H, m), 7.48-7.53 (2H, m), 7.64 (1H, s), 7.68 (1H, d, J = 7.4 Hz), 7.77 (1H, s), 10.01 (1H, s).	Ref. Ex. 77
844		1H-NMR (CDCl3) δ: 3.91 (3H, s), 7.15-7.23 (2H, m), 7.29-7.30 (1H, m), 7.33-7.34 (1H, m), 7.61-7.64 (3H, m), 10.01 (1H, s).	Ref. Ex. 77
845		1H-NMR (CDCl3) δ: 6.86-6.96 (2H, m), 7.19 (1H, d, J = 16.6 Hz), 7.34 (1H, d, J = 16.6 Hz), 7.56-7.62 (1H, m), 7.97 (1H, s), 8.03 (1H, s), 8.19 (1H, s), 10.11 (1H, s).	Ref. Ex. 77









[0506]








Ref. Ex. No.	STR	1H-NMR	ref.
846		1H-NMR (CDCl3) δ: 3.21 (3H, s), 5.41 (2H, s), 7.72 (1H, d, J = 5.1 Hz), 8.98 (1H, d, J = 5.1 Hz).	Ref. Ex. 103
847		1H-NMR (CDCl3) δ: 7.13 (1H, d, J = 16.3 Hz), 7.21 (1H, d, J = 16.3 Hz), 7.39-7.48 (4H, m), 7.59 (1H, s), 7.63 (1H, s), 7.96 (1H, s), 10.05 (1H, s).	Ref. Ex. 825
848		1H-NMR (CDCl3) δ: 7.01 (1H, d, J = 16.3 Hz), 7.07 (1H, d, J = 8.2 Hz), 7.18 (1H, d, J = 16.3 Hz), 7.20-7.29 (2H, m), 7.56 (1H, s), 7.62 (1H, s), 7.94 (1H, s), 10.04 (1H, s).	Ref. Ex. 825
849		1H-NMR (CDCl3) δ: 7.31 (1H, d, J = 16.1 Hz), 7.61-7.91 (6H, m), 10.13 (1H, s).	Ref. Ex. 75
850		1H-NMR (CDCl3) δ: 3.91 (3H, s), 6.84-6.94 (2H, m), 7.11 (1H, d, J = 16.4 Hz), 7.24-7.32 (2H, m), 7.55-7.61 (1H, m), 7.63 (1H, s), 10.01 (1H, s).	Ref. Ex. 77
851		1H-NMR (CDCl3) δ: 3.90 (3H, s), 7.02 (1H, d, J = 16.3 Hz), 7.05-7.09 (2H, m), 7.15 (1H, d, J = 16.3 Hz), 7.26-7.30 (2H, m), 7.48-7.51 (2H, m), 7.61 (1H, s), 10.00 (1H, s).	Ref. Ex. 91
852		1H-NMR (CDCl3) δ: 7.06-7.12 (3H, m), 7.24 (1H, d, J = 15.5 Hz), 7.51-7.54 (2H, m), 7.96 (1H, s), 8.00 (1H, s), 8.17 (1H, s), 10.10 (1H, s).	Ref. Ex. 91







Ref. Ex. No.	STR	1H-NMR	ref.
853		1H-NMR (CDCl3) δ: 7.21 (1H, t, J = 9.1 Hz), 7.27-7.38 (2H, m), 7.50-7.59 (2H, m), 7.79-7.91 (3H, m), 8.07 (1H, s), 10.07 (1H, s).	Ref. Ex. 825
854		1H-NMR (CDCl3) δ: 7.14-7.23 (2H, m), 7.51 (1H, d, J = 8.3 Hz), 7.56 (1H, t, J = 7.4 Hz), 7.62 (1H, dd, J = 2.1, 8.3 Hz), 7.75-7.82 (3H, m), 8.04-8.05 (1H, m), 10.06 (1H, s).	Ref. Ex. 825
855		1H-NMR (CDCl3) δ: 7.10-7.24 (3H, m), 7.56 (1H, t, J = 7.6 Hz), 7.67-7.71 (1H, m), 7.75-7.82 (3H, m), 8.03 (1H, s), 10.06 (1H, s).	Ref. Ex. 825
856		1H-NMR (CDCl3) δ: 7.25-7.29 (2H, m), 7.37 (1H, d, J = 16.6 Hz), 7.52-7.59 (2H, m), 7.79-7.84 (3H, m), 8.04 (1H, s), 10.07 (1H, s).	Ref. Ex. 825
857		1H-NMR (CDCl3) δ: 2.03-2.14 (2H, m), 2.24-2.41 (2H, m), 4.08 (2H, t, J = 6.0 Hz), 7.16 (1H, dd, J = 2.0, 2.4 Hz), 7.27 (1H, dd, J = 1.3, 2.4 Hz), 7.45 (1H, dd, J = 1.3, 1.8 Hz), 9.92 (1H, s).	Ref. Ex. 82
858		1H-NMR (CDCl3) δ: 5.19 (2H, s), 7.08-7.26 (4H, m), 7.38 (1H, dd, J = 1.3, 2.4 Hz), 7.49 (1H, dd, J = 1.3, 1.7 Hz), 9.93 (1H, s).	Ref. Ex. 82
859		1H-NMR (CDCl3) δ: 5.18 (2H, s), 7.08-7.22 (2H, m), 7.23-7.26 (1H, m), 7.31-7.41 (2H, m), 7.44-7.52 (2H, m), 9.92 (1H, s).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
860		1H-NMR (CDCl3) δ: 2.51 (3H, s), 7.35 (1H, s), 7.59 (1H, s), 7.73 (1H, s), 8.99 (1H, s).	Ref. Ex. 125
861		1H-NMR (CDCl3) δ: 2.49 (3H, s), 7.25 (2H, s), 7.61 (1H, s), 7.65 (1H, s), 7.78 (1H, s), 7.87 (1H, s), 7.94 (2H, s), 10.03 (1H, s).	Ref. Ex. 77
862		1H-NMR (CDCl3) δ: 2.46 (3H, s), 6.99-7.11 (3H, m), 7.16 (1H, d, J = 16.6 Hz), 7.47-7.52 (2H, m), 7.56 (1H, s), 7.58 (1H, s), 7.82 (1H, s), 10.02 (1H, s).	Ref. Ex. 91
863		1H-NMR (CDCl3) δ: 3.94 (3H, s), 5.36 (2H, s), 7.10 (1H, d, J = 8.8 Hz), 7.64 (1H, s), 7.77 (1H, d, J = 8.8 Hz), 7.88 (1H, s), 7.98-8.00 (2H, m).	Ref. Ex. 82
864		1H-NMR (CDCl3) δ: 4.68-4.71 (3H, m), 5.22 (2H, m), 7.09 (1H, d, J = 8.7 Hz), 7.26-7.35 (3H, m), 7.75 (1H, d, J = 8.5 Hz), 7.87 (1H, s).	Ref. Ex. 76
865		1H-NMR (CDCl3) δ: 4.64-4.80 (3H, m), 5.19 (2H, m), 7.26-7.37 (5H, m), 7.74 (1H, d, J = 8.1 Hz).	Ref. Ex. 113, Ref. Ex. 76
866		1H-NMR (CDCl3) δ: 5.29 (2H, s), 7.12 (1H, d, J = 8.6 Hz), 7.70-7.72 (1H, m), 7.76-7.81 (1H, m), 7.83-7.85 (2H, m), 7.89 (1H, s), 10.00 (1H, s).	Ref. Ex. 48
867		1H-NMR (CDCl3) δ: 5.27 (2H, s), 7.27 (1H, s), 7.37 (1H, d, J = 8.1 Hz), 7.70-7.72 (1H, m), 7.77 (1H, d, J = 8.1 Hz), 7.85 (2H, s), 10.00 (1H, s).	Ref. Ex. 48
868		1H-NMR (CDCl3) δ: 2.46 (3H, s), 7.11 (1H, d, J = 16.4 Hz), 7.20 (1H, d, J = 16.4 Hz), 7.28-7.32 (1H, m), 7.35-7.41 (2H, m), 7.51-7.55 (2H, m), 7.58 (2H, s), 7.83 (1H, s), 10.02 (1H, s).	Ref. Ex. 91










[0507]








Ref. Ex. No.	STR	1H-NMR	ref.
869		1H-NMR (CDCl3) δ: 5.10 (2H, s), 6.60-6.78 (3H, m), 7.21-7.30 (1H, m), 7.85 (1H, s), 7.87 (1H, s), 7.98 (1H, s), 9.98 (1H, s).	Ref. Ex. 113, Ref. Ex. 130, Ref. Ex. 159
870		1H-NMR (CDCl3) δ: 5.15 (2H, s), 7.14 (1H, dd, J = 2.5, 8.2 Hz), 7.21-7.30 (2H, m), 7.43 (1H, t, J = 8.0 Hz), 7.87 (1H, s), 7.88 (1H, s), 8.00 (1H, s), 9.99 (1H, s).	Ref. Ex. 113, Ref. Ex. 130, Ref. Ex. 159
871		1H-NMR (CDCl3) δ: 7.12 (1H, d, J = 16.1 Hz), 7.40 (1H, t, J = 7.6 Hz), 7.51-7.62 (3H, m), 7.69 (1H, d, J = 7.8 Hz), 7.76-7.85 (3H, m), 8.01 (1H, s), 10.07 (1H, s).	Ref. Ex. 186
872		1H-NMR (CDCl3) δ: 7.05 (1H, d, J = 16.4 Hz), 7.10 (1H, d, J = 16.4 Hz), 7.11-7.26 (2H, m), 7.35 (1H, ddd, J = 2.1, 7.6, 11.5 Hz), 7.54 (1H, t, J = 7.6 Hz), 7.71-7.76 (1H, m), 7.76-7.82 (1H, m), 8.01 (1H, s), 10.06 (1H, s).	Ref. Ex. 188
873		1H-NMR (CDCl3) δ: 7.19 (1H, ddd, J = 0.8, 4.8, 7.5 Hz), 7.27 (1H, d, J = 16.1 Hz), 7.40 (1H, d, J = 7.8 Hz), 7.55 (1H, t, J = 7.6 Hz), 7.66-7.75 (2H, m), 7.79-7.85 (2H, m), 8.10 (1H, s), 8.61-8.65 (1H, m), 10.06 (1H, s).	Ref. Ex. 186
874		1H-NMR (CDCl3) δ: 7.15-7.25 (2H, m), 7.49-7.60 (3H, m), 7.73-7.84 (4H, m), 8.05 (1H, s), 10.07 (1H, s).	Ref. Ex. 17, Ref. Ex. 151
875		1H-NMR (CDCl3) δ: 5.98 (2H, s), 6.81 (1H, d, J = 8.1 Hz), 6.95 (1H, dd, J = 1.6, 8.1 Hz), 6.96 (1H, d, J = 16.3 Hz), 7.07 (1H, d, J = 1.6 Hz), 7.11 (1H, d, J = 16.3 Hz), 7.50 (1H, t, J = 7.6 Hz), 7.69-7.76 (2H, m), 7.98 (1H, s), 10.04 (1H, s).	Ref. Ex. 17, Ref. Ex. 229
876		1H-NMR (CDCl3) δ: 6.91-7.22 (5H, m), 7.71-7.74 (2H, m), 7.87 (1H, s), 10.00 (1H, s).	Ref. Ex. 825







Ref. Ex. No.	STR	1H-NMR	ref.
877		1H-NMR (CDCl3) δ: 7.15-7.26 (3H, m), 7.39-7.41 (1H, m), 7.55-7.59 (2H, m), 7.76-7.84 (2H, m), 8.05 (1H, s), 10.07 (1H, s).	Ref. Ex. 107, Ref. Ex. 112
878		1H-NMR (CDCl3) δ: 5.33 (2H, s), 7.27-7.31 (1H, m), 7.48-7.56 (3H, m), 7.80 (1H, d, J = 5.1 Hz), 8.95 (1H, d, J = 5.1 Hz), 10.00 (1H, s).	Ref. Ex. 82
879		1H-NMR (CDCl3) δ: 7.02-7.19 (3H, m), 7.32-7.43 (1H, m), 7.56-7.59 (1H, m), 7.71-7.75 (2H, m), 7.87 (1H, s), 10.00 (1H, s).	Ref. Ex. 825
880		1H-NMR (CDCl3) δ: 7.06 (1H, d, J = 16.3 Hz), 7.19 (1H, d, J = 16.3 Hz), 7.20-7.23 (1H, m), 7.67-7.77 (4H, m), 7.89 (1H, s), 10.01 (1H, s).	Ref. Ex. 825
881		1H-NMR (CDCl3) δ: 6.61 (1H, t, J = 73.0 Hz), 6.99-7.24 (4H, m), 7.49-7.53 (4H, m), 7.86 (1H, s), 10.03 (1H, s).	Ref. Ex. 825
882		1H-NMR (CDCl3) δ: 6.93-6.97 (1H, m), 7.03-7.09 (1H, m), 7.19 (1H, d, J = 16.5 Hz), 7.28-7.33 (2H, m), 7.56 (1H, t, J = 7.5 Hz), 7.77-7.82 (2H, m), 8.04 (1H, s), 10.07 (1H, s).	Ref. Ex. 825
883		1H-NMR (CDCl3) δ: 6.94-7.00 (1H, m), 7.12 (1H, d, J = 16.5 Hz), 7.22-7.26 (1H, m), 7.39-7.45 (1H, m), 7.56 (1H, t, J = 7.6 Hz), 7.76-7.82 (2H, m), 8.03 (1H, s), 10.06 (1H, s).	Ref. Ex. 825

Ref. Ex. No.	STR	1H-NMR	ref.
884		1H-NMR (CDCl3) δ: 6.54 (1H, t, J = 73.7 Hz), 7.01-7.24 (4H, m), 7.52-7.54 (2H, m), 7.72-7.76 (2H, m), 7.88 (1H, s), 10.00 (1H, s).	Ref. Ex. 825
885		1H-NMR (CDCl3) δ: 7.06-7.22 (3H, m), 7.61-7.77 (4H, m), 7.80 (1H, s), 10.00 (1H, s).	Ref. Ex. 825
886		1H-NMR (CDCl3) δ: 7.24-7.27 (3H, m), 7.51-7.62 (2H, m), 7.71-7.82 (3H, m), 8.16-8.20 (1H, m), 10.01 (1H, s).	Ref. Ex. 77
887		1H-NMR (CDCl3) δ: 7.14-7.24 (3H, m), 7.49-7.53 (2H, m), 7.66-7.77 (3H, m), 8.01-8.04 (1H, m), 10.40 (1H, s).	Ref. Ex. 825
888		1H-NMR (CDCl3) δ: 6.61 (1H, t, J = 72.9 Hz), 7.08 (1H, d, J = 16.3 Hz), 7.17 (1H, d, J = 16.3 Hz), 7.35-7.52 (6H, m), 7.87 (1H, s), 10.03 (1H, s).	Ref. Ex. 825
889		1H-NMR (CDCl3) δ: 7.35 (2H, s), 7.52-7.80 (7H, m), 9.98 (1H, s).	Ref. Ex. 825
















[0508]

Ref. Ex. No.	STR	1H-NMR	ref.
890		1H-NMR (CDCl3) δ: 7.15-7.22 (2H, m), 7.44-7.54 (3H, m), 7.57 (1H, d, J = 7.6 Hz), 7.70 (1H, d, J = 7.6 Hz), 7.78 (1H, s), 7.83 (1H, s), 10.03 (1H, d, J = 1.7 Hz).	Ref. Ex. 75
891		1H-NMR (CDCl3) δ: 3.94 (3H, s), 5.30 (2H, s), 7.18-7.45 (4H, m), 8.28 (1H, s).	Ref. Ex. 82
892		1H-NMR (CDCl3) δ: 6.90-7.24 (1H, m), 7.28-7.34 (2H, m), 7.65 (4H, s), 7.79-7.85 (1H, m), 8.18-8.21 (1H, m), 10.02 (1H, s).	Ref. Ex. 91
893		1H-NMR (CDCl3) δ: 7.06-7.27 (5H, m), 7.51-7.56 (2H, m), 7.75-7.77 (1H, m), 8.14-8.17 (1H, m), 10.00 (1H, s).	Ref. Ex. 825
894		1H-NMR (CDCl3) δ: 7.29-7.39 (3H, m), 7.81-7.88 (2H, m), 7.97 (2H, s), 8.17-8.20 (1H, m), 10.02 (1H, s).	Ref. Ex. 77
895		1H-NMR (CDCl3) δ: 4.64 (2H, s), 5.17 (2H, s), 7.21-7.29 (3H, m), 7.40-7.44 (1H, m), 7.64 (1H, s).	Ref. Ex. 19
896		1H-NMR (CDCl3) δ: 5.25 (2H, s), 7.18-7.44 (4H, m), 8.31 (1H, s), 9.97 (1H, s).	Ref. Ex. 159
897		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.1 Hz), 4.39 (2H, q, J = 7.1 Hz), 7.33 (1H, d, J = 16.1 Hz), 7.59 (1H, d, J = 16.1 Hz), 7.66 (4H, s), 8.40 (1H, s).	Ref. Ex. 112
898		1H-NMR (CDCl3) δ: 2.05 (1H, brs), 4.90 (2H, d, J = 5.8 Hz), 7.31 (1H, d, J = 16.2 Hz), 7.41 (1H, d, J = 16.2 Hz), 7.63 (4H, s), 7.69 (1H, s).	Ref. Ex. 76

















Ref. Ex. No.	STR	1H-NMR	ref.
899		1H-NMR (CDCl3) δ: 7.38 (1H, d, J = 16.1 Hz), 7.68 (1H, d, J = 16.2 Hz), 7.68 (4H, s), 8.42 (1H, s), 10.05 (1H, s).	Ref. Ex. 159
900		1H-NMR (CDCl3) δ: 7.28-7.56 (4H, m), 7.76-7.90 (4H, m), 7.96 (1H, s), 10.45 (1H, s).	Ref. Ex. 825
901		1H-NMR (CDCl3) δ: 7.26-7.44 (2H, m), 7.76-7.90 (4H, m), 7.96 (2H, s), 10.45 (1H, s).	Ref. Ex. 75
902		1H-NMR (CDCl3) δ: 6.65 (1H, d, J = 3.6 Hz), 7.08 (1H, d, J = 16.3 Hz), 7.29 (1H, d, J = 3.6 Hz), 7.43 (1H, d, J = 16.3 Hz), 7.80-7.92 (3H, m), 9.66 (1H, s).	Ref. Ex. 75
903		1H-NMR (CDCl3) δ: 7.35 (1H, d, J = 16.0 Hz), 7.51 (1H, d, J = 8.2 Hz), 7.88 (1H, d, J = 16.0 Hz), 7.94-7.97 (1H, m), 8.08-8.09 (2H, m), 8.28 (1H, s), 8.89 (1H, s), 10.12 (1H, s).	Ref. Ex. 825
904		1H-NMR (CDCl3) δ: 7.30 (1H, d, J = 16.0 Hz), 7.43-7.45 (1H, m), 7.61 (1H, s), 7.86 (1H, d, J = 16.0 Hz), 8.06-8.08 (2H, m), 8.26 (1H, s), 8.82 (1H, d, J = 5.0 Hz), 10.11 (1H, s).	Ref. Ex. 825
905		1H-NMR (CDCl3) δ: 7.28 (1H, d, J = 16.0 Hz), 7.48 (1H, d, J = 8.3 Hz), 7.76-7.81 (3H, m), 7.92-7.98 (2H, m), 8.87 (1H, s), 10.01 (1H, s).	Ref. Ex. 825

Ref. Ex. No.	STR	1H-NMR	ref.
906		1H-NMR (CDCl3) δ: 7.39 (1H, d, J = 16.0 Hz), 7.41-7.43 (1H, m), 7.58 (1H, s), 7.73-7.80 (3H, m), 7.95-7.99 (1H, m), 8.80 (1H, d, J = 5.0 Hz), 10.09 (1H, s).	Ref. Ex. 825
907		1H-NMR (CDCl3) δ: 7.06 (1H, d, J = 16.1 Hz), 7.28-7.31 (1H, m), 7.39-7.51 (2H, m), 7.57 (1H, t, J = 7.7 Hz), 7.75-7.84 (3H, m), 7.99-8.00 (1H, m), 10.07 (1H, s).	Ref. Ex. 825
908		1H-NMR (CDCl3) δ: 7.05-7.15 (2H, m), 7.45-7.60 (3H, m), 7.67-7.72 (1H, m), 7.78-7.86 (2H, m), 8.01-8.02 (1H, m), 10.07 (1H, s).	Ref. Ex. 825
909		1H-NMR (CDCl3) δ: 7.26-7.45 (4H, m), 7.82-7.94 (2H, m), 7.96 (2H, s), 10.36 (1H, s).	Ref. Ex. 75
910		1H-NMR (CDCl3) δ: 6.61 (1H, d, J = 3.7 Hz), 7.03 (1H, d, J = 16.3 Hz), 7.28 (1H, d, J = 3.7 Hz), 7.43 (1H, d, J = 16.3 Hz), 7.62 (4H, m), 9.63 (1H, s).	Ref. Ex. 91
911		1H-NMR (CDCl3) δ: 7.44-7.51 (2H, m), 8.13 (2H, s), 8.18 (1H, d, J = 16.0 Hz), 8.32 (1H, s), 9.01 (1H, d, J = 5.0 Hz), 10.12 (1H, s).	Ref. Ex. 825






[0509]









Ref. Ex. No.	STR	1H-NMR	ref.
912		1H-NMR (CDCl3) δ: 7.55-7.61 (2H, m), 7.70 (1H, d, J = 8.5 Hz), 7.75-7.87 (3H, m), 8.10-8.16 (4H, m), 8.33-8.34 (1H, m), 10.15 (1H, s).	Ref. Ex. 825
913		1H-NMR (CDCl3) δ: 1.81 (3H, s), 3.20 (3H, s), 3.96 (3H, s), 7.37 (1H, d, J = 8.2 Hz), 8.06 (1H, dd, J = 1.9, 8.1 Hz), 8.37 (1H, d, J = 1.9 Hz).	Ref. Ex. 12
914		1H-NMR (CDCl3) δ: 2.07 (3H, s), 3.92 (3H, s), 7.61-7.68 (5H, m), 7.93 (1H, d, J = 1.7 Hz), 8.06-8.10 (1H, m), 8.40-8.50 (1H, br).	Ref. Ex. 112
915		1H-NMR (CDCl3) δ: 2.27 (3H, s), 3.94 (3H, s), 7.14-7.16 (2H, m), 7.52-7.76 (5H, m), 7.96-8.20 (3H, m).	Ref. Ex. 75
917		1H-NMR (CDCl3) δ: 6.62 (1H, d, J = 16.3 Hz), 7.00 (1H, d, J = 16.3 Hz), 7.27 (1H, s), 7.28 (1H, d, J = 3.7 Hz), 7.35 (1H, s), 7.36 (1H, t, J = 16.3 Hz), 7.55 (1H, s), 9.64 (1H, s).	Ref. Ex. 825
918		1H-NMR (CDCl3) δ: 6.55 (1H, d, J = 3.8 Hz), 7.83 (1H, d, J = 16.2 Hz), 7.07 (1H, d, J = 8.3 Hz), 7.19-7.29 (3H, m), 7.34 (1H, d, J = 16.2 Hz), 9.61 (1H, s).	Ref. Ex. 825
919		1H-NMR (CDCl3) δ: 1.71 (1H, bs), 2.04 (3H, s), 4.72 (2H, d, J = 5.8 Hz), 6.90-6.95 (1H, br), 7.27-7.68 (6H, m), 8.14-8.16 (1H, m).	Ref. Ex. 76
920		1H-NMR (CDCl3) δ: 2.26 (3H, s), 4.72 (2H, d, J = 5.6 Hz), 7.09-7.76 (10H, m).	Ref. Ex. 76
921		1H-NMR (CDCl3) δ: 1.80 (3H, s), 3.03 (3H, s), 3.97 (3H, s), 7.37 (1H, d, J = 8.7 Hz), 7.50-7.67 (4H, m), 8.11-8.15 (2H, m).	Ref. Ex. 112
922		1H-NMR (CDCl3) δ: 3.85 (3H, s), 6.55-6.83 (1H, m), 6.81-6.90 (2H, m), 7.04-7.19 (2H, m), 7.54-7.63 (2H, m), 7.95 (1H, s), 10.04 (1H, s).	Ref. Ex. 825
923		1H-NMR (CDCl3) δ: 7.11-7.21 (2H, m), 7.45-7.77 (7H, m), 7.58 (1H, s), 9.89 (1H, s).	Ref. Ex. 77
925		1H-NMR (CDCl3) δ: 2.09 (3H, s), 7.19 (1H, bns), 7.60-7.79 (5H, m), 7.93 (1H, dd, J = 1.9, 8.5 Hz), 8.59 (1H, d, J = 8.6 Hz), 9.98 (1H, s).	Ref. Ex. 159
926		1H-NMR (CDCl3) δ: 2.28 (3H, s), 7.16 (2H, d, J = 4.3 Hz), 7.30-7.85 (6H, m), 8.03 (1H, s), 8.22-8.35 (1H, br), 9.98 (1H, s).	Ref. Ex. 159
927		1H-NMR (CDCl3) δ: 0.86 (3H, t, J = 7.1 Hz), 2.58 (3H, s), 2.77 (2H, q, J = 7.1 Hz), 4.66 (2H, d, J = 5.8 Hz), 7.08 (1H, d, J = 8.2 Hz), 7.22-7.27 (2H, m), 7.43-7.61 (2H, m), 7.64-7.78 (1H, m), 7.87 (1H, s).	Ref. Ex. 76
928		1H-NMR (CDCl3) δ: 1.49 (1H, t, J = 6.0 Hz), 2.81 (3H, s), 3.83 (1H, s), 4.61 (2H, d, J = 5.5 Hz), 6.70 (1H, d, J = 8.3 Hz), 7.10 (1H, d, J = 2.1 Hz), 7.31 (1H, dd, J = 1.6, 7.8 Hz), 7.58-7.68 (4H, m).	Ref. Ex. 76
929		1H-NMR (CDCl3) δ: 2.32 (3H, s), 6.99-7.06 (2H, m), 7.16 (1H, d, J = 16.3 Hz), 7.31-7.38 (2H, m), 7.55-7.60 (2H, m), 7.93 (1H, s), 10.03 (1H, s).	Ref. Ex. 825
930		1H-NMR (CDCl3) δ: 7.59-7.81 (6H, m), 7.86 (1H, s), 7.96 (1H, s), 9.92 (1H, s).	Ref. Ex. 112
931		1H-NMR (CDCl3) δ: 0.94 (3H, t, J = 7.1 Hz), 2.68 (3H, s), 2.97 (2H, q, J = 7.1 Hz), 7.09 (1H, d, J = 8.6 Hz), 7.54-7.80 (6H, m), 9.87 (1H, s).	Ref. Ex. 48
932		1H-NMR (CDCl3) δ: 7.11 (1H, d, J = 15.9 Hz), 7.16-7.26 (1H, m), 7.62-7.67 (3H, m), 7.94 (1H, d, J = 15.9 Hz), 8.03 (1H, s), 7.18-8.19 (2H, m), 10.08 (1H, s).	Ref. Ex. 825
933		1H-NMR (CDCl3) δ: 2.91 (3H, d, J = 5.1 Hz), 4.45 (1H, bns), 6.74 (1H, d, J = 8.5 Hz), 7.59-7.69 (5H, m), 7.82 (1H, dd, J = 2.1, 8.6 Hz), 9.79 (1H, s).	Ref. Ex. 48
936		1H-NMR (CDCl3) δ: 1.55 (9H, s), 7.30 (1H, bns), 7.80 (1H, dd, J = 1.9, 8.6 Hz), 8.06 (1H, d, J = 1.9 Hz), 8.41 (1H, d, J = 8.6 Hz), 9.85 (1H, s).	Ref. Ex. 159
937		1H-NMR (CDCl3) δ: 1.56 (9H, s), 6.72 (1H, bns), 7.08-7.21 (2H, m), 7.54-7.84 (5H, m), 7.99 (1H, d, J = 2.0 Hz), 8.21 (1H, d, J = 8.6 Hz), 9.96 (1H, s).	Ref. Ex. 75







[0510]

Ref. Ex. No.	STR	1H-NMR	ref.
938		1H-NMR (CDCl3) δ: 6.93 (1H, d, J = 3.7 Hz), 7.39 (1H, d, J = 3.7 Hz), 7.45-7.52 (2H, m), 7.91-7.94 (1H, m), 8.00 (1H, s), 8.28-8.31 (1H, m), 9.70 (1H, s).	Ref. Ex. 112
939		1H-NMR (CDCl3) δ: 3.83 (3H, s), 6.51-6.62 (2H, m), 6.81-6.93 (3H, m), 7.26-7.27 (2H, m), 9.62 (1H, s).	Ref. Ex. 825
940		1H-NMR (CDCl3) δ: 7.16 (2H, t, J = 8.6 Hz), 7.54-7.88 (5H, m), 8.39 (1H, s), 9.90 (1H, s).	Ref. Ex. 112
941		1H-NMR (CDCl3) δ: 7.07 (1H, d, J = 16.3 Hz), 7.60 (1H, dd, J = 2.1, 8.4 Hz), 7.67 (1H, d, J = 8.4 Hz), 7.81 (1H, s), 7.84 (1H, d, J = 2.2 Hz), 7.96 (2H, m), 8.13 (1H, d, J = 16.3 Hz), 10.23 (1H, s).	Ref. Ex. 77
942		1H-NMR (CDCl3) δ: 6.96 (1H, d, J = 8.3 Hz), 7.31 (1H, d, J = 16.4 Hz), 7.53 (1H, d, J = 16.4 Hz), 7.74-7.77 (2H, m), 7.86 (1H, s), 7.95 (2H, s), 8.12 (1H, d, J = 1.9 Hz), 9.93 (1H, s).	Ref. Ex. 77
943		1H-NMR (CDCl3) δ: 1.57 (9H, s), 3.26 (3H, s), 7.12-7.26 (2H, m), 7.30-7.74 (5H, m), 7.82 (1H, dd, J = 1.9, 8.1 Hz), 8.22 (1H, d, J = 1.9 Hz), 10.06 (1H, s).	Ref. Ex. 12
944		1H-NMR (CDCl3) δ: 7.04-7.09 (2H, m), 7.21 (1H, d, J = 16.3 Hz), 7.72-7.78 (3H, m), 7.91 (2H, s), 9.88 (1H, s), 11.11 (1H, s).	Ref. Ex. 77
945		1H-NMR (CDCl3) δ: 7.16 (1H, d, J = 16.3 Hz), 7.44 (1H, t, J = 7.9 Hz), 7.59 (1H, d, J = 16.3 Hz), 7.67 (1H, dd, J = 1.6, 7.9 Hz), 7.83 (1H, s), 7.90 (1H, dd, J = 1.4, 7.9 Hz), 7.96 (2H, s).	Ref. Ex. 77
946		1H-NMR (CDCl3) δ: 7.15 (1H, d, J = 16.2 Hz), 7.45 (1H, t, J = 7.7 Hz), 7.79 (1H, d, J = 16.2 Hz), 7.82 (1H, s), 7.90-7.94 (2H, m), 7.97 (2H, s), 10.59 (1H, s).	Ref. Ex. 93
947		1H-NMR (CDCl3) δ: 6.57 (1H, d, J = 3.7 Hz), 6.90-7.04 (2H, m), 7.19-7.38 (5H, m), 9.62 (1H, s).	Ref. Ex. 112
948		1H-NMR (CDCl3) δ: 3.95 (3H, s), 6.56 (1H, d, J = 3.7 Hz), 6.80-6.97 (3H, m), 6.97-7.30 (2H, m), 9.61 (1H, s).	Ref. Ex. 825
949		1H-NMR (CDCl3) δ: 3.99 (3H, s), 7.05 (1H, d, J = 8.7 Hz), 7.10 (1H, d, J = 16.4 Hz), 7.20 (1H, d, J = 16.4 Hz), 7.71-7.74 (2H, m), 7.80 (2H, s), 8.04 (1H, d, J = 2.4 Hz), 10.50 (1H, s).	Ref. Ex. 82
950		1H-NMR (CDCl3) δ: 1.53 (3H, t, J = 7.0 Hz), 7.20 (2H, q, J = 7.0 Hz), 7.02 (1H, d, J = 8.7 Hz), 7.09 (1H, d, J = 16.3 Hz), 7.20 (1H, d, J = 16.3 Hz), 7.65-7.73 (2H, m), 7.89 (2H, s), 8.04 (1H, d, J = 2.4 Hz), 10.53 (1H, s).	Ref. Ex. 82
951		1H-NMR (CDCl3) δ: 5.25 (2H, s), 7.08-7.12 (2H, m), 7.20 (1H, d, J = 16.4 Hz), 7.42-7.47 (5H, m), 7.69-7.74 (2H, m), 7.90 (2H, s), 8.07 (1H, d, J = 2.4 Hz), 10.57 (1H, s).	Ref. Ex. 82
952		1H-NMR (CDCl3) δ: 3.85 (3H, s), 6.55-6.58 (1H, m), 6.84-6.87 (2H, m), 7.13 (2H, s), 7.55 (1H, t, J = 7.7 Hz), 7.74-7.80 (2H, m), 8.02 (1H, s), 10.06 (1H, s).	Ref. Ex. 825
953		1H-NMR CDCl3) δ: 7.24 (2H, d, J = 16.2 Hz), 7.30 (2H, d, J = 16.2 Hz), 7.49-7.59 (4H, m), 7.72 (2H, d, J = 7.0 Hz), 7.81 (2H, s), 7.90 (1H, t, J = 1.6 Hz), 7.97 (2H, d, J = 1.6 Hz), 10.10 (1H, s).	Ref. Ex. 75
954		1H-NMR (CDCl3) δ: 6.97 (1H, d, J = 16.1 Hz), 7.03 (1H, dd, J = 3.5, 5.1 Hz), 7.12 (1H, d, J = 3.5 Hz), 7.22-7.25 (1H, m), 7.35 (1H, d, J = 16.1 Hz), 7.52 (1H, t, J = 7.8 Hz), 7.73 (1H, dt, J = 1.5, 7.8 Hz), 7.75 (1H, dt, J = 1.5, 7.6 Hz), 7.98 (1H, t, J = 1.7 Hz), 10.04 (1H, s).	Ref. Ex. 190
955		1H-NMR (CDCl3) δ: 6.42 (1H, d, J = 3.3 Hz), 6.45 (1H, dd, J = 1.8, 3.3 Hz), 7.00 (1H, d, J = 16.3 Hz), 7.08 (1H, d, J = 16.3 Hz), 7.44 (1H, d, J = 1.8 Hz), 7.51 (1H, t, J = 7.5 Hz), 7.69-7.77 (2H, m), 7.98 (1H, t, J = 1.7 Hz), 10.04 (1H, s).	Ref. Ex. 190
956		1H-NMR (CDCl3) δ: 7.21 (1H, d, J = 16.1 Hz), 7.51-7.58 (4H, m), 7.78-7.87 (5H, m), 8.00 (1H, d, J = 16.1 Hz), 8.12 (1H, s), 8.19-8.25 (1H, m), 10.09 (1H, s).	Ref. Ex. 825
957		1H-NMR (CDCl3) δ: 3.85 (3H, s), 6.55-6.59 (1H, m), 6.84-6.88 (2H, m), 7.13 (2H, s), 7.55 (1H, t, J = 7.7 Hz), 7.74-7.80 (2H, m), 8.03 (1H, s), 10.06 (1H, s).	Ref. Ex. 825








[0511]








Ref. Ex. No.	STR	1H-NMR	ref.
958		1H-NMR (CDCl3) δ: 7.59-7.68 (4H, m), 7.81-7.89 (4H, m), 9.91 (1H, s).	Ref. Ex. 112
959		1H-NMR (CDCl3) δ: 2.50 (3H, s), 7.18-7.31 (3H, m), 7.52-7.59 (2H, m), 7.75-7.81 (3H, m), 8.03 (1H, s), 10.06 (1H, s).	Ref. Ex. 825
960		1H-NMR (CDCl3) δ: 1.56 (3H, t, J = 7.0 Hz), 4.26 (2H, q, J = 7.0 Hz), 7.04 (1H, d, J = 8.5 Hz), 7.29 (1H, d, J = 16.5 Hz), 7.56 (1H, d, J = 16.5 Hz), 7.76 (1H, s), 7.82 (1H, dd, J = 2.2, 8.6 Hz), 7.93 (2H, s), 8.12 (1H, d, J = 2.0 Hz), 9.94 (1H, s).	Ref. Ex. 82
961		1H-NMR (CDCl3) δ: 5.04 (2H, s), 7.16 (1H, d, J = 16.5 Hz), 7.30 (1H, t, J = 7.7 Hz), 7.36-7.44 (6H, m), 7.49 (1H, d, J = 7.7 Hz), 7.54 (1H, d, J = 7.7 Hz), 7.59 (1H, d, J = 7.7 Hz), 7.69 (1H, s), 7.81 (1H, dd, J = 1.7, 7.7 Hz), 7.90 (1H, d, J = 1.5, 7.7 Hz), 10.33 (1H, s).	Ref. Ex. 82
962		1H-NMR (CDCl3) δ: 2.51 (3H, s), 7.09 (1H, d, J = 16.5 Hz), 7.20 (1H, d, J = 16.5 Hz), 7.26-7.33 (1H, m), 7.57 (1H, d, J = 7.5 Hz), 7.74-7.75 (3H, m), 7.89 (1H, s), 10.00 (1H, s).	Ref. Ex. 825
963		1H-NMR (CDCl3) δ: 6.79-6.88 (3H, m), 7.18 (1H, d, J = 16.1 Hz), 7.52 (1H, t, J = 7.6 Hz), 7.66-7.69 (1H, m), 7.74-7.78 (1H, m), 7.96 (1H, s), 10.04 (1H, s).	Ref. Ex. 825
964		1H-NMR (CDCl3) δ: 6.99-7.04 (1H, m), 7.10 (1H, d, J = 16.3 Hz), 7.17 (1H, d, J = 16.3 Hz), 7.22-7.25 (1H, m), 7.28-7.30 (1H, m), 7.33-7.39 (1H, m), 7.44-7.49 (2H, m), 7.81 (1H, s), 10.02 (1H, d, J = 1.7 Hz).	Ref. Ex. 91








Ref. Ex. No.	STR	1H-NMR	ref.
965		1H-NMR (CDCl3) δ: 7.17 (1H, s), 7.28-7.38 (2H, m), 7.54-7.65 (2H, m), 7.81 (1H, s), 8.09 (1H, s), 8.23 (1H, s), 10.05 (1H, s).	Ref. Ex. 75
966		1H-NMR (CDCl3) δ: 7.00 (1H, d, J = 16.3 Hz), 7.08-7.12 (2H, m), 7.17 (1H, d, J = 16.3 Hz), 7.43-7.46 (2H, m), 7.48-7.53 (2H, m), 7.80 (1H, s), 10.02 (1H, d, J = 1.7 Hz).	Ref. Ex. 75
967		1H-NMR (CDCl3) δ: 7.17 (1H, d, J = 15.9 Hz), 7.58-7.60 (2H, m), 7.69 (1H, d, J = 7.9 Hz), 7.72 (1H, d, J = 8.4 Hz), 7.85 (1H, d, J = 2.3 Hz), 7.89 (1H, t, J = 7.9 Hz), 8.48 (1H, d, J = 15.9 Hz), 10.32 (1H, s).	Ref. Ex. 825
968		1H-NMR (CDCl3) δ: 7.28 (1H, d, J = 16.2 Hz), 7.55-7.59 (2H, m), 7.72-7.90 (4H, m), 7.97 (1H, s), 10.00 (1H, s).	Ref. Ex. 825
969		1H-NMR (CDCl3) δ: 1.55 (3H, t, J = 7.0 Hz), 4.23 (2H, q, J = 7.0 Hz), 7.02 (1H, d, J = 8.5 Hz), 7.26 (1H, d, J = 16.5 Hz), 7.47-7.54 (3H, m), 7.71 (1H, d, J = 7.3 Hz), 7.77-7.81 (2H, m), 8.13 (1H, d, J = 2.1 Hz), 9.93 (1H, s).	Ref. Ex. 82
970		1H-NMR (CDCl3) δ: 6.81 (1H, d, J = 3.9 Hz), 7.33 (1H, d, J = 3.9 Hz), 7.32-7.43 (2H, m), 7.79-7.86 (3H, m), 9.68 (1H, s).	Ref. Ex. 75
971		1H-NMR (CDCl3) δ: 3.61 (3H, s), 7.60 (1H, t, J = 7.7 Hz), 7.69 (1H, d, J = 7.8 Hz), 7.76-7.85 (3H, m), 7.96 (1H, d, J = 2.0 Hz), 9.97 (1H, s).	Ref. Ex. 112
972		1H-NMR (CDCl3) δ: 7.28-7.61 (5H, m), 7.74 (1H, s), 7.82 (1H, d, J = 8.1 Hz), 9.89 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
973		1H-NMR (CDCl3) δ: 7.41 (1H, d, J = 15.9 Hz), 7.50 (1H, d, J = 5.1 Hz), 7.72 (2H, s), 8.07-8.15 (2H, m), 9.00 (1H, d, J = 5.1 Hz), 10.06 (1H, s).	Ref. Ex. 825
974		1H-NMR (CDCl3) δ: 7.30-7.62 (4H, m), 7.74-7.96 (6H, m), 10.06 (1H, s).	Ref. Ex. 75
975		1H-NMR (CDCl3) δ: 7.20-7.23 (1H, m), 7.34-7.39 (1H, m), 7.53-7.64 (2H, m), 7.72-7.78 (2H, m), 7.86-7.87 (1H, m), 7.93-7.95 (1H, m), 8.21 (1H, d, J = 7.7 Hz), 10.06 (1H, s).	Ref. Ex. 75
976		1H-NMR (CDCl3) δ: 2.55-2.59 (2H, m), 2.87-2.92 (2H, m), 6.81 (1H, d, J = 7.5 Hz), 6.98 (1H, d, J = 7.5 Hz), 7.56-7.57 (1H, m), 7.68-7.72 (2H, m), 7.87-7.88 (1H, m), 10.03 (1H, s).	Ref. Ex. 75
977		1H-NMR (CDCl3) δ: 7.35-7.76 (4H, m), 7.89-8.09 (3H, m), 8.56 (1H, d, J = 6.0 Hz), 9.36 (1H, s), 10.07 (1H, s).	Ref. Ex. 75
978		1H-NMR (CDCl3) δ: 7.29-7.41 (2H, m), 7.58-7.70 (3H, m), 7.89-8.03 (2H, m), 8.11-8.14 (1H, m), 10.16 (1H, s).	Ref. Ex. 75
979		1H-NMR (CDCl3) δ: 7.01-7.07 (2H, m), 7.14 (1H, d, J = 16.7 Hz), 7.48-7.51 (2H, m), 7.65-7.70 (2H, m), 7.73-7.76 (2H, m), 9.95 (1H, s), 11.06 (1H, s).	Ref. Ex. 77


[0512]

Ref. Ex. No.	STR	1H-NMR	ref.
980		1H-NMR (CDCl3) δ: 1.51 (3H, t, J = 7.0 Hz), 4.21 (2H, q, J = 7.0 Hz), 7.01 (1H, d, J = 8.5 Hz), 7.07 (1H, d, J = 16.4 Hz), 7.12 (1H, d, J = 16.4 Hz), 7.44-7.52 (2H, m), 7.64-7.71 (2H, m), 7.73 (1H, s), 8.01 (1H, d, J = 2.4 Hz), 10.52 (1H, s).	Ref. Ex. 82
981		1H-NMR (CDCl3) δ: 7.62-7.97 (5H, m), 8.00-8.19 (2H, m), 8.37 (1H, s), 9.18 (1H, s), 10.10 (1H, s)	Ref. Ex. 75
982		1H-NMR (CDCl3) δ: 1.49 (9H, s), 6.59 (1H, brs), 7.59-7.76 (5H, m), 7.90 (1H, dd, J = 2.0, 8.6 Hz), 8.41 (1H, d, J = 8.6 Hz), 9.95 (1H, s).	Ref. Ex. 75
983		1H-NMR (CDCl3) δ: 7.08 (1H, d, J = 3.6 Hz), 7.40 (1H, d, J = 3.6 Hz), 7.60-7.65 (1H, m), 7.75-7.80 (1H, m), 7.92 (1H, d, J = 8.1 Hz), 8.14 (1H, d, J = 8.1 Hz), 8.64 (1H, s), 9.29 (1H, s), 9.73 (1H, s).	Ref. Ex. 75
984		1H-NMR (CDCl3) δ: 7.52-7.58 (2H, m), 7.72-7.75 (1H, m), 7.85-8.12 (7H, m), 10.08 (1H, s).	Ref. Ex. 75
985		1H-NMR (CDCl3) δ: 1.03 (6H, s), 3.81 (4H, s), 7.57-7.59 (2H, m), 7.95-7.98 (1H, m), 8.24 (1H, s), 9.87 (1H, s).	Ref. Ex. 107
986		1H-NMR (CDCl3) δ: 7.35 (1H, d, J = 8.2 Hz), 7.50 (1H, d, J = 9.4 Hz), 7.63 (1H, s), 7.66 (1H, s), 7.72-7.74 (2H, m), 7.95 (1H, s), 9.93 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
987		1H-NMR (CDCl3) δ: 7.54 (1H, d, J = 5.1 Hz), 7.68 (1H, s), 7.73 (1H, d, J = 8.7 Hz), 8.73-8.76 (1H, m), 8.98 (1H, s), 9.07 (1H, d, J = 5.1 Hz), 9.93 (1H, s).	Ref. Ex. 75
988		1H-NMR (CDCl3) δ: 1.25 (9H, s), 7.58 (1H, d, J = 8.5 Hz), 7.75 (4H, s), 7.87-7.90 (2H, m), 8.96 (1H, s).	Ex. 1
989		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.1 Hz), 4.46 (2H, q, J = 7.1 Hz), 7.31 (1H, t, J = 9.2 Hz), 8.18-8.27 (3H, m).	Ref. Ex. 14
990		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.1 Hz), 4.47 (2H, q, J = 7.1 Hz), 7.70 (1H, s), 8.13 (1H, s), 8.21 (1H, s), 8.25 (1H, s).	Ref. Ex. 14
991		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.1 Hz), 3.94 (3H, s), 4.46 (2H, q, J = 7.1 Hz), 7.21-7.24 (1H, m), 7.73-7.74 (1H, m), 7.79-7.81 (1H, m), 8.21 (1H, s).	Ref. Ex. 14
992		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.1 Hz), 3.98 (3H, s), 4.45 (2H, q, J = 7.1 Hz), 7.08 (1H, d, J = 9.4 Hz), 8.14 (1H, s), 8.16-8.19 (2H, m).	Ref. Ex. 14
993		1H-NMR (CDCl3) δ: 7.34 (1H, t, J = 9.2 Hz), 8.17-8.20 (1H, m), 8.22 (1H, s), 8.27 (1H, dd, J = 2.1, 6.5 Hz), 10.11 (1H, s).	Ref. Ex. 63
994		1H-NMR (CDCl3) δ: 7.21 (1H, s), 7.28-7.39 (1H, m), 7.51-7.72 (4H, m), 7.94 (1H, s), 8.29 (1H, s), 10.09 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
995		1H-NMR (CDCl3) δ: 7.00 (1H, d, J = 16.2 Hz), 7.19 (1H, d, J = 16.2 Hz), 7.31-7.39 (3H, m), 7.52 (1H, t, J = 7.8 Hz), 7.70-7.77 (2H, m), 7.99 (1H, s), 10.05 (1H, s).	Ref. Ex. 190
996		1H-NMR (CDCl3) δ: 2.37 (3H, s), 6.02-6.05 (1H, m), 6.30 (1H, d, J = 3.2 Hz), 6.91 (1H, d, J = 16.2 Hz), 6.99 (1H, d, J = 16.2 Hz), 7.50 (1H, t, J = 7.7 Hz), 7.66-7.74 (2H, m), 7.95 (1H, t, J = 1.7 Hz), 10.03 (1H, s).	Ref. Ex. 190
997		1H-NMR (CDCl3) δ: 6.75 (1H, s), 7.12 (1H, d, J = 16.1 Hz), 7.22 (1H, dt, J = 1.1, 7.5 Hz), 7.31 (1H, dt, J = 1.4, 8.1 Hz), 7.35 (1H, d, J = 16.1 Hz), 7.47-7.58 (3H, m), 7.76-7.81 (2H, m), 8.05 (1H, t, J = 1.7 Hz), 10.06 (1H, s).	Ref. Ex. 190
998		1H-NMR (CDCl3) δ: 7.03 (1H, d, J = 16.0 Hz), 7.31-7.37 (3H, m), 7.43 (1H, dd, J = 0.6, 16.0 Hz), 7.55 (1H, t, J = 7.7 Hz), 7.71-7.82 (4H, m), 8.03 (1H, t, J = 1.7 Hz), 10.06 (1H, s).	Ref. Ex. 190
999		1H-NMR (CDCl3) δ: 7.24 (1H, d, J = 16.2 Hz), 7.38-7.53 (3H, m), 7.57 (1H, t, J = 7.6 Hz), 7.63 (1H, s), 7.78-7.83 (2H, m), 7.88-7.92 (1H, m), 8.02-8.06 (1H, m), 8.08 (1H, t, J = 1.7 Hz), 10.08 (1H, s).	Ref. Ex. 190
1000		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.0 Hz), 4.09 (2H, q, J = 7.0 Hz), 6.85 (1H, ddd, J = 0.9, 2.5, 8.2 Hz), 7.06-7.22 (4H, m), 7.26-7.32 (1H, m), 7.53 (1H, t, J = 7.7 Hz), 7.73-7.89 (2H, m), 8.21 (1H, t, J = 1.7 Hz), 10.06 (1H, s).	Ref. Ex. 188
1001		1H-NMR (CDCl3) δ: 3.83 (3H, s), 7.13 (1H, d, J = 16.4 Hz), 7.12-7.38 (4H, m), 7.41 (1H, d, J = 16.4 Hz), 7.51 (1H, t, J = 7.7 Hz), 7.70 (1H, dt, J = 1.4, 7.7 Hz), 7.73-7.77 (1H, m), 7.89-8.03 (2H, m), 10.06 (1H, s).	Ref. Ex. 188







[0513]








Ref. Ex. No.	STR	1H-NMR	ref.
1002		1H-NMR (CDCl3) δ: 3.92 (3H, s), 6.97 (1H, t, J = 8.5 Hz), 7.00 (1H, d, J = 16.3 Hz), 7.11 (1H, d, J = 16.3 Hz), 7.19-7.25 (1H, m), 7.31 (1H, dd, J = 2.1, 12.5 Hz), 7.53 (1H, t, J = 7.6 Hz), 7.70-7.79 (2H, m), 8.01 (1H, m), 10.05 (1H, s).	Ref. Ex. 190
1003		1H-NMR (CDCl3) δ: 1.06 (3H, t, J = 7.4 Hz), 1.77-1.91 (2H, m), 3.97 (2H, t, J = 6.6 Hz), 6.82-6.87 (1H, m), 7.06-7.13 (2H, m), 7.13 (1H, d, J = 16.4 Hz), 7.18 (1H, d, J = 16.4 Hz), 7.29 (1H, t, J = 7.8 Hz), 7.53 (1H, t, J = 7.8 Hz), 7.72-7.79 (2H, m), 8.02 (1H, s), 10.05 (1H, s).	Ref. Ex. 100, Ref. Ex. 188
1004		1H-NMR (CDCl3) δ: 6.81 (1H, dd, J = 0.8, 3.2 Hz), 7.57 (1H, d, J = 3.2 Hz), 7.68-7.84 (6H, m), 8.01 (1H, s), 10.05 (1H, s).	Ref. Ex. 154
1005		1H-NMR (CDCl3) δ: 6.85 (1H, dd, J = 0.8, 3.4 Hz), 7.23-7.29 (1H, m), 7.31-7.41 (3H, m), 7.53 (1H, d, J = 8.6 Hz), 7.82 (1H, dd, J = 1.5, 8.6 Hz), 8.21-8.23 (1H, m), 10.07 (1H, s).	Ref. Ex. 154
1006		1H-NMR (CDCl3) δ: 6.89 (1H, dd, J = 0.7, 3.3 Hz), 7.44 (1H, d, J = 3.3 Hz), 7.58 (1H, d, J = 8.7 Hz), 7.67-7.74 (3H, m), 7.77 (1H, s), 7.84 (1H, dd, J = 1.6, 8.7 Hz), 8.22-8.25 (1H, m), 10.08 (1H, s).	Ref. Ex. 154
1007		1H-NMR (CDCl3) δ: 4.01 (3H, s), 7.19-7.26 (1H, m), 7.28-7.41 (5H, m), 7.66 (1H, d, J = 8.2 Hz), 7.97 (1H, dd, J = 0.9, 7.5 Hz).	Ref. Ex. 154







Ref. Ex. No.	STR	1H-NMR	ref.
1008		1H-NMR (CDCl3) δ: 4.02 (3H, s), 7.30 (1H, t, J = 7.9 Hz), 7.39 (1H, dd, J = 0.8, 3.3 Hz), 7.47 (1H, d, J = 3.3 Hz), 7.63-7.73 (4H, m), 7.75-7.78 (1H, m), 7.99 (1H, dd, J = 0.9, 7.5 Hz).	Ref. Ex. 154
1009		1H-NMR (CDCl3) δ: 5.37 (2H, s), 6.66 (1H, dd, J = 0.9, 3.3 Hz), 6.81-6.92 (2H, m), 7.06-7.16 (1H, m), 7.34 (1H, d, J = 3.2 Hz), 7.66 (1H, dd, J = 1.3, 8.2 Hz), 7.76 (1H, d, J = 8.2 Hz), 7.81 (1H, s), 10.02 (1H, s).	Ref. Ex. 184
1010		1H-NMR (CDCl3): δ 5.47 (2H, s), 6.67 (1H, dd, J = 0.8, 3.2 Hz), 7.20 (1H, d, J = 7.6 Hz), 7.35 (1H, d, J = 3.2 Hz), 7.40-7.50 (2H, m), 7.56 (1H, d, J = 7.8 Hz), 7.67 (1H, dd, J = 1.3, 8.2 Hz), 7.77 (1H, d, J = 8.2 Hz), 7.82 (1H, s), 10.02 (1H, s).	Ref. Ex. 184
1011		1H-NMR (CDCl3) δ: 6.77 (1H, d, J = 0.8, 3.2 Hz), 7.43-7.49 (2H, m), 7.51 (1H, d, J = 3.2 Hz), 7.52-7.57 (2H, m), 7.71 (1H, dd, J = 1.3, 8.2 Hz), 7.79 (1H, d, J = 8.2 Hz), 8.01 (1H, s), 10.04 (1H, s).	Ref. Ex. 154
1012		1H-NMR (CDCl3) δ: 3.90 (3H, s), 6.73 (1H, dd, J = 0.8, 3.2 Hz), 7.04-7.10 (2H, m), 7.38-7.44 (2H, m), 7.49 (1H, d, J = 3.2 Hz), 7.69 (1H, dd, J = 1.3, 8.2 Hz), 7.77 (1H, d, J = 8.2 Hz), 7.95 (1H, s), 10.01 (1H, s).	Ref. Ex. 154
1013		1H-NMR (CDCl3) δ: 6.10 (2H, s), 6.72 (1H, dd, J = 0.8, 3.2 Hz), 6.94-6.98 (3H, m), 7.48 (1H, d, J = 3.2 Hz), 7.69 (1H, dd, J = 1.3, 8.2 Hz), 7.77 (1H, d, J = 8.2 Hz), 7.98 (1H, s), 10.03 (1H, s).	Ref. Ex. 154

Ref. Ex. No.	STR	1H-NMR	ref.
1015		1H-NMR (CDCl3) δ: 3.87 (1H, d, J = 1.7 Hz), 3.95 (1H, d, J = 1.7 Hz), 7.32-7.42 (5H, m), 7.52 (2H, d, J = 8.2 Hz), 7.90 (2H, d, J = 8.2 Hz), 10.03 (1H, s).	Ex. 952
1016		1H-NMR (CDCl3) δ: 6.79 (1H, dd, J = 0.8, 3.3 Hz), 6.82-6.93 (1H, m), 7.05-7.13 (2H, m), 7.52 (1H, d, J = 3.3 Hz), 7.74 (1H, dd, J = 1.3, 8.2 Hz), 7.79 (1H, d, J = 8.2 Hz), 8.10 (1H, s), 10.07 (1H, s).	Ref. Ex. 154
1017		1H-NMR (CDCl3) δ: 3.52 (2H, t, J = 8.6 Hz), 4.00 (2H, t, J = 8.6 Hz), 6.89-6.96 (1H, m), 7.01-7.09 (1H, ddd, J = 2.7, 6.8, 12.3 Hz), 7.10-7.31 (4H, m), 10.09 (1H, s.).	Ref. Ex. 76, Ref. Ex. 48
1018		1H-NMR (CDCl3) δ: 7.21-7.28 (1H, m), 7.30-7.43 (3H, m), 7.45 (1H, d, J = 3.2 Hz), 7.50-7.52 (1H, m), 7.69-7.75 (2H, m), 10.29 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1019		1H-NMR (CDCl3) δ: 5.66 (2H, bns), 6.95 (1H, d, J = 8.5 Hz), 7.58 (1H, d, J = 2.2 Hz), 7.63 (1H, dd, J = 2.2, 8.4 Hz), 7.70-7.80 (4H, m).	Ex. 688
1020		1H-NMR (CDCl3) δ: 7.73 (1H, s), 8.13-8.14 (1H, m), 8.19-8.20 (1H, m), 8.26 (1H, s), 10.12 (1H, s).	Ref. Ex. 63
1021		1H-NMR (CDCl3) δ: 3.95 (3H, s), 7.23-7.28 (1H, m), 7.73 (1H, s), 7.80 (1H, s), 8.23 (1H, s), 10.12 (1H, s).	Ref. Ex. 63







[0514]







Ref. Ex. No.	STR	1H-NMR	ref.
1022		1H-NMR (CDCl3) δ: 3.99 (3H, s), 7.11 (1H, d, J = 8.6 Hz), 8.14-8.21 (3H, m), 10.09 (1H, s).	Ref. Ex. 63
1023		1H-NMR (CDCl3) δ: 1.06 (6H, s), 3.82 (4H, s), 7.15 (1H, t, J = 8.7 Hz), 7.93-7.98 (1H, m), 8.27-8.30 (1H, m), 9.98 (1H, s).	Ref. Ex. 107
1024		1H-NMR (CDCl3) δ: 7.37-7.43 (1H, m), 7.65 (1H, d, J = 5.0 Hz), 8.06-8.11 (1H, m), 8.72-8.75 (1H, m), 9.17 (1H, d, J = 5.0 Hz), 10.08 (1H, s).	Ref. Ex. 112
1025		1H-NMR (CDCl3) δ: 6.93-6.96 (1H, m), 7.13-7.16 (1H, m), 7.20-7.31 (1H, m), 7.61 (1H, s), 7.67 (2H, s), 7.85-7.86 (1H, m), 9.91 (1H, s).	Ref. Ex. 75
1026		1H-NMR (CDCl3) δ: 3.53 (2H, t, J = 8.5 Hz), 3.91 (3H, s), 4.03 (2H, t, J = 8.5 Hz), 7.13-7.31 (3H, m), 7.36-7.48 (4H, m).	Ref. Ex. 1014
1027		1H-NMR (CDCl3) δ: 3.55 (2H, t, J = 8.6 Hz), 4.09 (2H, t, J = 8.6 Hz), 7.22-7.36 (4H, m), 7.37-7.50 (3H, m), 1010 (1H, s).	Ref. Ex. 76 Ref. Ex. 48








Ref. Ex. No.	STR	1H-NMR	ref.
1028		1H-NMR (CDCl3) δ: 7.21-7.26 (1H, m), 7.50-7.61 (4H, m), 7.72-7.81 (3H, m), 8.20 (1H, d, J = 2.2 Hz), 10.04 (1H, s).	Ref. Ex. 77
1029		1H-NMR (CDCl3) δ: 3.05 (2H, t, J = 8.4 Hz), 3.42 (2H, t, J = 8.4 Hz), 3.88 (3H, s), 4.30 (2H, s), 6.96 (1H, dt, J = 6.4, 9.6 Hz), 7.10 (1H, d, J = 1.2 Hz), 7.11-7.24 (2H, m), 7.43 (1H, dd, J = 1.4, 7.5 Hz).	Ref. Ex. 113
1030		1H-NMR (CDCl3) δ: 3.04 (2H, t, J = 8.4 Hz), 3.36 (2H, t, J = 8.4 Hz), 3.87 (3H, s), 4.35 (2H, s), 7.11-7.18 (3H, m), 7.39-7.50 (2H, m), 7.52-7.58 (1H, m), 7.62 (1H, s).	Ref. Ex. 113
1031		1H-NMR (CDCl3) δ: 7.40 (1H, dd, J = 7.4, 8.2 Hz), 7.54 (2H, s), 7.67-7.78 (6H, m), 10.30 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1032		1H-NMR (CDCl3) δ: 5.38 (2H, s), 6.56-6.68 (1H, m), 6.99 (1H, dt, J = 6.4, 9.6 Hz), 7.32-7.41 (3H, m), 7.55 (1H, d, J = 8.2 Hz), 7.66 (1H, d, J = 7.3 Hz), 10.26 (1H, s).	Ref. Ex. 184
1033		1H-NMR (CDCl3) δ: 3.09 (2H, t, J = 8.4 Hz), 3.47 (2H, t, J = 8.4 Hz), 4.32 (2H, s), 6.93 (1H, s), 6.96 (1H, dt, J = 6.4, 9.5 Hz), 7.14-7.26 (3H, m), 9.87 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1034		1H-NMR (CDCl3) δ: 3.08 (2H, t, J = 8.4 Hz), 3.41 (2H, t, J = 8.4 Hz), 4.37 (2H, s), 6.96 (1H, s), 7.17-7.26 (2H, m), 7.47 (1H, t, J = 7.3 Hz), 7.51-7.58 (2H, m), 7.60 (1H, s), 9.87 (1H, s).	Ref. Ex. 76 Ref. Ex. 48

Ref. Ex. No.	STR	1H-NMR	ref.
1035		1H-NMR (CDCl3) δ: 1.37 (12H, s), 7.63-7.70 (1H, m), 7.73-7.77 (1H, m), 8.09 (1H, s), 10.02 (1H, d, J = 2.2 Hz).	Ref. Ex. 81
1036		1H-NMR (CDCl3) δ: 3.93 (3H, s), 5.37 (2H, s), 6.54-6.64 (2H, m), 6.99 (1H, dt, J = 6.4, 9.6 Hz), 7.28 (1H, d, J = 3.1 Hz), 7.67 (1H, dd, J = 0.5, 8.4 Hz), 7.83 (1H, dd, J = 1.4, 8.4 Hz), 8.06 (1H, s)	Ref. Ex. 184
1037		1H-NMR (CDCl3) δ: 7.35-7.42 (2H, m), 7.68 (2H, s), 7.78 (1H, s), 7.81-7.89 (2H, m), 8.13 (1H, s), 10.08 (1H, s).	Ref. Ex. 91
1038		1H-NMR (CDCl3) δ: 7.35-7.41 (2H, m), 7.80-8.02 (6H, m), 10.15 (1H, s).	Ref. Ex. 91
1039		1H-NMR (CDCl3) δ: 4.12 (2H, s), 7.21 (1H, d, J = 8.8 Hz), 7.39-7.53 (4H, m), 7.70-7.83 (2H, m), 9.92 (1H, s).	Ref. Ex. 91
1040		1H-NMR (CDCl3) δ: 4.09 (2H, s), 7.34-7.61 (6H, m), 7.72-7.74 (1H, m), 9.94 (1H, s).	Ref. Ex. 183







[0515]







Ref. Ex. No.	STR	1H-NMR	ref.
1041		1H-NMR (CDCl3) δ: 4.14 (2H, s), 7.27-7.55 (5H, m), 7.61-7.63 (2H, m), 9.97 (1H, s).	Ref. Ex. 183
1042		1H-NMR (CDCl3) δ: 4.15 (2H, s), 7.32-7.57 (6H, m), 9.86 (1H, s).	Ref. Ex. 183
1043		1H-NMR (CDCl3) δ: 7.15 (1H, s), 7.24-7.36 (3H, m), 7.55 (1H, d, J = 8.0 Hz), 7.63 (2H, t, J = 7.6 Hz), 7.87 (1H, d, J = 7.6 Hz), 8.13 (1H, d, J = 8.0 Hz), 10.11 (1H, s).	Ref. Ex. 91
1044		1H-NMR (CDCl3) δ: 7.38 (1H, d, J = 16.2 Hz), 7.49 (1H, d, J = 5.1 Hz), 7.84-7.87 (2H, m), 8.01 (1H, s), 8.10 (1H, d, J = 16.2 Hz), 8.99 (1H, d, J = 4.8 Hz), 10.02 (1H, s).	Ref. Ex. 825
1045		1H-NMR (CDCl3) δ: 1.47 (3H, t, J = 6.9 Hz), 4.14 (2H, q, J = 6.9 Hz), 7.34-7.42 (3H, m), 7.46 (1H, d, J = 5.1 Hz), 7.72 (1H, s), 8.11 (1H, d, J = 15.9 Hz), 8.98 (1H, d, J = 4.8 Hz), 10.01 (1H, s).	Ref. Ex. 825
1046		1H-NMR (CDCl3) δ: 4.02 (3H, s), 7.15-7.24 (1H, m), 7.26-7.41 (4H, m), 7.55 (1H, dd, J = 0.9, 8.4 Hz), 7.61 (1H, dd, J = 0.9, 7.3 Hz).	Ex. 108







Ref. Ex. No.	STR	1H-NMR	ref.
1047		1H-NMR (CDCl3) δ: 7.19-7.26 (1H, m), 7.29-7.43 (3H, m), 7.45 (1H, s), 7.53-7.68 (1H, m), 7.95-8.00 (1H, m), 11.27 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1048		1H-NMR (CDCl3) δ: 3.91 (3H, s), 6.72 (1H, dd, J = 0.8, 3.2 Hz), 7.21-7.28 (2H, m), 7.41-7.50 (3H, m), 7.70 (1H, dd, J = 0.5, 8.4 Hz), 7.86 (1H, dd, J = 1.4, 8.4 Hz), 8.16 (1H, s).	Ref. Ex. 154
1049		1H-NMR (CDCl3) δ: 3.92 (3H, s), 6.77 (1H, dd, J = 0.8, 3.3 Hz), 7.49 (1H, d, J = 3.3 Hz), 7.67-7.77 (5H, m), 7.90 (1H, dd, J = 1.4, 8.3 Hz), 8.32 (1H, dd, J = 0.6, 1.4 Hz).	Ref. Ex. 154
1050		1H-NMR (CDCl3) δ: 3.17 (2H, t, J = 8.4 Hz), 3.87 (3H, s), 3.95 (2H, t, J = 8.4 Hz), 7.04-7.12 (2H, m), 7.15-7.24 (3H, m), 7.46 (1H, dd, J = 1.4, 7.6 Hz), 7.54 (1H, d, J = 1.1 Hz).	Ref. Ex. 1014
1051		1H-NMR (CDCl3) δ: 3.21 (2H, t, J = 8.4 Hz), 3.89 (3H, s), 4.04 (2H, t, J = 8.4 Hz), 7.20-7.25 (2H, m), 7.38 (1H, s), 7.44-7.55 (3H, m), 7.74 (1H, d, J = 1.3 Hz).	Ref. Ex. 1014
1052		1H-NMR (CDCl3) δ: 3.20 (2H, t, J = 8.4 Hz), 3.98 (2H, t, J = 8.4 Hz), 7.04-7.13 (2H, m), 7.20-7.30 (4H, m), 7.37-7.39 (1H, m), 9.87 (1H, s).	Ref. Ex. 76 Ref. Ex. 48

Ref. Ex. No.	STR	1H-NMR	ref.
1053		1H-NMR (CDCl3) δ: 5.40 (2H, s), 6.58-6.68 (2H, m), 7.01 (1H, dt, J = 6.4, 9.5 Hz), 7.36 (1H, d, J = 3.1 Hz), 7.67 (1H, dd, J = 1.3, 8.2 Hz), 7.76 (1H, d, J = 8.2 Hz), 7.85 (1H, s), 10.05 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1054		1H-NMR (CDCl3) δ: 7.43-7.59 (2H, m), 7.94-7.99 (2H, m), 8.12 (1H, d, J = 8.0 Hz), 8.38-8.39 (1H, m), 8.43-8.46 (1H, m), 10.09 (1H, s).	Ref. Ex. 112
1055		1H-NMR (CDCl3) δ: 7.48-7.51 (1H, m), 7.70 (1H, t, J = 7.5 Hz), 7.93 (1H, d, J = 2.1 Hz), 8.00-8.05 (2H, m), 8.33-8.37 (1H, m), 8.56 (1H, s), 10.14 (1H, s).	Ref. Ex. 112
1056		1H-NMR (CDCl3) δ: 1.39 (9H, s), 6.67 (1H, s), 7.29-7.41 (2H, m), 7.59 (1H, d, J = 8.4 Hz), 7.68 (1H, s), 7.84 (2H, s), 8.22 (1H, d, J = 8.4 Hz), 10.02 (1H, s).	Ref. Ex. 112
1057		1H-NMR (CDCl3) δ: 7.63 (1H, d, J = 5.0 Hz), 7.72-7.94 (1H, m), 8.49-8.52 (1H, m), 8.84-8.85 (1H, m), 9.11 (1H, d, J = 5.0 Hz), 10.13 (1H, d, J = 2.1 Hz).	Ref. Ex. 75
1058		1H-NMR (CDCl3) δ: 4.14 (2H, s), 7.29-7.32 (3H, m), 7.58-7.63 (4H, m), 9.97 (1H, s).	Ref. Ex. 183
1059		1H-NMR (CDCl3) δ: 7.25-7.40 (3H, m), 7.52-7.67 (2H, m), 8.59 (1H, s), 9.03 (1H, s), 9.33 (1H, s), 10.21 (1H, s).	Ref. Ex. 183








[0516]







Ref. Ex. No.	STR	1H-NMR	ref.
1060		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.1 Hz), 4.47 (2H, q, J = 7.1 Hz), 7.64-7.93 (2H, m), 8.06 (1H, s), 8.38 (1H, s).	Ref. Ex. 14
1061		1H-NMR (CDCl3) δ: 7.87 (1H, d, J = 8.1 Hz), 7.95 (1H, d, J = 8.1 Hz), 8.10 (1H, s), 8.38 (1H, s), 10.14 (1H, s).	Ref. Ex. 63
1062		1H-NMR (CDCl3) δ: 4.01 (2H, s), 6.98-7.04 (2H, m), 7.10-7.16 (2H, m), 7.40 (1H, s), 7.56 (1H, s), 7.70 (1H, s), 9.93 (1H, s).	Ref. Ex. 183
1063		1H-NMR (CDCl3) δ: 2.39 (3H, s), 3.98 (2H, s), 6.98-7.02 (2H, m), 7.12-7.16 (2H, m), 7.25 (1H, s), 7.49 (1H, s), 7.54 (1H, s), 9.94 (1H, s).	Ref. Ex. 183
1064		1H-NMR (CDCl3) δ: 2.40 (3H, s), 4.07 (2H, s), 7.25-7.32 (3H, m), 7.49-7.58 (4H, m), 9.95 (1H, s).	Ref. Ex. 183
1065		1H-NMR (CDCl3) δ: 2.41 (3H, s), 4.07 (2H, s), 7.34-7.50 (6H, m), 7.56 (1H, s), 9.95 (1H, s).	Ref. Ex. 183







Ref. Ex. No.	STR	1H-NMR	ref.
1066		1H-NMR (CDCl3) δ: 4.09 (2H, s), 7.28-7.32 (2H, m), 7.42 (1H, s), 7.56-7.61 (3H, m), 7.73 (1H, s), 9.94 (1H, s).	Ref. Ex. 183
1067		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.1 Hz), 4.47 (2H, q, J = 7.1 Hz), 7.74-7.77 (2H, m), 8.12-8.15 (2H, m), 8.25 (1H, s).	Ref. Ex. 14
1068		1H-NMR (CDCl3) δ: 3.24 (2H, t, J = 8.4 Hz), 4.07 (2H, t, J = 8.4 Hz), 7.24-7.39 (4H, m), 7.45-7.58 (3H, m), 9.90 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1069		1H-NMR (CDCl3) δ: 3.92 (3H, s), 6.76 (1H, dd, J = 0.8, 3.3 Hz), 7.09-7.18 (1H, m), 7.22-7.35 (2H, m), 7.41 (1H, dd, J = 2.0, 3.3 Hz), 7.71 (1H, d, J = 8.3 Hz), 7.89 (1H, dd, J = 1.4, 8.3 Hz), 8.05 (1H, s).	Ref. Ex. 154
1070		1H-NMR (CDCl3) δ: 6.78 (1H, dd, J = 0.8, 3.2 Hz), 7.15 (1H, dt, J = 0.9, 8.3 Hz), 7.22-7.28 (1H, m), 7.34 (1H, ddd, J = 0.9, 2.0, 8.0 Hz), 7.50-7.58 (2H, m), 7.72 (1H, dd, J = 1.3, 8.2 Hz), 7.79 (1H, d, J = 8.2 Hz), 8.07 (1H, s), 10.05 (1H, s).	Ref. Ex. 154
1071		1H-NMR (CDCl3) δ: 6.82 (1H, dd, J = 0.8, 3.3 Hz), 7.57 (1H, d, J = 3.3 Hz), 7.66 (2H, J = 8.4 Hz), 7.74 (1H, dd, J = 1.3, 8.2 Hz), 7.81 (1H, d, J = 8.2 Hz), 7.85 (2H, d, J = 8.4 Hz), 8.09 (1H, s), 10.05 (1H, s).	Ref. Ex. 154

Ref. Ex. No.	STR	1H-NMR	ref.
1072		1H-NMR (CDCl3) δ: 6.76 (1H, dd, J = 0.8, 3.2 Hz), 7.23-7.30 (2H, m), 7.44-7.51 (3H, m), 7.70 (1H, dd, J = 1.3, 8.2 Hz), 7.79 (1H, d, J = 8.2 Hz), 7.96 (1H, s), 10.03 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1073		1H-NMR (CDCl3) δ: 3.21 (2H, t, J = 8.4 Hz), 3.87 (3H, s), 3.98 (2H, t, J = 8.4 Hz), 6.73-6.84 (1H, m), 7.02-7.16 (2H, m), 7.18-7.26 (2H, m), 7.51 (1H, dd, J = 1.4, 7.6 Hz).	Ref. Ex. 1014
1074		1H-NMR (CDCl3) δ: 3.24 (2H, t, J = 8.4 Hz), 4.01 (2H, t, J = 8.4 Hz), 6.76-6.86 (1H, m), 7.03-7.19 (3H, m), 7.29-7.31 (2H, m), 9.88 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1075		1H-NMR (CDCl3) δ: 6.79 (1H, dd, J = 0.8, 3.2 Hz), 7.04-7.15 (2H, m), 7.44 (1H, dd, J = 1.5, 3.2 Hz), 7.45-7.54 (1H, m), 7.71 (1H, dd, J = 1.3, 8.2 Hz), 7.76 (1H, s), 7.79 (1H, d, J = 8.2 Hz), 10.02 (1H, s).	Ref. Ex. 154
1076		1H-NMR (CDCl3) δ: 4.09 (2H, s), 7.05 (1H, d, J = 9.1 Hz), 7.20-7.26 (2H, m), 7.41 (1H, s), 7.58 (1H, s), 7.76 (1H, s), 9.95 (1H, s).	Ref. Ex. 183
1077		1H-NMR (CDCl3) δ: 2.46 (3H, s), 6.74 (1H, dd, J = 0.8, 3.2 Hz), 7.33-7.34 (4H, s), 7.53 (1H, d, J = 3.2 Hz), 7.70 (1H, dd, J = 1.3, 8.2 Hz), 7.78 (1H, d, J = 8.2 Hz), 8.01 (1H, s), 10.01 (1H, s).	Ref. Ex. 154








[0517]







Ref. Ex. No.	STR	1H-NMR	ref.
1078		1H-NMR (CDCl3) δ: 5.67 (2H, s), 6.74 (1H, dd, J = 0.7, 3.2 Hz), 6.79 (1H, s), 7.35 (1H, d, J = 3.2 Hz), 7.64-7.74 (3H, m), 7.80 (1H, d, J = 8.2 Hz), 7.90 (1H, d, J = 8.3 Hz), 10.01 (1H, s).	Ref. Ex. 184
1079		1H-NMR (CDCl3) δ: 5.54 (2H, s), 6.72 (1H, dd, J = 0.8, 3.2 Hz), 7.35 (1H, d, J = 3.2 Hz), 7.51 (2H, s), 7.69 (1H, dd, J = 1.2, 8.3 Hz), 7.78-7.84 (3H, m), 10.03 (1H, s).	Ref. Ex. 184
1080		1H-NMR (CDCl3) δ: 7.77-7.80 (2H, m), 8.11-8.15 (2H, m), 8.27 (1H, s), 10.13 (1H, s).	Ref. Ex. 63
1081		1H-NMR (CDCl3) δ: 4.14 (2H, s), 7.06 (1H, d, J = 8.7 Hz), 7.23-7.35 (3H, m), 7.63 (2H, s), 9.99 (1H, s).	Ref. Ex. 183
1082		1H-NMR (CDCl3) δ: 7.50-7.54 (1H, m), 7.85 (1H, s), 7.94 (1H, s), 8.03 (1H, d, J = 8.7 Hz), 8.22 (1H, s), 8.46 (1H, s), 10.12 (1H, s).	Ref. Ex. 183
1083		1H-NMR (CDCl3) δ: 3.92 (3H, s), 6.29 (1H, d, J = 4.2 Hz), 6.88-6.93 (1H, m), 6.97 (1H, d, J = 4.0 Hz), 7.13-7.31 (2H, m), 9.60 (1H, s).	Ref. Ex. 228
1084		1H-NMR (CDCl3) δ: 5.31 (2H, s), 7.26-7.36 (3H, m), 7.61 (1H, t, J = 7.5 Hz), 7.75 (1H, d, J = 8.1 Hz), 7.89 (1H, d, J = 7.5 Hz), 7.97 (1H, s), 10.06 (1H, s).	Ref. Ex. 82


Ref. Ex. No.	STR	1H-NMR	ref.
1085		1H-NMR (CDCl3) δ: 3.93 (3H, s), 6.31 (1H, d, J = 3.9 Hz), 6.99 (1H, d, J = 3.9 Hz), 7.32 (2H, d, J = 8.1 Hz), 7.44-7.47 (2H, m), 9.60 (1H, s).	Ref. Ex. 228
1086		1H-NMR (CDCl3) δ: 7.38-7.46 (1H, m), 7.50-7.54 (1H, m), 7.95-7.96 (1H, m), 8.04-8.10 (2H, m), 8.95-8.98 (1H, m), 10.11 (1H, s).	Ref. Ex. 183
1087		1H-NMR (CDCl3) δ: 3.17-3.22 (2H, m), 3.36-3.41 (2H, m), 7.15-7.30 (4H, m), 7.44-7.51 (2H, m), 8.91 (1H, d, J = 4.8 Hz), 9.99 (1H, s).	Ref. Ex. 34
1088		1H-NMR (CDCl3) δ: 3.27-3.32 (2H, m), 3.41-3.46 (2H, m), 7.42-7.54 (3H, m), 7.70-7.73 (1H, m), 7.77 (1H, s), 7.92 (1H, d, J = 4.8 Hz), 9.99 (1H, s).	Ref. Ex. 48
1089		1H-NMR (CDCl3) δ: 3.92 (3H, s), 6.82-6.84 (1H, m), 7.10-7.12 (3H, m), 7.27 (1H, s), 7.69-7.70 (1H, m), 9.88 (1H, s).	Ref. Ex. 234
1090		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.2 Hz), 4.03-4.11 (4H, m), 6.97-6.98 (1H, m), 7.24-7.29 (4H, m), 7.55 (1H, s), 7.57 (1H, s), 9.92 (1H, s).	Ref. Ex. 183

Ref. Ex. No.	STR	1H-NMR	ref.
1091		1H-NMR (CDCl3) δ: 3.99 (2H, s), 7.02-7.22 (3H, m), 7.40 (1H, s), 7.56 (1H, s), 7.73 (1H, s), 9.94 (1H, s).	Ref. Ex. 183
1092		1H-NMR (CDCl3) δ: 6.80 (1H, dd, J = 0.6, 3.3 Hz), 7.11-7.20 (1H, m), 7.23-7.37 (2H, m), 7.48 (1H, dd, J = 1.9, 3.2 Hz), 7.73 (1H, dd, J = 1.3, 8.2 Hz), 7.80 (1H, d, J = 8.2 Hz), 7.85 (1H, s), 10.05 (1H, s).	Ref. Ex. 154
1093		1H-NMR (CDCl3) δ: 4.12 (2H, s), 7.30-7.34 (3H, m), 7.55-7.63 (4H, m), 9.96 (1H, s).	Ref. Ex. 183
1094		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.1 Hz), 4.47 (2H, q, J = 7.1 Hz), 7.54-7.58 (2H, m), 7.72-7.82 (6H, m).	Ref. Ex. 112
1095		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.2 Hz), 4.47 (2H, q, J = 7.2 Hz), 7.55-7.59 (2H, m), 7.79-7.84 (2H, m). 7.89 (1H, s), 8.05 (2H, s).	Ref. Ex. 112
1096		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.1 Hz), 4.40 (2H, q, J = 7.1 Hz), 7.32 (2H, d, J = 8.1 Hz), 8.01-8.05 (2H, m), 8.42 (1H, s).	Ref. Ex. 14




[0518]



Ref. Ex. No.	STR	1H-NMR	ref.
1097		1H-NMR (CDCl3) δ: 7.70-7.79 (3H, m), 8.09-8.15 (2H, m), 8.39 (1H, s), 9.10 (1H, s), 10.11 (1H, s).	Ref. Ex. 112
1098		1H-NMR (CDCl3) δ: 7.59-7.63 (2H, m), 7.84 (1H, s), 7.89 (1H, s), 7.92 (1H, s), 8.07 (2H, s), 9.93 (1H, s).	Ref. Ex. 76, Ref. Ex. 48
1099		1H-NMR (CDCl3) δ: 7.59-7.63 (2H, m), 7.75 (4H, s), 7.78-7.87 (2H, m), 9.91 (1H, s).	Ref. Ex. 76, Ref. Ex. 48
1100		1H-NMR (CDCl3) δ: 4.13 (2H, s), 7.01-7.07 (1H, m), 7.33 (2H, d, J = 8.1 Hz), 7.54-7.61 (3H, m), 10.31 (1H, s).	Ref. Ex. 183
1101		1H-NMR (CDCl3) δ: 7.34 (2H, dd, J = 0.8, 8.9 Hz), 8.06-8.11 (2H, m), 8.45 (1H, s), 10.06 (1H, s).	Ref. Ex. 63
1102		1H-NMR (CDCl3) δ: 3.74 (3H, s), 6.27 (1H, d, J = 3.9 Hz), 6.98 (1H, d, J = 3.9 Hz), 7.06-7.12 (1H, m), 7.25-7.31 (1H, m), 7.79-7.84 (1H, m), 9.61 (1H, s).	Ref. Ex. 228
1103		1H-NMR (CDCl3) δ: 6.84-6.86 (1H, m), 7.28-7.31 (1H, m), 7.44-7.53 (2H, m), 7.66 (1H, s), 7.75 (1H, s), 7.91 (1H, s), 8.10 (1H, s), 8.29 (1H, bs), 10.09 (1H, s).	Ref. Ex. 112



Ref. Ex. No.	STR	1H-NMR	ref.
1104		1H-NMR (CDCl3) δ: 1.98-2.04 (2H, m), 2.07-2.13 (2H, m), 3.44 (2H, t, J = 6.8 Hz), 3.67 (2H, t, J = 6.8 Hz), 3.97 (3H, s), 6.98 (1H, s).	Ref. Ex. 1173
1107		1H-NMR (CDCl3) δ: 3.92 (3H, s), 4.00 (2H, s), 6.94 (1H, d, J = 8.7 Hz), 7.29-7.36 (3H, m), 7.54 (2H, d, J = 8.7 Hz), 7.68 (1H, s), 10.45 (1H, s).	Ref. Ex. 183
1108		1H-NMR (CDCl3) δ: 4.09 (2H, s), 6.96 (1H, d, J = 11.1 Hz), 7.10 (1H, d, J = 7.8 Hz), 7.30 (2H, d, J = 8.1 Hz), 7.59 (2H, d, J = 8.1 Hz), 7.82 (1H, t, J = 7.6 Hz), 10.32 (1H, s).	Ref. Ex. 183
1109		1H-NMR (CDCl3) δ: 6.68 (1H, s), 7.28-7.36 (3H, m), 7.49 (1H, d, J = 8.1 Hz), 7.73 (1H, s), 7.84 (1H, s), 8.15 (1H, s), 8.39 (1H, bs), 10.10 (1H, s).	Ref. Ex. 112
1110		1H-NMR (CDCl3) δ: 7.37-7.40 (1H, m), 7.64 (1H, d, J = 1.9 Hz), 7.70-7.76 (2H, m), 8.07-8.10 (1H, m), 8.48-8.52 (1H, m), 8.73-8.75 (1H, m), 10.14 (1H, s).	Ref. Ex. 76, Ref. Ex. 48
1111		1H-NMR (CDCl3) δ: 4.03 (2H, s), 6.79-6.80 (1H, m), 7.05-7.07 (1H, m), 7.20-7.35 (6H, m), 7.63-7.64 (1H, m), 9.85 (1H, s).	Ref. Ex. 234

Ref. Ex. No.	STR	1H-NMR	ref.
1112		1H-NMR (CDCl3) δ: 6.86-6.88 (1H, m), 7.19-7.21 (1H, m), 7.50-7.57 (4H, m), 7.61-7.68 (1H, m), 7.77-7.84 (3H, m), 7.94-7.99 (2H, m), 9.90 (1H, s).	Ref. Ex. 234
1113		1H-NMR (CDCl3) δ: 6.79-6.81 (1H, m), 7.03-7.20 (6H, m), 7.35-7.41 (4H, m), 7.61-7.62 (1H, m), 9.85 (1H, s).	Ref. Ex. 234
1114		1H-NMR (CDCl3) δ: 2.41 (3H, s), 4.02 (2H, s), 7.13-7.22 (5H, m), 7.51 (1H, s), 7.55 (1H, s), 9.95 (1H, s).	Ref. Ex. 183
1115		1H-NMR (CDCl3) δ: 3.86 (3H, s), 6.57-6.58 (1H, m), 7.13-7.14 (1H, m), 7.42-7.50 (2H, m), 7.65 (1H, s), 7.75 (1H, s), 7.88 (1H, s), 8.07-8.10 (1H, m), 10.07 (1H, s).	Ref. Ex. 112
1116		1H-NMR (CDCl3) δ: 6.85-6.86 (1H, m), 7.52-7.56 (1H, m), 7.63 (1H, d, J = 8.6 Hz), 7.69-7.73 (3H, m), 7.84 (1H, d, J = 1.8 Hz), 8.07 (1H, t, J = 1.5 Hz), 10.09 (1H, s).	Ref. Ex. 112
1117		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.1 Hz), 4.48 (2H, q, J = 7.1 Hz), 7.81 (1H, d, J = 8.2 Hz), 8.30 (1H, s), 8.55 (1H, dd, J = 1.6, 8.2 Hz), 9.28 (1H, d, J = 1.9 Hz).	Ref. Ex. 2







[0519]








Ref. Ex. No.	STR	1H-NMR	ref.
1118		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.1 Hz), 4.45 (2H, q, J = 7.1 Hz), 7.63 (1H, t, J = 7.8 Hz), 7.76 (1H, d, J = 7.7 Hz), 8.30-8.32 (2H, m), 8.41 (1H, s).	Ref. Ex. 2
1119		1H-NMR (CDCl3) δ: 7.37-7.40 (2H, m), 7.46 (1H, t, J = 7.7 Hz), 7.55 (1H, d, J = 5.6 Hz), 7.71 (1H, s), 7.78 (1H, s), 7.94-7.98 (1H, m), 8.04 (1H, t, J = 1.4 Hz), 10.10 (1H, s).	Ref. Ex. 112
1120		1H-NMR (CDCl3) δ: 7.40 (1H, d, J = 5.2 Hz), 7.55 (1H, d, J = 5.2 Hz), 7.81-7.84 (1H, m), 7.70-7.78 (2H, m), 7.94 (1H, d, J = 8.3 Hz), 8.11-8.15 (2H, m), 10.10 (1H, s).	Ref. Ex. 112
1121		1H-NMR (CDCl3) δ: 3.30 (2H, t, J = 8.7 Hz), 4.66 (2H, t, J = 8.7 Hz), 6.89 (1H, d, J = 8.3 Hz), 7.36-7.40 (1H, m), 7.46 (1H, s), 7.63 (2H, s), 7.98 (1H, s), 10.06 (1H, s).	Ref. Ex. 112
1122		1H-NMR (CDCl3) δ: 1.96-2.03 (4H, m), 3.57-3.67 (4H, m), 3.94 (3H, s), 6.45 (1H, s), 9.81 (1H, s).	Ref. Ex. 318
1124		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.1 Hz), 4.44 (2H, q, J = 7.1 Hz), 7.64 (1H, t, J = 7.9 Hz), 7.79 (1H, d, J = 7.8 Hz), 8.18 (1H, d, J = 7.9 Hz), 8.25 (1H, s).	Ref. Ex. 1123
1125		1H-NMR (CDCl3) δ: 7.84 (1H, d, J = 8.2 Hz), 8.32 (1H, s), 8.52 (1H, dd, J = 1.9, 8.1 Hz), 9.31 (1H, d, J = 1.8 Hz), 10.15 (1H, s).	Ref. Ex. 63







Ref. Ex. No.	STR	1H-NMR	ref.
1126		1H-NMR (CDCl3) δ: 6.85-6.87 (1H, m), 7.11-7.12 (1H, m), 7.62 (1H, s), 7.69-7.70 (1H, m), 7.76-7.79 (2H, m), 9.89 (1H, s).	Ref. Ex. 234
1127		1H-NMR (CDCl3) δ: 7.66 (1H, t, J = 7.8 Hz), 7.79 (1H, d, J = 7.8 Hz), 8.31 (1H, d, J = 7.8 Hz), 8.37 (1H, s), 8.40 (1H, s), 10.04 (1H, s).	Ref. Ex. 63
1128		1H-NMR (CDCl3) δ: 1.93-2.01 (4H, m), 3.62 (4H, brs), 3.93 (3H, s), 3.94 (3H, s), 6.61 (1H, s).	Ref. Ex. 1173
1129		1H-NMR (CDCl3) δ: 7.47-7.51 (2H, m), 7.96-8.01 (2H, m), 10.23 (1H, s).	Ref. Ex. 63
1130		1H-NMR (CDCl3) δ: 7.67 (1H, t, J = 7.9 Hz), 7.83 (1H, d, J = 7.9 Hz), 8.21 (1H, d, J = 7.9 Hz), 8.31 (1H, s), 10.26 (1H, s).	Ref. Ex. 63
1131		1H-NMR (CDCl3) δ: 5.17 (2H, s), 7.26-7.29 (2H, m), 7.48-7.50 (3H, m), 7.64 (1H, s), 7.75 (1H, s), 10.02 (1H, s).	Ref. Ex. 82
1132		1H-NMR (CDCl3) δ: 0.90-0.94 (3H, m), 1.33-1.39 (4H, m), 1.46-1.48 (2H, m), 1.78-1.85 (2H, m), 4.06 (2H, t, J = 6.5 Hz), 7.39 (1H, s), 7.55 (1H, s), 7.69 (1H, s), 10.01 (1H, s).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
1133		1H-NMR (CDCl3) δ: 7.43 (1H, d, J = 5.5 Hz), 7.55 (1H, d, J = 5.5 Hz), 7.58-7.62 (1H, m), 7.70-7.74 (1H, m), 7.78 (1H, s), 8.01 (1H, d, J = 8.4 Hz), 8.07 (1H, d, J = 1.7 Hz), 8.12 (1H, t, J = 1.7 Hz), 10.10 (1H, s).	Ref. Ex. 112
1134		1H-NMR (CDCl3) δ: 2.88-2.97 (4H, m), 7.32-7.55 (5H, m), 7.71 (1H, s), 7.71 (1H, s), 9.93 (1H, s).	Ref. Ex. 150
1135		1H-NMR (CDCl3) δ: 7.18 (2H, t, J = 8.7 Hz), 7.60-7.67 (3H, m), 8.00 (1H, d, J = 8.4 Hz), 8.06 (2H, s), 10.13 (1H, s).	Ref. Ex. 112
1136		1H-NMR (CDCl3) δ: 1.42-1.56 (2H, m), 1.75-1.80 (2H, m), 2.08-2.14 (1H, m), 3.42-3.51 (2H, m), 3.90-3.95 (2H, m), 4.02-4.07 (2H, m), 7.39 (1H, s), 7.55 (1H, s), 7.71 (1H, s), 10.01 (1H, s).	Ref. Ex. 82
1137		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.1 Hz), 4.46 (2H, q, J = 7.1 Hz), 7.54 (1H, d, J = 8.4 Hz), 7.83 (1H, dd, J = 2.1, 8.4 Hz), 8.15 (1H, d, J = 2.1 Hz), 8.20 (1H, s).	Ref. Ex. 2
1138		1H-NMR (CDCl3) δ: 5.40 (2H, s), 7.29-7.35 (1H, m), 7.52-7.60 (2H, m), 7.75 (1H, d, J = 8.7 Hz), 7.87 (1H, d, J = 8.2 Hz), 8.12 (1H, s), 9.93 (1H, s).	Ref. Ex. 82








[05520]







Ref. Ex. No.	STR	1H-NMR	ref.
1139		1H-NMR (CDCl3) δ: 5.39 (2H, s), 7.18-7.31 (2H, m), 7.50-7.55 (1H, m), 7.75 (1H, d, J = 7.9 Hz), 7.87 (1H, d, J = 7.9 Hz), 8.14 (1H, s), 10.42 (1H, s).	Ref. Ex. 82
1140		1H-NMR (CDCl3) δ: 7.78 (2H, d, J = 8.2 Hz), 8.24 (2H, d, J = 8.2 Hz), 8.37 (1H, s), 10.40 (1H, s).	Ref. Ex. 63
1141		1H-NMR (CDCl3) δ: 5.24 (2H, s), 7.13-7.25 (2H, m), 7.45-7.50 (1H, m), 7.58 (2H, d, J = 8.1 Hz), 7.68 (2H, d, J = 8.1 Hz), 10.40 (1H, s).	Ref. Ex. 82
1142		1H-NMR (CDCl3) δ: 2.05 (4H, brs), 3.44 (2H, brs), 3.76 (2H, brs), 4.59 (2H, d, J = 0.7 Hz), 4.70 (2H, s), 6.48 (1H, s), 7.30-7.43 (5H, m), 7.66 (2H, d, J = 8.1 Hz), 8.50 (2H, d, J = 8.1 Hz).	Ref. Ex. 1173
1143		1H-NMR (CDCl3) δ: 2.06 (4H, brs), 3.40 (2H, brs), 3.61 (1H, brs), 3.78 (2H, brs), 4.66 (2H, d, J = 2.0 Hz), 6.18 (1H, s), 7.69 (2H, d, J = 8.1 Hz), 8.54 (2H, d, J = 8.1 Hz).	Ref. Ex. 750
1144		1H-NMR (CDCl3) δ: 3.94 (3H, s), 6.34 (1H, d, J = 4.0 Hz), 6.99 (1H, d, J = 4.0 Hz), 7.27-7.29 (2H, m), 7.35-7.38 (1H, m), 7.48-7.53 (1H, m), 9.61 (1H, s).	Ref. Ex. 228







Ref. Ex. No.	STR	1H-NMR	ref.
1145		1H-NMR (CDCl3) δ: 3.05 (3H, s), 4.60 (2H, s), 6.72-6.77 (3H, m), 7.20-7.24 (2H, m), 7.49-7.51 (2H, m), 7.77 (2H, s), 10.00 (1H, s).	Ref. Ex. 82
1146		1H-NMR (CDCl3) δ: 4.05 (2H, s), 6.78-6.79 (1H, m), 7.05-7.06 (1H, m), 7.20-7.24 (5H, m), 7.30-7.43 (4H, m), 7.63-7.64 (1H, m), 9.84 (1H, s).	Ref. Ex. 234
1147		1H-NMR (CDCl3) δ: 2.97 (2H, t, J = 7.2 Hz), 4.10 (2H, t, J = 7.2 Hz), 5.94 (2H, s), 6.46-6.49 (1H, m), 6.53 (1H, s), 6.57-6.61 (2H, m), 7.71 (1H, d, J = 7.8 Hz), 7.13-7.14 (1H, m), 9.69 (1H, s).	Ref. Ex. 234
1148		1H-NMR (CDCl3) δ: 2.05-2.13 (4H, m), 3.46-3.50 (2H, m), 3.79-3.83 (2H, m), 6.80 (1H, s), 7.72 (2H, d, J = 8.2 Hz), 8.60 (2H, d, J = 8.2 Hz), 10.02 (1H, s).	Ref. Ex. 159
1149		1H-NMR (DMSO-d6) δ: 4.42 (2H, s), 5.53 (1H, brs), 6.42 (1H, brs), 7.88 (2H, d, J = 8.2 Hz), 8.32 (2H, d, J = 8.2 Hz), 12.68 (1H, brs).	Ref. Ex. 33
1150		1H-NMR (CDCl3) δ: 3.69-3.76 (4H, m), 3.81-3.83 (4H, m), 4.61 (2H, s), 4.70 (2H, s), 6.66 (1H, s), 7.30-7.44 (8H, m), 8.34-8.38 (2H, m).	Ref. Ex. 1173
1151		1H-NMR (CDCl3) δ: 6.67 (1H, d, J = 3.3 Hz), 7.20 (1H, dd, J = 2.0, 8.8 Hz), 7.39 (1H, d, J = 3.3 Hz), 7.49 (1H, d, J = 8.8 Hz), 7.67 (1H, d, J = 2.0 Hz), 7.69-7.80 (2H, m), 7.89 (1H, dt, J = 1.5, 7.2 Hz), 8.00 (1H, t, J = 1.6 Hz), 10.12 (1H, s).	Ref. Ex. 154

Ref. Ex. No.	STR	1H-NMR	ref.
1152		1H-NMR (CDCl3) δ: 3.17 (2H, t, J = 8.4 Hz), 4.02 (2H, t, J = 8.4 Hz), 6.81 (1H, dt, J = 1.0, 7.3 Hz), 7.08-7.15 (1H, m), 7.17-7.23 (2H, m), 7.41-7.55 (3H, m), 7.67-7.69 (1H, m), 10.00 (1H, s).	Ref. Ex. 114, Ref. Ex. 151
1153		1H-NMR (CDCl3) δ: 3.02 (2H, t, J = 5.8 Hz), 3.64 (2H, t, J = 5.8 Hz), 4.49 (2H, s), 7.16-7.25 (5H, m), 7.26-7.31 (1H, m), 7.41-7.48 (2H, m), 9.99 (1H, s).	Ref. Ex. 114 Ref. Ex. 151
1154		1H-NMR (CDCl3) δ: 3.03 (2H, t, J = 7.2 Hz), 4.13 (2H, t, J = 7.2 Hz), 6.56-6.63 (2H, m), 6.81 (1H, dd, J = 2.1, 8.2 Hz), 7.13-7.15 (2H, m), 7.34 (1H, d, J = 8.2 Hz), 9.70 (1H, s).	Ref. Ex. 234
1155		1H-NMR (CDCl3) δ: 2.18-2.26 (1H, m), 2.70-2.76 (1H, m), 2.93-3.01 (1H, m), 3.10-3.20 (1H, m), 5.81 (1H, t, J = 7.1 Hz), 6.64-6.69 (2H, m), 7.13 (1H, d, J = 7.5 Hz), 7.22-7.26 (2H, m), 7.33-7.35 (2H, m), 9.71 (1H, s).	Ref. Ex. 234
1156		1H-NMR (CDCl3) δ: 3.23 (2H, dd, J = 5.1, 16.2 Hz), 3.54 (2H, dd, J = 7.5, 16.2 Hz), 4.89-4.98 (1H, m), 6.60-6.61 (1H, m), 6.68-6.69 (1H, m), 7.23-7.31 (5H, m), 9.70 (1H, s).	Ref. Ex. 234
1157		1H-NMR (CDCl3) δ: 5.23 (2H, s), 7.14-7.28 (2H, m), 7.45-7.68 (4H, m), 7.72 (1H, s), 10.40 (1H, s).	Ref. Ex. 82








[0521]





Ref. Ex. No.	STR	1H-NMR	ref.
1158		1H-NMR (CDCl3) δ: 5.28 (2H, s), 7.18-7.36 (1H, m), 7.50-7.55 (1H, m), 7.89-7.94 (4H, m), 10.41 (1H, s).	Ref. Ex. 82
1159		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.1 Hz), 4.38 (2H, q, J = 7.1 Hz), 7.24-7.29 (2H, m), 7.36-7.41 (2H, m), 7.73 (1H, s).	Ref. Ex. 9
1160		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.1 Hz), 4.38 (2H, q, J = 7.1 Hz), 7.26-7.29 (2H, m), 7.34-7.39 (2H, m), 7.75 (1H, s).	Ref. Ex. 9
1161		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.1 Hz), 4.38 (2H, q, J = 7.1 Hz), 7.16-7.24 (2H, m), 7.40 (1H, dd, J = 2.7, 6.0 Hz), 7.75 (1H, s).	Ref. Ex. 9
1162		1H-NMR (CDCl3) δ: 7.27-7.32 (2H, m), 7.39-7.44 (2H, m), 7.74 (1H, s), 9.79 (1H, s).	Ref. Ex. 63
1163		1H-NMR (CDCl3) δ: 7.28-7.31 (2H, m), 7.38-7.43 (2H, m), 7.76 (1H, s), 9.79 (1H, s).	Ref. Ex. 63
1164		1H-NMR (CDCl3) δ: 7.18-7.29 (2H, m), 7.44 (1H, dd, J = 2.7, 6.0 Hz), 7.76 (1H, s), 9.79 (1H, s).	Ref. Ex. 63








Ref. Ex. No.	STR	1H-NMR	ref.
1165		1H-NMR (CDCl3) δ: 7.05 (1H, s), 7.86 (2H, d, J = 8.3 Hz), 8.40 (2H, d, J = 8.3 Hz), 10.02 (1H, s).	Ref. Ex. 159
1166		1H-NMR (CDCl3) δ: 5.42 (2H, m), 6.67 (1H, dd, J = 0.8, 3.2 Hz), 7.17 (2H, d, J = 7.9 Hz), 7.33-7.38 (2H, m), 7.54-7.61 (3H, m), 7.73 (1H, dd, J = 0.5, 8.2 Hz).	Ref. Ex. 184
1167		1H-NMR (CDCl3) δ: 5.48 (2H, s), 6.67 (1H, dd, J = 0.7, 3.1 Hz), 7.19 (2H, d, J = 8.0 Hz), 7.37 (1H, d, J = 3.1 Hz), 7.57 (2H, d, J = 8.0 Hz), 7.66 (1H, dd, J = 1.3, 8.2 Hz), 7.77 (1H, d, J = 8.2 Hz), 7.81 (1H, s), 10.02 (1H, s).	Ref. Ex. 318
1168		1H-NMR (CDCl3) δ: 3.64 (1H, brs), 3.73-3.77 (4H, m), 3.82-3.84 (4H, m), 4.66 (2H, s), 6.36 (1H, s), 7.42-7.48 (3H, m), 8.33-8.43 (2H, m).	Ref. Ex. 750
1169		1H-NMR (CDCl3) δ: 3.96 (3H, s), 5.86 (1H, s), 6.94-6.98 (1H, m), 7.04-7.08 (1H, m), 10.25 (1H, s).	Ref. Ex. 618
1170		1H-NMR (CDCl3) δ: 4.00 (3H, s), 5.34 (2H, s), 6.92-6.96 (1H, m), 7.16-7.19 (1H, m), 7.77 (1H, d, J = 8.2 Hz), 7.89 (1H, d, J = 8.2 Hz), 8.13 (1H, s), 10.40 (1H, d, J = 3.4 Hz).	Ref. Ex. 82







Ref. Ex. No.	STR	1H-NMR	ref.
1171		1H-NMR (CDCl3) δ: 3.65-4.06 (8H, m), 6.97 (1H, s), 7.46-7.52 (3H, m), 8.41-8.48 (2H, m), 10.03 (1H, s).	Ref. Ex. 159
1172		1H-NMR (CDCl3) δ: 4.00 (3H, s), 7.12-7.22 (1H, m), 7.35-7.38 (1H, m), 7.65 (1H, t, J = 7.8 Hz), 7.72-7.77 (1H, m), 8.22-8.26 (1H, m), 8.41-8.46 (1H, m), 8.89-8.91 (1H, m).	Ref. Ex. 129
1174		1H-NMR (CDCl3) δ: 3.53-3.57 (4H, m), 3.81-3.84 (4H, m), 7.50 (1H, s), 9.72 (1H, s).	Ref. Ex. 63
1175		1H-NMR (CDCl3) δ: 5.18 (2H, s), 7.24 (1H, s), 7.36 (1H, s), 7.48 (1H, s), 7.55 (2H, d, J = 7.8 Hz), 7.67 (2H, d, J = 7.8 Hz), 9.92 (1H, s).	Ref. Ex. 82
1176		1H-NMR (CDCl3) δ: 5.16 (2H, s), 7.24-7.25 (1H, m), 7.37-7.38 (1H, m), 7.48 (1H, s), 7.55 (1H, d, J = 7.5 Hz), 7.59-7.65 (2H, m), 7.71 (1H, s), 9.92 (1H, s).	Ref. Ex. 82
1177		1H-NMR (CDCl3) δ: 4.69 (2H, s), 4.71 (2H, s), 7.57 (1H, t, J = 7.5 Hz), 7.66 (1H, d, J = 7.5 Hz), 7.82-7.89 (3H, m), 10.05 (1H, s).	Ref. Ex. 100








[0522]






Ref. Ex. No.	STR	1H-NMR	ref.
1178		1H-NMR (CDCl3) δ: 4.74 (2H, s), 4.82 (2H, s), 7.56 (1H, t, J = 7.7 Hz), 7.67 (2H, d, J = 7.7 Hz), 7.79 (1H, d, J = 8.1 Hz), 7.84-7.87 (1H, m), 7.90 (1H, s), 8.05 (1H, s), 10.05 (1H, s).	Ref. Ex. 100
1179		1H-NMR (CDCl3) δ: 4.25 (2H, s), 7.34-7.36 (2H, m), 7.47-7.51 (3H, m), 7.60-7.62 (1H, m), 7.77-7.79 (1H, m), 7.86 (1H, s), 10.00 (1H, s).	Ref. Ex. 173
1180		1H-NMR (CDCl3) δ: 2.67 (3H, s), 7.57-7.68 (3H, m), 7.75-7.83 (3H, m), 7.88 (1H, s), 10.06 (1H, s).	Ref. Ex. 38, Ref. Ex. 19, Ref. Ex. 48
1181		1H-NMR (CDCl3) δ: 2.65 (3H, s), 7.17 (2H, t, J = 8.7 Hz), 7.52-7.63 (3H, m), 7.69-7.75 (2H, m), 10.05 (1H, s).	Ref. Ex. 38, Ref. Ex. 19, Ref. Ex. 48
1182		1H-NMR (CDCl3) δ: 3.05 (3H, s), 4.58 (2H, s), 6.53 (1H, dd, J = 3.0, 9.0 Hz), 6.78 (1H, d, J = 3.0 Hz), 7.21 (1H, d, J = 9.0 Hz), 7.44-7.54 (2H, m), 7.72 (1H, s), 7.79 (1H, d, J = 7.5 Hz), 10.00 (1H, m).	Ref. Ex. 82
1183		1H-NMR (CDCl3) δ: 3.14 (3H, s), 4.66 (2H, s), 6.73 (2H, d, J = 8.4 Hz), 7.43-7.54 (4H, m), 7.73 (1H, s), 7.79 (1H, d, J = 7.2 Hz), 10.00 (1H, s).	Ref. Ex. 82
1184		1H-NMR (CDCl3) δ: 5.16 (2H, s), 7.24-7.36 (4H, m), 7.50 (2H, s), 9.93 (1H, s).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
1185		1H-NMR (CDCl3) δ: 7.49 (2H, d, J = 8.7 Hz), 7.59 (2H, d, J = 8.7 Hz), 7.68 (1H, d, J = 8.5 Hz), 7.88 (1H, s), 7.92-7.96 (1H, m), 8.33 (1H, s), 10.10 (1H, s).	Ref. Ex. 147
1186		1H-NMR (CDCl3) δ: 5.23 (2H, s), 7.25-7.27 (1H, m), 7.37-7.44 (2H, m), 7.46-7.51 (2H, m), 7.62-7.69 (1H, m), 9.93 (1H, s).	Ref. Ex. 82
1187		1H-NMR (CDCl3) δ: 5.36 (2H, s), 7.24-7.27 (1H, m), 7.35-7.37 (1H, m), 7.51-7.52 (1H, m), 7.85-7.92 (2H, m), 7.98 (1H, s), 9.93 (1H, s).	Ref. Ex. 82
1188		1H-NMR (CDCl3) δ: 5.12 (2H, s), 7.24-7.25 (1H, m), 7.35-7.36 (1H, m), 7.49-7.50 (1H, m), 7.55 (3H, s), 9.93 (1H, s).	Ref. Ex. 82




Ref. Ex. No.	STR	1H-NMR	ref.
1189		1H-NMR (CDCl3) δ: 5.30 (2H, s), 7.51-7.61 (4H, m), 7.85-7.93 (2H, m), 9.95 (1H, s).	Ref. Ex. 82
1190		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.1 Hz), 4.46 (2H, q, J = 7.1 Hz), 7.42-7.46 (2H, m), 7.50-7.58 (4H, m), 7.71-7.76 (2H, m).	Ref. Ex. 112
1191		1H-NMR (CDCl3) δ: 1.05 (6H, s), 3.82 (4H, s), 7.84 (1H, d, J = 8.1 Hz), 7.92 (1H, d, J = 8.1 Hz), 8.03 (1H, s), 8.38 (1H, s), 10.12 (1H, s).	Ref. Ex. 75
1192		1H-NMR (CDCl3) δ: 7.43-7.48 (2H, m), 7.54-7.60 (4H, m), 7.77 (1H, s), 7.79-7.83 (1H, m), 9.89 (1H, s).	Ref. Ex. 19, Ref. Ex. 147
1193		1H-NMR (CDCl3) δ: 5.21 (2H, s), 7.13-7.17 (1H, m), 7.40 (1H, s), 7.51-7.66 (3H, m), 7.74 (1H, s), 7.85 (1H, d, J = 9.0 Hz), 7.95 (1H, s), 10.04 (1H, s).	Ref. Ex. 82
1194		1H-NMR (CDCl3) δ: 5.39 (2H, s), 7.18 (1H, dd, J = 2.3, 8.8 Hz), 7.41 (1H, d, J = 2.3 Hz), 7.74 (1H, d, J = 8.4 Hz), 7.88 (2H, d, J = 8.8 Hz), 7.97 (1H, s), 8.09 (1H, s), 10.05 (1H, s).	Ref. Ex. 82
1195		1H-NMR (CDCl3) δ: 7.41 (1H, d, J = 9.0 Hz), 7.67 (1H, s), 7.80 (1H, d, J = 8.7 Hz), 7.87 (1H, s), 7.94 (1H, d, J = 8.3 Hz), 8.01 (1H, d, J = 8.3 Hz), 8.10 (1H, s), 10.15 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
1196		1H-NMR (CDCl3) δ: 7.57 (1H, d, J = 5.0 Hz), 8.06-8.10 (2H, m), 8.60-8.63 (1H, m), 8.09 (1H, d, J = 5.0 Hz), 9.13 (1H, s), 10.16 (1H, s).	Ref. Ex. 91
1197		1H-NMR (CDCl3) δ: 2.85-3.01 (4H, m), 6.85-6.95 (2H, m), 7.39-7.49 (2H, m), 7.69-7.75 (2H, m), 10.00 (1H, s).	Ref. Ex. 150
1198		1H-NMR (CDCl3) δ: 2.99-3.05 (2H, m), 3.15-3.20 (2H, m), 7.45-7.52 (3H, m), 7.59 (1H, d, J = 7.8 Hz), 7.72-7.81 (3H, m), 10.02 (1H, s).	Ref. Ex. 150
1199		1H-NMR (CDCl3) δ: 4.19 (4H, s), 7.03-7.06 (1H, m), 7.16-7.18 (2H, m), 7.38-7.41 (1H, m), 7.47 (1H, t, J = 7.8 Hz), 7.69-7.76 (2H, m), 10.00 (1H, s).	Ref. Ex. 150
1200		1H-NMR (CDCl3) δ: 4.64 (2H, s), 4.68 (2H, s), 6.95-7.04 (2H, m), 7.16-7.22 (1H, m), 7.55 (1H, t, J = 7.5 Hz), 7.66 (1H, d, J = 7.5 Hz), 7.83 (1H, d, J = 7.5 Hz), 7.89 (1H, s), 10.04 (1H, s).	Ref. Ex. 100
1201		1H-NMR (CDCl3) δ: 5.05 (2H, s), 6.88-7.35 (4H, m), 7.47-7.50 (2H, m), 9.92 (1H, s).	Ref. Ex. 82


Ref. Ex. No.	STR	1H-NMR	ref.
1202		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.1 Hz), 4.39 (2H, q, J = 7.1 Hz), 7.21-7.25 (2H, m), 7.33-7.37 (2H, m), 7.51 (1H, brs), 7.55 (1H, s).	Ref. Ex. 184
1203		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.1 Hz), 4.45 (2H, q, J = 7.1 Hz), 5.44 (2H, s), 7.16 (1H, dd, J = 2.6, 8.3 Hz), 7.25-7.30 (2H, m), 7.43 (1H, t, J = 8.0 Hz), 8.22 (1H, s).	Ref. Ex. 82
1204		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.1 Hz), 4.45 (2H, q, J = 7.1 Hz), 5.40 (2H, s), 6.96-7.02 (2H, m), 7.16-7.19 (2H, m), 8.21 (1H, s).	Ref. Ex. 82
1205		1H-NMR (CDCl3) δ: 5.45 (2H, s), 7.18 (1H, dd, J = 2.6, 8.2 Hz), 7.23-7.33 (2H, m), 7.45 (1H, t, J = 8.0 Hz), 8.23 (1H, s), 10.05 (1H, s).	Ref. Ex. 63
1206		1H-NMR (CDCl3) δ: 5.40 (2H, s), 6.98-7.04 (2H, m), 7.17-7.20 (2H, m), 8.22 (1H, s), 10.04 (1H, s).	Ref. Ex. 63
1207		1H-NMR (CDCl3) δ: 4.66 (4H, s), 7.48-7.66 (6H, m), 7.82-7.85 (1H, m), 7.89 (1H, s), 10.04 (1H, s).	Ref. Ex. 100
1208		1H-NMR (CDCl3) δ: 5.25 (2H, s), 7.32 (1H, d, J = 8.7 Hz), 7.41-7.50 (3H, m), 7.55 (1H, s), 7.60-7.63 (1H, m), 9.95 (1H, s).	Ref. Ex. 82


Ref. Ex. No.	STR	1H-NMR	ref.
1209		1H-NMR (CDCl3) δ: 5.31 (2H, s), 7.47-7.52 (2H, m), 7.63 (1H, d, J = 8.1 Hz), 7.88 (1H, s), 7.98 (2H, s), 9.96 (1H, s).	Ref. Ex. 82
1210		1H-NMR (CDCl3) δ: 5.43 (2H, s), 7.48-7.50 (1H, m), 7.51 (1H, s), 7.63 (1H, d, J = 7.8 Hz), 7.74 (1H, d, J = 7.8 Hz), 7.86 (1H, d, J = 8.1 Hz), 8.26 (1H, s), 9.97 (1H, s).	Ref. Ex. 82
1211		1H-NMR (CDCl3) δ: 4.75 (2H, s), 4.78 (2H, s), 7.32-7.43 (5H, m), 7.79 (2H, d, J = 8.2 Hz), 8.14 (1H, s), 8.29 (2H, d,J = 8.2 Hz).	Ref. Ex. 38
1212		1H-NMR (CDCl3) δ: 4.65 (2H, s), 4.67 (2H, s), 7.48-7.67 (6H, m), 7.82-7.89 (2H, m), 10.04 (1H, s).	Ref. Ex. 100
1213		1H-NMR (CDCl3) δ: 3.05 (4H, s), 7.36-7.40 (1H, m), 7.47 (1H, t, J = 7.5 Hz), 7.65-7.76 (3H, m), 8.60 (1H, s), 8.74 (1H, s), 10.00 (1H, s).	Ref. Ex. 150


[0524]

Ref. Ex. No.	STR	1H-NMR	ref.
1214		1H-NMR (CDCl3) δ: 5.29 (2H, s), 7.30-7.34 (1H, m), 7.51-7.61 (2H, m), 7.89 (1H, s), 7.94 (2H, s), 9.93 (1H, s).	Ref. Ex. 82
1215		1H-NMR (CDCl3) δ: 4.26 (2H, s), 7.50-7.59 (2H, m), 7.65 (3H, s), 7.78-7.82 (2H, m), 10.00 (1H, s).	Ref. Ex. 173
1216		1H-NMR (CDCl3) δ: 2.76 (1H, t, J = 5.3 Hz), 4.96 (2H, d, J = 5.3 Hz), 7.81 (2H, d, J = 8.2 Hz), 8.04 (1H, s), 8.31 (2H, d, J = 8.2 Hz).	Ref. Ex. 750
1217		1H-NMR (CDCl3) δ: 5.23 (2H, s), 7.25-7.29 (1H, m), 7.43-7.60 (9H, m), 7.81 (1H, s), 7.86 (1H, s), 9.98 (1H, s).	Ref. Ex. 82
1218		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.1 Hz), 3.59 (3H, s), 4.37 (2H, q, J = 7.1 Hz), 7.26-7.29 (2H, m), 7.39-7.44 (3H, m).	Ref. Ex. 12
1219		1H-NMR (CDCl3) δ: 3.59 (3H, s), 7.30 (2H, d, J = 8.9 Hz), 7.42-7.45 (3H, m), 9.75 (1H, s).	Ref. Ex. 63
1220		1H-NMR (CDCl3) δ: 7.84 (2H, d, J = 8.3 Hz), 8.37 (2H, d, J = 8.3 Hz), 8.42 (1H, s), 10.17 (1H, s).	Ref. Ex. 159
1221		1H-NMR (CDCl3) δ: 0.90-1.10 (2H, m), 1.10-1.25 (3H, m), 1.57-1.88 (6H, m), 3.96 (2H, d, J = 7.2 Hz), 6.55 (1H, d, J = 3.1 Hz), 7.25-7.26 (1H, m), 7.32 (1H, dd, J = 1.2, 8.3 Hz), 7.64-7.68 (2H, m).	Ref. Ex. 184
1222		1H-NMR (CDCl3) δ: 1.85-2.00 (4H, m), 2.00-2.15 (2H, m), 2.75-2.90 (1H, m), 4.15 (2H, d, J = 7.3 Hz), 6.55 (1H, dd, J = 0.7, 3.1 Hz), 7.27 (1H, d, J = 3.1 Hz), 7.33 (1H, dd, J = 1.4, 8.2 Hz), 7.64-7.69 (2H, m).	Ref. Ex. 184
1223		1H-NMR (CDCl3) δ: 0.95-1.25 (5H, m), 1.55-1.80 (5H, m), 1.80-1.95 (1H, m), 4.02 (2H, d, J = 7.3 Hz), 6.55 (1H, dd, J = 0.6, 3.1 Hz), 7.30 (1H, d, J = 3.1 Hz), 7.61 (1H, dd, J = 1.3, 8.2 Hz), 7.72 (1H, d, J = 8.2 Hz), 7.91 (1H, s), 10.07 (1H, s).	Ref. Ex. 318
1224		1H-NMR (CDCl3) δ: 1.76-1.99 (4H, m), 2.02-2.14 (2H, m), 2.78-2.94 (1H, m), 4.20 (2H, d, J = 7.3 Hz), 6.55 (1H, dd, J = 0.6, 3.1 Hz), 7.32 (1H, d, J = 3.1 Hz), 7.61 (1H, dd, J = 1.3, 8.2 Hz), 7.71 (1H, d, J = 8.2 Hz), 7.92 (1H, s), 10.07 (1H, s).	Ref. Ex. 318
1225		1H-NMR (CDCl3) δ: 1.46-2.10 (4H, m), 3.70-3.87 (2H, m), 4.08-4.35 (3H, m), 6.57 (1H, d, J = 3.1 Hz), 7.31 (1H, dd, J = 1.3, 8.2 Hz), 7.38 (1H, d, J = 3.1 Hz), 7.66 (1H, d, J = 8.2 Hz), 7.73 (1H, s).	Ref. Ex. 184
1226		1H-NMR (CDCl3) δ: 0.00-0.05 (2H, m), 0.40-0.47 (2H, m), 0.54-0.67 (1H, m), 1.75 (2H, q, J = 6.8 Hz), 4.30 (2H, t, J = 6.8 Hz), 6.56 (1H, dd, J = 0.6, 3.1 Hz), 7.35 (1H, d, J = 3.1 Hz), 7.61 (1H, dd, J = 1.3, 8.1 Hz), 7.72 (1H, d, J = 8.1 Hz), 7.93 (1H, s), 10.06 (1H, s).	Ref. Ex. 184
1227		1H-NMR (CDCl3) δ: 1.97 (3H, d, J = 7.1 Hz), 5.73 (1H, q, J = 7.1 Hz), 7.07-7.13 (2H, m), 7.21-7.32 (4H, m), 7.37 (1H, dd, J = 0.6, 3.2 Hz), 7.49 (1H, d, J = 8.2 Hz), 7.52 (1H, d, J = 3.2 Hz), 7.60 (1H, dd, J = 0.9, 7.3 Hz), 10.25 (1H, s).	Ref. Ex. 184
1228		1H-NMR (CDCl3) δ: 2.63 (3H, s), 5.21 (2H, s), 7.12 (1H, d, J = 7.9 Hz), 7.35 (1H, t, J = 7.9 Hz), 7.50 (1H, dd, J = 1.0, 7.7 Hz), 7.88 (1H, s), 7.93 (2H, s), 10.35 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1229		1H-NMR (CDCl3) δ: 2.65 (3H, s), 5.33 (2H, s), 7.12 (1H, d, J = 7.7 Hz), 7.33 (1H, t, J = 7.9 Hz), 7.51 (1H, dd, J = 1.0, 7.7 Hz), 7.73 (1H, d, J = 8.2 Hz), 7.86 (1H, d, J = 8.2 Hz), 8.11 (1H, s), 10.35 (1H, s).	Ref. Ex. 62, Ref. Ex. 48
1230		1H-NMR (CDCl3) δ: 4.61 (2H, d, J = 0.7 Hz), 6.52 (1H, s), 7.29 (4H, s).	Ref. Ex. 318
1231		1H-NMR (CDCl3) δ: 7.33-7.40 (4H, m), 7.53 (1H, s), 9.78 (1H, s).	Ref. Ex. 159

[0525]


Ref. Ex. No.	STR	1H-NMR	ref.
1232		1H-NMR (CDCl3) δ: 2.40 (1H, brs), 4.62 (2H, s), 6.54 (1H, s), 7.20 (2H, d, J = 8.4 Hz), 7.36-7.41 (2H, m).	Ref. Ex. 318
1233		1H-NMR (CDCl3) δ: 7.27-7.29 (2H, m), 7.46 (1H, t, J = 2.1 Hz), 7.57-7.59 (1H, m), 7.73-7.75 (1H, m), 8.32 (1H, d, J = 5.3 Hz), 9.96 (1H, s).	Ref. Ex. 153
1234		1H-NMR (CDCl3) δ: 4.11 (2H, s), 7.02 (1H, t, J = 8.4 Hz), 7.10-7.17 (1H, m), 7.33 (1H, dd, J = 2.1, 6.8 Hz), 7.44-7.51 (2H, m), 7.75-7.79 (2H, m), 9.99 (1H, s).	Ref. Ex. 173
1235		1H-NMR (CDCl3) δ: 4.07 (2H, s), 6.71-6.86 (2H, m), 7.18-7.24 (1H, m), 7.40-7.48 (2H, m), 7.70-7.75 (2H, m), 9.96 (1H, s).	Ref. Ex. 173
1237		1H-NMR (CDCl3) δ: 7.23-7.26 (2H, m), 7.44-7.50 (2H, m), 7.55 (1H, s), 9.79 (1H, s).	Ref. Ex. 48
1238		1H-NMR (CDCl3) δ: 7.12-7.37 (2H, m), 7.70-7.76 (2H, m), 8.06 (1H, d, J = 7.5 Hz), 8.49 (1H, d, J = 7.5 Hz), 8.73 (1H, s), 10.14 (1H, s).	Ref. Ex. 130, Ref. Ex. 147


Ref. Ex. No.	STR	1H-NMR	ref.
1240		1H-NMR (CDCl3) δ: 5.16 (2H, s), 7.07 (1H, d, J = 8.4 Hz), 7.16-7.30 (3H, m), 7.46-7.57 (2H, m), 9.91 (1H, s).	Ref. Ex. 82
1241		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.1 Hz), 4.47 (2H, q, J = 7.1 Hz), 7.88 (1H, d, J = 8.2 Hz), 7.94-7.97 (2H, m), 8.37 (1H, s).	Ref. Ex. 2
1242		1H-NMR (CDCl3) δ: 7.90-8.02 (3H, m), 8.38 (1H, s), 10.14 (1H, s).	Ref. Ex. 63
1243		1H-NMR (CDCl3) δ: 7.76 (1H, d, J = 7.8 Hz), 8.04 (1H, t, J = 7.7 Hz), 8.32 (1H, s), 8.48 (1H, d, J = 8.0 Hz), 10.11 (1H, s).	Ref. Ex. 48
1244		1H-NMR (CDCl3) δ: 3.12-3.18 (2H, m), 3.24-3.29 (2H, m), 7.23-7.34 (3H, m), 7.43-7.48 (2H, m), 7.64-7.67 (1H, m), 7.72-7.78 (3H, m), 10.00 (1H, s).	Ref. Ex. 34
1245		1H-NMR (CDCl3) δ: 2.71 (2H, t, J = 7.5 Hz), 2.96 (2H, t, J = 7.5 Hz), 5.09 (2H, s), 5.15 (2H, s), 6.81-6.83 (3H, m), 7.18-7.24 (1H, m), 7.37-7.40 (2H, m), 7.51-7.68 (6H, m).	Ref. Ex. 82

Ref. Ex. No.	STR	1H-NMR	ref.
1246		1H-NMR (CDCl3) δ: 2.60 (2H, t, J = 7.5 Hz), 2.90 (2H, t, J = 7.5 Hz), 3.67 (3H, s), 5.10 (2H, s), 6.88-6.90 (2H, m), 7.12-7.15 (2H, m), 7.53-7.66 (4H, m).	Ref. Ex. 82
1247		1H-NMR (CDCl3) δ: 1.35 (1H, t, J = 6.0 Hz), 2.82 (2H, t, J = 6.5 Hz), 3.83 (2H, q, J = 6.5 Hz), 5.11 (2H, s), 6.90-6.93 (2H, m), 7.14-7.18 (2H, m), 7.54 (2H, d, J = 8.2 Hz), 7.64 (2H, d, J = 8.2 Hz).	Ref. Ex. 76
1248		1H-NMR (CDCl3) δ: 1.77 (1H, t, J = 5.9 Hz), 1.85-1.91 (2H, m), 2.70 (2H, t, J = 7.5 Hz), 3.65-3.70 (2H, m), 5.11 (2H, s), 6.78-6.84 (3H, m), 7.19-7.23 (1H, m), 7.48 (2H, d, J = 8.0 Hz), 7.55 (2H, d, J = 8.0 Hz).	Ref. Ex. 76
1249		1H-NMR (CDCl3) δ: 1.22 (1H, t, J = 5.3 Hz), 1.83-1.90 (2H, m), 2.66 (2H, t, J = 7.7 Hz), 3.65-3.69 (2H, m), 5.10 (2H, s), 6.88-6.90 (2H, m), 7.11-7.14 (2H, m), 7.54 (2H, d, J = 8.1 Hz), 7.63 (2H, d, J = 8.1 Hz).	Ref. Ex. 76
1250		1H-NMR (CDCl3) δ: 3.65 (2H, s), 5.13 (2H, s), 6.95-6.98 (2H, m), 7.14-7.16 (2H, m), 7.55 (2H, d, J = 8.4 Hz), 7.65 (2H, d, J = 8.4 Hz), 9.73-9.74 (1H, m).	Ref. Ex. 156
1251		1H-NMR (CDCl3) δ: 2.78-2.78 (2H, m), 2.92-2.97 (2H, m), 5.11 (2H, s), 6.79-6.84 (3H, m), 7.20-7.25 (1H, m), 7.55 (2H, d, J = 8.1 Hz), 7.65 (2H, d, J = 8.1 Hz), 9.82 (1H, s).	Ref. Ex. 156








[0526]








Ref. Ex. No.	STR	1H-NMR	ref.
1252		1H-NMR (CDCl3) δ: 2.73-2.79 (2H, m), 2.89-2.94 (2H, m), 5.11 (2H, s), 6.87-6.92 (2H, m), 7.10-7.14 (2H, m), 7.54 (2H, d, J = 8.1 Hz), 7.64 (2H, d, J = 8.1 Hz), 9.82 (1H, s).	Ref. Ex. 156
1253		1H-NMR (CDCl3) δ: 5.13 (2H, s), 7.10 (1H, s), 7.38 (1H, s), 7.42 (1H, s), 7.61-7.72 (3H, m), 9.96 (1H, s).	Ref. Ex. 82
1254		1H-NMR (CDCl3) δ: 5.24 (2H, s), 7.11 (1H, s), 7.39 (1H, s), 7.40-7.51 (3H, m), 7.63-7.70 (1H, m), 9.96 (1H, s).	Ref. Ex. 82
1255		1H-NMR (CDCl3) δ: 5.38 (2H, s), 7.10 (1H, s), 7.39-7.42 (2H, m), 7.86-7.93 (2H, m), 7.99 (1H, s), 9.96 (1H, s).	Ref. Ex. 82
1256		1H-NMR (CDCl3) δ: 3.01 (3H, s), 5.27 (2H, s), 7.48 (2H, d, J = 8.1 Hz), 7.71 (2H, d, J = 8.1 Hz).	Ref. Ex. 103








Ref. Ex. No.	STR	1H-NMR	ref.
1257		1H-NMR (CDCl3) δ: 2.97 (3H, s), 3.21 (2H, t, J = 6.6 Hz), 4.48 (2H, t, J = 6.6 Hz), 7.71 (2H, s), 7.81 (1H, s).	Ref. Ex. 103
1258		1H-NMR (CDCl3) δ: 1.26 (3H, t, J = 7.1 Hz), 4.33 (2H, q, J = 7.1 Hz), 7.22 (1H, t, J = 8.6 Hz), 7.39-7.46 (3H, m), 7.60 (1H, dd, J = 2.2, 6.9 Hz), 7.91-7.95 (2H, m).	Ref. Ex. 16
1259		1H-NMR (CDCl3) δ: 7.25-7.31 (1H, m), 7.45-7.54 (3H, m), 7.69 (1H, dd, J = 2.3, 8.8 Hz), 7.93-7.98 (2H, m), 10.06 (1H, s).	Ref. Ex. 63
1260		1H-NMR (DMSO-d6) δ: 7.37 (1H, dd, J = 2.1, 8.6 Hz), 7.74 (1H, s), 7.90 (1H, d, J = 2.1 Hz), 8.00 (1H, d, J = 8.6 Hz).	Ref. Ex. 138
1261		1H-NMR (CDCl3) δ: 7.30-7.34 (1H, m), 7.58 (1H, s), 7.63 (1H, t, J = 7.8 Hz), 7.77 (1H, d, J = 8.4 Hz), 7.78 (1H, s), 7.88 (1H, d, J = 7.8 Hz), 7.96 (1H, d, J = 8.4 Hz), 8.20 (1H, s), 10.10 (1H, s).	Ref. Ex. 75
1262		1H-NMR (CDCl3) δ: 7.26-7.36 (1H, m), 7.59 (1H, s), 7.76-7.78 (2H, m), 7.83 (1H, s), 7.91 (1H, s), 8.06 (1H, s), 10.04 (1H, s).	Ref. Ex. 75
1263		1H-NMR (CDCl3) δ: 2.51 (3H, s), 7.26-7.32 (1H, m), 7.56 (1H, s), 7.68-7.77 (4H, m), 8.00 (1H, s), 10.06 (1H, s).	Ref. Ex. 75
1264		1H-NMR (CDCl3) δ: 7.34-7.37 (1H, m), 7.61 (1H, s), 7.72 (1H, s), 7.77-7.81 (3H, m), 8.12 (1H, s), 10.08 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
1265		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.1 Hz), 4.41-4.48 (4H, m), 7.43-7.46 (2H, m), 7.60-7.62 (2H, m), 8.09 (1H, s).	Ref. Ex. 2
1266		1H-NMR (CDCl3) δ: 2.16 (1H, t, J = 6.0 Hz), 4.37 (2H, s), 4.76 (2H, d, J = 6.0 Hz), 7.10 (1H, s), 7.44 (2H, d, J = 8.1 Hz), 7.60 (2H, d, J = 8.2 Hz).	Ref. Ex. 19
1267		1H-NMR (CDCl3) δ: 4.45 (2H, s), 7.46 (2H, d, J = 8.1 Hz), 7.63 (2H, d, J = 8.1 Hz), 8.10 (1H, s), 10.01 (1H, s).	Ref. Ex. 48
1268		1H-NMR (CDCl3) δ: 3.77 (2H, s), 7.32-7.34 (2H, m), 7.54-7.62 (4H, m), 7.75-7.77 (1H, m), 7.82 (1H, s), 9.81 (1H, s).	Ref. Ex. 156
1269		1H-NMR (CDCl3) δ: 4.62 (2H, s), 4.66 (2H, s), 7.42-7.44 (2H, m), 7.55 (1H, t, J = 7.7 Hz), 7.64-7.66 (3H, m), 7.82-7.84 (1H, m), 7.89 (1H, s), 10.04 (1H, s).	Ref. Ex. 100
1270		1H-NMR (CDCl3) δ: 4.59 (2H, s), 4.64 (2H, s), 7.21 (2H, d, J = 7.8 Hz), 7.39-7.41 (2H, m), 7.54 (1H, t, J = 7.4 Hz), 7.63-7.66 (1H, m), 7.81-7.84 (1H, m), 7.89 (1H, s), 10.04 (1H, s).	Ref. Ex. 100
1271		1H-NMR (CDCl3) δ: 2.56 (3H, s), 5.20 (2H, s), 6.99-7.01 (2H, m), 7.55 (2H, d, J = 7.8 Hz), 7.66 (2H, d, J = 7.8 Hz), 7.94-7.96 (2H, m).	Ref. Ex. 82
1272		1H-NMR (CDCl3) δ: 7.11-7.18 (1H, m), 7.46-7.50 (1H, m), 7.61 (1H, s), 7.74-7.84 (2H, m), 7.92 (1H, t, J = 1.8 Hz), 8.06 (1H, t, J = 1.5 Hz), 10.04 (1H, s).	Ref. Ex. 75







[0527]








Ref. Ex. No.	STR	1H-NMR	ref.
1273		1H-NMR (CDCl3) δ: 7.12-7.18 (1H, m), 7.47-7.51 (1H, m), 7.63 (1H, s), 7.71 (1H, s), 7.75-7.82 (2H, m), 8.12 (1H, s), 10.08 (1H, s).	Ref. Ex. 75
1274		1H-NMR (CDCl3) δ: 7.06-7.16 (1H, m), 7.42-7.97 (6H, m), 8.20 (1H, s), 10.10 (1H, s).	Ref. Ex. 75
1275		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.1 Hz), 4.47 (2H, q, J = 7.1 Hz), 7.72 (2H, d, J = 8.2 Hz), 8.14 (2H, d, J = 8.1 Hz), 8.22 (1H, s).	Ref. Ex. 2
1276		1H-NMR (CDCl3) δ: 1.50-1.65 (1H, m), 1.68-1.94 (2H, m), 1.95-2.09 (1H, m), 3.70-3.89 (2H, m), 4.17-4.39 (3H, m), 6.58 (1H, dd, J = 0.7, 3.1 Hz), 7.43 (1H, d, J = 3.1 Hz), 7.62 (1H, dd, J = 1.3, 8.2 Hz), 7.71 (1H, d, J = 8.2 Hz), 7.95 (1H, s), 10.06 (1H, s).	Ref. Ex. 318
1277		1H-NMR (CDCl3) δ: 1.95 (3H, d, J = 7.1 Hz), 5.78 (1H, q, J = 7.1 Hz), 6.63 (1H, dd, J = 0.7, 3.2 Hz), 7.12-7.17 (2H, m), 7.22-7.35 (3H, m), 7.50 (1H, d, J = 3.2 Hz), 7.62 (1H, dd, J = 1.3, 8.2 Hz), 7.72 (1H, d, J = 8.2 Hz), 7.81 (1H, s), 9.98 (1H, s).	Ref. Ex. 318
1278		1H-NMR (CDCl3) δ: 2.54 (3H, s), 7.42-7.50 (3H, m), 7.54-7.60 (2H, m), 7.66 (1H, d, J = 7.7 Hz), 7.84-7.89 (1H, m), 10.38 (1H, s).	Ref. Ex. 600, Ref. Ex. 156
1279		1H-NMR (CDCl3) δ: 2.55 (3H, s), 3.84 (3H, s), 6.80-6.83 (1H, m), 6.84-6.88 (1H, m), 6.93 (1H, ddd, J = 0.9, 2.6, 8.3 Hz), 7.31-7.43 (2H, m), 7.47 (1H, dd, J = 1.6, 7.6 Hz), 7.83 (1H, dd, J = 1.6, 7.5 Hz), 10.38 (1H, s).	Ref. Ex. 600, Ref. Ex. 156






Ref. Ex. No.	STR	1H-NMR	ref.
1280		1H-NMR (CDCl3) δ: 1.93 (3H, s), 2.34 (3H, s), 2.36 (3H, s), 6.93 (1H, dd, J = 1.7, 7.1 Hz), 7.11-7.22 (2H, m), 7.33-7.43 (2H, m), 7.83 (1H, dd, J = 2.1, 7.1 Hz), 10.38 (1H, s).	Ref. Ex. 600, Ref. Ex. 156
1281		1H-NMR (CDCl3) δ: 2.21-2.31 (1H, br), 4.84 (2H, d, J = 4.4 Hz), 7.24-7.30 (2H, m), 7.47 (1H, t, J = 8.3 Hz), 7.83-7.86 (2H, m).	Ref. Ex. 19
1282		1H-NMR (CDCl3) δ: 2.43 (1H, t, J = 6.1 Hz), 4.76 (2H, d, J = 6.0 Hz), 7.28-7.32 (1H, m), 7.47 (1H, t, J = 8.3 Hz), 7.74-7.77 (2H, m).	Ref. Ex. 27
1283		1H-NMR (CDCl3) δ: 1.26 (1H, t, J = 5.8 Hz), 2.85 (2H, t, J = 6.9 Hz), 3.61-3.73 (2H, m), 7.21-7.24 (1H, m), 7.28-7.37 (3H, m), 7.52-7.63 (4H, m).	Ref. Ex. 77
1284		1H-NMR (CDCl3) δ: 3.67 (2H, s), 7.28-7.32 (2H, m), 7.37-7.45 (3H, m), 7.52-7.56 (2H, m), 7.63-7.65 (1H, m), 9.66 (1H, s).	Ref. Ex. 156
1285		1H-NMR (CDCl3) δ: 3.26 (2H, t, J = 6.3 Hz), 4.30 (2H, t, J = 6.3 Hz), 7.14-7.18 (1H, m), 7.37 (1H, s), 7.42-7.49 (2H, m), 7.77 (3H, s), 9.97 (1H, s).	Ref. Ex. 82
1286		1H-NMR (CDCl3) δ: 7.34-7.52 (2H, m), 7.62 (1H, t, J = 8.7 Hz), 7.76-8.02 (4H, m), 10.22 (1H, s).	Ref. Ex. 75
1287		1H-NMR (CDCl3) δ: 7.29-7.41 (2H, m), 7.55-7.70 (4H, m), 8.12-8.16 (1H, m), 10.24 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
1288		1H-NMR (CDCl3) δ: 2.47-2.51 (4H, m), 4.72 (2H, d, J = 5.8 Hz), 7.23-7.26 (1H, m), 7.44 (1H, t, J = 8.2 Hz), 7.76-7.78 (2H, m).	Ref. Ex. 38
1289		1H-NMR (CDCl3) δ: 2.85 (3H, s), 7.29-7.33 (1H, m), 7.49 (1H, d, J = 8.2 Hz), 7.81-7.83 (2H, m), 10.21 (1H, s).	Ref. Ex. 48
1290		1H-NMR (CDCl3) δ: 5.14 (2H, s), 7.10 (1H, s), 7.38-7.41 (2H, m), 7.56 (2H, s), 7.78 (1H, s), 9.56 (1H, s).	Ref. Ex. 82
1291		1H-NMR (CDCl3) δ: 3.71 (4H, s), 7.47-7.51 (2H, m), 7.67 (2H, s), 7.73-7.79 (3H, m), 10.00 (1H, s).	Ref. Ex. 173
1292		1H-NMR (CDCl3) δ: 1.31 (9H, s), 3.60 (2H, s), 3.69 (2H, s), 7.19-7.21 (2H, m), 7.31-7.35 (2H, m), 7.48 (1H, t, J = 7.5 Hz), 7.55-7.58 (1H, m), 7.75-7.79 (2H, m), 10.01 (1H, s).	Ref. Ex. 173
1293		1H-NMR (CDCl3) δ: 2.51 (3H, s), 7.07-7.14 (1H, m), 7.44-7.48 (1H, m), 7.58 (1H, s), 7.68 (1H, s), 7.75-7.79 (2H, m), 8.00 (1H, s), 10.08 (1H, s).	Ref. Ex. 75
1294		1H-NMR (CDCl3) δ: 5.20 (2H, s), 7.10-7.36 (1H, m), 7.49-7.51 (4H, m), 7.79 (1H, s), 9.92 (1H, s).	Ref. Ex. 82








[0528]







Ref. Ex. No.	STR	1H-NMR	ref.
1295		1H-NMR (CDCl3) δ: 1.05 (6H, s), 3.80 (4H, s), 7.30 (1H, dd, J = 1.9, 8.7 Hz), 7.72 (1H, s), 7.77-7.82 (2H, m).	Ref. Ex. 107
1296		1H-NMR (CDCl3) δ: 1.24 (3H, t, J = 7.1 Hz), 1.38 (3H, t, J = 7.1 Hz), 4.08 (2H, q, J = 7.1 Hz), 4.36 (2H, q, J = 7.1 Hz), 7.28-7.31 (2H, m), 7.35-7.40 (3H, m).	Ref. Ex. 12
1297		1H-NMR (CDCl3) δ: 2.19-2.27 (1H, br), 4.83 (2H, d, J = 4.4 Hz), 7.23 (1H, t, J = 0.8 Hz), 7.50 (1H, d, J = 8.4 Hz), 7.75 (1H, dd, J = 2.1, 8.4 Hz), 8.06 (1H, d, J = 2.1 Hz).	Ref. Ex. 19
1298		1H-NMR (CDCl3) δ: 2.49 (3H, s), 7.36-7.47 (2H, m), 7.64 (1H, t, J = 7.8 Hz), 7.74-7.92 (4H, m), 8.05 (1H, s), 10.10 (1H, s).	Ref. Ex. 75
1299		1H-NMR (CDCl3) δ: 7.32-7.37 (1H, m), 7.79-8.01 (6H, m), 10.14 (1H, s).	Ref. Ex. 75
1300		1H-NMR (CDCl3) δ: 1.27 (3H, t, J = 7.1 Hz), 4.06 (2H, q, J = 7.1 Hz), 7.29-7.33 (2H, m), 7.37-7.41 (3H, m), 9.73 (1H, s).	Ref. Ex. 63
1301		1H-NMR (CDCl3) δ: 4.29 (2H, s), 7.07 (1H, s), 7.29-7.37 (2H, m), 7.53-7.55 (1H, m), 7.69-7.77 (4H, m), 9.95 (1H, s).	Ref. Ex. 112
1302		1H-NMR (CDCl3) δ: 2.67 (3H, s), 2.81-3.18 (1H, br), 4.67 (2H, s).	Ref. Ex. 27
1303		1H-NMR (CDCl3) δ: 2.45 (1H, t, J = 6.1 Hz), 4.75 (2H, d, J = 6.1 Hz), 7.51 (1H, d, J = 8.4 Hz), 7.67 (1H, dd, J = 2.1, 8.4 Hz), 7.99 (1H, d, J = 2.1 Hz).	Ref. Ex. 27







Ref. Ex. No.	STR	1H-NMR	ref.
1304		1H-NMR (CDCl3) δ: 7.08 (1H, d, J = 3.9 Hz), 7.16 (1H, d, J = 3.9 Hz), 7.36 (1H, t, J = 7.8 Hz), 7.75-7.82 (2H, m), 8.01-8.02 (1H, m), 10.05 (1H, s).	Ref. Ex. 91
1305		1H-NMR (CDCl3) δ: 2.73-7.79 (2H, m), 3.03 (2H, t, J = 7.5 Hz), 5.15 (2H, s), 6.86-6.96 (2H, m), 7.17-7.22 (2H, m), 7.54 (2H, d, J = 8.1 Hz), 7.66 (2H, d, J = 8.1 Hz), 9.79 (1H, s).	Ref. Ex. 156
1306		1H-NMR (CDCl3) δ: 1.26 (1H, t, J = 7.2 Hz), 1.85-1.94 (2H, m), 2.80 (2H, t, J = 7.5 Hz), 3.61-3.67 (2H, m), 5.15 (2H, s), 6.87-6.97 (2H, m), 7.15-7.21 (2H, m), 7.55-7.58 (2H, m), 7.65-7.67 (2H, m).	Ref. Ex. 82, Ref. Ex. 76
1307		1H-NMR (CDCl3) δ: 1.36 (1H, t, J = 5.8 Hz), 2.59 (2H, t, J = 6.3 Hz), 3.84-3.90 (2H, m), 5.13 (2H, s), 6.82-6.88 (3H, m), 7.22-7.27 (1H, m), 7.54-7.57 (2H, m), 7.64-7.66 (2H, m).	Ref. Ex. 82, Ref. Ex. 76
1308		1H-NMR (CDCl3) δ: 3.67 (2H, s), 5.13 (2H, s), 6.84-6.93 (3H, m), 7.28-7.33 (1H, m), 7.55 (2H, d, J = 8.1 Hz), 7.65 (2H, d, J = 8.1 Hz), 9.75 (1H, s).	Ref. Ex. 156
1309		1H-NMR (CDCl3) δ: 4.19 (2H, s), 5.23 (2H, s), 6.95 (1H, t, J = 7.3 Hz), 7.04 (1H, d, J = 8.2 Hz), 7.25-7.27 (2H, m), 7.49-7.51 (2H, m), 7.70 (2H, d, J = 8.1 Hz).	Ref. Ex. 82, Ref. Ex. 76
1310		1H-NMR (CDCl3) δ: 3.73 (2H, s), 5.15 (2H, s), 6.93 (1H, d, J = 8.1 Hz), 7.00 (1H, t, J = 7.4 Hz), 7.19-7.21 (1H, m), 7.29-7.31 (1H, m), 7.50 (2H, d, J = 8.0 Hz), 7.65 (2H, d, J = 8.0 Hz), 9.74 (1H, s).	Ref. Ex. 48

Ref. Ex. No.	STR	1H-NMR	ref.
1311		1H-NMR (CDCl3) δ: 7.40 (1H, d, J = 3.9 Hz), 7.42 (1H, d, J = 3.9 Hz), 7.53-7.62 (3H, m), 7.80-7.84 (2H, m), 7.88-7.91 (2H, m), 8.14-8.15 (1H, m), 10.08 (1H, s).	Ref. Ex. 91
1312		1H-NMR (CDCl3) δ: 7.08-7.14 (2H, m), 7.25-7.28 (1H, m), 7.38 (1H, d, J = 4.5 Hz), 7.55-7.63 (3H, m), 7.78-7.82 (1H, m), 7.88-7.90 (1H, m), 8.11-8.12 (1H, m), 10.08 (1H, s).	Ref. Ex. 91
1313		1H-NMR (CDCl3) δ: 5.31 (2H, s), 7.04 (1H, s), 7.27-7.37 (5H, m), 7.67-7.76 (2H, m), 9.85 (1H, s).	Ref. Ex. 82
1314		1H-NMR (CDCl3) δ: 5.39 (2H, s), 7.27-7.41 (5H, m), 7.48 (1H, s), 7.76-7.85 (2H, m), 9.92 (1H, s).	Ref. Ex. 82
1315		1H-NMR (CDCl3) δ: 5.47 (2H, s), 7.23-7.28 (4H, m), 7.47-7.52 (1H, m), 7.62-7.65 (1H, m), 7.75-7.84 (2H, m), 9.90 (1H, s).	Ref. Ex. 82




[0529]







Ref. Ex. No.	STR	1H-NMR	ref.
1316		1H-NMR (CDCl3) δ: 2.83-2.89 (2H, m), 3.05 (2H, t, J = 7.5 Hz), 7.22-7.25 (1H, m), 7.38-7.47 (3H, m), 7.53-7.63 (2H, m), 7.74-7.81 (2H, m), 9.86 (1H, s).	Ref. Ex. 156
1317		1H-NMR (CDCl3) δ: 2.55-2.61 (2H, m), 2.89-2.94 (2H, m), 7.19-7.22 (1H, m), 7.26-7.36 (3H, m), 7.49-7.65 (4H, m), 9.66 (1H, m).	Ref. Ex. 156
1318		1H-NMR (CDCl3) δ: 2.47 (3H, s), 7.36-7.40 (1H, m), 7.61-7.63 (1H, m), 7.74-7.79 (3H, m), 7.97 (1H, s), 10.09 (1H, s).	Ref. Ex. 75
1320		1H-NMR (CDCl3) δ: 2.46 (3H, s), 7.14-7.21 (1H, m), 7.41-7.45 (1H, m), 7.64 (1H, s), 7.74-7.81 (2H, m), 7.97 (1H, t, J = 1.4 Hz), 10.08 (1H, s).	Ref. Ex. 75
1321		1H-NMR (CDCl3) δ: 2.37 (1H, t, J = 5.9 Hz), 2.48 (3H, s), 4.71 (2H, d, J = 5.9 Hz), 7.48 (1H, d, J = 8.4 Hz), 7.69 (1H, dd, J = 2.1, 8.4 Hz), 8.00 (1H, d, J = 2.1 Hz).	Ref. Ex. 38
1322		1H-NMR (CDCl3) δ: 2.60 (1H, brs), 2.74 (3H, s), 4.70 (2H, s), 7.57 (2H, d, J = 8.2 Hz), 7.69 (2H, d, J = 8.2 Hz).	Ref. Ex. 38
1323		1H-NMR (CDCl3) δ: 2.85 (3H, s), 7.54 (1H, d, J = 8.4 Hz), 7.74 (1H, dd, J = 2.1, 8.4 Hz), 8.05 (1H, d, J = 2.1 Hz), 10.20 (1H, s).	Ref. Ex. 48







Ref. Ex. No.	STR	1H-NMR	ref.
1324		1H-NMR (CDCl3) δ: 2.80 (3H, s), 7.66 (2H, d, J = 8.2 Hz), 7.75 (2H, d, J = 8.5 Hz), 9.94 (1H, s).	Ref. Ex. 48
1325		1H-NMR (CDCl3) δ: 1.99-2.17 (4H, m), 3.50 (2H, t, J = 6.4 Hz), 3.62 (2H, t, J = 6.4 Hz), 4.03 (3H, s), 7.06 (1H, s), 7.95 (1H, s), 8.92 (2H, d, J = 0.43 Hz).	Ref. Ex. 38
1326		1H-NMR (CDCl3) δ: 1.19-1.23 (2H, m), 1.61-1.64 (2H, m), 5.13 (4H, s), 6.91-6.94 (2H, m), 7.28-7.31 (4H, m), 7.54-7.58 (4H, m), 7.65 (2H, d, J = 8.1 Hz).	Ref. Ex. 82
1327		1H-NMR (CDCl3) δ: 7.47-7.52 (1H, m), 7.58-7.67 (2H, m), 7.97-7.99 (1H, m), 8.01 (2H, s), 8.08 (1H, s), 9.91 (1H, s).	Ref. Ex. 75
1328		1H-NMR (CDCl3) δ: 7.43-7.48 (1H, m), 7.55-7.60 (1H, m), 7.69-7.75 (3H, m), 7.80-7.85 (2H, m), 7.95-7.99 (1H, m), 9.92 (1H, s).	Ref. Ex. 75
1329		1H-NMR (CDCl3) δ: 2.00-2.16 (4H, m), 3.49 (2H, t, J = 6.5 Hz), 3.82 (2H, t, J = 6.5 Hz), 6.83 (1H, s), 7.97 (1H, s), 8.96 (2H, s), 10.03 (1H, s).	Ref. Ex. 318

Ref. Ex. No.	STR	1H-NMR	ref.
1330		1H-NMR (CDCl3) δ: 1.98-2.14 (4H, m), 3.44 (2H, t, J = 6.8 Hz), 3.67 (2H, t, J = 6.8 Hz), 6.75 (1H, s), 9.84 (1H, s).	Ref. Ex. 318
1331		1H-NMR (CDCl3) δ: 4.08 (3H, s), 7.81 (2H, d, J = 8.2 Hz), 8.30 (2H, d, J = 8.2 Hz), 8.40 (1H, s).	Ref. Ex. 38
1332		1H-NMR (CDCl3) δ: 4.11 (3H, s), 7.80 (2H, d, J = 8.3 Hz), 7.85 (2H, d, J = 8.3 Hz), 8.39 (1H, s), 8.41 (2H, d, J = 8.3 Hz), 8.75 (2H, d, J = 8.3 Hz).	Ref. Ex. 38
1333		1H-NMR (CDCl3) δ: 4.72 (2H, s), 4.73 (2H, d, J = 0.4 Hz), 7.30-7.36 (1H, m), 7.37-7.44 (4H, m), 7.50 (1H, d, J = 5.1 Hz), 7.73 (2H, d, J = 8.2 Hz), 8.55 (2H, d, J = 8.2 Hz), 8.82 (1H, d, J = 5.1 Hz).	Ref. Ex. 742
1334		1H-NMR (CDCl3) δ: 2.45 (3H, s), 7.13-7.20 (1H, m), 7.40-7.44 (1H, m), 7.76-7.81 (2H, m), 7.88-7.92 (2H, m), 10.05 (1H, s).	Ref. Ex. 75
1335		1H-NMR (CDCl3) δ: 7.11 (1H, d, J = 5.8 Hz), 7.24 (1H, d, J = 5.8 Hz), 7.72 (2H, s), 8.02 (1H, t, J = 1.4 Hz), 10.06 (1H, s).	Ref. Ex. 75









[0530]








Ref. Ex. No.	STR	1H-NMR	ref.
1336		1H-NMR (CDCl3) δ: 2.45 (3H, s), 7.11-7.18 (1H, m), 7.39-7.43 (1H, m), 7.65 (1H, t, J = 7.7 Hz), 7.75-7.82 (2H, m), 7.90-7.94 (1H, m), 8.03-8.05 (1H, m), 10.10 (1H, s).	Ref. Ex. 75
1337		1H-NMR (CDCl3) δ: 7.84 (4H, t, J = 8.7 Hz), 8.21 (1H, s), 8.41 (2H, d, J = 8.1 Hz), 8.78 (2H, d, J = 8.1 Hz), 10.22 (1H, s).	Ref. Ex. 318
1338		1H-NMR (CDCl3) δ: 1.97-2.05 (4H, m), 3.67-3.75 (4H, m), 4.00 (3H, s), 7.59 (1H, s), 7.73 (2H, d, J = 8.2 Hz), 8.23 (2H, d, J = 8.2 Hz).	Ref. Ex. 1173
1339		1H-NMR (CDCl3) δ: 4.10 (3H, s), 8.10 (1H, s), 8.42 (1H, s), 8.62 (2H, s).	Ref. Ex. 38
1340		1H-NMR (CDCl3) δ: 3.05 (2H, t, J = 6.6 Hz), 3.77-3.82 (2H, m), 4.62 (2H, s), 7.46-7.55 (2H, m), 7.69 (1H, s), 7.75-7.78 (4H, m), 10.01 (1H, s).	Ref. Ex. 189






Ref. Ex. No.	STR	1H-NMR	ref.
1341		1H-NMR (CDCl3) δ: 0.82-0.84 (4H, m), 1.78-1.80 (1H, m), 3.63 (2H, d, J = 5.7 Hz), 5.12 (2H, s), 6.90-6.93 (2H, m), 7.29-7.32 (2H, m), 7.48-7.56 (2H, m), 7.61-7.66 (2H, m).	Ref. Ex. 19
1342		1H-NMR (CDCl3) δ: 1.36-1.40 (2H, m), 1.52-1.55 (2H, m), 5.13 (2H, s), 6.94-6.97 (2H, m), 7.22-7.25 (2H, m), 7.55 (2H, d, J = 8.1 Hz), 7.65 (2H, d, J = 8.1 Hz), 9.19 (1H, s).	Ref. Ex. 156
1343		1H-NMR (CDCl3) δ: 3.38 (1H, t, J = 4.8 Hz), 4.85 (2H, d, J = 4.8 Hz), 7.28 (1H, d, J = 5.1 Hz), 7.76 (2H, d, J = 8.2 Hz), 8.58 (2H, d, J = 8.2 Hz), 8.81 (1H, d, J = 5.1 Hz).	Ref. Ex. 750
1344		1H-NMR (CDCl3) δ: 2.05 (4H, brs), 3.74 (4H, t, J = 6.7 Hz), 4.02 (3H, s), 7.60 (1H, s), 7.99 (1H, s), 8.56 (2H, s).	Ref. Ex. 1173
1345		1H-NMR (CDCl3) δ: 1.06 (6H, s), 2.59 (3H, s), 3.81 (4H, s), 7.08-7.15 (1H, m), 7.37-7.41 (1H, m), 7.74-7.79 (1H, m).	Ref. Ex. 107
1346		1H-NMR (CDCl3) δ: 1.05 (6H, s), 3.81 (4H, s), 7.08-7.15 (1H, m), 7.46-7.50 (1H, m), 7.74 (1H, s), 7.78-7.83 (1H, m).	Ref. Ex. 107
1347		1H-NMR (CDCl3) δ: 7.76 (1H, d, J = 4.8 Hz), 7.79 (2H d, J = 8.5 Hz), 8.68 (2H, dd, J = 0.7, 8.5 Hz), 9.11 (1H, dd, J = 0.7, 4.8 Hz), 10.15 (1H, d, J = 0.7 Hz).	Ref. Ex. 159

Ref. Ex. No.	STR	1H-NMR	ref.
1348		1H-NMR (CDCl3) δ: 2.05-2.08 (4H, m), 3.74 (4H, bs), 7.44 (1H, s), 7.73 (2H, d, J = 8.2 Hz), 8.23 (2H, d, J = 8.2 Hz), 9.93 (1H, s).	Ref. Ex. 318
1349		1H-NMR (CDCl3) δ: 1.98-2.10 (4H, m), 3.70 (4H, bs), 3.96 (1H, t, J = 4.7 Hz), 4.65 (2H, d, J = 4.7 Hz), 6.82 (1H, s), 7.71 (2H, d, J = 8.2 Hz), 8.18 (2H, d, J = 8.2 Hz).	Ref. Ex. 318
1350		1H-NMR (CDCl3) δ: 2.04-2.10 (4H, m), 3.75 (4H, bs), 7.45 (1H, s), 7.99 (1H, s), 8.56 (2H, s), 9.93 (1H, s).	Ref. Ex. 318
1351		1H-NMR (CDCl3) δ: 7.12-7.19 (1H, m), 7.49-7.52 (1H, m), 7.80-7.85 (1H, m), 7.88-7.96 (3H, m), 7.96-8.02 (1H, m), 10.14 (1H, s).	Ref. Ex. 91
1352		1H-NMR (CDCl3) δ: 7.52 (1H, dd, J = 1.3, 8.4 Hz), 7.62 (1H, s), 7.87 (1H, dd, J = 0.6, 8.4 Hz), 7.99 (1H, s).	Ref. Ex. 1319
1353		1H-NMR (CDCl3) δ: 7.59-7.62 (1H, m), 7.73 (1H, s), 7.86 (1H, s), 7.92-7.99 (2H, m), 8.09 (2H, s), 10.06 (1H, s).	Ref. Ex. 91







[0531]






Ref. Ex. No.	STR	1H-NMR	ref.
1354		1H-NMR (CDCl3) δ: 7.55-7.60 (1H, m), 7.65 (1H, t, J = 7.7 Hz), 7.72 (1H, s), 7.88-7.92 (1H, m), 7.94-8.00 (2H, m), 8.08 (1H, s), 8.23 (1H, t, J = 1.4 Hz), 10.11 (1H, s).	Ref. Ex. 91
1355		1H-NMR (CDCl3) δ: 3.23 (2H, t, J = 6.6 Hz), 4.30 (2H, t, J = 6.6 Hz), 7.26-7.28 (2H, m), 7.45 (1H, s), 7.53-7.60 (2H, m), 7.78-7.83 (2H, m), 10.03 (1H, s).	Ref. Ex. 80
1356		1H-NMR (CDCl3) δ: 3.18 (2H, t, J = 6.6 Hz), 4.61 (2H, t, J = 6.6 Hz), 6.89 (1H, d, J = 8.4 Hz), 7.24-7.26 (1H, m), 7.49 (1H, t, J = 7.5 Hz), 7.57-7.59 (1H, m), 7.67-7.78 (2H, m), 7.82 (1H, s), 10.02 (1H, s).	Ref. Ex. 189
1357		1H-NMR (CDCl3) δ: 3.25 (2H, t, J = 6.9 Hz), 4.69 (2H, t, J = 6.9 Hz), 7.26-7.28 (1H, m), 7.50 (1H, t, J = 7.5 Hz), 7.59-7.62 (1H, m), 7.75-7.79 (1H, m), 7.83 (1H, s), 8.76 (1H, d, J = 4.8 Hz), 10.02 (1H, s).	Ref. Ex. 189
1358		1H-NMR (CDCl3) δ: 1.06 (6H, s), 3.82 (4H, s), 7.54-7.58 (1H, m), 7.86 (1H, s), 7.99 (1H, d, J = 8.6 Hz), 8.10 (1H, s).	Ref. Ex. 107
1359		1H-NMR (CDCl3) δ: 7.59-7.68 (1H, m), 7.91-8.06 (5H, m), 8.12 (1H, s), 10.16 (1H, s).	Ref. Ex. 91
1360		1H-NMR (CDCl3) δ: 7.52-7.57 (1H, m), 7.62 (1H, s), 7.81 (1H, d, J = 8.4 Hz), 8.04-8.07 (1H, m).	Ref. Ex. 1319
1361		1H-NMR (CDCl3) δ: 1.50 (3H, t, J = 7.0 Hz), 4.18 (2H, q, J = 7.0 Hz), 7.38-7.44 (1H, m), 7.48-7.50 (1H, m), 7.55-7.61 (1H, m), 7.69 (1H, s), 7.79 (1H, t, J = 1.4 Hz), 7.93-7.98 (1H, m), 8.07 (1H, s), 10.05 (1H, s).	Ref. Ex. 91








Ref. Ex. No.	STR	1H-NMR	ref.
1362		1H-NMR (CDCl3) δ: 2.49 (3H, s), 7.16-7.23 (1H, m), 7.59-7.61 (2H, m), 7.74 (1H, d, J = 8.1 Hz), 7.80 (1H, s), 7.92 (1H, s), 8.07 (1H, s), 10.04 (1H, s).	Ref. Ex. 91
1363		1H-NMR (CDCl3) δ: 7.59-7.68 (2H, m), 7.70 (1H, s), 7.88-7.93 (2H, m), 7.96-8.01 (1H, m), 8.14 (1H, s), 8.23 (1H, t, J = 1.5 Hz), 10.11 (1H, s).	Ref. Ex. 91
1364		1H-NMR (CDCl3) δ: 2.67 (3H, s), 7.14-7.20 (1H, m), 7.43-7.47 (1H, m), 7.61-7.70 (1H, m), 7.76-7.81 (1H, m), 7.87-7.91 (1H, m), 10.23 (1H, s).	Ref. Ex. 91
1365		1H-NMR (CDCl3) δ: 2.55 (3H, s), 7.49-7.53 (1H, m), 7.80 (1H, s), 8.00 (1H, s), 8.17 (1H, s), 8.33 (1H, s), 8.90 (1H, d, J = 5.1 Hz), 10.10 (1H, s).	Ref. Ex. 91
1366		1H-NMR (CDCl3) δ: 7.57 (1H, d, J = 5.0 Hz), 7.83 (1H, s), 8.01 (1H, s), 8.24 (1H, s), 8.49 (1H, t, J = 1.4 Hz), 8.93 (1H, d, J = 5.0 Hz), 10.13 (1H, s).	Ref. Ex. 91
1367		1H-NMR (CDCl3) δ: 7.03-7.09 (1H, m), 7.31-7.38 (1H, m), 7.57-7.68 (3H, m), 7.87-7.98 (2H, m), 8.23 (1H, s), 10.10 (1H, s).	Ref. Ex. 91
1368		1H-NMR (CDCl3) δ: 7.59-7.64 (1H, m), 7.90-8.05 (5H, m), 8.18 (1H, s), 10.16 (1H, s).	Ref. Ex. 107, Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
1369		1H-NMR (CDCl3) δ: 2.71 (3H, s), 2.75 (3H, s), 4.12 (3H, s), 7.36 (1H, s), 7.67 (1H, t, J = 7.5 Hz), 7.93-7.96 (1H, m), 8.41-8.44 (1H, m), 8.61 (1H, s), 10.14 (1H, s).	Ref. Ex. 91
1370		1H-NMR (CDCl3) δ: 6.85-6.90 (1H, m), 7.23-7.28 (1H, m), 7.69-7.74 (2H, m), 7.79 (1H, s), 7.83-7.87 (1H, m), 7.91-7.95 (1H, m), 8.10-8.11 (1H, m), 8.34-8.36 (1H, m), 10.11 (1H, s).	Ref. Ex. 91
1371		1H-NMR (CDCl3) δ: 2.12 (3H, s), 2.45 (3H, s), 3.82 (3H, s), 5.15 (2H, s), 6.39 (1H, s), 7.32 (2H, s), 7.80 (1H, s).	Ref. Ex. 184
1372		1H-NMR (CDCl3) δ: 2.55 (3H, s), 7.81 (1H, s), 7.93 (1H, d, J = 8.2 Hz), 8.01-8.06 (1H, m), 8.18 (1H, s), 8.33 (1H, s), 8.98 (1H, s), 10.10 (1H, s).	Ref. Ex. 91
1373		1H-NMR (CDCl3) δ: 7.84 (1H, s), 7.95 (1H, d, J = 8.3 Hz), 8.07-8.10 (1H, m), 8.24 (1H, s), 8.50 (1H, t, J = 1.4 Hz), 9.00 (1H, s), 10.12 (1H, s).	Ref. Ex. 107, Ref. Ex. 14








[0532]










Ref. Ex. No.	STR	1H-NMR	ref.
1374		1H-NMR (CDCl3) δ: 2.05 (6H, s), 4.52 (2H, d, J = 5.1 Hz), 5.11 (2H, s), 6.00 (1H, s), 7.31 (2H, s), 7.78 (1H, s).	Ref. Ex. 76
1375		1H-NMR (CDCl3) δ: 7.37-7.40 (1H, m), 7.58 (1H, t, J = 7.5 Hz), 7.64-7.67 (1H, m), 7.75 (1H, d, J = 9.6 Hz), 8.01 (1H, s), 8.18-8.21 (1H, m), 8.26 (1H, s), 8.54 (1H, s).	Ref. Ex. 89
1376		1H-NMR (CDCl3) δ: 7.06-7.13 (1H, m), 7.34-7.41 (1H, m), 7.63 (1H, d, J = 8.0 Hz), 7.69-7.73 (2H, m), 7.79 (1H, s), 8.14 (1H, s), 10.08 (1H, s).	Ref. Ex. 91
1378		1H-NMR (CDCl3) δ: 4.09-4.24 (4H, m), 5.36 (2H, s), 5.90 (1H, s), 7.00 (1H, s), 7.16 (1H, dd, J = 2.5, 9.2 Hz), 7.45 (1H, d, J = 2.5 Hz), 7.63 (2H, d, J = 8.2 Hz), 7.70 (2H, d, J = 8.2 Hz), 8.12 (1H, d, J = 9.2 Hz).	Ref. Ex. 100
1379		1H-NMR (CDCl3) δ: 2.90-2.95 (2H, m), 3.18-3.23 (2H, m), 6.44-6.79 (1H, br), 7.18-7.43 (1H, br), 7.35 (2H, d, J = 8.0 Hz), 7.55 (2H, d, J = 8.1 Hz).	Ref. Ex. 1477
1380		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.1 Hz), 3.17-3.23 (2H, m), 3.36-3.42 (2H, m), 4.44 (2H, q, J = 7.1 Hz), 7.32 (2H, d, J = 8.0 Hz), 7.55 (2H, d, J = 8.0 Hz), 8.05 (1H, s).	Ref. Ex. 2









Ref. Ex. No.	STR	1H-NMR	ref.
1381		1H-NMR (CDCl3) δ: 2.15 (1H, brs), 3.15-3.20 (2H, m), 3.29-3.34 (2H, m), 4.76 (2H, s), 7.04 (1H, s), 7.32 (2H, d, J = 8.0 Hz), 7.55 (2H, d, J = 8.1 Hz).	Ref. Ex. 19
1382		1H-NMR (CDCl3) δ: 3.23-3.28 (2H, m), 3.39-3.44 (2H, m), 7.35 (2H, d, J = 8.1 Hz), 7.58 (2H, d, J = 8.0 Hz), 8.07 (1H, s), 10.03 (1H, s).	Ref. Ex. 48
1383		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.1 Hz), 4.33 (2H, q, J = 7.1 Hz), 4.50 (2H, d, J = 5.7 Hz), 7.31 (4H, s), 7.39 (1H, s).	Ref. Ex. 2
1384		1H-NMR (CDCl3) δ: 3.99 (3H, s), 5.41 (2H, s), 7.30 (1H, dd, (J = 2.5, 9.2 Hz), 7.36 (1H, s), 7.51 (1H, d, J = 2.5 Hz), 7.64 (2H, d, J = 8.0 Hz), 7.71 (2H, d, J = 8.0 Hz), 8.20 (1H, d, J = 9.2 Hz), 10.13 (1H, s).	Ref. Ex. 151
1385		1H-NMR (CDCl3) δ: 7.36-7.39 (1H, m), 7.73 (2H, d, J = 8.1 Hz), 8.09-8.14 (4H, m), 8.23 (1H, d, J = 6.9 Hz), 10.02 (1H, s).	Ref. Ex. 48

Ref. Ex. No.	STR	1H-NMR	ref.
1386		1H-NMR (CDCl3) δ: 4.75 (2H, s), 6.82-6.85 (1H, m), 7.61 (1H, s), 7.69 (2H, d, J = 8.1 Hz), 7.90 (1H, s), 8.04-8.11 (4H, m).	Ref. Ex. 76
1387		1H-NMR (CDCl3) δ: 1.25 (3H, t, J = 6.9 Hz), 1.33-1.55 (4H, m), 2.02-2.32 (5H, m), 3.31-3.39 (1H, m), 4.12 (2H, q, J = 6.9 Hz), 4.61 (2H, s), 7.45 (2H, d, J = 8.4 Hz), 7.60 (2H, d, J = 8.4 Hz).	Ref. Ex. 100
1388		1H-NMR (CDCl3) δ: 1.24-1.40 (2H, m), 1.19-1.54 (5H, m), 1.85-1.89 (2H, m), 2.13-2.16 (2H, m), 3.28-3.49 (2H, d, J = 8.4 Hz), 4.62 (2H, s), 7.45 (2H, d, J = 8.1 Hz), 7.60 (2H, d, J = 8.1 Hz).	Ref. Ex. 19
1389		1H-NMR (CDCl3) δ: 1.30-1.48 (4H, m), 2.05-2.30 (5H, m), 3.32-3.39 (1H, m), 4.62 (2H, s), 7.46 (2H, d, J = 8.1 Hz), 7.60 (2H, d, J = 8.1 Hz), 9.66 (1H, s).	Ref. Ex. 156
1390		1H-NMR (CDCl3) δ: 7.39 (1H, dd, J = 1.5, 9.3 Hz), 7.65 (1H, t, J = 7.8 Hz), 7.82 (1H, d, J = 9.3 Hz), 7.88-7.92 (1H, m), 8.05 (1H, s), 8.23-8.26 (1H, m), 8.44-8.45 (1H, m), 8.54-8.55 (1H, m), 10.12 (1H, s).	Ref. Ex. 93
1391		1H-NMR (CDCl3) δ: 1.51 (3H, t, J = 7.2 Hz), 4.54 (2H, q, J = 7.2 Hz), 6.89 (1H, t, J = 7.2 Hz), 7.69 (2H, d, J = 8.1 Hz), 7.96-7.8.00 (2H, m), 8.14 (2H, d, J = 8.1 Hz), 8.30-8.32 (1H, m).	Ref. Ex. 1377
1392		1H-NMR (DMSO-d6) δ: 4.00 (3H, s), 7.44 (1H, dd, J = 2.7, 9.3 Hz), 7.72 (1H, d, J = 2.7 Hz), 7.77 (1H, s), 7.79-7.83 (3H, m), 7.97 (2H, d, J = 8.1 Hz), 10.16 (1H, s).	Ref. Ex. 151










[0533]









Ref. Ex. No.	STR	1H-NMR	ref.
1393		1H-NMR (CDCl3) δ: 3.96 (3H, s), 4.11-4.26 (4H, m), 6.00 (1H, s), 7.18 (1H, dd, J = 2.6, 9.2 Hz), 7.46 (1H, s), 7.58 (1H, d, J = 2.6 Hz), 7.62 (2H, d, J = 8.0 Hz), 7.68 (1H, d, J = 9.2 Hz), 7.98 (2H, d, J = 8.1 Hz).	Ref. Ex. 38
1394		1H-NMR (CDCl3) δ: 2.54 (3H, s), 7.65-7.71 (1H, m), 7.79 (1H, s), 7.93-8.00 (2H, m), 8.21 (1H, s), 8.33 (1H, s), 10.10 (1H, s).	Ref. Ex. 75
1395		1H-NMR (CDCl3) δ: 5.58 (2H, s), 7.30 (1H, d, J = 4.8 Hz), 7.56 (1H, t, J = 7.5 Hz), 7.77-7.81 (1H, m), 7.85-7.88 (1H, m), 8.04 (1H, s), 8.89 (1H, d, J = 4.8 Hz), 10.04 (1H, s).	Ref. Ex. 100
1396		1H-NMR (CDCl3) δ: 5.51 (2H, s), 6.99 (1H, d, J = 8.4 Hz), 7.28 (1H, d, J = 7.5 Hz), 7.55 (1H, t, J = 7.5 Hz), 7.71-7.78 (2H, m), 7.83-7.86 (1H, m), 8.03 (1H, s), 10.04 (1H, s).	Ref. Ex. 100
1397		1H-NMR (CDCl3) δ: 1.37 (3H, t, J = 7.1 Hz), 3.05 (3H, s), 4.35 (2H, q, J = 7.1 Hz), 4.71 (2H, s), 7.20-7.23 (2H, m), 7.28-7.32 (2H, m), 7.40 (1H, s).	Ref. Ex. 12
1398		1H-NMR (CDCl3) δ: 3.07 (3H, s), 4.73 (2H, s), 7.21-7.24 (2H, m), 7.30-7.33 (2H, m), 7.43 (1H, s), 9.73 (1H, s).	Ref. Ex. 63
1399		1H-NMR (CDCl3) δ: 2.14 (3H, s), 2.43 (3H, s), 5.18 (2H, s), 6.43 (1H, s), 7.34 (2H, s), 7.83 (1H, s), 9.88 (1H, s).	Ref. Ex. 48








Ref. Ex. No.	STR	1H-NMR	ref.
1400		1H-NMR (CDCl3) δ: 4.02 (3H, s), 7.21-7.25 (2H, m), 7.30 (1H, dd, J = 2.6, 9.3 Hz), 7.46-7.52 (2H, m), 7.62 (1H, d, J = 2.6 Hz), 7.83-7.85 (2H, m), 10.24 (1H, s).	Ref. Ex. 38
1401		1H-NMR (CDCl3) δ: 6.90-6.98 (2H, m), 7.15-7.19 (1H, m), 7.37-7.41 (1H, m).	Ref. Ex. 1319
1402		1H-NMR (CDCl3) δ: 4.73 (2H, s), 4.76 (2H, s), 7.41-7.46 (2H, m), 7.59 (1H, t, J = 7.8 Hz), 7.84 (3H, s).	Ref. Ex. 100
1403		1H-NMR (CDCl3) δ: 4.69 (2H, s), 4.71 (2H, s), 7.39-7.64 (7H, m).	Ref. Ex. 100
1404		1H-NMR (CDCl3) δ: 7.03-7.10 (1H, m), 7.14 (1H, s), 7.27-7.30 (1H, m), 7.46-7.50 (2H, m), 7.83 (1H, s), 8.07 (1H, s), 8.21 (1H, s), 10.05 (1H, s).	Ref. Ex. 75
1405		1H-NMR (CDCl3) δ: 7.43-7.49 (2H, m), 7.58-7.60 (1H, m), 7.68-7.72 (1H, m), 7.96 (1H, d, J = 8.7 Hz), 8.02 (1H, s), 8.11 (1H, s), 10.11 (1H, s).	Ref. Ex. 75
1406		1H-NMR (CDCl3) δ: 4.78 (4H, s), 7.63-7.66 (1H, m), 7.72-7.74 (1H, m), 7.84-7.91 (4H, m).	Ref. Ex. 89
1407		1H-NMR (CDCl3) δ: 4.73 (4H, s), 7.49-7.52 (2H, m), 7.61-7.65 (3H, m), 7.73-7.76 (1H, m), 7.86 (1H, t, J = 7.8 Hz).	Ref. Ex. 89
1408		1H-NMR (CDCl3) δ: 6.86 (1H, d, J = 3.8 Hz), 7.33 (1H, d, J = 3.8 Hz), 7.60 (1H, d, J = 8.3 Hz), 7.82 (1H, s), 7.95 (1H, d, J = 8.3 Hz), 8.08 (1H, s), 9.71 (1H, s).	Ref. Ex. 43

Ref. Ex. No.	STR	1H-NMR	ref.
1409		1H-NMR (CDCl3) δ: 7.00-7.08 (1H, m), 7.11 (1H, s), 7.28-7.29 (1H, m), 7.45-7.49 (1H, m), 7.64 (1H, d, J = 7.6 Hz), 7.86-7.90 (1H, m), 8.08-8.12 (1H, m), 8.36 (1H, s), 10.11 (1H, s).	Ref. Ex. 75
1410		1H-NMR (CDCl3) δ: 6.80-6.85 (1H, m), 7.18-7.24 (1H, m), 7.59-7.67 (2H, m), 7.84-7.87 (1H, m), 7.96 (1H, s), 8.14-8.17 (1H, m), 8.24-8.28 (1H, m), 8.45-8.46 (1H, m), 10.11 (1H, s).	Ref. Ex. 93
1411		1H-NMR (CDCl3) δ: 7.12-7.15 (1H, m), 7.59-7.65 (2H, m), 7.86-7.88 (1H, m), 7.97 (1H, s), 8.09-8.11 (1H, m), 8.22-8.25 (1H, m), 8.42-8.43 (1H, m), 10.11 (1H, s).	Ref. Ex. 93
1412		1H-NMR (CDCl3) δ: 2.05 (1H, t, J = 6.2 Hz), 4.58 (2H, dd, J = 0.9, 6.2 Hz), 6.71 (1H, t, J = 0.9 Hz), 7.21-7.25 (2H, m), 7.35-7.40 (2H, m).	Ref. Ex. 19
1413		1H-NMR (CDCl3) δ: 1.99 (1H, t, J = 6.2 Hz), 4.60 (2H, dd, J = 1.0, 6.2 Hz), 6.76 (1H, t, J = 1.0 Hz), 7.48-7.56 (4H, m).	Ref. Ex. 19
1414		1H-NMR (CDCl3) δ: 2.05 (1H, t, J = 6.3 Hz), 4.55 (2H, d, J = 6.4 Hz), 7.46-7.55 (4H, m).	Ref. Ex. 27
1416		1H-NMR (CDCl3) δ: 4.81 (2H, s), 4.85 (2H, s), 7.70-7.73 (1H, m), 7.83-7.93 (5H, m), 10.07 (1H, s).	Ref. Ex. 48
1417		1H-NMR (CDCl3) δ: 2.01 (1H, t, J = 6.1 Hz), 2.33 (3H, s), 4.50 (2H, d, J = 6.0 Hz), 7.19-7.23 (2H, m), 7.33-7.37 (2H, m).	Ref. Ex. 38









[0534]








Ref. Ex. No.	STR	1H-NMR	ref.
1418		1H-NMR (CDCl3) δ: 1.97-2.04 (1H, m), 2.35 (3H, s), 4.45-4.52 (2H, m), 7.28-7.67 (4H, m).	Ref. Ex. 38
1419		1H-NMR (CDCl3) δ: 2.71 (3H, s), 7.25-7.28 (2H, m), 7.36-7.40 (2H, m), 9.90 (1H, s).	Ref. Ex. 159
1420		1H-NMR (CDCl3) δ: 2.73 (3H, s), 7.52-7.61 (4H, m), 9.90 (1H, s).	Ref. Ex. 159
1421		1H-NMR (CDCl3) δ: 3.96 (3H, s), 4.12-4.18 (2H, m), 4.19-4.25 (2H, m), 5.98 (1H, s), 7.18 (1H, dd, J = 2.7, 9.2 Hz), 7.33 (1H, dd, J = 1.3, 4.9 Hz), 7.49-7.51 (2H, m), 7.52-7.53 (H, m), 7.54 (1H, d, J = 2.7 Hz), 7.95 (1H, d, J = 9.2 Hz).	Ref. Ex. 38
1422		1H-NMR (CDCl3) δ: 4.64 (2H, s), 4.69 (2H, s), 6.89-6.97 (1H, m), 7.29-7.35 (1H, m), 7.39-7.46 (2H, m), 7.55-7.60 (1H, m).	Ref. Ex. 100
1423		1H-NMR (CDCl3) δ: 7.37-7.44 (1H, m), 7.58 (1H, d, J = 7.5 Hz), 7.62 (1H, s), 7.87 (1H, d, J = 8.0 Hz).	Ref. Ex. 1319
1424		1H-NMR (CDCl3) δ: 7.68 (1H, t, J = 7.7 Hz), 7.99-8.10 (3H, m), 8.30 (1H, t, J = 1.5 Hz), 8.86-8.89 (1H, m), 10.11 (1H, s).	Ref. Ex. 75
1425		1H-NMR (CDCl3) δ: 4.66 (2H, s), 4.74 (2H, s), 6.90-6.99 (1H, m), 7.28-7.35 (1H, m), 7.62 (1H, d, J = 7.8 Hz), 7.72 (1H, d, J = 7.8 Hz), 7.87 (1H, t, J = 7.8 Hz).	Ref. Ex. 89
1426		1H-NMR (CDCl3) δ: 6.99 (1H, t, J = 6.6 Hz), 7.72 (2H, d, J = 8.1 Hz), 7.85-7.88 (1H, m), 8.05 (1H, s), 8.14 (2H, d, J = 8.1 Hz), 8.37-8.39 (1H, m), 10.88 (1H, s).	Ref. Ex. 76 Ref. Ex. 48











Ref. Ex. No.	STR	1H-NMR	ref.
1427		1H-NMR (CDCl3) δ: 3.60 (1H, t, J = 5.1 Hz), 4.77 (6H, s), 7.18 (1H, d, J = 7.8 Hz), 7.39 (1H, d, J = 7.8 Hz), 7.73 (1H, t, J = 7.8 Hz), 7.82-7.85 (3H, m).	Ref. Ex. 93
1428		1H-NMR (CDCl3) δ: 3.66-3.69 (1H, s), 4.72-4.76 (6H, m), 7.15-7.17 (1H, m), 7.36-7.41 (1H, m), 7.50-7.53 (2H, m), 7.62-7.74 (3H, m).	Ref. Ex. 93
1429		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.2 Hz), 4.46 (2H, q, J = 7.2 Hz), 7.59-7.64 (1H, m), 7.89 (1H, s), 7.92 (1H, d, J = 8.7 Hz), 8.14-8.16 (1H, m), 8.20 (1H, s).	Ref. Ex. 14
1430		1H-NMR (CDCl3) δ: 7.45-7.51 (1H, m), 7.60-7.67 (2H, m), 7.71 (1H, s), 7.87-7.91 (1H, m), 7.95-8.01 (2H, m), 8.24 (1H, t, J = 1.5 Hz), 10.10 (1H, s).	Ref. Ex. 75
1431		1H-NMR (CDCl3) δ: 4.02 (3H, s), 7.32 (1H, dd, J = 2.6, 9.3 Hz), 7.35 (1H, dd, J = 1.3, 4.9 Hz), 7.52-7.57 (2H, m), 7.60 (1H, d, J = 2.6 Hz), 7.90 (1H, s), 8.06 (1H, d, J = 9.3 Hz), 10.23 (1H, s).	Ref. Ex. 151
1432		1H-NMR (CDCl3) δ: 7.41 (1H, d, J = 3.9 Hz), 7.56-7.62 (1H, m), 7.65 (1H, s), 7.73 (1H, d, J = 4.0 Hz), 7.92 (1H, d, J = 8.3 Hz), 8.07 (1H, s), 9.92 (1H, s).	Ref. Ex. 43
1433		1H-NMR (CDCl3) δ: 7.60-7.65 (1H, m), 7.89 (1H, s), 7.94 (1H, d, J = 8.4 Hz), 8.17 (1H, s), 8.22 (1H, s), 10.12 (1H, s).	Ref. Ex. 19, Ref. Ex. 48
1434		1H-NMR (CDCl3) δ: 7.45-7.52 (1H, m), 7.67-7.72 (2H, m), 7.85 (1H, s), 7.96-8.00 (2H, m), 8.11 (1H, s), 10.05 (1H, s).	Ref. Ex. 75

Ref. Ex. No.	STR	1H-NMR	ref.
1435		1H-NMR (CDCl3) δ: 7.12-7.18 (1H, m), 7.48-7.52 (1H, m), 7.58 (1H, s), 7.69 (1H, d, J = 8.2 Hz), 7.77-7.85 (2H, m), 8.08 (1H, d, J = 1.9 Hz), 10.04 (1H, s).	Ref. Ex. 75
1436		1H-NMR (CDCl3) δ: 7.50-7.56 (1H, m), 7.80-7.88 (1H, m), 7.89 (1H, s), 8.26 (1H, s), 8.34 (1H, s), 8.58 (1H, s), 10.06 (1H, s).	Ref. Ex. 75
1437		1H-NMR (CDCl3) δ: 3.96 (3H, s), 4.11-4.18 (2H, m), 4.19-4.27 (2H, m), 5.99 (1H, s), 7.17 (1H, dd, J = 2.6, 9.2 Hz), 7.42-7.47 (3H, m), 7.48-7.52 (2H, m), 7.55 (1H, d, J = 2.6 Hz), 7.72 (1H, d, J = 9.2 Hz).	Ref. Ex. 38
1438		1H-NMR (DMSO-d6) δ: 4.00 (3H, s), 7.44 (1H, dd, J = 2.7, 9.3 Hz), 7.58-7.63 (2H, m), 7.65-7.68 (2H, m), 7.70 (1H, d, J = 2.7 Hz), 7.72 (1H, s), 7.83 (1H, d, J = 9.3 Hz), 10.15 (1H, s).	Ref. Ex. 151
1439		1H-NMR (CDCl3) δ: 4.69 (2H, s), 4.81 (2H, s), 6.90-6.98 (1H, m), 7.30-7.38 (1H, m), 7.70-7.73 (1H, m), 7.88-7.94 (2H, m), 10.06 (1H, s).	Ref. Ex. 318
1440		1H-NMR (CDCl3) δ: 4.76 (2H, s), 4.80 (2H, s), 7.52 (2H, d, J = 8.1 Hz), 7.64 (2H, d, J = 8.1 Hz), 7.72-7.75 (1H, m), 7.87-7.94 (2H, m), 10.06 (1H, s).	Ref. Ex. 48
1441		1H-NMR (CDCl3) δ: 6.92-6.99 (2H, m), 7.10-7.17 (1H, m), 7.28 (1H, d, J = 1.0 Hz).	Ref. Ex. 1319














[0535]

Ref. Ex. No.	STR	1H-NMR	ref.
1442		1H-NMR (CDCl3) δ: 4.13 (2H, s), 7.42 (1H, s), 7.58 (1H, s), 7.65 (2H, s), 7.75 (1H, s), 8.62 (1H, s), 9.95 (1H, s).	Ref. Ex. 91
1443		1H-NMR (CDCl3) δ: 5.22 (2H, s), 7.25-7.26 (1H, m), 7.38 (1H, s), 7.51 (1H, s), 7.75 (1H, d, J = 8.1 Hz), 7.97 (1H, d, J = 8.1 Hz), 8.81 (1H, s), 9.32 (1H, s).	Ref. Ex. 82
1444		1H-NMR (CDCl3) δ: 4.05 (2H, s), 7.21-7.32 (1H, m), 7.41 (1H, s), 7.42-7.49 (1H, m), 7.58 (1H, s), 7.72 (1H, s), 8.51-8.53 (2H, m), 9.93 (1H, s).	Ref. Ex. 75
1445		1H-NMR (CDCl3) δ: 7.03-7.22 (3H, m), 7.36-7.40 (1H, m), 7.65 (1H, t, J = 7.8 Hz), 7.88-7.91 (1H, m), 8.13-8.17 (1H, m), 8.34 (1H, s), 10.12 (1H, s).	Ref. Ex. 91
1446		1H-NMR (CDCl3) δ: 2.38 (6H, s), 4.07 (2H, s), 7.42-7.45 (2H, m), 7.87-7.90 (2H, m), 10.19 (1H, s).	Ref. Ex. 1494, Ref. Ex. 1173
1447		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.1 Hz), 1.76-2.04 (4H, m), 2.70-2.79 (1H, m), 3.15 (2H, dt, J = 3.0, 12.7 Hz), 4.17-4.21 (2H, m), 4.36 (2H, q, J = 7.1 Hz), 7.20-7.35 (5H, m), 7.43 (1H, s).	Ref. Ex. 184
1448		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.1 Hz), 3.39-3.43 (4H, m), 3.69-3.72 (4H, m), 4.37 (2H, q, J = 7:1 Hz), 6.96 (2H, d, J = 8.7 Hz), 7.49 (1H, s), 7.51 (2H, d, J = 8.9 Hz).	Ref. Ex. 184
1449		1H-NMR (CDCl3) δ: 1.77-2.00 (4H, m), 2.72-2.80 (1H, m), 3.19 (2H, dt, J = 3.0, 12.8 Hz), 4.21 (2H, dt, J = 12.9, 2.2 Hz), 7.21-7.35 (5H, m), 7.46 (1H, s), 9.71 (1H, s).	Ref. Ex. 63







Ref. Ex. No.	STR	1H-NMR	ref.
1450		1H-NMR (CDCl3) δ: 3.40-3.44 (4H, m), 3.72-3.75 (4H, m), 6.97 (2H, d, J = 8.6 Hz), 7.51-7.54 (3H, m), 9.73 (1H, s).	Ref. Ex. 63
1451		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.1 Hz), 3.24-3.28 (4H, m), 3.67-3.71 (4H, m), 4.36 (2H, q, J = 7.1 Hz), 6.86-6.89 (2H, m), 7.22-7.25 (2H, m), 7.48 (1H, s).	Ref. Ex. 184
1452		1H-NMR (CDCl3) δ: 3.25 (6H, s), 7.37-7.40 (2H, m), 7.73-7.76 (2H, m), 9.95 (1H, s).	Ref. Ex. 1173
1453		1H-NMR (CDCl3) δ: 3.26-3.29 (4H, m), 3.70-3.74 (4H, m), 6.86-6.90 (2H, m), 7.22-7.26 (2H, m), 7.50 (1H, s), 9.72 (1H, s).	Ref. Ex. 63
1454		1H-NMR (CDCl3) δ: 7.06-7.11 (1H, m), 7.17-7.22 (2H, m), 7.38-7.41 (1H, m), 7.85 (1H, s), 8.11 (1H, s), 8.25 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
1455		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.1 Hz), 7.42 (2H, q, J = 7.1 Hz), 7.30-7.35 (1H, m), 7.72 (1H, s), 7.86 (1H, d, J = 8.8 Hz), 8.04 (1H, s).	Ref. Ex. 1415
1456		1H-NMR (CDCl3) δ: 4.15 (2H, s), 7.43-7.54 (2H, m), 7.63 (2H, s), 7.72 (1H, s), 7.78 (1H, d, J = 7.2 Hz), 8.62 (1H, s), 10.00 (1H, s).	Ref. Ex. 91








Ref. Ex. No.	STR	1H-NMR	ref.
1457		1H-NMR (CDCl3) δ: 5.23 (2H, s), 7.24-7.28 (1H, m), 7.47-7.54 (3H, m), 7.74 (1H, d, J = 7.8 Hz), 7.98 (1H, d, J = 9.0 Hz), 8.82 (1H, s), 10.00 (1H, s).	Ref. Ex. 82
1458		1H-NMR (CDCl3) δ: 1.53 (3H, d, J = 6.6 Hz), 4.56 (2H, s), 4.61-4.66 (1H, m), 7.39-7.47 (4H, m), 7.56-7.61 (3H, m).	Ref. Ex. 100
1459		1H-NMR (CDCl3) δ: 1.56 (3H, d, J = 6.5 Hz), 4.55-4.73 (3H, m), 7.41-7.45 (2H, m), 7.60 (1H, t, J = 7.7 Hz), 7.78 (3H, s).	Ref. Ex. 100
1460		1H-NMR (CDCl3) δ: 7.16-7.21 (1H, m), 7.54 (1H, s), 7.56-7.58 (1H, m), 7.76 (1H, d, J = 8.8 Hz).	Ref. Ex. 1319
1461		1H-NMR (CDCl3) δ: 6.79-6.86 (1H, m), 7.22 (1H, dd, J = 2.2, 8.7 Hz), 7.50 (1H, d, J = 3.3 Hz).	Ref. Ex. 1319
1462		1H-NMR (CDCl3) δ: 6.86-6.93 (1H, m), 7.29-7.33 (1H, m), 7.62-7.67 (2H, m), 7.89-7.97 (2H, m), 8.21 (1H, s), 10.10 (1H, s).	Ref. Ex. 91
1463		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.5 Hz), 1.42 (3H, t, J = 7.2 Hz), 3.13 (2H, q, J = 7.5 Hz), 4.43 (2H, q, J = 7.2 Hz), 7.42-7.45 (2H, m), 8.01-8.03 (2H, m).	Ref. Ex. 133
1464		1H-NMR (CDCl3) δ: 1.30 (3H, t, J = 7.5 Hz), 2.76 (2H, q, J = 7.5 Hz), 3.25 (1H, bs), 4.59 (2H, s), 7.39-7.43 (2H, m), 7.91-7.95 (2H, m).	Ref. Ex. 19
1465		1H-NMR (CDCl3) δ: 7.22-7.25 (1H, m), 7.61-7.84 (3H, m), 7.87-7.98 (3H, m), 8.21 (1H, s), 10.10 (1H, s).	Ref. Ex. 91
1466		1H-NMR (CDCl3) δ: 1.58 (3H, d, J = 6.6 Hz), 4.54-4.77 (3H, m), 7.63-7.66 (1H, m), 7.70-7.73 (1H, m), 7.79-7.81 (3H, m), 7.89 (1H, t, J = 7.8 Hz).	Ref. Ex. 89




[0536]








Ref. Ex. No.	STR	1H-NMR	ref.
1467		1H-NMR (CDCl3) δ: 7.61-7.66 (3H, m), 7.85 (1H, d, J = 8.7 Hz), 7.87-7.90 (1H, m), 7.94-7.98 (1H, m), 8.21 (1H, t, J = 1.5 Hz), 10.10 (1H, s).	Ref. Ex. 91
1468		1H-NMR (CDCl3) δ: 7.74 (2H, d, J = 8.2 Hz), 8.05 (2H, d, J = 8.1 Hz), 10.13 (1H, s).	Ref. Ex. 159
1469		1H-NMR (CDCl3) δ: 7.62 (1H, t, J = 7.8 Hz), 7.76 (1H, d, J = 7.9 Hz), 8.10 (1H, d, J = 7.8 Hz), 8.20 (1H, s), 10.13 (1H, s).	Ref. Ex. 159
1470		1H-NMR (CDCl3) δ: 7.34-7.37 (1H, m), 7.52 (1H, t, J = 8.2 Hz), 7.81-7.83 (2H, m), 10.12 (1H, s).	Ref. Ex. 159
1471		1H-NMR (CDCl3) δ: 7.56 (1H, d, J = 8.4 Hz), 7.73 (1H, dd, J = 2.1, 8.4 Hz), 8.06 (1H, d, J = 2.1 Hz), 10.10 (1H, s).	Ref. Ex. 159
1472		1H-NMR (CDCl3) δ: 1.58 (3H, t, J = 7.0 Hz), 4.38 (2H, q, J = 7.0 Hz), 7.39-7.42 (2H, m), 7.79-7.82 (2H, m), 10.00 (1H, s).	Ref. Ex. 184
1473		1H-NMR (CDCl3) δ: 4.23 (3H, s), 7.70 (2H, d, J = 8.2 Hz), 7.99 (2H, d, J = 8.1 Hz), 10.04 (1H, s).	Ref. Ex. 184
1474		1H-NMR (CDCl3) δ: 4.23 (3H, s), 7.58 (1H, t, J = 7.8 Hz), 7.69 (1H, d, J = 7.9 Hz), 8.06 (1H, d, J = 7.9 Hz), 8.13 (1H, s), 10.04 (1H, s).	Ref. Ex. 184
1475		1H-NMR (CDCl3) δ: 4.22 (3H, s), 7.28-7.31 (1H, m), 7.45-7.50 (1H, m), 7.76-7.80 (2H, m), 10.03 (1H, s).	Ref. Ex. 184
1476		1H-NMR (CDCl3) δ: 4.22 (3H, s), 7.51 (1H, d, J = 8.4 Hz), 7.68 (1H, dd, J = 2.1, 8.4 Hz), 8.00 (1H, d, J = 2.1 Hz), 10.01 (1H, s).	Ref. Ex. 184
1478		1H-NMR (CDCl3) δ: 1.62 (3H, d, J = 6.6 Hz), 4.57-4.67 (2H, m), 4.80 (1H, q, J = 6.6 Hz), 7.69-7.72 (1H, m), 7.80 (3H, s), 7.89-7.96 (2H, m), 10.07 (1H, s).	Ref. Ex. 318
1479		1H-NMR (CDCl3) δ: 7.10-7.17 (1H, m), 7.38-7.39 (1H, m), 7.44-7.48 (1H, m), 7.55 (1H, s), 7.72-7.73 (2H, m), 9.91 (1H, s).	Ref. Ex. 91
1480		1H-NMR (CDCl3) δ: 6.88-6.95 (1H, m), 7.30-7.40 (1H, m), 7.61-7.64 (1H, m), 7.85-7.88 (1H, m), 7.92-7.93 (1H, m), 8.07-8.08 (1H, m), 10.05 (1H, s).	Ref. Ex. 91
1481		1H-NMR (CDCl3) δ: 4.01 (3H, s), 4.88 (2H, s), 4.91 (2H, s), 7.72-7.74 (1H, m), 7.83-7.98 (4H, m), 8.06-8.09 (1H, m).	Ref. Ex. 100
1482		1H-NMR (CDCl3) δ: 4.01 (3H, s), 4.89 (4H, s), 7.66-7.81 (3H, m), 7.91 (1H, t, J = 7.8 Hz), 8.07-8.10 (2H, m).	Ref. Ex. 100
1483		1H-NMR (CDCl3) δ: 5.42 (2H, s), 7.28-7.31 (6H, m), 7.93 (1H, d, J = 8.7 Hz), 8.04 (1H, s), 9.99 (1H, s).	Ref. Ex. 80
1484		1H-NMR (CDCl3) δ: 5.39 (2H, s), 6.84-6.91 (1H, m), 7.17-7.36 (3H, m), 7.46-7.54 (3H, m), 9.99 (1H, s).	Ref. Ex. 80
1485		1H-NMR (CDCl3) δ: 1.52 (9H, s), 3.95 (3H, s), 7.42-7.45 (2H, m), 7.97-8.00 (2H, m).	Ref. Ex. 133
1486		1H-NMR (CDCl3) δ: 3.74 (1H, bs), 4.78 (4H, s), 4.91 (2H, s), 7.18 (1H, d, J = 8.1 Hz), 7.40 (1H, d, J = 8.1 Hz), 7.73 (1H, t, J = 8.1 Hz), 7.84 (1H, d, J = 8.1 Hz), 7.91 (1H, s), 7.98 (1H, d, J = 8.1 Hz).	Ref. Ex. 19
1487		1H-NMR (CDCl3) δ: 3.66-3.68 (1H, m), 4.76-4.80 (4H, m), 4.89 (2H, s), 7.18 (1H, d, J = 8.4 Hz), 7.40 (1H, d, J = 8.4 Hz), 7.66-7.81 (3H, m), 8.10 (1H, s).	Ref. Ex. 19
1488		1H-NMR (CDCl3) δ: 4.87 (2H, s), 4.94 (2H, s), 7.73-7.76 (1H, m), 7.84-7.99 (5H, m), 10.07 (1H, s).	Ref. Ex. 156
1489		1H-NMR (CDCl3) δ: 4.88 (2H, s), 4.93 (2H, s), 7.67-7.75 (2H, m), 7.81 (1H, d, J = 8.4 Hz), 7.90-7.94 (2H, m), 8.10 (1H, s), 10.07 (1H, s).	Ref. Ex. 156










[0537]









Ref. Ex. No.	STR	1H-NMR	ref.
1490		1H-NMR (CDCl3) δ: 1.53 (3H, d, J = 6.5 Hz), 4.54-4.60 (2H, m), 4.70 (1H, q, J = 6.5 Hz), 7.44-7.47 (2H, m), 7.60-7.64 (3H, m), 7.72-7.76 (1H, m), 7.87 (1H, t, J = 7.8 Hz).	Ref. Ex. 89
1491		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 3.12 (2H, q, J = 7.5 Hz), 7.45-7.48 (2H, m), 7.99-8.02 (2H, m), 10.03 (1H, s).	Ref. Ex. 48
1495		1H-NMR (CDCl3) δ: 7.66 (1H, d, J = 5.0 Hz), 7.72-7.76 (1H, m), 7.81-7.84 (1H, m), 8.33-8.38 (1H, m), 9.18 (1H, d, J = 5.0 Hz), 10.08 (1H, d, J = 1.6 Hz).	Ref. Ex. 91
1496		1H-NMR (CDCl3) δ: 7.10-7.17 (1H, m), 7.46-7.50 (1H, m), 7.65 (1H, s), 7.76-7.81 (1H, m), 7.86 (2H, d, J = 8.4 Hz), 7.95 (2H, d, J = 8.4 Hz), 10.05 (1H, s).	Ref. Ex. 91
1498		1H-NMR (CDCl3) δ: 1.55 (3H, d, J = 6.6 Hz), 3.87 (1H, bs), 4.52-4.55 (2H, m), 4.66 (1H, q, J = 6.6 Hz), 4.77 (2H, s), 7.15 (1H, d, J = 7.5 Hz), 7.39 (1H, d, J = 7.5 Hz), 7.46 (2H, d, J = 7.8 Hz), 7.60 (2H, d, J = 7.8 Hz), 7.72 (1H, t, J = 7.5 Hz).	Ref. Ex. 19
1499		1H-NMR (CDCl3) δ: 7.13-7.32 (1H, m), 7.68-7.69 (2H, m), 7.84-7.89 (3H, m), 7.95-7.98 (2H, m), 10.06 (1H, s).	Ref. Ex. 91
1500		1H-NMR (CDCl3) δ: 7.63 (1H, d, J = 5.0 Hz), 7.99-8.05 (1H, m), 8.34-7.38 (1H, m), 8.45 (1H, d, J = 8.2 Hz), 9.12 (1H, d, J = 4.9 Hz), 10.46 (1H, s).	Ref. Ex. 91
1501		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.1 Hz), 2.46 (3H, s), 3.86 (3H, s), 4.33 (2H, q, J = 7.1 Hz).	Ref. Ex. 12

Ref. Ex. No.	STR	1H-NMR	ref.
1502		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.1 Hz), 2.57 (3H, s), 3.55 (3H, s), 4.36 (2H, q, J = 7.1 Hz).	Ref. Ex. 12
1503		1H-NMR (CDCl3) δ: 4.32 (2H, s), 7.09 (1H, s), 7.30-7.34 (1H, m), 7.48-7.52 (2H, m), 7.82 (1H, d, J = 2.0 Hz), 7.75-7.80 (3H, m), 10.00 (1H, s).	Ref. Ex. 91
1504		1H-NMR (CDCl3) δ: 5.32 (2H, s), 7.28-7.38 (2H, m), 7.42-7.59 (4H, m), 7.78-7.85 (2H, m), 10.00 (1H, s).	Ref. Ex. 82
1505		1H-NMR (CDCl3) δ: 1.37 (6H, d, J = 7.2 Hz), 3.81-3.91 (1H, m), 3.96 (3H, s), 7.54 (1H, d, J = 8.5 Hz), 7.69-7.93 (1H, m), 8.17-8.18 (1H, m).	Ref. Ex. 133
1506		1H-NMR (CDCl3) δ: 1.37 (6H, d, J = 6.9 Hz), 3.81-3.90 (1H, m), 3.95 (3H, s), 7.21-7.26 (1H, m), 7.94-7.99 (1H, m), 8.15 (1H, dd, J = 2.1, 7.2 Hz).	Ref. Ex. 133
1507		1H-NMR (CDCl3) δ: 2.69 (3H, s), 7.60-7.63 (1H, m), 7.84-7.86 (2H, m), 8.14-8.17 (1H, m), 9.15 (1H, d, J = 4.8 Hz), 10.09 (1H, s).	Ref. Ex. 91
1508		1H-NMR (CDCl3) δ: 1.34 (6H, d, J = 6.9 Hz), 2.67-2.71 (1H, m), 3.13-3.23 (1H, m), 4.61 (2H, d, J = 5.7 Hz), 7.51 (1H, d, J = 8.4 Hz), 7.82 (1H, dd, J = 2.1, 8.4 Hz), 8.07 (1H, d, J = 2.1 Hz).	Ref. Ex. 19
1509		1H-NMR (CDCl3) δ: 1.41 (6H, d, J = 7.0 Hz), 3.67-3.74 (1H, m), 7.56 (1H, d, J = 8.4 Hz), 7.90 (1H, dd, J = 2.0, 8.4 Hz), 8.15 (1H, d, J = 2.0 Hz), 10.03 (1H, s).	Ref. Ex. 147

















Ref. Ex. No.	STR	1H-NMR	ref.
1510		1H-NMR (CDCl3) δ: 1.39 (6H, d, J = 6.9 Hz), 3.81-3.93 (1H, m), 3.97 (3H, s), 7.61 (1H, t, J = 7.8 Hz), 7.73 (1H, d, J = 7.8 Hz), 8.27 (1H, d, J = 7.8 Hz), 8.34 (1H, s).	Ref. Ex. 133
1511		1H-NMR (CDCl3) δ: 1.36 (6H, d, J = 6.9 Hz), 2.27 (1H, t, J = 5.7 Hz), 3.15-3.24 (1H, m), 4.63 (2H, d, J = 5.7 Hz), 7.58 (1H, t, J = 7.8 Hz), 7.68 (1H, d, J = 7.8 Hz), 8.19 (1H, d, J = 7.8 Hz), 8.26 (1H, s).	Ref. Ex. 19
1512		1H-NMR (CDCl3) δ: 1.43 (6H, d, J = 7.0 Hz), 3.69-3.76 (1H, m), 7.63 (1H, t, J = 7.8 Hz), 7.75 (1H, d, J = 7.8 Hz), 8.28 (1H, d, J = 7.8 Hz), 8.32 (1H, s), 10.06 (1H, s).	Ref. Ex. 147
1513		1H-NMR (CDCl3) δ: 1.34 (6H, d, J = 6.9 Hz), 3.05-3.22 (2H, m), 4.61 (2H, d, J = 6.0 Hz), 7.20 (1H, t, J = 8.7 Hz), 7.85-7.91 (1H, m), 8.04 (1H, dd, J = 2.1, 7.2 Hz).	Ref. Ex. 19
1514		1H-NMR (CDCl3) δ: 1.41 (6H, d, J = 7.0 Hz), 3.67-3.74 (1H, m), 7.24-7.28 (1H, m), 7.94-7.98 (1H, m), 8.13 (1H, dd, J = 2.2, 6.9 Hz), 10.03 (1H, s).	Ref. Ex. 147
1515		1H-NMR (CDCl3) δ: 1.42 (9H, s), 2.87 (1H, d, J = 6.0 Hz), 4.70 (1H, d, J = 6.0 Hz), 7.40-7.42 (2H, m), 7.90-7.93 (2H, m).	Ref. Ex. 19
1516		1H-NMR (CDCl3) δ: 1.54 (9H, s), 7.45-7.47 (2H, m), 8.00-8.02 (2H, m), 10.15 (1H, s).	Ref. Ex. 147
1517		1H-NMR (CDCl3) δ: 7.67-7.72 (1H, m), 7.99-8.04 (4H, m), 8.23-8.28 (2H, m), 10.11 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
1518		1H-NMR (CDCl3) δ: 3.98 (3H, s), 7.18 (1H, dd, J = 4.7, 8.0 Hz), 7.50 (1H, s), 7.62 (1H, t, J = 7.6 Hz), 7.76-7.81 (1H, m), 7.88-7.93 (1H, m), 8.14 (1H, t, J = 1.7 Hz), 8.24 (1H, dd, J = 1.5, 8.0 Hz), 8.42 (1H, dd, J = 1.5, 4.7 Hz), 10.10 (1H, s).	Ref. Ex. 91
1519		1H-NMR (CDCl3) δ: 7.55-7.57 (1H, m), 7.71-7.75 (1H, m), 7.81-7.84 (1H, m), 8.11 (1H, s), 8.27 (1H, t, J = 7.6 Hz), 8.95 (1H, d, J = 5.0 Hz), 10.07 (1H, d, J = 1.8 Hz).	Ref. Ex. 91
1520		1H-NMR (CDCl3) δ: 2.53 (3H, s), 5.53 (2H, s), 7.28 (2H, d, J = 8.1 Hz), 7.59 (2H, d, J = 8.1 Hz), 7.64 (1H s), 9.81 (1H, d, J = 0.7 Hz).	Ref. Ex. 184
1521		1H-NMR (CDCl3) δ: 2.46 (3H, s), 5.19 (2H, s), 7.18 (2H, d, J = 8.1 Hz), 7.55 (1H, s), 7.64 (2H, d, J = 8.1 Hz), 9.98 (1H s).	Ref. Ex. 184
1522		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.1 Hz), 1.49 (18H, s), 4.44 (2H, q, J = 7.1 Hz), 5.52 (1H, s), 7.78 (2H, s), 8.07 (1H, s).	Ref. Ex. 2
1523		1H-NMR (CDCl3) δ: 1.03 (3H, t, J = 7.2 Hz), 1.76-1.83 (2H, m), 3.09 (2H, t, J = 7.2 Hz), 3.95 (3H, s), 7.20-7.26 (1H, m), 7.94-7.99 (1H, m), 8.14-8.17 (1H, m).	Ref. Ex. 133
1524		1H-NMR (CDCl3) δ: 1.04 (3H, t, J = 7.5 Hz), 1.78-1.85 (2H, m), 3.12 (2H, t, J = 7.5 Hz), 3.97 (3H, s), 7.60 (1H, t, J = 7.8 Hz), 7.73 (1H, d, J = 7.8 Hz), 8.27 (1H, d, J = 7.8 Hz), 8.34 (1H, s).	Ref. Ex. 133










Ref. Ex. No.	STR	1H-NMR	ref.
1525		1H-NMR (CDCl3) δ: 2.16 (3H, s), 2.77-2.95 (1H, br), 4.79 (2H, d, J = 5.7 Hz), 5.19 (1H, s), 5.31 (1H, t, J = 1.4 Hz), 7.38-7.43 (2H, m), 7.83-7.87 (2H, m).	Ref. Ex. 43
1526		1H-NMR (CDCl3) δ: 2.16 (3H, s), 2.80 (1H, t, J = 5.7 Hz), 4.79 (2H, d, J = 5.7 Hz), 5.20 (1H, s), 5.32 (1H, t, J = 1.3 Hz), 7.20 (1H, t, J = 8.6 Hz), 7.74-7.79 (1H, m), 7.99 (1H, dd, J = 2.2, 6.9 Hz).	Ref. Ex. 43
1527		1H-NMR (CDCl3) δ: 1.49 (18H, s), 4.79 (2H, s), 7.06 (1H, s), 7.74 (2H, s).	Ref. Ex. 76
1528		1H-NMR (CDCl3) δ: 0.99 (3H, t, J = 7.2 Hz), 1.68-1.79 (3H, m), 2.71 (2H, t, J = 7.2 Hz), 4.59 (2H, s), 7.21 (1H, t, J = 8.7 Hz), 7.85-7.91 (1H, m), 8.05 (1H, dd, J = 2.1, 7.2 Hz).	Ref. Ex. 19
1529		1H-NMR (CDCl3) δ: 1.00 (3H, t, J = 7.5 Hz), 1.69-1.81 (2H, m), 2.34-2.38 (1H, m), 2.74 (2H, t, J = 7.5 Hz), 4.61 (2H, d, J = 5.4 Hz), 7.58 (1H, t, J = 7.8 Hz), 7.68 (1H, d, J = 7.8 Hz), 8.18 (1H, d, J = 7.8 Hz), 8.26 (1H, s).	Ref. Ex. 19
1530		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.1 Hz), 2.53 (3H, s), 3.87 (3H, s), 4.36 (2H, q, J = 7.1 Hz), 7.43-7.46 (2H, m), 7.50-7.55 (2H, m).	Ref. Ex. 38
1531		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.1 Hz), 2.53 (3H, s), 3.86 (3H, s), 4.36 (2H, q, J = 7.1 Hz), 7.14-7.20 (2H, m), 7.53-7.63 (2H, m).	Ref. Ex. 38
1532		1H-NMR (CDCl3) δ: 1.54 (1H, brs), 2.27 (3H, s), 3.70 (3H, s), 4.68 (2H, s), 7.43 (2H, d, J = 8.6 Hz), 7.54 (2H, d, J = 8.6 Hz).	Ref. Ex. 76
1533		1H-NMR (CDCl3) δ: 1.34 (6H, d, J = 7.0 Hz), 2.71 (1H, t, J = 6.0 Hz), 3.13-3.23 (1H, m), 4.62 (2H, d, J = 6.0 Hz), 7.26-7.30 (2H, m), 8.01-8.06 (2H, m).	Ref. Ex. 133, Ref. Ex. 19








Ref. Ex. No.	STR	1H-NMR	ref.
1534		1H-NMR (CDCl3) δ: 2.49 (3H, s), 7.31 (1H, s), 7.41 (1H, d, J = 4.9 Hz), 7.54 (1H, s), 7.63 (1H, s), 8.79 (1H, d, J = 4.9 Hz), 9.99 (1H, s).	Ref. Ex. 113
1535		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.1 Hz), 2.55 (3H, s), 3.90 (3H, s), 4.37 (2H, q, J = 7.1 Hz), 7.74 (4H, s).	Ref. Ex. 38
1536		1H-NMR (CDCl3) δ: 2.55 (3H, s), 3.95 (3H, s), 7.47-7.51 (2H, m), 7.57-7.61 (2H, m), 9.88 (1H, s).	Ref. Ex. 159
1537		1H-NMR (CDCl3) δ: 1.34 (6H, d, J = 6.8 Hz), 2.44 (1H, t, J = 5.7 Hz), 3.28-3.37 (1H, m), 4.72 (2H, d, J = 5.6 Hz), 7.37-7.41 (2H, m), 7.81-7.85 (2H, m).	Ref. Ex. 34
1538		1H-NMR (CDCl3) δ: 1.35 (6H, d, J = 6.8 Hz), 2.35 (1H, t, J = 5.8 Hz), 3.30-3.35 (1H, m), 4.72 (2H, d, J = 5.8 Hz), 7.16-7.22 (1H, m), 7.72-7.77 (1H, m), 7.98 (1H, dd, J = 2.3, 7.0 Hz).	Ref. Ex. 34
1539		1H-NMR (CDCl3) δ: 1.39 (6H, d, J = 6.8 Hz), 4.10-4.19 (1H, m), 7.41-7.46 (2H, m), 7.86-7.90 (2H, m), 10.20 (1H, s).	Ref. Ex. 48
1540		1H-NMR (CDCl3) δ: 1.50 (18H, s), 5.57 (1H, s), 7.80 (2H, s), 8.09 (1H, s), 10.09 (1H, s).	Ref. Ex. 48
1541		1H-NMR (CDCl3) δ: 1.39 (6H, d, J = 6.8 Hz), 4.10-4.19 (1H, m), 7.20-7.26 (1H, m), 7.77-7.82 (1H, m), 8.03 (1H, dd, J = 2.2, 6.9 Hz), 10.19 (1H, s).	Ref. Ex. 48








[0539]

Ref. Ex. No.	STR	1H-NMR	ref.
1542		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.1 Hz), 2.62 (3H, s), 3.57 (3H, s), 4.39 (2H, q, J = 7.1 Hz), 7.12-7.17 (2H, m), 7.55-7.60 (2H, m).	Ref. Ex. 38
1543		1H-NMR (CDCl3) δ: 1.49 (1H, t, J = 4.2 Hz), 2.28 (3H, s), 3.69 (3H, s), 4.67 (2H, d, J = 4.2 Hz), 7.11-7.18 (2H, m), 7.54-7.61 (2H, m).	Ref. Ex. 76
1544		1H-NMR (CDCl3) δ: 1.68 (1H, brs), 2.28 (3H, s), 3.74 (3H, s), 4.69 (2H, s), 7.67-7.75 (4H, m).	Ref. Ex. 76
1545		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.1 Hz), 4.43 (2H, s), 4.46 (2H, q, J = 7.1 Hz), 4.56 (2H, s), 7.56 (1H, t, J = 7.6 Hz), 7.67 (1H, d, J = 7.7 Hz), 7.78 (1H, s), 8.27 (1H, s).	Ref. Ex. 2
1546		1H-NMR (CDCl3) δ: 2.54 (3H, s), 3.94 (3H, s), 7.16-7.23 (2H, m), 7.61-7.66 (2H, m), 9.88 (1H, s).	Ref. Ex. 159
1547		1H-NMR (CDCl3) δ: 2.56 (3H, s), 3.98 (3H, s), 7.74-7.84 (4H m), 9.91 (1H, s).	Ref. Ex. 159
1548		1H-NMR (CDCl3) δ: 7.45-7.51 (2H, m), 7.73-7.80 (2H, m), 8.81 (1H, d, J = 4.8 Hz), 10.01 (1H, s).	Ref. Ex. 113
1549		1H-NMR (CDCl3) δ: 2.41 (3H, s), 4.47 (2H, s), 7.06 (1H, s), 7.26-7.48 (5H, m), 7.75 (1H, d, J = 7.8 Hz), 10.11 (1H, s).	Ref. Ex. 91
1550		1H-NMR (CDCl3) δ: 1.57-1.58 (3H, m), 4.57 (2H, s), 4.77 (1H, q, J = 6.6 Hz), 7.45-7.48 (2H, m), 7.60-7.62 (2H, m), 7.72-7.75 (1H, m), 7.88-7.92 (2H, m), 10.08 (1H, s).	Ref. Ex. 156
1551		1H-NMR (CDCl3) δ: 4.45 (2H, s), 4.56 (2H, s), 7.58 (1H, t, J = 7.7 Hz), 7.69 (1H, d, J = 7.7 Hz), 7.78 (1H, d, J = 7.6 Hz), 7.84 (1H, s), 8.30 (1H, s), 10.10 (1H, s).	Ref. Ex. 63
1552		1H-NMR (CDCl3) δ: 2.25 (3H, s), 5.44 (1H, s), 5.53 (1H, t, J = 1.3 Hz), 7.42-7.46 (2H, m), 7.90-7.95 (2H, m), 10.07 (1H, s).	Ref. Ex. 48
1553		1H-NMR (CDCl3) δ: 2.48 (1H, t, J = 6.2 Hz), 4.95 (2H, d, J = 6.2 Hz), 7.45-7.48 (2H, m), 7.88-7.91 (2H, m).	Ref. Ex. 89
1554		1H-NMR (CDCl3) δ: 1.36 (6H, d, J = 6.9 Hz), 3.80-3.90 (1H, m), 3.95 (3H, s), 7.13-7.18 (2H, m), 8.05-8.09 (2H, m).	Ref. Ex. 133
1555		1H-NMR (CDCl3) δ: 1.34 (6H, d, J = 6.9 Hz), 2.48 (1H, d, J = 6.0 Hz), 3.10-3.24 (1H, m), 4.61 (2H, d, J = 6.0 Hz), 7.10-7.16 (2H, m), 7.97-8.02 (2H, m).	Ref. Ex. 19
1556		1H-NMR (CDCl3) δ: 1.41 (6H, d, J = 6.9 Hz), 3.65-3.74 (1H, m), 7.15-7.21 (2H, m), 8.05-8.09 (2H, m), 10.04 (1H, s).	Ref. Ex. 147
1557		1H-NMR (CDCl3) δ: 1.17-1.26 (4H, m), 2.79-2.88 (1H, m), 3.97 (3H, s), 7.40-7.43 (2H, m), 7.91-7.94 (2H, m).	Ref. Ex. 133
1558		1H-NMR (CDCl3) δ: 0.96-1.05 (4H, m), 1.94-2.05 (1H, m), 2.22 (1H, bs), 4.66 (2H, s), 7.39-7.42 (2H, m), 7.87-7.90 (2H, m).	Ref. Ex. 19
1559		1H-NMR (CDCl3) δ: 1.24-1.30 (4H, m), 2.65-2.74 (1H, m), 7.43-7.46 (2H, m), 7.90-7.93 (2H, m), 10.04 (1H, s).	Ref. Ex. 147
1560		1H-NMR (CDCl3) δ: 1.36 (6H, d, J = 6.9 Hz), 3.80-3.90 (1H, m), 3.95 (3H, s), 7.21-7.30 (1H, m), 7.81-7.93 (2H, m).	Ref. Ex. 133
1561		1H-NMR (CDCl3) δ: 1.34 (6H, d, J = 6.9 Hz), 2.35-2.38 (1H, m), 3.10-3.24 (1H, m), 4.60 (2H, d, J = 5.7 Hz), 7.19-7.28 (1H, m), 7.73-7.85 (2H, m).	Ref. Ex. 19
1562		1H-NMR (CDCl3) δ: 3.75 (3H, s), 3.89 (3H, s), 7.45 (1H, d, J = 1.1 Hz), 7.58 (1H, d, J = 1.1 Hz).	Ref. Ex. 12
1563		1H-NMR (CDCl3) δ: 7.49-7.53 (2H, m), 7.93-7.98 (2H, m), 10.18 (1H, s).	Ref. Ex. 48
1564		1H-NMR (CDCl3) δ: 7.77-7.83 (3H, m), 8.03-8.13 (3H, m), 9.00 (1H, s), 10.11 (1H, s).	Ref. Ex. 112
1565		1H-NMR (CDCl3) δ: 1.20-1.27 (4H, m), 2.81-2.91 (1H, m), 3.98 (3H, s), 7.69-7.71 (2H, m), 8.10-8.13 (2H, m).	Ref. Ex. 133

[0540]

Ref. Ex. No.	STR	1H-NMR	ref.
1566		1H-NMR (CDCl3) δ: 0.97-1.10 (4H, m), 1.97-2.06 (1H, m), 2.27-2.31 (1H, m), 4.68 (2H, d, J = 5.7 Hz), 7.69 (2H, d, J = 8.4 Hz), 8.06 (2H, d, J = 8.4 Hz).	Ref. Ex. 19
1567		1H-NMR (CDCl3) δ: 1.27-1.33 (4H, m), 2.68-2.77 (1H, m), 7.73 (2H, d, J = 8.1 Hz), 8.10 (2H, d, J = 8.1 Hz), 10.06 (1H, s).	Ref. Ex. 147
1568		1H-NMR (CDCl3) δ: 2.28 (3H, s), 2.97 (1H, brs), 3.54 (3H, s), 4.60 (2H, s), 7.12-7.17 (2H, m), 7.52-7.58 (2H, m).	Ref. Ex. 76
1569		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.1 Hz), 2.62 (3H, s), 3.58 (3H, s), 4.40 (2H, q, J = 7.1 Hz), 7.39-7.45 (2H, m), 7.51-7.58 (2H, m).	Ref. Ex. 75
1570		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.1 Hz), 2.64 (3H, s), 3.62 (3H, s), 4.41 (2H, q, J = 7.1 Hz), 7.68-7.76 (4H, m).	Ref. Ex. 75
1571		1H-NMR (CDCl3) δ: 2.62 (3H, s), 3.61 (3H, s), 7.15-7.22 (2H, m), 7.57-7.64 (2H, m), 9.99 (1H, s).	Ref. Ex. 159
1572		1H-NMR (CDCl3) δ: 2.31 (3H, s), 2.53 (1H, t, J = 5.3 Hz), 3.61 (3H, s), 4.63 (2H, d, J = 5.3 Hz), 7.72 (4H, s).	Ref. Ex. 76
1573		1H-NMR (CDCl3) δ: 2.29 (3H, s), 2.32 (1H, brs), 3.56 (3H, s), 4.61 (2H, d, J = 3.7 Hz), 7.41-7.45 (2H, m), 7.50-7.54 (2H, m).	Ref. Ex. 76
1574		1H-NMR (CDCl3) δ: 1.02 (6H, s), 1.29 (6H, d, J = 6.9 Hz), 2.98-3.03 (1H, m), 3.80 (4H, s), 7.82-7.83 (1H, m), 7.93 (1H, s), 8.11 (1H, s), 10.03 (1H, s).	Ref. Ex. 107







Ref. Ex. No.	STR	1H-NMR	ref.
1575		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.1 Hz), 4.42 (2H, q, J = 7.1 Hz), 7.20-7.26 (1H, m), 7.54-7.59 (1H, m), 7.75 (1H, dd, J = 2.3, 6.8 Hz), 8.05 (1H, s).	Ref. Ex. 10
1576		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.1 Hz), 4.43 (2H, q, J = 7.1 Hz), 7.58 (1H, t, J = 7.8 Hz), 7.71 (1H, d, J = 7.9 Hz), 7.83 (1H, d, J = 7.8 Hz), 7.92 (1H, s), 8.08 (1H, s).	Ref. Ex. 10
1577		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.1 Hz), 1.77-1.89 (2H, m), 2.06-2.13 (4H, m), 2.94-2.98 (2H, m), 3.09-3.17 (1H, m), 3.49 (2H, s), 4.42 (2H, q, J = 7.1 Hz), 7.25-7.31 (4H, m), 8.07 (1H, s).	Ref. Ex. 113
1578		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.1 Hz), 1.80-1.92 (2H, m), 2.10-2.18 (4H, m), 2.95-2.99 (2H, m), 3.09-3.19 (1H, m), 3.58 (2H, s), 4.42 (2H, q, J = 7.1 Hz), 7.46 (2H, d, J = 8.1 Hz), 7.58 (2H, d, J = 8.0 Hz), 8.07 (1H, s).	Ref. Ex. 113
1579		1H-NMR (CDCl3) δ: 2.11 (1H, brs), 4.74 (2H, d, J = 5.1 Hz), 7.13-7.22 (2H, m), 7.48-7.53 (1H, m), 7.67-7.71 (1H, m).	Ref. Ex. 19
1580		1H-NMR (CDCl3) δ: 2.00-2.28 (1H, br), 4.76 (2H, s), 7.18 (1H, s), 7.53 (1H, t, J = 7.8 Hz), 7.65 (1H, d, J = 7.9 Hz), 7.76 (1H, d, J = 7.7 Hz), 7.85 (1H, s).	Ref. Ex. 19
1581		1H-NMR (CDCl3) δ: 1.82-1.95 (2H, m), 2.10-2.17 (4H, m), 2.95-3.13 (3H, m), 3.50 (2H, s), 7.26-7.32 (4H, m), 8.08 (1H, s), 10.00 (1H, s).	Ref. Ex. 63









Ref. Ex. No.	STR	1H-NMR	ref.
1582		1H-NMR (CDCl3) δ: 1.84-1.97 (2H, m), 2.12-2.21 (4H, m), 2.96-3.13 (3H, m), 3.59 (2H, s), 7.47 (2H, d, J = 8.3 Hz), 7.58 (2H, d, J = 8.2 Hz), 8.08 (1H, s), 10.00 (1H, s).	Ref. Ex. 63
1583		1H-NMR (CDCl3) δ: 2.62 (3H, s), 3.62 (3H, s), 7.46-7.49 (2H, m), 7.52-7.60 (2H, m), 9.99 (1H, s).	Ref. Ex. 159
1584		1H-NMR (CDCl3) δ: 2.64 (3H, s), 3.66 (3H, s), 7.76 (4H, s), 10.01 (1H, s).	Ref. Ex. 159
1585		1H-NMR (CDCl3) δ: 7.68 (1H, d, J = 5.1 Hz), 7.73-7.79 (1H, m), 8.05-8.11 (1H, m), 9.18 (1H, d, J = 5.1 Hz), 10.43 (1H, s).	Ref. Ex. 91
1586		1H-NMR (CDCl3) δ: 1.35 (6H, d, J = 6.9 Hz), 3.03-3.10 (1H, m), 7.09-7.14 (1H, m), 7.45-7.48 (1H, m), 7.59 (1H, s), 7.75-7.80 (3H, m), 8.02 (1H, s), 10.07 (1H, s).	Ref. Ex. 91
1587		1H-NMR (CDCl3) δ: 1.27 (6H, d, J = 6.9 Hz), 2.92-3.01 (1H, m), 4.10 (2H, s), 7.32-7.50 (6H, m), 7.63 (1H, s), 9.97 (1H, s).	Ref. Ex. 91
1588		1H-NMR (CDCl3) δ: 1.37 (6H, d, J = 6.9 Hz), 3.05-3.20 (1H, m), 7.57 (1H, d, J = 5.0 Hz), 7.95 (1H, s), 8.66 (1H, s), 8.83 (1H, s), 9.09 (1H, d, J = 5.0 Hz), 10.14 (1H, s).	Ref. Ex. 91







[0541]

Ref. Ex. No.	STR	1H-NMR	ref.
1589		1H-NMR (CDCl3) δ: 1.40 (6H, d, J = 6.9 Hz), 3.65-3.75 (1H, m), 7.24-7.33 (1H, m), 7.81-7.92 (2H, m), 10.03 (1H, s).	Ref. Ex. 147
1590		1H-NMR (CDCl3) δ: 1.18-1.25 (4H, m), 2.79-2.88 (1H, m), 3.97 (3H, s), 7.21 (1H, t, J = 8.4 Hz), 7.88-7.91 (1H, m), 8.05-8.08 (1H, m).	Ref. Ex. 133
1591		1H-NMR (CDCl3) δ: 0.96-1.08 (4H, m), 1.95-2.01 (1H, m), 2.41 (1H, bs), 4.65 (2H, s), 7.19 (1H, t, J = 8.4 Hz), 7.80-7.86 (1H, m), 8.00 (1H, dd, J = 2.1, 8.4 Hz).	Ref. Ex. 19
1592		1H-NMR (CDCl3) δ: 1.24-1.33 (4H, m), 2.65-2.74 (1H, m), 7.21-7.26 (1H, m), 7.85-7.90 (1H, m), 8.04 (1H, dd, J = 2.1, 6.9 Hz), 10.04 (1H, s).	Ref. Ex. 147
1593		1H-NMR (CDCl3) δ: 7.25 (1H, t, J = 8.6 Hz), 7.57-7.61 (1H, m), 7.76 (1H, dd, J = 2.3, 6.8 Hz), 8.05 (1H, s), 9.96 (1H, s).	Ref. Ex. 48
1594		1H-NMR (CDCl3) δ: 7.60 (1H, t, J = 7.9 Hz), 7.73 (1H, d, J = 7.9 Hz), 7.85 (1H, d, J = 7.7 Hz), 7.93 (1H, s), 8.08 (1H, s), 9.97 (1H, s).	Ref. Ex. 48
1595		1H-NMR (CDCl3) δ: 1.28 (3H, t, J = 7.6 Hz), 2.51 (3H, s), 2.63 (2H, q, J = 7.6 Hz), 5.50 (2H, s), 6.95-6.98 (2H, m), 7.24-7.29 (2H, m), 9.75 (1H, s).	Ref. Ex. 12
1596		1H-NMR (CDCl3) δ: 1.30 (3H, t, J = 7.5 Hz), 2.45 (3H, s), 2.62 (2H, q, J = 7.5 Hz), 5.06 (2H, s), 6.85-6.89 (2H, m), 7.31-7.37 (2H, m), 9.96 (1H, s).	Ref. Ex. 12
1597		1H-NMR (CDCl3) δ: 1.34 (6H, d, J = 6.9 Hz), 3.02-3.09 (1H, m), 7.16 (2H, t, J = 8.7 Hz), 7.56-7.62 (2H, m), 7.66 (1H, t, J = 1.6 Hz), 7.73 (1H, t, J = 1.6 Hz), 7.87 (1H, t, J = 1.6 Hz), 10.07 (1H, s).	Ref. Ex. 91
1598		1H-NMR (CDCl3) δ: 1.42 (9H, s), 7.14-7.20 (2H, m), 7.56-7.61 (2H, m), 7.81-7.90 (3H, m), 10.08 (1H, s).	Ref. Ex. 91
1599		1H-NMR (CDCl3) δ: 1.39 (6H, d, J = 6.9 Hz), 3.83-3.92 (1H, m), 3.97 (3H, s), 7.76-7.74 (2H, m), 8.18-8.21 (2H, m).	Ref. Ex. 133
1600		1H-NMR (CDCl3) δ: 0.91-0.99 (3H, m), 1.37-1.49 (5H, m), 1.69-1.79 (2H, m), 3.11 (2H, t, J = 7.8 Hz), 4.42 (2H, q, J = 7.2 Hz), 7.42-7.45 (2H, m), 8.00-8.03 (2H, m).	Ref. Ex. 133
1601		1H-NMR (CDCl3) δ: 1.38 (6H, d, J = 6.9 Hz), 2.29 (1H, bs), 3.15-3.25 (1H, m), 4.63 (2H, bs), 7.69-7.72 (2H, m), 8.10-8.13 (2H, m).	Ref. Ex. 19
1602		1H-NMR (CDCl3) δ: 0.95 (3H, t, J = 7.5 Hz), 1.30-1.46 (2H, m), 1.63-1.73 (2H, m), 2.11-2.15 (1H, m), 2.73 (2H, t, J = 7.5 Hz), 4.59 (1H, d, J = 5.4 Hz), 7.40-7.43 (2H, m), 7.92-7.95 (2H, m).	Ref. Ex. 19
1603		1H-NMR (CDCl3) δ: 1.43 (6H, d, J = 6.9 Hz), 3.68-3.78 (1H, m), 7.74-7.77 (2H, m), 8.18-8.20 (2H, m), 10.06 (1H, s).	Ref. Ex. 147
1604		1H-NMR (CDCl3) δ: 0.97 (3H, t, J = 7.5 Hz), 1.38-1.50 (2H, m), 1.71-1.82 (2H, m), 3.09 (2H, t, J = 7.5 Hz), 7.45-7.48 (2H, m), 7.99-8.02 (2H, m), 10.02 (1H, s).	Ref. Ex. 147
1605		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.1 Hz), 1.88-2.01 (2H, m), 2.26-2.29 (2H, m), 2.92-3.01 (2H, m), 3.27-3.36 (1H, m), 3.89-3.93 (2H, m), 4.43 (2H, q, J = 7.1 Hz), 6.96 (2H, d, J = 8.6 Hz), 7.49 (2H, d, J = 8.6 Hz), 8.09 (1H, s).	Ref. Ex. 16
1606		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.1 Hz), 1.89-2.03 (2H, m), 2.25-2.29 (2H, m), 2.80-2.89 (2H, m), 3.21-3.31 (1H, m), 3.71-3.75 (2H, m), 4.43 (2H, q, J = 7.1 Hz), 6.85-6.91 (2H, m), 7.19-7.23 (2H, m), 8.09 (1H, s).	Ref. Ex. 16
1607		1H-NMR (CDCl3) δ: 2.14 (3H, s), 5.25 (2H, s), 7.30 (1H, s), 7.40-7.44 (2H, m), 7.87-7.91 (2H, m).	Ref. Ex. 935
1608		1H-NMR (CDCl3) δ: 1.93-2.06 (2H, m), 2.27-2.30 (2H, m), 2.85-2.93 (2H, m), 3.17-3.32 (1H, m), 3.72-3.78 (2H, m), 6.87-6.92 (2H, m), 7.20-7.23 (2H, m), 8.11 (1H, s), 10.01 (1H, s).	Ref. Ex. 63
1609		1H-NMR (CDCl3) δ: 1.94-2.08 (2H, m), 2.26-2.30 (2H, m), 2.84-2.93 (2H, m), 3.17-3.28 (1H, m), 3.72-3.76 (2H, m), 6.87-6.90 (2H, m), 7.20-7.23 (2H, m), 8.11 (1H, s), 10.01 (1H, s).	Ref. Ex. 63
1610		1H-NMR (CDCl3) δ: 2.67 (3H, s), 3.93 (3H, s), 7.39-7.43 (2H, m), 7.54-7.57 (2H, m).	Ref. Ex. 10
1611		1H-NMR (CDCl3) δ: 2.69 (3H, s), 3.93 (3H, s), 7.18-7.23 (1H, m), 7.49-7.54 (1H, m), 7.70 (1H, dd, J = 2.3, 6.8 Hz).	Ref. Ex. 10
1612		1H-NMR (CDCl3) δ: 3.47 (3H, s), 3.98 (3H, s), 4.87 (2H, s), 7.44-7.47 (2H, m), 8.05-8.08 (2H, m).	Ref. Ex. 133
1613		1H-NMR (CDCl3) δ: 3.47 (3H, s), 3.98 (3H, s), 4.87 (2H, s), 7.56 (1H, d, J = 8.4 Hz), 7.94-7.97 (1H, m), 8.24 (1H, s).	Ref. Ex. 133









[0542]










Ref. Ex. No.	STR	1H-NMR	ref.
1614		1H-NMR (CDCl3) δ: 1.30 (6H, d, J = 6.9 Hz), 2.91-3.05 (1H, m), 5.22 (2H, s), 7.16-7.18 (1H, m), 7.30-7.32 (1H, m), 7.42 (1H, s), 7.87 (1H, s), 7.93 (2H, s), 9.98 (1H, s).	Ref. Ex. 82
1615		1H-NMR (CDCl3) δ: 1.30 (6H, d, J = 7.2 Hz), 2.93-3.04 (1H, m), 5.33 (2H, s), 7.17 (1H, s), 7.30 (1H, s), 7.43 (1H, s), 7.73 (1H, d, J = 7.8 Hz), 7.88 (1H, d, J = 8.4 Hz), 8.09 (1H, s), 9.97 (1H, s).	Ref. Ex. 82
1616		1H-NMR (CDCl3) δ: 3.88 (3H, s), 3.95 (3H, s), 7.48-7.49 (2H, m), 7.56-7.59 (2H, m), 7.83 (1H, s).	Ref. Ex. 75
1617		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.1 Hz), 3.94 (3H, s), 4.35 (2H, q, J = 7.1 Hz), 7.46-7.49 (2H, m), 7.55-7.59 (2H, m), 7.82 (1H, s).	Ref. Ex. 75
1618		1H-NMR (CDCl3) δ: 1.36 (6H, d, J = 6.9 Hz), 3.04-3.14 (1H, m), 7.14 (1H, s), 7.23-7.35 (2H, m), 7.54-7.63 (2H, m), 7.74 (1H, s), 7.98-7.99 (1H, m), 8.16-8.19 (1H, m), 10.09 (1H, s).	Ref. Ex. 91
1619		1H-NMR (CDCl3) δ: 2.57 (1H, bs), 3.43 (3H, s), 4.56 (2H, s), 4.69 (2H, bs), 7.42-7.45 (2H, m), 7.96-7.99 (2H, m).	Ref. Ex. 19
1620		1H-NMR (CDCl3) δ: 2.46 (1H, bs), 3.44 (3H, s), 4.57 (2H, s), 4.69 (2H, s), 7.53 (1H, d, J = 8.4 Hz), 7.86 (1H, dd, J = 1.8, 8.4 Hz), 8.13 (1H, d, J = 1.8 Hz).	Ref. Ex. 19










Ref. Ex. No.	STR	1H-NMR	ref.
1621		1H-NMR (CDCl3) δ: 3.48 (3H, s), 4.84 (2H, s), 7.46-7.49 (2H, m), 8.03-8.06 (2H, m), 10.09 (1H, s).	Ref. Ex. 147
1622		1H-NMR (CDCl3) δ: 3.49 (3H, s), 4.84 (2H, s), 7.58 (1H, d, J = 8.4 Hz), 7.94 (1H, dd, J = 2.1, 8.4 Hz), 8.21 (1H, d, J = 2.1 Hz), 10.09 (1H, s).	Ref. Ex. 147
1623		1H-NMR (CDCl3) δ: 2.70 (3H, s), 7.40-7.43 (2H, m), 7.56-7.59 (2H, m), 10.06 (1H, s).	Ref. Ex. 63
1624		1H-NMR (CDCl3) δ: 2.71 (3H, s), 7.19-7.25 (1H, m), 7.51-7.56 (1H, m), 7.72 (1H, dd, J = 2.3, 6.8 Hz), 10.06 (1H, s).	Ref. Ex. 63
1625		1H-NMR (CDCl3) δ: 1.36 (6H, d, J = 6.9 Hz), 3.04-3.14 (1H, m), 7.59-7.71 (3H, m), 7.77-7.86 (3H, m), 7.92 (1H, t, J = 1.6 Hz), 10.09 (1H, s).	Ref. Ex. 91
1626		1H-NMR (CDCl3) δ: 0.89 (3H, t, J = 7.4 Hz), 1.30-1.40 (2H, m), 1.64-1.72 (2H, m), 2.61 (2H, t, J = 7.8 Hz), 5.51 (2H, s), 6.97-7.00 (2H, m), 7.28-7.32 (2H, m), 9.74 (1H, s).	Ref. Ex. 12
1627		1H-NMR (CDCl3) δ: 0.89 (3H, t, J = 7.4 Hz), 1.30-1.40 (2H, m), 1.64-1.72 (2H, m), 2.58-2.62 (2H, m), 5.14 (2H, s), 6.96-7.02 (2H, m), 7.31-7.36 (2H, m), 9.92 (1H, s).	Ref. Ex. 12
1628		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 6.9 Hz), 4.46 (2H, q, J = 6.9 Hz), 7.17-7.23 (2H, m), 7.46-7.49 (2H, m), 8.08-8.17 (4H, m).	Ref. Ex. 133

Ref. Ex. No.	STR	1H-NMR	ref.
1629		1H-NMR (CDCl3) δ: 7.80-7.86 (2H, m), 7.94-7.96 (1H, m), 7.99-8.01 (1H, m), 8.06-8.11 (1H, m), 8.97 (1H, d, J = 2.1 Hz), 10.07 (1H, s).	Ref. Ex. 91
1630		1H-NMR (CDCl3) δ: 1.54 (9H, s), 3.97 (3H, s), 7.60 (1H, t, J = 7.8 Hz), 7.72 (1H, d, J = 7.8 Hz), 8.23 (1H, d, J = 7.8 Hz), 8.31 (1H, s).	Ref. Ex. 133
1631		1H-NMR (CDCl3) δ: 1.44 (9H, s), 2.66 (1H, s), 4.72 (2H, d, J = 5.7 Hz), 7.57 (1H, t, J = 7.8 Hz), 7.67 (1H, d, J = 7.8 Hz), 8.16 (1H, d, J = 7.8 Hz), 8.23 (1H, s).	Ref. Ex. 19
1632		1H-NMR (CDCl3) δ: 7.55 (1H, d, J = 4.0 Hz), 7.77 (1H, d, J = 8.2 Hz), 7.82 (1H, d, J = 4.0 Hz), 8.09-8.13 (1H, m), 9.04 (1H, d, J = 1.8 Hz), 9.96 (1H, s).	Ref. Ex. 91
1633		1H-NMR (CDCl3) δ: 7.22-7.27 (2H, m), 7.50-7.53 (2H, m), 8.08-8.11 (2H, m), 8.24-8.29 (2H, m), 10.15 (1H, s).	Ref. Ex. 19, Ref. Ex. 147
1634		1H-NMR (CDCl3) δ: 1.56 (9H, s), 7.62 (1H, t, J = 7.8 Hz), 7.74 (1H, d, J = 7.8 Hz), 8.25-8.32 (2H, m), 10.17 (1H, s).	Ref. Ex. 147
1635		1H-NMR (CDCl3) δ: 2.22-2.30 (1H, bs), 4.63 (2H, s), 4.77 (2H, d, J = 5.7 Hz), 4.80 (2H, s), 7.20 (1H, s), 7.29-7.36 (4H, m).	Ref. Ex. 100, Ref. Ex. 19
1636		1H-NMR (CDCl3) δ: 2.23-2.39 (1H, bs), 4.72 (2H, s), 4.77 (2H, d, J = 5.9 Hz), 4.84 (2H, s), 7.21 (1H, s), 7.49 (2H, d, J = 8.0 Hz), 7.63 (2H, d, J = 8.2 Hz).	Ref. Ex. 100, Ref. Ex. 19









[0543]










Ref. Ex. No.	STR	1H-NMR	ref.
1637		1H-NMR (CDCl3) δ: 2.13-2.32 (1H, br), 4.66 (2H, s), 4.77 (2H, s), 4.82 (2H, s), 7.19-7.23 (3H, m), 7.38-7.42 (2H, m).	Ref. Ex. 100, Ref. Ex. 19
1638		1H-NMR (CDCl3) δ: 1.93 (3H, dd, J = 1.7, 6.7 Hz), 2.45-2.61 (1H, br), 4.78 (2H, s), 6.11 (1H, dq, J = 15.5, 6.7 Hz), 6.57 (1H, dq, J = 15.4, 1.7 Hz), 7.67 (2H, d, J = 8.2 Hz), 8.00 (2H, d, J = 8.2 Hz).	Ref. Ex. 43
1639		1H-NMR (CDCl3) δ: 1.92 (3H, dd, J = 1.8, 6.7 Hz), 2.49 (1H, brs), 4.77 (2H, s), 6.09 (1H, dq, J = 15.5, 6.7 Hz), 6.56 (1H, dq, J = 15.4, 1.7 Hz), 7.24-7.27 (1H, m), 7.45 (1H, t, J = 8.3 Hz), 7.78-7.81 (2H, m).	Ref. Ex. 43
1640		1H-NMR (CDCl3) δ: 4.67 (2H, s), 4.86 (2H, s), 7.30-7.37 (4H, m), 8.19 (1H, s), 10.01 (1H, s).	Ref. Ex. 48
1641		1H-NMR (CDCl3) δ: 4.76 (2H, s), 4.90 (2H, s), 7.50 (2H, d, J = 8.0 Hz), 7.64 (2H, d, J = 8.2 Hz), 8.20 (1H, s), 10.02 (1H, s).	Ref. Ex. 48
1642		1H-NMR (CDCl3) δ: 4.70 (2H, s), 4.88 (2H, s), 7.23 (2H, d, J = 7.8 Hz), 7.42 (2H, d, J = 8.8 Hz), 8.20 (1H, s), 10.01 (1H, s).	Ref. Ex. 48
1644		1H-NMR (CDCl3) δ: 7.67-7.70 (1H, m), 7.82 (1H, d, J = 8.3 Hz), 8.08-8, 16 (4H, m), 9.03 (1H, s), 10.16 (1H, s).	Ref. Ex. 91
1645		1H-NMR (CDCl3) δ: 1.37 (6H, d, J = 7.0 Hz), 3.82-3.89 (1H, m), 3.95 (3H, s), 7.29-7.32 (2H, m), 8.11-8.13 (2H, m).	Ref. Ex. 133









Ref. Ex. No.	STR	1H-NMR	ref.
1646		1H-NMR (CDCl3) δ: 1.36 (6H, d, J = 7.0 Hz), 1.44 (3H, t, J = 7.0 Hz), 3.80-3.87 (1H, m), 3.94 (3H, s), 4.09 (2H, q, J = 7.0 Hz), 6.94-6.96 (2H, m), 7.99-8.01 (2H, m).	Ref. Ex. 133
1647		1H-NMR (CDCl3) δ: 1.34 (6H, d, J = 7.0 Hz), 2.27 (1H, bs), 3.13-3.23 (1H, m), 4.61 (2H, s), 7.26-7.30 (2H, m), 8.02-8.05 (2H, m).	Ref. Ex. 19
1648		1H-NMR (CDCl3) δ: 1.41 (6H, d, J = 7.0 Hz), 3.66-3.76 (1H, m), 7.26-7.35 (2H, m), 8.10-8.13 (2H, m), 10.04 (1H, s).	Ref. Ex. 48
1649		1H-NMR (CDCl3) δ: 1.33 (6H, d, J = 6.9 Hz), 1.44 (3H, t, J = 7.2 Hz), 2.24 (1H, bs), 3.11-3.20 (1H, m), 4.09 (2H, q, J = 7.2 Hz), 4.59 (2H, s), 6.93-6.96 (2H, m), 7.91-7.94 (2H, m).	Ref. Ex. 19
1650		1H-NMR (CDCl3) δ: 1.40 (6H, d, J = 7.2 Hz), 1.44 (3H, t, J = 7.2 Hz), 3.63-3.72 (1H, m), 4.10 (2H, q, J = 7.2 Hz), 6.96-6.99 (2H, m), 7.97-8.00 (2H, m), 10.03 (1H, s).	Ref. Ex. 147
1651		1H-NMR (CDCl3) δ: 2.40 (3H, s), 7.66 (1H, s), 7.79 (1H, d, J = 8.1 Hz), 7.98 (1H, dd, J = 2.1, 8.1 Hz), 8.87 (1H, d, J = 2.1 Hz), 9.90 (1H, s).	Ref. Ex. 91
1652		1H-NMR (CDCl3) δ: 7.06 (1H, d, J = 3.7 Hz), 7.37 (1H, d, J = 3.7 Hz), 7.78 (1H, d, J = 8.5 Hz), 8.27-8.32 (1H, m), 9.13 (1H, s), 9.74 (1H, s).	Ref. Ex. 91
1653		1H-NMR (CDCl3) δ: 1.01 (3H, t, J = 7.3 Hz), 1.68-1.76 (2H, m), 2.43 (1H, t, J = 5.9 Hz), 2.83 (2H, t, J = 7.5 Hz), 4.73 (2H, d, J = 5.8 Hz), 7.68 (2H, d, J = 8.2 Hz), 8.00 (2H, d, J = 8.0 Hz).	Ref. Ex. 33
1654		1H-NMR (CDCl3) δ: 1.01 (3H, t, J = 7.3 Hz), 1.65-1.77 (2H, m), 2.43 (1H, t, J = 5.9 Hz), 2.82 (2H, t, J = 7.5 Hz), 4.71 (2H, d, J = 5.8 Hz), 7.24-7.26 (1H, m), 7.45 (1H, t, J = 8.3 Hz), 7.78-7.80 (2H, m).	Ref. Ex. 33











Ref. Ex. No.	STR	1H-NMR	ref.
1655		1H-NMR (CDCl3) δ: 1.06 (3H, t, J = 7.4 Hz), 1.73-1.86 (2H, m), 3.29 (2H, t, J = 7.6 Hz), 7.72 (2H, d, J = 8.2 Hz), 8.06 (2H, d, J = 8.1 Hz), 10.22 (1H, s).	Ref. Ex. 48
1656		1H-NMR (CDCl3) δ: 1.16-1.26 (4H, m), 2.81-2.87 (1H, m), 3.97 (3H, s), 7.26-7.29 (2H, m), 8.02-8.04 (2H, m).	Ref. Ex. 133
1657		1H-NMR (CDCl3) δ: 1.19-1.21 (4H, m), 2.80-2.87 (1H, m), 3.97 (3H, s), 7.34-7.41 (2H, m), 7.47-7.51 (1H, m), 8.20-8.22 (1H, m).	Ref. Ex. 133
1658		1H-NMR (CDCl3) δ: 2.55 (3H, s), 7.68 (1H, s), 7.79 (1H, s), 7.92 (1H, s), 8.13 (1H, s), 8.92 (1H, s), 9.06 (1H, s), 10.09 (1H, s).	Ref. Ex. 91
1659		1H-NMR (CDCl3) δ: 2.39 (3H, s), 7.66 (1H, s), 8.02 (1H, s), 8.92-8.95 (2H, m), 9.90 (1H, s).	Ref. Ex. 91
1660		1H-NMR (CDCl3) δ: 7.54 (1H, d, J = 3.9 Hz), 7.82 (1H, d, J = 3.9 Hz), 8.14 (1H, s), 8.90 (1H, s), 9.12 (1H, s), 9.96 (1H, s).	Ref. Ex. 91
1661		1H-NMR (CDCl3) δ: 7.79 (2H, d, J = 8.1 Hz), 8.03-8.06 (2H, m), 8.15 (1H, s), 8.95 (1H, s), 9.08 (1H, s), 10.11 (1H, s).	Ref. Ex. 91
1662		1H-NMR (CDCl3) δ: 1.14-1.27 (4H, m), 2.80-2.89 (1H, m), 3.97 (3H, s), 7.29-7.32 (1H, m), 7.48 (1H, t, J = 8.1 Hz), 7.83 (1H, s), 7.92-7.96 (1H, m).	Ref. Ex. 133
1663		1H-NMR (CDCl3) δ: 1.18-1.28 (10H, m), 2.79-2.99 (2H, m), 3.96 (3H, s), 7.26-7.30 (2H, m), 7.90-7.93 (2H, m).	Ref. Ex. 133








[0544]









Ref. Ex. No.	STR	1H-NMR	ref.
1664		1H-NMR (CDCl3) δ: 1.21-1.26 (4H, m), 2.81-2.90 (1H, m), 3.98 (3H, s), 7.43-7.51 (2H, m), 7.20 (1H, t, J = 7.5 Hz).	Ref. Ex. 133
1665		1H-NMR (CDCl3) δ: 1.05 (3H, t, J = 7.3 Hz), 1.72-1.85 (2H, m), 3.28 (2H, t, J = 7.6 Hz), 7.29-7.32 (1H, m), 7.49 (1H, t, J = 8.3 Hz), 7.82-7.85 (2H, m), 10.20 (1H, s).	Ref. Ex. 159
1667		1H-NMR (CDCl3) δ: 2.07 (3H, s), 4.31 (2H, s), 5.23 (2H, s), 7.35-7.40 (4H, m), 7.59 (2H, d, J = 8.3 Hz), 7.79-7.83 (2H, m).	Ref. Ex. 1666
1669		1H-NMR (CDCl3) δ: 1.78-1.94 (2H, m), 2.00-2.10 (2H, m), 2.34-2.45 (1H, m), 2.71-2.82 (2H, m), 3.26-3.36 (2H, m), 6.71-6.83 (1H, m), 6.85-6.97 (1H, m), 9.71 (1H, d, J = 0.9 Hz).	Ref. Ex. 114 Ref. Ex. 151 Ref. Ex. 48
1670		1H-NMR (CDCl3) δ: 1.0-2.0 (12H, m), 2.30-2.41 (1H, m), 2.50-2.60 (1H, m), 2.94-3.06 (1H, m), 3.09-3.27 (2H, m), 3.45-3.62 (2H, m), 3.78-3.91 (1H, m), 4.52-4.59 (1H, m).	Ref. Ex. 643
1671		1H-NMR (CDCl3) δ: 1.66-1.89 (3H, m), 1.92-2.05 (1H, m), 2.54-2.62 (1H, m), 2.89-3.00 (1H, m), 3.16 (1H, dd, J = 8.0, 12.3 Hz), 3.22-3.33 (1H, m), 3.52 (1H, dd, J = 3.7, 12.3 Hz), 6.85-6.92 (2H, m), 7.17-7.24 (2H, m), 9.76 (1H, s).	Ref. Ex. 114 Ref. Ex. 151 Ref. Ex. 48
1672		1H-NMR (CDCl3) δ: 1.70-1.97 (4H, m), 2.57-2.67 (1H, m), 2.78-2.88 (1H, m), 3.00-3.17 (2H, m), 3.31 (1H, dd, J = 3.5, 11.8 Hz), 6.74-6.97 (2H, m), 9.79 (1H, s).	Ref. Ex. 114 Ref. Ex. 151 Ref. Ex. 48
1673		1H-NMR (CDCl3) δ: 7.00 (1H, d, J = 2.6 Hz), 7.48-7.52 (2H, m), 7.68-7.74 (2H, m), 7.95 (1H, dd, J = 0.7, 2.6 Hz), 10.08 (1H, s).	Ref. Ex. 76 Ref. Ex. 48

Ref. Ex. No.	STR	1H-NMR	ref.
1674		1H-NMR (CDCl3) δ: 7.03 (1H, d, J = 2.6 Hz), 7.64-7.68 (2H, m), 7.92-8.00 (1H, m), 8.04 (1H, dd, J = 0.7, 2.6 Hz), 8.95-8.08 (1H, m), 10.11 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1675		1H-NMR (CDCl3) δ: 7.69 (1H, d, J = 5.1 Hz), 7.90-7.93 (1H, m), 8.01-8.05 (2H, m), 9.18 (1H, d, J = 5.1 Hz), 10.07 (1H, s).	Ref. Ex. 91
1676		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.2 Hz), 4.46 (2H, q, J = 7.2 Hz), 7.47-7.50 (4H, m), 8.07-8.11 (4H, m).	Ref. Ex. 133
1677		1H-NMR (CDCl3) δ: 1.26 (3H, t, J = 7.2 Hz), 4.33 (2H, q, J = 7.2 Hz), 7.26-7.61 (6H, m), 8.07-8.11 (2H, m).	Ref. Ex. 133
1678		1H-NMR (CDCl3) δ: 1.43 (18H, s), 4.04 (2H, s), 5.25 (1H, s), 6.76 (1H, brs), 7.02 (2H, s), 7.49 (1H, brs).	Ref. Ex. 1477
1679		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.31 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.51 (1H, d, J = 8.4 Hz), 7.74 (1H, dd, J = 2.1, 8.4 Hz), 8.06 (1H, d, J = 2.1 Hz).	Ref. Ex. 2
1680		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.31 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.34-7.42 (2H, m), 7.77-7.80 (1H, m), 7.95-7.97 (1H, m).	Ref. Ex. 2
1681		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 3.98 (3H, s), 7.70 (2H, d, J = 8.2 Hz), 8.05 (2H, d J = 8.1 Hz).	Ref. Ex. 2
1682		1H-NMR (CDCl3) δ: 4.68 (2H, s), 7.40-7.44 (4H, m), 7.60 (2H, d, J = 8.1 Hz), 7.81-7.86 (2H, m), 10.25 (1H, s).	Ref. 19 Ref. 159








Ref. Ex. No.	STR	1H-NMR	ref.
1683		1H-NMR (CDCl3) δ: 4.58 (2H, s), 7.22-7.26 (2H, m), 7.29-7.32 (2H, m), 7.39-7.43 (2H, m), 7.80-7.85 (2H, m), 10.24 (1H, s).	Ref. 19 Ref. 159
1684		1H-NMR (CDCl3) δ: 1.39-1.43 (21H, m), 4.29 (2H, s), 4.43 (2H, q, J = 7.1 Hz), 5.18 (1H, s), 7.11 (2H, s), 8.04 (1H, s).	Ref. Ex. 2
1685		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 7.53 (1H, d, J = 8.4 Hz), 7.75 (1H, dd, J = 2.1, 8.4 Hz), 8.06 (1H, d, J = 2.1 Hz), 10.19 (1H, s).	Ref. Ex. 63
1686		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 7.36-7.45 (2H, m), 7.79 (1H, dt, J = 6.9, 1.8 Hz), 7.95-7.97 (1H, m), 10.20 (1H, s).	Ref. Ex. 63
1687		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.34 (2H, q, J = 7.5 Hz), 7.72 (2H, d, J = 8.3 Hz), 8.06 (2H, d, J = 8.1 Hz), 10.22 (1H, s).	Ref. Ex. 63
1688		1H-NMR (CDCl3) δ: 1.43 (18H, s), 4.28 (2H, s), 5.19 (1H, s), 7.11 (2H, s), 8.04 (1H, s), 10.01 (1H, s).	Ref. Ex. 63
1689		1H-NMR (CDCl3) δ: 8.00 (1H, s), 8.07-8.09 (2H, m), 8.88 (1H, s), 9.06 (1H, s), 10.02 (1H, s).	Ref. Ex. 91
1690		1H-NMR (CDCl3) δ: 1.03 (6H, s), 3.75 (4H, s), 8.02 (1H, s), 8.18 (1H, s), 9.93 (1H, s).	Ref. Ex. 107







Ref. Ex. No.	STR	1H-NMR	ref.
1691		1H-NMR (CDCl3) δ: 7.65-7.85 (3H, m), 8.15 (1H, s), 8.96 (1H, s), 9.02 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
1692		1H-NMR (CDCl3) δ: 7.75 (1H, d, J = 8.3 Hz), 7.99 (1H, dd, J = 2.1, 8.3 Hz), 8.37-8.40 (2H, m), 8.90 (1H, s), 10.01 (1H, d, J = 1.1 Hz).	Ref. Ex. 91
1693		1H-NMR (CDCl3) δ: 7.52 (1H, d, J = 5.0 Hz), 8.60 (1H, d, J = 1.3 Hz), 8.78 (1H, t, J = 1.3 Hz), 9.01 (1H, d, J = 5.0 Hz), 10.02 (1H, d, J = 1.3 Hz).	Ref. Ex. 91
1694		1H-NMR (CDCl3) δ: 1.37 (3H, t, J = 7.5 Hz), 2.39 (3H, s), 3.30 (2H, q, J = 7.5 Hz), 3.96 (3H, s), 7.23 (2H, d, J = 7.9 Hz), 7.82 (2H, d, J = 8.2 Hz).	Ref. Ex. 2
1695		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 3.30 (2H, q, J = 7.5 Hz), 3.96 (3H, s), 7.09-7.15 (2H, m), 7.89-7.94 (2H, m).	Ref. Ex. 2
1696		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 3.31 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.20 (1H, t, J = 8.6 Hz), 7.76-7.81 (1H, m), 8.03 (1H, dd, J = 2.2, 6.9 Hz).	Ref. Ex. 2
1697		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 2.41 (3H, s), 3.31 (2H, q, J = 7.5 Hz), 7.26 (2H, d, J = 7.9 Hz), 7.82 (2H, d, J = 8.2 Hz), 10.20 (1H, s).	Ref. Ex. 63
1698		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 3.31 (2H, q, J = 7.5 Hz), 7.11-7.19 (2H, m), 7.89-7.96 (2H, m), 10.19 (1H, s).	Ref. Ex. 63
1699		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 7.19-7.26 (1H, m), 7.77-7.82 (1H, m), 8.03 (1H, dd, J = 2.1, 6.9 Hz), 10.19 (1H, s).	Ref. Ex. 63
1700		1H-NMR (CDCl3) δ: 3.91 (3H, s), 4.11 (2H, s), 7.23-7.27 (2H, m), 7.68 (1H, s), 7.99-8.03 (2H, m), 8.68 (1H, s), 8.76 (1H, s).	Ref. Ex. 91








Ref. Ex. No.	STR	1H-NMR	ref.
1701		1H-NMR (CDCl3) δ: 0.19-0.28 (2H, m), 0.58-0.60 (2H, m), 0.92-1.09 (1H, m), 1.35 (12H, s), 2.62 (2H, d, J = 6.9 Hz), 7.89 (1H, s), 7.92 (1H, s), 8.14 (1H, s), 10.04 (1H, s).	Ref. Ex. 81
1702		1H-NMR (CDCl3) δ: 0.24-0.29 (2H, m), 0.57-0.63 (2H, m), 1.00-1.12 (1H, m), 2.69 (2H, d, J = 6.9 Hz), 7.13-7.19 (2H, m), 7.56-7.61 (2H, m), 7.69 (1H, s), 7.76 (1H, s), 7.89 (1H, s), 10.07 (1H, s).	Ref. Ex. 91
1703		1H-NMR (CDCl3) δ: 0.26-0.31 (2H, m), 0.58-0.65 (2H, m), 1.00-1.16 (1H, m), 2.74 (2H, d, J = 6.9 Hz), 7.57 (1H, d, J = 4.9 Hz), 7.99 (1H, s), 8.67 (1H, s), 8.85 (1H, s), 9.08 (1H, d, J = 5.0 Hz), 10.15 (1H, s).	Ref. Ex. 91
1704		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 3.31 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.50 (1H, d, J = 8.4 Hz), 7.74 (1H, dd, J = 2.1, 8.4 Hz), 8.06 (1H, d, J = 2.1 Hz).	Ref. Ex. 2
1705		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.41 (1H, t, J = 1.9 Hz), 7.82 (2H, d, J = 1.9 Hz).	Ref. Ex. 2
1706		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.26-7.30 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.81-7.86 (2H, m).	Ref. Ex. 2
1707		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.25-7.31 (1H, m), 8.09-8.18 (2H, m).	Ref. Ex. 2

Ref. Ex. No.	STR	1H-NMR	ref.
1708		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 7.53 (1H, d, J = 8.4 Hz), 7.75 (1H, dd, J = 2.1, 8.4 Hz), 8.06 (1H, d, J = 2.1 Hz), 10.19 (1H, s).	Ref. Ex. 63
1709		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 7.43 (1H, t, J = 1.9 Hz), 7.82 (2H, d, J = 1.9 Hz), 10.19 (1H, s).	Ref. Ex. 63
1710		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 7.29-7.33 (1H, m), 7.49 (1H, t, J = 8.3 Hz), 7.82-7.85 (2H, m), 10.21 (1H, s).	Ref. Ex. 63
1711		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 7.31 (1H, t, J = 9.2 Hz), 8.09-8.14 (1H, m), 8.19 (1H, dd, J = 2.3, 6.6 Hz), 10.20 (1H , s).	Ref. Ex. 63
1712		1H-NMR (CDCl3) δ: 0.26-0.31 (2H, m), 0.59-0.66 (2H, m), 1.00-1.12 (1H, m), 2.73 (2H, d, J = 7.0 Hz), 7.76 (1H, s), 7.80 (1H, d, J = 8.1 Hz), 7.88 (1H, s), 7.95 (1H, s), 8.07-8.11 (1H, m), 8.99 (1H, s), 10.11 (1H, s).	Ref. Ex. 91
1713		1H-NMR (CDCl3) δ: 0.28-0.33 (2H, m), 0.60-0.66 (2H, m), 1.04-1.20 (1H, m), 2.75 (2H, d, J = 6.9 Hz), 7.91-7.97 (2H, m), 8.03-8.07 (1H, m), 8.27 (1H, s), 8.38 (1H, s), 8.99 (1H, s), 10.14 (1H, s).	Ref. Ex. 91
1715		1H-NMR (CDCl3) δ: 3.88 (2H, s), 6.96-7.04 (2H, m), 7.08-7.15 (2H, m), 7.22-7.24 (2H, m), 7.51 (1H, t, J = 1.6 Hz).	Ref. Ex. 140
1716		1H-NMR (CDCl3) δ: 4.00 (2H, s), 6.98-7.04 (2H, m), 7.11-7.16 (2H, m), 7.55-7.61 (2H, m), 7.85 (1H, s), 9.91 (1H, s).	Ref. Ex. 138

[0546]

Ref. Ex. No.	STR	1H-NMR	ref.
1717		1H-NMR (CDCl3) δ: 1.40 (12H, s), 4.04 (2H, s), 6.97-7.03 (2H, m), 7.14-7.18 (2H, m), 7.79 (1H, s), 7.92 (1H, s), 8.18 (1H, s), 10.03 (1H, s).	Ref. Ex. 81
1718		1H-NMR (CDCl3) δ: 7.44-7.56 (4H, m), 7.59-7.66 (2H, m), 8.10-8.13 (2H, m), 9.98 (1H, s).	Ref. Ex. 63
1719		1H-NMR (CDCl3) δ: 7.50-7.54 (4H, m), 8.08-8.11 (2H, m), 8.18-8.21 (2H, m), 10.16 (1H, s).	Ref. Ex. 63
1720		1H-NMR (CDCl3) δ: 1.26-1.31 (4H, m), 2.67-2.76 (1H, m), 7.31-7.35 (1H, m), 7.51 (1H, t, J = 8.4 Hz), 7.82 (1H, s), 7.91-7.94 (1H, m), 10.05 (1H, s).	Ref. Ex. 63
1721		1H-NMR (CDCl3) δ: 1.23-1.26 (10H, m), 2.84-2.73 (1H, m), 2.91-3.00 (1H, m), 7.30-7.33 (2H, m), 7.89-7.91 (2H, m), 10.05 (1H, s).	Ref. Ex. 63
1722		1H-NMR (CDCl3) δ: 1.26-1.32 (4H, m), 2.71-2.80 (1H, m), 7.46-7.54 (2H, m), 8.13-8.18 (1H, m), 10.08 (1H, s).	Ref. Ex. 63
1723		1H-NMR (CDCl3) δ: 4.11 (2H, s), 6.98-7.04 (2H, m), 7.16-7.21 (2H, m), 7.54-7.78 (5H, m), 7.83 (1H, s), 7.95 (1H, s), 10.06 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
1724		1H-NMR (CDCl3) δ: 1.44 (9H, s), 7.85 (1H, t, J = 1.8 Hz), 7.92 (1H, t, J = 1.6 Hz), 8.01 (1H, t, J = 1.6 Hz), 8.12 (1H, s), 8.92 (1H, s), 9.05 (1H, d, J = 1.8 Hz), 10.11 (1H, s).	Ref. Ex. 91
1725		1H-NMR (CDCl3) δ: 1.43 (9H, s), 7.80 (1H, d, J = 8.2 Hz), 7.85 (1H, t, J = 1.8 Hz), 7.91 (1H, t, J = 1.8 Hz), 8.01 (1H, t, J = 1.8 Hz), 8.06-8.10 (1H, m), 8.97 (1H, d, J = 2.1 Hz), 10.11 (1H, s).	Ref. Ex. 91
1727		1H-NMR (CDCl3) δ: 4.15 (2H, s), 7.35 (2H, d, J = 8.1 Hz), 7.70 (1H, s), 7.86 (2H, d, J = 8.1 Hz), 8.69 (1H, s), 8.78 (1H, s), 10.01 (1H, s).	Ref. Ex. 76, Ref. Ex. 147
1728		1H-NMR (CDCl3) δ: 4.14 (2H, s), 6.97-7.05 (2H, m), 7.16-7.21 (2H, m), 7.78 (1H, s), 7.90 (1H, s), 8.00-8.04 (1H, m), 8.19 (1H, s), 8.37 (1H, s), 8.97 (1H, s), 10.08 (1H, s).	Ref. Ex. 91
1731		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.6 Hz), 2.86 (2H, q, J = 7.6 Hz), 2.58 (1H, d, J = 5.0 Hz), 7.92 (1H, s), 8.83 (1H, s), 8.83 (1H, s), 9.06 (1H, d, J = 5.0 Hz), 10.14 (1H, s).	Ref. Ex. 91
1732		1H-NMR (CDCl3) δ: 1.33 (3H, t, J = 7.7 Hz), 2.80 (2H, q, J = 7.7 Hz), 7.14-7.18 (2H, m), 7.57-7.60 (2H, m), 7.64 (1H, s), 7.70 (1H, s), 7.87 (1H, s), 10.07 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
1733		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.6 Hz), 2.85 (2H, q, J = 7.6 Hz), 7.84 (1H, s), 7.93 (1H, d, J = 8.3 Hz), 8.04 (1H, dd, J = 2.0, 8.3 Hz), 8.20 (1H, s), 8.34-8.35 (1H, m), 8.98 (1H, s), 10.11 (1H, s).	Ref. Ex. 91
1734		1H-NMR (CDCl3) δ: 1.92 (3H, dd, J = 1.7, 6.7 Hz), 2.39 (1H, t, J = 5.9 Hz), 4.76 (2H, d, J = 5.7 Hz), 6.03-6.12 (1H, m), 6.52-6.57 (1H, m), 7.19 (1H, t, J = 8.6 Hz), 7.73-7.77 (1H, m), 7.98 (1H, dd, J = 2.2, 7.0 Hz).	Ref. Ex. 43
1735		1H-NMR (CDCl3) δ: 0.53-0.57 (2H, m), 0.86-0.91 (2H, m), 1.53-1.62 (1H, m), 2.40 (1H, t, J = 5.9 Hz), 4.76 (2H, d, J = 5.8 Hz), 5.57 (1H, dd, J = 9.0, 15.4 Hz), 6.60 (1H, d, J = 15.4 Hz), 7.18 (1H, t, J = 8.6 Hz), 7.71-7.75 (1H, m), 7.97 (1H, dd, J = 2.2, 7.0 Hz).	Ref. Ex. 43
1736		1H-NMR (CDCl3) δ: 1.22 (3H, t, J = 7.2 Hz), 2.96 (2H, q, J = 7.2 Hz), 7.85 (1H, t, J = 1.7 Hz), 8.00 (2H, d, J = 1.7 Hz).	Ref. Ex. 147
1738		1H-NMR (CDCl3) δ: 0.99 (6H, d, J = 6.7 Hz), 2.24-2.32 (1H, m), 2.78 (2H, d, J = 6.9 Hz), 7.84 (1H, t, J = 1.6 Hz), 7.98 (2H, t, J = 1.6 Hz).	Ref. Ex. 48
1740		1H-NMR (CDCl3) δ: 0.96 (3H, t, J = 7.5 Hz), 1.68 (2H, q, J = 7.5 Hz), 2.65 (2H, t, J = 7.5 Hz), 7.59 (1H, s), 7.62 (1H, s), 7.83 (1H, s), 9.93 (1H, s).	Ref. Ex. 138
1741		1H-NMR (CDCl3) δ: 0.53-0.56 (2H, m), 0.88-0.90 (2H, m), 1.54-1.61 (1H, m), 2.55-2.63 (1H, br), 4.76 (2H, d, J = 5.7 Hz), 5.55 (1H, dd, J = 9.1, 15.4 Hz), 6.60 (1H, d, J = 15.4 Hz), 7.37-7.40 (2H, m), 7.81 (2H, d, J = 8.5 Hz).	Ref. Ex. 77








[0547]







Ref. Ex. No.	STR	1H-NMR	ref.
1742		1H-NMR (CDCl3) δ: 1.13 (9H, s), 2.48 (1H, t, J = 5.9 Hz), 4.77 (2H, d, J = 5.9 Hz), 6.10 (1H, d, J = 15.8 Hz), 6.43 (1H, d, J = 15.9 Hz), 7.39-7.41 (2H, m), 7.83-7.84 (2H, m).	Ref. Ex. 77
1743		1H-NMR (CDCl3) δ: 1.00 (3H, t, J = 7.4 Hz), 1.66-1.74 (2H, m), 2.34 (1H, t, J = 5.9 Hz); 2.81 (2H, t, J = 7.5 Hz), 4.70 (2H, d, J = 5.9 Hz), 7.19 (1H, t, J = 8.6 Hz), 7.73-7.76 (1H, m), 7.98 (1H, dd, J = 2.2, 6.9 Hz).	Ref. Ex. 34
1744		1H-NMR (CDCl3) δ: 0.07-0.10 (2H, m), 0.46-0.49 (2H, m), 0.71-0.77 (1H, m), 1.54-1.59 (2H, m), 2.42 (1H, t, J = 5.9 Hz), 2.93 (2H, t, J = 7.4 Hz), 4.72 (2H, d, J = 5.7 Hz), 7.18 (1H, t, J = 8.6 Hz), 7.72-7.75 (1H, m), 7.97 (1H, dd, J = 2.2, 7.0 Hz).	Ref. Ex. 34
1745		1H-NMR (CDCl3) δ: 1.05 (3H, t, J = 7.4 Hz), 1.74-1.82 (2H, m), 3.27 (2H, q, J = 7.8 Hz), 7.22-7.25 (1H, m), 7.78-7.81 (1H, m), 8.03 (1H, dd, J = 2.2, 6.9 Hz), 10.18 (1H, s).	Ref. Ex. 48
1746		1H-NMR (CDCl3) δ: 0.07-0.10 (2H, m), 0.45-0.49 (2H, m), 0.70-0.78 (1H, m), 1.54-1.58 (2H, m), 2.41 (1H, t, J = 5.9 Hz), 2.93 (2H, t, J = 7.5 Hz), 4.72 (2H, d, J = 5.8 Hz), 7.38-7.40 (2H, m), 7.81-7.83 (2H, m).	Ref. Ex. 34
1747		1H-NMR (CDCl3) δ: 0.09-0.12 (2H, m), 0.47-0.50 (2H, m), 0.74-0.82 (1H, m), 1.62-1.66 (2H, m), 3.38 (2H, t, J = 7.5 Hz), 7.23 (1H, t, J = 8.6 Hz), 7.78-7.81 (1H, m), 8.03 (1H, dd, J = 2.2, 6.9 Hz), 10.19 (1H, s).	Ref. Ex. 48
1748		1H-NMR (CDCl3) δ: 0.09-0.12 (2H, m), 0.46-0.50 (2H, m), 0.74-0.82 (1H, m), 1.62-1.66 (2H, m), 3.38 (2H, t, J = 7.5 Hz), 7.42-7.45 (2H, m), 7.86-7.89 (2H, m), 10.19 (1H, s).	Ref. Ex. 48
1749		1H-NMR (CDCl3) δ: 2.31 (1H, t, J = 6.7 Hz), 4.98 (2H, d, J = 6.7 Hz), 7.79 (2H, d, J = 8.2 Hz), 8.20 (2H, d, J = 8.2 Hz).	Ref. Ex. 19









Ref. Ex. No.	STR	1H-NMR	ref.
1750		1H-NMR (CDCl3) δ: 1.17-1.22 (4H, m), 2.32 (3H, s), 2.79-2.86 (1H, m), 3.96 (3H, s), 7.05 (1H, t, J = 8.9 Hz), 7.75-7.79 (1H, m), 7.86-7.88 (1H, m).	Ref. Ex. 133
1751		1H-NMR (CDCl3) δ: 0.99 (3H, t, J = 7.3 Hz), 1.69-1.77 (2H, m), 2.74 (2H, t, J = 7.6 Hz), 7.16 (2H, t, J = 8.6 Hz), 7.56-7.60 (2H, m), 7.62 (1H, s), 7.68 (1H, s), 7.87 (1H, s), 10.06 (1H, s).	Ref. Ex. 91
1753		1H-NMR (CDCl3) δ: 0.94 (3H, t, J = 7.3 Hz), 1.37 (12H, s), 1.64-1.72 (2H, m), 2.65-2.68 (2H, m), 7.80 (1H, s), 7.88 (1H, s), 8.12 (1H, s), 10.03 (1H, s).	Ref. Ex. 81
1754		1H-NMR (CDCl3) δ: 0.98 (9H, s), 1.54-1.58 (2H, m), 2.44 (1H, t, J = 5.8 Hz), 2.77-2.80 (2H, m), 4.70 (2H, d, J = 5.9 Hz), 7.38-7.40 (2H, m), 7.80-7.83 (2H, m)	Ref. Ex. 34
1755		1H-NMR (CDCl3) δ: 1.00 (9H, s), 1.60-1.63 (2H, m), 3.24-3.28 (2H, m), 7.42-7.45 (2H, m), 7.85-7.88 (2H, m), 10.19 (1H, s).	Ref. Ex. 48
1756		1H-NMR (CDCl3) δ: 1.23-1.28 (4H, m), 2.33 (3H, s), 2.79-2.86 (1H, m), 7.08 (1H, t, J = 8.9 Hz), 7.76-7.79 (1H, m), 7.84-7.86 (1H, m), 10.04 (1H, s).	Ref. Ex. 63
1757		1H-NMR (CDCl3) δ: 1.18-1.23 (4H, m), 2.42 (3H, s), 2.80-2.86 (1H, m), 3.96 (3H, s), 7.28-7.30 (1H, m), 7.77-7.79 (1H, m), 7.96 (1H, s).	Ref. Ex. 133
1758		1H-NMR (CDCl3) δ: 1.18-1.20 (4H, m), 1.25 (3H, t, J = 7.6 Hz), 2.68 (2H, q, J = 7.6 Hz), 2.80-2.86 (1H, m), 3.96 (3H, s), 7.25-7.27 (2H, m), 7.89-7.91 (2H, m).	Ref. Ex. 133

Ref. Ex. No.	STR	1H-NMR	ref.
1759		1H-NMR (CDCl3) δ: 1.25-1.29 (4H, m), 2.43 (3H, s), 2.66-2.73 (1H, m), 7.31-7.33 (1H, m), 7.76-7.78 (1H, m), 7.94 (1H, s), 10.04 (1H, s).	Ref. Ex. 63
1760		1H-NMR (CDCl3) δ: 1.24-1.28 (7H, m), 2.65-2.73 (3H, m), 7.26-7.30 (2H, m), 7.88-7.90 (2H, m), 10.05 (1H, s).	Ref. Ex. 63
1761		1H-NMR (CDCl3) δ: 1.00 (3H, t, J = 7.3 Hz), 1.72-1.80 (2H, m), 2.78-2.81 (2H, m), 7.57 (1H, d, J = 5.0 Hz), 7.89 (1H, s), 8.60 (1H, s), 8.83 (1H, s), 9.09 (1H, d, J = 5.0 Hz), 10.14 (1H, s).	Ref. Ex. 91
1762		1H-NMR (CDCl3) δ: 0.95 (6H, d, J = 6.5 Hz), 1.49-1.63 (3H, m), 2.65-2.69 (2H, m), 7.59 (1H, s), 7.62 (1H, s), 7.82 (1H, s), 9.93 (1H, s).	Ref. Ex. 138
1763		1H-NMR (CDCl3) δ: 2.75 (3H, s), 5.19 (2H, d, J = 0.5 Hz), 6.96-7.02 (1H, m), 7.14-7.21 (2H, m), 7.31-7.32 (1H, m), 9.92 (1H, d, J = 1.6 Hz).	Ref. Ex. 82
1764		1H-NMR (CDCl3) δ: 0.94 (6H, d, J = 6.5 Hz), 1.37 (12H, s), 1.49-1.63 (3H, m), 2.67-2.70 (2H, m), 7.81 (1H, s), 7.88 (1H, s), 8.11 (1H, s), 10.02 (1H, s).	Ref. Ex. 81









[0548]







Ref. Ex. No.	STR	1H-NMR	ref.
1765		1H-NMR (CDCl3) δ: 1.36 (3H, t, J = 7.6 Hz), 2.85 (2H, q, J = 7.6 Hz), 7.69 (1H, s), 7.82 (1H, s), 7.94 (1H, s), 8.14 (1H, s), 8.92 (1H, s), 9.07 (1H, s), 10.10 (1H, s).	Ref. Ex. 91
1766		1H-NMR (CDCl3) δ: 1.00 (3H, t, J = 7.5 Hz), 1.71-1.79 (2H, *m*), 2.78 (2H, t, J = 7.5 Hz), 7.67 (1H, s), 7.79-7.81 (2H, m), 7.93 (1H, s), 8.08-8.10 (1H, m), 7.97 (1H, s), 10.10 (1H, s).	Ref. Ex. 91
1767		1H-NMR (CDCl3) δ: 1.18-1.25 (4H, m), 2.80-2.87 (1H, m), 3.97 (3H, s), 7.52 (1H, d, J = 8.4 Hz), 7.81-7.84 (1H, m), 8.08 (1H, s).	Ref. Ex. 133
1768		1H-NMR (CDCl3) δ: 1.15-1.24 (4H, m), 2.79-2.86 (1H, m), 3.97 (3H, s), 7.10-7.15 (2H, m), 7.97-8.01 (2H, m).	Ref. Ex. 133
1769		1H-NMR (CDCl3) δ: 1.23-1.28 (4H, m), 2.65-2.72 (1H, m), 7.13-7.17 (2H, m), 7.96-8.00 (2H, m), 10.04 (1H, s).	Ref. Ex. 63
1770		1H-NMR (CDCl3) δ: 1.23-1.32 (4H, m), 2.67-2.74 (1H, m), 7.54 (1H, d, J = 8.4 Hz), 7.82 (1H, dd, J = 2.0, 8.4 Hz), 8.06 (1H, d, J = 2.0 Hz), 10.04 (1H, s).	Ref. Ex. 63
1771		1H-NMR (CDCl3) δ: 6.70 (1H, t, J = 55.9 Hz), 7.92 (1H, s), 7.96 (1H, s), 8.13 (1H, s), 10.01 (1H, s).	Ref. Ex. 138









Ref. Ex. No.	STR	1H-NMR	ref.
1772		1H-NMR (CDCl3) δ: 1.34-1.37 (3H, *m*), 2.83-2.87 (2H, *m*), 7.69 (1H, s), 7.79-7.82 (2H, m), 7.93 (1H, s), 8.09-8.10 (1H, m), 8.98 (1H, s), 10.10 (1H, s).	Ref. Ex. 91
1773		1H-NMR (CDCl3) δ: 1.27 (12H, s), 6.72 (1H, t, J = 56.0 Hz), 8.13 (1H, s), 8.19 (1H, s), 8.41 (1H, s), 10.09 (1H, s).	Ref. Ex. 81
1774		1H-NMR (CDCl3) δ: 6.84 (1H, t, J = 56.0 Hz), 7.64 (1H, d, J = 5.0 Hz), 8.23 (1H, s), 8.94 (1H, s), 9.13-9.15 (2H, m), 10.21 (1H, s).	Ref. Ex. 91
1775		1H-NMR (CDCl3) δ: 6.83 (1H, t, J = 56.0 Hz), 7.84 (1H, d, J = 8.0 Hz), 8.01 (1H, s), 8.13 (2H, s), 8.24 (1H, s), 9.01 (1H, s), 10.17 (1H, s).	Ref. Ex. 91
1776		1H-NMR (CDCl3) δ: 0.97-0.99 (6H, m), 1.52-1.65 (3H, m), 2.80-2.83 (2H, m), 7.58 (1H, d, J = 5.0 Hz), 7.90 (1H, s), 8.60 (1H, s), 8.83 (1H, s), 9.09 (1H, d, J = 5.0 Hz), 10.14 (1H, s).	Ref. Ex. 91
1777		1H-NMR (CDCl3) δ: 0.97-1.00 (6H, m), 1.57-1.66 (3H, m), 2.78-2.81 (2H, m), 7.67 (1H, s), 7.79-7.81 (2H, m), 7.92 (1H, s), 8.08-8.10 (1H, m), 8.97 (1H, s), 10.09 (1H, s).	Ref. Ex. 91

Ref. Ex. No.	STR	1H-NMR	ref.
1778		1H-NMR (CDCl3) δ: 3.46 (3H, s), 4.41-4.45 (1H, *m*), 7.52 (2H, s), 7.72 (1H, s).	Ref. Ex. 115
1779		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.2 Hz), 4.47 (2H, q, J = 7.1 Hz), 8.07 (1H, dd, J = 1.9, 8.3 Hz), 8.32 (1H, s), 8.47 (1H, d, J = 8.3 Hz), 8.86-8.87 (1H, m).	Ref. Ex. 2
1780		1H-NMR (CDCl3) δ: 8.10 (1H, dd, J = 2.2, 8.2 Hz), 8.34 (1H, s), 8.42 (1H, d, J = 8.3 Hz), 8.88-8.90 (1H, m), 10.12 (1H, s).	Ref. Ex. 63
1781		1H-NMR (CDCl3) δ: 3.50 (3H, s), 4.54-4.58 (1H, m), 7.85 (1H, s), 7.88 (1H, s), 8.06 (1H, s), 9.99 (1H, s).	Ref. Ex. 138
1782		1H-NMR (CDCl3) δ: 3.56 (3H, s), 4.68-4.73 (1H, m), 7.83 (1H, d, J = 8.0 Hz), 7.94 (1H, s), 8.04 (1H, s), 8.10-8.13 (1H, m), 8.17 (1H, t, J = 1.6 Hz), 8.99 (1H, d, J = 1.9 Hz), 10.15 (1H, s).	Ref. Ex. 112
1783		1H-NMR (CDCl3) δ: 3.52 (3H, s), 4.64-4.68 (1H, m), 7.17-7.22 (2H, m), 7.59-7.62 (2H, m), 7.88 (1H, s), 7.92 (1H, s), 8.10 (1H, s), 10.11 (1H, s).	Ref. Ex. 112
1784		1H-NMR (CDCl3) δ: 2.52 (3H, s), 7.50-7.54 (1H, m), 7.75 (1H, s), 7.79-7.82 (1H, m), 8.09 (1H, s), 8.23 (1H, s), 8.57 (1H, s), 10.08 (1H, s).	Ref. Ex. 112
1785		1H-NMR (CDCl3) δ: 2.53 (3H, s), 7.75-7.79 (3H, *m*), 8.11 (1H, s), 8.25 (1H, s), 8.67 (1H, s), 10.08 (1H, s).	Ref. Ex. 112


[0549]


Ref. Ex. No.	STR	1H-NMR	ref.
1786		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.0 Hz), 4.45 (2H, q, J = 7.0 Hz), 7.86 (1H, d, J = 8.0 Hz), 8.18 (1H, d, J = 8.5 Hz), 8.24-8.26 (1H, m), 8.59 (1H, d, J = 6.0 Hz), 8.70 (1H, s), 9.42 (1H, s).	Ref. Ex. 112
1788		1H-NMR (CDCl3) δ: 0.87 (1H, d, J = 8.4 Hz), 8.08-8.10 (1H, m), 8.27 (1H, d, J = 8.4 Hz), 8.52 (1H, m), 8.60-8.62 (1H, m), 9.44 (1H, m), 10.16 (1H, s).	Ref. Ex. 76, Ref. Ex. 147
1789		1H-NMR (CDCl3) δ: 7.63-7.65 (1H, m), 7.82 (1H, s), 7.92 (1H, s), 7.97 (1H, s), 8.56 (1H, d, J = 2.5 Hz), 8.70 (1H, s), 10.06 (1H, s).	Ref. Ex. 112
1790		1H-NMR (CDCl3) δ: 2.38 (1H, t, J = 5.8 Hz), 4.82 (2H, d, J = 5.8 Hz), 5.41 (1H, d, J = 11.0 Hz), 5.70 (1H, d, J = 17.2 Hz), 6.89 (1H, dd, J = 11.0, 17.2 Hz), 7.68 (1H, dd, J = 0.8, 7.8 Hz), 7.97 (1H, t, J = 7.8 Hz), 8.34 (1H, d, J = 7.8 Hz).	Ref. Ex. 77
1791		1H-NMR (CDCl3) δ: 1.58 (3H, d, J = 6.5 Hz), 2.13 (1H, d, J = 3.6 Hz), 5.23-5.27 (1H, m), 6.93 (1H, d, J = 5.3 Hz), 7.23 (1H, d, J = 5.3 Hz).	Ref. Ex. 1737
1792		1H-NMR (CDCl3) δ: 3.40 (3H, s), 4.40 (2H, s), 7.42 (2H, s), 7.58 (1H, s).	Ref. Ex. 115
1793		1H-NMR (CDCl3) δ: 3.44 (3H, s), 4.51 (2H, s), 7.76 (1H, s), 7.77 (1H, s), 7.93 (1H, s), 9.96 (1H, s).	Ref. Ex. 138
1794		1H-NMR (CDCl3) δ: 7.48 (1H, d, J = 3.9 Hz), 7.64-7.67 (1H, m), 7.80 (1H, d, J = 3.9 Hz), 8.50 (1H, d, J = 2.6 Hz), 8.77 (1H, s), 9.94 (1H, s).	Ref. Ex. 112


Ref. Ex. No.	STR	1H-NMR	ref.
1795		1H-NMR (CDCl3) δ: 1.28 (3H, t, J = 7.0 Hz), 3.59 (2H, q, J = 7.0 Hz), 4.55 (2H, s), 7.76 (1H, s), 7.78 (1H, s), 7.92 (1H, s), 9.96 (1H, s).	Ref. Ex. 138
1796		1H-NMR (CDCl3) δ: 1.31 (3H, t, J = 7.0 Hz), 3.65 (2H, q, J = 7.0 Hz), 4.67 (2H, s), 7.80 (1H, d, J = 8.1 Hz), 7.87 (1H, s), 7.95 (1H, s), 8.03 (1H, s), 8.10-8.12 (1H, m), 8.99 (1H, s), 10.12 (1H, s).	Ref. Ex. 112
1797		1H-NMR (CDCl3) δ: 3.50 (3H, s), 4.63 (2H, s), 7.81 (1H, d, J = 8.1 Hz), 7.86 (1H, s), 7.95 (1H, s), 8.04 (1H, s), 8.09-8.12 (1H, m), 8.99 (1H, s), 10.12 (1H, s).	Ref. Ex. 112
1798		1H-NMR (CDCl3) δ: 3.47 (3H, s), 4.59 (2H, s), 7.15-7.18 (2H, m), 7.58-7.62 (2H, m), 7.80 (1H, s), 7.82 (1H, s), 7.98 (1H, s), 10.09 (1H, s).	Ref. Ex. 112
1799		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.5 Hz), 2.35 (1H, t, J = 5.8 Hz), 2.89 (2H, q, J = 7.5 Hz), 4.74 (2H, d, J = 5.8 Hz), 7.65 (1H, dd, J = 0.8, 7.8 Hz), 7.92-7.96 (1H, m), 8.31 (1H, d, J = 7.8 Hz).	Ref. Ex. 34
1800		1H-NMR (CDCl3) δ: 0.24-0.29 (1H, m), 0.45-0.52 (2H, m), 0.64-0.70 (1H, m), 1.04-1.10 (1H, m), 3.27 (3H, s), 3.46 (1H, d, J = 7.9 Hz), 7.27 (1H, s), 7.36 (1H, s), 7.44 (1H, s).	Ref. Ex. 115

Ref. Ex. No.	STR	1H-NMR	ref.
1801		1H-NMR (CDCl3) δ: 0.27-0.32 (1H, m), 0.47-0.57 (2H, m), 0.68-0.74 (1H, m), 1.07-1.15 (1H, m), 3.30 (3H, s), 3.60 (1H, d, J = 8.0 Hz), 7.60 (1H, s), 7.73 (1H, s), 7.78 (1H, s), 9.99 (1H, s).	Ref. Ex. 138
1802		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.5 Hz), 3.34 (2H, q, J = 7.5 Hz), 7.72 (1H, dd, J = 0.7, 7.8 Hz), 8.01 (1H, t, J = 7.8 Hz), 8.41 (1H, d, J = 8.0 Hz), 10.20 (1H, s).	Ref. Ex. 48
1803		1H-NMR (CDCl3) δ: 2.82 (3H, s), 3.97 (3H, s), 7.20 (1H, t, J = 8.6 Hz), 7.75-7.79 (1H, m), 8.02 (1H, dd, J = 2.2, 6.9 Hz).	Ref. Ex. 2
1804		1H-NMR (CDCl3) δ: 1.26-1.34 (1H, m), 1.62-1.66 (1H, m), 2.05-2.13 (1H, m), 4.09-4.13 (2H, m), 7.19-7.21 (1H, m), 7.39 (1H, s), 7.45-7.50 (2H, m), 9.98 (1H, s).	Ref. Ex. 80
1805		1H-NMR (CDCl3) δ: 2.25 (3H, s), 2.49 (3H, s), 7.08 (1H, d, J = 5.0 Hz), 7.49 (1H, s), 7.58 (1H, d, J = 5.0 Hz), 7.72 (1H, s), 7.74 (1H, s), 10.03 (1H, s).	Ref. Ex. 112
1806		1H-NMR (CDCl3) δ: 1.30 (3H, t, J = 7.0 Hz), 3.64 (2H, q, J = 7.0 Hz), 4.66 (2H, s), 7.74 (4H, s), 7.86 (1H, s), 7.90 (1H, s), 8.03 (1H, s), 10.11 (1H, s).	Ref. Ex. 112
1807		1H-NMR (CDCl3) δ: 2.87 (3H, s), 3.99 (3H, s), 7.77 (1H, d, J = 8.2 Hz), 8.46 (1H, dd, J = 1.9, 8.2 Hz), 9.18 (1H, d, J = 1.9 Hz).	Ref. Ex. 2
1808		1H-NMR (CDCl3) δ: 1.24-1.31 (1H, m), 1.57-1.65 (1H, m), 2.00-2.10 (1H, m), 3.96-4.05 (2H, m), 7.00 (2H, d, J = 1.6 Hz), 7.28 (1H, d, J = 1.6 Hz).	Ref. Ex. 80









[0550]







Ref. Ex. No.	STR	1H-NMR	ref.
1809		1H-NMR (CDCl3) δ: 1.20-1.32 (1H, m), 1.61-1.67 (1H, m), 2.05-2.13 (1H, m), 4.09-4.14 (2H, m), 7.30-7.34 (2H, m), 7.61 (1H, s), 9.91 (1H, s).	Ref. Ex. 138
1810		1H-NMR (CDCl3) δ: 1.58-1.67 (2H, m), 1.73-1.94 (6H, m), 4.68-4.72 (1H, m), 6.95 (2H, d, J = 1.5 Hz), 7.20 (1H, t, J = 1.5 Hz).	Ref. Ex. 80
1811		1H-NMR (CDCl3) δ: 1.70-1.96 (8H, m), 4.79-4.82 (1H, m), 7.27-7.30 (2H, m), 7.54 (1H, s), 9.89 (1H, s).	Ref. Ex. 138
1812		1H-NMR (CDCl3) δ: 1.42 (3H, s), 4.00 (2H, s), 4.46 (2H, d, J = 6.0 Hz), 4.58 (2H, d, J = 6.0 Hz), 7.04 (2H, d, J = 1.6 Hz), 7.28 (1H, t, J = 1.6 Hz).	Ref. Ex. 80
1813		1H-NMR (CDCl3) δ: 1.45 (3H, s), 4.09 (2H, s), 4.48 (2H, d, J = 6.0 Hz), 4.61 (2H, d, J = 6.0 Hz), 7.37-7.38 (2H, m), 7.61 (1H, s), 9.92 (1H, s).	Ref. Ex. 138
1814		1H-NMR (CDCl3) δ: 1.32-1.36 (1H, m), 1.65-1.68 (1H, m), 2.12-2.16 (1H, m), 4.19 (2H, m), 7.42 (1H, s), 7.47 (1H, s), 7.71 (1H, s), 7.81 (1H, d, J = 8.0 Hz), 8.08-8.10 (1H, m), 8.98 (1H, s), 10.07 (1H, s).	Ref. Ex. 112
1815		1H-NMR (CDCl3) δ: 1.66-2.02 (8H, m), 4.89-4.92 (1H, m), 7.36 (1H, s), 7.46 (1H, s), 7.64 (1H, s), 7.79 (1H, d, J = 8.5 Hz), 8.07-8.09 (1H, m), 8.97 (1H, s), 10.05 (1H, s).	Ref. Ex. 112










Ref. Ex. No.	STR	1H-NMR	ref.
1816		1H-NMR (CDCl3) δ: 1.49 (3H, s), 4.18 (2H, s), 4.52 (2H, d, J = 6.0 Hz), 4.66 (2H, d, J = 6.0 Hz), 7.45 (1H, s), 7.53 (1H, s), 7.72 (1H, s), 7.81 (1H, d, J = 8.0 Hz), 8.09-8.11 (1H, m), 8.98 (1H, s), 10.08 (1H, s).	Ref. Ex. 112
1817		1H-NMR (CDCl3) δ: 1.65-1.69 (2H, m), 1.81-2.00 (6H, m), 4.88-4.91 (1H, m), 7.13-7.17 (2H, m), 7.31-7.35 (2H, m), 7.58-7.60 (3H, m), 10.02 (1H, s).	Ref. Ex. 112
1818		1H-NMR (CDCl3) δ: 2.63-2.70 (1H, m), 2.75-2.82 (1H, m), 4.10 (2H, d, J = 4.2 Hz), 4.62-4.66 (1H, m), 4.70-4.74 (1H, m), 5.09-5.13 (1H, m), 7.07 (2H, d, J = 1.6 Hz), 7.27 (1H, d, J = 1.6 Hz).	Ref. Ex. 80
1819		1H-NMR (CDCl3) δ: 2.68-2.84 (2H, m), 4.16-4.21 (2H, m), 4.63-4.78 (2H, m), 5.12-5.17 (1H, m), 7.38-7.41 (2H, m), 7.61 (1H, s), 9.91 (1H, s).	Ref. Ex. 138
1820		1H-NMR (CDCl3) δ: 1.49 (3H, t, J = 7.0 Hz), 4.18 (2H, q, J = 7.0 Hz), 7.38-7.39 (1H, m), 7.47-7.48 (1H, m), 7.67 (1H, t, J = 1.4 Hz), 7.80 (1H, d, J = 8.2 Hz), 8.07-8.09 (1H, m), 8.97 (1H, d, J = 2.0 Hz), 10.06 (1H, s).	Ref. Ex. 112
1821		1H-NMR (CDCl3) δ: 1.41 (6H, d, J = 6.1 Hz), 4.70-4.75 (1H, m), 7.36-7.37 (1H, m), 7.46-7.47 (1H, m), 7.65 (1H, s), 7.80 (1H, d, J = 8.2 Hz), 8.07-8.09 (1H, m), 8.96 (1H, s), 10.05 (1H, s).	Ref. Ex. 112

Ref. Ex. No.	STR	1H-NMR	ref.
1822		1H-NMR (CDCl3) δ: 2.70-2.87 (2H, m), 4.25-4.31 (2H, m), 4.66-4.78 (2H, m), 5.18-5.23 (1H, m), 7.49 (1H, s), 7.54 (1H, s), 7.71 (1H, s), 7.80 (1H, d, J = 8.5 Hz), 8.08-8.10 (1H, m), 8.98 (1H, s), 10.07 (1H, s).	Ref. Ex. 112
1823		1H-NMR (CDCl3) δ: 4.22 (3H, s), 7.13 (1H, s), 7.37-7.42 (2H, m), 7.71-7.77 (2H, m), 9.90 (1H, s).	Ref. Ex. 48
1824		1H-NMR (CDCl3) δ: 1.71-1.79 (1H, m), 1.87-1.95 (1H, m), 2.17-2.26 (2H, m), 2.48-2.56 (2H, m), 4.72-4.80 (1H, m), 7.13-7.18 (2H, m), 7.24-7.28 (2H, m), 7.54-7.62 (3H, m), 10.01 (1H, s).	Ref. Ex. 112
1825		1H-NMR (CDCl3) δ: 1.46 (6H, d, J = 6.1 Hz), 4.75-4.81 (1H, m), 7.15 (1H, d, J = 8.8 Hz), 7.75 (1H, d, J = 8.1 Hz), 7.78-7.80 (1H, m), 8.03-8.05 (1H, m), 8.09 (1H, d, J = 2.5 Hz), 8.93 (1H, d, J = 2.1 Hz), 10.54 (1H, s).	Ref. Ex. 112
1826		1H-NMR (CDCl3) δ: 1.88-2.18 (8H, m), 4.43-4.48 (1H, m), 7.00 (2H, d, J = 1.6 Hz), 7.26-7.27 (1H, m).	Ref. Ex. 80
1827		1H-NMR (CDCl3) δ: 1.36 (3H, t, J = 7.5 Hz), 2.30 (1H, t, J = 5.8 Hz), 2.91 (2H, q, J = 7.5 Hz), 4.76 (2H, d, J = 5.8 Hz), 8.00 (1H, dd, J = 1.8, 8.3 Hz), 8.26 (1H, d, J = 8.3 Hz), 8.82-8.83 (1H, m).	Ref. Ex. 19
1828		1H-NMR (CDCl3) δ: 1.93-2.19 (8H, m), 4.58 (1H, m), 7.33 (2H, s), 7.59 (1H, s), 9.90 (1H, s).	Ref. Ex. 138










[0551]









Ref. Ex. No.	STR	1H-NMR	ref.
1829		1H-NMR (CDCl3) δ: 1.92-2.18 (8H, m), 4.60 (1H, brs), 7.18-7.22 (1H, m), 7.40 (1H, s), 7.45-7.47 (2H, m), 9.98 (1H, s).	Ref. Ex. 80
1830		1H-NMR (CDCl3) δ: 1.94-2.24 (8H, m), 4.66-4.70 (1H, m), 7.40 (1H, t, J = 2.1 Hz), 7.48-7.49 (1H, m), 7.69 (1H, d, J = 1.4 Hz), 7.80 (1H, d, J = 8.1 Hz), 8.08 (1H, dd, J = 2.1, 8.1 Hz), 8.96 (1H, d, J = 2.1 Hz), 10.06 (1H, s).	Ref. Ex. 112
1831		1H-NMR (CDCl3) δ: 1.96-2.20 (8H, m), 4.65 (1H, m), 7.15-7.18 (2H, m), 7.35-7.38 (2H, m), 7.56-7.59 (2H, m), 7.64 (1H, s), 10.03 (1H, s).	Ref. Ex. 112
1832		1H-NMR (CDCl3) δ: 2.28 (1H, t, J = 5.8 Hz), 2.53 (3H, s), 4.76 (2H, d, J = 5.8 Hz), 7.74 (1H, d, J = 8.3 Hz), 8.35-8.37 (1H, m), 9.18 (1H, s).	Ref. Ex. 19
1833		1H-NMR (CDCl3) δ: 2.89 (3H, s), 7.80 (1H, d, J = 8.2 Hz), 8.43 (1H, dd, J = 1.8, 8.2 Hz), 9.22 (1H, d, J = 1.8 Hz), 10.24 (1H, s).	Ref. Ex. 48
1834		1H-NMR (CDCl3) δ: 1.17-1.23 (4H, m), 2.80-2.86 (1H, m), 3.97 (3H, s), 7.22-7.25 (1H, m), 7.78-7.81 (1H, m), 7.87-7.90 (1H, m), .	Ref. Ex. 133
1835		1H-NMR (CDCl3) δ: 1.18-1.24 (4H, m), 2.81-2.87 (1H, m), 3.97 (3H, s), 7.12-7.17 (1H, m), 7.39-7.44 (1H, m), 7.67-7.70 (1H, m), 7.77-7.80 (1H, m).	Ref. Ex. 133
1836		1H-NMR (CDCl3) δ: 1.21-1.31 (4H, m), 2.69-2.74 (1H, m), 7.16-7.19 (1H, m), 7.42-7.47 (1H, m), 7.67 (1H, d, J = 8.0 Hz), 7.78 (1H, d, J = 8.0 Hz), 10.05 (1H, s).	Ref. Ex. 63








Ref. Ex. No.	STR	1H-NMR	ref.
1837		1H-NMR (CDCl3) δ: 1.22-1.30 (4H, m), 2.71-2.76 (1H, m), 7.28-7.30 (1H, m), 7.81-7.86 (2H, m), 10.06 (1H, s).	Ref. Ex. 63
1838		1H-NMR (CDCl3) δ: 1.15-1.21 (4H, m), 2.78-2.84 (1H, m), 3.95 (3H, s), 6.03 (2H, s), 6.85 (1H, d, J = 8.2 Hz), 7.45 (1H, d, J = 1.6 Hz), 7.53 (1H, dd, J = 1.6, 8.2 Hz).	Ref. Ex. 133
1839		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.0 Hz), 4.20 (2H, q, J = 7.0 Hz), 7.14 (1H, d, J = 8.6 Hz), 7.76 (1H, d, J = 8.0 Hz), 7.88-7.89 (1H, m), 7.94 (1H, dd, J = 2.0, 8.6 Hz), 8.03-8.07 (1H, m), 8.94 (1H, s), 9.96 (1H, s).	Ref. Ex. 112
1840		1H-NMR (CDCl3) δ: 0.71-0.76 (1H, m), 1.07-1.60 (6H, m), 1.74-1.94 (1H, m), 2.22-2.37 (3H, m), 3.59-3.92 (2H, m), 6.98-7.00 (2H, m), 7.22-7.23 (1H, m).	Ref. Ex. 80
1841		1H-NMR (CDCl3) δ: 0.74-0.88 (1H, m), 1.08-1.61 (6H, m), 1.78-2.00 (1H, m), 2.25-2.38 (3H, m), 3.70-4.00 (2H, m), 7.31-7.33 (2H, m), 7.56 (1H, s), 9.90 (1H, s).	Ref. Ex. 138
1842		1H-NMR (CDCl3) δ: 0.78-0.82 (1H, m), 1.10-1.62 (6H, m), 1.80-2.04 (1H, m), 2.25-2.44 (3H, m), 3.77-4.10 (2H, m), 7.39-7.41 (1H, m), 7.46-7.50 (1H, m), 7.66-7.67 (1H, m), 7.80 (1H, d, J = 8.1 Hz), 8.07-8.10 (1H, m), 8.97-8.98 (1H, m), 10.05-10.07 (1H, m).	Ref. Ex. 112

Ref. Ex. No.	STR	1H-NMR	ref.
1843		1H-NMR (CDCl3) δ: 1.22-1.28 (4H, m), 2.64-2.69 (1H, m), 6.04 (2H, m), 6.87 (1H, d, J = 8.5 Hz), 7.43 (1H, s), 7.51-7.53 (1H, m), 10.03 (1H, s).	Ref. Ex. 63
1844		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.77 (1H, dd, J = 2.4, 8.5 Hz), 8.20 (1H, dd, J = 0.6, 8.5 Hz), 8.53 (1H, dd, J = 0.6, 2.4 Hz).	Ref. Ex. 2
1845		1H-NMR (CDCl3) δ: 1.15-1.25 (4H, m), 2.80-2.86 (1H, m), 3.97 (3H, s), 7.12 (1H, d, J = 8.3 Hz), 7.71 (1H, d, J = 1.7 Hz), 7.77 (1H, dd, J = 1.7, 8.3 Hz).	Ref. Ex. 133
1846		1H-NMR (CDCl3) δ: 0.95 (3H, t, J = 7.4 Hz), 1.40 (3H, t, J = 7.1 Hz), 1.87-1.95 (2H, m), 4.37 (2H, q, J = 7.1 Hz), 4.55 (2H, t, J = 7.3 Hz), 7.09 (1H, s), 7.35-7.39 (2H, m), 7.72-7.75 (2H, m).	Ref. Ex. 113
1847		1H-NMR (CDCl3) δ: 1.19 (3H, t, J = 7.0 Hz), 3.70 (2H, q, J = 7.0 Hz), 7.38 (1H, t, J = 7.7 Hz), 7.62-7.65 (1H, m), 7.80 (1H, d, J = 8.2 Hz), 7.95-7.97 (1H, m), 8.16 (1H, d, J = 7.7 Hz), 8.97 (1H, s), 10.47 (1H, s).	Ref. Ex. 112
1848		1H-NMR (CDCl3) δ: 1.07 (6H, d, J = 6.1 Hz), 3.79-3.84 (1H, m), 7.36 (1H, t, J = 7.7 Hz), 7.61-7.63 (1H, m), 7.79 (1H, d, J = 8.1 Hz), 7.95-7.97 (1H, m), 8.14 (1H, d, J = 8.1 Hz), 8.96 (1H, s), 10.48 (1H, s).	Ref. Ex. 112
1849		1H-NMR (CDCl3) δ: 1.22-1.31 (4H, m), 2.66-2.73 (1H, m), 7.14 (1H, d, J = 8.5 Hz), 7.69 (1H, d, J = 1.6 Hz), 7.75-7.77 (1H, m), 10.04 (1H, s).	Ref. Ex. 63
1850		1H-NMR (CDCl3) δ: 1.34 (3H, t, J = 7.5 Hz), 2.38 (1H, t, J = 5.6 Hz), 2.89 (2H, q, J = 7.5 Hz), 4.73 (2H, d, J = 5.6 Hz), 7.74 (1H, dd, J = 2.4, 8.5 Hz), 8.09 (1H, dd, J = 0.6, 8.5 Hz), 8.52 (1H, dd, J = 0.6, 2.4 Hz).	Ref. Ex. 19
1851		1H-NMR (CDCl3) δ: 3.37 (2H, t, J = 8.7 Hz), 4.85 (2H, t, J = 8.7 Hz), 7.67 (1H, s), 7.75 (1H, d, J = 8.1 Hz), 7.85 (1H, s), 8.01-8.03 (1H, s), 8.91 (1H, s), 10.28 (1H, s).	Ref. Ex. 112









[0552]








Ref. Ex. No.	STR	1H-NMR	ref.
1852		1H-NMR (CDCl3) δ: 1.20-1.31 (4H, m), 2.83-2.90 (1H, m), 3.98 (3H, s), 7.39-7.44 (1H, m), 7.85-7.90 (1H,m), 8.06 (1H, s).	Ref. Ex. 133
1853		1H-NMR (CDCl3) δ: 1.20-1.31 (4H, m), 2.85-2.90 (1H, m), 3.99 (3H, s), 7.77 (1H, d, J = 8.2 Hz), 8.46 (1H, dd, J = 1.8, 8.2 Hz), 9.28 (1H, d, J = 1.8 Hz).	Ref. Ex. 133
1854		1H-NMR (CDCl3) δ: 1.25-1.35 (4H, m), 2.70-2.76 (1H, m), 7.43 (1H, d, J = 8.3 Hz), 7.86 (1H, d, J = 8.7 Hz), 8.04 (1H, s), 10.05 (1H, s).	Ref. Ex. 63
1855		1H-NMR (CDCl3) δ: 0.44-0.49 (2H, m), 0.49-0.55 (2H, m), 1.38-1.45 (4H, m), 4.37 (2H, q, J = 7.1 Hz), 4.47 (2H, d, J = 7.2 Hz), 7.11 (1H, s), 7.35-7.39 (2H, m), 7.73-7.77 (2H, m).	Ref. Ex. 113
1856		1H-NMR (CDCl3) δ: 0.44-0.48 (2H, m), 0.52-0.57 (2H, m), 1.34-1.44 (1H, m), 4.44 (2H, d, J = 7.1 Hz), 7.15 (1H, s), 7.39 (2H, d, J = 8.4 Hz), 7.75 (2H, d, J = 8.4 Hz), 9.89 (1H, s).	Ref. Ex. 63
1857		1H-NMR (CDCl3) δ: 1.46 (6H, d, J = 6.1 Hz), 4.76-4.81 (1H, m), 7.16 (1H, s), 7, 21 (1H, d, J = 7.9 Hz), 7.80 (1H, d, J = 8.1 Hz), 7.97 (1H, d, J = 8.1 Hz), 8.04-8.07 (1H, m), 8.94 (1H, s), 10.53 (1H, s).	Ref. Ex. 112
1858		1H-NMR (CDCl3) δ: 1.35 (6H, d, J = 6.1 Hz), 4.70-4.77 (1H, m), 7.50-7.56 (3H, m), 7.76 (1H, d, J = 8.0 Hz), 8.05-8.07 (1H, m), 8.92 (1H, s), 10.03 (1H, s).	Ref. Ex. 112
1859		1H-NMR (CDCl3) δ: 1.25-1.36 (4H, m), 2.73-2.78 (1H, m), 7.80 (1H, d, J = 8.5 Hz), 8.43-8.45 (1H, m), 9.29 (1H, s), 10.07 (1H, s).	Ref. Ex. 63
1860		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 6.9 Hz), 4.18 (2H, q, J = 6.9 Hz), 7.50-7.53 (2H, m), 7.57-7.58 (1H, m), 7.76 (1H, d, J = 8.1 Hz), 8.07-8.09 (1H, m), 8.93 (1H, s), 10.04 (1H, s).	Ref. Ex. 112







Ref. Ex. No.	STR	1H-NMR	ref.
1861		1H-NMR (CDCl3) δ: 0.81 (3H, t, J = 7.4 Hz), 1.41 (3H, t, J = 7.0 Hz), 1.77-1.87 (2H, m), 4.13 (2H, t, J = 7.5 Hz), 4.43 (2H, q, J = 7.0 Hz), 6.80 (1H, s), 7.30-7.34 (2H, m), 7.44-7.48 (2H, m).	Ref. Ex. 184
1862		1H-NMR (CDCl3) δ: 0.85 (3H, t, J = 7.4 Hz), 1.82-1.91 (2H, m), 4.13 (2H, t, J = 7.3 Hz), 6.79 (1H, s), 7.31-7.34 (2H, m), 7.45-7.49 (2H, m), 9.99 (1H, s).	Ref. Ex. 63
1864		1H-NMR (CDCl3) δ: 1.17-1.21 (2H, m), 1.34-1.38 (2H, m), 2.48-2.54 (1H, m), 7.40-7.44 (2H, m), 7.78-7.91 (2H, m), 10.22 (1H, s).	Ref. Ex. 63
1865		1H-NMR (CDCl3) δ: 1.54 (3H, t, J = 6.9 Hz), 4.26 (2H, q, J = 6.9 Hz), 7.15 (1H, s), 7.22-7.25 (1H, m), 7.80 (1H, d, J = 8.2 Hz), 7.97 (1H, d, J = 8.0 Hz), 8.05-8.08 (1H, m), 8.95 (1H, s), 10.56 (1H, s).	Ref. Ex. 112
1866		1H-NMR (CDCl3) δ: 1.44 (6H, d, J = 5.9 Hz), 4.70-4.75 (1H, m), 7.07 (1H, d, J = 8.7 Hz), 7.10-7.13 (2H, m), 7.51-7.54 (2H, m), 7, 71 (1H, dd, J = 2.6, 8.6 Hz), 8.01 (1H, d, J = 2.6 Hz), 10.53 (1H, s).	Ref. Ex. 112
1867		1H-NMR (CDCl3) δ: 1.51 (3H, t, J = 6.9 Hz), 4.19-4.23 (2H, m), 7.05 (1H, d, J = 8.6 Hz), 7.10-7.14 (2H, m), 7.51-7.54 (2H, m), 7.72 (1H, dd, J = 2.6, 8.6 Hz), 8.02 (1H, d, J = 2.5 Hz), 10.55 (1H, s).	Ref. Ex. 112
1868		1H-NMR (CDCl3) δ: 1.40 (1H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 7.80 (1H, dd, J = 2.4, 8.4 Hz), 8.18 (1H, dd, J = 0.6, 8.4 Hz), 8.55 (1H, dd, J = 0.6, 2.4 Hz), 10.19 (1H, s).	Ref. Ex. 48
1869		1H-NMR (CDCl3) δ: 4.02 (3H, s), 7.17 (1H, d, J = 8.6 Hz), 7.76 (1H, d, J = 8.1 Hz), 7.83 (1H, dd, J = 2.5, 8.6 Hz), 8.03-8.05 (1H, m), 8.10 (1H, d, J = 2.5 Hz), 8.93 (1H, s), 10.54 (1H, s).	Ref. Ex. 112

Ref. Ex. No.	STR	1H-NMR	ref.
1870		1H-NMR (CDCl3) δ: 6.22 (2H, s), 7.42 (1H, d, J = 1.4 Hz), 7.66 (1H, d, J = 1.4 Hz), 7.80 (1H, d, J = 8.0 Hz), 8.22-8.25 (1H, m), 9.11 (1H, d, J = 1.8 Hz), 9.92 (1H, s).	Ref. Ex. 112
1871		1H-NMR (CDCl3) δ: 3.31 (2H, t, J = 8.9 Hz), 4.80 (2H, t, J = 8.9 Hz), 7.10-7.14 (2H, m), 7.48-7.52 (2H, m), 7.60 (1H, s), 7.76 (1H, s), 10.25 (1H, s).	Ref. Ex. 112
1872		1H-NMR (CDCl3) δ: 1.65-1.74 (1H, m), 1.84-1.92 (1H, m), 2.19-2.28 (2H, m), 2.42-2.50 (2H, m), 3.89 (3H, s), 4.64-4.70 (1H, m), 6.69 (1H, d, J = 8.8 Hz), 7.49 (1H, dd, J = 2.7, 8.8 Hz), 7.90 (1H, d, J = 2.7 Hz).	Ref. Ex. 80
1873		1H-NMR (DMSO-d6) δ: 7.71 (1H, dd, J = 1.3, 5.1 Hz), 7.76 (1H, d, J = 1.3 Hz), 8.49 (1H, d, J = 5.1 Hz), 9.87 (1H, brs), 10.34 (1H, brs).	Ref. Ex. 1477
1874		1H-NMR (CDCl3) δ: 1.69-1.79 (1H, m), 1.88-1.96 (1H, m), 2.19-2.28 (2H, m), 2.46-2.53 (2H, m), 4.68-4.75 (1H, m), 6.72 (1H, d, J = 8.9 Hz), 7.57 (1H, dd, J = 2.7, 8.9 Hz), 7.92 (1H, d, J = 2.7 Hz), 10.41 (1H, s).	Ref. Ex. 76 Ref. Ex. 48
1875		1H-NMR (CDCl3) δ: 1.74-1.84 (1H, m), 1.92-2.00 (1H, m), 2.25-2.35 (2H, m), 2.54-2.60 (2H, m), 4.80-4.86 (1H, m), 6.98 (1H, d, J = 8.7 Hz), 7.74-7.78 (2H, m), 8.02-8.04 (1H, m), 8.09 (1H, d, J = 2.5 Hz), 8.92 (1H, s), 10.55 (1H, s).	Ref. Ex. 112
1876		1H-NMR (CDCl3) δ: 2.86 (3H, s), 3.99 (3H, s), 7.70 (1H, dd, J = 1.2, 5.2 Hz), 7.86 (1H, d, J = 1.2 Hz), 8.47 (1H, d, J = 5.2 Hz).	Ref. Ex. 2











[0553]










Ref. Ex. No.	STR	1H-NMR	ref.
1877		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.5 Hz), 3.34 (2H, q, J = 7.5 Hz), 3.99 (3H, s), 7.71 (1H, dd, J = 1.5, 5.2 Hz), 7.87 (1H, t, J = 0.7 Hz), 8.47 (1H, d, J = 5.2 Hz).	Ref. Ex. 2
1878		1H-NMR (CDCl3) δ: 8.23 (1H, s), 9.09-9.10 (2H, m).	Ref. Ex. 89
1879		1H-NMR (CDCl3) δ: 1.45 (6H, d, J = 6.1 Hz), 4.75-4.80 (1H, m), 7.11 (1H, s), 7.14-7.18 (3H, m), 7.54-7.58 (2H, m), 7.89 (1H, d, J = 8.0 Hz), 10.50 (1H, s).	Ref. Ex. 112
1881		1H-NMR (CDCl3) δ: 1.41 (6H, d, J = 7.0 Hz), 3.67-3.73 (1H, m), 7.17 (1H, d, J = 8.4 Hz), 7.78 (1H, d, J = 1.6 Hz), 7.86 (1H, dd, J = 1.6, 8.4 Hz), 10.03 (1H, s).	Ref. Ex. 133, Ref. Ex. 63
1882		1H-NMR (CDCl3) δ: 2.31 (1H, t, J = 5.9 Hz), 2.53 (3H, s), 4.75 (2H, d, J = 5.8 Hz), 7.65 (1H, dd, J = 1.5, 5.2 Hz), 7.81-7.82 (1H, m), 8.43-8.45 (1H, m).	Ref. Ex. 19
1883		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.5 Hz), 2.35 (1H, t, J = 5.9 Hz), 2.92 (2H, q, J = 7.5 Hz), 4.75 (2H, d, J = 5.9 Hz), 7.66 (1H, dd, J = 1.3, 5.2 Hz), 7.82 (1H, d, J = 5.2 Hz), 8.44 (1H, d, J = 5.2 Hz).	Ref. Ex. 19
1884		1H-NMR (CDCl3) δ: 2.89 (3H, s), 7.71 (1H, dd, J = 1.5, 5.1 Hz), 7.86 (1H, dd, J = 0.5, 1.5 Hz), 8.50 (1H, dd, J = 0.5, 5.1 Hz), 10.22 (1H , s).	Ref. Ex. 48
1885		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.5 Hz), 3.36 (2H, q, J = 7.5 Hz), 7.72 (1H, dd, J = 1.5, 5.2 Hz), 7.87-7.88 (1H, m), 8.50-8.51 (1H, m), 10.22 (1H , s).	Ref. Ex. 48
1886		1H-NMR (CDCl3) δ: 1.29-1.44 (3H, m), 1.56-1.76 (3H, m), 1.81-1.87 (2H, m), 2.05-2.14 (2H, m), 2.82-2.89 (1H, m), 8.17 (1H, s), 9.92 (1H, s).	Ref. Ex. 63










Ref. Ex. No.	STR	1H-NMR	ref.
1887		1H-NMR (CDCl3) δ: 1.23-1.26 (4H, m), 2.87-2.93 (1H, m), 4.00 (3H, s), 7.50-7.57 (2H, m), 7.63-7.67 (1H, m), 7.89 (1H, d, J = 8.4 Hz), 7.96 (1H, d, J = 8.2 Hz), 8.08 (1H, d, J = 7.2 Hz), 9.09 (1H, d, J = 8.7 Hz).	Ref. Ex. 133
1888		1H-NMR (CDCl3) δ: 1.30-1.32 (4H, m), 2.77-2.83 (1H, m), 7.52-7.60 (2H, m), 7.65-7.69 (1H, m), 7.91 (1H, d, J = 8.4 Hz), 7.98 (1H, d, J = 8.2 Hz), 8.07-8.09 (1H, m), 9.26 (1H, d, J = 8.6 Hz), 10.15 (1H, s).	Ref. Ex. 63
1889		1H-NMR (CDCl3) δ: 1.46 (6H, d, J = 6.0 Hz), 4.75-4.80 (1H, m), 7.15 (1H, d, J = 8.5 Hz), 7.77-7.79 (1H, m), 8.09 (2H, s), 8.85 (1H, s), 9.01 (1H, s), 10.54 (1H, s).	Ref. Ex. 112
1893		1H-NMR (CDCl3) δ: 1.05-1.27 (4H, m), 2.39-2.44 (1H, m), 3.85 (3H, s), 3.87 (3H, s), 5.61 (1H, d, J = 6.4 Hz), 7.06-7.09 (1H, m), 7.34-7.42 (4H, m).	Ref. Ex. 1892
1894		1H-NMR (CDCl3) δ: 1.19-1.23 (4H, m), 2.81-2.87 (1H, m), 3.96 (3H, s), 7.31-7.40 (2H, m), 7.46-7.49 (1H, m), 7.98-8.01 (1H, m).	Ref. Ex. 133
1895		1H-NMR (CDCl3) δ: 1.25-1.30 (4H, m), 2.72-2.77 (1H, m), 7.35-7.43 (2H, m), 7.49-7.51 (1H, m), 7.95-7.97 (1H, m), 10.08 (1H, s).	Ref. Ex. 63
1896		1H-NMR (CDCl3) δ: 7.28 (1H, brs), 7.77 (1H, brs), 8.45-8.46 (1H, m), 8.99 (1H, d, J = 1.2 Hz), 9.19 (1H, d, J = 1.8 Hz).	Ref. Ex. 1477

Ref. Ex. No.	STR	1H-NMR	ref.
1897		1H-NMR (CDCl3) δ: 7.21 (1H, brs), 7.68 (1H, brs), 8.24 (1H, t, J = 2.2 Hz), 8.68 (1H, d, J = 2.2 Hz), 8.87 (1H, d, J = 2.2 Hz).	Ref. Ex. 1477
1898		1H-NMR (CDCl3) δ: 7.50 (1H, dd, J = 0.8, 7.8 Hz), 7.66 (1H, brs), 7.81 (1H, t, J = 7.8 Hz), 8.62 (1H, dd, J = 0.8, 7.8 Hz), 9.34 (1H, brs).	Ref. Ex. 1477
1900		1H-NMR (CDCl3) δ: 1.18-1.23 (4H, m), 2.81-2.87 (1H, m), 3.87 (3H, s), 3.97 (3H, s), 6.98-7.01 (1H, m), 7.34 (1H, t, J = 7.9 Hz), 7.52-7.58 (2H, m).	Ref. Ex. 1899
1901		1H-NMR (CDCl3) δ: 1.24-1.29 (4H, m), 2.66-2.73 (1H, m), 3.88 (3H, s), 7.00-7.04 (1H, m), 7.37 (1H, t, J = 7.9 Hz), 7.52-7.56 (2H, m), 10.06 (1H, s).	Ref. Ex. 63
1902		1H-NMR (CDCl3) δ: 1.23-1.32 (4H, m), 2.66-2.73 (1H, m), 7.42-7.60 (1H, m), 7.64-7.84 (2H, m), 10.04 (1H, s).	Ref. Ex. 63
1903		1H-NMR (CDCl3) δ: 1.90-2.21 (8H, m), 2.41 (3H, s), 4.57 (1H, s), 7.01 (1H, s), 7.21 (1H, s), 7.28 (1H, s), 9.93 (1H, s).	Ref. Ex. 80
1904		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.5 Hz), 1.48 (3H, t, J = 7.1 Hz), 3.32 (2H, q, J = 7.5 Hz), 4.46 (2H, q, J = 7.1 Hz), 8.03 (1H, dd, J = 1.7, 8.3 Hz), 8.40 (1H, d, J = 8.3 Hz), 8.82-8.84 (1H, m).	Ref. Ex. 2
1905		1H-NMR (CDCl3) δ: 1.10-1.30 (4H, m), 2.41-2.46 (1H, m), 3.89 (3H, s), 5.62 (1H, d, J = 6.3 Hz), 7.41 (1H, d, J = 6.5 Hz), 7.64 (1H, d, J = 8.5 Hz), 7.91 (1H, s), 7.97 (1H, d, J = 8.5 Hz), 8.17 (1H, s).	Ref. Ex. 1892










[0554]









Ref. Ex. No.	STR	1H-NMR	ref.
1906		1H-NMR (CDCl3) δ: 2.33 (1H, t, J = 5.8 Hz), 2.51 (3H, s), 4.74 (2H, d, J = 5.6 Hz), 8.21 (1H, t, J = 2.1 Hz), 8.58 (1H, d, J = 2.1 Hz), 8.93 (1H, d, J = 2.1 Hz).	Ref. Ex. 318
1907		1H-NMR (CDCl3) δ: 2.87 (3H, s), 4.00 (3H, s), 8.51 (1H, dd, J = 1.5, 1.9 Hz), 8.93 (1H, d, J = 1.5 Hz), 9.26 (1H, d, J = 1.9 Hz).	Ref. Ex. 2
1908		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.5 Hz), 3.35 (2H, q, J = 7.5 Hz), 4.00 (3H, s), 8.51-8.52 (1H, m), 8.93 (1H, d, J = 1.2 Hz), 9.28 (1H, d, J = 1.9 Hz).	Ref. Ex. 2
1909		1H-NMR (CDCl3) δ: 1.46 (6H, d, J = 6.1 Hz), 4.77-4.83 (1H, m), 7.14 (1H, d, J = 8.9 Hz), 7.87 (1H, d, J = 8.4 Hz), 7.93-7.98 (1H, m), 8.36-8.39 (1H, m), 8.44 (1H, d, J = 2.5 Hz), 8.90 (1H, s), 10.54 (1H, s).	Ref. Ex. 112
1910		1H-NMR (CDCl3) δ: 1.22-1.28 (4H, m), 2.84-2.90 (1H, m), 3.98 (3H, s), 7.60-7.64 (1H, m), 7.91-7.94 (2H, m), 8.15 (1H, s).	Ref. Ex. 1899
1911		1H-NMR (CDCl3) δ: 1.28-1.34 (4H, m), 2.72-2.78 (1H, m), 7.62-7.65 (1H, m), 7.90 (1H, s), 7.94 (1H, d, J = 8.4 Hz), 8.16 (1H, s), 10.06 (1H, s).	Ref. Ex. 63
1912		1H-NMR (CDCl3) δ: 2.85 (3H, s), 3.99 (3H, s), 8.31 (1H, t, J = 2.1 Hz), 8.62 (1H, d, J = 2.1 Hz), 8.94 (1H, d, J = 2.1 Hz).	Ref. Ex. 2
1913		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.5 Hz), 3.34 (2H, q, J = 7.5 Hz), 3.99 (3H, s), 8.31 (1H, t, J = 2.1 Hz), 8.62 (1H, d, J = 2.1 Hz), 8.96 (1H, d, J = 2.1 Hz).	Ref. Ex. 2
1914		1H-NMR (CDCl3) δ: 2.84 (3H, s), 3.97 (3H, s), 7.35 (1H, dd, J = 0.7, 7.8 Hz), 7.75 (1H, t, J = 7.8 Hz), 8.17 (1H, dd, J = 0.7, 7.8 Hz).	Ref. Ex. 2
1915		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.35 (1H, dd, J = 0.7, 7.8 Hz), 7.75 (1H, t, J = 7.8 Hz), 8.17 (1H, dd, J = 0.7, 7.8 Hz).	Ref. Ex. 2









Ref. Ex. No.	STR	1H-NMR	ref.
1916		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.0 Hz), 1.90-2.20 (8H, m), 4.05-4.10 (2H, m), 4.53-4.57 (1H, m), 6.71 (1H, t, J = 2.3 Hz), 7.00 (1H, s), 7.01 (1H, s), 9.89 (1H, s).	Ref. Ex. 80
1917		1H-NMR (CDCl3) δ: 2.88 (3H, s), 8.28 (1H, t, J = 1.9 Hz), 8.64 (1H, d, J = 1.9 Hz), 8.97 (1H, d, J = 1.9 Hz), 10.22 (1H, s).	Ref. Ex. 318
1918		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.5 Hz), 2.47 (1H, brs), 2.91 (2H, q, J = 7.5 Hz), 4.74 (2H, s), 8.22 (1H, t, J = 2.1 Hz), 8.58 (1H, d, J = 2.1 Hz), 8.95 (1H, d, J = 2.1 Hz).	Ref. Ex. 318
1919		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.5 Hz), 3.35 (2H, q, J = 7.5 Hz), 8.29 (1H, t, J = 2.1 Hz), 8.64 (1H, d, J = 2.1 Hz), 8.98 (1H, d, J = 2.1 Hz), 10.22 (1H, s).	Ref. Ex. 318
1920		1H-NMR (CDCl3) δ: 2.29 (1H, t, J = 5.8 Hz), 2.50 (3H, s), 4.73 (2H, d, J = 5.8 Hz), 7.31 (1H, dd, J = 0.8, 7.8 Hz), 7.72 (1H, t, J = 7.8 Hz), 8.04 (1H, dd, J = 0.8, 7.8 Hz).	Ref. Ex. 318
1921		1H-NMR (CDCl3) δ: 2.86 (3H, s), 7.38 (1H, dd, J = 0.7, 7.8 Hz), 7.78 (1H, t, J = 7.8 Hz), 8.14 (1H, dd, J = 0.7, 7.8 Hz), 10.19 (1H, s).	Ref. Ex. 318
1922		1H-NMR (CDCl3) δ: 1.34 (3H, t, J = 7.5 Hz), 2.33 (1H, t, J = 5.8 Hz), 2.89 (2H, q, J = 7.5 Hz), 4.73 (2H, d, J = 5.8 Hz), 7.31 (1H, dd, J = 0.7, 7.8 Hz), 7.72 (1H, t, J = 7.8 Hz), 8.05 (1H, dd, J = 0.7, 7.8 Hz).	Ref. Ex. 318
1923		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 7.38 (1H, dd, J = 0.6, 7.8 Hz), 7.78 (1H, t, J = 7.8 Hz), 8.14 (1H, dd, J = 0.6, 7.8 Hz), 10.19 (1H, s).	Ref. Ex. 318
1924		1H-NMR (CDCl3) δ: 1.13-1.29 (4H, m), 2.79-2.85 (1H, m), 3.24 (2H, t, J = 8.7 Hz), 3.95 (3H, s), 4.64 (2H, t, J = 8.7 Hz), 6.81 (1H, d, J = 8.4 Hz), 7.74-7.77 (1H, m), 7.86 (1H, s).	Ref. Ex. 133

Ref. Ex. No.	STR	1H-NMR	ref.
1925		1H-NMR (CDCl3) δ: 1.22-1.26 (4H, m), 2.64-2.70 (1H, m), 3.26 (2H, t, J = 8.8 Hz), 4.65 (2H, t, J = 8.8 Hz), 6.83 (1H, d, J = 8.4 Hz), 7.74-7.76 (1H, m), 7.84 (1H, s), 10.03 (1H, s).	Ref. Ex. 63
1926		1H-NMR (CDCl3) δ: 2.80 (3H, s), 3.86 (3H, s), 3.96 (3H, s), 6.94 (2H, d, J = 8.7 Hz), 7.86 (2H, d, J = 8.7 Hz).	Ref. Ex. 2
1927		1H-NMR (CDCl3) δ: 1.37 (3H, t, J = 7.5 Hz), 3.29 (2H, q, J = 7.5 Hz), 3.86 (3H, s), 3.96 (3H, s), 6.92-6.96 (2H, m), 7.85-7.89 (2H, m).	Ref. Ex. 2
1928		1H-NMR (CDCl3) δ: 2.82 (3H, s), 3.87 (3H, s), 6.95-6.99 (2H, m), 7.84-7.88 (2H, m), 10.19 (1H, s).	Ref. Ex. 318
1929		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 3.30 (2H, q, J = 7.5 Hz), 3.87 (3H, s), 6.95-6.99 (2H, m), 7.85-7.89 (2H, m), 10.18 (1H, s).	Ref. Ex. 318
1930		1H-NMR (DMSO-d6) δ: 7.85-7.90 (1H, m), 8.57-8.60 (2H, m), 9.87 (1H, brs), 10.17 (1H, brs).	Ref. Ex. 1477
1931		1H-NMR (CDCl3) δ: 7.77 (1H, dd, J = 0.9, 5.0 Hz), 7.93 (1H, s), 8.95 (1H, d, J = 5.0 Hz).	Ref. Ex. 89
1932		1H-NMR (CDCl3) δ: 2.04-2.14 (4H, m), 3.35-3.39 (4H, m), 4.00-4.07 (2H, m), 4.10-4.16 (2H, m), 5.77 (1H, s), 6.93-6.96 (1H, m), 6.99 (1H, d, J = 7.6 Hz), 7.06 (1H, s), 7.29 (1H, d, J = 7.9 Hz).	Ref. Ex. 114
1933		1H-NMR (CDCl3) δ: 2.04-2.12 (4H, m), 3.36-3.40 (4H, m), 4.01-4.12 (4H, m), 5.73 (1H, s), 6.88 (1H, t, J = 2.1 Hz), 6.91 (1H, s), 6.96 (1H, s).	Ref. Ex. 114







[0555]






Ref. Ex. No.	STR	1H-NMR	ref.
1934		1H-NMR (CDCl3) δ: 2.06-2.14 (4H, m), 3.43-3.47 (4H, m), 7.12-7.14 (1H, m), 7.28-7.31 (2H, m), 9.90 (1H, s).	Ref. Ex. 151
1935		1H-NMR (CDCl3) δ: 1.92-2.23 (8H, m), 4.64 (1H, m), 7.01 (2H, d, J = 8.7 Hz), 7.84 (2H, d, J = 8.7 Hz), 9.89 (1H, s).	Ref. Ex. 80
1936		1H-NMR (CDCl3) δ: 2.06-2.16 (4H, m), 3.42-3.46 (4H, m), 7.19-7.22 (1H, m), 7.34-7.37 (1H, m), 7.41-7.46 (2H, m), 9.97 (1H, s).	Ref. Ex. 151
1937		1H-NMR (CDCl3) δ: 2.83 (3H, s), 3.97 (3H, s), 7.48-7.53 (1H, m), 8.28 (1H, dd, J = 4.5, 8.8 Hz), 8.44 (1H, d, J = 2.8 Hz).	Ref. Ex. 2
1938		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.6 Hz), 3.31 (2H, q, J = 7.6 Hz), 3.97 (3H, s), 7.47-7.54 (1H, m), 8.28 (1H, dd, J = 4.5, 8.8 Hz), 8.44 (1H, d, J = 2.8 Hz).	Ref. Ex. 2
1939		1H-NMR (CDCl3) δ: 1.42 (9H, s), 6.97-6.99 (1H, m), 7.81 (1H, s), 7.84 (1H, s), 7.96 (1H, s), 7.99-8.05 (1H, m), 10.08 (1H, s).	Ref. Ex. 112
1940		1H-NMR (CDCl3) δ: 2.86 (3H, s), 7.46-7.56 (1H, m), 8.25 (1H, dd, J = 4.5, 8.7 Hz), 8.46 (1H, d, J = 2.8 Hz), 10.19 (1H, s).	Ref. Ex. 318, Ref. Ex. 48
1941		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 7.49-7.56 (1H, m), 8.18-8.30 (1H, m), 8.46 (1H, d, J = 2.8 Hz), 10.18 (1H, s).	Ref. Ex. 318, Ref. Ex. 48
1942		1H-NMR (CDCl3) δ: 1.70-1.80 (2H, m), 1.94-2.00 (2H, m), 2.10-2.20 (1H, m), 2.68-2.75 (2H, m), 3.75-3.81 (2H, m), 4.00-4.07 (2H, m), 4.10-4.16 (2H, m), 5.78 (1H, s), 6.94 (1H, d, J = 8.0 Hz), 6.99 (1H, d, J = 7.4 Hz), 7.06 (1H, s), 7.28 (1H, d, J = 8.0 Hz).	Ref. Ex. 114








Ref. Ex. No.	STR	1H-NMR	ref.
1943		1H-NMR (CDCl3) δ: 1.71-1.80 (2H, m), 1.98-2.03 (2H, m), 2.16-2.25 (1H, m), 2.75-2.82 (2H, m), 3.82-3.88 (2H, m), 7.19-7.22 (1H, m), 7.33-7.36 (1H, m), 7.40-7.45 (2H, m), 9.96 (1H, s).	Ref. Ex. 151
1944		1H-NMR (CDCl3) δ: 1.27-1.98 (10H, m), 3.50-3.58 (1H, m), 3.97 (3H, s), 7.60 (1H, t, J = 7.8 Hz), 7.72 (1H, d, J = 7.8 Hz), 8.26 (1H, d, J = 7.8 Hz), 8.33 (1H, s).	Ref. Ex. 133
1945		1H-NMR (CDCl3) δ: 1.92-2.05 (4H, m), 3.19-3.26 (2H, m), 3.35-3.42 (2H, m), 4.00-4.13 (4H, m), 4.75-4.90 (1H, m), 5.73 (1H, s), 6.86-6.94 (3H, m) .	Ref. Ex. 114
1946		1H-NMR (CDCl3) δ: 1.27-1.99 (10H, m), 3.49-3.58 (1H, m), 3.95 (3H, s), 7.38-7.47 (2H, m), 7.95-7.98 (1H, m), 8.06-8.08 (1H, m).	Ref. Ex. 133
1947		1H-NMR (CDCl3) δ: 1.95-2.05 (4H, m), 3.30-3.47 (4H, m), 4.81-4.92 (1H, m), 7.11-7.12 (1H, m), 7.27-7.28 (2H, m), 9.89 (1H, s).	Ref. Ex. 151
1948		1H-NMR (CDCl3) δ: 1.53 (3H, t, J = 7.0 Hz), 4.23 (2H, q, J = 7.0 Hz), 6.92-6.94 (1H, m), 7.09 (1H, d, J = 8.8 Hz), 7.74-7.77 (1H, m), 7.95-8.01 (2H, m), 10.54 (1H, s).	Ref. Ex. 112
1949		1H-NMR (CDCl3) δ: 1.23-1.35 (4H, m), 2.83-2.91 (1H, m), 3.98 (3H, s), 8.02-8.06 (1H, m), 8.29-8.33 (1H, m), 8.95 (1H, s).	Ref. Ex. 133
1950		1H-NMR (CDCl3) δ: 1.33-1.50 (4H, m), 1.65-2.04 (6H, m), 3.34-3.39 (1H, m), 7.41-7.47 (2H, m), 7.95-7.97 (1H, m), 8.04-8.05 (1H, m), 10.04 (1H, s).	Ref. Ex. 63

Ref. Ex. No.	STR	1H-NMR	ref.
1951		1H-NMR (CDCl3) δ: 1.31-1.99 (10H, m), 3.35-3.41 (1H, m), 7.63 (1H, t, J = 7.8 Hz), 7.74 (1H, d, J = 7.8 Hz), 8.26 (1H, d, J = 7.8 Hz), 8.31 (1H, s), 10.05 (1H, s).	Ref. Ex. 63
1953		1H-NMR (CDCl3) δ: 1.72-1.94 (6H, m), 2.07-2.15 (2H, m), 3.92-4.00 (1H, m), 3.95 (3H, s), 7.38-7.47 (2H, m), 7.94-7.97 (1H, m), 8.05-8.07 (1H, m).	Ref. Ex. 133
1954		1H-NMR (CDCl3) δ: 1.73-1.96 (6H, m), 2.08-2.16 (2H, m), 3.91-3.98 (1H, m), 3.96 (3H, s), 7.60 (1H, t, J = 7.7 Hz), 7.72 (1H, d, J = 7.7 Hz), 8.25 (1H, d, J = 7.7 Hz), 8.32 (1H, s).	Ref. Ex. 133
1955		1H-NMR (CDCl3) δ: 1.85-2.52 (6H, m), 3.95 (3H, s), 4.30-4.38 (1H, m), 7.59-7.64 (1H, m), 7.74 (1H, d, J = 7.3 Hz), 8.30 (1H, d, J = 7.5 Hz), 8.37 (1H, s).	Ref. Ex. 133
1956		1H-NMR (CDCl3) δ: 1.97-2.17 (2H, m), 2.37-2.50 (4H, m), 3.94 (3H, s), 4.29-4.37 (1H, m), 7.39-7.47 (2H, m), 7.99-8.02 (1H, m), 8.10-8.12 (1H, m).	Ref. Ex. 133
1957		1H-NMR (CDCl3) δ: 1.76-2.00 (6H, m), 2.11-2.18 (2H, m), 3.75-3.81 (1H, m), 7.40-7.47 (2H, m), 7.94-7.96 (1H, m), 8.04-8.05 (1H, m), 10.03 (1H, s).	Ref. Ex. 63
1958		1H-NMR (CDCl3) δ: 1.76-1.98 (6H, m), 2.12-2.20 (2H, m), 3.77-3.82 (1H, m), 7.63 (1H, t, J = 7.9 Hz), 7.75 (1H, d, J = 7.9 Hz), 8.25 (1H, d, J = 7.9 Hz), 8.31 (1H, s), 10.05 (1H, s).	Ref. Ex. 63
1959		1H-NMR (CDCl3) δ: 2.02-2.23 (2H, m), 2.40-2.56 (4H, m), 4.16-4.24 (1H, m), 7.64 (1H, t, J = 7.8 Hz), 7.76 (1H, d, J = 7.8 Hz), 8.29 (1H, d, J = 7.8 Hz), 8.35 (1H, s), 10.01 (1H, s).	Ref. Ex. 63










[0556]









Ref. Ex. No.	STR	1H-NMR	ref.
1960		1H-NMR (CDCl3) δ: 2.00-2.22 (2H, m), 2.40-2.56 (4H, m), 4.17-4.26 (1H, m), 7.42-7.53 (2H, m), 7.98-8.03 (1H, m), 8.08-8.13 (1H, m), 9.99 (1H, s).	Ref. Ex. 63
1961		1H-NMR (CDCl3) δ: 2.84 (3H, s), 3.98 (3H, s), 7.69 (2H, d, J = 8.2 Hz), 8.04 (2H, d, J = 8.2 Hz).	Ref. Ex. 2
1962		1H-NMR (CDCl3) δ: 2.84 (3H, s), 3.98 (3H, s), 7.57 (1H, t, J = 7.8 Hz), 7.68 (1H, d, J = 7.8 Hz), 8.09 (1H, d, J = 7.8 Hz), 8.19 (1H, s).	Ref. Ex. 2
1963		1H-NMR (CDCl3) δ: 1.98-2.20 (2H, m), 2.37-2.50 (4H, m), 3.94 (3H, s), 4.28-4.36 (1H, m), 7.22-7.25 (1H, m), 7.98-8.02 (1H, m), 8.17-8.20 (1H, m).	Ref. Ex. 133
1964		1H-NMR (CDCl3) δ: 1.73-1.93 (6H, m), 2.07-2.15 (2H, m), 3.89-3.97 (1H, m), 3.95 (3H, s), 7.21-7.25 (1H, m), 7.93-7.97 (1H, m), 8.13 (1H, dd, J = 2.1, 7.0 Hz).	Ref. Ex. 133
1965		1H-NMR (CDCl3) δ: 1.75-1.96 (6H, m), 2.11-2.17 (2H, m), 3.73-3.80 (1H, m), 7.24-7.27 (1H, m), 7.93-7.97 (1H, m), 8.11-8.12 (1H, m), 10.02 (1H, s).	Ref. Ex. 63
1966		1H-NMR (CDCl3) δ: 2.00-2.21 (2H, m), 2.42-2.51 (4H, m), 4.14-4.22 (1H, m), 7.25–7.29 (1H, m), 7.98-8.01 (1H, m), 8.16-8.17 (1H, m), 9.98 (1H, s).	Ref. Ex. 63
1967		1H-NMR (CDCl3) δ: 1.24-1.69 (5H, m), 1.75-1.97 (5H, m), 3.45-3.55 (1H, m), 3.95 (3H, s), 7.21-7.24 (1H, m), 7.95-7.98 (1H, m), 8.14 (1H, dd, J = 2.2, 6.9 Hz).	Ref. Ex. 133
1968		1H-NMR (CDCl3) δ: 1.25-1.49 (4H, m), 1.64-1.98 (6H, m), 3.32-3.38 (1H, m), 7.22–7.27 (1H, m), 7.94-7.98 (1H, m), 8.11-8.13 (1H, m), 10.03 (1H, s).	Ref. Ex. 63









Ref. Ex. No.	STR	1H-NMR	ref.
1969		1H-NMR (CDCl3) δ: 1.33 (12H, s), 1.69-1.80 (1H, m), 1.88-1.96 (1H, m), 2.18-2.32 (2H, m), 2.47-2.56 (2H, m), 4.76-4.82 (1H, m), 6.80 (1H, d, J = 8.4 Hz), 7.91 (1H, dd, J = 1.7, 8.4 Hz), 8.29 (1H, d, J = 1.7 Hz), 10.48 (1H, s).	Ref. Ex. 81
1970		1H-NMR (CDCl3) δ: 1.73-1.83 (1H, m), 1.90-2.00 (1H, m), 2.25-2.35 (2H, m), 2.52–2.60 (2H, m), 4.83-4.90 (1H, m), 6.95 (1H, d, J = 8.8 Hz), 7.47 (1H, d, J = 4.9 Hz), 8.67 (1H, dd, J = 2.4, 8.8 Hz), 8.98 (1H, d, J = 2.4 Hz), 9.01 (1H, d, J = 4.9 Hz), 10.54 (1H, s).	Ref. Ex. 112
1971		1H-NMR (CDCl3) δ: 1.75-1.83 (1H, m), 1.93-1.99 (1H, m), 2.25-2.34 (2H, m), 2.51–2.60 (2H, m), 4.82-4.89 (1H, m), 6.97 (1H, d, J = 8.8 Hz), 7.86 (1H, d, J = 8.2 Hz), 7.96-7.98 (1H, m), 8.34-8.36 (1H, m), 8.44 (1H, d, J = 2.4 Hz), 8.91 (1H, s), 10.54 (1H, s).	Ref. Ex. 112
1972		1H-NMR (CDCl3) δ: 1.24-1.31 (4H, m), 2.85-2.90 (1H, m), 3.99 (3H, s), 7.94 (1H, s), 8.42 (2H, s).	Ref. Ex. 133
1973		1H-NMR (CDCl3) δ: 1.46 (6H, d, J = 6.1 Hz), 4.79-4.84 (1H, m), 7.11 (1H, d, J = 9.0 Hz), 7.47 (1H, d, J = 4.9 Hz), 8.67-8.70 (1H, m), 8.98 (1H, d, J = 2.3 Hz), 9.01 (1H, d, J = 4.9 Hz), 10.54 (1H, s).	Ref. Ex. 112
1974		1H-NMR (CDCl3) δ: 1.45 (6H, d, J = 6.1 Hz), 4.76-4.81 (1H, m), 7.13 (1H, d, J = 8.8 Hz), 7.58 (1H, d, J = 7.4 Hz), 7.89-7.96 (2H, m), 8.41-8.45 (2H, m), 10.54 (1H, s).	Ref. Ex. 112

Ref. Ex. No.	STR	1H-NMR	ref.
1975		1H-NMR (CDCl3) δ: 7.22 (1H, brs), 7.29 (1H, dd, J = 2.0, 8.4 Hz), 7.40 (1H, d, J = 2.0 Hz), 7.67 (1H, d, J = 8.4 Hz), 8.00 (1H, brs).	Ref. Ex. 1477
1976		1H-NMR (CDCl3) δ: 6.95-7.09 (1H, m), 7.12 (1H, dd, J = 2.5, 8.5 Hz), 7.27 (1H, brs), 7.76 (1H, dd, J = 6.0, 8.5 Hz), 8.09 (1H, brs).	Ref. Ex. 1477
1977		1H-NMR (CDCl3) δ: 2.83 (3H, s), 3.97 (3H, s), 7.02-7.12 (1H, m), 7.23 (1H, dd, J = 2.6, 8.6 Hz), 8.20 (1H, dd, J = 6.1, 8.6 Hz).	Ref. Ex. 2
1978		1H-NMR (CDCl3) δ: 2.40 (1H, t, J = 5.8 Hz), 2.50 (3H, s), 4.74 (2H, d, J = 5.8 Hz), 7.06-7.11 (1H, m), 7.23 (1H, dd, J = 2.6, 8.7 Hz), 8.17 (1H, dd, J = 6.2, 8.7 Hz).	Ref. Ex. 19
1979		1H-NMR (CDCl3) δ: 1.31-1.36 (4H, m), 2.71-2.77 (1H, m), 7.97 (1H, s), 8.41 (2H, s), 10.07 (1H, s).	Ref. Ex. 63
1980		1H-NMR (CDCl3) δ: 1.72-1.93 (6H, m), 2.07-2.14 (2H, m), 3.89-3.94 (1H, m), 3.95 (3H, s), 7.22-7.28 (1H, m), 7.80-7.84 (1H, m), 7.86-7.91(1H, m).	Ref. Ex. 133
1981		1H-NMR (CDCl3) δ: 2.86 (3H, s), 7.11-7.16 (1H, m), 7.24-7.31 (1H, m), 8.26 (1H, dd, J = 6.1, 8.9 Hz), 10.23 (1H, s).	Ref. Ex. 48
1982		1H-NMR (CDCl3) δ: 1.99-2.20 (2H, m), 2.41-2.50 (4H, m), 3.96 (3H, s), 4.31-4.39 (1H, m), 7.81 (1H, d, J = 8.2 Hz), 8.55-8.59 (1H, m), 9.40-9.42 (1H, m).	Ref. Ex. 133
1983		1H-NMR (CDCl3) δ: 2.83 (3H, s), 3.97 (3H, s), 7.35 (1H, dd, J = 2.1, 8.6 Hz), 7.50 (1H, d, J = 2.1 Hz), 8.19 (1H, d, J = 8.6 Hz).	Ref. Ex. 2











[0557]










Ref. Ex. No.	STR	1H-NMR	ref.
1984		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.06-7.15 (1H, m), 7.23 (1H, dd, J = 2.6, 8.6 Hz), 8.20 (1H, dd, J = 6.1, 8.6 Hz).	Ref. Ex. 2
1985		1H-NMR (CDCl3) δ: 3.99 (3H, s), 7.10-7.18 (1H, m), 7.24-7.30 (1H, m), 8.26-8.37 (2H, m).	Ref. Ex. 2
1986		1H-NMR (CDCl3) δ: 2.02-2.24 (3H, m), 2.44-2.53 (5H, m), 4.18-4.25 (1H, m), 7.82 (1H, d, J = 8.2 Hz), 8.53-8.56 (1H, m), 9.41 (1H, s), 10.02 (1H, s).	Ref. Ex. 63
1987		1H-NMR (CDCl3) δ: 2.02-2.10 (1H, m), 2.13-2.23 (1H, m), 2.45-2.53 (4H, m), 4.18–4.26 (1H, m), 7.83 (1H, d, J = 8.2 Hz), 8.53-8.56 (1H, m), 9.41 (1H, s), 10.02 (1H, s).	Ref. Ex. 63
1988		1H-NMR (CDCl3) δ: 1.09-1.15 (2H, m), 1.20-1.24 (2H, m), 3.01-3.07 (1H, m), 3.91 (3H, s), 7.20 (1H, t, J = 8.6 Hz), 7.77 (1H, ddd, J = 2.2, 4.5, 8.6 Hz), 8.00 (1H, dd, J = 2.2, 7.0 Hz).	Ref. Ex. 1863
1989		1H-NMR (CDCl3) δ: 2.44 (1H, t, J = 5.8 Hz), 2.50 (3H, s), 4.74 (2H, d, J = 5.8 Hz), 7.34 (1H, dd, J = 2.1, 8.6 Hz), 7.50 (1H, d, J = 2.1 Hz), 8.16 (1H, d, J = 8.6 Hz).	Ref. Ex. 19
1990		1H-NMR (CDCl3) δ: 2.32 (1H, t, J = 6.0 Hz), 4.86 (2H, d, J = 6.0 Hz), 7.05-7.13 (1H, m), 7.24-7.30 (1H, m), 7.34 (1H, s), 8.22 (1H, dd, J = 6.2, 8.9 Hz).	Ref. Ex. 19
1991		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.5 Hz), 2.45 (1H, t, J = 5.8 Hz), 2.90 (2H, q, J = 7.5 Hz), 4.74 (2H, d, J = 5.8 Hz), 7.03-7.13 (1H, m), 7.23 (1H, dd, J = 2.6, 8.7 Hz), 8.17 (1H, dd, J = 6.2, 8.7 Hz).	Ref. Ex. 19
1992		1H-NMR (CDCl3) δ: 1.01 (6H, d, J = 6.7 Hz), 2.11-2.20 (1H, m), 3.01 (2H, d, J = 7.2 Hz), 3.95 (3H, s), 7.38-7.47 (2H, m), 7.95-7.98 (1H, m), 8.07-8.09 (1H, m).	Ref. Ex. 133









Ref. Ex. No.	STR	1H-NMR	ref.
1993		1H-NMR (CDCl3) δ: 1.01 (6H, d, J = 6.5 Hz), 2.12-2.18 (1H, m), 3.00 (2H, d, J =7.0 Hz), 3.94 (3H, s), 7.23 (1H, t, J =8.5 Hz), 7.95-7.98 (1H, m), 8.14-8.16 (1H, m).	Ref. Ex. 133
1994		1H-NMR (CDCl3) δ: 2.86 (3H, s), 7.39 (1H, dd, J = 2.1, 8.6 Hz), 7.53 (1H, d, J = 2.1 Hz), 8.24 (1H, d, J = 8.6 Hz), 10.23 (1H, s).	Ref. Ex. 48
1995		1H-NMR (CDCl3) δ: 7.13-7.18 (1H, m), 7.28 (1H, dd, J = 2.6, 8.3 Hz), 8.30 (1H, s), 8.35 (1H, dd, J = 6.1, 8.9 Hz), 10.14 (1H, s).	Ref. Ex. 48
1996		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.5 Hz), 3.34 (2H, q, J = 7.5 Hz), 7.07-7.16 (1H, m), 7.21-7.30 (1H, m), 8.26 (1H, dd, J = 6.1, 8.9 Hz), 10.23 (1H, s).	Ref. Ex. 48
1998		1H-NMR (CDCl3) δ: 1.22-1.28 (4H, m), 2.66-2.72 (1H, m), 7.10-7.13 (1H, m), 7.45–7.47 (1H, m), 7.63–7.65 (1H, m), 10.02 (1H, s).	Ref. Ex. 133, Ref. Ex. 63
1999		1H-NMR (CDCl3) δ: 1.02 (6H, d, J = 6.5 Hz), 2.12-2.32 (1H, m), 2.98 (2H, d, J = 6.0 Hz), 7.41-7.48 (2H, m), 7.96 (1H, d, J = 7.0 Hz), 8.06 (1H, s), 10.02 (1H, s).	Ref. Ex. 63
2000		1H-NMR (CDCl3) δ: 1.02 (6H, d, J = 6.5 Hz), 2.13-2.19 (1H, m), 2.97 (2H, d, J = 7.0 Hz), 7.22-7.28 (1H, m), 7.94-7.98 (1H, m), 8.12-8.14 (1H, m), 10.00 (1H, s).	Ref. Ex. 63
2001		1H-NMR (CDCl3) δ: 1.05-1.27 (4H, m), 2.39-2.44 (1H, m), 2.41 (3H, s), 3.86 (3H, s), 5.62 (1H, d, J = 6.4 Hz), 7.24-7.27 (2H, m), 7.32-7.36 (1H, m), 7.74-7.76 (2H, m).	Ref. Ex. 1892

Ref. Ex. No.	STR	1H-NMR	ref.
2002		1H-NMR (CDCl3) δ: 1.17-1.22 (4H, m), 2.39 (3H, s), 2.80-2.87 (1H, m), 3.96 (3H, s), 7.24 (2H, d, J = 8.2 Hz), 7.88 (2H, d, J = 8.2 Hz).	Ref. Ex. 1899
2003		1H-NMR (CDCl3) δ: 1.25-1.27 (4H, m), 2.41 (3H, s), 2.66-2.72 (1H, m), 7.25-7.28 (2H, m), 7.85-7.88 (2H, m), 10.05 (1H, s).	Ref. Ex. 63
2004		1H-NMR (CDCl3) δ: 7.15 (1H, dd, J = 2.0, 12.1 Hz), 7.22-7.25 (1H, m), 7.71 (1H, brs), 7.93 (1H, brs), 8.35 (1H, t, J = 8.9 Hz).	Ref. Ex. 1477
2005		1H-NMR (CDCl3) δ: 1.02 (6H, d, J = 6.7 Hz), 2.13-2.22 (1H, m), 3.03 (2H, d, J = 7.2 Hz), 3.96 (3H, s), 7.60 (1H, t, J = 7.8 Hz), 7.73 (1H, d, J = 7.8 Hz), 7.26 (1H, d, J = 7.8 Hz), 8.34 (1H, s).	Ref. Ex. 133
2006		1H-NMR (CDCl3) δ: 7.13 (1H, brs), 7.22-7.25 (1H, m), 7.46-7.52 (1H, m), 7.60-7.61 (1H, m), 7.66 (1H, brs).	Ref. Ex. 1477
2007		1H-NMR (CDCl3) δ: 3.99 (3H, s), 7.23-7.31 (2H, m), 8.30 (1H, s), 8.34-8.40 (1H, m).	Ref. Ex. 2
2008		1H-NMR (CDCl3) δ: 1.47 (3H, t, J = 7.1 Hz), 4.50 (2H, q, J = 7.1 Hz), 6.62-6.63 (1H, m), 7.43 (1H, t, J = 7.8 Hz), 7.46-7.48 (1H, m), 7.64-7.66 (1H, m), 7.68-7.70 (1H, m), 8.05-8.07 (1H, m), 8.18 (1H, t, J = 1.6 Hz).	Ref. Ex. 133
2009		1H-NMR (CDCl3) δ: 1.00-1.06 (6H, m), 2.13-2.22 (1H, m), 3.00 (2H, d, J = 7.0 Hz), 7.61-7.65 (1H, m), 7.75 (1H, d, J = 8.1 Hz), 8.26 (1H, d, J = 8.1 Hz), 8.33 (1H, s), 10.03 (1H, s).	Ref. Ex. 63









[0558]








Ref. Ex. No.	STR	1H-NMR	ref.
2010		1H-NMR (CDCl3) δ: 2.83 (3H, s), 3.98 (3H, s), 7.21-7.29 (2H, m), 8.27 (1H, t, J = 8.3 Hz).	Ref. Ex. 2
2011		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.20-7.26 (2H, m), 8.27 (1H, t, J = 8.4 Hz).	Ref. Ex. 2
2012		1H-NMR (CDCl3) δ: 3.99 (3H, s), 7.18-7.23 (1H, m), 7.60-7.65 (1H, m), 7.81 (1H, t, J = 1.6 Hz), 8.24 (1H, s).	Ref. Ex. 2
2013		1H-NMR (CDCl3) δ: 2.83 (3H, s), 3.97 (3H, s), 7.14-7.17 (1H, m), 7.53-7.56 (1H, m), 7.72 (1H, t, J = 1.6 Hz).	Ref. Ex. 2
2014		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.12-7.18 (1H, m), 7.54-7.57 (1H, m), 7.73-7.74 (1H, m).	Ref. Ex. 2
2015		1H-NMR (CDCl3) δ: 6.66-6.67 (1H, m), 7.45 (1H, t, J = 7.8 Hz), 7.49-7.51 (1H, m), 7.57-7.58 (1H, m), 7.69-7.71 (1H, m), 8.04-8.07 (1H, m), 8.16 (1H, t, J = 1.7 Hz), 10.27 (1H, s).	Ref. Ex. 63
2016		1H-NMR (CDCl3) δ: 2.36 (1H, t, J = 5.7 Hz), 4.86 (2H, d, J = 5.7 Hz), 7.23-7.26 (2H, m), 7.33 (1H, s), 8.23 (1H, t, J = 8.4 Hz).	Ref. Ex. 19
2017		1H-NMR (CDCl3) δ: 2.45 (1H, t, J = 5.7 Hz), 2.49 (3H, s), 4.74 (2H, d, J = 5.7 Hz), 7.18-7.25 (2H, m), 8.19 (1H, t, J = 7.1 Hz).	Ref. Ex. 19
2018		1H-NMR (CDCl3) δ: 1.34 (3H, t, J = 7.5 Hz), 2.44 (1H, t, J = 5.7 Hz), 2.89 (2H, q, J = 7.5 Hz), 4.74 (2H, d, J = 5.7 Hz), 7.17-7.25 (2H, m), 8.19 (1H, t, J = 8.4 Hz).	Ref. Ex. 19
2019		1H-NMR (CDCl3) δ: 7.28-7.36 (2H, m), 8.30 (1H, s), 8.35 (1H, t, J = 8.3 Hz), 10.13 (1H, s).	Ref. Ex. 48










Ref. Ex. No.	STR	1H-NMR	ref.
2020		1H-NMR (CDCl3) δ: 2.85 (3H, s), 7.22-7.30 (2H, m), 8.27 (1H, t, J = 8.8 Hz), 10.23 (1H, s).	Ref. Ex. 48
2021		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 7.18-7.34 (2H, m), 8.27 (1H, t, J = 8.3 Hz), 10.22 (1H, s).	Ref. Ex. 48
2022		1H-NMR (CDCl3) δ: 2.38 (1H, t, J = 5.7 Hz), 4.84 (2H, d, J = 5.7 Hz), 7.11-7.19 (1H, m), 7.26-7.34 (1H, m), 7.55-7.61 (1H, m), 7.73-7.74 (1H, m).	Ref. Ex. 19
2023		1H-NMR (CDCl3) δ: 2.36 (1H, t, J = 5.9 Hz), 2.49 (3H, s), 4.72 (2H, d, J = 5.9 Hz), 7.10-7.15 (1H, m), 7.48-7.52 (1H, m), 7.67-7.69 (1H, m).	Ref. Ex. 19
2024		1H-NMR (CDCl3) δ: 1.33 (3H, t, J = 7.5 Hz), 2.41 (1H, brs), 2.88 (2H, q, J = 7.5 Hz), 4.72 (2H, s), 7.10-7.13 (1H, m), 7.49-7.56 (1H, m), 7.68-7.69 (1H, m).	Ref. Ex. 19
2025		1H-NMR (CDCl3) δ: 6.93-7.00 (1H, m), 7.14 (1H, brs), 7.35-7.41 (2H, m), 7.70 (1H, brs).	Ref. Ex. 1477
2026		1H-NMR (CDCl3) δ: 7.00 (1H, brs), 7.15 (1H, t, J = 8.3 Hz), 7.64 (1H, brs), 7.80-7.84 (1H, m), 8.12 (1H, dd, J = 2.4, 6.4 Hz).	Ref. Ex. 1477
2027		1H-NMR (CDCl3) δ: 1.31-1.39 (4H, m), 2.74-2.80 (1H, m), 8.06-8.08 (1H, m), 8.23 (1H, d, J = 8.5 Hz), 8.97 (1H, s), 10.09 (1H, s).	Ref. Ex. 318, Ref. Ex. 48
2028		1H-NMR (CDCl3) δ: 7.20-7.23 (1H, m), 7.63-7.66 (1H, m), 7.81-7.83 (1H, m), 8.23 (1H, s), 10.10 (1H, s).	Ref. Ex. 48

Ref. Ex. No:	STR	1H-NMR	ref.
2029		1H-NMR (CDCl3) δ: 2.86 (3H, s), 7.12-7.21 (1H, m), 7.54-7.57 (1H, m), 7.67-7.72 (1H, m), 10.20 (1H, s).	Ref. Ex. 48
2030		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.28 (2H, q, J = 7.5 Hz), 7.16-7.19 (1H, m), 7.55-7.61 (1H, m), 7.72-7.73 (1H, m), 10.19 (1H, s).	Ref. Ex. 48
2031		1H-NMR (CDCl3) δ: 2.74 (3H, s), 3.97 (3H, s), 7.60 (1H, t, J = 7.8 Hz), 7.72 (1H, d, J = 7.8 Hz), 8.26 (1H, d, J = 7.8 Hz), 8.35 (1H, s).	Ref. Ex. 133
2032		1H-NMR (CDCl3) δ: 2.74 (3H, s), 7.63 (1H, t, J = 7.8 Hz), 7.75 (1H, d, J = 7.9 Hz), 8.25 (1H, d, J = 7.8 Hz), 8.33 (1H, s), 10.00 (1H, s).	Ref. Ex. 63
2033		1H-NMR (CDCl3) δ: 2.72 (3H, s), 3.96 (3H, s), 7.39 (1H, t, J = 7.8 Hz), 7.44 (1H, dt, J = 1.5, 8.0 Hz), 7.96 (1H, dt, J = 1.3, 7.6 Hz), 8.08 (1H, t, J = 1.7 Hz).	Ref. Ex. 133
2034		1H-NMR (CDCl3) δ: 1.37 (3H, t, J = 7.6 Hz), 1.43 (3H, t, J = 7.1 Hz), 3.16 (2H, q, J = 7.6 Hz), 4.44 (2H, q, J = 7.1 Hz), 7.60 (1H, t, J = 8.0 Hz), 7.72 (1H, d, J = 8.0 Hz), 8.27 (1H, d, J = 8.0 Hz), 8.35 (1H, s).	Ref. Ex. 133
2035		1H-NMR (CDCl3) δ: 1.57 (3H, t, J = 7.6 Hz), 3.15 (2H, q, J = 7.6 Hz), 7.63 (1H, t, J = 7.8 Hz), 7.75 (1H, d, J = 7.7 Hz), 8.26 (1H, d, J = 7.8 Hz), 8.33 (1H, s), 10.05 (1H, s).	Ref. Ex. 63
2036		1H-NMR (CDCl3) δ: 0.98-1.07 (4H, m), 1.96-2.00 (1H, m), 2.24 (1H, bs), 4.66 (2H, s), 7.26-7.28 (2H, m), 7.97-7.99 (2H, m).	Ref. Ex. 19









[0559]








Ref. Ex. No.	STR	1H-NMR	ref.
2037		1H-NMR (CDCl3) δ: 1.01-1.05 (4H, m), 1.98-2.05 (1H, m), 2.13-2.16 (1H, m), 4.68 (2H, s), 7.33-7.40 (2H, m), 7.43-7.45 (1H, m), 8.08-8.11 (1H, m).	Ref. Ex. 19
2038		1H-NMR (CDCl3) δ: 1.23-1.32 (4H, m), 2.67-2.74 (1H, m), 7.30-7.32 (2H, m), 8.01-8.03 (2H, m), 10.05 (1H, s).	Ref. Ex. 147
2039		1H-NMR (CDCl3) δ: 1.26-1.28 (4H, m), 2.70-2.77 (1H, m), 7.37-7.44 (2H, m), 7.50-7.54 (1H, m), 8.16 (1H, dd, J = 1.7, 7.9 Hz), 10.07 (1H, s).	Ref. Ex. 147
2040		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.0 Hz), 1.52 (9H, s), 4.43 (2H, q, J = 7.0 Hz), 7.23 (1H, t, J = 8.6 Hz), 7.92-7.95 (1H, m), 8.12 (1H, dd, J = 2.1, 6.9 Hz).	Ref. Ex. 133
2041		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.2 Hz), 1.51 (9H, s), 4.43 (2H, q, J = 7.2 Hz), 7.22-7.28 (1H, m), 7.79-7.83 (1H, m), 7.85-7.89 (1H, m).	Ref. Ex. 133
2042		1H-NMR (CDCl3) δ: 1.54 (9H, s), 7.23-7.25 (1H, m), 7.94-7.99 (1H, m), 8.12-8.15 (1H, m), 10.15 (1H, s).	Ref. Ex. 63
2043		1H-NMR (CDCl3) δ: 1.54 (9H, s), 7.25-7.31 (1H, m), 7.82-7.85 (1H, m), 7.86-7.91 (1H, m), 10.15 (1H, s).	Ref. Ex. 63
2044		1H-NMR (CDCl3) δ: 3.99 (3H, s), 4.02-4.08 (2H, m), 7.46-7.48 (2H, m), 8.03-8.05 (2H, m).	Ref. Ex. 133









Ref. Ex. No.	STR	1H-NMR	ref.
2045		1H-NMR (CDCl3) δ: 4.01 (3H, s), 4.07 (2H, q, J = 9.8 Hz), 7.64 (1H, t, J = 7.9 Hz), 7.78 (1H, d, J = 7.7 Hz), 8.29 (1H, d, J = 7.9 Hz), 8.38 (1H, s).	Ref. Ex. 133
2046		1H-NMR (CDCl3) δ: 3.97-4.03 (2H, m), 7.48-7.50 (2H, m), 8.01-8.03 (2H, m), 10.05 (1H, s).	Ref. Ex. 63
2047		1H-NMR (CDCl3) δ: 4.00-4.06 (2H, m), 7.67 (1H, t, J = 7.9 Hz), 7.80 (1H, d, J = 7.9 Hz), 8.27 (1H, d, J = 7.9 Hz), 8.35 (1H, s), 10.07 (1H, s).	Ref. Ex. 63
2048		1H-NMR (CDCl3) δ: 3.99 (3H, s), 4.05 (2H, q, J = 9.8 Hz), 7.25-7.28 (1H, m), 7.98-8.01 (1H, m), 8.19 (1H, dd, J = 2.1, 6.9 Hz).	Ref. Ex. 133
2049		1H-NMR (CDCl3) δ: 3.99 (3H, s), 4.05 (2H, q, J = 9.8 Hz), 7.30 (1H, t, J = 8.1 Hz), 7.86-7.88 (1H, m), 7.92-7.96 (1H, m).	Ref. Ex. 133
2050		1H-NMR (CDCl3) δ: 3.95-4.03 (2H, m), 7.29-7.34 (1H, m), 7.84-7.93 (2H, m), 10.05 (1H, s).	Ref. Ex. 63
2051		1H-NMR (CDCl3) δ: 3.97-4.03 (2H, m), 7.27-7.31 (1H, m), 7.96-7.99 (1H, m), 8.15-8.16 (1H, m), 10.05 (1H, s).	Ref. Ex. 63

Ref. Ex. No.	STR	1H-NMR	ref.
2052		1H-NMR (CDCl3) δ: 1.44 (9H, s), 7.93-7.95 (1H, m), 8.05 (1H, t, J = 1.6 Hz), 8.07 (1H, dd, J = 2.1, 8.3 Hz), 8.33 (1H, t, J = 1.6 Hz), 8.42 (1H, t, J = 1.8 Hz), 8.98-8.99 (1H, m), 10.12 (1H, s).	Ref. Ex. 43
2053		1H-NMR (CDCl3) δ: 1.43 (9H, s), 7.22-7.24 (1H, m), 7.63 (1H, s), 7.66 (1H, s), 7.84 (1H, d, J = 8.5 Hz), 7.91-7.92 (1H, m), 7.96-7.97 (1H, m), 8.01-8.02 (1H, m), 10.09 (1H, s).	Ref. Ex. 43
2054		1H-NMR (CDCl3) δ: 1.43 (9H, s), 6.86-6.90 (1H, m), 7.31 (1H, dd, J = 2.2, 8.8 Hz), 7.60 (1H, d, J = 3.4 Hz), 7.92-7.93 (1H, m), 7.95-7.96 (1H, m), 8.01-8.02 (1H, m), 10.09 (1H, s).	Ref. Ex. 43
2055		1H-NMR (CDCl3) δ: 1.41 (6H, d, J = 7.0 Hz), 3.67-3.74 (1H, m), 7.32-7.34 (2H, m), 8.10-8.12 (2H, m), 10.04 (1H, s).	Ref. Ref. 147
2056		1H-NMR (CDCl3) δ: 3.99 (3H, s), 7.21 (1H, t, J = 8.3 Hz), 7.87-7.95 (1H, m), 8.19 (1H, s), 8.27 (1H, dd, J = 2.2, 6.4 Hz).	Ref. Ex. 2
2057		1H-NMR (CDCl3) δ: 2.82 (3H, s), 3.97 (3H, s), 7.18 (1H, t, J = 8.3 Hz), 7.79-7.83 (1H, m), 8.17 (1H, dd, J = 2.2, 6.4 Hz).	Ref. Ex. 2
2058		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 3.31 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 7.18 (1H, t, J = 8.3 Hz), 7.81-7.85 (1H, m), 8.18 (1H, dd, J = 2.2, 6.5 Hz).	Ref. Ex. 2
2059		1H-NMR (CDCl3) δ: 2.23 (1H, t, J = 6.0 Hz), 4.83 (2H, d, J = 6.0 Hz), 7.19 (1H, t, J = 8.4 Hz), 7.21 (1H, s), 7.83-7.86 (1H, m), 8.19 (1H, dd, J = 2.2, 6.5 Hz).	Ref. Ex. 19
2060		1H-NMR (CDCl3) δ: 2.37 (1H, t, J = 5.9 Hz), 2.48 (3H, s), 4.71 (2H, d, J = 5.9 Hz), 7.16 (1H, t, J = 8.4 Hz), 7.75-7.79 (1H, m), 8.12 (1H, dd, J = 2.2, 6.5 Hz).	Ref. Ex. 19








[0560]









Ref. Ex. No.	STR	1H-NMR	ref.
2061		1H-NMR (CDCl3) δ: 1.33 (3H, t, J = 7.5 Hz), 2.34 (1H, t, J = 5.9 Hz), 2.87 (2H, q, J = 7.5 Hz), 4.71 (2H, d, J = 5.9 Hz), 7.16 (1H, t, J = 8.4 Hz), 7.77-7.80 (1H, m), 8.13 (1H, dd, J = 2.2, 6.5 Hz).	Ref. Ex. 19
2062		1H-NMR (CDCl3) δ: 7.24 (1H, t, J = 8.4 Hz), 7.90-7.94 (1H, m), 8.19 (1H, s), 8.26 (1H, dd, J = 2.2, 6.4 Hz), 10.09 (1H, s).	Ref. Ex. 48
2063		1H-NMR (CDCl3) δ: 2.84 (3H, s), 7.21 (1H, t, J = 8.3 Hz), 7.81-7.85 (1H, m), 8.18 (1H, dd, J = 2.2, 6.4 Hz), 10.19 (1H, s).	Ref. Ex. 48
2064		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.32 (2H, q, J = 7.5 Hz), 7.21 (1H, t, J = 8.3 Hz), 7.82-7.86 (1H, m), 8.18 (1H, dd, J = 2.2, 6.5 Hz), 10.19 (1H, s).	Ref. Ex. 48
2066		1H-NMR (CDCl3) δ: 1.02 (6H, d, J = 6.7 Hz), 2.19-2.26 (1H, m), 3.04 (2H, d, J = 7.2 Hz), 8.09-8.12 (1H, m), 8.32 (1H, d, J = 8.3 Hz), 9.01 (1H, s), 10.07 (1H, s).	Ref. Ex. 133, Ref. Ex. 318, Ref. Ex. 48
2067		1H-NMR (CDCl3) δ: 7.50-7.52 (2H, m), 7.61-7.64 (2H, m), 9.49 (1H, s), 10.00 (1H, s).	Ref. Ex. 63
2068		1H-NMR (CDCl3) δ: 7.46-7.48 (2H, m), 7.91-7.93 (2H, m), 8.07 (1H, s), 10.17 (1H, s).	Ref. Ex. 63
2070		1H-NMR (CDCl3) δ: 1.27 (3H, t, J = 7.2 Hz), 4.28 (2H, q, J = 7.2 Hz), 7.28 (2H, d, J = 8.3 Hz), 7.66-7.70 (2H, m), 9.38 (1H, s).	Ref. Ex. 2069











Ref. Ex. No.	STR	1H-NMR	ref.
2071		1H-NMR (CDCl3) δ: 7.34 (2H, d, J = 8.7 Hz), 8.01-8.03 (2H, m), 8.08 (1H, s), 10.18 (1H, s).	Ref. Ex. 63
2072		1H-NMR (CDCl3) δ: 1.05 (3H, t, J = 7.4 Hz), 1.80-1.89 (2H, m), 3.09 (2H, t, J = 7.4 Hz), 763 (1H, t, J = 7.8 Hz), 7.75 (1H, d, J = 7.8 Hz), 8.26 (1H, d, J = 7.8 Hz), 8.33 (1H, s), 10.04 (1H, s).	Ref. Ex. 147
2073		1H-NMR (CDCl3) δ: 1.04 (3H, t, J = 7.4 Hz), 1.78-1.87 (2H, m), 3.07 (2H, t, J = 7.4 Hz), 7.24-7.28 (1H, m), 7.94-7.98 (1H, m), 8.13 (1H, dd, J = 2.2, 7.0 Hz), 10.01 (1H, s).	Ref. Ex. 147
2074		1H-NMR (CDCl3) δ: 7.37-7.38 (2H, m), 7.72-7.75 (2H, m), 9.50 (1H, s), 10.02 (1H, s).	Ref. Ex. 63
2075		1H-NMR (CDCl3) δ: 7.46-7.48 (2H, m), 7.91-7.93 (2H, m), 8.07 (1H, s), 10.17 (1H, s).	Ref. Ex. 63
2076		1H-NMR (CDCl3) δ: 7.78-7.82 (4H, m), 9.52 (1H, s), 10.03 (1H, s).	Ref. Ex. 63
2077		1H-NMR (CDCl3) δ: 7.76 (2H, d, J = 8.5 Hz), 8.10 (2H, d, J = 8.5 Hz), 8.15 (1H, s), 10.19 (1H, s).	Ref. Ex. 63

Ref. Ex. No.	STR	1H-NMR	ref.
2078		1H-NMR (CDCl3) δ: 7.43-7.51 (2H, m), 8.24 (1H, d, J = 7.5 Hz), 8.36 (1H, s), 10.20 (1H, s).	Ref. Ex. 318
2081		1H-NMR (DMSO-d6) δ: 2.72 (3H, s), 7.60-7.63 (2H, m), 8.10-8.13 (2H, m), 9.99 (1H, s), 12.94 (1H, brs).	Ref. Ex. 63
2082		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.1 Hz), 1.98-2.18 (2H, m), 2.38-2.52 (4H, m), 4.29-4.36 (1H, m), 4.42 (2H, d, J = 7.1 Hz), 7.28-7.31 (1H, m), 7.70 (1H, s), 7.88 (1H, d, J = 8.8 Hz), 7.99 (1H, s).	Ref. Ex. 2080
2084		1H-NMR (CDCl3) δ: 1.24 (3H, t, J = 7.5 Hz), 3.11 (2H, q, J = 7.5 Hz), 3.88 (3H, s), 4.53 (2H, d, J = 5.8 Hz), 5.57 (1H, brs), 7.47 (2H, d, J = 8.0 Hz), 7.62 (2H, J = 8.0 Hz).	Ref. Ex. 2083
2085		1H-NMR (CDCl3) δ: 2.60 (3H, s), 4.54 (2H, s), 7.30 (4H, s), 9.82 (1H, s).	Ref. Ex. 63
2086		1H-NMR (CDCl3) δ: 2.60 (3H, s), 4.66 (2H, s), 7.49 (2H, d, J = 8.0 Hz), 7.54 (1H, brs), 7.59 (2H, d, J = 8.0 Hz), 9.82 (1H, s).	Ref. Ex. 63
2087		1H-NMR (CDCl3) δ: 1.28 (3H, t, J = 7.5 Hz), 3.04 (2H, q, J = 7.5 Hz), 4.70 (2H, s), 7.50 (2H, d, J = 8.1 Hz), 7.58 (2H, d, J = 8.1 Hz), 8.58 (1H, s), 9.79 (1H, s).	Ref. Ex. 63
2088		1H-NMR (CDCl3) δ: 2.00-2.20 (2H, m), 2.43-2.53 (4H, m), 4.19-4.24 (1H, m), 7.30-7.34 (1H, m), 7.72 (1H, s), 7.89 (1H, d, J = 8.8 Hz), 7.99 (1H, s), 10.00 (1H, s).	Ref. Ex. 63










[0561]









Ref. Ex. No.	STR	1H-NMR	ref.
2089		1H-NMR (CDCl3) δ: 7.67 (1H, t, J = 7.9 Hz), 7.77 (1H, d, J = 7.4 Hz), 8.01 (1H, s), 8.48 (1H, s), 8.50 (1H, d, J = 7.9 Hz), 10.15 (1H, s).	Ref. Ex. 63
2090		1H-NMR (CDCl3) δ: 7.45-7.51 (2H, m), 7.97 (1H, s), 8.14-8.16 (1H, m), 8.18-8.20 (1H, m), 10.13 (1H, s).	Ref. Ex. 63
2091		1H-NMR (DMSO-d6) δ: 1.27 (3H, t, J = 7.5 Hz), 3.16 (2H, q, J = 7.5 Hz), 3.82 (3H, s), 7.61-7.63 (2H, m), 8.11-8.13 (2H, m), 12.94 (1H, brs).	Ref. Ex. 2079
2092		1H-NMR (CDCl3) δ: 7.30 (1H, t, J = 8.6 Hz), 7.96 (1H, s), 8.22-8.25 (1H, m), 8.35-8.36 (1H, m), 10.11 (1H, s).	Ref. Ex. 63
2093		1H-NMR (DMSO-d6) δ: 1.23 (3H, t, J = 7.5 Hz), 2.96 (2H, q, J = 7.5 Hz), 3.91 (3H, s), 3.96 (3H, s), 7.54-7.56 (2H, m), 8.20-8.22 (2H, m).	Ref. Ex. 12
2095		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.6 Hz), 2.92 (2H, q, J = 7.6 Hz), 3.96 (3H, s), 7.61 (1H, t, J = 7.7 Hz), 7.70 (1H, d, J = 7.7 Hz), 8.33 (1H, d, J = 7.7 Hz), 8.36 (1H, s).	Ref. Ex. 2080
2096		1H-NMR (CDCl3) δ: 3.86 (3H, s), 7.61 (2H, d, J = 8.2 Hz), 7.71 (2H, d, J = 8.2 Hz).	Ref. Ex. 1643









Ref. Ex. No.	STR	1H-NMR	ref.
2097		1H-NMR (CDCl3) δ: 3.99 (3H, s), 6.89-6.94 (1H, m), 7.49-7.58 (2H, m), 8.23 (1H, s).	Ref. Ex. 2
2098		1H-NMR (CDCl3) δ: 2.83 (3H, s), 3.97 (3H, s), 6.85-6.93 (1H, m), 7.42-7.50 (2H, m).	Ref. Ex. 2
2099		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.31 (2H, q, J = 7.5 Hz), 3.97 (3H, s), 6.85-6.93 (1H, m), 7.41-7.51 (2H, m).	Ref. Ex. 2
2100		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.6 Hz), 2.93 (2H, q, J = 7.6 Hz), 7.65 (1H, t, J = 7.8 Hz), 7.74 (1H, d, J = 7.8 Hz), 8.37 (1H, s), 8.43 (1H, d, J = 8.1 Hz), 10.09 (1H, s).	Ref. Ex. 63
2102		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.6 Hz), 3.12 (2H, q, J = 7.6 Hz), 4.14 (3H, s), 7.41-7.44 (2H, m), 8.26-8.29 (2H, m), 9.96 (1H, s).	Ref. Ex. 63
2103		1H-NMR (CDCl3) δ: 7.68 (2H, d, J = 8.2 Hz), 7.76 (2H, d, J = 8.2 Hz), 9.94 (1H, s).	Ref. Ex. 63
2104		1H-NMR (CDCl3) δ: 2.04-2.23 (2H, m), 2.44-2.55 (4H, m), 4.19-4.26 (1H, m), 8.60 (1H, s), 9.00 (1H, s), 9.50 (1H, s), 10.02 (1H, s).	Ref. Ex. 63
2105		1H-NMR (CDCl3) δ: 2.24 (1H, t, J = 6.0 Hz), 4.84 (2H, dd, J = 0.8, 6.0 Hz), 6.85-6.90 (1H, m), 7.26 (1H, s), 7.45-7.52 (2H, m).	Ref. Ex. 19

Ref. Ex. No.	STR	1H-NMR	ref.
2106		1H-NMR (CDCl3) δ: 2.39 (1H, t, J = 5.9 Hz), 2.49 (3H, s), 4.72 (2H, d, J = 5.9 Hz), 6.80-6.88 (1H, m), 7.37-7.44 (2H, m).	Ref. Ex. 19
2107		1H-NMR (CDCl3) δ: 1.33 (3H, t, J = 7.5 Hz), 2.51 (1H, t, J = 5.8 Hz), 2.88 (2H, q, J = 7.5 Hz), 4.71 (2H, d, J = 5.8 Hz), 6.81-6.86 (1H, m), 7.38-7.44 (2H, m).	Ref. Ex. 19
2108		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.6 Hz), 1.42 (3H, t, J = 7.1 Hz), 3.13 (2H, q, J = 7.6 Hz), 4.43 (2H, q, J = 7.1 Hz), 7.23 (1H, t, J = 8.6 Hz), 7.95-7.98 (1H, m), 8.16 (1H, dd, J = 2.1, 6.9 Hz).	Ref. Ex. 133
2109		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.1 Hz), 2.71 (3H, s), 4.43 (2H, q, J = 7.1 Hz), 7.23 (1H, t, J = 8.5 Hz), 7.95-7.98 (1H, m), 8.16 (1H, dd, J = 2.2, 6.9 Hz).	Ref. Ex. 133
2110		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.5 Hz), 2.91 (2H, q, J = 7.5 Hz), 7.43-7.48 (2H, m), 8.06-8.09 (2H, m), 10.08 (1H, s).	Ref. Ex. 2080, Ref. Ex. 48
2111		1H-NMR (CDCl3) δ: 2.72 (3H, s), 7.24-7.28 (1H, m), 7.94-7.97 (1H, m), 8.13-8.15 (1H, m), 10.02 (1H, s).	Ref. Ex. 63
2112		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 3.12 (2H, q, J = 7.5 Hz), 7.05-7.32 (1H, m), 7.95-7.98 (1H, m), 8.13-8.15 (1H, m), 10.02 (1H, s).	Ref. Ex. 63
2113		1H-NMR (CDCl3) δ: 1.37 (3H, t, J = 7.6 Hz), 1.43 (3H, t, J = 7.2 Hz), 3.16 (2H, q, J = 7.6 Hz), 4.44 (2H, q, J = 7.2 Hz), 7.72 (2H, d, J = 8.3 Hz), 8.20 (2H, d, J = 8.3 Hz).	Ref. Ex. 133
2114		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.1 Hz), 2.74 (3H, s), 4.44 (2H, q, J = 7.1 Hz), 7.72 (2H, d, J = 8.4 Hz), 8.20 (2H, d, J = 8.4 Hz).	Ref. Ex. 133
2115		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.6 Hz), 1.42 (3H, t, J = 7.2 Hz), 3.14 (2H, q, J = 7.6 Hz), 4.43 (2H, q, J = 7.2 Hz), 7.54 (1H, d, J = 8.4 Hz), 7.91 (1H, dd, J = 2.0, 8.4 Hz), 8.18 (1H, d, J = 1.9 Hz).	Ref. Ex. 133



















[0562]

Ref. Ex. No.	STR	1H-NMR	ref.
2116		1H-NMR (CDCl3) δ: 2.75 (3H, s), 7.75 (2H, d, J = 8.2 Hz), 8.18 (2H, d, J = 8.2 Hz), 10.05 (1H, s).	Ref. Ex. 63
2117		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.6 Hz), 3.15 (2H, q, J = 7.6 Hz), 7.75 (2H, d, J = 8.2 Hz), 8.19 (2H, d, J = 8.2 Hz), 10.05 (1H, s).	Ref. Ex. 63
2118		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.6 Hz), 3.12 (2H, q, J = 7.6 Hz), 7.57 (1H, d, J = 8.4 Hz), 7.90 (1H, dd, J = 1.9, 8.4 Hz), 8.16 (1H, d, J = 1.9 Hz), 10.02 (1H, s).	Ref. Ex. 63
2119		1H-NMR (CDCl3) δ: 2.73 (3H, s), 7.57 (1H, d, J = 8.4 Hz), 7.89 (1H, dd, J = 2.0, 8.4 Hz), 8.16 (1H, d, J = 2.0 Hz), 10.02 (1H, s).	Ref. Ex. 63
2120		1H-NMR (CDCl3) δ: 6.92-6.97 (1H, m), 7.52-7.58 (2H, m), 8.23 (1H, s), 10.11 (1H, s).	Ref. Ex. 48
2121		1H-NMR (CDCl3) δ: 2.85 (3H, s), 6.88-6.93 (1H, m), 7.43-7.49 (2H, m), 10.20 (1H, s).	Ref. Ex. 48
2122		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 6.83-6.93 (1H, m), 7.41-7.57 (2H, m), 10.19 (1H, s).	Ref. Ex. 48
2123		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.5 Hz), 1.44 (3H, t, J = 7.2 Hz), 3.18 (2H, q, J = 7.5 Hz), 4.45 (2H, q, J = 7.2 Hz), 7.80 (1H, d, J = 8.5 Hz), 8.55 (1H, dd, J = 1.9, 8.5 Hz), 9.37 (1H, d, J = 1.9 Hz).	Ref. Ex. 2080
2124		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.2 Hz), 1.98-2.18 (2H, m), 2.40-2.50 (4H, m), 4.30-4.35 (1H, m), 4.42 (2H, q, J = 7.1 Hz), 6.93-6.97 (1H, m), 7.34-7.37 (1H, m), 7.97 (1H, d, J = 3.2 Hz).	Ref. Ex. 2080







Ref. Ex. No.	STR	1H-NMR	ref.
2125		1H-NMR (CDCl3) δ: 3.27-3.29 (4H, m), 3.69-3.71 (4H, m), 3.80 (3H, s), 6.87-6.91 (2H, m), 7.24-7.26 (2H, m), 7.58 (2H, d, J = 8.2 Hz), 7.64 (2H, d, J = 8.2 Hz).	Ref. Ex. 184
2126		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.5 Hz), 1.42 (3H, t, J = 7.1 Hz), 3.14 (2H, q, J = 7.5 Hz), 4.43 (2H, q, J = 7.1 Hz), 7.38-7.45 (2H, m), 7.95-7.98 (1H, m), 8.08-8.09 (1H, m).	Ref. Ex. 133
2127		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.6 Hz), 3.17 (2H, q, J = 7.6 Hz), 7.82 (1H, d, J = 8.3 Hz), 8.53 (1H, d, J = 8.3 Hz), 9.38 (1H, s), 10.06 (1H, s).	Ref. Ex. 318, Ref. Ex. 48
2128		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.6 Hz), 3.13 (2H, q, J = 7.6 Hz), 7.40-7.48 (2H, m), 7.94-7.97 (1H, m), 8.06 (1H, d, J = 1.6 Hz), 10.03 (1H, s).	Ref. Ex. 63
2129		1H-NMR (CDCl3) δ: 2.72 (3H, s), 7.15-7.19 (2H, m), 8.04-8.08 (2H, m), 10.02 (1H, s).	Ref. Ex. 63
2130		1H-NMR (CDCl3) δ: 1.44 (3H, t, J = 7.1 Hz), 2.76 (3H, s), 4.45 (2H, q, J = 7.1 Hz), 7.80 (1H, d, J = 8.2 Hz), 8.53-8.57 (1H, m), 9.37 (1H, s).	Ref. Ex. 2080
2131		1H-NMR (CDCl3) δ: 1.42 (3H, t, J = 7.2 Hz), 2.71 (3H, s), 4.43 (2H, q, J = 7.2 Hz), 7.13 (1H, d, J = 8.3 Hz), 7.79 (1H, d, J = 1.6 Hz), 7.86 (1H, dd, J = 1.6, 8.3 Hz).	Ref. Ex. 2080
2132		1H-NMR (CDCl3) δ: 2.72 (3H, s), 7.17 (1H, d, J = 8.4 Hz), 7.77 (1H, d, J = 1.7 Hz), 7.85 (1H, dd, J = 1.7, 8.4 Hz), 10.01 (1H, s).	Ref. Ex. 63






Ref. Ex. No.	STR	1H-NMR	ref.
2133		1H-NMR (CDCl3) δ: 3.27-3.30 (4H, m), 3.74-3.77 (4H, m), 6.87-6.91 (2H, m), 7.23-7.27 (2H, m), 7.61 (2H, d, J = 8.0 Hz), 7.71 (2H, d, J = 8.0 Hz), 9.74 (1H, s).	Ref. Ex. 63
2134		1H-NMR (CDCl3) δ: 2.78 (3H, s), 7.82 (1H, d, J = 8.2 Hz), 8.52 (1H, dd, J = 1.6, 8.2 Hz), 9.37 (1H, d, J = 1.6 Hz), 10.06 (1H, s).	Ref. Ex. 318, Ref. Ex. 48
2135		1H-NMR (CDCl3) δ: 2.01-2.21 (2H, m), 2.42-2.55 (4H, m), 4.17-4.25 (1H, m), 6.95-6.99 (1H, m), 7.37 (1H, dd, J = 2.1, 8.5 Hz), 7.96 (1H, d, J = 3.2 Hz), 10.00 (1H, s).	Ref. Ex. 63
2136		1H-NMR (CDCl3) δ: 1.35 (3H, t, J = 7.5 Hz), 1.42 (3H, t, J = 7.1 Hz), 3.14 (2H, q, J = 7.5 Hz), 4.43 (2H, q, J = 7.1 Hz), 7.30 (2H, d, J = 8.7 Hz), 8.12 (2H, d, J = 8.7 Hz).	Ref. Ex. 133
2137		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.1 Hz), 2.72 (3H, s), 4.43 (2H, q, J = 7.1 Hz), 7.30 (2H, d, J = 8.2 Hz), 8.10-8.13 (2H, m).	Ref. Ex. 133
2138		1H-NMR (CDCl3) δ: 1.38 (3H, t, J = 7.6 Hz), 3.13 (2H, q, J = 7.6 Hz), 7.33 (2H, d, J = 8.1 Hz), 8.10-8.13 (2H, m), 10.03 (1H, s).	Ref. Ex. 63
2139		1H-NMR (CDCl3) δ: 2.73 (3H, s), 7.33 (2H, d, J = 8.2 Hz), 8.08-8.12 (2H, m), 10.03 (1H, s).	Ref. Ex. 63
2140		1H-NMR (CDCl3) δ: 4.00 (3H, s), 7.45 (1H, dd, J = 0.6, 8.4 Hz), 8.26 (1H, s), 8.31 (1H, dd, J = 2.5, 8.4 Hz), 8.96 (1H, dd, J = 0.6, 2.5 Hz).	Ref. Ex. 2








[0563]

Ref. Ex. No.	STR	1H-NMR	ref.
2141		1H-NMR (CDCl3) δ: 2.84 (3H, s), 3.98 (3H, s), 7.42 (1H, dd, J = 0.6, 8.4 Hz), 8.23 (1H, dd, J = 2.5, 8.4 Hz), 8.86 (1H, dd, J = 0.6, 2.5 Hz).	Ref. Ex. 2
2142		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.33 (2H, q, J = 7.5 Hz), 3.98 (3H, s), 7.42 (1H, d, J = 8.4 Hz), 8.24 (1H, dd, J = 2.5, 8.4 Hz), 8.88 (1H, d, J = 2.5 Hz).	Ref. Ex. 2
2144		1H-NMR (CDCl3) δ: 7.19 (1H, d, J = 8.3 Hz), 7.83 (1H, d, J = 1.6 Hz), 7.91 (1H, dd, J = 1.6, 8.3 Hz), 8.32 (1H, s), 10.01 (1H, s).	Ref. Ex. 63
2145		1H-NMR (CDCl3) δ: 1.43 (3H, t, J = 7.1 Hz), 4.46 (2H, q, J = 7.1 Hz), 7.83 (1H, d, J = 8.2 Hz), 8.38 (1H, s), 8.58-8.62 (1H, m), 9.43 (1H, s).	Ref. Ex. 2080
2146		1H-NMR (CDCl3) δ: 2.18 (1H, t, J = 5.7 Hz), 4.85 (2H, d, J = 5.7 Hz), 7.29 (1H, t, J = 0.7 Hz), 7.42 (1H, dd, J = 0.7, 8.3 Hz), 8.20 (1H, dd, J = 2.5, 8.3 Hz), 8.93 (1H, dd, J = 0.7, 2.5 Hz).	Ref. Ex. 19
2147		1H-NMR (CDCl3) δ: 1.57 (1H, brs), 2.50 (3H, s), 4.73 (2H, s), 7.39 (1H, dd, J = 0.5, 8.3 Hz), 8.15 (1H, dd, J = 2.5, 8.3 Hz), 8.85 (1H, dd, J = 0.5, 2.5 Hz).	Ref. Ex. 19
2148		1H-NMR (CDCl3) δ: 1.36 (3H, t, J = 7.6 Hz), 1.43 (3H, t, J = 7.1 Hz), 3.15 (2H, q, J = 7.6 Hz), 4.44 (2H, q, J = 7.1 Hz), 7.30-7.34 (1H, m), 7.50 (1H, t, J = 8.1 Hz), 7.93 (1H, s), 8.01-8.04 (1H, m).	Ref. Ex. 2080
2149		1H-NMR (CDCl3) δ: 1.33 (3H, t, J = 7.5 Hz), 3.25 (2H, q, J = 7.5 Hz), 3.93 (3H, s).	Ref. Ex. 1643
2150		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.2 Hz), 4.44 (2H, q, J = 7.2 Hz), 6.59 (1H, t, J = 73.1 Hz), 7.22 (2H, d, J = 8.9 Hz), 8.13 (2H, d, J = 8.9 Hz), 8.27 (1H, s).	Ref. Ex. 2080
2151		1H-NMR (CDCl3) δ: 1.39 (3H, t, J = 7.6 Hz), 3.13 (2H, q, J = 7.6 Hz), 7.33-7.36 (1H, m), 7.53 (1H, t, J = 8.0 Hz), 7.92 (1H, s), 8.00-8.03 (1H, m), 10.04 (1H, s).	Ref. Ex. 63
2152		1H-NMR (CDCl3) δ: 1.28 (3H, t, J = 7.5 Hz), 2.17 (1H, t, J = 6.2 Hz), 2.82 (2H, q, J = 7.5 Hz), 4.62 (2H, d, J = 6.2 Hz).	Ref. Ex. 19
2153		1H-NMR (CDCl3) δ: 1.34 (3H, t, J = 7.5 Hz), 2.30 (1H, t, J = 5.8 Hz), 2.89 (2H, q, J = 7.5 Hz), 4.73 (2H, d, J = 5.8 Hz), 7.39 (1H, dd, J = 0.6, 8.3 Hz), 8.16 (1H, dd, J = 2.5, 8.3 Hz), 8.87 (1H, dd, J = 0.6, 2.5 Hz).	Ref. Ex. 19
2154		1H-NMR (CDCl3) δ: 6.60 (1H, t, J = 73.3 Hz), 7.24-7.26 (2H, m), 8.12-8.14 (2H, m), 8.32 (1H, s), 10.01 (1H, s).	Ref. Ex. 63
2155		1H-NMR (CDCl3) δ: 7.85 (1H, d, J = 8.2 Hz), 8.43 (1H, s), 8.58-8.60 (1H, m), 9.43 (1H, s), 10.05 (1H, s).	Ref. Ex. 63
2156		1H-NMR (CDCl3) δ: 7.48 (1H, dd, J = 0.6, 8.4 Hz), 8.25 (1H, s), 8.29 (1H, dd, J = 2.5, 8.4 Hz), 8.99 (1H, dd, J = 0.6, 2.5 Hz), 10.12 (1H, s).	Ref. Ex. 48
2157		1H-NMR (CDCl3) δ: 2.87 (3H, s), 7.45 (1H, dd, J = 0.6, 8.4 Hz), 8.22 (1H, dd, J = 2.5, 8.4 Hz), 8.89 (1H, dd, J = 0.6, 2.5 Hz), 10.21 (1H, s).	Ref. Ex. 48
2158		1H-NMR (CDCl3) δ: 1.40 (3H, t, J = 7.5 Hz), 3.34 (2H, q, J = 7.5 Hz), 7.45 (1H, dd, J = 0.5, 8.3 Hz), 8.23 (1H, dd, J = 2.5, 8.3 Hz), 8.90 (1H, dd, J = 0.5, 2.5 Hz), 10.21 (1H, s).	Ref. Ex. 48
2159		1H-NMR (CDCl3) δ: 1.33 (3H, t, J = 7.5 Hz), 3.25 (2H, q, J = 7.5 Hz), 10.04 (1H, s).	Ref. Ex. 48
2163		1H-NMR (CDCl3) δ: 3.06 (1H, t, J = 6.1 Hz), 5.05 (2H, d, J = 6.1 Hz), 7.02-7.06 (2H, m), 7.12-7.16 (1H, m), 7.19 (1H, dd, J = 2.4, 8.9 Hz), 7.34-7.39 (2H, m), 7.45 (1H, d, J = 2.4 Hz), 7.92 (1H, d, J = 8.9 Hz).	Ref. Ex. 19
2164		1H-NMR (CDCl3) δ: 7.09-7.12 (2H, m), 7.20-7.24 (1H, m), 7.33 (1H, dd, J = 2.4, 9.0 Hz), 7.40-7.45 (3H, m), 8.18 (1H, d, J = 9.0 Hz), 10.11 (1H, s).	Ref. Ex. 48
2165		1H-NMR (CDCl3) δ: 7.24-7.78 (5H, m), 8.18 (1H, d, J = 1.6 Hz), 8.23 (1H, dd, J = 0.3, 8.5 Hz), 9.05 (1H, s).	Ref. Ex. 2161
2166		1H-NMR (CDCl3) δ: 4.11 (3H, s), 7.74-7.79 (4H, m), 7.82 (1H, dd, J = 1.8, 8.6 Hz), 8.19 (1H, dd, J = 0.4, 1.8 Hz), 8.33 (1H, d, J = 0.4, 8.6 Hz).	Ref. Ex. 2162
2167		1H-NMR (CDCl3) δ: 2.91 (1H, t, J = 6.1 Hz), 5.12 (2H, d, J = 6.1 Hz), 7.70-7.76 (5H, m), 8.07 (1H, d, J = 8.5 Hz), 8.11 (1H, d, J = 1.6 Hz).	Ref. Ex. 19
2168		1H-NMR (CDCl3) δ: 7.75-7.80 (4H, m), 7.85 (1H, dd, J = 1.8, 8.6 Hz), 8.22 (1H, d, J = 1.8 Hz), 8.33 (1H, d, J = 8.6 Hz), 10.19 (1H, s).	Ref. Ex. 48
2169		1H-NMR (CDCl3) δ: 2.23 (1H, t, J = 5.6 Hz), 4.87 (2H, d, J = 5.6 Hz), 7.40 (1H, t, J = 0.8 Hz), 8.02-8.06 (1H, m), 8.30 (1H, d, J = 8.3 Hz), 8.85-8.86 (1H, m).	Ref. Ex. 19
2170		1H-NMR (CDCl3) δ: 7.44 (1H, dd, J = 1.6, 10.9 Hz), 7.54 (1H, dd, J = 1.2, 8.1 Hz), 7.82-7.84 (1H, m), 8.02-8.06 (1H, m), 8.07-8.12 (1H, m), 8.97 (1H, d, J = 2.1 Hz), 10.43 (1H, d, J = 0.4 Hz).	Ref. Ex. 112
2171		1H-NMR (CDCl3) δ: 5.23 (2H, brs), 7.02-7.06 (3H, m), 7.31 (1H, d, J = 2.4 Hz), 7.53-7.57 (3H, m).	Ref. Ex. 2160
2172		1H-NMR (CDCl3) δ: 7.14 (2H, d, J = 8.4 Hz), 7.26 (1H, dd, J = 2.4, 8.8 Hz), 7.60-7.62 (3H, m), 8.13 (1H, d, J = 8.8 Hz), 8.97 (1H, s).	Ref. Ex. 2161
2173		1H-NMR (CDCl3) δ: 6.96-7.00 (2H, m), 7.23 (1H, dd, J = 2.4, 8.9 Hz), 7.30-7.34 (2H, m), 7.51 (1H, d, J = 2.4 Hz), 8.09 (1H, d, J = 8.9 Hz), 8.93 (1H, s).	Ref. Ex. 2161








[0564]







Ref. Ex. No.	STR	1H-NMR	ref.
2174		1H-NMR (CDCl3) δ: 4.09 (3H, s), 7.14 (2H, d, J = 8.4 Hz), 7.32 (1H, dd, J = 2.4, 9.0 Hz), 7.56 (1H, d, J = 2.4 Hz), 7.65 (2H, d, J = 8.4 Hz), 8.23 (1H, d, J = 9.0 Hz).	Ref. Ex. 2162
2175		1H-NMR (CDCl3) δ: 2.73 (1H, t, J = 6.1 Hz), 5.08 (2H, d, J = 6.1 Hz), 7.08 (2H, d, J = 8.4 Hz), 7.22 (1H, dd, J = 2.4, 8.8 Hz), 7.55 (1H, d, J = 2.4 Hz), 7.60 (2H, d, J = 8.4 Hz), 7.98 (1H, d, J = 8.8 Hz).	Ref. Ex. 19
2176		1H-NMR (CDCl3) δ: 7.16 (2H, d, J = 8.4 Hz), 7.35 (1H, dd, J = 2.4, 9.0 Hz), 7.56 (1H, d, J = 2.4 Hz), 7.66 (2H, d, J = 8.4 Hz), 8.23 (1H, d, J = 9.0 Hz), 10.14 (1H, s).	Ref. Ex. 48
2177		1H-NMR (CDCl3) δ: 4.08 (3H, s), 7.00-7.05 (2H, m), 7.28 (1H, dd, J = 2.4, 9.0 Hz), 7.34-7.38 (2H, m), 7.44 (1H, d, J = 2.4 Hz), 8.18 (1H, d, J = 9.0 Hz).	Ref. Ex. 2162
2178		1H-NMR (CDCl3) δ: 3.03 (1H, t, J = 6.1 Hz), 5.06 (2H, d, J = 6.1 Hz), 6.95-6.99 (2H, m), 7.17 (1H, dd, J = 2.4, 8.9 Hz), 7.30-7.34 (2H, m), 7.45 (1H, d, J = 2.4 Hz), 7.93 (1H, d, J = 8.9 Hz).	Ref. Ex. 19
2179		1H-NMR (CDCl3) δ: 2.36 (3H, s), 6.95-6.98 (2H, m), 7.18 (2H, d, J = 8.1 Hz), 7.22 (1H, dd, J = 2.4, 8.9 Hz), 7.46 (1H, d, J = 2.4 Hz), 8.06 (1H, d, J = 8.9 Hz), 8.89 (1H, s).	Ref. Ex. 2161
2180		1H-NMR (CDCl3) δ: 7.02-7.06 (2H, m), 7.31 (1H, dd, J = 2.4, 9.0 Hz), 7.36-7.40 (2H, m), 7.45 (1H, d, J = 2.4 Hz), 8.19 (1H, d, J = 9.0 Hz), 10.1 (1H, s).	Ref. Ex. 48
2181		1H-NMR (CDCl3) δ: 2.37 (3H, s), 4.07 (3H, s), 6.98-7.00 (2H, m), 7.21 (2H, d, J = 8.1 Hz), 7.28 (1H, dd, J = 2.5, 9.0 Hz), 7.37 (1H, d, J = 2.5 Hz), 8.15 (1H, d, J = 9.0 Hz).	Ref. Ex. 2162
2182		1H-NMR (CDCl3) δ: 2.61 (1H, brs), 5.13 (2H, d, J = 6.2 Hz), 7.45-7.49 (2H, m), 7.89-7.96 (2H, m).	Ref. Ex. 38



Ref. Ex. No.	STR	1H-NMR	ref.
2183		1H-NMR (CDCl3) δ: 2.29 (3H, d, J = 0.8 Hz), 7.10-7.11 (1H, m), 7.34 (1H, d, J = 3.2 Hz), 7.89-7.90 (1H, m), 8.09-8.10 (2H, m), 10.12 (1H, s).	Ref. Ex. 112
2184		1H-NMR (CDCl3) δ: 7.66 (1H, d, J = 8.3 Hz), 7.83 (1H, dd, J = 2.0, 8.3 Hz), 8.01 (1H, d, J = 2.0 Hz), 8.52 (1H, d, J = 2.0 Hz), 8.93 (1H, d, J = 2.0 Hz), 10.06 (1H, s).	Ref. Ex. 112
2185		1H-NMR (CDCl3) δ: 7.49-7.54 (2H, m), 8.00-8.03 (2H, m), 10.25 (1H, s).	Ref. Ex. 48
2186		1H-NMR (CDCl3) δ: 2.35 (3H, s), 2.75 (1H, t, J = 6.1 Hz), 5.04 (2H, d, J = 6.1 Hz), 6.93-6.97 (2H, m), 7.15-7.19 (3H, m), 7.40 (1H, d, J = 2.4 Hz), 7.9 (1H, d, J = 8.9 Hz).	Ref. Ex. 19
2187		1H-NMR (CDCl3) δ: 2.46 (6H, s), 6.75 (1H, d, J = 0.7 Hz), 7.86-7.87 (1H, m), 8.05 (2H, d, J = 1.5 Hz), 10.10 (1H, s).	Ref. Ex. 112
2188		1H-NMR (CDCl3) δ: 2.38 (3H, s), 6.99-7.02 (2H, m), 7.22 (2H, d, J = 8.1 Hz), 7.31 (1H, dd, J = 2.4, 9.0 Hz), 7.38 (1H, d, J = 2.4 Hz), 8.15 (1H, d, J = 9.0 Hz), 10.11 (1H, s).	Ref. Ex. 48
2189		1H-NMR (CDCl3) δ: 7.78 (1H, d, J = 1.9 Hz), 8.12 (1H, s), 8.49 (1H, s), 8.62 (1H, s), 8.95 (1H, d, J = 1.9 Hz), 10.15 (1H, s).	Ref. Ex. 112
2190		1H-NMR (DMSO-d6) δ: 8.10-8.15 (4H, m), 10.09 (1H, s).	Ex. 125

Ref. Ex. No.	STR	1H-NMR	ref.
2191		1H-NMR (DMSO-d6) δ: 4.58 (2H, s), 5.36 (1H, br.), 7.54 (2H, d, J = 8.4 Hz), 7.84 (2H, d, J = 8.4 Hz).	Ref. Ex. 102
2193		1H-NMR (CDCl3) δ: 3.95 (3H, s), 4.12-4.17 (2H, m), 4.19-4.24 (2H, m), 5.93 (1H, s), 7.28-7.30 (1H, m), 7.49 (1H, d, J = 2.5 Hz), 7.60 (1H, s), 8.11 (1H, d, J = 9.2 Hz).	Ref. Ex. 116
2194		1H-NMR (CDCl3) δ: 2.47 (3H, s), 4.41 (2H, d, J = 1.1 Hz), 4.65 (2H, s), 6.56 (1H, s), 7.31-7.33 (1H, m), 7.35-7.39 (4H, m), 12.98 (1H, brs).	Ref. Ex. 760
2195		1H-NMR (CDCl3) δ: 2.68 (3H, s), 4.58 (2H, s), 4.67 (2H, s), 7.32-7.33 (1H, m), 7.34-7.40 (5H, m).	Ref. Ex. 831
2196		1H-NMR (CDCl3) δ: 4.57 (2H, s), 4.75 (2H, s), 6.72 (1H, s), 7.31-7.34 (1H, m), 7.37-7.42 (4H, m), 7.52-7.58 (3H, m), 8.13-8.15 (2H, m).	Ref. Ex. 760
2197		1H-NMR (CDCl3) δ: 4.67 (2H, s), 4.69 (2H, s), 7.31-7.50 (9H, m), 8.40-8.44 (2H, m).	Ref. Ex. 831
2198		1H-NMR (CDCl3) δ: 1.63-1.73 (6H, m), 3.74 (4H, bs), 4.64 (2H, s), 4.75 (2H, s), 6.71 (1H, s), 7.31-7.43 (6H, m), 8.35-8.37 (2H, m).	Ref. Ex. 1173
2199		1H-NMR (CDCl3) δ: 1.63-1.75 (6H, m), 3.73 (4H, bs), 3.78 (1H, bs), 4.70 (2H, s), 6.39 (1H, s), 7.43-7.46 (3H, m), 8.39-8.42 (2H, m).	Ref. Ex. 750

[0565]

Ref. Ex. No.	STR	1H-NMR	ref.
2200		1H-NMR (CDCl3) δ: 1.67-1.69 (4H, m), 1.70-1.75 (2H, m), 3.94 (4H, brs), 7.01 (1H, s), 7.47-7.48 (3H, m), 8.45-8.47 (2H, m), 10.09 (1H, s).	Ref. Ex. 159
2201		1H-NMR (CDCl3) δ: 2.03-2.04 (4H, m), 3.44 (2H, brs), 3.76 (2H, brs), 4.60 (2H, d, J = 0.5 Hz), 4.70 (2H, s), 6.44 (1H, s), 7.29-7.44 (8H, m), 8.38-8.40 (2H, m).	Ref. Ex. 1173
2202		1H-NMR (CDCl3) δ: 2.04 (4H, brs), 3.38 (2H, brs), 3.78 (2H, brs), 3.84 (1H, brs), 4.64 (2H, s), 6.11 (1H, s), 7.43-7.46 (3H, m), 8.43-8.46 (2H, m).	Ref. Ex. 750
2203		1H-NMR (CDCl3) δ: 2.05 (2H, brs), 2.10 (2H, brs), 3.46 (2H, brs), 3.81 (2H, brs), 6.80 (1H, s), 7.46-7.49 (3H, m), 8.48-8.50 (2H, m), 10.02 (1H, s).	Ref. Ex. 159
2204		1H-NMR (CDCl3) δ: 4.54 (2H, s), 4.68 (2H, s), 6.97 (1H, s), 7.31-7.35 (1H, m), 7.37-7.40 (4H, m).	Ref. Ex. 760
2205		1H-NMR (CDCl3) δ: 4.68 (4H, s), 7.33-7.45 (5H, m), 7.84 (1H, s).	Ref. Ex. 831
2206		1H-NMR (CDCl3) δ: 1.61-1.65 (4H, m), 1.68-1.73 (2H, m), 3.68 (4H, brs), 4.53 (2H, s), 4.63 (2H, s), 6.78 (1H, s), 7.30-7.33 (1H, m), 7.34-7.39 (4H, m).	Ref. Ex. 1173

Ref. Ex. No.	STR	1H-NMR	ref.
2207		1H-NMR (CDCl3) δ: 1.62-1.66 (4H, m), 1.69-1.75 (2H, m), 2.85 (1H, t, J = 5.4 Hz), 3.69 (4H, brs), 4.64 (2H, d, J = 5.4 Hz), 6.62 (1H, s).	Ref. Ex. 750
2208		1H-NMR (CDCl3) δ: 1.65-1.69 (4H, m), 1.73-1.78 (2H, m), 3.49-3.99 (4H, m), 7.12 (1H, s), 9.94 (1H, s).	Ref. Ex. 159
2209		1H-NMR (CDCl3) δ: 3.13 (3H, s), 3.99 (3H, s), 3.99(3H, s), 5.13 (2H, d, J = 0.8 Hz), 6.52 (1H, t, J = 0.8 Hz).	Ref. Ex. 103
2210		1H-NMR (CDCl3) δ: 3.97 (3H, s), 4.01 (3H, m), 5.07 (2H, d, J = 0.9 Hz), 6.56 (1H, t, J = 0.9 Hz), 7.23-7.26 (1H, m), 7.44-7.45 (1H, m), 7.48-7.53 (2H, m), 9.98 (1H, s).	Ref. Ex. 82
2211		1H-NMR (CDCl3) δ: 6.59 (1H, t, J = 73.4 Hz), 7.21-7.23 (1H, m), 7.37 (1H, s), 7.46-7.52 (2H, m), 7.66 (1H, s), 7.74 (1H, s), 8.02 (1H, s), 10.09 (1H, s).	Ref. Ex. 75
2212		1H-NMR (CDCl3) δ: 4.05-4.13 (2H, m), 4.15-4.23 (2H, m), 6.08 (1H, s), 7.34-7.41 (2H, m), 7.45 (1H, d, J = 0.4 Hz), 7.81-7.84 (1H, m), 8.00-8.01 (1H, m).	Ref. Ex. 116

Ref. Ex. No.	STR	1H-NMR	ref.
2215		1H-NMR (CDCl3) δ: 7.46 (1H, t, J = 7.8 Hz), 7.52-7.54 (1H, m), 7.85-7.87 (1H, m), 8.04 (1H, t, J = 1.8 Hz), 10.21 (1H, s).	Ref. Ex. 151
2216		1H-NMR (CDCl3) δ: 5.37 (2H, s), 7.48-7.53 (2H, m), 7.60-7.65 (2H, m), 7.72-7.76 (3H, m), 10.03 (1H, s).	Ref. Ex. 82

[0566]

Example 1

Synthesis of 5-(3-chloro-5-cyclopropylmethyl-phenyl)-3H-[1,2,3]triazole-4-carbonitrile

To a solution of 3-chloro-5-cyclopropylmethyl-benzaldehyde (238 mg, 1.223 mmol) in toluene (7 ml) were added phenylsulfonylacetonitrile (222 mg, 1.223 mmol) and AcOK (120 mg, 1.223 mmol). After the reaction mixture was stirred for 1.5 hr at 80°C, it was concentrated *in vacuo*. DMF (1.5 ml) and sodium azide (119 mg, 1.834 mmol) were added to the residue and stirring was continued for 1 hr at 110°C. Saturated aqueous NH_4Cl solution was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water (twice) and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=90:10-35:65) to give the title compound (296 mg, 94%) as a brown oil.

^{1}H-NMR ($CDCl_3$) δ: 0.24-0.27 (2H, m), 0.59-0.63 (2H, m), 0.99-1.06 (1H, m), 2.62 (2H, d, J = 7.0 Hz), 7.38-7.40 (1H, m), 7.79-7.83 (2H, m).

[0567]

Example 2

Synthesis of 5-[3-(4,4,4-trifluoro-butoxy)-5-trifluoromethyl-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

To a solution of 220 mg of 3-(4,4,4-trifluoro-butoxy)-5-trifluoromethyl-benzaldehyde in 4 mL of toluene were added 139 mg of phenylsulfonylacetonitrile and 36.0 mg of AcOK. The reaction mixture was stirred at 80°C for 2 hr. After cooling to 40°C, 2 mL of NMP and 57.2 mg of sodium azide were added and the reaction mixture was stirred at 80°C for 2 hr. The reaction was quenched by addition of 5wt% aqueous $NaHCO_3$ solution, and then the mixture was washed with toluene. The aqueous solution was acidified with 5N HCl and extracted with TBME. The organic phase was washed with water and brine, and concentrated to

give a dark red oil. The oil was purified by silica gel column chromatography (Hexane/AcOEt 5% -> Hexane/AcOEt 40%) to give the title compound (232 mg) as a white solid. The white solid was recrystallized (hexane/CH_2Cl_2) to afford the title compound (164 mg, 61%) as a white powder.

Melting point 84-87°C

[0568]

Example 3

Synthesis of 5-(3-cyclohexylmethoxymethyl-phenyl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-cyclohexylmethoxymethyl-benzaldehyde in the same manner as in Example 1.

white powder

Melting point 101.3-104.8°C

[0569]

Example 4

Synthesis of 5-(4-chloro-3'-trifluoromethyl-biphenyl-2-yl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-chloro-3'-trifluoromethyl-biphenyl-2-carbaldehyde in the same manner as in Example 2.

white solid (hexane/AcOEt)

Melting point 156-159°C

[0570]

Example 5

Synthesis of 5-[2-(3,5-bis-trifluoromethyl-benzyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3,5-bis-trifluoromethyl-benzyl)-benzaldehyde in the same manner as in Example 1.

white powder (hexane)

^{1}H-NMR (DMSO-d_6) δ: 4.26 (2H, s), 7.47-7.60 (6H, m), 7.89 (1H, s).

[0571]

Example 6

Synthesis of 5-[2-((E)-styryl)-5-trifluoromethyl-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-((E)-styryl)-5-trifluoromethyl-benzaldehyde in the same manner as in Example 1.

white solid

Melting point 206.0-206.3°C

[0572]

Example 7

Synthesis of 5-(2-phenethyl-5-trifluoromethyl-phenyl)-3H-[1,2,3]triazole-4-carbonitrile

To a solution of 138 mg of 5-[2-((*E*)-styryl)-5-trifluoromethyl-phenyl]-3H-[1,2,3]triazole-4-carbonitrile in 4 ml of EtOH was added 40 mg of 5% Pd/C (56% wet). The reaction mixture was stirred at room temperature under hydrogen for 2 hr and then filtered through a Celite pad followed by concentration to give a crude product. The crude product was purified by silica gel column chromatography (Hexane/AcOEt 10% -> Hexane/AcOEt 30%) to give the title compound as a white solid. The white solid was recrystallized (hexane/AcOEt) to afford the title compound (88 mg, 64%) as a white powder.

Melting point 121-124°C

[0573]

Example 8

Synthesis of 5-{5-chloro-2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-chloro-2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde in the same manner as in Example 2.

white solid (hexane/AcOEt)

Melting point 151-154°C

[0574]

Example 9

Synthesis of 5-[5-fluoro-2-(3-fluoro-5-trifluoromethyl-

benzyloxy)-3-methyl-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-fluoro-2-(3-fluoro-5-trifluoromethyl-benzyloxy)-3-methyl-benzaldehyde in the same manner as in Example 1.

beige powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 2.39 (3H, s), 4.77 (2H, s), 7.28-7.43 (4H, m), 7.60-7.63 (1H, m).

[0575]

Example 10

Synthesis of 5-(3-(thiophen-3-yl)-5-trifluoromethyl-phenyl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(thiophen-3-yl)-5-trifluoromethyl-benzaldehyde in the same manner as in Example 1.

white powder (hexane)

Melting point 126.9-129.4°C

[0576]

Example 11

Synthesis of 5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde in the same manner as in Example 1.

white powder (AcOEt-hexane)

Melting point 229-230°C

[0577]

Example 12

Synthesis of 5-[3-cyclopropyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-cyclopropyl-5-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde in the same manner as in Example 1.

pale brown powder (AcOEt-hexane)

^{1}H-NMR (DMSO-d_6) δ: 0.88-0.93 (2H, m), 1.07-1.11 (2H, m), 2.10-2.17 (1H, m), 7.66 (1H, s), 7.71 (1H, s), 8.01-8.03 (1H, m),

8.05-8.07 (1H, m), 8.41-8.45 (1H, m), 8.15 (1H, d, J = 1.9 Hz).

[0578]

Example 13

Synthesis of 5-[3-tert-butyl-5-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-tert-butyl-5-(5-trifluoromethyl-pyridin-2-yl)-benzaldehyde in the same manner as in Example 1.

white powder (AcOEt-hexane)

Melting point 171-174°C

[0579]

Example 14

Synthesis of 5-[3-trifluoromethyl-5-(6-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-trifluoromethyl-5-(6-trifluoromethyl-pyridin-2-yl)-benzaldehyde in the same manner as in Example 2.

white powder (hexane/AcOEt)

Melting point 151-154°C

[0580]

Example 15

Synthesis of 5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-benzaldehyde in the same manner as in Example 1.

white powder

Melting point 209-211°C

[0581]

Example 16

Synthesis of 5-[2-ethoxy-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-ethoxy-5-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde in the same manner as in Example 1.

pale brown powder (AcOEt-hexane)

Melting point 207-209°C

[0582]

Example 17

Synthesis of 5-[4-isopropoxy-3-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-isopropoxy-3-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde in the same manner as in Example 1.

pale brown powder (AcOEt-hexane)

Melting point 239—242°C

[0583]

Example 18

Synthesis of 5-[3-cyclopropylmethoxy-5-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-cyclopropylmethoxy-5-(5-trifluoromethyl-pyridin-2-yl)-benzaldehyde in the same manner as in Example 1.

white powder (IPA/hexane)

Melting point 168-171°C

[0584]

Example 19

Synthesis of 5-[3-cyclobutoxy-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-cyclobutoxy-5-(6-trifluoromethyl-pyridin-3-yl)-benzaldehyde in the same manner as in Example 1.

white powder (AcOEt-hexane)

Melting point 222-224°C

[0585]

Example 20

Synthesis of 5-[3-(3-trifluoromethyl-benzyloxy)-5-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(3-

trifluoromethyl-benzyloxy)-5-(5-trifluoromethyl-pyridin-2-yl)-benzaldehyde in the same manner as in Example 1.

pale yellow powder (hexane/CH_2Cl_2)

Melting point 210-212°C

[0586]

Example 21

Synthesis of 5-[3-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(4-trifluoromethyl-pyrimidin-2-yl)-benzaldehyde in the same manner as in Example 1.

beige powder (CH_3CN)

^{1}H-NMR (DMSO-d_6) δ: 7.84 (1H, t, J = 7.8 Hz), 8.04 (1H, d, J = 5.0 Hz), 8.13 (1H, d, J = 7.8 Hz), 8.57 (1H, d, J = 7.8 Hz), 9.00 (1H, s), 9.35 (1H, d, J = 5.0 Hz).

[0587]

Example 22

Synthesis of 5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-benzaldehyde in the same manner as in Example 1.

beige powder (CH_3CN)

^{1}H-NMR ($CDCl_3$) δ: 2.53 (3H, s), 7.94 (1H, s), 8.02 (1H, d, J = 5.0 Hz), 8.38 (1H, s), 8.80 (1H, s), 9.32 (1H, d, J = 5.0 Hz).

[0588]

Example 23

Synthesis of 5-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-benzaldehyde in the same manner as in Example 1.

beige powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 8.09 (1H, d, J = 5.0 Hz), 8.15 (1H, s), 8.48 (1H, s), 8.92 (1H, s), 9.36 (1H, d, J = 5.0 Hz).

[0589]

Example 24

Synthesis of 5-[3-chloro-5-(4-trifluoromethyl-piperidin-1-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-chloro-5-(4-trifluoromethyl-piperidin-1-yl)-benzaldehyde in the same manner as in Example 1.

brown amorphous

^{1}H-NMR ($CDCl_3$) δ: 1.70-1.78 (2H, m), 2.00 (2H, d, J = 12.5 Hz), 2.20-2.25 (1H, m), 2.84 (2H, t, J = 12.5 Hz), 3.85 (2H, d, J = 12.5 Hz), 6.99 (1H, s), 7.38 (1H, s), 7.40 (1H, s).

[0590]

Example 25

Synthesis of 5-(3-(benzo[*b*]thiophen-3-yl)-5-chloro-phenyl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(benzo[*b*]thiophen-3-yl)-5-chloro-benzaldehyde in the same manner as in Example 1.

beige powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.47-7.49 (2H, m), 7.87-7.88 (1H, m), 7.97-8.02 (2H, m), 8.08-8.14 (3H, m).

[0591]

Example 26

Synthesis of 5-(3-(benzofuran-2-yl)-4-fluoro-phenyl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(benzofuran-2-yl)-4-fluoro-benzaldehyde in the same manner as in Example 1.

pink powder (AcOEt-hexane)

Melting point 224-225°C

[0592]

Example 27

Synthesis of 5-[3-(5-fluoro-benzoxazol-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(5-fluoro-benzoxazol-2-yl)-benzaldehyde in the same manner as in Example

1.

beige powder (AcOEt)

Melting point 292°C

[0593]

Example 28

Synthesis of 5-(5-fluoro-3'-trifluoromethyl-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-fluoro-3'-trifluoromethyl-biphenyl-3-carbaldehyde in the same manner as in Example 1.

white powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.71-7.90 (4H, m), 8.10-8.12 (3H, m).

[0594]

Example 29

Synthesis of 5-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-chloro-4'-trifluoromethoxy-biphenyl-3-carbaldehyde in the same manner as in Example 1.

beige amorphous

^{1}H-NMR (DMSO-d_6) δ: 7.54 (2H, d, J = 8.2 Hz), 7.90-7.98 (4H, m), 8.12-8.13 (1H, m).

[0595]

Example 30

Synthesis of 5-[3-chloro-5-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-chloro-5-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-benzaldehyde in the same manner as in Example 1.

beige powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.56-7.65 (2H, m), 7.89-7.91 (2H, m), 7.96 (1H, s), 8.11 (1H, s).

[0596]

Example 31

Synthesis of 5-(5'-fluoro-5-methyl-3'-trifluoromethyl-

biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5'-fluoro-5-methyl-3'-trifluoromethyl-biphenyl-3-carbaldehyde in the same manner as in Example 1.

white granules (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 2.49 (3H, s), 7.75 (1H, s), 7.76 (1H, s), 7.86 (1H, s), 7.95 (1H, s), 7.98 (1H, s), 8.06 (1H, s).

[0597]

Example 32

Synthesis of 5-(3',4'-difluoro-6-methoxy-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3',4'-difluoro-6-methoxy-biphenyl-3-carbaldehyde in the same manner as in Example 1.

white powder (EtOH)

Melting point 266-267°C

[0598]

Example 33

Synthesis of 5-(5-ethoxymethyl-4'-fluoro-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-ethoxymethyl-4'-fluoro-biphenyl-3-carbaldehyde in the same manner as in Example 1.

pale brown powder (AcOEt-hexane)

Melting point 138-140°C

[0599]

Example 34

Synthesis of 5-[3-(4-fluoro-benzyl)-5-trifluoromethoxy-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(4-fluoro-benzyl)-5-trifluoromethoxy-benzaldehyde in the same manner as in Example 1.

colorless oil

^{1}H-NMR ($CDCl_3$) δ: 4.05 (2H, s), 6.99-7.06 (2H, m), 7.14-7.20 (3H, m), 7.70 (1H, s), 7.76 (1H, s).

[0600]

Example 35

Synthesis of 5-[3-(2,5-bis-trifluoromethyl-benzyl)-5-chloro-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(2,5-bis-trifluoromethyl-benzyl)-5-chloro-benzaldehyde in the same manner as in Example 1.

white powder (hexane)

^{1}H-NMR (DMSO-d_6) δ: 4.40 (2H, s), 7.50 (1H, s), 7.52 (1H, s), 7.76 (1H, s), 7.91 (1H, d, J = 8.3 Hz), 7.93 (1H, s), 8.03 (1H, d, J = 8.3 Hz).

[0601]

Example 36

Synthesis of 5-[3-(2,3-dihydro-indol-1-ylmethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(2,3-dihydro-indol-1-ylmethyl)-benzaldehyde in the same manner as in Example 1.

pale brown powder (CH_2Cl_2-hexane)

^{1}H-NMR ($CDCl_3$) δ: 3.01 (2H, t, J = 8.3 Hz), 3.38 (2H, t, J = 8.3 Hz), 4.34 (2H, s), 6.50 (1H, d, J = 7.7 Hz), 6.70 (1H, t, J = 7.5 Hz), 7.06 (1H, t, J = 7.7 Hz), 7.12 (1H, d, J = 7.5 Hz), 7.50-7.52 (2H, m), 7.86-7.89 (1H, m), 7.95 (1H, s).

[0602]

Example 37

Synthesis of 5-(3-phenoxy-5-trifluoromethyl-phenyl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-phenoxy-5-trifluoromethyl-benzaldehyde in the same manner as in Example 1.

white powder (toluene-hexane)

^{1}H-NMR ($CDCl_3$) δ: 7.10 (2H, m), 7.24 (1H, m), 7.34 (1H, s), 7.44 (2H, t, J = 7.9 Hz), 7.77 (1H, s), 7.94 (1H, s).

[0603]

Example 38

Synthesis of 5-[3-(4-chloro-phenylsulfanyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(4-chloro-phenylsulfanyl)-benzaldehyde in the same manner as in Example 1.

brown prisms (hexane-Et_2O)

Melting point 134-138°C

[0604]

Example 39

Synthesis of 5-{3-trifluoromethyl-5-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-trifluoromethyl-5-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-benzaldehyde in the same manner as in Example 2.

brown amorphous (hexane/CH_2Cl_2)

^{1}H-NMR (DMSO-d_6) δ: 3.25 (4H, s), 7.62 (1H, d, J = 7.8 Hz), 7.72 (1H, d, J = 7.8 Hz), 7.78 (1H, s), 7.97-8.01 (2H, m), 8.05 (1H, s).

[0605]

Example 40

Synthesis of 5-{3-[2-(2,4-difluoro-phenyl)-ethyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[2-(2,4-difluoro-phenyl)-ethyl]-benzaldehyde in the same manner as in Example 2.

pale yellow solid (hexane/AcOEt)

Melting point 146-147°C

[0606]

Example 41

Synthesis of 5-{3-[(E)-2-(4-cyano-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-[(E)-2-(3-formyl-phenyl)-vinyl]-benzonitrile in the same manner as in Example 1.

pale yellow powder (AcOEt-hexane)

Melting point 215.5-217.6°C

[0607]

Example 42

Synthesis of 5-{2-chloro-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-chloro-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde in the same manner as in Example 2.

light pink solid (hexane/AcOEt)

Melting point 187-190°C

[0608]

Example 43

Synthesis of 5-{2-ethoxy-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-ethoxy-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde in the same manner as in Example 2.

white solid (hexane/AcOEt)

Melting point 192-194°C

[0609]

Example 44

Synthesis of 5-{3-[(*E*)-2-(4-ethoxy-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[(*E*)-2-(4-ethoxy-phenyl)-vinyl]-benzaldehyde in the same manner as in Example 1.

white powder (AcOEt-hexane)

^{1}H-NMR ($CDCl_3$) δ: 1.44 (3H, t, J = 7.0 Hz), 4.07 (2H, d, J = 7.0 Hz), 6.89-6.94 (2H, m), 7.02 (1H, d, J = 16.3 Hz), 7.16 (1H, d, J = 16.3 Hz), 7.45-7.53 (3H, m), 7.60-7.65 (1H, m), 7.80-7.85 (1H, m), 8.07 (1H, brs).

[0610]

Example 45

Synthesis of 5-{4-cyano-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-formyl-2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzonitrile in the same manner as in Example 2.

light brown solid (hexane/AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.60 (1H, d, J = 16.4 Hz), 7.70 (1H, d, J = 16.4 Hz), 7.70-7.76 (2H, m), 7.97 (1H, dd, J = 1.7, 6.4 Hz), 8.02-8.04 (2H, m), 8.15 (1H, d, J = 8.1 Hz), 8.46 (1H, d, J = 1.6 Hz).

[0611]

Example 46

Synthesis of 5-{4-trifluoromethyl-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-trifluoromethyl-3-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde in the same manner as in Example 2.

white solid (hexane/AcOEt)

Melting point 196-199°C

[0612]

Example 47

Synthesis of 5-{3-chloro-5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-chloro-5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde in the same manner as in Example 1.

white powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.53-7.57 (2H, m), 7.64-7.68 (2H, m), 7.82 (1H, s), 7.94-7.96 (2H, m), 8.02 (1H, s), 8.05 (1H, s).

[0613]

Example 48

Synthesis of 5-{3-[(*E*)-2-(5-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[(*E*)-2-(5-trifluoromethyl-pyridin-2-yl)-vinyl]-benzaldehyde in the same manner as in Example 2.

white solid (hexane/AcOEt)

Melting point 185-187°C

[0614]

Example 49

Synthesis of 5-{3-[(*E*)-2-(5-trifluoromethyl-pyridin-3-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[(*E*)-2-(5-trifluoromethyl-pyridin-3-yl)-vinyl]-benzaldehyde in the same manner as in Example 2.

light orange powder (hexane/AcOEt)

Melting point 209-211°C

[0615]

Example 50

Synthesis of 5-{3-[(*E*)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[(*E*)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-benzaldehyde in the same manner as in Example 2.

pale yellow solid (hexane/AcOEt)

Melting point 192-196°C

[0616]

Example 51

Synthesis of 5-{3-trifluoromethyl-5-[(*E*)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-trifluoromethyl-5-[(*E*)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-benzaldehyde in the same manner as in Example 2.

light brown solid (hexane/AcOEt)

Melting point 213-216°C

[0617]

Example 52

Synthesis of 5-{3-[(*E*)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[(*E*)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-benzaldehyde in the same manner as in Example 2.

pale yellow solid (hexane/AcOEt)

Melting point 201-204°C

[0618]

Example 53

Synthesis of 5-{3-[(*Z*)-2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[(*Z*)-2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-benzaldehyde in the same manner as in Example 1.

white powder (CH_2Cl_2-hexane)

Melting point 143.9-146.7°C

[0619]

Example 54

Synthesis of 5-(3-{[N-(4-fluoro-phenyl)-N-methyl-amino]-methyl}-phenyl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-{[N-(4-fluoro-phenyl)-N-methyl-amino]-methyl}-benzaldehyde in the same manner as in Example 2.

white solid (hexane/CH_2Cl_2)

Melting point 122-124°C

[0620]

Example 55

Synthesis of 5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-benzaldehyde in the same manner as in Example 2.

pale yellow solid (AcOEt-hexane)

Melting point 147.3-147.4°C

[0621]

Example 56

Synthesis of 5-[3-(5-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(5-trifluoromethyl-pyridin-2-yloxymethyl)-benzaldehyde in the same manner as in Example 2.

light yellow solid (AcOEt-hexane)

Melting point 134.4-134.6°C

[0622]

Example 57

Synthesis of 5-[3-(3,5-bis-trifluoromethyl-phenoxymethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(3,5-bis-trifluoromethyl-phenoxymethyl)-benzaldehyde in the same manner as in Example 1.

slightly brown powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 5.43 (2H, s), 7.64-7.70 (5H, m), 7.87-7.91 (1H, m), 8.03 (1H, s).

[0623]

Example 58

Synthesis of 5-{3-[N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-amino]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-amino]-benzaldehyde in the same manner as in Example 1.

white powder (CH_3CN)

^{1}H-NMR (DMSO-d_6) δ: 3.13 (3H, s), 4.84 (2H, s), 6.93-6.97 (1H, m), 7.18 (1H, t, J = 7.6 Hz), 7.21-7.22 (1H, m), 7.40 (1H, t, J = 7.6 Hz), 7.88 (2H, s), 8.00 (1H, s).

[0624]

Example 59

Synthesis of 5-[3-(benzofuran-2-ylmethoxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(benzofuran-2-ylmethoxy)-benzaldehyde in the same manner as in Example 1.

beige powder (AcOEt-hexane)

Melting point 176-177°C

[0625]

Example 60

Synthesis of 5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(2,5-bis-trifluoromethyl-benzyloxy)-benzaldehyde in the same manner as

in Example 1.

slightly yellow granules (CH_3CN)

Melting point 180°C

[0626]

Example 61

Synthesis of 5-[3-(2-methoxy-benzyloxy)-5-trifluoromethyl-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(2-methoxy-benzyloxy)-5-trifluoromethyl-benzaldehyde in the same manner as in Example 2.

white solid (hexane/CH_2Cl_2)

^{1}H-NMR (DMSO-d_6) δ: 3.84 (3H, s), 5.23 (2H, s), 7.02 (1H, d, J = 7.4 Hz), 7.08 (1H, d, J = 8.2 Hz), 7.38 (1H, t, J = 8.2 Hz), 7.45 (1H, d, J = 7.4 Hz), 7.55 (1H, s), 7.77 (2H, s).

[0627]

Example 62

Synthesis of 5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-5-methoxy-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(2,5-bis-trifluoromethyl-benzyloxy)-5-methoxy-benzaldehyde in the same manner as in Example 2.

white powder (hexane/TBME)

Melting point 168-169°C

[0628]

Example 63

Synthesis of 5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethyl-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethyl-benzaldehyde in the same manner as in Example 1.

white powder (hexane/AcOEt)

Melting point 125°C

[0629]

Example 64

Synthesis of 5-[3-(1-phenyl-ethoxy)-5-trifluoromethyl-phenyl]-

3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(1-phenyl-ethoxy)-5-trifluoromethyl-benzaldehyde in the same manner as in Example 2.

light yellow powder (hexane/CH_2Cl_2)

Melting point 105-108°C

[0630]

Example 65

Synthesis of 5-[3-(4-trifluoromethoxy-benzylsulfanylmethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(4-trifluoromethoxy-benzylsulfanylmethyl)-benzaldehyde in the same manner as in Example 2.

light brown solid (hexane/CH_2Cl_2)

Melting point 95-97°C

[0631]

Example 66

Synthesis of 5-{3-[2-(5-trifluoromethyl-pyridin-2-yloxy)-ethyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[2-(5-trifluoromethyl-pyridin-2-yloxy)-ethyl]-benzaldehyde in the same manner as in Example 2.

pale yellow solid (hexane/CH_2Cl_2)

Melting point 115.2-115.3°C

[0632]

Example 67

Synthesis of 5-[3-(1-methyl-2-phenyl-ethoxy)-5-trifluoromethyl-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(1-methyl-2-phenyl-ethoxy)-5-trifluoromethyl-benzaldehyde in the same manner as in Example 2.

colorless oil

^{1}H-NMR ($CDCl_3$) δ: 1.41 (3H, d, J = 6.1 Hz), 2.94 (1H, dd, J = 6.2, 7.8 Hz), 3.15 (1H, dd, J = 6.2, 7.8 Hz), 4.71-4.77 (1H, m), 7.22-7.33 (6H, m), 7.69 (1H, s), 7.79 (1H, s).

[0633]

Example 68

Synthesis of 5-(3'-trifluoromethyl-biphenyl-4-yl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3'-trifluoromethyl-biphenyl-4-carbaldehyde in the same manner as in Example 1.

slightly brown flakes (CH_3CN)

Melting point 248°C

[0634]

Example 69

Synthesis of 5-[4-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-(4-trifluoromethyl-pyridin-2-yl)-benzaldehyde in the same manner as in Example 1.

colorless flakes (AcOEt)

Melting point 252-253°C

[0635]

Example 70

Synthesis of 5-[4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-(4-trifluoromethyl-pyrimidin-2-yl)-benzaldehyde in the same manner as in Example 1.

white granules (CH_3CN)

Melting point 236-237°C

[0636]

Example 71

Synthesis of 5-[3-methyl-4-(3-trifluoromethyl-benzyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-methyl-4-(3-trifluoromethyl-benzyl)-benzaldehyde in the same manner as in Example 1.

pale brown powder (AcOEt-hexane)

Melting point 160-162°C

[0637]

Example 72

Synthesis of 5-[3-fluoro-4-(3-trifluoromethyl-phenoxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-fluoro-4-(3-trifluoromethyl-phenoxy)-benzaldehyde in the same manner as in Example 1.

beige powder (hexane-AcOEt)

Melting point 149-151°C

[0638]

Example 73

Synthesis of 5-{2-fluoro-4-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-fluoro-4-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-benzaldehyde in the same manner as in Example 1.

white granules (AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.56-7.85 (7H, m), 7.94-7.96 (1H, m), 8.00 (1H, s).

[0639]

Example 74

Synthesis of 5-[4-(4-trifluoromethoxy-phenyl)-thiazol-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-(4-trifluoromethoxy-phenyl)-thiazole-2-carbaldehyde in the same manner as in Example 1.

pale yellow solid

^{1}H-NMR (DMSO-d_6) δ: 7.52-7.55 (2H, m), 8.17-8.20 (2H, m), 8.49 (1H, s).

[0640]

Example 75

Synthesis of 5-[2-(4-chloro-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-thiazole-4-carbaldehyde in the same manner as in

Example 1.

pale brown solid (AcOEt-hexane)

Melting point 221.3-223.8°C

[0641]

Example 76

Synthesis of 5-[2-(3-chloro-4-fluoro-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3-chloro-4-fluoro-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 233.8-236.2°C

[0642]

Example 77

Synthesis of 5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3,4-dichloro-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 237.7-243.2°C

[0643]

Example 78

Synthesis of 5-[2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 2.

white solid (AcOEt-hexane)

Melting point 212.8-217.1°C

[0644]

Example 79

Synthesis of 5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3-

trifluoromethoxy-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 222.3-224.2°C

[0645]

Example 80

Synthesis of 5-[2-(4-trifluoromethoxy-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-trifluoromethoxy-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 191.1-192.8°C

[0646]

Example 81

Synthesis of 5-{2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazol-4-yl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 206.8-211.2°C

[0647]

Example 82

Synthesis of 5-[2-(4-chloro-benzyloxy)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-benzyloxy)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid

^{1}H-NMR (DMSO-d_6) δ: 5.54 (2H, s), 7.48 (2H, d, J = 8.4 Hz), 7.61 (2H, d, J = 8.4 Hz), 7.71 (1H, s).

[0648]

Example 83

Synthesis of 5-{2-[N-(4-chloro-phenyl)-N-methyl-amino]-

thiazol-4-yl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-[N-(4-chloro-phenyl)-N-methyl-amino]-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

^{1}H-NMR (DMSO-d_6) δ: 3.55 (3H, s), 7.45 (1H, s), 7.50-7.53 (2H, m), 7.63-7.66 (2H, m).

[0649]

Example 84

Synthesis of 5-{2-[N-ethyl-N-(3-trifluoromethyl-phenyl)-amino]-thiazol-4-yl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-[N-ethyl-N-(3-trifluoromethyl-phenyl)-amino]-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 163.3-165.3°C

[0650]

Example 85

Synthesis of 5-[2-(3-trifluoromethyl-phenoxy)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3-trifluoromethyl-phenoxy)-thiazole-4-carbaldehyde in the same manner as in Example 1.

pale yellow solid

^{1}H-NMR (DMSO-d_6) δ: 7.71-7.78 (2H, m), 7.80-7.89 (2H, m), 7.93 (1H, s).

[0651]

Example 86

Synthesis of 5-[2-(4-chloro-phenylsulfanyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenylsulfanyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 192.7-194.7°C

[0652]

Example 87

Synthesis of 5-(2-hexyl-thiazol-4-yl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-hexyl-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid

Melting point 87.3-89.7°C

[0653]

Example 88

Synthesis of 5-(2-(adamantan-1-yl)-thiazol-4-yl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(adamantan-1-yl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid

Melting point 180.1-183.5°C

[0654]

Example 89

Synthesis of 5-[2-(4-chloro-phenyl)-5-methyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-5-methyl-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

^{1}H-NMR (DMSO-d_6) δ: 2.78 (3H, s), 7.61-7.64 (2H, m), 7.96-7.99 (2H, m).

[0655]

Example 90

Synthesis of 5-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 210.1-211.4°C

[0656]

Example 91

Synthesis of 5-[5-methyl-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-methyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 217.9-219.9°C

[0657]

Example 92

Synthesis of 5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 288.3-292.0°C

[0658]

Example 93

Synthesis of 5-[5-methyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-methyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

colorless powder (AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 2.82 (3H, s), 8.29 (1H, d, J = 8.3 Hz), 8.49 (1H, dd, J = 1.8, 8.3 Hz), 9.06-9.07 (1H, m).

[0659]

Example 94

Synthesis of 5-[5-methyl-2-(6-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-methyl-2-(6-trifluoromethyl-pyridin-2-yl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

beige powder

^{1}H-NMR (DMSO-d_6) δ: 2.82 (3H, s), 7.98 (1H, d, J = 7.6 Hz), 8.31 (1H, t, J = 7.6 Hz), 8.37 (1H, d, J = 7.6 Hz).

[0660]

Example 95

Synthesis of 5-[2-(5-chloro-pyridin-2-yl)-5-methyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(5-chloro-pyridin-2-yl)-5-methyl-thiazole-4-carbaldehyde in the same manner as in Example 1.

colorless powder (AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 2.80 (3H, s), 8.12 (1H, dd, J = 0.5, 8.5 Hz), 8.21 (1H, dd, J = 2.4, 8.5 Hz), 8.73 (1H, dd, J = 0.5, 2.4 Hz).

[0661]

Example 96

Synthesis of 5-[5-methyl-2-(4-trifluoromethoxy-phenoxy)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-methyl-2-(4-trifluoromethoxy-phenoxy)-thiazole-4-carbaldehydein the same manner as in Example 1.

pale yellow solid

^{1}H-NMR (DMSO-d_6) δ: 2.62 (3H, s), 7.45-7.48 (2H, m), 7.61-7.66 (2H, m).

[0662]

Example 97

Synthesis of 5-[5-methyl-2-(3-trifluoromethyl-phenylsulfanyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-methyl-2-(3-trifluoromethyl-phenylsulfanyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid

Melting point 118.5-121.7°C

[0663]

Example 98

Synthesis of 5-[2-(4-chloro-phenyl)-5-ethyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-5-ethyl-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 253.4-255.8°C

[0664]

Example 99

Synthesis of 5-[5-ethyl-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-ethyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 185.7-188.5°C

[0665]

Example 100

Synthesis of 5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

^{1}H-NMR (DMSO-d_6) δ: 1.35 (3H, t, J = 7.5 Hz), 3.27 (2H, q, J = 7.5 Hz), 8.28 (1H, d, J = 8.3 Hz), 8.48-8.50 (1H, m), 9.05 (1H, s).

[0666]

Example 101

Synthesis of 5-[5-ethyl-2-(6-trifluoromethyl-pyridin-3-yl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-ethyl-2-(6-trifluoromethyl-pyridin-3-yl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

beige powder

^{1}H-NMR (DMSO-d_6) δ: 1.32 (3H, t, J = 7.9 Hz), 3.28-3.45 (2H, m), 8.00-8.08 (1H, m), 8.54 (1H, dd, J = 4.6, 10.7 Hz), 9.30-9.31 (1H, m).

[0667]

Example 102

Synthesis of 5-[2-(4-chloro-phenoxy)-5-ethyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenoxy)-5-ethyl-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid

^{1}H-NMR (DMSO-d_6) δ: 1.21-1.25 (3H, m), 3.07-3.11 (2H, m), 7.52-7.57 (4H, m).

[0668]

Example 103

Synthesis of 5-[2-(4-chloro-phenyl)-5-propyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-5-propyl-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 222.5-222.8°C

[0669]

Example 104

Synthesis of 5-[5-propyl-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-propyl-2-(3-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid

Melting point 177.0-178.2°C

[0670]

Example 105

Synthesis of 5-[2-(4-chloro-phenyl)-5-cyclopropyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-5-cyclopropyl-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 268.0-271.2°C

[0671]

Example 106

Synthesis of 5-[2-(4-chloro-phenyl)-5-isobutyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-5-isobutyl-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid

^{1}H-NMR (DMSO-d_6) δ: 0.96 (6H, d, J = 6.6 Hz), 1.94-2.00 (1H, m), 3.16 (2H, d, J = 6.8 Hz), 7.63 (2H, d, J = 8.5 Hz), 8.01 (2H, d, J = 8.5 Hz).

[0672]

Example 107

Synthesis of 5-[2-(4-chloro-phenyl)-5-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-5-(4-trifluoromethyl-phenyl)-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

Melting point 275.7-278.4°C

[0673]

Example 108

Synthesis of 5-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

To the solution of 5-[2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile (24 mg, 0.075 mmol) in CH_3CN (4 ml) was added NCS (10.9 mg, 0.082 mmol). The reaction mixture was stirred at 50°C for 5 hr. After concentration, saturated aqueous $NaHCO_3$ solution was added to the residue and the mixture was washed with toluene. Then the

aqueous solution was acidified with 5N HCl and extracted with AcOEt. The combined organic layers were washed with brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue obtained was purified by Solid Phase Extraction (SAX) (AcOEt) to give the title compound (10 mg, 38%) as a white solid.
Melting point 204.1-205.5°C

[0674]

Example 109

Synthesis of 5-[5-chloro-2-(4-trifluoromethoxy-phenoxy)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

To a solution of 2-(4-trifluoromethoxy-phenoxy)-thiazole-4-carbaldehyde (118 mg, 0.408 mmol) in toluene (4 ml) were added phenylsulfonylacetonitrile (78 mg, 0.428 mmol) and AcOK (40 mg, 0.408 mmol). After the reaction mixture was refluxed for 1 hr, it was concentrated *in vacuo*. DMF (1.5 ml) and sodium azide (119 mg, 1.834 mmol) were added to the residue and stirring was continued for 0.5 hr at 50°C and for 2 hr at room temperature. Aqueous HCl solution was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over $MgSO_4$, and concentrated *in vacuo*. NCS (75 mg, 0.563 mmol) and DMF (4 ml) were added to the residue, and the reaction mixture was stirred for 3 days at room temperature. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over $MgSO_4$, and concentrated *in vacuo*. The residue was purified by flash column chromatography (Hexane:AcOEt =1:1-1:4) to give the title compound (66 mg, 42%) as a white solid.
Melting point 143.5-145.1°C

[0675]

Example 110

Synthesis of 5-[2-(4-chloro-phenyl)-5-methoxy-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-

phenyl)-5-methoxy-thiazole-4-carbaldehyde in the same manner as in Example 1.

white solid (AcOEt-hexane)

^{1}H-NMR (DMSO-d_6) δ: 4.19 (3H, s), 7.62 (2H, d, J = 8.5 Hz), 7.93 (2H, d, J = 8.5 Hz).

[0676]

Example 111

Synthesis of 5-[2-(3-trifluoromethyl-phenyl)-thiazol-5-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3-trifluoromethyl-phenyl)-thiazole-5-carbaldehyde in the same manner as in Example 1.

white solid

Melting point 196.8-198.6°C

[0677]

Example 112

Synthesis of 5-{2-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazol-5-yl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiazole-5-carbaldehyde in the same manner as in Example 1.

pale yellow solid

^{1}H-NMR (DMSO-d_6) δ: 7.62-7.78 (4H, m), 8.06 (1H, d, J = 7.5 Hz), 8.13 (1H, s), 8.20 (1H, s).

[0678]

Example 113

Synthesis of 5-[2-(4-chloro-phenyl)-4-methyl-thiazol-5-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-4-methyl-thiazole-5-carbaldehyde in the same manner as in Example 1.

white solid

Melting point 239.8-245.0°C

[0679]

Example 114

Synthesis of 5-[4-methyl-2-(3-trifluoromethyl-phenyl)-thiazol-5-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-methyl-2-(3-trifluoromethyl-phenyl)-thiazole-5-carbaldehyde in the same manner as in Example 1.

white solid

Melting point 188.2-192.0°C

[0680]

Example 115

Synthesis of 5-[2-(4-chloro-phenyl)-4-ethyl-thiazol-5-yl]-1H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-4-ethyl-thiazole-5-carbaldehyde in the same manner as in Example 1.

white powder (EtOH-water)

Melting point 205.2-208.7°C

[0681]

Example 116

Synthesis of 5-[2-(3-chloro-4-fluoro-phenyl)-4-trifluoromethyl-thiazol-5-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3-chloro-4-fluoro-phenyl)-4-trifluoromethyl-thiazole-5-carbaldehyde in the same manner as in Example 1.

pale yellow solid

^{1}H-NMR (DMSO-d_6) δ: 7.65 (1H, t, J = 8.9 Hz), 8.06-8.12 (1H, m), 8.27 (1H, dd, J = 2.2, 7.0 Hz).

[0682]

Example 117

Synthesis of 5-[2-(4-trifluoromethoxy-phenyl)-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-trifluoromethoxy-phenyl)-oxazole-4-carbaldehyde in the same manner as in Example 1.

white solid

Melting point 179.6-183.4°C

[0683]

Example 118

Synthesis of 5-[2-(4-chloro-phenyl)-5-methyl-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-5-methyl-oxazole-4-carbaldehyde in the same manner as in Example 2.

light brown solid (hexane/CH_2Cl_2)

^{1}H-NMR (DMSO-d_6) δ: 2.68 (3H, s), 7.64-7.67 (2H, m), 7.97-8.00 (2H, m).

[0684]

Example 119

Synthesis of 5-[2-(4-chloro-phenyl)-5-propyl-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-5-propyl-oxazole-4-carbaldehyde in the same manner as in Example 2.

yellow solid (AcOEt-hexane)

^{1}H-NMR (DMSO-d_6) δ: 0.97 (3H, t, J = 7.4 Hz), 1.72-1.82 (2H, m), 3.07 (2H, t, J = 7.4 Hz), 7.66-7.68 (2H, m), 8.00-8.02 (2H, m).

[0685]

Example 120

Synthesis of 5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazole-4-carbaldehyde in the same manner as in Example 2.

white solid (AcOEt-hexane)

Melting point 195.6-195.7°C

[0686]

Example 121

Synthesis of 5-[2-(3-chloro-phenyl)-5-cyclopropyl-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(3-chloro-

phenyl)-5-cyclopropyl-oxazole-4-carbaldehyde in the same manner as in Example 2.

white solid (AcOEt-hexane)

Melting point 174.2-174.9°C

[0687]

Example 122

Synthesis of 5-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-chloro-phenyl)-5-isopropyl-oxazole-4-carbaldehyde in the same manner as in Example 2.

white solid (hexane/CH_2Cl_2)

Melting point 197-199°C

[0688]

Example 123

Synthesis of 5-[2-(4-fluoro-phenyl)-5-isopropyl-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 2-(4-fluoro-phenyl)-5-isopropyl-oxazole-4-carbaldehyde in the same manner as in Example 2.

white solid (AcOEt-hexane)

Melting point 183-185°C

[0689]

Example 124

Synthesis of 5-[5-isopropyl-2-(4-trifluoromethoxy-phenyl)-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-isopropyl-2-(4-trifluoromethoxy-phenyl)-oxazole-4-carbaldehyde in the same manner as in Example 2.

white solid (AcOEt-hexane)

Melting point 190.8-191.1°C

[0690]

Example 125

Synthesis of 5-[2-(3,4-difluoro-phenyl)-5-isobutyl-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

To a solution of 2-(3,4-difluoro-phenyl)-5-isobutyl-oxazole-4-carbaldehyde (92.9 mg, 0.350 mmol) in DMF (3 ml) were added (phenylsulfonyl)acetonitrile (63.5 mg, 0.350 mmol) and sodium azide (34.2 mg, 0.525 mmol). After the reaction mixture was stirred for 1.5 hr at 80°C, saturated aqueous NH_4Cl solution was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water twice and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The crude product obtained was recrystallized from hexane-AcOEt to give the title compound (61.8 mg, 54%) as a pale brown powder.

pale brown powder (AcOEt-hexane)

^{1}H-NMR ($CDCl_3$) δ: 0.96 (6H, d, J = 6.7 Hz), 2.12-2.17 (1H, m), 2.99 (2H, d, J = 7.0 Hz), 7.66-7.71 (1H, m), 7.84-7.89 (1H, m), 7.93-7.97 (1H, m).

[0691]

Example 126

Synthesis of 5-[3-(3,5-bis-trifluoromethyl-phenyl)-thiophen-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(3,5-bis-trifluoromethyl-phenyl)-thiophene-2-carbaldehyde in the same manner as in Example 1.

brown powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.58 (1H, d, J = 5.2 Hz), 8.00 (2H, s), 8.00-8.02 (1H, m), 8.10 (1H, s).

[0692]

Example 127

Synthesis of 5-{3-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-thiophen-2-yl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-thiophene-2-carbaldehyde in the same manner as in Example 1.

pale yellow amorphous

^{1}H-NMR (DMSO-d_6) δ: 5.27 (2H, s), 6.89-6.91 (2H, m), 7.04 (1H, d, J = 7.1 Hz), 7.34 (1H, t, J = 7.6 Hz), 7.41 (1H, d, J = 4.7

Hz), 7.94-8.10 (4H, m).

[0693]

Example 128

Synthesis of 5-(4-phenyl-5-trifluoromethyl-thiophen-2-yl)-3H-[1,2,3]triazole-4-carbonitrile

To a solution of 250 mg of (4-phenyl-5-trifluoromethyl-thiophen-2-yl)methanol and 1 ml of TEA in 2 ml of DMSO, 400 mg of SO_3Py complex was added portionwise and the mixture was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with n-hexane. The organic layer was washed with water 3 times and purified by column chromatography on silica gel (n-hexane:AcOEt=9:1 to 2:1) to give 242 mg of colorless oil. The oil was dissolved in 3 ml of toluene, and then 110 mg of AcOK and 185 mg of phenylsulfonylacetonitrile were added to the solution. The mixture was stirred at 100°C for 2 hr, and then concentrated. The residue was dissolved in 3 ml of DMF, and 180 mg of NaN_3 was added to the solution. The mixture was stirred at 110°C for 2 hr. Saturated aqueous NH_4Cl solution was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water (twice) and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue obtained was purified by silica gel flash column chromatography (Hexane:AcOEt=9:1 to 2:1) to give the title compound (198 mg, 62%) as a white powder.

Melting point 140.6-142.1°C

[0694]

Example 129

Synthesis of 5-[5-(3-fluoro-5-trifluoromethyl-phenyl)-thiophen-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-(3-fluoro-5-trifluoromethyl-phenyl)-thiophene-2-carbaldehyde in the same manner as in Example 1.

slightly yellow powder (CH_3CN)

Melting point 189-192°C

[0695]

Example 130

Synthesis of 5-[4-methyl-5-(4-trifluoromethyl-phenyl)-thiophen-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-methyl-5-(4-trifluoromethyl-phenyl)-thiophene-2-carbaldehyde in the same manner as in Example 1.

white powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 2.39 (3H, s), 7.62 (1H, s), 7.80-7.85 (4H, m).

[0696]

Example 131

Synthesis of 5-[5-(4-chloro-benzyl)-thiophen-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-(4-chloro-benzyl)-thiophene-2-carbaldehyde in the same manner as in Example 1.

brown powder (CH_3CN)

Melting point 173-175°C

[0697]

Example 132

Synthesis of 5-[5-(3-trifluoromethyl-phenoxy)-thiophen-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-(3-trifluoromethyl-phenoxy)-thiophene-2-carbaldehyde in the same manner as in Example 1.

brown powder (hexane-*i*-Pr_2O)

^{1}H-NMR (DMSO-d_6) δ: 6.89 (1H, d, J = 4.0 Hz), 7.49 (1H, d, J = 4.0 Hz), 7.52-7.55 (2H, m), 7.58 (1H, d, J = 8.0 Hz), 7.66 (1H, t, J = 8.0 Hz).

[0698]

Example 133

Synthesis of 5-{5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-thiophen-2-yl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-[(*E*)-2-(3-

trifluoromethyl-phenyl)-vinyl]-thiophene-2-carbaldehyde in the same manner as in Example 1.

yellow needles (CH_3CN)

^{1}H-NMR (DMSO-d_6) δ: 7.22 (1H, d, J = 16.4 Hz), 7.39-7.40 (1H, m), 7.60-7.63 (3H, m), 7.76 (1H, d, J = 16.4 Hz), 7.93-7.94 (1H, m), 8.01 (1H, s).

[0699]

Example 134

Synthesis of 5-[4-(3,5-bis-trifluoromethyl-phenyl)-thiophen-3-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-(3,5-bis-trifluoromethyl-phenyl)-thiophene-3-carbaldehyde in the same manner as in Example 1.

pale yellow powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.88 (2H, s), 8.08 (1H, s), 8.17 (1H, d, J = 3.2 Hz), 8.20 (1H, d, J = 3.2 Hz).

[0700]

Example 135

Synthesis of 5-{4-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-yl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 4-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-carbaldehyde in the same manner as in Example 1.

brown powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.25 (1H, d, J = 16.5 Hz), 7.36 (1H, d, J = 16.5 Hz), 7.48 (1H, s), 7.61-7.63 (2H, m), 7.87-7.89 (1H, m), 7.92 (1H, s), 8.19 (1H, s).

[0701]

Example 136

Synthesis of 5-[5-(4-chloro-phenyl)-furan-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-(4-chloro-phenyl)-furan-2-carbaldehyde in the same manner as in Example 1.

pale yellow powder (AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 7.23 (1H, d, J = 3.6 Hz), 7.32 (1H, d, J = 3.6 Hz), 7.59 (2H, d, J = 8.7 Hz), 7.86 (2H, d, J = 8.7 Hz).

[0702]

Example 137

Synthesis of 5-{5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-yl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-carbaldehyde in the same manner as in Example 1.

brown powder (hexane-AcOEt)

^{1}H-NMR (DMSO-d_6) δ: 6.86 (1H, d, J = 3.6 Hz), 7.18 (1H, d, J = 3.6 Hz), 7.24 (1H, d, J = 16.4 Hz), 7.46 (1H, d, J = 16.4 Hz), 7.60-7.65 (2H, m), 7.89-7.93 (1H, m), 7.94 (1H, s).

[0703]

Example 138

Synthesis of 5-[1-(2,4-bis-trifluoromethyl-benzyl)-1H-pyrrol-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 1-(2,4-bis-trifluoromethyl-benzyl)-1H-pyrrole-2-carbaldehyde in the same manner as in Example 1.

white powder (CH_2Cl_2-hexane)

Melting point 120.5-123.0°C

[0704]

Example 139

Synthesis of 5-[5-(3-fluoro-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrrol-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 5-(3-fluoro-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrrole-2-carbaldehyde in the same manner as in Example 2.

brown solid (hexane/AcOEt)

Melting point 164-167°C

[0705]

Example 140

Synthesis of 5-[1-(2,5-bis-trifluoromethyl-phenyl)-1H-pyrrol-3-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 1-(2,5-bis-trifluoromethyl-phenyl)-1H-pyrrole-3-carbaldehyde in the same manner as in Example 2.

pale brown solid (hexane/AcOEt)

Melting point 171-174°C

[0706]

Example 141

Synthesis of 5-[6-(3-trifluoromethyl-phenyl)-pyridin-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 6-(3-trifluoromethyl-phenyl)-pyridine-2-carbaldehyde in the same manner as in Example 1.

brown powder (CH_3CN)

^{1}H-NMR (DMSO-d_6) δ: 7.78 (1H, t, J = 7.8 Hz), 7.85 (1H, d, J = 7.8 Hz), 8.05 (1H, d, J = 7.8 Hz), 8.17 (1H, t, J = 7.9 Hz), 8.30 (1H, d, J = 7.9 Hz), 8.59 (1H, d, J = 7.9 Hz), 8.77 (1H, s).

[0707]

Example 142

Synthesis of 5-{6-[1-(4-trifluoromethyl-benzyloxy)-propyl]-pyridin-2-yl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 6-[1-(4-trifluoromethyl-benzyloxy)-propyl]-pyridine-2-carbaldehyde in the same manner as in Example 2.

dark blue oil

^{1}H-NMR ($CDCl_3$) δ: 0.98 (3H, t, J = 7.4 Hz), 1.87-2.05 (2H, m), 4.50-4.61 (3H, m), 7.45 (2H, d, J = 8.1 Hz), 7.50 (1H, d, J = 7.8 Hz), 7.61 (2H, d, J = 8.1 Hz), 7.93 (1H, t, J = 7.8 Hz), 8.07 (1H, d, J = 7.8 Hz).

[0708]

Example 143

Synthesis of 5-[6-(3-trifluoromethyl-phenyl)-pyridin-3-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 6-(3-trifluoromethyl-phenyl)-pyridine-3-carbaldehyde in the same

manner as in Example 1.

colorless flakes (CH_3CN)

Melting point 201-202°C

[0709]

Example 144

Synthesis of 5-[1-(2,5-bis-trifluoromethyl-phenyl)-piperidin-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 1-(2,5-bis-trifluoromethyl-phenyl)-piperidine-4-carbaldehyde in the same manner as in Example 1.

white powder (AcOEt-hexane)

Melting point 201.4-203.1°C

[0710]

Example 145

Synthesis of 5-[1-(3,4-difluoro-phenyl)-1H-indol-6-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 1-(3,4-difluoro-phenyl)-1H-indole-6-carbaldehyde in the same manner as in Example 1.

pale yellow powder (AcOEt-hexane)

^{1}H-NMR ($CDCl_3$-DMSO-d_6) δ: 6.74 (1H, dd, J = 0.8, 3.3 Hz), 7.26-7.50 (4H, m), 7.79 (2H, s), 8.15 (1H, s).

[0711]

Example 146

Synthesis of 5-[1-(4,4,4-trifluoro-butyl)-1H-indol-6-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 1-(4,4,4-trifluoro-butyl)-1H-indole-6-carbaldehyde in the same manner as in Example 1.

pale brown powder (AcOEt-hexane)

Melting point 197.3-200.3°C

[0712]

Example 147

Synthesis of 5-[6-(4-fluoro-phenyl)-benzofuran-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 6-(4-fluoro-phenyl)-benzofuran-2-carbaldehyde in the same manner as in Example 1.

brown powder (hexane-AcOEt)

Melting point 233°C

[0713]

Example 148

Synthesis of 5-[3-(4-fluoro-phenyl)-benzo[b]thiophen-2-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-(4-fluoro-phenyl)-benzo[b]thiophene-2-carbaldehyde in the same manner as in Example 1.

beige powder (hexane)

^{1}H-NMR (DMSO-d_6) δ: 7.31-7.58 (6H, m), 7.65-7.70 (1H, m), 8.17 (1H, d, J = 7.3 Hz).

[0714]

Example 149

Synthesis of 5-(3'-trifluoromethyl-biphenyl-3-ylmethyl)-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using (3'-trifluoromethyl-biphenyl-3-yl)-acetaldehyde in the same manner as in Example 2.

colorless oil

^{1}H-NMR (DMSO-d_6) δ: 4.32 (2H, s), 7.30 (1H, d, J = 7.7 Hz), 7.49 (1H, t, J = 7.7 Hz), 7.66-7.76 (4H, m), 7.97-7.99 (2H, m).

[0715]

Example 150

Synthesis of 5-{2-[2-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-ethyl}-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 3-[2-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-propionaldehyde in the same manner as in Example 2.

colorless oil

^{1}H-NMR (DMSO-d_6) δ: 2.97-3.07 (4H, m), 5.31 (2H, s), 6.92 (1H, t, J = 7.4 Hz), 7.07-7.10 (2H, m), 7.23-7.27 (1H, m), 7.99 (1H,

d, J = 8.3 Hz), 8.07 (1H, d, J = 8.3 Hz), 8.12 (1H, s), 15.88 (1H, s).

[0716]

Example 151

Synthesis of 5-[1-(2,4,5-trifluoro-benzyl)-piperidin-4-yl]-3H-[1,2,3]triazole-4-carbonitrile

The title compound was obtained using 1-(2,4,5-trifluoro-benzyl)-piperidine-4-carbaldehyde in the same manner as in Example 1.

pale yellow powder (CH_2Cl_2-hexane)

^{1}H-NMR ($CDCl_3$-CD_3OD) δ: 1.8-2.0 (4H, m), 2.23-2.31 (2H, m), 2.9-3.3 (3H, m), 3.62 (2H, s), 6.92-7.00 (1H, m), 7.23-7.26 (1H, m).





















[0717]

The structures of the compounds of Examples 1-151 are shown in the following Table 3. The compounds of Examples in Table 3 are shown as one tautomer, which are not limited, and the other two tautomers are also encompassed therein.





















[0718]

Table 3





















[0719]

Ex. No.	STR	Ex. No.	STR
1		11	
2		12	
3		13	
4		14	
5		15	
6		16	
7		17	
8		18	
9		19	
10		20	





















[0720]

Ex. No.	STR	Ex. No.	STR
21		31	
22		32	
23		33	
24		34	
25		35	
26		36	
27		37	
28		38	
29		39	
30		40	





















[0721]

Ex. No.	STR	Ex. No.	STR
41		51	
42		52	
43		53	
44		54	
45		55	
46		56	
47		57	
48		58	
49		59	
50		60	





















[0722]

Ex. No.	STR	Ex. No.	STR
61		71	
62		72	
63		73	
64		74	
65		75	
66		76	
67		77	
68		78	
69		79	
70		80	





















[0723]

Ex. No.	STR	Ex. No.	STR
81		91	
82		92	
83		93	
84		94	
85		95	
86		96	
87		97	
88		98	
89		99	
90		100	












[0724]

Ex. No.	STR	Ex. No.	STR
101		111	
102		112	
103		113	
104		114	
105		115	
106		116	
107		117	
108		118	
109		119	
110		120	

[0725]

Ex. No.	STR	Ex. No.	STR
121		131	
122		132	
123		133	
124		134	
125		135	
126		136	
127		137	
128		138	
129		139	
130		140	

[0726]


Ex. No.	STR	Ex. No.	STR
141		151	
142			
143			
144			
145			
146			
147			
148			
149			
150			

[0727]

Example 191

Synthesis of 5-[3-(2,2-dimethyl-propoxy)-5-trifluoromethyl-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

[0728]



[0729]

To a solution of 5-[3-(2,2-dimethyl-propoxy)-5-(trifluoromethyl)-phenyl]-2-trityl-2H-[1,2,3]triazole-4-carbonitrile (285 mg, 0.503 mmol) in THF (2 ml) and H_2O (0.5 ml) was added AcOH (1 ml). After being stirred for 6 hr under reflux, the reaction mixture was concentrated, and the residue was purified by flash column chromatography (AcOEt/hexane = 5 % to 50 %) to give a colorless oil (119 mg). The oil was crystallized (hexane/CH_2Cl_2) to give the title compound (86 mg, 53%) as a white powder.


^{1}H-NMR ($CDCl_3$) δ: 1.07 (9H, s), 3.71 (2H, s), 7.26 (1H, s), 7.70 (1H, s), 7.81 (1H, s).

[0730]

Example 316

Synthesis of 5-(6-dimethylamino-3'-trifluoromethyl-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile

[0731]



[0732]

Sodium cyanoborohydride (19.08 mg, 0.304 mmol) was added to a solution of 5-[4-amino-3-[3-(trifluoromethyl)phenyl]-

phenyl]-3H-[1,2,3]triazole-4-carbonitrile (50 mg, 0.152 mmol), formaldehyde (0.5 ml, 18.15 mmol) and AcOH (20 µl, 0.349 mmol) in MeOH (3 ml). After being stirred at room temperature for 2 hr, the reaction mixture was concentrated *in vacuo*. Water was added to the reaction mixture. The reaction mixture was extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous $MgSO_4$, and then concentrated *in vacuo*. The obtained residue was purified by flash column chromatography (hexane/AcOEt = 4/1 to 1/1), and crystallized (AcOEt-hexane) to give the title compound (30 mg, 55%) as a yellow solid.


^{1}H-NMR (DMSO-d_6) δ: 2.58 (6H, s), 7.29 (1H, d, J = 8.6 Hz), 7.72-7.74 (3H, m), 7.83 (1H, dd, J = 2.3, 8.5 Hz), 7.87-7.89 (2H, m).

[0733]

Example 688

Synthesis of 5-{4-amino-3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

[0734]



[0735]

To a solution of {4-(5-cyano-1H-[1,2,3]triazol-4-yl)-2-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-carbamic acid tert-butyl ester (228 mg, 0.501 mmol) in CH_2Cl_2 (4 ml) was added TFA (2 ml). After being stirred at room temperature for 1 hr, the reaction mixture was concentrated *in vacuo*, neutralized with aqueous $NaHCO_3$ solution, and extracted with AcOEt. The organic layer was separated, washed with brine, dried over anhydrous $MgSO_4$, and then concentrated *in vacuo*. The obtained residue was purified by flash column chromatography (hexane/AcOEt = 3/2 to 1/4) and crystallized (IPA-hexane) to give the title compound (90 mg, 51%) as a

yellow solid.


1H-NMR (DMSO-d_6) δ: 6.06-6.40 (2H, br), 6.83 (1H, d, J = 8.5 Hz), 7.15 (1H, d, J = 16.0 Hz), 7.52-7.64 (4H, m), 7.89-8.05 (3H, m).

[0736]

Example 693

Synthesis of N-{4-(5-cyano-1H-[1,2,3]triazol-4-yl)-2-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-methanesulfonamide

[0737]



[0738]

To a solution of 5-{4-amino-3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (40 mg, 0.113 mmol) in CH_2Cl_2 (2 ml) were added pyridine (30 µl) and mesyl chloride (20 µl, 1.292 mmol). The reaction mixture was stirred at room temperature overnight. To the reaction mixture were added pyridine (80 µl) and mesyl chloride (130 µl). After being stirred at room temperature overnight, water was added to the reaction mixture. The reaction mixture was extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous $MgSO_4$ and then concentrated *in vacuo*. To the obtained residue in acetonitrile (2 ml) was added N, N-dimethylethylendiamine (0.5 ml). After being stirred at room temperature overnight, the reaction mixture was concentrated *in vacuo*, the residue was acidified with HCl, and the mixture was extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous $MgSO_4$, and then concentrated *in vacuo*. The suspension of the obtained residue in IPE was filtrated to give the title compound (17 mg, 35%) as a white solid.


^{1}H-NMR (DMSO-d_0) δ: 3.10 (3H, s), 7.39 (1H, d, J = 16.2 Hz), 7.62-7.85 (5H, m), 7.96-8.01 (2H, m), 8.31 (1H, d, J = 2.1 Hz), 9.78 (1H, s).

[0739]

Example 952

Synthesis of 5-{3-chloro-5-[3-(3-trifluoromethyl-phenyl)-oxiran-2-yl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile

[0740]



[0741]

To a solution of 5-{3-Chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile (200 mg, 0.534 mmol) in CH_2Cl_2 (4 ml) and MeOH (0.2 ml) was added 70 % m-chloroperoxybenzoic acid (140 mg). After the reaction mixture was stirred at room temperature for 3 days, 70 % m-chloroperoxybenzoic acid (140 mg) was added thereto. The reaction mixture was stirred at 40°C for 4 hr, then at room temperature for 3 days. To the reaction mixture were added saturated aqueous $NaHCO_3$ solution and $Na_2S_2O_3$. After being stirred for 10 min, the reaction mixture was diluted with AcOEt. The organic layer were separated, washed with diluted aqueous HCl solution and brine, and then dried over anhydrous Na_2SO_4. After diluted with hexane, the organic layer was purified by silica gel column chromatography (hexane/AcOEt = 1/1) to give a pale yellow amorphous solid. The obtained amorphous solid was recrystallized (Et_2O/hexane) to give the title compound (40 mg, 19%) as a white powder.


^{1}H-NMR ($CDCl_3$) δ: 3.94 (1H, d, J = 1.7 Hz), 3.97 (1H, d, J = 1.7 Hz), 7.47 (1H, d, J = 1.7 Hz), 7.49-7.57 (2H, m), 7.59-7.65 (2H, m), 7.88 (1H, t, J = 1.5 Hz), 7.96 (1H, d, J = 1.7 Hz).

[0742]

Example 1110

Synthesis of N-(4-chloro-phenyl)-3-(5-cyano-1H-[1,2,3]triazol-4-yl)-N-methyl-benzamide

[0743]



[0744]

To a solution of 3-(5-cyano-1H-[1,2,3]triazol-4-yl)-benzoic acid (0.37 g, 1.73 mmol) in DMF (7 ml) were added 4-chloro-N-methylanilene (0.29 g, 2.07 mmol), WSC (0.40 g, 2.07 mmol) and HOBt (0.32 g, 2.09 mmol). The reaction mixture was stirred at room temperature for 3 hr, then at 40°C for 4 hr. The reaction mixture was concentrated *in vacuo*, and the residue was diluted with CH_2Cl_2 and water. After the reaction mixture was acidified with HCl, the organic layer was separated, washed with water and brine, dried over anhydrous Na_2SO_4, and then concentrated *in vacuo*. The obtained residue was purified by silica gel thin layer chromatography (hexane/AcOEt = 1/2) and recrystallized (Et_2O - hexane) give the title compound (87 mg, 21%) as a beige powder.


Melting point 185-189°C

[0745]

Example 1145

Synthesis of 5-[3-(3,4-dichloro-benzenesulfonylmethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile

[0746]



[0747]


To a solution of 5-[3-[[(3,4-dichlorophenyl)sulfanyl]-methyl]-phenyl]-3-trityl-3H-[1,2,3]triazole-4-carbonitrile (102.6 mg, 1.7 mmol) in CH_2Cl_2 (2 ml) was added 70% *m*-chloroperoxybenzoic acid (100 mg) at 0°C. The reaction mixture was stirred at room temperature for 3 hr. To a reaction mixture were added saturated aqueous $NaHCO_3$ solution and $Na_2S_2O_3$. After being stirred for 10 min, the organic layer was purified by silica gel column chromatography (CH_2CH_2) to give a white solid. The white solid was stirred in TFA (4 ml) for 7 hr. The reaction mixture was concentrated, and the residue was stirred in water. The precipitate was collected by filtration. The obtained white powder was recrystallized (AcOEt/hexane) to give the title compound (52 mg, 77%) as a white powder.
^{1}H-NMR ($CDCl_3$-DMSO-d_6) δ: 4.42 (2H, s), 7.28 (1H, d, J = 7.8 Hz), 7.45-7.52 (2H, m), 7.57 (1H, d, J = 8.4 Hz), 7.70-7.75 (2H, m), 8.01 (1H, d, J = 7.8 Hz).

[0748]

Example 1473

Synthesis of 5-{5-[4-(1-hydroxy-ethyl)-phenyl]-thiophen-2-yl}-3H-[1,2,3]triazole-4-carbonitrile

[0749]



[0750]

To a solution of 5-[5-(4-acetyl-phenyl)-thiophen-2-yl]-3H-[1,2,3]triazole-4-carbonitrile (0.15 g, 0.51 mmol) in EtOH (4.5 ml) was added $NaBH_4$ (58 mg, 1.53 mmol) at 0°C. The reaction mixture was stirred at room temperature for 1.5 hr. After water was added, the reaction mixture was acidified with HCl, and extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous $MgSO_4$ and then concentrated *in vacuo*. The suspension of the obtained residue in acetonitrile was filtrated to give the title compound (86 mg, 57%) as a yellow powder.


^{1}H-NMR (DMSO-d_6) δ: 1.33 (3H, d, J = 6.4 Hz), 4.71-4.77 (1H, m), 5.22 (1H, brs), 7.40 (2H, d, J = 8.3 Hz), 7.51 (1H, d, J = 3.8 Hz), 7.54 (1H, d, J = 3.8 Hz), 7.65 (2H, d, J = 8.3 Hz).

[0751]

Example 1779

Synthesis of 5-[3-(4-trifluoromethyl-benzyloxy)-benzoyl]-3H-[1,2,3]triazole-4-carbonitrile

[0752]



[0753]

To a solution of 1-(3-(4-(trifluoromethyl)benzyloxy)phenyl)ethanone (589 mg, 2.00 mmol) in DMSO (3 ml) was added 48% HBr (0.91 ml, 8.00 mmol). The reaction mixture was stirred at 70°C for 16 hr. The reaction was quenched by addition of water, and the mixture was extracted with AcOEt. The combined organic layers were washed with water and brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (hexane/AcOEt 4/1 to 3/2) to give a mixture of 2,2-dihydroxy-1-(3-(4-(trifluoromethyl)benzyloxy)phenyl)ethanone (414 mg) as a yellow oil.


To a solution of 2,2-dihydroxy-1-(3-(4-(trifluoromethyl)benzyloxy)phenyl)ethanone (414 mg) in toluene (3 ml) were added phenylsulfonylacetonitrile (241 mg, 1.33 mmol) and Potassium acetate (12.45 mg, 0.13 mmol). The reaction mixture was stirred at 30°C for 2 days. NMP and NaN_3 were added to the reaction mixture, and the reaction was stirred at 30°C for 15 hr. The reaction was quenched by addition of 5% $NaHCO_3$ aq. and then washed with toluene. The aqueous solution was acidified with 1N HCl aq. and extracted with TBME. The combined organic layers were washed with water and brine, filtered through a silica gel short column, and concentrated *in vacuo*. The yellow solid was recrystallized (hexane/CH_2Cl_2) to give the title compound (102 mg, 22%) as a light yellow solid.

[0754]

Example 1802

Synthesis of [4-(5-cyano-1H-[1,2,3]triazol-4-yl)-benzyl]-triphenyl-phosphonium chloride

[0755]



[0756]

To a solution of 5-[4-(chloromethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (63.6 mg, 0.291 mmol) in toluene (1 ml) was added triphenylphosphine (500 mg, 1.906 mmol). The reaction mixture was stirred at 110°C for 5 hr. After cooling to room temperature, the precipitate was collected by filtration. The obtained solid was recrystallized (MeOH/IPA) to give the title compound (100 mg, 71%) as a pale yellow powder.

^{1}H-NMR (DMSO-d_6) δ: 5.29 (2H, d, J = 16.1 Hz), 7.18 (2H, dd, J

= 2.3, 8.4 Hz), 7.68-7.80 (14H, m), 7.89-7.95 (3H, m).

[0757]

The following compounds were synthesized in the same manner as in the above-mentioned Examples. The structures and physical property thereof (melting point, ^{1}H-NMR data mass spectrum etc.) are shown in the following Table 4. The "ref." in Table 4 means "Example No." or "Reference Example No." which the compound was synthesized in reference to.

[0758]

Table 4









Ex. No.	STR	m.p.	ref.
152		112-114	Ex.1
153		183-184	Ex. 1
154		79-81	Ex. 1
155		124-126	Ex. 1
156		180-183	Ex. 1

Ex. No.	STR	m.p.	ref.
157		167-171	Ex. 1
158		209-210	Ex. 1
159		202-203	Ex. 1
160		113-115	Ex. 1
161		115-118	Ex. 1








Ex. No.	STR	1H-NMR	ref.
162		1H-NMR (DMSO-d6) δ: 7.16 (1H, t, J = 74.5 Hz), 7.34 (2H, s), 7.51 (1H, s), 10.51 (1H, s).	Ex. 1
163		1H-NMR (CDCl3) δ: 7.92 (1H, d, J = 8.6 Hz), 8.01 (1H, d, J = 8.6 Hz), 8.06 (1H, s).	Ex. 1
164		1H-NMR (DMSO-d6) δ: 7.77-7.84 (1H, m), 8.23-8.28 (2H, m).	Ex. 1
165		1H-NMR (CDCl3) δ: 6.9-7.0 (1H, m), 7.1-7.2 (2H, m), 7.2-7.3 (2H, m), 7.4-7.5 (3H, m), 8.20 (1H, d, J = 7.4 Hz), 13.0 (1H, br.).	Ex. 128
166		1H-NMR (CDCl3) δ: 2.99-3.14 (4H, m), 7.18-7.34 (5H, m), 7.53 (1H, s), 8.00 (1H, s), 8.10 (1H, s).	Ex. 7
167		1H-NMR (CDCl3) δ: 7.92 (1H, s), 8.24 (1H, s), 8.37 (1H, s).	Ex. 1
168		1H-NMR (DMSO-d6) δ: 7.22 (1H, s), 7.59 (1H, s), 7.63 (1H, s), 10.72 (1H, s).	Ex. 1








The compounds of Examples in Table 4 are shown as one tautomer, which are not limited, and the other two tautomers are also encompassed therein.

[0760]








Ex. No.	STR	1H-NMR	ref.
169		1H-NMR (CDCl3) δ: 1.07-1.34 (6H, m), 1.70-1.91 (5H, m), 3.87 (2H, d, J = 6.0 Hz), 7.24 (1H, s), 7.69 (1H, s), 7.80 (1H, s).	Ex. 2
170		1H-NMR (CDCl3) δ: 0.42-0.45 (2H, m), 0.69-0.75 (2H, m), 1.32-1.37 (1H, m), 3.96 (2H, d, J = 7.0 Hz), 7.28 (1H, s), 7.74 (1H, s), 7.83 (1H, s).	Ex. 2
171		1H-NMR (CDCl3) δ: 0.99-1.07 (2H, m), 1.22-1.32 (3H, m), 1.56-1.82 (8H, m), 4.14 (2H, t, J = 6.6 Hz), 7.27 (1H, s), 7.72 (1H, s), 7.83 (1H, s).	Ex. 2
172		1H-NMR (CDCl3) δ: 0.99 (3H, t, J = 7.4 Hz), 1.41-1.65 (2H, m), 1.86-1.91 (1H, m), 2.05-2.13 (1H, m), 5.23-5.27 (1H, m), 7.26-7.43 (6H, m), 7.66 (1H, s), 7.75 (1H, s).	Ex. 2
173		1H-NMR (DMSO-d6) δ: 1.06-1.34 (7H, m), 1.59-1.91 (4H, m), 3.82 (2H, d, J = 6.0 Hz), 7.03 (1H, d, J = 8.0 Hz), 7.39-7.54 (3H, m).	Ex. 1
174		1H-NMR (DMSO-d6) δ: 1.25-1.63 (6H, m), 1.73-2.07 (4H, m), 4.40-4.44 (1H, m), 7.12-7.15 (1H, m), 7.41-7.53 (3H, m).	Ex. 1
175		1H-NMR (CDCl3) δ: 1.50-1.80 (8H, m), 4.07-4.15 (1H, m), 4.59 (2H, s), 7.44-7.53 (2H, m), 7.83-7.92 (1H, m), 7.98 (1H, s), 13.0 (1H, br.).	Ex. 1
176		1H-NMR (CDCl3) δ: 1.16-1.61 (6H, m), 1.72-1.88 (2H, m), 2.00-2.11 (2H, m), 3.45-3.58 (1H, m), 4.70 (2H, s), 7.41-7.51 (2H, m), 7.80-7.89 (1H, m), 8.01 (1H, s), 13.0 (1H, br.).	Ex. 1
177		1H-NMR (CDCl3) δ: 1.38-2.01 (14H, m), 3.62-3.73 (1H, m), 4.64 (2H, s), 7.42-7.51 (2H, m), 7.81-7.90 (1H, m), 7.99 (1H, s), 13.0 (1H, br.).	Ex. 1
178		1H-NMR (CDCl3) δ: 1.20-1.34 (2H, m), 1.48-1.86 (6H, m), 2.20-2.32 (1H, m), 3.44 (2H, d, J = 7.1 Hz), 4.63 (2H, s), 7.45-7.55 (2H, m), 7.86-7.94 (1H, m), 7.99 (1H, s), 13.0 (1H, br.).	Ex. 1
179		1H-NMR (CDCl3) δ: 1.33-1.48 (2H, m), 1.60-1.68 (4H, m), 1.84-1.91 (2H, m), 2.38-2.44 (1H, m), 3.95 (2H, t, J = 6.9 Hz), 7.25 (1H, s), 7.69 (1H, s), 7.80 (1H, s).	Ex. 2
180		1H-NMR (CDCl3) δ: 1.20-1.35 (2H, m), 1.39-1.76 (12H, m), 1.82-1.97 (1H, m), 3.32 (2H, d, J = 6.8 Hz), 4.60 (2H, s), 7.46-7.55 (2H, m), 7.85-7.92 (1H, m), 7.96 (1H, s), 12.8 (1H, br.).	Ex. 1
181		1H-NMR (DMSO-d6) δ: 0.33-0.37 (2H, m), 0.57-0.61 (2H, m), 1.23-1.29 (1H, m), 3.84-3.91 (2H, m), 7.11-7.15 (1H, m), 7.41-7.59 (3H, m).	Ex. 1
182		1H-NMR (CDCl3) δ: 1.40-1.83 (14H, m), 2.05-2.09 (1H, m), 3.84 (2H, d, J = 6.6 Hz), 7.26 (1H, s), 7.70 (1H, s), 7.81 (1H, s).	Ex. 2
183		1H-NMR (CDCl3) δ: 1.65-1.99 (8H, m), 4.85-4.90 (1H, m), 7.22 (1H, s), 7.68 (1H, s), 7.77 (1H, s).	Ex. 2
184		1H-NMR (CDCl3) δ: 1.33-1.47 (3H, m), 1.56-1.63 (3H, m), 1.82-1.86 (2H, m), 2.02-2.05 (2H, m), 4.36-4.41 (1H, m), 7.24 (1H, s), 7.71 (1H, s), 7.78 (1H, s).	Ex. 7







[0761]









Ex. No.	STR	1H-NMR	ref.
185		1H-NMR (CDCl3) δ: 3.16 (2H, t, J = 6.9 Hz), 4.30 (2H, t, J = 6.9 Hz), 7.26-7.37 (6H, m), 7.69 (1H, s), 7.80 (1H, s).	Ex. 1
186		1H-NMR (CDCl3) δ: 0.99 (6H, d, J = 6.6 Hz), 1.70-1.92 (3H, m), 4.11 (2H, t, J = 6.5 Hz), 7.24 (1H, s), 7.70 (1H, s), 7.81 (1H, s).	Ex. 2
187		1H-NMR (CDCl3) δ: 1.07 (6H, d, J = 6.7 Hz), 2.10-2.19 (1H, m), 3.84 (2H, d, J = 6.5 Hz), 7.26 (1H, s), 7.70 (1H, s), 7.81 (1H, s).	Ex. 2
188		1H-NMR (CDCl3) δ: 2.12-2.21 (2H, m), 2.82-2.87 (2H, m), 4.06-4.10 (2H, m), 7.18-7.33 (6H, m), 7.71 (1H, s), 7.82 (1H, s).	Ex. 2
189		1H-NMR (CDCl3) δ: 2.36-2.42 (2H, m), 3.30-3.41 (1H, m), 4.23-4.27 (2H, m), 7.26 (1H, s), 7.72 (1H, s), 7.89 (1H, s).	Ex. 2
190		1H-NMR (CDCl3) δ: 4.49 (2H, q, J = 7.9 Hz), 7.33 (1H, s), 7.78 (1H, s), 7.92 (1H, s).	Ex. 2
192		1H-NMR (CDCl3) δ: 2.02-2.15 (2H, m), 2.25-2.40 (2H, m), 2.41 (3H, s), 4.08 (2H, t, J = 5.9 Hz), 6.86 (1H, s), 7.29 (1H, s), 7.38 (1H, s), 12.2 (1H, br.).	Ref. Ex. 82, Ex. 1

Ex. No.	STR	1H-NMR	ref.
193		1H-NMR (CDCl3) δ: 2.39 (3H, s), 3.55 (3H, s), 3.83-3.87 (2H, m), 4.19-4.23 (2H, m), 6.83 (1H, s), 7.36 (2H, br.s), 12.7 (1H, br.).	Ex. 1
194		1H-NMR (CDCl3) δ: 2.06-2.11 (2H, m), 2.30-2.38 (2H, m), 3.87 (3H, s), 4.08 (2H, t, J = 5.9 Hz), 6.58 (1H, s), 7.11 (2H, bs).	Ex. 2
195		1H-NMR (CDCl3) δ: 2.04-2.17 (2H, m), 2.25-2.43 (2H, m), 4.09 (2H, t, J = 6.0 Hz), 7.03 (1H, t, J = 2.0 Hz), 7.43 (1H, s), 7.59 (1H, s), 12.0 (1H, br.).	Ex. 1
196		1H-NMR (CDCl3) δ: 0.76-0.80 (2H, m), 1.02-1.07 (2H, m), 1.95-2.02 (1H, m), 7.20-7.22 (1H, m), 7.41 (1H, t, J = 7.8 Hz), 7.65 (1H, s), 7.72 (1H, d, J = 7.8 Hz).	Ex. 2
197		1H-NMR (DMSO-d6) δ: 2.92-3.00 (4H, m), 7.16-7.29 (5H, m), 7.42 (1H, d, J = 7.7 Hz), 7.51 (1H, t, J = 7.7 Hz), 7.71 (1H, d, J = 7.7 Hz), 7.78 (1H, s).	Ex. 1
198		1H-NMR (DMSO-d6) δ: 0.87-0.90 (3H, m), 1.29-1.34 (4H, m), 1.40-1.46 (2H, m), 1.73-1.80 (2H, m), 4.14 (2H, t, J = 6.5 Hz), 7.45 (1H, s), 7.70 (1H, s), 7.75 (1H, s).	Ex. 2
199		1H-NMR (CDCl3) δ: 1.30 (3H, t, J = 7.0 Hz), 3.62 (2H, q, J = 7.0 Hz), 4.58 (2H, s), 7.64 (1H, s), 7.92 (1H, s), 8.03 (1H, s).	Ex. 1



[0762]

Ex. No.	STR	m.p.	ref.
200		119-121	Ex. 1
201		223-225	Ex. 1
202		173-175	Ex. 1
203		197-198	Ex. 1
204		197-198	Ex. 1
205		175-176	Ex. 1
206		104-108	Ex. 1















Ex. No.	STR	m.p.	ref.
207		167-169	Ex. 1
208		193-194	Ex. 1
209		142.9-143.5	Ex. 1
210		128-130	Ex. 1
211		142-149	Ex. 1
212		153-160	Ex. 1

Ex. No.	STR	1H-NMR	ref.
213		1H-NMR (DMSO-d6) δ: 7.59 (2H, d, J = 8.6 Hz), 7.72 (1H, t, J = 7.8 Hz), 7.77 (2H, d, J = 8.6 Hz), 7.86-7.90 (2H, m), 8.16 (1H, s).	Ref. Ex. 271, Ex. 1
214		1H-NMR (CDCl3) δ: 7.41-7.67 (3H, m), 7.73-7.75 (1H, m), 7.83 (1H, d, J = 7.7 Hz), 7.89 (1H, s), 8.03 (1H, d, J = 7.7 Hz), 8.21 (1H, s).	Ref. Ex. 271, Ex. 1
215		1H-NMR (CDCl3) δ: 7.62-7.66 (1H, m), 7.78-7.86 (2H, m), 7.95-7.99 (3H, m), 8.09-8.11 (1H, m).	Ex. 1
216		1H-NMR (DMSO-d6) δ: 7.44-7.58 (3H, m), 7.74-7.79 (2H, m), 8.02-8.08 (2H, m), 8.15-8.18 (1H, m).	Ex. 1
217		1H-NMR (DMSO-d6) δ: 2.29 (3H, s), 7.13-7.17 (1H, m), 7.21-7.24 (1H, m), 7.30-7.33 (1H, m), 7.55 (1H, d, J = 7.8 Hz), 7.70 (1H, t, J = 7.8 Hz), 7.83 (1H, s), 7.90 (1H, d, J = 7.8 Hz).	Ex. 1
218		1H-NMR (CDCl3) δ: 7.4-7.6 (3H, m), 7.6-7.7 (2H, m), 7.96 (1H, s), 8.21 (1H, s), 8.42 (1H, s).	Ex. 1
219		1H-NMR (DMSO-d6) δ: 7.58-7.62 (2H, m), 7.22 (1H, t, J = 7.8 Hz), 7.84-7.90 (3H, m), 8.17 (1H, s).	Ex. 1
220		1H-NMR (DMSO-d6) δ: 7.75-7.78 (2H, m), 7.95-8.03 (4H, m), 8.27 (1H, s).	Ex. 1














[0763]

Ex. No.	STR	1H-NMR	ref.
221		1H-NMR (DMSO-d6) δ: 3.90 (3H, s), 7.76 (1H, t, J = 7.8 Hz), 7.90-7.96 (4H, m), 8.10 (2H, d, J = 8.3 Hz), 8.23 (1H, s).	Ex. 1
222		1H-NMR (CDCl3) δ: 7.45-7.50 (2H, m), 7.60-7.65 (2H, m), 7.92 (1H, s), 8.24 (1H, s), 8.39 (1H, s).	Ex. 1
223		1H-NMR (DMSO-d6) δ: 7.58-7.61 (2H, m), 7.67-7.69 (1H, m), 7.76-7.82 (3H, m), 8.02 (1H, s).	Ex. 1
224		1H-NMR (CDCl3) δ: 7.36-7.42 (3H, m), 7.52-7.55 (1H, m), 7.85 (1H, s), 8.27 (1H, s), 8.29 (1H, s), 12.1 (1H, br.).	Ex. 1
225		1H-NMR (CDCl3) δ: 7.33-7.40 (2H, m), 7.56 (1H, d, J = 1.7 Hz), 7.81 (1H, s), 8.26 (1H, s), 8.28 (1H, s), 12.0 (1H, br.).	Ex. 1
226		1H-NMR (CDCl3) δ: 7.23-7.26 (1H, m), 7.30-7.33 (1H, m), 7.40-7.45 (1H, m), 7.52-7.56 (1H, m), 7.95 (1H, s), 8.26 (1H, s), 8.40 (1H, s).	Ex. 1
227		1H-NMR (DMSO-d6) δ: 7.48-7.51 (2H, m), 7.76-7.77 (2H, m), 7.97 (1H, m), 8.07 (1H, s).	Ex. 1
228		1H-NMR (DMSO-d6) δ: 7.47 (1H, t, J = 7.3 Hz), 7.55 (2H, t, J = 7.3 Hz), 7.68 (1H, d, J = 9.1 Hz), 7.77-7.79 (3H, m), 8.04 (1H, s).	Ex. 1
229		1H-NMR (DMSO-d6) δ: 7.47 (1H, t, J = 7.4 Hz), 7.55 (2H, t, J = 7.4 Hz), 7.78 (2H, d, J = 7.4 Hz), 7.90 (1H, s), 7.94 (1H, s), 8.13 (1H, s).	Ex. 1
230		1H-NMR (CDCl3) δ: 7.43-7.45 (2H, m), 7.54-7.57 (1H, m), 7.64 (1H, s), 7.93 (1H, s), 8.26 (1H, s), 8.39 (1H, s).	Ex. 1
231		1H-NMR (CDCl3) δ: 7.27-7.51 (3H, m), 7.89 (1H, s), 8.25 (1H, s), 8.36 (1H, s).	Ex. 1
232		1H-NMR (CDCl3) δ: 6.98-7.06 (2H, m), 7.48-7.56 (1H, m), 7.91 (1H, s), 8.27 (1H, s), 8.36 (1H, s).	Ex. 1
233		1H-NMR (DMSO-d6) δ: 7.77-7.85 (2H, m), 7.94-7.96 (1H, m), 8.05-8.12 (3H, m), 8.19 (1H, s).	Ex. 1
234		1H-NMR (CDCl3) δ: 7.15-7.18 (2H, m), 7.21-7.25 (4H, m), 7.33-7.37 (1H, m), 7.45-7.50 (4H, m), 7.70-7.83 (2H, m), 12.0 (1H, br.).	Ex. 1

[0764]

Ex. No.	STR	1H-NMR	ref.
235		1H-NMR (DMSO-d6) δ: 7.68-7.76 (2H, m), 7.92-7.96 (2H, m), 8.08-8.13 (2H, m), 8.21 (1H, s).	Ex. 1
236		1H-NMR (DMSO-d6) δ: 7.12 (1H, t, J = 55.7 Hz), 7.56 (1H, t, J = 8.8 Hz), 7.72-7.85 (4H, m), 7.96-8.10 (1H, m), 8.10 (1H, s).	Ex. 1
237		1H-NMR (DMSO-d6) δ: 6.89 (1H, t, J = 54.4 Hz), 7.36-7.38 (1H, m), 7.46-7.50 (1H, m), 7.59 (1H, d, J = 7.8 Hz), 7.75 (1H, t, J = 7.8 Hz), 7.84-7.87 (1H, m), 7.90 (1H, s), 7.99 (1H, d, J = 8.0 Hz).	Ex. 1
238		1H-NMR (DMSO-d6) δ: 2.47 (3H, s), 7.42 (1H, s), 7.69 (1H, s), 7.82 (1H, s), 7.85 (1H, s), 8.07 (1H, d, J = 8.3 Hz), 8.15 (1H, d, J = 8.3 Hz).	Ex. 1
239		1H-NMR (DMSO-d6) δ: 7.77-7.79 (1H, m), 8.06 (1H, t, J = 9.9 Hz), 8.19-8.21 (2H, m), 8.48 (2H, s).	Ex. 1
240		1H-NMR (DMSO-d6) δ: 7.62-7.67 (2H, m), 7.85 (1H, m), 7.93 (1H, s), 7.94-7.96 (1H, m), 8.20 (1H, s).	Ex. 1
241		1H-NMR (DMSO-d6) δ: 7.78-7.86 (2H, m), 7.89 (1H, s), 8.02 (1H, s), 8.12 (1H, d, J = 7.8 Hz), 8.15 (1H, s), 8.28 (1H, s).	Ex. 1
242		1H-NMR (DMSO-d6) δ: 7.82 (1H, d, J = 8.8 Hz), 7.90 (1H, s), 8.04 (2H, s), 8.07 (1H, s), 8.31 (1H, s)	Ex. 1
243		1H-NMR (DMSO-d6) δ: 7.75-7.90 (4H, m), 8.08 (1H, s).	Ex. 1
244		1H-NMR (DMSO-d6) δ: 7.93 (1H, s), 8.19 (1H, s), 8.22 (1H, s), 8.36 (1H, s), 8.51 (2H, s),	Ex. 1
245		1H-NMR (DMSO-d6) δ: 7.47 (1H, d, J = 8.2 Hz), 7.68 (1H, t, J = 8.0 Hz), 7.73 (1H, s), 7.75 (1H, s), 7.81 (1H, d, J = 8.2 Hz), 7.83 (1H, s), 8.19 (1H, s).	Ex. 1
246		1H-NMR (DMSO-d6) δ: 7.48 (1H, d, J = 8.3 Hz), 7.68 (1H, t, J = 8.3 Hz), 7.71-7.73 (1H, m), 7.79 (1H, s), 7.83-7.86 (2H, m), 8.07 (1H, s).	Ex. 1
247		1H-NMR (DMSO-d6) δ: 7.48-7.66 (5H, m), 7.88 (1H, s), 7.97 (1H, s).	Ex. 1
248		1H-NMR (DMSO-d6) δ: 7.80 (1H, d, J = 8.6 Hz), 7.97 (1H, s), 8.02 (1H, s), 8.04-8.06 (1H, m), 8.12 (1H, s), 8.22 (1H, s).	Ex. 1

[0765]

Ex. No.	STR	1H-NMR	ref.
249		1H-NMR (DMSO-d6) δ: 7.58 (1H, t, J = 7.8 Hz), 7.89-7.91 (2H, m), 7.98-8.02 (1H, m), 8.01 (1H, s), 8.05 (1H, s).	Ex. 1
250		1H-NMR (DMSO-d6) δ: 7.73 (1H, s), 7.84 (1H, s), 7.94 (1H, s), 8.04 (1H, s), 8.09 (1H, d, J = 8.2 Hz), 8.16 (1H, d, J = 8.2 Hz).	Ex. 1
251		1H-NMR (DMSO-d6) δ: 2.30 (3H, s), 7.15-7.19 (1H, m), 7.24-7.27 (1H, m), 7.36-7.39 (1H, m), 7.59 (1H, s), 7.85-7.89 (2H, m).	Ex. 1
252		1H-NMR (DMSO-d6) δ: 7.93 (2H, d, J = 8.2 Hz), 8.07 (2H, d, J = 8.2 Hz), 8.25 (1H, s), 8.27 (1H, s), 8.51 (1H, s).	Ex. 1
253		1H-NMR (DMSO-d6) δ: 7.73-7.77 (1H, m), 7.78-7.82 (1H, m), 7.94-7.98 (1H, m), 8.01-8.07 (2H, m), 8.14 (1H, t, J = 1.4 Hz).	Ex. 1
254		1H-NMR (DMSO-d6) δ: 7.52-7.57 (1H, m), 7.74 (1H, s), 7.80-7.84 (1H, m), 7.93 (1H, s), 8.09 (1H, d, J = 8.4 Hz), 8.16 (1H, d, J = 8.4 Hz).	Ex. 1
255		1H-NMR (DMSO-d6) δ: 7.66 (1H, d, J = 9.5 Hz), 7.73-7.89 (3H, m), 7.94 (1H, s).	Ex. 1
256		1H-NMR (DMSO-d6) δ: 7.82 (1H, d, J = 8.6 Hz), 8.10-8.14 (2H, m), 8.25 (1H, s), 8.38 (1H, s), 8.54 (1H, s).	Ex. 1
257		1H-NMR (CDCl3) δ: 7.41 (1H, d, J = 7.3 Hz), 7.59-7.67 (2H, m), 7.76 (1H, s), 7.84 (1H, d, J = 7.3 Hz), 8.20 (1H, m), 8.33 (1H, s).	Ex. 1
258		1H-NMR (DMSO-d6) δ: 6.68-7.01 (1H, m), 7.40-7.41 (1H, m), 7.62-7.86 (5H, m), 8.05-8.06 (1H, m).	Ex. 1
259		1H-NMR (CDCl3) δ: 7.62-7.73 (2H, m), 7.84-7.89 (2H, m), 7.95 (1H, s), 8.28 (1H, s), 8.42 (1H, s).	Ex. 1
260		1H-NMR (DMSO-d6) δ: 7.90-8.04 (6H, m), 8.26 (1H, s).	Ex. 1
261		1H-NMR (DMSO-d6) δ: 7.73-7.76 (1H, m), 7.85 (1H, s), 7.91 (2H, d, J = 8.1 Hz), 8.01 (2H, d, J = 8.1 Hz), 8.09 (1H, s).	Ex. 1
262		1H-NMR (DMSO-d6) δ: 7.34 (1H, t, J = 73.7 Hz), 7.35 (2H, d, J = 8.6 Hz), 7.83 (2H, s), 7.86 (2H, d, J = 8.6 Hz), 8.20 (1H, s).	Ex. 1

[0766]

Ex. No.	STR	1H-NMR	ref.
263		1H-NMR (DMSO-d6) δ: 7.54 (2H, d, J = 8.0 Hz), 7.69-7.82 (2H, m), 7.89-7.92 (2H, m), 8.03-8.04 (1H, m).	Ex. 1
264		1H-NMR (DMSO-d6) δ: 7.55 (2H, d, J = 8.0 Hz), 7.82-7.98 (4H, m), 8.22 (1H, s).	Ex. 1
265		1H-NMR (DMSO-d6) δ: 7.46 (1H, t, J = 73.5 Hz), 7.55 (2H, d, J = 8.1 Hz), 7.68-7.70 (2H, m), 7.91 (2H, d, J = 8.8 Hz), 8.06 (1H, s).	Ex. 1
266		1H-NMR (DMSO-d6) δ: 7.48 (1H, t, J = 73.5 Hz), 7.64-7.86 (4H, m), 7.94-8.09 (3H, m).	Ex. 1
267		1H-NMR (DMSO-d6) δ: 7.30 (1H, d, J = 8.1 Hz), 7.38 (1H, t, J = 74.0 Hz), 7.58-7.67 (3H, m), 7.86 (1H, s), 7.94 (1H, s), 8.23 (1H, s).	Ex. 1
268		1H-NMR (DMSO-d6) δ: 7.90 (2H, d, J = 8.4 Hz), 7.97-8.05 (4H, m), 8.18 (1H, s).	Ex. 1
269		1H-NMR (DMSO-d6) δ: 7.45 (1H, t, J = 73.5 Hz), 7.60-7.69 (4H, m), 7.81 (2H, d, J = 8.5 Hz), 8.04-8.05 (1H, m).	Ex. 1
270		1H-NMR (DMSO-d6) δ: 6.65 (1H, t, J = 73.5 Hz), 7.32 (1H, s), 7.46 (1H, s), 7.47-7.63 (3H, m), 7.78 (1H, s), 8.08 (1H, s).	Ex. 1
271		1H-NMR (DMSO-d6) δ: 7.49 (1H, t, J = 73.5 Hz), 7.74 (1H, s), 7.93 (1H, s), 8.20 (2H, s), 8.47 (2H, s).	Ex. 1
272		1H-NMR (DMSO-d6) δ: 7.47 (1H, t, J = 73.4 Hz), 7.54-7.72 (3H, m), 8.02-8.05 (2H, m), 8.15 (1H, s).	Ex. 1
273		1H-NMR (DMSO-d6) δ: 7.41 (1H, t, J = 73.2 Hz), 7.45 (1H, s), 7.77-7.79 (2H, m), 7.92 (1H, s), 8.08-8.18 (2H, m).	Ex. 1
274		1H-NMR (DMSO-d6) δ: 7.48 (1H, d, J = 8.1 Hz), 7.68 (1H, t, J = 8.1 Hz), 7.80 (1H, s), 7.84 (1H, d, J = 4.7 Hz), 7.94 (1H, s), 8.03 (1H, s), 8.17 (1H, s).	Ex. 1
275		1H-NMR (DMSO-d6) δ: 7.99 (1H, s), 8.20 (1H, s), 8.23 (1H, s), 8.28 (1H, s), 8.48 (2H, s).	Ex. 1
276		1H-NMR (DMSO-d6) δ: 7.71-7.75 (2H, m), 7.94-8.16 (3H, m), 8.16 (1H, s).	Ex. 1

[0767]



Ex. No.	STR	1H-NMR	ref.
277		1H-NMR (DMSO-d6) δ: 7.93 (1H, d, J = 11.1 Hz), 7.96 (1H, s), 8.07-8.08 (2H, m), 8.18-8.20 (2H, m).	Ex. 1
278		1H-NMR (DMSO-d6) δ: 6.68-7.02 (1H, m), 7.45 (2H, d, J = 8.7 Hz), 7.86-7.94 (4H, m), 8.12 (1H, t, J = 1.5 Hz)	Ex. 1
279		1H-NMR (DMSO-d6) δ: 7.70 (1H, t, J = 10.1 Hz), 7.94 (1H, s), 8.07 (1H, s), 8.14-8.16 (3H, m).	Ex. 1
280		1H-NMR (DMSO-d6) δ: 7.33 (1H, t, J = 73.9 Hz), 7.34 (2H, d, J = 8.6 Hz), 7.84 (2H, d, J = 8.6 Hz), 7.90 (1H, s), 7.95 (1H, s), 8.11 (1H, s).	Ex. 1
281		1H-NMR (DMSO-d6) δ: 7.47 (1H, d, J = 8.0 Hz), 7.68 (1H, t, J = 8.0 Hz), 7.85-7.88 (2H, m), 8.19 (1H, s), 8.24 (1H, s), 8.46 (1H, s).	Ex. 2
282		1H-NMR (DMSO-d6) δ: 7.85 (1H, t, J = 51.8 Hz), 7.47 (2H, d, J = 8.5 Hz), 7.83-7.91 (4H, m), 8.21 (1H, s).	Ex. 1
283		1H-NMR (DMSO-d6) δ: 7.70 (1H, s), 7.79-7.83 (2H, m), 8.05-8.06 (1H, m), 8.19-8.22 (2H, m).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
284		1H-NMR (DMSO-d6) δ: 2.33 (3H, s), 7.31-7.47 (3H, m), 7.68 (1H, s), 7.80 (1H, m), 7.95 (1H, s).	Ex. 1
285		1H-NMR (DMSO-d6) δ: 7.65 (1H, s), 7.82 (1H, d, J = 8.5 Hz), 7.91 (1H, s), 7.98 (1H, s), 8.21-8.23 (2H, m).	Ex. 1
286		1H-NMR (DMSO-d6) δ: 2.51 (3H, s), 7.42-7.45 (1H, m), 7.64-7.80 (5H, m), 8.00 (1H, s).	Ex. 1
287		1H-NMR (DMSO-d6) δ: 2.48 (3H, s), 6.66-7.03 (1H, m), 7.43 (2H, d, J = 8.6 Hz), 7.71 (2H, s), 7.80-7.84 (2H, m), 7.97 (1H, s).	Ex. 1
288		1H-NMR (DMSO-d6) δ: 2.48 (3H, s), 7.59-7.77 (4H, m), 7.88-7.95 (1H, m), 8.00 (1H, s).	Ex. 1
289		1H-NMR (DMSO-d6) δ: 2.53 (3H, s), 7.54 (1H, s), 7.70-7.76 (4H, m), 7.82 (1H, s), 8.00 (1H, s).	Ex. 1
290		1H-NMR (DMSO-d6) δ: 2.51 (3H, s), 7.31 (2H, d, J = 8.1 Hz), 7.51 (1H, s), 7.62-7.67 (2H, m), 7.78 (1H, s), 7.96 (1H, s).	Ex. 1


Ex. No.	STR	1H-NMR	ref.
291		1H-NMR (DMSO-d6) δ: 2.48 (3H, s), 7.31-7.34 (2H, m), 7.32 (1H, t, J = 74.0 Hz), 7.69 (2H, s), 7.77-7.80 (2H, m), 7.95 (1H, s).	Ex. 1
292		1H-NMR (DMSO-d6) δ: 2.51 (3H, s), 7.65-7.72 (1H, m), 7.73 (1H, s), 7.79 (1H, s), 8.00 (1H, s), 8.07-8.12 (2H, m).	Ex. 1
293		1H-NMR (DMSO-d6) δ: 2.51 (3H, s), 7.58 (2H, d, J = 8.6 Hz), 7.71 (2H, s), 7.76 (2H, d, J = 8.6 Hz), 7.96 (1H, s).	Ex. 1
294		1H-NMR (DMSO-d6) δ: 2.50 (3H, s), 7.75-7.81 (4H, m), 8.03-8.06 (3H, m).	Ex. 1
295		1H-NMR (DMSO-d6) δ: 2.50 (3H, s), 7.78-7.80 (2H, m), 7.84 (1H, s), 7.91-7.95 (2H, m), 8.06 (1H, s).	Ex. 1
296		1H-NMR (DMSO-d6) δ: 2.31 (3H, s), 2.46 (3H, s), 7.29-7.40 (4H, m), 7.67 (1H, s), 7.75 (1H, s),	Ex. 1
297		1H-NMR (DMSO-d6) δ: 2.55 (3H, s), 7.54 (1H, s), 7.88-7.90 (2H, m). 7.99 (1H, s), 8.05 (2H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
298		1H-NMR (DMSO-d6) δ: 7.43-7.56 (4H, m), 7.90 (1H, s), 8.14 (1H, s).	Ex. 1
299		1H-NMR (DMSO-d6) δ: 7.56-7.62 (1H, m), 7.77-7.82 (3H, m), 8.01-8.05 (1H, m), 8.17 (1H, s).	Ex. 1
300		1H-NMR (DMSO-d6) δ: 7.39 (2H, t, J = 8.9 Hz), 7.83 (1H, s), 7.82-7.86 (2H, m), 7.87 (1H, s), 8.19 (1H, s).	Ex. 1
301		1H-NMR (CDCl3) δ: 1.48 (3H, t, J = 7.0 Hz), 4.19 (2H, t, J = 7.0 Hz), 7.25 (1H, s), 7.52-7.61 (3H, m), 7.76-7.86 (3H, m).	Ex. 2
302		1H-NMR (CDCl3) δ: 1.43 (6H, d, J = 6.1 Hz), 4.68-4.76 (1H, m), 7.23 (1H, s), 7.56-7.66 (3H, m), 7.74 (1H, s), 7.80-7.86 (2H, m).	Ex. 2
303		1H-NMR (CDCl3) δ: 1.48 (3H, t, J = 7.0 Hz), 4.18 (2H, t, J = 7.0 Hz), 7.25 (1H, s), 7.39-7.49 (4H, m), 7.62-7.65 (2H, m), 7.77 (1H, bs).	Ex. 2
304		1H-NMR (CDCl3) δ: 1.42 (6H, d, J = 6.1 Hz), 4.67-4.75 (1H, m), 7.25 (1H, s), 7.39-7.49 (4H, m), 7.62-7.65 (2H, m), 7.75 (1H, bs).	Ex. 2


















[0769]

Ex. No.	STR	1H-NMR	ref.
305		1H-NMR (DMSO-d6) δ: 3.26 (3H, m), 7.75 (1H, t, J = 7.8 Hz), 7.93-8.07 (6H, m), 8.21-8.22 (1H, m).	Ex. 1
306		1H-NMR (DMSO-d6) δ: 3.28 (3H, m), 8.06-8.12 (4H, m), 8.24 (1H, s), 8.26 (1H, s), 8.49 (1H, s).	Ex. 1
307		1H-NMR (CDCl3) δ: 3.95 (3H, s), 7.22-7.35 (2H, m), 7.47-7.57 (4H, m), 7.78 (1H, s).	Ex. 1
308		1H-NMR (CDCl3) δ: 3.96 (3H, s), 7.22-7.23 (1H, m), 7.36 (1H, d, J = 8.6 Hz), 7.50-7.53 (1H, m), 7.58 (1H, s), 7.67 (1H, s), 7.76 (1H, s).	Ex. 1
309		1H-NMR (CDCl3) δ: 0.40-0.44 (2H, m), 0.68-0.73 (2H, m), 1.31-1.39 (1H, m), 3.96 (2H, d, J = 7.0 Hz), 7.27-7.28 (1H, m), 7.54 (1H, s), 7.59 (1H, t, J = 7.8 Hz), 7.65 (1H, d, J = 7.8 Hz), 7.78 (1H, s), 7.82 (1H, d, J = 7.6 Hz), 7.86 (1H, s).	Ex. 2
310		1H-NMR (CDCl3) δ: 0.41-0.45 (2H, m), 0.69-0.74 (2H, m), 1.30-1.39 (1H, m), 3.97 (2H, d, J = 7.0 Hz), 7.26-7.27 (1H, m), 7.59 (1H, s), 7.78 (1H, s), 7.91 (1H, s), 8.05 (2H, s).	Ex. 2
311		1H-NMR (DMSO-d6) δ: 1.91 (3H, s), 7.73-7.80 (5H, m), 7.89-7.92 (2H, m), 9.64 (1H, s), 16.15-16.84 (1H, br).	Ex. 1
312		1H-NMR (DMSO-d6) δ: 0.83 (3H, t, J = 7.0 Hz), 2.62 (3H, s), 2.83 (2H, q, J = 6.9 Hz), 7.32 (1H, d, J = 8.6 Hz), 7.72-7.74 (3H, m), 7.82-7.91 (3H, m).	Ex. 1
313		1H-NMR (DMSO-d6) δ: 1.68 (3H, s), 2.95 (3H, s), 7.74-8.03 (7H, m).	Ex. 1
314		1H-NMR (CDCl3) δ: 3.59 (3H, s), 7.60 (1H, t, J = 7.7 Hz), 7.63 (1H, d, J = 8.2 Hz), 7.80 (1H, d, J = 7.7 Hz), 7.89-7.90 (2H, m), 8.06 (1H, d, J = 2.2 Hz).	Ex. 1
315		1H-NMR (DMSO-d6) δ: 7.76-7.80 (1H, m), 7.85-7.90 (4H, m), 7.94-7.97 (2H, m).	Ex. 2
317		1H-NMR (DMSO-d6) δ: 0.88 (6H, t, J = 7.0 Hz), 2.92 (4H, q, J = 7.0 Hz), 7.37 (1H, d, J = 8.5 Hz), 7.72-7.76 (3H, m), 7.82-7.89 (2H, m), 7.93 (1H, s).	Ex. 316
318		1H-NMR (CDCl3) δ: 2.21 (3H, s), 7.37-7.69 (7H, m), 11.8 (1H, br.).	Ex. 1





[0770]





Ex. No.	STR	1H-NMR	ref.
319		1H-NMR (CDCl3) δ: 2.23 (3H, s), 3.85 (3H, s), 6.85-6.89 (1H, m), 6.89-6.96 (2H, m), 7.32-7.46 (4H, m).	Ex. 1
320		1H-NMR (CDCl3) δ: 1.99 (3H, s), 2.05 (3H, s), 2.35 (3H, s), 6.98 (1H, dd, J = 2.0, 7.0 Hz), 7.12-7.22 (2H, m), 7.30 (1H, dd, J = 1.7, 7.4 Hz), 7.38 (1H, t, J = 7.4 Hz), 7.43 (1H, dd, J = 1.7, 7.6 Hz).	Ex. 1
321		1H-NMR (DMSO-d6) δ: 1.43 (9H, s), 7.13-7.20 (2H, m), 7.57-7.63 (2H, m), 7.67-7.69 (1H, m), 7.94 (1H, t, J = 1.6 Hz), 7.99 (1H, t, J = 1.6 Hz).	Ex. 1
322		1H-NMR (DMSO-d6) δ: 1.37 (6H, d, J = 6.9 Hz), 3.05-3.14 (1H, m), 7.54-7.68 (3H, m), 7.78-7.90 (3H, m), 8.00 (1H, t, J = 1.7 Hz).	Ex. 1
323		1H-NMR (DMSO-d6) δ: 0.25-0.32 (2H, m), 0.58-0.65 (2H, m), 1.02-1.15 (1H, m), 2.69 (2H, d, J = 6.9 Hz), 7.12-7.20 (2H, m), 7.55-7.63 (3H, m), 7.87 (1H, s), 7.97 (1H, s).	Ex. 1
324		1H-NMR (CDCl3) δ: 1.34 (3H, d, J = 7.6 Hz), 2.81 (2H, q, J = 7.6 Hz), 7.13-7.19 (2H, m), 7.51 (1H, s), 7.58-7.63 (2H, m), 7.77 (1H, s), 7.95 (1H, s).	Ex. 1
325		1H-NMR (DMSO-d6) δ: 0.95 (3H, t, J = 7.3 Hz), 1.66-1.74 (2H, m), 2.72 (2H, t, J = 7.3 Hz), 7.34-7.38 (2H, m), 7.67 (1H, s), 7.70 (1H, s), 7.75-7.79 (2H, m), 7.95-7.97 (1H, m).	Ex. 1
326		1H-NMR (CDCl3) δ: 3.54 (3H, s), 4.64-4.69 (1H, m), 7.17-7.21 (2H, m), 7.61-7.65 (2H, m), 7.75 (1H, s), 8.00 (1H, s), 8.22 (1H, s).	Ex. 1
327		1H-NMR (DMSO-d6) δ: 3.38 (3H, s), 4.59 (2H, s), 7.35-7.39 (2H, m), 7.77-7.80 (3H, m), 7.84 (1H, s), 8.07 (1H, s).	Ex. 1
328		1H-NMR (DMSO-d6) δ: 1.62-1.70 (2H, m), 1.78-2.50 (6H, m), 4.90 (1H, m), 7.12-7.19 (3H, m), 7.44-7.46 (1H, m), 7.56-7.61 (2H, m), 7.69 (1H, s).	Ex. 1
329		1H-NMR (DMSO-d6) δ: 1.41 (3H, t, J = 6.9 Hz), 4.23 (2H, q, J = 6.9 Hz), 7.28-7.35 (3H, m), 7.70-7.75 (2H, m), 7.81-7.87 (2H, m).	Ex. 1
330		1H-NMR (DMSO-d6) δ: 1.35 (6H, d, J = 6.0 Hz), 4.79-4.86 (1H, m), 7.28-7.35 (3H, m), 7.70-7.75 (2H, m), 7.80-7.85 (2H, m).	Ex. 1



[0771]



Ex. No.	STR	m.p.	ref.
331		173-177	Ex. 1
332		296-298	Ex. 1
333		285-290	Ex. 1
334		211-212	Ex. 1
335		209	Ex. 1
336		242-245	Ex. 1
337		210-211	Ex. 1
338		292-293	Ex. 1
339		271-274	Ex. 1
340		256	Ex. 1
341		168-170	Ex. 1
342		206-207	Ex. 1
343		237-241	Ex. 1
344		156-159	Ex. 1
345		224	Ex. 1
346		127-128	Ex. 1
347		216-218	Ex. 1


[07721]

Ex. No.	STR	1H-NMR	ref.
348		1H-NMR (DMSO-d6) δ: 7.86 (1H, d, J = 8.4 Hz), 8.02 (4H, m), 8.09 (1H, d, J = 8.4 Hz), 8.16 (1H, s).	Ex. 1
349		1H-NMR (DMSO-d6) δ: 7.48-7.54 (2H, m), 7.74-7.76 (1H, m), 7.83-7.84 (1H, m), 7.96-8.01 (4H, m).	Ex. 1
350		1H-NMR (DMSO-d6) δ: 7.64 (2H, d, J = 8.1 Hz), 7.86 (1H, s), 7.99 (2H, d, J = 8.1 Hz), 8.06 (1H, d, J = 8.3 Hz), 8.14 (1H, d, J = 8.3 Hz).	Ex. 1
351		1H-NMR (DMSO-d6) δ: 2.22 (3H, s), 2.32 (3H, s), 7.08-7.22 (3H, m), 7.57-7.60 (2H, m), 7.94-7.97 (2H, m).	Ex. 1







Ex. No.	STR	1H-NMR	ref.
352		1H-NMR (DMSO-d6) δ: 7.79 (2H, d, J = 8.3 Hz), 7.94-8.03 (1H, m), 8.06 (2H, d, J = 8.3 Hz).	Ex. 1
353		1H-NMR (DMSO-d6) δ: 7.55-7.58 (3H, m), 7.64-7.68 (1H, m), 7.78-7.80 (1H, m), 7.96 (2H, d, J = 8.2 Hz).	Ex. 1
354		1H-NMR (DMSO-d6) δ: 7.38-7.40 (1H, m), 7.51-7.53 (1H, m), 7.60-7.66 (2H, m), 7.85-7.88 (1H, m), 7.94-7.96 (1H, m).	Ex. 1
355		1H-NMR (CDCl3) δ: 7.14-7.17 (2H, m), 7.20-7.26 (3H, m), 7.29-7.32 (2H, m), 7.46 (4H, s), 7.83 (2H, d, J = 8.0 Hz), 12.2 (1H, br.).	Ex. 1








Ex. No.	STR	m.p.	ref.
356		138.6-139.4	Ex. 1
357		141.3-142.4	Ex. 1







Ex. No.	STR	m.p.	ref.
358		118.8-119.3	Ex. 1
359		117.5-118.2	Ex. 1

Ex. No.	STR	m.p.	ref.
360		91.7-92.9	Ex. 1






[0773]







Ex. No.	STR	1H-NMR	ref.
361		1H-NMR (CDCl3) δ: 7.15-7.21 (2H, m), 7.37 (3H, br.s), 7.49-7.63 (2H, m), 7.57-7.63 (1H, t, J = 7.3 Hz), 7.73 (1H, br.s), 11.5 (1H, br.).	Ex. 1
362		1H-NMR (CDCl3) δ: 7.08-7.13 (2H, m), 7.29-7.35 (2H, m), 7.46-7.68 (4H, m), 11.8 (1H, br.).	Ex. 1
363		1H-NMR (DMSO-d6) δ: 7.06-7.11 (2H, m), 7.13-7.35 (8H, m), 7.42-7.50 (2H, m), 7.54-7.61 (1H, m).	Ex. 1
364		1H-NMR (DMSO-d6) δ: 7.15-7.19 (2H, m), 7.35-7.40 (3H, m), 7.81 (1H, d, J = 8.5 Hz), 8.03-8.05 (2H, m).	Ex. 1
365		1H-NMR (CDCl3) δ: 6.96-7.00 (2H, m), 7.03-7.05 (2H, m), 7.12-7.17 (3H, m), 7.33-7.40 (2H, m), 7.68 (1H, d, J = 7.8 Hz), 7.85-7.87 (2H, m).	Ex. 1
366		1H-NMR (DMSO-d6) δ: 7.43 (2H, d, J = 8.0 Hz), 7.76 (2H, d, J = 8.0 Hz), 7.87 (1H, d, J = 8.6 Hz), 8.08-8.10 (2H, m).	Ex. 1







Ex. No.	STR	m.p.	ref.
367		153	Ex. 1
368		127-131	Ex. 1
369		117-118	Ex. 1
370		216	Ex. 1
371		138-140	Ex. 1
372		139-141	Ex. 1
373		123-134	Ex. 1

Ex. No.	STR	m.p.	ref.
374		123-125	Ex. 1
375		141-142	Ex. 1
376		98-101	Ex. 1
377		119	Ex. 1
378		108-112	Ex. 1
379		106-109	Ex. 1



[0774]


Ex. No.	STR	m.p.	ref.
380		134-136	Ex. 1
381		124-127	Ex. 1
382		136-139	Ex. 1
383		199	Ex. 1
384		226-227	Ex. 1




Ex. No.	STR	1H-NMR	ref.
385		1H-NMR (DMSO-d6) δ: 4.29 (2H, s), 7.53-7.59 (2H, m), 7.74 (1H, d, J = 7.5 Hz), 7.82 (1H, s), 7.96 (1H, s), 8.05 (2H, s).	Ex. 1
386		1H-NMR (DMSO-d6) δ: 4.06 (2H, s), 7.15-7.17 (1H, m), 7.34-7.58 (2H, m), 7.71 (1H, s), 7.72-7.75 (2H, m).	Ex. 1
387		1H-NMR (DMSO-d6) δ: 4.39 (2H, s), 7.96 (1H, s), 8.00 (1H, s), 8.05 (1H, s), 8.11 (1H, s), 8.13 (2H, s).	Ex. 1
388		1H-NMR (DMSO-d6) δ: 4.40 (2H, s), 7.28 (1H, d, J = 8.7 Hz), 7.43 (1H, s), 7.56 (1H, d, J = 8.7 Hz), 7.90 (1H, d, J = 8.2 Hz), 7.91 (1H, s), 8.02 (1H, d, J = 8.2 Hz).	Ex. 1
389		1H-NMR (DMSO-d6) δ: 4.08 (2H, s), 7.17 (1H, s), 7.21-7.36 (5H, m), 7.78 (1H, s), 8.08 (1H, s).	Ex. 1
390		1H-NMR (DMSO-d6) δ: 4.16 (2H, s), 7.33-7.39 (4H, m), 7.85 (1H, s), 8.04 (2H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
391		1H-NMR (CDCl3) δ: 4.21 (2H, s), 7.28-7.44 (3H, m), 7.61 (1H, s), 8.07 (1H, s), 8.14 (1H, s).	Ex. 1
392		1H-NMR (CDCl3) δ: 4.40 (2H, s), 7.51 (2H, s), 7.67-7.69 (1H, m), 7.88 (1H, d, J = 8.2 Hz), 7.94 (1H, s), 8.16 (1H, s).	Ex. 2
393		1H-NMR (CDCl3) δ: 4.31 (2H, s), 7.23-7.26 (1H, m), 7.35-7.41 (1H, m), 7.50 (2H, s), 7.71 (1H, d, J = 7.3 Hz), 7.93 (1H, s), 8.09 (1H, s).	Ex. 2
394		1H-NMR (DMSO-d6) δ: 4.10 (2H, s), 7.29 (1H, s), 7.32 (1H, s), 7.43 (2H, d, J = 8.6 Hz), 7.58 (1H, s), 7.75 (2H, d, J = 8.6 Hz).	Ex. 1
395		1H-NMR (DMSO-d6) δ: 2.37 (3H, s), 4.24 (2H, s), 7.36 (1H, s), 7.55 (1H, s), 7.60 (1H, s), 7.95 (1H, s), 8.03 (2H, s).	Ex. 1
396		1H-NMR (DMSO-d6) δ: 2.37 (3H, s), 4.33 (2H, s), 7.22 (1H, s), 7.40 (1H, s), 7.58 (1H, s), 7.83 (1H, s), 7.88 (1H, d, J = 8.5 Hz), 8.02 (1H, d, J = 8.5 Hz).	Ex. 1

[0775]

Ex. No.	STR	m.p.	ref.
400		209-210	Ex. 1
401		195-197	Ex. 1
402		144-146	Ex. 1








Ex. No.	STR	m.p.	ref.
409		142-144	Ex. 1








Ex. No.	STR	1H-NMR	ref.
403		1H-NMR (DMSO-d6) δ: 2.32-2.38 (3H, m), 4.00-4.05 (2H, m), 7.22-7.41 (5H, m), 7.53-7.63 (2H, m).	Ex. 1
404		1H-NMR (DMSO-d6) δ: 4.14 (2H, s), 7.01-7.19 (2H, m), 7.20-7.30 (2H, m), 7.75-7.80 (2H, m).	Ex. 1
405		1H-NMR (DMSO-d6) δ: 1.28 (6H, d, J = 6.9 Hz), 2.91-3.02 (1H, m), 4.10 (2H, s), 7.19 (1H, s), 7.40-7.51 (4H, m), 7.57 (1H, s), 7.70 (1H, s).	Ex. 1
406		1H-NMR (DMSO-d6) δ: 4.00 (2H, s), 6.97-7.05 (2H, m), 7.15-7.20 (2H, m), 7.43 (1H, s), 7.74 (1H, s), 7.95-7.98 (1H, m).	Ex. 1
407		1H-NMR (DMSO-d6) δ: 4.27 (2H, s), 7.57 (2H, d, J = 8.1 Hz), 7.84 (2H, d, J = 8.1 Hz), 7.96 (1H, s), 8.05 (2H, s).	Ex. 1
408		1H-NMR (DMSO-d6) δ: 4.17 (2H, s), 7.16-7.58 (4H, m), 7.65-7.80 (3H, m).	Ex. 1









Ex. No.	STR	1H-NMR	ref.
397		1H-NMR (DMSO-d6) δ: 4.12 (2H, s), 7.16 (1H, s), 7.38-7.56 (4H, m), 7.73 (1H, s), 7.77 (1H, s).	Ex. 1
398		1H-NMR (DMSO-d6) δ: 4.23 (2H, s), 7.52-7.57 (3H, m), 7.66-7.71 (3H, m), 7.81 (1H, s).	Ex. 1
399		1H-NMR (DMSO-d6) δ: 2.35 (3H, s), 4.10 (2H, s), 7.52-7.65 (7H, m).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
410		1H-NMR (DMSO-d6) δ: 2.41 (3H, s), 4.14 (2H, s), 7.13-7.19 (2H, m), 7.22-7.26 (2H, m), 7.34 (1H, t, J = 7.6 Hz), 7.40-7.45 (2H, m).	Ex. 1

[0776]

Ex. No.	STR	m.p.	ref.
411		119-123	Ex. 1
412		177	Ex. 1
413		171-172	Ex. 1
414		140-142	Ex. 1
415		134-135	Ex. 1
416		195-197	Ex. 1
417		141.9-142.3	Ex. 1

Ex. No.	STR	1H-NMR	ref.
418		1H-NMR (CDCl3) δ: 5.24 (2H, s), 6.88 (1H, dt, J = 2.3, 10.0 Hz), 7.38-7.43 (1H, m), 7.45-7.47 (1H, m), 7.89 (1H, s), 7.94 (2H, s), 12.20 (1H, brs).	Ex. 2
419		1H-NMR (CDCl3) δ: 5.24 (2H, s), 6.84 (1H, dt, J = 2.3, 10.1 Hz), 7.35-7.41 (2H, m), 7.45-7.50 (2H, m), 7.66-7.71 (1H, m).	Ex. 2
420		1H-NMR (CDCl3) δ: 5.38 (2H, s), 6.82 (1H, dt, J = 2.3, 10.1 Hz), 7.36-7.41 (1H, m), 7.43-7.44 (1H, m), 7.86-7.98 (3H, m), 12.16 (1H, brs).	Ex. 2
421		1H-NMR (CDCl3) δ: 5.27 (2H, s), 6.80 (1H, dt, J = 2.3, 10.1 Hz), 7.30-7.34 (1H, m), 7.34-7.38 (1H, m), 7.42-7.46 (2H, m), 7.70-7.57 (1H, m), 12.12 (1H, brs).	Ex. 2
422		1H-NMR (CDCl3) δ: 5.14 (2H, s), 6.82 (1H, dt, J = 2.3, 10.1 Hz), 7.31-7.40 (1H, m), 7.40-7.44 (1H, m), 7.54-7.61 (2H, m), 7.77-7.79 (1H, m), 12.40 (1H, brs).	Ex. 2
423		1H-NMR (CDCl3) δ: 5.26 (2H, s), 7.11-7.14 (1H, m), 7.46-7.51 (1H, m), 7.59-7.61 (1H, m), 7.62-7.68 (1H, m), 7.77-7.83 (1H, m), 7.89-7.96 (2H, m), 12.19 (1H, brs).	Ex. 2
424		1H-NMR (CDCl3) δ: 5.25 (2H, s), 6.84 (1H, dt, J = 2.3, 10.0 Hz), 7.37-7.41 (1H, m), 7.44-7.45 (1H, m), 7.78-7.81 (1H, m), 7.90-7.94 (2H, m).	Ex. 2

Ex. No.	STR	1H-NMR	ref.
425		1H-NMR (CDCl3) δ: 5.16 (2H, s), 7.09-7.13 (1H, m), 7.47 (1H, t, J = 8.0 Hz), 7.53-7.64 (4H, m), 7.79-7.80 (1H, m).	Ex. 2
426		1H-NMR (CDCl3) δ: 5.30 (2H, s), 6.81 (1H, dt, J = 2.3, 10.1 Hz), 7.24-7.29 (1H, m), 7.30-7.38 (3H, m), 7.41-7.42 (1H, m).	Ex. 2
427		1H-NMR (CDCl3) δ: 5.14 (2H, s), 7.08-7.12 (1H, m), 7.24-7.29 (1H, m), 7.31-7.37 (2H, m), 7.47 (1H, t, J = 8.0 Hz), 7.56-7.58 (1H, m), 7.61-7.64 (1H, m).	Ex. 2
428		1H-NMR (CDCl3) δ: 5.34 (2H, s), 7.51-7.59 (2H, m), 7.88-7.90 (1H, m), 7.95-7.97 (2H, m), 12.90 (1H, brs).	Ex. 2
429		1H-NMR (CDCl3) δ: 5.10 (2H, s), 6.81 (1H, dt, J = 2.3, 10.2 Hz), 7.22-7.28 (1H, m), 7.34-7.43 (4H, m).	Ex. 2
430		1H-NMR (CDCl3) δ: 5.14 (2H, s), 6.81 (1H, dt, J = 2.2, 10.2 Hz), 7.02-7.09 (1H, m), 7.16-7.20 (1H, m), 7.21-7.25 (1H, m), 7.32-7.39 (2H, m), 7.41-7.43 (1H, m).	Ex. 2
431		1H-NMR (CDCl3) δ: 5.10 (2H, s), 6.81 (1H, dt, J = 2.3, 10.3 Hz), 7.07-7.14 (2H, m), 7.30-7.36 (1H, m), 7.41-7.46 (3H, m).	Ex. 2
432		1H-NMR (CDCl3) δ: 5.13 (2H, s), 6.82 (1H, dt, J = 2.3, 10.2 Hz), 7.25-7.28 (2H, m), 7.33-7.37 (1H, m), 7.42-7.43 (1H, m), 7.48-7.51 (2H, m).	Ex. 2








[0777]








Ex. No.	STR	1H-NMR	ref.
433		1H-NMR (CDCl3) δ: 5.18 (2H, s), 6.83 (1H, dt, J = 2.3, 10.2 Hz), 7.34-7.38 (1H, m), 7.43-7.45 (1H, m), 7.52-7.57 (1H, m), 7.61-7.67 (2H, m), 7.72-7.73 (1H, m).	Ex. 2
434		1H-NMR (CDCl3) δ: 5.20 (2H, s), 6.82 (1H, dt, J = 2.2, 10.1 Hz), 7.34-7.37 (1H, m), 7.42-7.43 (1H, m), 7.57-7.59 (2H, m), 7.66-7.69 (2H, m), 12.10 (1H, brs).	Ex. 2
435		1H-NMR (CDCl3) δ: 5.12 (2H, s), 7.09-7.13 (1H, m), 7.21-7.27 (1H, m), 7.37-7.40 (1H, m), 7.42-7.49 (2H, m), 7.57-7.58 (1H, m), 7.61-7.64 (1H, m).	Ex. 2
436		1H-NMR (CDCl3) δ: 5.12 (2H, s), 7.09-7.13 (1H, m), 7.34-7.42 (2H, m), 7.44-7.49 (1H, m), 7.57-7.58 (1H, m), 7.60-7.64 (2H, m).	Ex. 2
437		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.81 (1H, dt, J = 2.3, 10.1 Hz), 7.35-7.42 (4H, m), 7.59-7.60 (1H, m).	Ex. 2
438		1H-NMR (CDCl3) δ: 5.13 (2H, s), 7.08-7.12 (1H, m), 7.33-7.39 (1H, m), 7.43-7.44 (1H, m), 7.46-7.52 (2H, m), 7.56-7.58 (1H, m), 7.61-7.64 (1H, m).	Ex. 2
439		1H-NMR (CDCl3) δ: 5.12 (2H, s), 6.81 (1H, dt, J = 2.3, 10.1 Hz), 7.34-7.38 (2H, m), 7.41-7.43 (2H, m), 7.50-7.53 (1H, m).	Ex. 2
440		1H-NMR (CDCl3) δ: 1.33 (9H, s), 5.09 (2H, s), 6.83 (1H, dt, J = 2.3, 10.4 Hz), 7.29-7.33 (1H, m), 7.37-7.40 (2H, m), 7.42-7.46 (3H, m).	Ex. 2









Ex. No.	STR	1H-NMR	ref.
441		1H-NMR (CDCl3) δ: 5.16 (2H, s), 6.83 (1H, dt, J = 2.3, 10.1 Hz), 7.36-7.41 (1H, m), 7.42-7.43 (1H, m), 7.60-7.61 (2H, m), 7.65-7.66 (1H, m).	Ex. 2
442		1H-NMR (CDCl3) δ: 5.12 (2H, s), 6.82 (1H, dt, J = 2.3, 10.1 Hz), 7.21-7.23 (2H, m), 7.36-7.42 (3H, m), 11.89 (1H, brs).	Ex. 2
443		1H-NMR (DMSO-d6) δ: 5.25 (2H, s), 7.20 (1H, dt, J = 2.2, 10.9 Hz), 7.28-7.38 (3H, m), 7.44-7.47 (2H, m).	Ex. 2
444		1H-NMR (CDCl3) δ: 5.17 (2H, s), 7.09-7.14 (1H, m), 7.48 (1H, t, J = 8.0 Hz), 7.60-7.67 (5H, m).	Ex. 2
445		1H-NMR (CDCl3) δ: 5.13 (2H, s), 7.08-7.12 (1H, m), 7.20-7.25 (2H, m), 7.41-7.42 (1H, m), 7.44-7.50 (1H, m), 7.57-7.58 (1H, m), 7.61-7.65 (1H, m).	Ex. 2
446		1H-NMR (CDCl3) δ: 5.11 (2H, s), 7.04-7.11 (3H, m), 7.25-7.27 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.55-7.57 (1H, m), 7.61-7.64 (1H, m).	Ex. 2
447		1H-NMR (DMSO-d6) δ: 5.33 (2H, s), 7.20-7.25 (1H, m), 7.29-7.33 (1H, m), 7.39-7.40 (1H, m), 7.69-7.77 (3H, m).	Ex. 2

Ex. No.	STR	m.p.	ref.
448		167-168	Ex. 1
449		107-109	Ex. 1
450		142-144	Ex. 1
451		129-130	Ex. 1
452		153	Ex. 1
453		167	Ex. 1
454		146-148	Ex. 1

[0778]

Ex. No.	STR	1H-NMR	ref.
470		1H-NMR (CDCl3) δ: 5.21 (2H, s), 7.37-7.51 (6H, m), 7.81 (1H, s), 7.87 (1H, s).	Ex. 1
471		1H-NMR (CDCl3) δ: 5.31 (2H, s), 7.40 (1H, s), 7.84 (1H, s), 7.92-7.97 (4H, m).	Ex. 1
472		1H-NMR (CDCl3) δ: 5.16 (2H, s), 7.33 (1H, s), 7.37-7.43 (4H, m), 7.78 (1H, s), 7.87 (1H, s).	Ex. 1
473		1H-NMR (DMSO-d6) δ: 5.32 (2H, s), 7.24-7.26 (1H, m), 7.50-7.58 (3H, m), 7.69 (2H, d, J = 9.1 Hz), 7.74 (1H, s).	Ex. 1
474		1H-NMR (CDCl3) δ: 5.39 (2H, s), 7.36 (1H, s), 7.50 (1H, t, J = 7.6 Hz), 7.63 (1H, t, J = 7.6 Hz), 7.74-7.81 (3H, m), 7.90 (1H, s).	Ex. 1
475		1H-NMR (DMSO-d6) δ: 5.51 (2H, s), 7.27-7.32 (1H, m), 7.56 (2H, d, J = 4.5 Hz), 8.03 (1H, d, J = 8.3 Hz), 8.10 (1H, d, J = 8.3 Hz), 8.30 (1H, s).	Ex. 1
476		1H-NMR (DMSO-d6) δ: 5.26 (2H, s), 7.26-7.29 (1H, m), 7.51-7.66 (4H, m).	Ex. 1

Ex. No.	STR	m.p.	ref.
463		183-184	Ex. 1
464		109-111	Ex. 1
465		121	Ex. 1
466		139-140	Ex. 1
467		128-129	Ex. 1
468		115-116	Ex. 1
469		135-136	Ex. 1

Ex. No.	STR	m.p.	ref.
455		175-176	Ex. 1
456		175-177	Ex. 1
457		168	Ex. 1
458		168	Ex. 1
459		133-135	Ex. 1
460		189-191	Ex. 1
461		220-222	Ex. 1
462		202-203	Ex. 1

[0779]








Ex. No.	STR	1H-NMR	ref.
477		1H-NMR (DMSO-d6) δ: 5.19 (2H, s), 7.25-7.28 (1H, m), 7.50-7.77 (5H, m).	Ex. 1
478		1H-NMR (CDCl3) δ: 5.23 (2H, s), 7.36 (1H, s), 7.52-7.57 (1H, m), 7.62-7.68 (2H, m), 7.75 (1H, s), 7.81 (1H, s), 7.89 (1H, s).	Ex. 2
479		1H-NMR (CDCl3) δ: 5.29 (2H, s), 7.25-7.28 (1H, m), 7.40 (1H, s), 7.68-7.71 (1H, m), 7.85-7.89 (2H, m), 7.94 (1H, s).	Ex. 2
480		1H-NMR (CDCl3) δ: 5.22 (2H, s), 7.32-7.42 (3H, m), 7.54 (1H, s), 7.80 (1H, s), 7.91 (1H, s).	Ex. 2
481		1H-NMR (CDCl3) δ: 2.43 (3H, s), 5.18 (2H, s), 7.23-7.32 (3H, m), 7.38 (1H, s), 7.44 (1H, d, J = 7.2 Hz), 7.83 (1H, s), 7.88 (1H, s).	Ex. 2
482		1H-NMR (CDCl3) δ: 5.42 (2H, s), 7.31-7.34 (1H, m), 7.40-7.43 (3H, m), 7.87 (1H, s), 7.91 (1H, s).	Ex. 2
483		1H-NMR (CDCl3) δ: 5.12 (2H, s), 7.09-7.12 (1H, m), 7.30-7.35 (3H, m), 7.43-7.48 (2H, m), 7.55-7.62 (2H, m).	Ex. 2
484		1H-NMR (CDCl3) δ: 5.20 (2H, s), 7.14 (1H, ddd, J = 0.8, 2.6, 8.4 Hz), 7.23-7.27 (1H, m), 7.35 (1H, d, J = 8.4 Hz), 7.48 (1H, t, J = 8.0 Hz), 7.58-7.66 (3H, m).	Ex. 2
485		1H-NMR (CDCl3) δ: 5.25 (2H, s), 7.15 (1H, ddd, J = 1.0, 2.6, 8.3 Hz), 7.49 (1H, d, J = 8.0 Hz), 7.61-7.68 (2H, m), 7.87 (1H, s), 7.94 (2H, s).	Ref. Ex. 82, Ex. 1
486		1H-NMR (CDCl3) δ: 5.45 (2H, s), 7.36 (1H, s), 7.81 (1H, s), 7.89-8.01 (4H, m).	Ex. 1
487		1H-NMR (CDCl3) δ: 5.24 (2H, s), 7.22-7.27 (2H, m), 7.43-7.48 (2H, m), 7.77 (1H, s), 7.87 (1H, s).	Ex. 1
488		1H-NMR (DMSO-d6) δ: 5.35 (2H, s), 7.45-7.49 (2H, m), 7.53-7.60 (2H, m), 7.72-7.75 (1H, m), 7.79 (1H, s), 7.81 (1H, s).	Ex. 2
489		1H-NMR (DMSO-d6) δ: 5.35 (2H, s), 7.66-7.84 (6H, m).	Ex. 2
490		1H-NMR (DMSO-d6) δ: 5.40 (2H, s), 7.61-7.67 (2H, m), 7.72-7.78 (2H, m), 7.83 (1H, s), 7.88-7.93 (1H, m).	Ex. 2
491		1H-NMR (CDCl3) δ: 5.36 (2H, s), 7.11-7.17 (1H, m), 7.33 (1H, s), 7.47-7.51 (1H, m), 7.71-7.78 (2H, m), 7.90 (1H, s).	Ex. 2
492		1H-NMR (CDCl3) δ: 5.33 (2H, s), 7.34 (1H, s), 7.45 (1H, d, J = 8.5 Hz), 7.66 (1H, d, J = 8.5 Hz), 7.76 (1H, s), 7.79 (1H, s), 7.90 (1H, s).	Ex. 2
493		1H-NMR (CDCl3) δ: 5.22 (2H, s), 7.37 (1H, s), 7.57-7.65 (2H, m), 7.81-7.83 (2H, m), 7.92 (1H, s).	Ex. 2
494		1H-NMR (CDCl3) δ: 2.34 (3H, s), 2.36 (3H, s), 5.12 (2H, s), 7.11-7.15 (2H, m), 7.24 (1H, s), 7.35 (1H, s), 7.80 (1H, s), 7.85 (1H, s).	Ex. 1
495		1H-NMR (CDCl3) δ: 2.36 (3H, s), 2.40 (3H, s), 5.14 (2H, s), 7.06-7.10 (2H, m), 7.30-7.36 (2H, m), 7.81 (1H, s), 7.87 (1H, s).	Ex. 2
496		1H-NMR (CDCl3) δ: 5.25 (2H, s), 7.34 (1H, s), 7.60 (2H, d, J = 8.1 Hz), 7.68 (2H, d, J = 8.1 Hz), 7.79 (1H, s), 7.88 (1H, s).	Ex. 2
497		1H-NMR (CDCl3) δ: 5.36 (2H, s), 7.36 (1H, s), 7.48-7.53 (1H, m), 7.67-7.77 (3H, m), 7.81 (1H, s), 7.88 (1H, s).	Ex. 191








Ex. No.	STR	1H-NMR	ref.
498		1H-NMR (CDCl3) δ: 5.30 (2H, s), 7.33-7.38 (3H, m), 7.45-7.48 (1H, m), 7.58-7.61 (1H, m), 7.83 (1H, s), 7.90 (1H, s).	Ex. 2
499		1H-NMR (DMSO-d6) δ: 5.34 (2H, s), 7.25-7.33 (1H, m), 7.48-7.62 (3H, m), 8.00-8.20 (2H, m).	Ex. 2
500		1H-NMR (CDCl3) δ: 5.23 (2H, s), 7.25-7.38 (3H, m), 7.59 (1H, s), 7.81 (1H, s), 7.90 (1H, s).	Ex. 2
501		1H-NMR (DMSO-d6) δ: 5.24 (2H, s), 7.15 (1H, t, J = 2.1 Hz), 7.54 (1H, t, J = 1.5 Hz), 7.66 (1H, t, J = 1.5 Hz), 7.89 (1H, s), 7.93 (2H, s).	Ex. 1
502		1H-NMR (DMSO-d6) δ: 5.44 (2H, s), 7.45 (1H, t, J = 2.0 Hz), 7.50 (1H, t, J = 1.5 Hz), 7.56 (1H, t, J = 1.5 Hz), 8.03 (1H, d, J = 8.4 Hz), 8.09 (1H, d, J = 8.4 Hz), 8.24 (1H, s).	Ex. 1
503		1H-NMR (CDCl3) δ: 5.14 (2H, s), 7.03-7.12 (1H, m), 7.32-7.48 (5H, m), 7.51 (1H, s), 7.80 (1H, s).	Ex. 1
504		1H-NMR (DMSO-d6) δ: 5.47 (2H, s), 7.36 (1H, s), 7.49 (1H, s), 7.57 (1H, s), 8.02 (1H, d, J = 8.1 Hz), 8.09 (1H, d, J = 8.1 Hz), 8.25 (1H, s).	Ex. 1







Ex. No.	STR	1H-NMR	ref.
505		1H-NMR (DMSO-d6) δ: 5.26 (2H, s), 7.00 (1H, s), 7.55 (1H, s), 7.60 (1H, s), 7.89 (1H, s), 7.94 (2H, s).	Ex. 2
506		1H-NMR (CDCl3) δ: 5.35 (2H, s), 6.81-6.89 (1H, m), 7.36-7.43 (1H, m), 7.44-7.48 (1H, m), 7.72-7.77 (1H, m), 7.85-7.90 (1H, m), 8.03-8.07 (1H, m).	Ex. 1
507		1H-NMR (DMSO-d6) δ: 5.37 (2H, s), 7.29 (1H, s), 7.46 (1H, s), 7.56 (1H, d, J = 1.6 Hz), 7.72 (2H, d, J = 8.2 Hz), 7.79 (2H, d, J = 8.2 Hz).	Ex. 1
508		1H-NMR (CDCl3) δ: 2.44 (3H, s), 5.34 (2H, s), 6.97 (1H, s), 7.39 (1H, s), 7.46 (1H, s), 7.72 (1H, d, J = 8.1 Hz), 7.85 (1H, d, J = 8.1 Hz), 8.09 (1H, s), 12.0 (1H, br.).	Ex. 1
509		1H-NMR (CDCl3) δ: 2.44 (3H, s), 5.23 (2H, s), 6.97 (1H, s), 7.41 (1H, s), 7.46 (1H, s), 7.87 (1H, s), 7.94 (2H, s), 12.0 (1H, br.).	Ex. 1
510		1H-NMR (DMSO-d6) δ: 5.24 (2H, s), 7.26 (1H, s), 7.36-7.51 (6H, m), 7.55 (1H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
511		1H-NMR (DMSO-d6) δ: 5.25 (2H, s), 7.27 (1H, s), 7.44 (1H, s), 7.47-7.55 (5H, m).	Ex. 1
512		1H-NMR (DMSO-d6) δ: 5.22 (2H, s), 7.22-7.28 (3H, m), 7.44 (1H, s), 7.55-7.58 (3H, m).	Ex. 1
513		1H-NMR (DMSO-d6) δ: 5.37 (2H, s), 7.32 (1H, s), 7.47 (1H, s), 7.57 (1H, s), 7.68-7.73 (2H, m). 7.76 (1H, s).	Ex. 1
514		1H-NMR (DMSO-d6) δ: 5.42 (2H, s), 7.14 (1H,t, J = 2.1 Hz), 7.31 (1H, s), 7.35 (1H,t, J = 73.5 Hz), 7.44 (1H, s), 8.13 (1H, s), 8.22 (2H, s).	Ex. 1
515		1H-NMR (CDCl3) δ: 2.41 (3H, s), 5.13 (2H, s), 6.95 (1H, s), 7.30-7.49 (7H, m), 12.2 (1H, br.).	Ex. 1
516		1H-NMR (CDCl3) δ: 2.41 (3H, s), 5.12 (2H, s), 6.93 (1H, s), 6.98-7.07 (1H, m), 7.15-7.26 (2H, m), 7.32-7.41 (3H, m).	Ex. 1
517		1H-NMR (CDCl3) δ: 2.41 (3H, s), 5.09 (2H, s), 6.93 (1H, s), 7.04-7.12 (2H, m), 7.34-7.48 (4H, m).	Ex. 1


[07811]

Ex. No.	STR	1H-NMR	ref.
518		1H-NMR (CDCl3) δ: 2.43 (3H, s), 5.17 (2H, s), 6.96 (1H, s), 7.35-7.46 (2H, m), 7.52 (1H, t, J = 7.8 Hz), 7.57-7.67 (2H, m), 7.73 (1H, s), 12.2 (1H, br.).	Ex. 1
519		1H-NMR (DMSO-d6) δ: 5.21 (2H, s), 7.07 (1H, d, J = 2.1 Hz), 7.27 (1H, s), 7.34 (1H, t, J = 73.5 Hz), 7.36-7.50 (6H, m).	Ex. 1
520		1H-NMR (DMSO-d6) δ: 5.43 (2H, s), 7.13-7.15 (1H, m), 7.32 (1H, s), 7.36 (1H, t, J = 73.5 Hz), 7.41-7.43 (1H, m), 8.02 (1H, d, J = 8.7 Hz), 8.09 (1H, d, J = 8.7 Hz), 8.23 (1H, s).	Ex. 1
521		1H-NMR (DMSO-d6) δ: 5.34 (2H, s), 7.09-7.10 (1H, m), 7.29 (1H, s), 7.35 (1H, t, J = 73.5 Hz), 7.41-7.42 (1H, m), 7.71 (2H, d, J = 8.2 Hz), 7.79 (2H, d, J = 8.2 Hz).	Ex. 1
522		1H-NMR (DMSO-d6) δ: 5.22 (2H, s), 7.06 (1H, s), 7.07-7.53 (7H, m).	Ex. 1
523		1H-NMR (DMSO-d6) δ: 5.20 (2H, s), 7.07 (1H, s), 7.20-7.27 (3H, m), 7.35 (1H, t, J = 73.1 Hz), 7.40 (1H, s), 7.55 (2H, t, J = 6.3 Hz).	Ex. 1
524		1H-NMR (CDCl3) δ: 2.42 (3H, s), 5.13 (2H, s), 6.82-6.97 (3H, m), 7.34-7.55 (3H, m).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
525		1H-NMR (CDCl3) δ: 2.44 (3H, s), 5.21 (2H, s), 6.97 (1H, s), 7.18-7.26 (1H, m), 7.40 (1H, s), 7.44 (1H, s), 7.59-7.67 (1H, m), 7.83-7.90 (1H, m).	Ref. Ex. 82, Ex. 1
526		1H-NMR (DMSO-d6) δ: 5.27 (2H, s), 710 (1H, s), 7.28-7.66 (6H, m).	Ex. 1
527		1H-NMR (DMSO-d6) δ: 3.80 (3H, s), 5.15 (2H, s), 6.77-6.79 (1H, m), 7.02-7.03 (1H, m), 7.09-7.10 (1H, m), 7.32-7.47 (5H, m).	Ex. 1
528		1H-NMR (CDCl3) δ: 2.43 (3H, s), 5.17 (2H, s), 6.95 (1H, s), 7.26-7.34 (1H, m), 7.37-7.44 (3H, m), 7.52 (1H, s).	Ex. 1
529		1H-NMR (CDCl3) δ: 2.42 (3H, s), 5.12 (2H, s), 6.72-6.81 (1H, m), 6.93 (1H, s), 6.95-7.01 (2H, m), 7.35 (1H, s), 7.42 (1H, s), 11.9 (1H, br.).	Ex. 2
530		1H-NMR (CDCl3) δ: 3.13 (3H, s), 5.22 (2H, s), 6.67-6.68 (1H, m), 7.21 (2H, s), 7.87 (1H, s), 7.93 (2H, s).	Ex. 2
531		1H-NMR (CDCl3) δ: 2.43 (3H, s), 5.16 (2H, s), 6.95 (1H, s), 6.95-7.15 (2H, m), 7.20-7.29 (1H, m), 7.38 (1H, s), 7.42 (1H, s), 11.9 (1H, br.).	Ex. 2










Ex. No.	STR	1H-NMR	ref.
532		1H-NMR (CDCl3) δ: 2.42 (3H, s), 5.07 (2H, s), 6.92 (1H, s), 7.15-7.21 (2H, m), 7.25-7.32 (1H, m), 7.35 (1H, s), 7.41 (1H, s), 11.9 (1H, br.).	Ex. 1
533		1H-NMR (CDCl3) δ: 2.43 (3H, s), 5.13 (2H, s), 6.94 (1H, s), 7.37 (1H, s), 7.43 (1H, s), 7.53 (1H, d, J = 8.4 Hz), 7.58 (1H, dd, J = 1.7, 8.4 Hz), 7.79 (1H, d, J = 1.7 Hz), 12.0 (1H, br.).	Ex. 1
534		1H-NMR (CDCl3) δ: 1.33 (9H, s), 2.41 (3H, s), 5.08 (2H, s), 6.95 (1H, s), 7.37-7.45 (6H, m), 12.0 (1H, br.).	Ex. 1
535		1H-NMR (CDCl3) δ: 2.41 (3H, s), 3.83 (3H, s), 5.10 (2H, s), 6.87 (1H, dd, J = 2.5, 8.3 Hz), 6.95 (1H, s), 6.99-7.06 (2H, m), 7.31 (1H, t, J = 7.8 Hz), 7.37 (2H, s), 12.1 (1H, br.).	Ex. 1
536		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.80 (1H, dt, J = 2.3, 10.1 Hz), 7.16-7.21 (1H, m), 7.25-7.31 (1H, m), 7.33-7.38 (1H, m), 7.41-7.46 (2H, m).	Ex. 1
537		1H-NMR (CDCl3) δ: 5.08 (2H, s), 7.08 (1H, t, J = 2.0 Hz), 7.15-7.22 (2H, m), 7.26-7.32 (1H, m), 7.49 (1H, t, J = 1.9 Hz), 7.61 (1H, t, J = 2.0 Hz), 12.1 (1H, br.).	Ex. 1



[0782]

Ex. No.	STR	1H-NMR	ref.
538		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.74-6.83 (1H, m), 6.94-7.03 (2H, m), 7.09 (1H, t, J = 1.9 Hz), 7.49 (1H, s), 7.62 (1H, s), 12.1 (1H, br.).	Ex. 1
539		1H-NMR (CDCl3) δ: 5.13 (2H, s), 7.00-7.08 (1H, m), 7.11 (1H, t, J = 2.0 Hz), 7.14-7.24 (2H, m), 7.33-7.42 (1H, m), 7.50 (1H, s), 7.60 (1H, s).	Ex. 1
540		1H-NMR (CDCl3) δ: 5.09 (2H, s), 7.06-7.13 (3H, m), 7.40-7.46 (2H, m), 7.49-7.51 (1H, m), 7.59 (1H, t, J = 1.6 Hz).	Ex. 1
541		1H-NMR (CDCl3) δ: 1.86-1.98 (4H, m), 4.07-4.10 (2H, m), 4.47-4.50 (1H, m), 4.59-4.51 (1H, m), 5.22 (2H, s), 6.67-6.68 (1H, m), 7.21 (2H, bs), 7.87 (1H, s), 7.93 (2H, s).	Ex. 1
542		1H-NMR (CDCl3) δ: 0.38-0.39 (2H, m), 0.67-0.69 (2H, m), 1.25-1.35 (1H, m), 3.88 (2H, d, J = 7.4 Hz), 5.22 (2H, s), 6.69 (1H, t, J = 2.2 Hz), 7.20 (2H, bs), 7.86 (1H, s), 7.93 (2H, s).	Ex. 1
543		1H-NMR (CDCl3) δ: 5.20 (2H, s), 7.09-7.29 (4H, m), 7.52 (1H, s), 7.62 (1H, s), 12.3 (1H, br.).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
544		1H-NMR (CDCl3) δ: 4.43 (2H, q, J = 7.9 Hz), 5.24 (2H, s), 6.45 (1H, t, J = 2.3 Hz), 7.24 (1H, s), 7.35 (1H, s), 7.88 (1H, s), 7.93 (2H, s).	Ex. 1
545		1H-NMR (CDCl3-DMSO-d6) δ: 5.18 (2H, s), 7.06-7.14 (2H, m), 7.19 (1H, t, J = 8.0 Hz), 7.32-7.38 (1H, m), 7.48-7.55 (2H, m), 7.61 (1H, s).	Ex. 2
546		1H-NMR (DMSO-d6) δ: 5.43 (2H, s), 7.53-7.54 (1H, m), 7.57-7.58 (1H, m), 7.69-7.70 (1H, m), 8.03 (1H, d, J = 8.4 Hz), 8.09 (1H, d, J = 8.4 Hz), 8.24 (1H, s).	Ex. 2
547		1H-NMR (DMSO-d6) δ: 5.32 (2H, s), 7.49-7.53 (2H, m), 7.61-7.68 (2H, m), 7.74 (1H, dd, J = 2.7, 9.2 Hz), 8.87 (1H, dd, J = 5.5, 8.5 Hz).	Ex. 2
548		1H-NMR (DMSO-d6) δ: 5.33 (2H, s), 7.51-7.54 (2H, m), 7.65-7.69 (2H, m), 7.74 (1H, d, J = 7.7 Hz), 7.80 (1H, d, J = 7.5 Hz), 7.86 (1H, s).	Ex. 2
549		1H-NMR (DMSO-d6) δ: 0.33-0.36 (2H, m), 0.57-0.62 (2H, m), 1.21-1.31 (1H, m), 3.90 (2H, d, J = 7.1 Hz), 5.39 (2H, s), 6.85-6.86 (1H, m), 7.08-7.11 (2H, m), 8.01 (1H, d, J = 8.3 Hz), 8.08 (1H, d, J = 8.3 Hz), 8.21 (1H, s).	Ex. 2

[0783]





Ex. No.	STR	1H-NMR	ref.
550		1H-NMR (DMSO-d6) δ: 0.32-0.36 (2H, m), 0.57-0.61 (2H, m), 1.18-1.30 (1H, m), 3.89 (2H, d, J = 7.1 Hz), 5.29 (2H, s), 6.82-6.84 (1H, m), 7.05-7.06 (1H, m), 7.11-7.12 (1H, m), 7.66 (1H, t, J = 7.7 Hz), 7.72 (1H, d, J = 7.9 Hz), 7.79 (1H, d, J = 7.7 Hz), 7.85 (1H, s).	Ex. 2
551		1H-NMR (DMSO-d6) δ: 5.34 (2H, s), 7.42 (2H, d, J = 7.9 Hz), 7.59 (1H, s), 7.64-7.66 (2H, m), 7.79-7.80 (2H, m).	Ex. 2
552		1H-NMR (CDCl3) δ: 2.34 (3H, s), 5.36 (2H, s), 7.06 (1H, d, J = 7.9 Hz), 7.13 (1H, d, J = 7.6 Hz), 7.33 (1H, t, J = 7.9 Hz), 7.71-7.77 (1H, m), 7.87 (1H, d, J = 8.0 Hz), 8.13 (1H, s), 12.4 (1H, br.).	Ex. 1
553		1H-NMR (DMSO-d6) δ: 5.47 (2H, s), 7.42 (1H, t, J = 2.0 Hz), 7.48 (1H, t, J = 2.0 Hz), 7.56 (1H, t, J = 1.5 Hz), 8.04-8.20 (3H, m).	Ex. 1
554		1H-NMR (CDCl3) δ: 2.32 (3H, s), 5.24 (2H, s), 7.05 (1H, d, J = 8.3 Hz), 7.13 (1H, d, J = 7.6 Hz), 7.33 (1H, t, J = 7.9 Hz), 7.88 (1H, s), 7.94 (2H, s).	Ex. 1
555		1H-NMR (DMSO-d6) δ: 5.48 (2H, s), 7.53 (1H, s), 7.55 (1H, s), 7.75 (1H, d, J = 7.9 Hz), 8.13 (1H, s), 8.21 (2H, m).	Ex. 1
556		1H-NMR (CDCl3) δ: 5.36 (2H, s), 7.15-7.19 (1H, m), 7.27 (1H, dd, J = 7.5, 8.6 Hz), 7.37-7.40 (2H, m), 7.48 (1H, t, J = 8.2 Hz), 7.61-7.65 (2H, m), 12.2 (1H, br.).	Ex. 1
557		1H-NMR (CDCl3) δ: 5.20 (2H, s), 6.90-7.01 (2H, m), 7.11-7.17 (1H, m), 7.30-7.41 (1H, m), 7.46 (1H, t, J = 8.2 Hz), 7.58-7.64 (2H, m).	Ex. 1
558		1H-NMR (DMSO-d6) δ: 5.37 (2H, s), 7.51 (1H, s), 7.54 (1H, s), 7.73 (1H, d, J = 8.2 Hz), 7.75-7.82 (2H, m), 7.99 (1H, s).	Ex. 1


Ex. No.	STR	m.p	ref.
559		153-156	Ex. 1
560		170-171	Ex. 1
561		123-126	Ex. 1



[0784]





Ex. No.	STR	1H-NMR	ref.
562		1H-NMR (CDCl3) δ: 5.72 (2H, s), 7.21-7.24 (2H, m), 7.42-7.50 (5H, m), 7.51-7.57 (1H, m), 8.25 (1H, d, J = 7.6 Hz), 13.0 (1H, br.).	Ex. 1
563		1H-NMR (DMSO-d6) δ: 3.87 (3H, s), 5.44 (2H, s), 7.02-7.07 (2H, m), 7.67 (1H, brs), 7.81 (1H, d, J = 8.1 Hz), 7.88 (1H, s), 7.93 (1H, d, J = 8.1 Hz).	Ex. 1
564		1H-NMR (DMSO-d6) δ: 5.09 (2H, s), 7.67 (1H, s), 7.93-7.96 (4H, m).	Ex. 1
565		1H-NMR (DMSO-d6) δ: 5.31 (2H, s), 7.36-7.44 (2H, m), 7.57-7.61 (1H, m), 7.83 (1H, s), 7.93-7.97 (2H, m).	Ex. 1
566		1H-NMR (DMSO-d6) δ: 5.36 (2H, s), 7.29-7.82 (4H, m), 7.82 (2H, s).	Ex. 1
567		1H-NMR (DMSO-d6) δ: 5.38 (2H, s), 7.31 (1H, d, J = 9.0 Hz), 7.58-7.69 (5H, m).	Ex. 1
568		1H-NMR (DMSO-d6) δ: 5.19 (2H, s), 7.34-7.43 (4H, m), 7.56-7.62 (2H, m).	Ex. 1
569		1H-NMR (DMSO-d6) δ: 4.95 (2H, s), 7.37 (1H, d, J = 9.1 Hz), 7.42 (1H, s), 7.50-7.53 (1H, m), 7 .62 (1H, d, J = 9.1 Hz), 7.85-7.87 (1H, m).	Ex. 1
570		1H-NMR (DMSO-d6) δ: 5.12 (2H, s), 7.34-7.37 (2H, m), 7.39 (1H, s), 7 .62 (1H, d, J = 8.7 Hz), 7.67-7.72 (1H, m).	Ex. 1
571		1H-NMR (DMSO-d6) δ: 4.97 (2H, s), 7 .39 (1H, d, J = 9.1 Hz), 7.43 (1H, s), 7 .62 (1H, d, J = 9.1 Hz), 7 .67 (1H, d, J = 2.6 Hz), 7.97 (1H, d, J = 2.6 Hz).	Ex. 1
572		1H-NMR (DMSO-d6) δ: 5.02 (2H, s), 6.97 (1H, m), 7.09-7.17 (1H, m), 7.28-7.38 (3H, m), 7.51-7.57 (1H, m).	Ex. 1
573		1H-NMR (DMSO-d6) δ: 5.29 (2H, s), 7.35-7.44 (2H, m), 7.54-7.61 (1H, m), 7.90 (2H, s), 8.04 (1H, s).	Ex. 1
574		1H-NMR (DMSO-d6) δ: 5.38 (2H, s), 7.25 (1H, d, J = 8.9 Hz), 7.59 (1H, d, J = 9.4 Hz), 7.65 (1H, s), 7.66 (1H, s), 7.73-7.79 (1H, m), 7.80 (1H, s).	Ex. 1
575		1H-NMR (DMSO-d6) δ: 5.12 (2H, s), 7.14 (1H, s), 7.20 (1H, d, J = 7.6 Hz), 7.28 (1H, d, J = 8.2 Hz), 7.32-7.43 (3H, m), 7.53-7.58 (1H, m).	Ex. 1
576		1H-NMR (DMSO-d6) δ: 5.15 (2H, s), 7.30-7.63 (7H, m).	Ex. 1
577		1H-NMR (DMSO-d6) δ: 5.44 (2H, s), 7.32-7.37 (1H, m), 7.43-7.54 (2H, m), 8.08 (1H, s), 8.11 (2H, s).	Ex. 1
578		1H-NMR (DMSO-d6) δ: 5.29 (2H, s), 7.30-7.54 (4H, m), 7.73-7.83 (2H, m).	Ex. 1
579		1H-NMR (DMSO-d6) δ: 5.04 (2H, s), 7.27-7.42 (4H, m), 7.54-7.59 (1H, m).	Ex. 1





[0785]

Ex. No.	STR	1H-NMR	ref.
586		1H-NMR (DMSO-d6) δ: 7.17-7.19 (1H, m), 7.28 (1H, d, J = 8.8 Hz), 7.44-7.45 (1H, m), 7.48-7.51 (1H, m), 7.62-7.82 (2H, m), 7.83 (1H, s).	Ex. 1
589		1H-NMR (DMSO-d6) δ: 7.12-7.16 (2H, m), 7.22-7.24 (1H, m), 7.46-7.50 (2H, m), 7.51 (1H, t, J = 1.8 Hz), 7.63-7.69 (2H, m).	Ex. 1
590		1H-NMR (CDCl3) δ: 7.0-7.1 (2H, m), 7.33 (1H, s), 7.3-7.4 (2H, m), 7.77 (1H, s), 7.97 (1H, s).	Ex. 1
591		1H-NMR (CDCl3) δ: 6.95-7.0 (1H, m), 7.05 (1H, s), 7.15-7.25 (1H, m), 7.3-7.4 (2H, m), 7.79 (1H, s), 8.00 (1H, s).	Ex. 1

Ex. No.	STR	m.p.	ref.
592		166-167	Ex. 1
593		174-176	Ex. 1

Ex. No.	STR	m.p.	ref.
594		130-135	Ex. 1
595		92-93	Ex. 1

Ex. No.	STR	m.p.	ref.
584		139-142	Ex. 1
585		153	Ex. 1
587		144-147	Ex. 1
588		129	Ex. 1

Ex. No.	STR	m.p.	ref.
580		244-246	Ex. 1
581		219-220	Ex. 1
582		260-262	Ex. 1
583		176-177	Ex. 1

[0786]

Ex. No.	STR	1H-NMR	ref.
596		1H-NMR (DMSO-d6) δ: 7.36 (1H, d, J = 8.7 Hz), 7.45-7.47 (1H, m), 7.54 (1H, s), 7.64 (1H, d, J = 7.8 Hz), 7.71 (1H, t, J = 7.8 Hz), 8.16-8.30 (1H, m), 8.30 (1H, s).	Ex. 1
597		1H-NMR (DMSO-d6) δ: 7.33-7.35 (1H, m), 7.37 (1H, d, J = 8.6 Hz), 7.43 (1H, s), 7.57 (1H, d, J = 8.0 Hz), 7.67 (1H, d, J = 8.0 Hz), 7.93-7.95 (1H, m), 8.26 (1H, s).	Ex. 1
598		1H-NMR (DMSO-d6) δ: 7.27 (2H, d, J = 8.1 Hz), 7.41-7.57 (4H, m), 7.74 (1H, d, J = 8.4 Hz).	Ex. 1
599		1H-NMR (DMSO-d6) δ: 7.35-7.45 (3H, m), 7.58 (1H, d, J = 7.8 Hz), 7.67 (1H, t, J = 7.8 Hz), 7.90 (1H, d, J = 8.5 Hz), 8.12 (1H, s).	Ex. 1
















Ex. No.	STR	m.p.	ref.
600		189-192	Ex. 2
601		191-194	Ex. 2
602		231-234	Ex. 2
603		284-286	Ex. 2

Ex. No.	STR	m.p.	ref.
604		269-272	Ex. 2
605		243-244	Ex. 2
606		196	Ex. 1
607		194-196	Ex. 1

Ex. No.	STR	1H-NMR	ref.
608		1H-NMR (DMSO-d6) δ: 7.13-7.18 (1H, m), 7.43-7.47 (4H, m), 7.52-7.54 (1H, m), 7.58-7.63 (1H, m), 7.71-7.73 (1H, m), 7.92 (1H, brs).	Ex. 2
609		1H-NMR (DMSO-d6) δ: 7.31-7.36 (1H, m), 7.41-7.59 (4H, m), 7.67-7.69 (2H, m), 8.06 (1H, s), 8.17 (1H, s), 8.37 (1H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
610		1H-NMR (DMSO-d6) δ: 7.67 (1H, d, J = 16.4 Hz), 7.79 (1H, d, J = 16.4 Hz), 7.85 (1H, s), 7.94 (1H, s), 8.01 (1H, s), 8.07 (1H, s), 8.36 (2H, s).	Ex. 1
611		1H-NMR (DMSO-d6) δ: 7.68-7.88 (4H, m), 8.02 (1H, s), 8.15 (1H, s), 8.37 (2H, s).	Ex. 1








[0787]








Ex. No.	STR	1H-NMR	ref.
612		1H-NMR (DMSO-d6) δ: 7.59-7.69 (4H, m), 7.75 (1H, s), 7.87 (1H, s), 7.96-7.98 (1H, m), 8.04 (1H, s), 8.15 (1H, s).	Ex. 1
613		1H-NMR (DMSO-d6) δ: 7.47 (1H, d, J = 16.5 Hz), 7.58 (1H, d, J = 16.5 Hz), 7.63-7.68 (3H, m), 7.79-7.86 (2H, m), 7.96-7.98 (1H, m), 8.02 (1H, s), 8.13 (1H, s).	Ex. 1
614		1H-NMR (DMSO-d6) δ: 7.39 (1H, t, J = 73.5 Hz), 7.51-7.67 (6H, m), 7.96-7.99 (2H, m), 8.01 (1H, d, J = 10.1 Hz).	Ex. 1
615		1H-NMR (DMSO-d6) δ: 7.58 (1H, d, J = 16.5 Hz), 7.68 (1H, t, J = 7.8 Hz), 7.79-7.86 (3H, m), 7.99 (1H, s), 8.14 (1H, s), 8.37 (2H, s).	Ex. 1
616		1H-NMR (DMSO-d6) δ: 7.52 (1H, d, J = 16.6 Hz), 7.57 (1H, d, J = 16.6 Hz), 7.77 (2H, d, J = 8.3 Hz), 7.82-7.87 (3H, m), 7.97 (1H, s), 8.07 (1H, s).	Ex. 1
617		1H-NMR (DMSO-d6) δ: 7.46 (1H, d, J = 16.5 Hz), 7.55 (1H, d, J = 16.5 Hz), 7.66 (1H, t, J = 7.8 Hz), 7.75-7.88 (6H, m), 8.13 (1H, s).	Ex. 1
618		1H-NMR (DMSO-d6) δ: 7.16-7.22 (1H, m), 7.39-7.56 (4H, m), 7.83 (1H, s), 7.91 (1H, s), 8.02 (1H, s).	Ex. 1
619		1H-NMR (CDCl3) δ: 7.29-7.38 (2H, m), 7.82 (1H, s), 7.92 (1H, s), 7.99 (2H, s), 8.21 (1H, s), 8.38 (1H, s).	Ex. 1
620		1H-NMR (CDCl3) δ: 7.22-7.38 (2H, m), 7.50-7.59 (2H, m), 7.73 (1H, d, J = 8.0 Hz), 7.81 (1H, s), 7.89 (1H, s), 8.16 (1H, s), 8.34 (1H, s).	Ex. 1
621		1H-NMR (DMSO-d6) δ: 7.13-7.19 (1H, m), 7.31-7.83 (7H, m), 8.08 (1H, s).	Ex. 1
622		1H-NMR (DMSO-d6) δ: 7.31-7.44 (5H, m), 7.63-7.67 (3H, m), 7.77-7.80 (2H, m), 8.09 (1H, s).	Ex. 1
623		1H-NMR (DMSO-d6) δ: 7.26 (2H, t, J = 7.2 Hz), 7.31 (1H, d, J = 16.4 Hz), 7.47 (1H, d, J = 16.4 Hz), 7.68-7.71 (2H, m), 7.79 (1H, s), 7.91 (1H, s), 8.01 (1H, s).	Ex. 1
624		1H-NMR (DMSO-d6) δ: 7.59 (2H, s), 7.76-7.89 (6H, m), 8.15 (1H, s).	Ex. 1
625		1H-NMR (DMSO-d6) δ: 7.39 (1H, t, J = 73.4 Hz), 7.55-7.60 (3H, m), 7.70 (1H, s), 7.77 (2H, d, J = 8.2 Hz), 7.88 (2H, d, J = 8.2 Hz), 8.01 (1H, s).	Ex. 1
626		1H-NMR (CDCl3) δ: 2.49 (3H, s), 7.18-7.32 (2H, m), 7.50 (1H, s), 7.55 (1H, s), 7.77 (1H, s), 7.94-7.97 (3H, m), 12.1 (1H, br.).	Ex. 1
627		1H-NMR (CDCl3) δ: 2.47 (3H, s), 7.00-7.18 (4H, m), 7.45-7.54 (3H, m), 7.67 (1H, s), 7.90 (1H, s), 12.2 (1H, br.).	Ex. 1
628		1H-NMR (DMSO-d6) δ: 7.17-7.23 (1H, m), 7.40-7.45 (2H, m), 7.54 (1H, d, J = 16.5 Hz), 7.64 (1H, d, J = 16.5 Hz), 8.10 (1H, s), 8.16 (1H, s), 8.34 (1H, s).	Ex. 2
629		1H-NMR (DMSO-d6) δ: 7.66 (2H, s), 7.79 (2H, d, J = 8.2 Hz), 7.89 (2H, d, J = 8.2 Hz), 8.11 (1H, s), 8.24 (1H, s), 8.41 (1H, s).	Ex. 2
630		1H-NMR (DMSO-d6) δ: 7.67 (1H, d, J = 16.5 Hz), 7.80 (1H, d, J = 16.5 Hz), 7.98-8.01 (2H, m), 8.09-8.10 (2H, m), 8.35 (2H, s).	Ex. 2

[0788]















Ex. No.	STR	1H-NMR	ref.
631		1H-NMR (DMSO-d6) δ: 7.25-7.61 (2H, m), 7.63-7.69 (2H, m), 7.95-7.96 (2H, m), 8.02 (1H, s), 8.09-8.10 (2H, m).	Ex. 2
632		1H-NMR (DMSO-d6) δ: 1.41 (3H, t, J = 7.0 Hz), 4.18 (2H, q, J = 7.0 Hz), 7.40 (1H, s), 7.44 (1H, s), 7.60 (1H, d, J = 16.4 Hz), 7.70 (1H, s), 7.74 (1H, d, J = 16.4 Hz), 7.99 (1H, s), 8.34 (2H, s).	Ex. 2
633		1H-NMR (CDCl3) δ: 2.47 (3H, s), 7.12 (1H, d, J = 16.4 Hz), 7.20 (1H, d, J = 16.4 Hz), 7.25-7.32 (1H, m), 7.34-7.42 (2H, m), 7.48 (1H, s), 7.51-7.57 (2H, m), 7.66 (1H, s), 7.90 (1H, s), 12.0 (1H, br.).	Ex. 1
634		1H-NMR (CDCl3) δ: 3.85 (3H, s), 6.88-6.95 (2H, m), 7.02 (1H, d, J = 16.3 Hz), 7.17 (1H, d, J = 16.3 Hz), 7.45-7.54 (3H, m), 7.59-7.66 (1H, m), 7.79-7.88 (1H, m), 8.07 (1H, s), 12.0 (1H, br.).	Ex. 1
635		1H-NMR (DMSO-d6) δ: 7.32-7.38 (2H, m), 7.46 (2H, d, J = 8.5 Hz), 7.61-7.69 (3H, m), 7.80 (2H, t, J = 7.8 Hz), 8.09 (1H, s).	Ex. 1
636		1H-NMR (DMSO-d6) δ: 7.33-7.51 (4H, m), 7.59-7.67 (2H, m), 7.76-7.83 (3H, m), 8.10 (1H, s).	Ex. 1
637		1H-NMR (DMSO-d6) δ: 7.39-7.46 (4H, m), 7.55-7.60 (1H, m), 7.76 (1H, s), 7.81 (1H, s), 7.92 (1H, s), 8.03 (1H, s).	Ex. 1
638		1H-NMR (DMSO-d6) δ: 7.37-7.52 (4H, m), 7.61 (1H, d, J = 7.6 Hz), 7.74 (1H, s), 7.77 (1H, s), 7.84 (1H, s), 8.12 (1H, s).	Ex. 1
639		1H-NMR (DMSO-d6) δ: 7.27 (2H, t, J = 8.9 Hz), 7.32 (1H, t, J = 16.6 Hz), 7.38 (1H, d, J = 16.6 Hz), 7.70-7.73 (3H, m), 7.82 (1H, s), 8.10 (1H, s).	Ex. 1
640		1H-NMR (DMSO-d6) δ: 7.24 (2H, t, J = 8.9 Hz), 7.34 (2H, d, J = 4.4 Hz), 7.60-7.81 (5H, m), 8.08 (1H, s).	Ex. 1
641		1H-NMR (DMSO-d6) δ: 7.38 (1H, d, J = 16.5 Hz), 7.51 (1H, d, J = 16.5 Hz), 7.57-7.68 (2H, m), 7.80-7.88 (4H, m), 8.09 (1H, s).	Ex. 1
642		1H-NMR (DMSO-d6) δ: 4.37 (1H, d, J = 16.5 Hz), 7.44-7.49 (3H, m), 7.67 (2H, d, J = 8.5 Hz), 7.79 (1H, s), 7.91 (1H, s), 8.02 (1H, s).	Ex. 1
643		1H-NMR (DMSO-d6) δ: 7.48 (1H, d, J = 14.1 Hz), 7.68-7.90 (5H, m), 8.02 (1H, d, J = 8.3 Hz), 8.18 (1H, s), 8.41 (1H, s).	Ex. 1
644		1H-NMR (DMSO-d6) δ: 1.40 (3H, t, J = 6.9 Hz), 4.18 (2H, q, J = 6.9 Hz), 7.34-7.35 (1H, m), 7.43-7.44 (1H, m), 7.51 (2H, s), 7.64-7.66 (2H, m), 7.69 (1H, s), 7.94-7.96 (1H, m), 8.00 (1H, s).	Ex. 2
645		1H-NMR (DMSO-d6) δ: 7.17-7.23 (1H, m), 7.32-7.38 (1H, m), 7.48-7.57 (2H, m), 7.88-7.94 (1H, m), 8.09 (1H, s), 8.19 (1H, s), 8.41 (1H, s).	Ex. 2
646		1H-NMR (DMSO-d6) δ: 7.15-7.20 (1H, m), 7.30-7.44 (3H, m), 7.64 (1H, t, J = 7.8 Hz), 7.80-7.82 (2H, m), 7.88-7.94 (1H, m), 8.12 (1H, s).	Ex. 2
647		1H-NMR (CDCl3) δ: 3.91 (3H, s), 6.90-7.02 (2H, m), 7.17 (1H, d, J = 16.5 Hz), 7.24-7.32 (1H, m), 7.46-7.65 (3H, m), 7.69 (1H, d, J = 7.9 Hz), 7.84 (1H, d, J = 7.7 Hz), 8.08 (1H, s), 12.0 (1H, br.).	Ex. 1
648		1H-NMR (DMSO-d6) δ: 7.36-7.54 (4H, m), 7.76-7.80 (3H, m), 7.92 (1H, s), 8.03 (1H, s).	Ex. 1
649		1H-NMR (DMSO-d6) δ: 7.31 (1H, d, J = 8.3 Hz), 7.45-7.58 (3H, m), 7.67-7.70 (2H, m), 7.81 (1H, s), 7.93 (1H, s), 8.04 (1H, s).	Ex. 1
650		1H-NMR (DMSO-d6) δ: 7.05-7.20 (1H, m), 7.34-7.56 (5H, m), 7.64 (1H, t, J = 7.7 Hz), 7.78-7.83 (2H, m), 8.09 (1H, s).	Ex. 1
651		1H-NMR (DMSO-d6) δ: 7.14-7.18 (1H, m), 7.43-7.54 (5H, m), 7.81 (1H, s), 7.92 (1H, s), 8.03 (1H, s).	Ex. 1








[0789]








Ex. No.	STR	1H-NMR	ref.
652		1H-NMR (CDCl3) δ: 6.90 (1H, d, J = 16.5 Hz), 7.12 (1H, d, J = 16.5 Hz), 7.12-7.26 (2H, m), 7.32-7.41 (1H, m), 7.53 (1H, t, J = 7.7 Hz), 7.60-7.66 (1H, m), 7.84-7.96 (1H, m), 8.11 (1H, s), 12.0 (1H, br.).	Ex. 1
653		1H-NMR (CDCl3) δ: 7.14 (1H, d, J = 16.0 Hz), 7.40 (1H, t, J = 7.6 Hz), 7.53-7.62 (3H, m), 7.67-7.73 (2H, m), 7.81 (1H, d, J = 7.9 Hz), 7.89-7.96 (1H, m), 8.10 (1H, s), 12.0 (1H, br.).	Ex. 1
654		1H-NMR (CDCl3) δ: 3.87 (3H, s), 6.82-6.89 (1H, m), 7.05-7.24 (4H, m), 7.30 (1H, t, J = 7.9 Hz), 7.52 (1H, t, J = 7.7 Hz), 7.65 (1H, d, J = 7.8 Hz), 7.83-7.92 (1H, m), 8.10 (1H, s), 12.3 (1H, br.).	Ex. 1
655		1H-NMR (DMSO-d6) δ: 7.41 (1H, d, J = 16.5 Hz), 7.57 (1H, t, J = 16.5 Hz), 7.59-7.69 (2H, m), 7.76 (1H, d, J = 7.7 Hz), 7.78-7.85 (2H, m), 7.97 (1H, d, J = 7.9 Hz), 8.10 (1H, s), 8.17 (1H, s).	Ex. 1
656		1H-NMR (DMSO-d6) δ: 3.91 (3H, s), 7.39-7.40 (1H, m), 7.46 (1H, s), 7.61 (1H, d, J = 16.5 Hz), 7.72-7.79 (2H, m), 8.00 (1H, s), 8.36 (2H, s).	Ex. 2
657		1H-NMR (DMSO-d6) δ: 3.90 (3H, s), 7.36-7.37 (1H, m), 7.44-7.45 (1H, m), 7.47-7.56 (2H, m), 7.64-7.67 (2H, m), 7.71 (1H, s), 7.95-7.97 (1H, m), 8.01 (1H, s).	Ex. 2
658		1H-NMR (DMSO-d6) δ: 3.90 (3H, s), 7.37-7.38 (1H, m), 7.45-7.54 (3H, m), 7.72-7.77 (3H, m), 7.85-7.87 (2H, m).	Ex. 2

Ex. No.	STR	1H-NMR	ref.
659		1H-NMR (DMSO-d6) δ: 7.48 (1H, d, J = 16.3 Hz), 7.58-7.69 (3H, m), 7.82-7.91 (4H, m), 8.11 (1H, s).	Ex. 2
660		1H-NMR (DMSO-d6) δ: 7.32 (1H, d, J = 7.7 Hz), 7.52-7.59 (3H, m), 7.69-7.71 (2H, m), 7.74 (1H, s), 7.83 (1H, s), 8.13 (1H, s).	Ex. 1
661		1H-NMR (DMSO-d6) δ: 7.45 (1H, d, J = 16.6 Hz), 7.52 (1H, t, J = 9.5 Hz), 7.64-7.76 (3H, m), 7.83-7.88 (2H, m), 8.17 (1H, s), 8.26-8.28 (1H, m).	Ex. 2
662		1H-NMR (DMSO-d6) δ: 7.48 (1H, d, J = 16.6 Hz), 7.59 (1H, d, J = 16.6 Hz), 7.66 (1H, t, J = 7.6 Hz), 7.76 (1H, d, J = 8.3 Hz), 7.80-7.85 (2H, m), 7.97-8.00 (1H, m), 8.11 (2H, s).	Ex. 2
663		1H-NMR (DMSO-d6) δ: 7.46 (1H, d, J = 16.5 Hz), 7.52 (1H, d, J = 16.5 Hz), 7.54-7.59 (1H, m), 7.65 (1H, t, J = 7.6 Hz), 7.79-7.83 (2H, m), 8.03-8.06 (2H, m), 8.10 (1H, s).	Ex. 2
664		1H-NMR (DMSO-d6) δ: 7.44-7.49 (2H, m), 7.58 (1H, d, J = 16.7 Hz), 7.67 (1H, t, J = 7.9 Hz), 7.73 (1H, t, J = 7.2 Hz), 7.83-7.87 (2H, m), 8.17-8.23 (2H, m).	Ex. 2
665		1H-NMR (DMSO-d6) δ: 3.89 (3H, s), 7.15-7.20 (1H, m), 7.30-7.39 (5H, m), 7.71 (1H, s), 7.86-7.92 (1H, m).	Ex. 2














[0790]

Ex. No.	STR	1H-NMR	ref.
666		1H-NMR (DMSO-d6) δ: 7.13-7.49 (5H, m), 7.56 (1H, s), 7.63-7.70 (3H, m), 7.96 (1H, s).	Ex. 1
667		1H-NMR (DMSO-d6) δ: 7.25-7.29 (2H, m), 7.43 (1H, d, J = 16.5 Hz), 7.56 (1H, d, J = 16.5 Hz), 7.71-7.75 (2H, m), 8.06 (1H, s), 8.16 (1H, s), 8.35 (1H, s).	Ex. 2
668		1H-NMR (DMSO-d6) δ: 3.89 (3H, s), 7.22-7.40 (6H, m), 7.66-7.71 (3H, m).	Ex. 2
669		1H-NMR (DMSO-d6) δ: 7.14-7.47 (5H, m), 7.55 (1H, s), 7.63 (1H, s), 7.63-7.73 (2H, m), 7.95 (1H, s).	Ex. 1
670		1H-NMR (DMSO-d6) δ: 7.46-7.61 (3H, m), 7.82 (1H, s), 7.93 (1H, s), 8.00-8.06 (3H, m).	Ex. 1
671		1H-NMR (DMSO-d6) δ: 7.38-7.50 (3H, m), 7.63-7.68 (1H, m), 7.81 (1H, s), 7.90-7.94 (2H, m), 8.01 (1H, s).	Ex. 1
672		1H-NMR (DMSO-d6) δ: 7.18-7.24 (1H, m), 7.30-7.40 (2H, m), 7.55 (1H, d, J = 16.3 Hz), 7.65 (1H, t, J = 7.7 Hz), 7.74-7.78 (1H, m), 7.81-7.84 (2H, m), 8.14 (1H, s).	Ex. 2
673		1H-NMR (DMSO-d6) δ: 7.33 (1H, d, J = 16.6 Hz), 7.50 (1H, d, J = 16.6 Hz), 7.59-7.67 (2H, m), 7.80-7.84 (2H, m), 8.01-8.08 (1H, m), 8.12 (1H, s).	Ex. 2
674		1H-NMR (DMSO-d6) δ: 7.04-7.53 (5H, m), 7.71 (2H, d, J = 8.7 Hz), 7.79 (1H, s), 7.91 (1H, s), 8.02 (1H, s).	Ex. 1
675		1H-NMR (DMSO-d6) δ: 7.48-7.67 (5H, m), 7.83-7.86 (1H, m), 7.99-8.04 (2H, m), 8.29 (1H, dd, J = 2.2, 7.2 Hz).	Ex. 1
676		1H-NMR (DMSO-d6) δ: 7.45 (1H, d, J = 16.6 Hz), 7.53-7.57 (2H, m), 7.63-7.65 (2H, m), 7.90-7.94 (2H, m), 7.99 (1H, s), 8.03-8.05 (1H, m).	Ex. 1
677		1H-NMR (DMSO-d6) δ: 7.52-7.59 (2H, m), 7.77 (1H, d, J = 8.2 Hz), 7.83-7.92 (5H, m), 8.29-8.33 (1H, m).	Ex. 1
678		1H-NMR (DMSO-d6) δ: 7.22-7.28 (2H, m), 7.34-7.56 (3H, m), 7.71-7.81 (3H, m), 8.26 (1H, dd, J = 2.2, 7.1 Hz).	Ex. 1
679		1H-NMR (DMSO-d6) δ: 7.53-7.59 (1H, m), 7.61 (1H, d, J = 16.7 Hz), 7.77 (1H, d, J = 16.7 Hz), 7.86-7.89 (1H, m), 8.02 (1H, s), 8.27-8.30 (1H, m), 8.42 (2H, s).	Ex. 1





Ex. No.	STR	1H-NMR	ref.
680		1H-NMR (DMSO-d6) δ: 7.49-7.59 (3H, m), 7.62-7.68 (3H, m), 7.95-7.97 (2H, m), 8.02 (1H, brs).	Ex. 2
681		1H-NMR (DMSO-d6) δ: 7.51 (1H, t, J = 7.8 Hz), 7.65 (1H, d, J = 16.7 Hz), 7.72-7.77 (1H, m), 7.81 (1H, d, J = 16.7 Hz), 8.02 (2H, s), 8.44 (2H, s).	Ex. 1
682		1H-NMR (DMSO-d6) δ: 7.45-7.86 (5H, m), 8.02 (2H, s), 8.43 (2H, s).	Ex. 1
683		1H-NMR (DMSO-d6) δ: 2.17 (3H, s), 7.35 (1H, d, J = 16.2 Hz), 7.59-7.69 (3H, m), 7.78 (1H, dd, J = 2.0, 8.4 Hz), 7.87 (1H, d, J = 8.4 Hz), 7.97-7.99 (2H, m), 8.25 (1H, d, J = 2.0 Hz), 9.86 (1H, s).	Ex. 1
684		1H-NMR (DMSO-d6) δ: 3.83 (3H, s), 6.77-6.82 (1H, m), 7.08-7.14 (2H, m), 7.44 (1H, d, J = 16.6 Hz), 7.52 (1H, d, J = 16.6 Hz), 7.74 (1H, s), 7.82 (1H, s), 8.10 (1H, s).	Ex. 1
685		1H-NMR (DMSO-d6) δ: 2.28 (3H, s), 7.19 (1H, t, J = 9.1 Hz), 7.34 (1H, d, J = 16.4 Hz), 7.44 (1H, d, J = 16.4 Hz), 7.49-7.53 (1H, m), 7.61 (1H, d, J = 7.7 Hz), 7.71 (1H, s), 7.80 (1H, s), 8.09 (1H, s).	Ex. 1
686		1H-NMR (DMSO-d6) δ: 1.50 (9H, s), 7.30 (1H, d, J = 16.2 Hz), 7.61-7.68 (3H, m), 7.76-7.77 (2H, m), 7.87-7.96 (1H, m), 7.98 (1H, s), 8.22 (1H, s), 9.32 (1H, s).	Ex. 1




Ex. No.	STR	1H-NMR	ref.
687		1H-NMR (DMSO-d6) δ: 1.06-1.69 (9H, br), 3.22 (3H, s), 7.17-7.32 (1H, m), 7.43 (1H, d, J = 16.4 Hz), 7.56 (1H, d, J = 8.2 Hz), 7.66-7.68 (2H, m), 7.84 (1H, dd, J = 2.1, 8.2 Hz), 7.87-7.99 (2H, br), 8.30 (1H, d, J = 2.2 Hz).	Ex. 1
689		1H-NMR (CDCl3) δ: 1.45 (3H, t, J = 7.0 Hz), 4.09 (2H, q, J = 7.0 Hz), 6.85 (1H, ddd, J = 0.8, 2.5, 8.1 Hz), 7.07-7.16 (3H, m), 7.18 (1H, d, J = 16.5 Hz), 7.30 (1H, t, J = 7.8 Hz), 7.52 (1H, t, J = 7.8 Hz), 7.65 (1H, d, J = 7.9 Hz), 7.86 (1H, d, J = 7.8 Hz), 8.09 (1H, s).	Ex. 1
690		1H-NMR (DMSO-d6) δ: 7.17 (1H, d, J = 16.3 Hz), 7.48 (1H, d, J = 7.6 Hz), 7.54 (1H, dd, J = 1.8, 7.6 Hz), 7.69 (1H, d, J = 16.3 Hz), 7.81 (1H, s), 7.86 (1H, dd, J = 1.7, 7.7 Hz), 7.97 (2H, s).	Ex. 2
691		1H-NMR (DMSO-d6) δ: 5.32 (2H, s), 7.30-7.46 (7H, m), 7.70 (1H, d, J = 16.8 Hz), 7.81 (1H, d, J = 7.4 Hz), 7.90 (1H, d, J = 2.2 Hz), 7.95 (1H, s), 8.28 (2H, s).	Ex. 2
692		1H-NMR (DMSO-d6) δ: 1.25 (6H, d, J = 6.1 Hz), 3.68-3.90 (1H, m), 5.86-5.97 (1H, m), 6.86 (1H, d, J = 8.7 Hz), 7.14 (1H, d, J = 16.3 Hz), 7.60-7.68 (4H, m), 7.97-8.00 (3H, m).	Ex. 316
694		1H-NMR (DMSO-d6) δ: 7.10 (1H, t, J = 7.7 Hz), 7.38 (1H, d, J = 16.3 Hz), 7.52 (1H, dd, J = 1.5, 7.7 Hz), 7.64-7.67 (2H, m), 7.78 (1H, d, J = 16.3 Hz), 7.86-7.88 (1H, m), 7.93-7.95 (1H, m), 8.01 (1H, s).	Ex. 2
695		1H-NMR (DMSO-d6) δ: 4.68 (2H, s), 7.15-7.17 (2H, m), 7.26-7.32 (3H, m), 7.43 (1H, t, J = 7.7 Hz), 7.49 (2H, s), 7.55 (1H, dd, J = 1.6, 7.7 Hz), 7.61-7.67 (2H, m), 7.84 (2H, bs), 8.01-8.03 (1H, m).	Ex. 2



[0792]






Ex. No.	STR	1H-NMR	ref.
696		1H-NMR (DMSO-d6) δ: 1.46 (3H, t, J = 7.0 Hz), 4.26 (2H, q, J = 7.0 Hz), 7.30-7.34 (1H, m), 7.54 (1H, d, J = 16.2 Hz), 7.72 (1H, d, J = 16.2 Hz), 7.82 (1H, d, J = 7.7 Hz), 7.99 (1H, s), 8.15 (1H, s), 8.28 (2H, s).	Ex. 2
697		1H-NMR (DMSO-d6) δ: 2.85 (3H, d, J = 3.5 Hz), 6.50 (1H, brs), 6.77 (1H, d, J = 8.8 Hz), 7.17 (1H, d, J = 15.9 Hz), 7.56-7.72 (4H, m), 7.89-7.94 (1H, m), 8.00-8.04 (2H, m).	Ex. 690
698		1H-NMR (DMSO-d6) δ: 1.11 (3H, t, J = 7.1 Hz), 2.80 (3H, s), 3.07 (2H, q, J = 7.1 Hz), 7.23 (1H, d, J = 3.5 Hz), 7.31 (1H, d, J = 4.4 Hz), 7.47 (1H, d, J = 16.4 Hz), 7.64-7.66 (2H, m), 7.78 (1H, dd, J = 2.2, 8.4 Hz), 7.90-7.98 (2H, m), 8.12 (1H, d, J = 2.2 Hz).	Ex. 316
699		1H-NMR (CDCl3) δ: 3.92 (3H, s), 6.95 (1H, t, J = 8.6 Hz), 6.99 (1H, d, J = 16.3 Hz), 7.09 (1H, d, J = 16.3 Hz), 7.20-7.24 (1H, m), 7.30 (1H, dd, J = 2.0, 12.5 Hz), 7.50 (1H, t, J = 7.7 Hz), 7.59-7.63 (1H, m), 7.83-7.87 (1H, m), 8.07 (1H, s).	Ex. 1
700		1H-NMR (CDCl3) δ: 1.07 (3H, t, J = 7.4 Hz), 1.78-1.91 (2H, m), 3.98 (2H, t, J = 6.6 Hz), 6.82-6.87 (1H, m), 7.07-7.16 (3H, m), 7.19 (1H, d, J = 16.2 Hz), 7.28 (1H, t, J = 7.8 Hz), 7.52 (1H, t, J = 7.8 Hz), 7.62-7.67 (1H, m), 7.87-7.89 (1H, m), 8.08-8.10 (1H, m).	Ex. 1
701		1H-NMR (DMSO-d6) δ: 2.46 (3H, s), 7.41-7.50 (3H, m), 7.64 (1H, t, J = 7.8 Hz), 7.78-7.87 (3H, m), 7.91 (1H, s), 8.11 (1H, s).	Ex. 1
702		1H-NMR (DMSO-d6) δ: 2.45 (3H, s), 7.39-7.55 (3H, m), 7.78 (1H, s), 7.83 (1H, d, J = 8.2 Hz), 7.90 (2H, s), 8.02 (1H, s).	Ex. 1
703		1H-NMR (DMSO-d6) δ: 3.17 (3H, s), 3.27 (3H, s), 7.47 (1H, d, J = 16.5 Hz), 7.61 (1H, d, J = 16.6 Hz), 7.66-7.70 (2H, m), 7.81 (1H, d, J = 8.3 Hz), 7.87-7.95 (3H, m), 8.37 (1H, d, J = 1.9 Hz).	Ex. 693
704		1H-NMR (DMSO-d6) δ: 7.11 (1H, d, J = 8.2 Hz), 7.39 (1H, d, J = 16.3 Hz), 7.58 (1H, d, J = 16.3 Hz), 7.63-7.68 (3H, m), 7.91-7.93 (2H, m), 8.12 (1H, d, J = 2.3 Hz), 10.68 (1H, bs).	Ex. 2
705		1H-NMR (DMSO-d6) δ: 1.45 (3H, t, J = 7.0 Hz), 4.23 (2H, q, J = 7.0 Hz), 7.31 (1H, d, J = 8.7 Hz), 7.42 (1H, d, J = 16.5 Hz), 7.57 (1H, d, J = 16.5 Hz), 7.64-7.66 (2H, m), 7.80 (1H, dd, J = 2.3, 8.7 Hz), 7.90-7.94 (2H, m), 8.17 (1H, d, J = 2.3 Hz).	Ex. 2
706		1H-NMR (DMSO-d6) δ: 7.08 (1H, d, J = 8.6 Hz), 7.25 (1H, d, J = 16.7 Hz), 7.43 (1H, d, J = 16.7 Hz), 7.59-7.61 (2H, m), 7.69 (1H, dd, J = 2.1, 8.6 Hz), 7.82 (1H, d, J = 2.1 Hz), 7.87-7.92 (2H, m).	Ex. 2
707		1H-NMR (DMSO-d6) δ: 1.39 (3H, t, J = 6.9 Hz), 4.21 (2H, q, J = 6.9 Hz), 7.28-7.35 (2H, m), 7.47 (1H, d, J = 16.5 Hz), 7.60-7.64 (2H, m), 7.80 (1H, dd, J = 2.2, 8.7 Hz), 7.87-7.94 (3H, m).	Ex. 2
708		1H-NMR (DMSO-d6) δ: 7.49 (1H, d, J = 16.2 Hz), 7.63-7.72 (3H, m), 7.78 (1H, d, J = 8.3 Hz), 7.83 (1H, dd, J = 2.2, 8.3 Hz), 8.00-8.02 (2H, m), 8.34 (1H, d, J = 2.2 Hz).	Ex. 2

[0793]







Ex. No.	STR	1H-NMR	ref.
709		1H-NMR (DMSO-d6) δ: 7.53 (2H, s), 7.64-7.66 (2H, m), 7.88-8.00 (6H, m).	Ex. 1
710		1H-NMR (DMSO-d6) δ: 7.51 (1H, d, J = 16.6 Hz), 7.59 (1H, d, J = 16.6 Hz), 7.65-7.81 (4H, m), 8.00-8.08 (3H, m).	Ex. 1
711		1H-NMR (DMSO-d6) δ: 7.64-7.90 (5H, m), 8.06 (1H, s), 8.34 (2H, s).	Ex. 1
712		1H-NMR (DMSO-d6) δ: 7.62 (1H, d, J = 16.5 Hz), 7.77 (1H, d, J = 16.5 Hz), 7.86-8.00 (5H, m), 8.41 (2H, s).	Ex. 1







Ex. No.	STR	1H-NMR	ref.
713		1H-NMR (DMSO-d6) δ: 7.52 (2H, s), 7.72-7.82 (2H, m), 7.85-7.92 (6H, m).	Ex. 1
714		1H-NMR (DMSO-d6) δ: 7.22-7.32 (3H, m), 7.42 (1H, d, J = 16.7 Hz), 7.68-7.73 (2H, m), 7.82 (2H, d, J = 8.4 Hz), 7.91 (2H, d, J = 8.4 Hz).	Ex. 1
717		1H-NMR (DMSO-d6) δ: 7.38 (1H, d, J = 16.3 Hz), 7.57 (1H, d, J = 16.3 Hz), 7.73-7.82 (4H, m), 7.98-8.00 (2H, m), 8.24 (1H, d, J = 8.9 Hz).	Ex. 1









Ex. No.	STR	m.p.	ref.
715		206.0-206.3	Ex. 1
716		210-213	Ex. 2

Ex. No.	STR	m.p.	ref.
718		231-233	Ex. 1
719		225-227	Ex. 1
720		255-258	Ex. 1
721		235-237	Ex. 1
722		253-255	Ex. 1
723		251	Ex. 1
724		208-209	Ex. 1

[0794]

Ex. No.	STR	m.p.	ref.
725		253	Ex. 1
726		243-247	Ex. 1
727		258-259	Ex. 1
728		265-266	Ex. 1
729		220-221	Ex. 1
730		219-220	Ex. 1

Ex. No.	STR	m.p.	ref.
732		256-257	Ex. 1
733		270-271	Ex. 1
734		267-268	Ex. 1
735		204-205	Ex. 1
736		179-183	Ex. 1
737		182-191	Ref. Ex. 112, Ex. 1
738		147.1-149.7	Ex. 125

Ex. No.	STR	1H-NMR	ref.
731		1H-NMR (DMSO-d6) δ: 7.65 (1H, t, J= 8.1 Hz), 7.76 (1H, t, J= 7.8 Hz), 7.83 (1H, d, J = 7.3 Hz), 7.94 (1H, d, J = 7.8 Hz), 8.06 (1H, d, J= 7.3 Hz), 8.16 (1H, s), 8.23 (1H, d, J = 7.8 Hz), 8.30-8.33 (1H, m).	Ex. 1
739		1H-NMR (DMSO-d6) δ: 7.42-7.45 (2H, m), 7.91-7.95 (1H, m), 8.05-8.08 (1H, m), 8.17 (1H, s), 8.21 (1H, s), 8.33 (1H, s), 8.48 (1H, s).	Ex. 1
740		1H-NMR (DMSO-d6) δ: 7.45 (1H, dd, J = 2.0, 8.6 Hz), 7.93 (1H, s), 7.97 (1H, d, J = 2.0 Hz), 8.05 (1H, s), 8.08-8.10 (1H, m), 8.11 (1H, s), 8.17 (1H, s).	Ex. 1
741		1H-NMR (DMSO-d6) δ: 7.25-7.33 (1H, m), 7.69-7.81 (2H, m), 7.89-8.02 (3H, m), 8.05-8.12 (1H, m), 8.25-8.29 (1H, m).	Ex. 1
742		1H-NMR (DMSO-d6) δ: 7.28-3.36 (1H, m), 7.69-7.74 (1H, m), 7.93 (1H, t, J = 1.6 Hz), 8.06-8.13 (3H, m), 8.18 (1H, t, J = 1.6 Hz).	Ex. 1
743		1H-NMR (DMSO-d6) δ: 7.29-7.36 (1H, m), 7.71-7.76 (1H, m), 7.85-7.88 (1H, m), 8.01-8.04 (1H, m), 8.08-8.15 (2H, m), 8.24-8.27 (1H, m).	Ex. 1
744		1H-NMR (DMSO-d6) δ: 2.52 (3H, s), 7.06-7.14 (1H, m), 7.44-7.48 (1H, m), 7.58 (1H, s), 7.64 (1H, s), 7.73-7.80 (2H, m), 8.13 (1H, s).	Ex. 1
745		1H-NMR (DMSO-d6) δ: 2.52 (3H, s), 7.42-7.50 (2H, m), 7.75-7.78 (2H, m), 7.87 (1H, d, J =7.9 Hz), 7.93-7.96 (1H, m), 8.02 (1H, d, J =7.9 Hz), 8.10 (1H, s).	Ex. 1








[0795]





Ex. No.	STR	1H-NMR	ref.
746		1H-NMR (DMSO-d6) δ: 2.51 (3H, s), 7.49 (1H, dd, J = 2.0, 8.6 Hz), 7.78 (1H, s), 7.92 (1H, s), 7.98 (1H, d, J = 2.0 Hz), 8.04-8.12 (2H, m).	Ex. 1
747		1H-NMR (DMSO-d6) δ: 7.68-7.73 (1H, m), 7.77 (1H, t, J = 7.9 Hz), 7.92-7.97 (1H, m), 8.00-8.05 (1H, m), 8.12 (1H, s), 8.28-8.34 (3H, m).	Ex. 1
748		1H-NMR (DMSO-d6) δ: 7.70-7.81 (2H, m), 7.92-7.97 (1H, m), 8.03-8.15 (3H, m), 8.31 (1H, s), 8.59 (1H, s).	Ex. 1
749		1H-NMR (DMSO-d6) δ: 7.26-7.33 (1H, m), 7.44-7.52 (1H, m), 7.72-7.80 (2H, m), 7.91-7.96 (1H, m), 8.01-8.06 (1H, m), 8.09 (1H, d, J =3.7 Hz), 8.30 (1H, t, J = 1.7 Hz).	Ex. 1
750		1H-NMR (DMSO-d6) δ: 7.93 (1H, d, J = 7.6 Hz), 8.02-8.10 (2H, m), 7.25 (1H, t, J = 7.8 Hz), 8.35-8.43 (3H, m).	Ex. 1
751		1H-NMR (DMSO-d6) δ: 7.42-7.51 (1H, m), 7.64-7.70 (1H, m), 7.97 (1H, t, J = 1.7 Hz), 8.15 (1H, t, J = 1.7 Hz), 8.18 (1H, d, J = 3.6 Hz), 8.22 (1H, t, J = 1.5 Hz).	Ex. 1
752		1H-NMR (DMSO-d6) δ: 1.42 (9H, s), 7.39-7.45 (1H, m), 7.64-7.67 (1H, m), 7.99-8.02 (2H, m), 8.08-8.13 (2H, m).	Ex. 125



Ex. No.	STR	m.p.	ref.
753		294-296	Ex. 1
754		281-282	Ex. 1
755		111-113	Ex. 1
756		190-191	Ex. 1









Ex. No.	STR	1H-NMR	ref.
757		1H-NMR (DMSO-d6) δ: 7.59 (1H, d, J = 8.9 Hz), 7.65 (1H, d, J = 5.0 Hz), 7.73-7.75 (1H, m), 7.83 (1H, d, J = 10.1 Hz), 8.08-8.09 (2H, m).	Ex. 1
758		1H-NMR (DMSO-d6) δ: 7.49 (1H, t, J = 7.8 Hz), 7.55-7.56 (1H, m), 7.70-7.75 (2H, m), 7.93-7.96 (2H, m).	Ex. 1
759		1H-NMR (DMSO-d6) δ: 7.65-7.66 (1H, m), 7.73-7.74 (1H, m), 7.82 (1H, s), 8.02 (1H, s), 8.11 (1H, s), 8.17 (1H, s).	Ex. 1
760		1H-NMR (DMSO-d6) δ: 7.54-7.61 (2H, m), 7.75-7.77 (1H, m), 7.85-7.88 (1H, m), 7.95-7.96 (1H, m), 8.21-8.23 (1H, m).	Ex. 1
761		1H-NMR (DMSO-d6) δ: 3.93 (3H, s), 7.30 (1H, d, J = 8.8 Hz), 7.56-7.57 (1H, m), 7.66-7.67 (1H, m), 7.84-7.85 (1H, m), 7.90-7.98 (1H, m), 7.99 (1H, s).	Ex. 1
762		1H-NMR (CDCl3) δ: 7.43-7.47 (2H, m), 7.54-7.58 (2H, m), 7.73-7.75 (1H, m), 7.89-7.94 (1H, m), 8.23 (1H, s).	Ex. 1
763		1H-NMR (DMSO-d6) δ: 7.64-7.67 (1H, m), 7.73-7.75 (1H, m), 7.95 (1H, s), 8.11-8.12 (1H, m), 8.15 (1H, s), 8.21 (1H, s).	Ex. 1
764		1H-NMR (DMSO-d6) δ: 7.43-7.49 (1H, m), 7.52-7.58 (2H, m), 7.70-7.76 (2H, m), 7.81-7.86 (2H, m), 8.06-8.08 (1H, m), 8.11-8.13 (1H, m), 8.16-8.20 (2H, m).	Ex. 1

[0796]







Ex. No.	STR	1H-NMR	ref.
765		1H-NMR (DMSO-d6) δ: 1.40 (3H, t, J = 7.0 Hz), 4.19 (2H, q, J = 7.0 Hz), 7.34 (1H, s), 7.46 (1H, s), 7.60-7.62 (1H, m), 7.70-7.71 (1H, m), 7.78 (1H, s), 8.80-8.01 (1H, m).	Ex. 1
766		1H-NMR (DMSO-d6) δ: 3.28 (3H, s), 7.47-7.49 (1H, m), 7.59-7.60 (1H, m), 7.68-7.72 (2H, m), 8.02 (1H, s).	Ex. 1
767		1H-NMR (DMSO-d6) δ: 1.35 (6H, d, J = 6.0 Hz), 4.76-4.86 (1H, m), 7.32-7.33 (1H, m), 7.43-7.44 (1H, m), 7.60-7.61 (1H, m), 7.69-7.70 (1H, m), 7.75-7.76 (1H, m), 7.99-8.01 (1H, m).	Ex. 1
768		1H-NMR (DMSO-d6) δ: 2.45 (3H, s), 7.58-7.62 (2H, m), 7.70-7.72 (1H, m), 7.76 (1H, s), 7.95 (1H, s), 8.01 (1H, s).	Ex. 1
769		1H-NMR (DMSO-d6) δ: 2.46 (3H, s), 7.34-7.36 (1H, m), 7.45 (1H, s), 7.77-7.85 (2H, m), 8.06 (1H, d, J = 5.1 Hz).	Ex. 1
770		1H-NMR (DMSO-d6) δ: 7.38 (1H, d, J = 5.8 Hz), 7.67 (1H, d, J = 5.8 Hz), 7.79 (1H, s), 7.87 (1H, s), 8.18 (1H, t, J = 1.5 Hz).	Ex. 1
771		1H-NMR (DMSO-d6) δ: 2.20 (3H, s), 2.46 (3H, s), 7.24 (1H, d, J = 5.0 Hz), 7.48 (1H, s), 7.73 (1H, s), 7.76 (1H, s), 8.01 (1H, d, J = 5.0 Hz).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
772		1H-NMR (DMSO-d6) δ: 7.11-7.13 (1H, m), 7.34 (1H, d, J = 1.0 Hz), 7.35 (1H, d, J = 1.0 Hz), 7.42-7.43 (1H, m), 7.53-7.56 (1H, m), 7.73-7.75 (1H, m), 8.23 (1H, s).	Ex. 1
773		1H-NMR (DMSO-d6) δ: 2.57 (3H, s), 7.93 (1H, d, J = 4.0 Hz), 8.03 (1H, d, J = 4.0 Hz), 8.18 (1H, s), 8.30 (1H, s), 8.47 (1H, s).	Ex. 1
774		1H-NMR (DMSO-d6) δ: 7.25 (1H, dd, J = 3.7, 5.0 Hz), 7.74 (1H, dd, J = 1.0, 5.0 Hz), 7.82 (1H, dd, J = 1.0, 3.7 Hz), 8.10 (1H, s), 8.18 (1H, s), 8.41 (1H, s).	Ex. 1
776		1H-NMR (DMSO-d6) δ: 2.52 (3H, s), 7.84 (1H, s), 7.92 (1H, d, J = 7.8 Hz), 8.12 (1H, s), 8.25 (1H, t, J = 8.0 Hz), 8.34 (1H, d, J = 8.0 Hz), 8.47 (1H, s).	Ex. 1


Ex. No.	STR	m.p.	ref.
775		144-145	Ex. 1
777		190	Ex. 1

Ex. No.	STR	m.p.	ref.
778		197	Ex. 1
779		242-244	Ex. 1
780		128-130	Ref. Ex. 91, Ex. 1
781		180-183	Ex. 1
782		253-255	Ex. 1
783		225-228	Ex. 1
784		220−223	Ex. 125
785		168-171	Ex. 125

[0797]

Ex. No.	STR	1H-NMR	ref.
786		1H-NMR (CDCl3) δ: 7.53-7.55 (1H, m), 8.03 (1H, s), 8.34 (1H, s), 8.42 (1H, s), 8.84 (1H, s), 8.92 (1H, d, J = 5.0 Hz).	Ex. 2
787		1H-NMR (DMSO-d6) δ: 8.31 (1H, s), 8.40-8.43 (2H, m), 8.62 (1H, s), 8.95 (1H, s), 9.13 (1H, s).	Ex. 2
788		1H-NMR (DMSO-d6) δ: 7.83 (1H, t, J = 7.8 Hz), 8.04 (1H, d, J = 5.0 Hz), 8.12 (1H, d, J = 7.8 Hz), 8.56 (1H, d, J = 7.8 Hz), 9.00 (1H, s), 9.35 (1H, d, J = 5.0 Hz).	Ex. 1
789		1H-NMR (CDCl3) δ: 7.59-7.65 (2H, m), 7.98-8.06 (3H, m), 8.17-8.20 (1H, m), 8.82 (1H, s).	Ex. 1
790		1H-NMR (CDCl3) δ: 7.47 (1H, d, J = 5.0 Hz), 7.63 (1H, t, J = 7.8 Hz), 8.01 (1H, s), 8.07 (1H, d, J = 7.8 Hz), 8.15 (1H, d, J = 7.8 Hz), 8.62 (1H, s), 8.87 (1H, d, J = 5.0 Hz).	Ex. 1
791		1H-NMR (CDCl3) δ: 3.96 (3H, s), 7.57 (1H, s), 7.68-7.74 (2H, m), 7.98-8.03 (2H, m), 8.16 (1H, s).	Ex. 1
792		1H-NMR (DMSO-d6) δ: 3.95 (3H, s), 7.57-7.58 (1H, m), 7.87-7.88 (1H, m), 8.28-8.31 (2H, m), 8.37-8.39 (1H, m), 9.11 (1H, s).	Ex. 1
793		1H-NMR (CDCl3) δ: 5.24 (2H, s), 7.35-7.44 (3H, m), 7.49-7.51 (2H, m), 7.74 (2H, s), 7.92 (1H, d, J = 8.4 Hz), 8.08-8.11 (1H, m), 8.30 (1H, s), 9.01 (1H, s).	Ex. 1
794		1H-NMR (DMSO-d6) δ: 2.69 (3H, s), 7.71 (1H, s), 7.77 (1H, t, J = 8.0 Hz), 7.99-8.01 (1H, m), 8.18 (1H, s), 8.35-8.38 (1H, m), 8.72-8.73 (1H, m).	Ex. 1
795		1H-NMR (CDCl3) δ: 2.10-2.17 (2H, m), 2.32-2.42 (2H, m), 4.20 (2H, t, J = 5.9 Hz), 7.65-7.66 (1H, m), 7.72-7.73 (1H, m), 7.95 (1H, d, J = 8.4 Hz), 8.06-8.09 (1H, m), 8.28 (1H, s), 8.99 (1H, s).	Ex. 1
796		1H-NMR (CDCl3) δ: 1.88-2.05 (4H, m), 4.17-4.21 (2H, m), 4.46-4.50 (1H, m), 4.62-4.66 (1H, m), 7.66 (2H, s), 7.95 (1H, d, J = 8.4 Hz), 8.09-8.12 (1H, m), 8.28 (1H, s), 9.01 (1H, s).	Ex. 1
797		1H-NMR (DMSO-d6) δ: 7.98 (1H, d, J = 7.6 Hz), 8.05-8.06 (1H, m), 8.29 (1H, t, J = 8.0 Hz), 8.35-8.36 (1H, m), 8.44 (1H, d, J = 8.0 Hz), 8.65 (1H, s),	Ex. 1
798		1H-NMR (DMSO-d6) δ: 7.85 (1H, d, J = 4.4 Hz), 8.03 (1H, s), 8.48 (1H, s), 8.51 (1H, s), 8.71 (1H, s), 9.02 (1H, d, J = 4.4 Hz),	Ex. 1
799		1H-NMR (CDCl3) δ: 1.50 (3H, t, J = 7.3 Hz), 4.21 (2H, q, J = 7.3 Hz), 7.62-7.63 (1H, m), 7.65-7.66 (1H, m), 7.95 (1H, d, J = 8.3 Hz), 8.11 (1H, dd, J = 1.8, 8.5 Hz), 8.28 (1H, s), 9.01-9.02 (1H, m).	Ex. 1
800		1H-NMR (DMSO-d6) δ: 5.02 (2H, q, J = 8.9 Hz), 7.68 (1H, s), 8.01 (1H, s), 8.34-8.43 (3H, m), 9.21 (1H, s).	Ex. 1
801		1H-NMR (DMSO-d6) δ: 8.05 (1H, d, J = 1.8 Hz), 8.06-8.43 (3H, m), 8.67 (1H, s), 9.13 (1H, s).	Ex. 1
802		1H-NMR (DMSO-d6) δ: 0.38-0.41 (2H, m), 0.60-0.65 (2H, m), 1.29-1.34 (1H, m), 4.03 (2H, d, J = 6.9 Hz), 7.55-7.57 (1H, m), 7.82-7.83 (1H, m), 7.92-7.95 (1H, m), 8.23-8.27 (2H, m), 8.39 (1H, d, J = 8.0 Hz).	Ex. 2
803		1H-NMR (DMSO-d6) δ: 0.38-0.42 (2H, m), 0.60-0.65 (2H, m), 1.28-1.35 (1H, m), 4.04 (2H, d, J = 7.0 Hz), 7.53-7.54 (1H, m), 7.80-7.82 (1H, m), 7.91-7.92 (1H, m), 8.30-8.31 (1H, m), 8.43 (1H, s), 8.99 (1H, d, J = 4.9 Hz).	Ex. 2
804		1H-NMR (DMSO-d6) δ: 5.26 (3H, s), 7.72-7.80 (2H, m), 7.83-7.87 (1H, m), 7.96-8.01 (2H, m).	Ex. 1

[0798]





Ex. No.	STR	1H-NMR	ref.
805		1H-NMR (DMSO-d6) δ: 2.52 (3H, s), 7.78-7.84 (2H, m), 8.24 (1H, s), 8.38 (1H, s), 8.53 (1H, s), 8.99 (1H, d, J = 5.0 Hz).	Ex. 1
806		1H-NMR (DMSO-d6) δ: 7.88 (1H, d, J = 4.5 Hz), 7.97 (1H, s), 8.42 (1H, s), 8.54 (1H, s), 8.79 (1H, t, J = 1.5 Hz), 9.03 (1H, d, J = 4.5 Hz).	Ex. 1
807		1H-NMR (DMSO-d6) δ: 2.52 (3H, s), 7.84 (1H, s), 8.18 (1H, s), 8.25 (1H, d, J = 8.4 Hz), 8.37 (1H, dd, J = 2.0, 8.4 Hz), 8.49 (1H, s), 9.09 (1H, s).	Ex. 1
809		1H-NMR (DMSO-d6) δ: 0.27-0.34 (2H, m), 0.52-0.59 (2H, m), 1.02-1.15 (1H, m), 2.72 (2H, d, J = 6.8 Hz), 7.97 (1H, s), 8.22 (1H, s), 8.27 (1H, d, J = 8.5 Hz), 8.35-8.40 (1H, m), 8.51-8.53 (1H, m), 9.09-9.11 (1H, m).	Ex. 1
810		1H-NMR (DMSO-d6) δ: 2.51 (3H, s), 7.79 (1H, s), 8.06-8.10 (3H, m), 8.41 (1H, s), 8.75-8.77 (1H, m).	Ex. 1
811		1H-NMR (DMSO-d6) δ: 1.37 (6H, d, J = 6.0 Hz), 4.86-4.92 (1H, m), 7.42 (1H, d, J = 9.0 Hz), 8.22 (1H, d, J = 8.5 Hz), 8.28-8.31 (1H, m), 8.33-8.37 (1H, m), 8.39 (1H, d, J = 2.3 Hz), 9.03 (1H, s).	Ex. 1
812		1H-NMR (DMSO-d6) δ: 1.42 (9H, s), 8.09 (1H, t, J = 1.5 Hz), 8.31-8.34 (2H, m), 8.46-8.51 (2H, m), 9.16-9.17 (1H, m).	Ex. 125




Ex. No.	STR	m.p.	ref.
808		168-169	Ex. 1
813		204-206	Ex. 1
814		198-200	Ex. 1
815		243-244	Ex. 1
816		204-208	Ex. 1
817		185-186	Ex. 1
818		213-217	Ex. 1







Ex. No.	STR	1H-NMR	ref.
819		1H-NMR (DMSO-d6) δ: 7.97-7.99 (1H, m), 8.11-8.13 (1H, m), 8.20-8.24 (2H, m), 8.68 (1H, d, J = 2.6 Hz), 8.90 (1H, s).	Ex. 1
820		1H-NMR (DMSO-d6) δ: 1.21 (3H, t, J = 7.0 Hz), 3.59 (2H, q, J = 7.0 Hz), 4.66 (2H, s), 7.94 (1H, s), 7.98 (1H, s), 8.08 (1H, d, J = 8.2 Hz), 8.21 (1H, s), 8.43-8.46 (1H, m), 9.16 (1H, q, J = 1.9 Hz).	Ex. 1






Ex. No.	STR	m.p.	ref.
821		180-203	Ex. 1
822		158-161	Ex. 1
823		243-247	Ex. 1
824		183 – 185	Ex. 1

[0799]


Ex. No.	STR	m.p.	ref.
825		220—222	Ex. 1
826		197-200	Ex. 1
827		250-254	Ex. 1
828		169-174	Ex. 1

Ex. No.	STR	1H-NMR	ref.
829		1H-NMR (DMSO-d6) δ: 1.43 (9H, s), 6.96-6.99 (1H, m), 7.67-7.69 (1H, m), 7.90-7.94 (1H, m), 8.00-8.10 (2H, m).	Ex. 1
830		1H-NMR (CDCl3) δ: 7.72-7.78 (2H, m), 8.17-8.21 (1H, m), 8.26 (1H, s), 8.37 (1H, s), 8.98 (1H, s), 9.25 (1H, s).	Ex. 1
831		1H-NMR (CDCl3) δ: 7.92 (1H, s), 8.18 (1H, s), 8.37 (1H, s), 8.44 (1H, s), 8.97 (1H, s), 9.12 (1H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
832		1H-NMR (DMSO-d6) δ: 0.28-0.34 (2H, m), 0.51-0.59 (2H, m), 1.03-1.15 (1H, m), 2.70 (2H, d, J = 7.0 Hz), 7.92 (2H, d, J = 8.5 Hz), 8.07 (1H, d, J = 8.5 Hz), 8.11 (1H, s), 8.40-8.46 (1H, m), 9.13-9.17 (1H, m).	Ex. 1
833		1H-NMR (DMSO-d6) δ: 1.42 (9H, s), 8.01-8.04 (2H, m), 8.09-8.11 (1H, m), 8.57 (1H, s), 9.03 (1H, s), 9.28 (1H, s).	Ex. 1
834		1H-NMR (DMSO-d6) δ: 1.42 (9H, s), 7.95-7.99 (1H, m), 8.03-8.10 (3H, m), 8.42-8.48 (1H, m), 9.14-9.17 (1H, m).	Ex. 1
835		1H-NMR (DMSO-d6) δ: 0.95 (6H, d, J = 6.2 Hz), 1.55-1.65 (3H, m), 2.78 (2H, t, J = 7.6 Hz), 7.83 (1H, s), 7.86 (1H, s), 8.06 (1H, d, J = 8.2 Hz), 8.09 (1H, t, J = 1.5 Hz), 8.43 (1H, dd, J = 2.0, 8.2 Hz), 9.15 (1H, d, J = 2.0 Hz).	Ex. 1
836		1H-NMR (DMSO-d6) δ: 7.26 (1H, t, J = 55.5 Hz), 8.11 (1H, d, J = 8.5 Hz), 8.18 (1H, s), 8.22 (1H, s), 8.46 (1H, s), 8.49-8.51 (1H, m), 9.20 (1H, s).	Ex. 1
837		1H-NMR (DMSO-d6) δ: 3.60 (3H, s), 5.26-5.35 (1H, m), 8.06 (1H, s), 8.10 (2H, d, J = 7.5 Hz), 8.37 (1H, s), 8.45 (1H, d, J = 7.5 Hz), 9.16 (1H, s).	Ex. 1

Ex. No.	STR	m.p.	ref.
838		227-229	Ex. 1
839		179-182	Ex. 1
841		236-238	Ex. 1
843		231-232	Ex. 1
844		218-220	Ex. 1

[0800]









Ex. No.	STR	1H-NMR	ref.
840		1H-NMR (DMSO-d6) δ: 1.59-1.85 (6H, m), 1.97-2.07 (2H, m), 5.02-5.07 (1H, m), 7.50 (1H, s), 7.52 (1H, s), 7.82 (1H, s), 8.05 (1H, d, J = 8.3 Hz), 8.44 (1H, dd, J = 2.0, 8.3 Hz), 9.15 (1H, d, J = 2.0 Hz).	Ex. 1
842		1H-NMR (DMSO-d6) δ: 1.41 (3H, t, J = 7.0 Hz), 4.25 (2H, q J = 7.0 Hz), 7.31-7.34 (1H, m), 7.38 (1H, d, J = 8.8 Hz), 7.76-7.82 (2H, m), 8.32-8.38 (1H, m).	Ex. 1
845		1H-NMR (DMSO-d6) δ: 7.93 (1H, d, J = 7.6 Hz), 8.07 (2H, d, J = 8.4 Hz), 8.25 (1H, t, J = 7.6 Hz), 8.38 (2H, d, J = 8.4 Hz), 8.41 (1H, d, J = 8.2 Hz).	Ex. 1









Ex. No.	STR	m.p.	ref.
846		300-303	Ex. 1
847		218-220	Ex. 1
848		278	Ex. 1









Ex. No.	STR	m.p.	ref.
849		248-249	Ex. 1
850		204-205	Ex. 1
851		201-206	Ex. 1
852		170-173	Ex. 1
853		177-178	Ex. 1

Ex. No.	STR	1H-NMR	ref.
854		1H-NMR (DMSO-d6) δ: 7.92-7.99 (2H, m), 8.05-8.09 (2H, m), 8.53 (1H, dd, J = 1.9, 8.1 Hz), 9.23 (1H, d, J = 1.9 Hz).	Ex. 125
855		1H-NMR (DMSO-d6) δ: 8.01-8.06 (4H, m), 8.17-8.21 (1H, m), 8.63 (1H, d, J = 2.5 Hz), 8.91 (1H, s).	Ex. 1
856		1H-NMR (DMSO-d6) δ: 5.34 (2H, s), 7.25-7.35 (3H, m), 7.66 (2H, d, J = 7.7 Hz), 7.86-7.90 (1H, m), 8.01 (1H, s).	Ex. 1
857		1H-NMR (CDCl3) δ: 5.16 (2H, s), 6.94-7.04 (3H, m), 7.27-7.34 (2H, m), 7.52-7.62 (2H, m), 7.92-7.97 (1H, m), 8.05 (1H, s).	Ex. 1
858		1H-NMR (CDCl3) δ: 5.27 (2H, s), 7.01-7.07 (2H, m), 7.46-7.65 (4H, m), 7.93-7.98 (1H, m), 8.04 (1H, s), 12.0 (1H, br.).	Ex. 1
859		1H-NMR (CDCl3) δ: 5.18 (2H, s), 7.16 (1H, dd, J = 2.4, 8.4 Hz), 7.23-7.26 (2H, m), 7.38-7.45 (1H, m), 7.54-7.61 (2H, m), 7.96-8.00 (1H, m), 8.07 (1H, s).	Ex. 1
860		1H-NMR (CDCl3) δ: 5.20 (2H, s), 7.06 (2H, d, J = 8.5 Hz), 7.54-7.59 (4H, m), 7.94-8.00 (1H, m), 8.06 (1H, s), 12.0 (1H, br.)	Ex. 1
861		1H-NMR (CDCl3) δ: 5.24 (2H, s), 6.93-7.02 (2H, m), 7.19-7.22 (1H, m), 7.40 (1H, dd, J = 1.6, 7.9 Hz), 7.56-7.64 (2H, m), 7.97-7.99 (1H, m), 8.07 (1H, s), 12.1 (1H, br.).	Ex. 1








[0801]








Ex. No.	STR	1H-NMR	ref.
862		1H-NMR (CDCl3) δ: 5.14 (2H, s), 6.86-6.91 (1H, m), 6.94-7.02 (2H, m), 7.22 (1H, t, J = 8.1 Hz), 7.53-7.59 (2H, m), 7.93-7.99 (1H, m), 8.04 (1H, s), 12.1 (1H, br.).	Ex. 1
863		1H-NMR (CDCl3) δ: 5.13 (2H, s), 6.90-6.95 (2H, m), 7.23-7.26 (2H, m), 7.55-7.58 (2H, m), 7.93-7.98 (1H, m), 8.04 (1H, s), 12.2 (1H, br.).	Ref. Ex. 499, Ex. 1
864		1H-NMR (CDCl3) δ: 5.24 (2H, s), 6.91 (1H, dd, J = 2.3, 7.4 Hz), 7.09-7.18 (2H, m), 7.54-7.66 (2H, m), 7.94-7.99 (1H. m), 8.06 (1H, s).	Ex. 1
865		1H-NMR (CDCl3) δ: 5.21 (2H, s), 6.92 (1H, d, J = 8.8 Hz), 7.18 (1H, dd, J = 2.5, 8.8 Hz), 7.40 (1H, d, J = 2.5 Hz), 7.54-7.64 (2H, m), 7.94-7.99 (1H, m), 8.05 (1H, s), 12.2 (1H, br.).	Ex. 1
866		1H-NMR (CDCl3) δ: 5.19 (2H, s), 6.92 (1H, dd, J = 2.2, 8.4 Hz), 6.99 (1H, d, J = 2.2 Hz), 7.31 (1H, d, J = 8.4 Hz), 7.54-7.64 (2H, m), 7.95-7.98 (1H, m), 8.06 (1H, s).	Ex. 1
867		1H-NMR (CDCl3) δ: 5.13 (2H, s), 7.04 (1H, dd, J = 7.8, 8.3 Hz), 7.34 (2H, d, J = 8.0 Hz), 7.58 (1H, t, J = 7.7 Hz), 7.72 (1H, d, J = 7.7 Hz), 7.99 (1H, d, J = 7.7 Hz), 8.18 (1H, s), 12.2 (1H, br.).	Ex. 1
868		1H-NMR (CDCl3) δ: 5.12 (2H, s), 6.85 (1H, dd, J = 2.9, 8.8 Hz), 7.10 (1H, d, J = 2.9 Hz), 7.34 (1H, d, J = 8.8 Hz), 7.53-7.60 (2H, m), 7.93-8.00 (1H. m), 8.04 (1H, s).	Ex. 1
869		1H-NMR (CDCl3) δ: 5.12 (2H, s), 6.90 (2H, d, J = 1.7 Hz), 6.99 (1H, t, J = 1.7 Hz), 7.53-7.61 (2H, m), 7.97-8.00 (1H. m), 8.03 (1H, s).	Ex. 1








Ex. No.	STR	1H-NMR	ref.
870		1H-NMR (CDCl3) δ: 5.10 (2H, s), 7.35 (2H, s), 7.58 (1H, t, J = 7.7 Hz), 7.69 (1H, d, J = 7.7 Hz), 7.99 (1H, d, J = 7.7 Hz), 8.16 (1H, s).	Ex. 1
871		1H-NMR (CDCl3) δ: 5.18 (2H, s), 6.73-6.83 (1H, m), 6.84-7.04 (2H, m), 7.52-7.61 (2H, m), 7.93-7.99 (1H, m), 8.04 (1H, s).	Ex. 1
872		1H-NMR (CDCl3) δ: 5.18 (2H, s), 6.62-6.75 (2H, m), 7.75-7.63 (2H, m), 7.97 (1H, d, J = 7.2 Hz), 8.04 (1H, s), 12.3 (1H, br.).	Ex. 1
873		1H-NMR (CDCl3) δ: 5.16 (2H, s), 7.17 (1H, dd, J = 2.5, 8.4 Hz), 7.22-7.29 (2H, m), 7.43 (1H, t, J = 8.0 Hz), 7.59 (1H, s), 7.94-8.00 (2H, m).	Ex. 1
874		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.69-6.80 (3H, m), 7.21-7.29 (1H, m), 7.57 (1H, s), 7.96 (2H, s), 12.3 (1H, br.).	Ex. 1
875		1H-NMR (CDCl3) δ: 5.14 (2H, s), 6.74-6.84 (1H, m), 6.85-7.03 (2H, m), 7.59 (1H, s), 7.95 (2H, s), 12.3 (1H, br.).	Ex. 1
876		1H-NMR (CDCl3) δ: 5.15 (2H, s), 6.66-6.76 (2H, m), 7.60 (1H, s), 7.96 (2H, s), 12.3 (1H, br.).	Ex. 1
877		1H-NMR (CDCl3) δ: 5.30 (2H, s), 7.14 (1H, d, J = 8.7 Hz), 7.59 (1H, s), 7.79 (1H, d, J = 8.7 Hz), 7.89 (1H, s), 7.95 (1H, s), 7.98 (1H, s).	Ex. 1









Ex. No.	STR	1H-NMR	ref.
878		1H-NMR (CDCl3) δ: 5.29 (2H, s), 7.31 (1H, s), 7.37 (1H, d, J = 8.2 Hz), 7.63 (1H, s), 7.77 (1H, d, J = 7.9 Hz), 7.99 (1H, s), 8.00 (1H, s).	Ex. 1
879		1H-NMR (CDCl3) δ: 5.17 (2H, s), 7.17 (1H, dd, J = 2.1, 8.0 Hz), 7.22-7.30 (2H, m), 7.43 (1H, t, J = 8.0 Hz), 7.75 (1H, s), 8.03 (1H, s), 8.12 (1H, s), 12.0 (1H, br.).	Ex. 1
880		1H-NMR (CDCl3) δ: 5.11 (2H, s), 6.65-6.82 (3H, m), 7.21-7.31 (1H, m), 7.72 (1H, s), 8.00 (1H, s), 8.10 (1H, s), 12.2 (1H, br.).	Ex. 1
881		1H-NMR (DMSO-d6) δ: 5.52 (2H, s), 7.51 (1H, d, J = 8.2 Hz), 7.64-7.69 (2H, m), 7.76 (1H, s), 7.87-7.92 (2H, m), 8.00 (1H, s).	Ex. 2
882		1H-NMR (DMSO-d6) δ: 5.34 (2H, s), 7.01-7.05 (1H, m), 7.11-7.17 (2H, m), 7.66-7.67 (2H, m), 7.87-7.89 (1H, m), 8.00 (1H, s).	Ex. 2
883		1H-NMR (DMSO-d6) δ: 2.53 (3H, s), 2.57 (3H, s), 7.73-7.78 (1H, m), 7.81-7.85 (1H, m), 7.97-8.01 (1H, m), 8.12-8.13 (1H, m), 8.48 (1H, s).	Ex. 2
884		1H-NMR (DMSO-d6) δ: 4.04 (6H, s), 6.26 (1H, s), 7.77 (1H, t, J = 7.8 Hz), 8.07-8.09 (1H, m), 8.52-8.55 (1H, m), 9.07-9.08 (1H, m).	Ex. 2
885		1H-NMR (DMSO-d6) δ: 7.58 (1H, t, J = 7.8 Hz), 8.00 (1H, dt, J = 1.5, 7.8 Hz), 8.24 (1H, dt, J = 1.5, 7.8 Hz), 8.93 (1H, t, J = 1.5 Hz), 9.03 (2H, s).	Ex. 2

[0802]







Ex. No.	STR	m.p.	ref.
886		219-221	Ex. 1
887		153-155	Ex. 1
888		272-275	Ex. 1
889		303-305	Ex. 1
890		306-307	Ex. 1
891		224	Ex. 1
892		187-189	Ex. 1



Ex. No.	STR	m.p.	ref.
893		209	Ex. 1
894		266-268	Ex. 1
895		281-283	Ex. 1
896		255-258	Ex. 1
897		288-291	Ex. 1
898		241	Ex. 1
899		136-139	Ex. 1





Ex. No.	STR	m.p.	ref.
900		285-286	Ex. 1
901		122-123	Ex. 1
902		170-173	Ex. 1
903		170-171	Ex. 1
904		95-98	Ex. 1
905		153-154	Ex. 1
906		171-174	Ex. 1








Ex. No.	STR	m.p.	ref.
907		290	Ex. 1
908		173.0-174.5	Ex. 2
909		192.0-194.0	Ex. 2
910		248-249	Ex. 1
911		226	Ex. 1
913		191	Ex. 1
914		171-172	Ex. 1
915		186-187	Ref. Ex. 91, Ex. 1

[0803]






















Ex. No.	STR	m.p.	ref.
916		175-180	Ex. 1
917		108-111	Ex. 1
918		177-180	Ex. 1
919		160-164	Ex. 1
920		157-166	Ex. 1
921		205-210	Ex. 1

Ex. No.	STR	m.p.	ref.
922		202-214	Ex. 125
923		182-186	Ex. 125








Ex. No.	STR	1H-NMR	ref.
912		1H-NMR (DMSO-d6) δ: 3.91 (3H, s), 7.23 (1H, dd, J = 4.7, 8.0 Hz), 7.68 (1H, t J = 7.8 Hz), 7.73-7.79 (1H, m), 7.86-7.92 (1H, m), 8.06 (1H, s), 8.21 (1H, s), 8.35-8.38 (1H, m), 8.42-8.46 (1H, m).	Ex. 1
924		1H-NMR (DMSO-d6) δ: 7.86 (1H, t, J = 7.8 Hz), 8.07 (2H, dd, J = 1.8, 7.8 Hz), 8.44 (1H, t, J = 1.8 Hz).	Ex. 125
925		1H-NMR (CDCl3) δ: 7.60-7.62 (4H, m), 7.87-7.89 (4H, m), 8.10 (1H, s), 8.15 (2H, s).	Ex. 1
926		1H-NMR (CDCl3) δ: 6.81-6.82 (1H, m), 7.56-7.57 (1H, m), 7.84 (1H, s), 7.90 (1H, s), 8.15 (1H, s), 8.34 (1H, s).	Ex. 1
927		1H-NMR (DMSO-d6) δ: 7.70-7.73 (2H, m), 7.74-7.76 (2H, m), 8.10-8.12 (4H, m), 8.24 (1H, s).	Ex. 1







Ex. No.	STR	1H-NMR	ref.
928		1H-NMR (CDCl3) δ: 7.46-7.50 (2H, m), 7.61 (1H, s), 7.94-8.01 (3H, m), 8.29 (1H, s), 8.44 (1H, s).	Ex. 1
929		1H-NMR (DMSO-d6) δ: 3.90 (3H, s), 7.97 (1H, s), 8.07 (1H, s), 8.10 (1H, s), 8.33 (1H, s), 8.40 (1H, s).	Ex. 1
930		1H-NMR (DMSO-d6) δ: 7.58-7.61 (2H, m), 7.96-8.12 (4H, m), 8.20 (1H, s), 8.33 (1H, s), 8.43 (1H, s), 8.59 (1H, s).	Ex. 2
931		1H-NMR (DMSO-d6) δ: 7.55-7.61 (2H, m), 7.72 (1H, t, J = 7.8 Hz), 7.82-7.90 (3H, m), 8.15 (1H, s).	Ex. 1
932		1H-NMR (DMSO-d6) δ: 2.52 (3H, s), 7.56 (2H, s), 7.70 (2H, s), 7.79 (1H, s), 7.94 (1H, s).	Ex. 1
933		1H-NMR (DMSO-d6) δ: 2.51 (3H, s), 7.37 (1H, t, J = 8.0 Hz), 7.45-7.56 (2H, m), 7.74 (1H, s), 7.79 (1H, s), 8.07 (1H, s).	Ex. 1
934		1H-NMR (DMSO-d6) δ: 7.55-7.68 (2H, m), 7.84 (1H, s), 7.90 (2H, s), 8.19 (1H, s).	Ex. 1







[0804]

Ex. No.	STR	1H-NMR	ref.
935		1H-NMR (CDCl3) δ: 7.19-7.26 (1H, m), 7.35-7.40 (2H, m), 7.88 (1H, s), 8.25 (1H, s), 8.35 (1H, s).	Ex. 2
936		1H-NMR (CDCl3) δ: 7.12-7.15 (1H, m), 7.21-7.26 (1H, m), 7.36-7.39 (1H, m), 8.05 (1H, s), 8.29 (1H, s), 8.54 (1H, s).	Ex. 2
937		1H-NMR (DMSO-d6) δ: 6.11 (2H, s), 7.09 (1H, d, J = 8.1 Hz), 7.28-7.31 (1H, m), 7.40 (1H, d, J = 1.8 Hz), 7.76 (1H, s), 7.81 (1H, s), 8.14 (1H, t, J = 1.5 Hz).	Ex. 1
938		1H-NMR (DMSO-d6) δ: 8.08 (1H, d, J = 5.1 Hz), 8.38 (1H, s), 8.71 (1H, s), 9.17 (1H, s), 9.35 (1H, d, J = 5.1 Hz).	Ex. 2
939		1H-NMR (DMSO-d6) δ: 8.08-8.12 (2H, m), 8.40 (1H, s), 9.01 (1H, s), 9.38 (1H, d, J = 5.0 Hz).	Ex. 1
940		1H-NMR (DMSO-d6) δ: 7.66 (1H, d, J = 8.8 Hz), 7.94 (1H, d, J = 1.8 Hz), 8.08 (1H, d, J = 1.8 Hz), 8.18-8.23 (2H, m), 8.36 (1H, s).	Ex. 1
941		1H-NMR (DMSO-d6) δ: 7.58 (1H, t, J = 4.9 Hz), 8.09 (1H, t, J = 1.9 Hz), 8.51 (1H, t, J = 1.5 Hz), 8.92 (1H, t, J = 1.5 Hz), 9.00 (2H, d, J = 4.9 Hz).	Ex. 1
942		1H-NMR (DMSO-d6) δ: 8.04 (1H, t, J = 1.7 Hz), 8.40 (1H, t, J = 1.7 Hz), 8.65 (1H, t, J = 1.5 Hz), 8.73 (1H, s), 8.80-8.81 (1H, m), 9.39 (1H, s).	Ex. 1
943		1H-NMR (CDCl3) δ: 7.24-7.26 (1H, m), 7.58-7.67 (2H, m), 7.84-7.89 (2H, m), 8.01-8.04 (1H, m), 8.18 (1H, s).	Ex. 1
944		1H-NMR (DMSO-d6) δ: 1.42 (3H, t, J = 6.2 Hz), 4.22 (2H, q, J = 6.2 Hz), 7.63-7.64 (1H, m), 8.02-8.05 (1H, m), 8.17 (1H, s), 8.57 (1H, s), 9.31-9.33 (1H, m).	Ex. 1
945		1H-NMR (DMSO-d6) δ: 1.37 (6H, d, J = 6.0 Hz), 4.73-4.85 (1H, m), 7.63-7.64 (1H, m), 8.01-8.04 (2H, m), 8.54 (1H, s), 9.32 (1H, d, J = 5.0 Hz).	Ex. 1
946		1H-NMR (DMSO-d6) δ: 3.95 (3H, s), 7.67-7.68 (1H, m), 8.04 (1H, d, J = 5.0 Hz), 8.07-8.08 (1H, m), 8.60-8.61 (1H, m), 9.34 (1H, d, J = 5.0 Hz).	Ex. 1
947		1H-NMR (DMSO-d6) δ: 8.05-8.09 (1H, m), 8.44 (1H, s), 8.85 (1H, s), 9.09 (2H, s).	Ex. 1
948		1H-NMR (DMSO-d6) δ: 4.10 (3H, s), 7.37 (1H, d, J = 9.3 Hz), 7.63 (1H, t, J = 7.8 Hz), 7.96-8.02 (2H, m), 8.18 (1H, d, J = 9.3 Hz), 8.59 (1H, t, J = 1.7 Hz).	Ex. 2
949		1H-NMR (DMSO-d6) δ: 2.69 (3H, s), 3.95 (3H, s), 7.56-7.57 (1H, m), 7.73 (1H, d, J = 8.7 Hz), 7.83-7.84 (1H, m), 8.21 (1H, d, J = 8.7 Hz), 8.27-8.28 (1H, m).	Ex. 1
950		1H-NMR (DMSO-d6) δ: 7.73-7.90 (4H, m), 7.96-8.06 (2H, m), 8.27 (1H, d, J = 8.0 Hz), 8.54 (1H, d, J = 6.0 Hz), 9.46 (1H, s).	Ex. 1
951		1H-NMR (DMSO-d6) δ: 7.56-7.62 (2H, m), 7.90-8.12 (6H, m), 8.28 (1H, s), 8.38 (1H, s).	Ex. 1
953		1H-NMR (CDCl3) δ: 7.61 (1H, d, J = 5.0 Hz), 7.87-7.90 (1H, m), 8.35-8.38 (1H, m), 9.00 (1H, t, J = 1.3 Hz), 9.12 (1H, d, J = 5.0 Hz), 12.31 (1H, brs).	Ex. 2
954		1H-NMR (DMSO-d6) δ: 1.31 (9H, s), 6.92 (1H, s), 7.27-7.43 (2H, m), 7.67 (1H, d, J = 7.2 Hz), 7.79 (1H, t, J = 1.8 Hz), 7.92-7.97 (2H, m), 8.13-8.18 (1H, m).	Ex. 1
955		1H-NMR (DMSO-d6) δ: 7.65 (1H, dd, J = 2.2, 8.7 Hz), 7.73 (1H, dd, J = 8.7, 11.3 Hz), 8.09-8.15 (1H, m), 8.17 (1H, d, J = 8.7 Hz), 8.40 (1H, d, J = 2.2 Hz), 8.91 (1H, dd, J = 2.2, 7.0 Hz).	Ex. 1
956		1H-NMR (CDCl3) δ: 3.18 (2H, t, J = 8.4 Hz), 4.02 (2H, t, J = 8.4 Hz), 6.81 (1H, t, J = 7.3 Hz), 7.13 (1H, t, J = 7.7 Hz), 7.20 (1H, d, J = 7.0 Hz), 7.25-7.29 (1H, m), 7.35-7.53 (3H, m), 7.78 (1H, s).	Ex. 1

[0805]

Ex. No.	STR	1H-NMR	ref.
957		1H-NMR (CDCl3) δ: 6.67 (1H, dd, J = 0.7, 3.3 Hz), 7.22 (1H, dd, J = 2.0, 8.8 Hz), 7.42 (1H, d, J = 3.3 Hz), 7.54 (1H, J = 8.8 Hz), 7.60-7.74 (3H, m), 7.94-8.04 (1H, m), 8.11 (1H, s).	Ex. 1
958		1H-NMR (CDCl3) δ: 3.03 (2H, t, J = 5.9 Hz), 3.66 (2H, t, J = 5.9 Hz), 4.51 (2H, s), 7.08 (1H, dd, J = 2.5, 8.2 Hz), 7.16-7.22 (4H, m), 7.31-7.36 (1H, m), 7.42 (1H, t, J = 7.9 Hz), 7.51 (1H, s).	Ex. 1
959		1H-NMR (CDCl3) δ: 2.00-2.11 (2H, m), 2.85 (2H, t, J = 6.3 Hz), 3.70 (2H, t, J = 5.8 Hz), 6.76-6.83 (1H, m), 6.91-7.04 (2H, m), 7.07-7.12 (1H, m), 7.35-7.41 (1H, m), 7.45 (1H, t, J = 7.7 Hz), 7.57-7.63 (1H, m), 7.67 (1H, s), 12.,2 (1H, br.).	Ex. 1
960		1H-NMR (DMSO-d6) δ: 7.52 (1H, d, J = 5.4 Hz), 7.76-7.84 (2H, m), 7.87 (1H, d, J = 5.4 Hz), 7.97 (1H, s), 8.04 (1H, d, J = 8.3 Hz), 8.29 (1H, s), 8.49 (1H, s).	Ex. 1
961		1H-NMR (DMSO-d6) δ: 2.63 (3H, s), 2.75 (3H, s), 4.02 (3H, s), 7.64 (1H, s), 7.76 (1H, t, J = 7.9 Hz), 7.99 (1H, t, J = 7.9 Hz), 8.35 (1H, t, J = 7.9 Hz), 8.84 (1H, s).	Ex. 2
962		1H-NMR (DMSO-d6) δ: 7.06-7.09 (1H, m), 7.42-7.46 (1H, m), 7.74-7.96 (5H, m), 8.18 (1H, s), 8.73 (1H, d, J = 7.0 Hz).	Ex. 2
963		1H-NMR (DMSO-d6) δ: 7.53 (1H, dd, J = 1.5, 9.5 Hz), 7.73 (1H, t, J = 7.8 Hz), 7.83 (1H, d, J = 9.5 Hz), 7.88 (1H, d, J = 7.8 Hz), 8.17 (1H, d, J = 7.8 Hz), 8.55 (1H, s), 8.60 (1H, s), 9.29 (1H, s).	Ex. 2

Ex. No.	STR	1H-NMR	ref.
964		1H-NMR (DMSO-d6) δ: 6.93-6.97 (1H, m), 7.28-7.33 (1H, m), 7.63 (1H, d, J = 8.8 Hz), 7.69 (1H, t, J = 7.8 Hz), 7.83-7.86 (1H, m), 8.12-8.14 (1H, m), 8.50-8.53 (2H, m), 8.59-8.61 (1H, m).	Ex. 2
965		1H-NMR (DMSO-d6) δ: 7.36-7.42 (1H, m), 7.68-7.72 (2H, m), 7.84-7.86 (1H, m), 8.12-8.14 (1H, m), 8.50-8.52 (2H, m), 8.83-8.85 (1H, m).	Ex. 2
966		1H-NMR (DMSO-d6) δ: 7.16-7.24 (1H, m), 7.51-7.56 (2H, m), 7.67-7.74 (1H, m), 7.78 (1H, d, J = 7.7 Hz), 7.91-7.97 (1H, m), 8.09-8.14 (1H, m), 8.42 (1H, s).	Ex. 1
967		1H-NMR (DMSO-d6) δ: 7.19-7.27 (1H, m), 7.55 (1H, dd, J = 2.5, 8.7 Hz), 7.68 (1H, s), 7.69-7.74 (1H, m), 7.94 (1H, s), 8.19 (1H, s), 8.36 (1H, s).	Ex. 1
968		1H-NMR (DMSO-d6) δ: 0.27-0.33 (2H, m), 0.53-0.60 (2H, m), 1.01-1.14 (1H, m), 2.75 (2H, d, J = 7.0 Hz), 8.02 (1H, d, J = 5.1 Hz), 8.06-8.08 (1H, m), 8.46 (1H, s), 8.84 (1H, t, J = 1.6 Hz), 8.34 (1H, d, J = 5.1 Hz).	Ex. 1
969		1H-NMR (DMSO-d6) δ: 4.20 (2H, s), 7.10-7.18 (2H, m), 7.33-7.40 (2H, m), 7.97-8.03 (2H, m), 8.42 (1H, s), 8.84 (1H, s), 9.31 (1H, d, J = 5.0 Hz).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
970		1H-NMR (DMSO-d6) δ: 4.11 (2H, s), 6.97-7.04 (2H, m), 7.18-7.25 (2H, m), 7.51-7.68 (3H, m), 7.75-7.84 (3H, m), 8.02-8.05 (1H, m).	Ex. 1
971		1H-NMR (DMSO-d6) δ: 4.16 (2H, s), 7.10-7.18 (2H, m), 7.35-7.41 (2H, m), 7.89 (1H, s), 8.21-8.26 (2H, m), 8.34-8.40 (1H, m), 8.50-8.54 (1H, m), 9.07-9.11 (1H, m).	Ex. 1
972		1H-NMR (DMSO-d6) δ: 0.97 (3H, t, J = 7.3 Hz), 1.68-1.75 (2H, m), 2.79 (2H, t, J = 7.4 Hz), 7.96 (1H, s), 8.03 (1H, d, J = 5.0 Hz), 8.38 (1H, s), 8.83 (1H, s), 9.34 (1H, d, J = 5.0 Hz).	Ex. 1
973		1H-NMR (DMSO-d6) δ: 0.95 (6H, d, J = 6.5 Hz), 1.55-1.66 (3H, m), 2.82 (2H, t, J = 7.5 Hz), 7.97 (1H, s), 8.03 (1H, d, J = 5.0 Hz), 8.40 (1H, s), 8.82 (1H, s), 9.34 (1H, d, J = 5.0 Hz).	Ex. 1
974		1H-NMR (DMSO-d6) δ: 7.36 (1H, t, J = 55.5 Hz), 8.10 (1H, d, J = 5.0 Hz), 8.33 (1H, s), 8.72 (1H, s), 9.16 (1H, s), 9.39 (1H, d, J = 5.0 Hz).	Ex. 1
975		1H-NMR (DMSO-d6) δ: 1.84-2.16 (8H, m), 4.83 (1H, m), 7.34-7.38 (2H, m), 7.46 (2H, s), 7.72 (1H, s), 7.77-7.81 (2H, m).	Ex. 1

[0806]





Ex. No.	STR	1H-NMR	ref.
976		1H-NMR (DMSO-d6) δ: 2.06-2.16 (4H, m), 3.45-3.49 (4H, m), 7.06 (1H, t, J = 2.0 Hz), 7.41-7.43 (2H, m).	Ex. 1
977		1H-NMR (DMSO-d6) δ: 2.08-2.17 (4H, m), 3.43-3.47 (4H, m), 7.06-7.09 (1H, m), 7.39-7.46 (2H, m), 7.51-7.53 (1H, m).	Ex. 1
978		1H-NMR (DMSO-d6) δ: 1.96-2.10 (4H, m), 3.30-3.36 (2H, m), 3.42-3.50 (2H, m), 4.80-4.95 (1H, m), 7.00 (1H, s), 7.35 (1H, s), 7.41 (1H, s).	Ex. 1
979		1H-NMR (DMSO-d6) δ: 1.73-1.82 (2H, m), 1.98-2.04 (2H, m), 2.15-2.27 (1H, m), 2.77-2.85 (2H, m), 3.83-3.89 (2H, m), 7.06-7.09 (1H, m), 7.39-7.44 (2H, m), 7.51 (1H, s).	Ex. 1





Ex. No.	STR	m.p.	ref.
980		243-244	Ex. 1
981		207	Ex. 1



Ex. No.	STR	m.p.	ref.
982		244-246	Ex. 1
983		255	Ex. 1
984		217	Ex. 1
985		172-173	Ex. 1
986		196	Ex. 1







Ex. No.	STR	m.p.	ref.
987		225-226	Ex. 1
988		183-185	Ex. 1
989		214-218	Ex. 1
990		183-186	Ex. 1
991		192-195	Ex. 1

[0807]

Ex. No.	STR	1H-NMR	ref.
992		1H-NMR (CDCl3) δ: 7.56-7.59 (2H, m), 7.94-7.97 (2H, m), 8.03-8.10 (6H, m), 8.35 (1H, s).	Ex. 1
993		1H-NMR (DMSO-d6) δ: 7.46-7.52 (3H, m), 7.83-7.86 (3H, m), 8.05-8.10 (3H, m).	Ex. 1
994		1H-NMR (DMSO-d6) δ: 7.52 (1H, d, J = 5.4 Hz), 7.78-7.84 (2H, m), 7.92-8.08 (5H, m), 8.45 (1H, s).	Ex. 1
995		1H-NMR (DMSO-d6) δ: 1.69-1.77 (2H, m), 1.87-1.91 (2H, m), 2.74-2.79 (1H, m), 2.92 (2H, t, J = 10.8 Hz), 4.03-4.05 (2H, m), 7.16-7.21 (3H, m), 7.26-7.32 (4H, m), 7.74 (2H, d, J = 8.9 Hz).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
996		1H-NMR (DMSO-d6) δ: 3.29-3.31 (4H, m), 3.44-3.46 (4H, m), 7.01-7.04 (2H, m), 7.19 (2H, d, J = 9.0 Hz), 7.25-7.28 (2H, m), 7.76 (2H, d, J = 9.0 Hz).	Ex. 1
997		1H-NMR (DMSO-d6) δ: 7.25 (1H, s), 7.93-7.96 (3H, m), 8.01-8.04 (2H, m), 8.55 (1H, s).	Ex. 1
998		1H-NMR (CDCl3) δ: 3.89 (1H, d, J = 1.8 Hz), 3.94 (1H, d, J = 1.8 Hz), 7.33-7.42 (5H, m), 7.50 (2H, d, J = 8.3 Hz), 8.00 (2H, d, J = 8.3 Hz).	Ex. 1
999		1H-NMR (DMSO-d6) δ: 7.55 (2H, d, J = 16.6 Hz), 7.61 (2H, d, J = 16.6 Hz), 7.64-7.69 (4H, m), 7.97-8.03 (6H, m), 8.18 (1H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1004		1H-NMR (CDCl3-CD3OD) δ: 7.04 (1H, d, J = 16.1 Hz), 7.31-7.35 (3H, m), 7.44 (1H, d, J = 16.1 Hz), 7.53 (1H, t, J = 7.7 Hz), 7.61-7.65 (1H, m), 7.71-7.75 (1H, m), 7.78-7.81 (1H, m), 7.85-7.89 (1H, m), 8.09-8.11 (1H, m).	Ex. 1
1006		1H-NMR (DMSO-d6) δ: 7.56-7.61 (2H, m), 7.66 (1H, t, J = 7.6 Hz), 7.75-7.79 (1H, m), 7.85-8.04 (6H, m), 8.24 (1H, s), 8.39 (1H, d, J = 8.6 Hz).	Ex. 2

Ex. No.	STR	m.p.	ref.
1000		234-236	Ex. 2
1001		192-194	Ex. 2
1002		214-217	Ex. 2
1003		186-188	Ex. 2
1005		169-171	Ex. 1
1007		176-177	Ex. 1

[0808]

Ex. No.	STR	1H-NMR	ref.
1008		1H-NMR (DMSO-d6) δ: 1.16-1.33 (5H, m), 1.71-1.80 (5H, m), 2.10-2.27 (1H, m), 6.45-6.47 (2H, m), 7.68 (1H, s), 7, 72 (1H, s), 7.85 (1H, s),	Ex. 1
1009		1H-NMR (DMSO-d6) δ: 0.57-0.60 (2H, m), 0.84-0.88 (2H, m), 1.62-1.67 (1H, m), 6.09 (1H, dd, J = 9.4, 15.8 Hz), 6.60 (1H, d, J = 15.8 Hz), 7.59 (1H, s), 7.61 (1H, s), 8.10 (1H, s).	Ex. 1
1010		1H-NMR (DMSO-d6) δ: 0.56-0.59 (2H, m), 0.83-0.87 (2H, m), 1.62 (1H, m), 6.05 (1H, dd, J = 9.3, 15.8 Hz), 6.55 (1H, d, J = 15.8 Hz), 7.64 (1H, s), 7.68 (1H, s), 7.77 (1H, s).	Ex. 1
1011		1H-NMR (DMSO-d6) δ: 7.18 (1H, d, J = 16.4 Hz), 7.47 (1H, d, J = 16.4 Hz), 7.52-7.67 (3H, m), 7.76 (1H, s), 7.84 (1H, s), 7.97 (1H, s).	Ex. 1
1012		1H-NMR (DMSO-d6) δ: 1.09-1.41 (5H, m), 1.58-1.85 (5H, m), 2.50 (1H, m), 6.50 (2H, m), 7.60 (1H, s), 7.65 (1H, s), 7.93 (1H, s).	Ex. 1
1013		1H-NMR (DMSO-d6) δ: 1.11-1.28 (2H, m), 1.40-2.05 (7H, m), 2.22-2.26 (2H, m), 6.50-6.52 (2H, m), 7.69 (1H, s), 7.73 (1H, s), 7.85 (1H, s).	Ex. 1
1014		1H-NMR (DMSO-d6) δ: 0.58-0.62 (2H, m), 0.85-0.89 (2H, m), 1.62-1.70 (1H, m), 6.15 (1H, dd, J = 9.4, 15.8 Hz), 6.66 (1H, d, J = 15.8 Hz), 7.90 (1H, s), 7.96 (1H, s), 8.10 (1H, s).	Ex. 2

Ex. No.	STR	1H-NMR	ref.
1015		1H-NMR (DMSO-d6) δ: 1.55-1.77 (4H, m), 2.10-2.31 (4H, m), 6.07 (1H, s), 6.58 (1H, d, J = 16.2 Hz), 7.07 (1H, d, J = 16.2 Hz), 7.63 (1H, s), 7.68 (1H, s), 7.99 (1H, s).	Ex. 1
1016		1H-NMR (DMSO-d6) δ: 1.58-1.69 (4H, m), 2.18-2.23 (4H, m), 6.05 (1H, s), 6.53 (1H, d, J = 16.2 Hz), 7.05 (1H, d, J = 16.2 Hz), 7.71 (1H, s), 7.76 (1H, s), 7.90 (1H, s).	Ex. 1
1017		1H-NMR (DMSO-d6) δ: 7.39-7.44 (4H, m), 7.65 (1H, t, J = 7.6 Hz), 7.77-7.82 (3H, m), 8.06 (1H, s).	Ex. 1
1018		1H-NMR (DMSO-d6) δ: 7.52 (1H, d, J = 16.4 Hz), 7.67 (1H, t, J = 7.8 Hz), 7.78-7.87 (3H, m), 7.93 (1H, d, J = 7.6 Hz), 7.98 (1H, d, J = 8.0 Hz), 8.13 (1H, t, J = 7.8 Hz), 8.21 (1H, s).	Ref. Ex. 107, Ref. Ex. 91, Ex. 2
1019		1H-NMR (CDCl3-CD3OD) δ: 7.22-7.27 (1H, m), 7.28 (1H, d, J = 16.4 Hz), 7.53-7.59 (2H, m), 7.60 (1H, d, J = 16.4 Hz), 7.67-7.73 (1H, m), 7.76 (1H, dt, J = 1.8, 7.7 Hz), 7.90-7.95 (1H, m), 8.15 (1H, s), 8.55-8.58 (1H, m).	Ex. 1
1020		1H-NMR (DMSO-d6) δ: 6.06 (2H, s), 6.95 (1H, d, J = 8.0 Hz), 7.07 (1H, dd, J = 1.6, 8.0 Hz), 7.21 (1H, d, J = 16.4 Hz), 7.29 (1H, d, J = 16.4 Hz), 7.34 (1H, d, J = 1.6 Hz), 7.60 (1H, t, J = 7.7 Hz), 7.71-7.78 (2H, m), 8.04 (1H, s).	Ex. 1
1021		1H-NMR (DMSO-d6) δ: 7.41-7.52 (4H, m), 7.72-7.81 (3H, m), 8.07 (1H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1022		1H-NMR (DMSO-d6) δ: 7.34-7.52 (4H, m), 7.79 (1H, s), 7.80 (1H, s), 7.89 (1H, s), 7.99 (1H, s).	Ex. 1
1023		1H-NMR (DMSO-d6) δ: 7.53-7.55 (3H, m), 7.82 (1H, t, J = 1.7 Hz), 7.92 (1H, t, J = 1.7 Hz), 8.02-8.08 (2H, m), 8.21 (1H, s).	Ex. 1

Ex. No.	STR	m.p.	ref.
1024		230-233	Ex. 1
1029		193-195	Ex. 2

[08809]

Ex. No.	STR	1H-NMR	ref.
1025		1H-NMR (CDCl3) δ: 6.98 (1H, d, J = 16.1 Hz), 7.03 (1H, dd, J = 3.6. 5.1 Hz), 7.12 (1H, d, J = 3.6 Hz), 7.24 (1H, d, J = 5.1 Hz), 7.34 (1H, d, J = 16.1 Hz), 7.51 (1H, t, J = 7.8 Hz), 7.59-7.62 (1H, m), 7.84-7.88 (1H, m), 8.06 (1H, s).	Ex. 1
1026		1H-NMR (CDCl3) δ: 6.42 (1H, d, J = 3.3 Hz), 6.45 (1H, dd, J = 1.8, 3.3 Hz), 6.98 (1H, d, J = 16.2 Hz), 7.08 (1H, d, J = 16.2 Hz), 7.43-7.44 (1H, m), 7.50 (1H, t, J = 7.7 Hz), 7.57-7.62 (1H, m), 7.82-7.87 (1H, m), 8.06 (1H, s).	Ex. 1
1027		1H-NMR (DMSO-d6) δ: 7.59-7.63 (1H, m), 7.75-7.82 (2H, m), 7.94 (1H, d, J = 8.9 Hz), 7.98-8.06 (3H, m), 8.14 (1H, s), 8.32 (1H, s), 8.43 (1H, d, J = 8.4 Hz), 8.53 (1H, s).	Ex. 2
1028		1H-NMR (DMSO-d6) δ: 7.47 (2H, s), 7.66 (2H, t, J = 7.8 Hz), 7.80-7.87 (4H, m), 8.13 (2H, bs).	Ex. 2
1030		1H-NMR (CDCl3) δ: 7.00 (1H, d, J = 16.2 Hz), 7.23 (1H, d, J = 16.2 Hz), 7.32-7.39 (3H, m), 7.51 (1H, t, J = 7.7 Hz), 7.61 (1H, d, J = 7.9 Hz), 7.85 (1H, d, J = 7.7 Hz), 8.06 (1H, s).	Ex. 1
1031		1H-NMR (CDCl3) δ: 2.37 (3H, s), 6.03 (1H, dd, J = 1.0, 3.1 Hz), 6.30 (1H, d, J = 3.1 Hz), 6.91 (1H, d, J = 16.2 Hz), 7.00 (1H, d, J = 16.2 Hz), 7.49 (1H, d, J = 7.7 Hz), 7.57 (1H, d, J = 7.9 Hz), 7.81 (1H, d, J = 7.5 Hz), 8.03 (1H, s).	Ex. 1
1032		1H-NMR (CDCl3) δ: 6.75 (1H, s), 7.11 (1H, d, J = 16.2 Hz), 7.19-7.33 (2H, m), 7.37 (1H, d, J = 16.2 Hz), 7.47-7.57 (3H, m), 7.66 (1H, d, J = 7.7 Hz), 7.89 (1H, d, J = 7.5 Hz), 8.14 (1H, s), 12.2 (1H, br.).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1033		1H-NMR (DMSO-d6) δ: 7.40-7.47 (2H, m), 7.70-7.74 (3H, m), 7.97-8.11 (3H, m), 8.12-8.26 (2H, m), 8.54-8.56 (1H, m).	Ex. 1
1034		1H-NMR (CDCl3) δ: 7.22 (1H, d, J = 16.1 Hz), 7.36-7.56 (4H, m), 7.61 (1H, s), 7.67 (1H, d, J = 7.8 Hz), 7.87-7.91 (2H, m), 8.03 (1H, d, J = 7.8 Hz), 8.15 (1H, s).	Ex. 1
1035		1H-NMR (CDCl3) δ: 3.82 (3H, s), 7.13 (1H, d, J = 16.4 Hz), 7.23-7.38 (4H, m), 7.41 (1H, d, J = 16.4 Hz), 7.50 (1H, t, J = 7.8 Hz), 7.62-7.65 (1H, m), 7.75-7.80 (1H, m), 7.98-8.02 (1H, m), 8.08 (1H, s).	Ex. 1
1036		1H-NMR (DMSO-d6) δ: 7.62 (1H, d, J = 16.1 Hz), 7.77-7.82 (2H, m), 7.86-7.87 (1H, m), 7.94 (1H, d, J = 7.9 Hz), 8.06-8.07 (1H, m), 8.12-8.16 (2H, m).	Ex. 2
1037		1H-NMR (DMSO-d6) δ: 1.39 (3H, t, J = 7.0 Hz), 4.20 (2H, q, J = 7.0 Hz), 7.42 (1H, s), 7.52 (1H, d, J = 15.7 Hz), 7.60 (1H, s), 7.85 (1H, s), 7.88 (1H, d, J = 5.0 Hz), 8.06 (1H, d, J = 15.7 Hz), 9.20 (1H, d, J = 5.0 Hz).	Ex. 2
1038		1H-NMR (DMSO-d6) δ: 7.59 (1H, d, J = 16.2 Hz), 7.91-7.92 (2H, m), 8.08 (1H, d, J = 16.2 Hz), 8.18 (1H, s), 8.26 (1H, s), 9.22 (1H, d, J = 5.0 Hz).	Ex. 2

Ex. No.	STR	m.p.	ref.
1039		167-168	Ex. 1
1040		156-158	Ex. 1
1041		205-206	Ex. 1

[0810]

Ex. No.	STR	1H-NMR	ref.
1042		1H-NMR (DMSO-d6) δ: 7.36-7.43 (2H, m), 7.58-7.64 (1H, m), 7.89 (1H, s), 7.94-7.96 (1H, m), 8.80-8.81 (1H, m).	Ex. 1
1043		1H-NMR (CDCl3) δ: 1.70-2.16 (6H, m), 4.95 (1H, bs), 5.89-5.95 (1H, m), 6.04-6.10 (1H, m), 7.30 (1H, s), 7.75 (1H, s), 7.82 (1H, s).	Ex. 2
1044		1H-NMR (CDCl3) δ: 3.23 (2H, d, J = 16.9 Hz), 3.48 (2H, dd, J = 6.3, 16.9 Hz), 5.27-5.31 (1H, m), 7.20-7.29 (5H, m), 7.74 (1H, s), 7.83 (1H, s).	Ex. 191
1045		1H-NMR (CDCl3) δ: 2.27-2.31 (1H, m), 2.67-2.72 (1H, m), 3.02-3.06 (1H, m), 3.19-3.22 (1H, m), 5.90-5.93 (1H, m), 7.29-7.38 (4H, m), 7.47-7.49 (1H, m), 7.87 (2H, s).	Ex. 191
1046		1H-NMR (CDCl3) δ: 1.84-1.89 (1H, m), 2.01-2.23 (3H, m), 2.81-2.93 (2H, m), 5.50-5.53 (1H, m), 7.13-7.43 (5H, m), 7.84 (2H, s).	Ex. 191
1047		1H-NMR (CDCl3) δ: 7.48 (1H, d, J = 4.9 Hz), 7.66 (1H, s), 8.14 (1H, s), 8.21 (1H, s), 8.85 (1H, d, J = 4.9 Hz).	Ex. 2
1048		1H-NMR (DMSO-d6) δ: 7.56-7.64 (3H, m), 7.68 (1H, t, J = 1.5 Hz), 7.82 (1H, t, J = 1.5 Hz), 8.45 (1H, d, J = 5.2 Hz).	Ex. 1

Ex. No.	STR	m.p.	ref.
1049		162-166	Ex. 1
1050		138-143	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1051		1H-NMR (CDCl3) δ: 1.90-2.20 (8H, m), 4.54-4.59 (1H, m), 7.19-7.21 (1H, m), 7.49 (1H, s), 7.72 (1H, s).	Ex. 1
1052		1H-NMR (CDCl3) δ: 1.90-2.20 (8H, m), 2.41 (3H, s), 4.54-4.60 (1H, m), 6.88 (1H, s), 7.32 (1H, s), 7.37 (1H, s).	Ex. 1
1053		1H-NMR (DMSO-d6) δ: 1.44 (3H, t, J = 7.0 Hz), 1.90-2.22 (8H, m), 4.06-4.16 (3H, m), 6.58-6.59 (1H, m), 7.11 (2H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1054		1H-NMR (DMSO-d6) δ: 2.45 (2H, t, J = 7.2 Hz), 2.88 (2H, t, J = 7.2 Hz), 6.90-7.01 (3H, m), 7.14-7.17 (2H, m), 7.85-7.88 (2H, m), 10.1 (1H, s).	Ex. 1
1055		1H-NMR (DMSO-d6) δ: 2.44 (2H, t, J = 7.3 Hz), 2.77 (2H, t, J = 7.3 Hz), 6.67 (1H, d, J = 7.9 Hz), 6.78 (1H, d, J = 7.9 Hz), 7.13 (2H, d, J = 8.8 Hz), 7.21 (1H, t, J = 7.9 Hz), 7.87 (2H, d, J = 8.8 Hz), 10.3 (1H, s).	Ex. 1
1056		1H-NMR (DMSO-d6) δ: 2.55 (2H, t, J = 7.9 Hz), 2.88 (2H, t, J = 7.9 Hz), 3.27 (3H, s), 7.02-7.06 (2H, m), 7.14-7.20 (3H, m), 7.88 (2H, d, J = 8.3 Hz).	Ex. 1
1057		1H-NMR (DMSO-d6) δ: 2.51-2.55 (2H, m), 2.75-2.79 (2H, m), 3.29 (3H, s), 6.78-6.81 (1H, m), 7.04 (1H, d, J = 7.8 Hz), 7.12-7.16 (2H, m), 7.35 (1H, t, J = 8.2 Hz), 7.85-7.89 (2H, m).	Ex. 1










[0811]


Ex. No.	STR	m.p.	ref.
1058		177-179	Ex. 1
1059		186-187	Ex. 1
1060		223−226	Ex. 1
1061		241	Ex. 1






Ex. No.	STR	m.p.	ref.
1062		110-111	Ex. 1
1063		116-117	Ex. 1
1064		148-151	Ex. 1
1065		167-168	Ex. 1
1066		162-163	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1067		1H-NMR (CDCl3) δ: 5.43 (2H, s), 6.91 (1H, dt, J = 2.3, 11.0 Hz), 7.20-7.25 (1H, m), 7.41-7.42 (1H, m), 7.60-7.66 (1H, m), 7.72 (1H, d, J = 8.5 Hz), 7.77-7.83 (1H, m), 8.00-8.06 (2H, m), 8.45 (1H, d, J = 8.5 Hz).	Ex. 2
1068		1H-NMR (CDCl3) δ: 5.47 (2H, s), 7.27-7.31 (1H, m), 7.49-7.66 (4H, m), 7.72 (1H, d, J = 8.5 Hz), 7.78-7.83 (1H, m), 8.00-8.05 (2H, m), 8.45 (1H, d, J = 8.5 Hz).	Ex. 2
1069		1H-NMR (DMSO-d6) δ: 1.08-1.21 (2H, m), 1.24-1.38 (2H, m), 1.76-1.83 (1H, m), 1.91-1.96 (4H, m), 2.21-2.28 (1H, m), 3.89 (2H, d, J = 6.4 Hz), 7.13-7.16 (1H, m), 7.42-7.47 (1H, m), 7.50-7.55 (1H, m).	Ex. 2
1070		1H-NMR (CDCl3) δ: 1.09-1.22 (2H, m), 1.32-1.45 (2H, m), 1.79-1.89 (1H, m), 2.02-2.10 (5H, m), 3.86 (2H, d, J = 6.2 Hz), 7.01-7.05 (1H, m), 7.43 (1H, t, J = 8.0 Hz), 7.47 (1H, t, J = 2.0 Hz), 7.54-7.56 (1H, m).	Ex. 2
1071		1H-NMR (CDCl3) δ: 1.60-1.72 (4H, m), 1.77-1.85 (4H, m), 2.17-2.19 (2H, m), 3.97 (2H, d, J = 7.2 Hz), 6.75 (1H, dt, J = 2.3, 10.4 Hz), 7.28-7.32 (1H, m), 7.33-7.34 (1H, m).	Ex. 2
1072		1H-NMR (CDCl3) δ: 1.62-1.72 (4H, m), 1.74-1.86 (4H, m), 2.13-2.20 (2H, m), 3.99 (2H, d, J = 7.2 Hz), 7.03-7.07 (1H, m), 7.44 (1H, t, J = 8.0 Hz), 7.49-7.50 (1H, m), 7.55-7.58 (1H, m).	Ex. 2
1073		1H-NMR (DMSO-d6) δ: 5.41 (2H, s), 7.29-7.33 (1H, m), 7.51-7.61 (7H, m), 8.39-8.44 (2H, m), 8.95 (1H, d, J = 4.8 Hz).	Ex. 2
1074		1H-NMR (CDCl3) δ: 5.34 (2H, s), 7.13 (1H, dd, J = 2.1, 8.1 Hz), 7.50 (1H, t, J = 8.1 Hz), 7.62 (1H, t, J = 2.1 Hz), 7.68 (1H, d, J = 7.7 Hz), 7.84 (1H, d, J = 5.1 Hz), 8.95 (1H, d, J = 5.1 Hz), 12.26 (1H, brs).	Ex. 2


[0812]

Ex. No.	STR	m.p.	ref.
1075		176	Ex. 1
1076		145-147	Ex. 1
1077		115-117	Ex. 1
1078		168-170	Ex. 1
1079		205	Ex. 1
1081		191	Ex. 1
1082		185-186	Ex. 1
1083		206-207	Ex. 1
1085		97-100	Ex. 1
1086		126-132	Ex. 1








Ex. No.	STR	1H-NMR	ref.
1080		1H-NMR (DMSO-d6) δ: 5.39 (2H, s), 7.25-7.31 (1H, m), 7.49-7.61 (3H, m), 7.96 (1H, d, J = 8.1 Hz), 8.20 (1H, d, J = 7.8 Hz), 8.90 (1H, s).	Ex. 1
1084		1H-NMR (DMSO-d6) δ: 2.67 (3H, s), 5.21 (2H, s), 7.18-7.22 (1H, m), 7.26-7.29 (1H, m), 7.36-7.37 (1H, m), 7.63 (1H, s).	Ex. 1








Ex. No.	STR	1H-NMR	ref.
1087		1H-NMR (DMSO-d6) δ: 1.75-1.89 (4H, m), 2.91-2.94 (2H, m), 4.10 (2H, t, J = 6.1 Hz), 7.12-7.14 (1H, m), 7.42-7.54 (3H, m), 7.79 (1H, d, J =8.2 Hz), 7.92 (1H, s), 7.93 (1H, s).	Ex. 1
1088		1H-NMR (DMSO-d6) δ: 5.34 (2H, s), 7.44-7.48 (1H, m), 7.58 (1H, s), 7.79 (2H, s), 7.94 (1H, d, J = 7.8 Hz), 8.56-8.59 (1H, m), 8.72 (1H, s).	Ex. 1
1089		1H-NMR (DMSO-d6) δ: 5.36 (2H, s), 7.35-7.38 (1H, m), 7.57-7.59 (2H, m), 7.78-7.86 (3H, m), 8.57-8.60 (1H, m).	Ex. 1
1090		1H-NMR (DMSO-d6) δ: 5.29 (2H, s), 7.22-7.24 (1H, m), 7.56-7.60 (2H, m), 7.66 (1H, s), 7.78 (2H, s).	Ex. 1
1091		1H-NMR (CDCl3) δ: 1.70-1.82 (12H, m), 2.06 (3H, s), 3.63 (2H, s), 7.28 (1H, s), 7.71 (1H, s), 7.81 (1H, s).	Ex. 2
1092		1H-NMR (CDCl3) δ: 1.06 (3H, s), 1.26-1.52 (10H, m), 3.84 (2H, s), 7.26 (1H, s), 7.69 (1H, s), 7.79 (1H, s).	Ex. 191
1093		1H-NMR (CDCl3) δ: 1.06 (4H, s), 4.15 (2H, s), 7.20-7.34 (4H, m), 7.41-7.44 (2H, m), 7.63 (1H, s), 7.77 (1H, s).	Ex. 191





[0813]




Ex. No.	STR	1H-NMR	ref.
1094		1H-NMR (CDCl3) δ: 0.99-1.08 (4H, m), 4.11 (2H, s), 7.19 (1H, s), 7.26-7.37 (4H, m), 7.63 (1H, s), 7.80 (1H, s).	Ex. 191
1095		1H-NMR (CDCl3) δ: 3.12 (2H, t, J = 6.6 Hz), 4.28 (2H, t, J = 6.6 Hz), 7.23-7.32 (5H, m), 7.68 (1H, s), 7.82 (1H, s).	Ex. 185
1096		1H-NMR (CDCl3) δ: 1.71 (3H, d, J = 6.2 Hz), 5.78-5.84 (1H, m), 7.22 (1H, s), 7.39 (1H, t, J = 7.7 Hz), 7.55 (1H, t, J = 7.7 Hz), 7.67-7.74 (4H, m).	Ex. 2
1097		1H-NMR (CDCl3) δ: 1.15 (3H, t, J = 7.4 Hz), 1.91-2.00 (2H, m), 5.50-5.54 (1H, m), 7.22 (1H, s), 7.38 (1H, t, J = 7.8 Hz), 7.53 (1H, t, J = 7.8 Hz), 7.68-7.69 (3H, m), 7.74 (1H, s).	Ex. 2
1098		1H-NMR (CDCl3) δ: 1.08-1.32 (9H, m), 1.68-1.95 (5H, m), 4.22-4.30 (1H, m), 7.23 (1H, s), 7.68 (1H, s), 7.77 (1H, s).	Ex. 191
1099		1H-NMR (DMSO-d6) δ: 5.20 (2H, s), 7.22 (1H, d, J = 7.9 Hz), 7.35 (1H, d, J = 7.9 Hz), 7.42-7.61 (5H, m).	Ex. 1
1100		1H-NMR (DMSO-d6) δ: 5.12 (2H, s), 6.95 (1H, s), 7.08 (1H, d, J = 8.1 Hz), 7.17-7.20 (2H, m), 7.53 (1H, s), 7.54 (1H, s).	Ex. 1
1101		1H-NMR (CDCl3) δ: 0.47-0.88 (4H, m), 1.26 (3H, s), 3.85 (2H, s), 7.26 (1H, s), 7.69 (1H, s), 7.81 (1H, s).	Ex. 191
1102		1H-NMR (CDCl3) δ: 0.95-1.00 (2H, m), 1.19-1.26 (2H, m), 4.19 (2H, s), 7.26 (1H, s), 7.70 (1H, s), 7.87 (1H, s).	Ex. 191
1103		1H-NMR (CDCl3) δ: 1.40-1.56 (2H, m), 1.71-2.05 (5H, m), 2.13-2.19 (2H, m), 3.94 (2H, d, J = 5.9 Hz), 7.24 (1H, s), 7.70 (1H, s), 7.83 (1H, s).	Ex. 2
1104		1H-NMR (DMSO-d6) δ: 5.22 (2H, s), 7.08 (1H, s), 7.27-7.46 (4H, m), 7.35 (1H, t, J = 73.5 Hz), 7.57 (1H, s).	Ex. 1
1105		1H-NMR (CDCl3) δ: 2.43 (3H, s), 5.24 (2H, s), 6.95 (1H, s), 7.40 (1H, s), 7.45 (1H, s), 7.75 (1H, d, J = 7.9 Hz), 8.02 (1H, d, J = 7.9 Hz), 8.84 (1H, s), 12.0 (1H, br.).	Ex. 1
1106		1H-NMR (DMSO-d6) δ: 3.90 (3H, s), 3.91 (3H, s), 5.16 (2H, s), 6.60 (1H, s), 7.23-7.27 (1H, m), 7.49-7.58 (3H, m).	Ex. 2
1107		1H-NMR (DMSO-d6) δ: 1.31-1.41 (2H, m), 1.68-1.72 (2H, m), 2.03-2.09 (1H, m), 3.32-3.36 (2H, m), 3.87-3.91 (2H, m), 4.02 (2H, d, J = 6.5 Hz), 7.47 (1H, s), 7.72 (1H, s), 7.76 (1H, s).	Ex. 2
1108		1H-NMR (CDCl3) δ: 3.33-3.35 (2H, m), 4.38 (2H, t, J = 6.7 Hz), 7.14-7.17 (1H, m), 7.41-7.55 (3H, m), 7.97 (1H, s), 8.11 (2H, s).	Ex. 2
1109		1H-NMR (DMSO-d6) δ: 5.62 (2H, s), 7.34-7.41 (2H, m), 7.49-7.55 (2H, m), 7.60 (1H, s), 7.81-7.87 (2H, m), 7.95-8.00 (1H, m).	Ex. 1
1111		188	Ex. 1
1112		212-215	Ex. 1
1113		84.0-87.7	Ex. 2
1114		87.6-88.0	Ex. 2
1115		89.4-90.5	Ex. 2

[0814]






Ex. No.	STR	m.p.	ref.
1116		138.6-139.0	Ex. 2
1117		130.2-131.3	Ex. 2
1118		123.6-124.1	Ex. 2
1119		92.5-93.0	Ex. 2
1120		146.3-149.3	Ex. 2
1121		156.7-157.1	Ex. 2
1122		87.2-88.4	Ex. 2






Ex. No.	STR	m.p.	ref.
1123		138.4-138.8	Ex. 2
1124		142.9-143.0	Ex. 2
1125		109.1-109.2	Ex. 2
1126		144-146	Ex. 1
1127		149.5-150.5	Ex. 2
1128		122.9-123.2	Ex. 2
1129		139.9-140.4	Ex. 2

Ex. No.	STR	m.p.	ref.
1130		136.7-137.0	Ex. 2
1131		147.3-147.4	Ex. 2
1132		140-141	Ex. 1
1177		188-189	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1133		1H-NMR (DMSO-d6) δ: 0.33-0.64 (4H, m), 1.02-1.10 (1H, m), 3.22 (3H, s), 3.73 (1H, d, J = 8.0 Hz), 7.58 (1H, s), 7.83 (1H, s), 7.84 (1H, s).	Ex. 1
1134		1H-NMR (DMSO-d6) δ: 7.42-7.45 (2H, m), 7.77 (1H, t, J = 7.8 Hz), 7.82-7.85 (2H, m), 8.09-8.44 (2H, m), 8.45 (1H, s), 10.56 (1H, s).	Ex. 1110
1135		1H-NMR (DMSO-d6) δ: 3.11 (3H, s), 4.75 (2H, s), 6.90-6.94 (1H, m), 7.15 (1H, d, J = 7.6 Hz), 7.22 (1H, s), 7.37 (1H, t, J = 8.0 Hz), 7.50-7.62 (4H, m).	Ex. 1

[0815]

Ex. No.	STR	1H-NMR	ref.
1136		1H-NMR (DMSO-d6) δ: 3.09 (3H, s), 4.65 (2H, s), 6.89-6.92 (1H, m), 7.13 (1H, d, J = 7.4 Hz), 7.22-7.38 (7H, m).	Ex. 1
1137		1H-NMR (DMSO-d6) δ: 3.39 (3H, s), 7.25-7.33 (4H, m), 7.48-7.60 (4H, m).	Ex. 1
1138		1H-NMR (DMSO-d6) δ: 3.38 (3H, s), 7.03-7.19 (4H, m), 7.33-7.42 (5H, m).	Ex. 1
1139		1H-NMR (CDCl3) δ: 0.85 (3H, s), 0.86 (3H, s), 0.93 (3H, s), 1.13 (1H, dd, J = 3.3, 13.0 Hz), 1.22-1.34 (2H, m), 1.65-1.77 (2H, m), 2.03-2.24 (2H, m), 3.72-3.78 (1H, m), 4.53 (1H, d, J = 12.5 Hz), 4.65 (1H, d, J = 12.5 Hz), 7.46-7.54 (2H, m), 7.83-7.90 (1H, m), 7.94 (1H, s).	Ex. 1
1140		1H-NMR (CDCl3) δ: 1.50-1.91 (10H, m), 2.10-2.20 (4H, m), 3.64 (1H, s), 4.65 (2H, s), 7.46-7.53 (2H, m), 7.83-7.90 (1H, m), 8.00 (1H, s).	Ex. 1
1141		1H-NMR (CDCl3) δ: 1.56-1.77 (12H, m), 1.95-2.00 (3H, m), 3.09 (2H, s), 4.58 (2H, s), 7.46-7.55 (2H, m), 7.85-7.91 (1H, m), 7.93 (1H, s).	Ex. 1
1142		1H-NMR (CDCl3) δ: 0.73 (3H, d, J = 7.0 Hz), 0.91 (3H, d, J = 7.0 Hz), 0.95 (3H, d, J = 6.5 Hz), 0.80-1.70 (7H, m), 2.17-2.34 (2H, m), 3.26 (1H, dt, J = 4.1, 10.5 Hz), 4.51 (1H, d, J = 11.5 Hz), 4.76 (1H, d, J = 11.5 Hz), 7.46-7.53 (2H, m), 7.84-7.92 (1H, m), 7.95 (1H, s).	Ex. 1















Ex. No.	STR	1H-NMR	ref.
1143		1H-NMR (CDCl3) δ: 0.73 (3H, d, J = 7.0 Hz), 0.91 (3H, d, J = 7.0 Hz), 0.95 (3H, d, J = 6.5 Hz), 0.80-1.70 (7H, m), 2.17-2.34 (2H, m), 3.26 (1H, dt, J = 4.1, 10.5 Hz), 4.51 (1H, d, J = 11.5 Hz), 4.76 (1H, d, J = 11.5 Hz), 7.46-7.53 (2H, m), 7.84-7.92 (1H, m), 7.96 (1H, s).	Ex. 1
1144		1H-NMR (CDCl3) δ: 4.17 (2H, s), 7.12 (1H, dd, J = 2.2, 8.4 Hz), 7.31 (1H, d, J = 8.4 Hz), 7.37 (1H, d, J = 2.2 Hz), 7.39-7.44 (1H, m), 7.47 (1H, t, J = 7.7 Hz), 7.85-7.91 (2H, m).	Ex. 191
1146		1H-NMR (CDCl3-CD3OD) δ: 1.40-1.80 (2H, m), 1.85-1.97 (4H, m), 2.67-3.48 (4H, m), 4.30 (2H, s), 7.55-7.67 (2H, m), 8.01 (1H, s), 8.06 (1H, d, J = 6.8 Hz).	Ex. 316
1147		1H-NMR (DMSO-d6) δ: 3.16 (3H, s), 4.66 (2H, s), 6.61 (1H, s), 7.16 (1H, s), 7.43-7.53 (5H, m).	Ex. 1
1148		1H-NMR (CDCl3) δ: 5.42 (2H, s), 6.60 (1H, dd, J = 0.7, 3.2 Hz), 7.09-7.31 (5H, m), 7.46 (1H, t, J = 7.8 Hz), 7.64-7.73 (2H, m), 7.88 (1H, d, J = 7.8 Hz).	Ex. 1
1149		1H-NMR (CDCl3) δ: 5.16 (2H, s), 6.23 (2H, t, J = 2.1 Hz), 6.74 (2H, t, J = 2.1 Hz), 7.22-7.26 (1H, m), 7.49 (1H, t, J = 7.7 Hz), 7.66 (1H, s), 7.87-7.92 (1H, m).	Ex. 1
1150		1H-NMR (CDCl3) δ: 3.10-3.30 (4H, m), 4.06 (2H, s), 4.08 (2H, s), 7.02-7.08 (1H, m), 7.15-7.32 (4H, m), 7.47 (1H, t, J = 7.8 Hz), 7.95-8.00 (1H, m), 8.47 (1H, s).	Ex. 1

[0816]











Ex. No.	STR	1H-NMR	ref.
1151		1H-NMR (CDCl3) δ: 2.01-2.12 (2H, m), 2.84 (2H, t, J = 6.1 Hz), 3.43 (2H, t, J = 5.7 Hz), 4.55 (2H, s), 6.46 (1H, d, J = 8.1 Hz), 6.56-6.63 (1H, m), 6.90-7.03 (2H, m), 7.39-7.52 (2H, m), 7.80-7.86 (2H, m).	Ex. 1
1152		1H-NMR (CDCl3) δ: 1.55-1.66 (2H, m), 1.70-1.80 (4H, m), 3.41-3.50 (2H, m), 3.81-3.89 (2H, m), 7.36-7.42 (1H, m), 7.49 (1H, t, J = 7.9 Hz), 7.97 (1H, br.s), 8.20 (1H, br.).	Ex. 1110
1153		1H-NMR (DMSO-d6) δ: 1.00-1.22 (1H, m), 1.22-1.42 (4H, m), 1.56-1.68 (1H, m), 1.68-1.93 (4H, m), 3.72-3.86 (1H, m), 7.70 (1H, t, J = 7.8 Hz), 7.97-8.04 (2H, m), 8.35 (1H, s), 8.40 (1H, d, J = 7.8 Hz).	Ex. 1110
1154		1H-NMR (CDCl3) δ: 0.96-1.37 (5H, m), 1.58-1.87 (6H, m), 3.44 (2H, t, J = 6.5 Hz), 6.51 (1H, br.t, J = 6.5 Hz), 7.60 (1H, t, J = 7.8 Hz), 7.73 (1H, d, J = 7.9 Hz), 8.23 (1H, d, J = 7.7 Hz), 8.75 (1H, s).	Ex. 1110
1155		1H-NMR (DMSO-d6) δ: 3.11 (2H, t, J = 8.2 Hz), 4.06 (2H, t, J = 8.2 Hz), 7.07 (1H, t, J = 7.3 Hz), 7.20 (1H, br.), 7.30 (1H, d, J = 7.3 Hz), 7.71-7.82 (2H, m), 7.91-8.21 (3H, m).	Ex. 1110
1156		1H-NMR (DMSO-d6) δ: 4.08 (2H, s), 7.12-7.15 (1H, m), 7.32-7.37 (2H, m), 7.46 (1H, d, J = 7.7 Hz), 7.54 (1H, t, J = 7.7 Hz), 7.71-7.75 (2H, m).	Ex. 1
1157		1H-NMR (CDCl3) δ: 1.42-1.76 (12H, m), 2.20-2.27 (2H, m), 3.18 (2H, s), 4.58 (2H, s), 7.39-7.45 (1H, m), 7.49 (1H, t, J = 7.6 Hz), 7.84-7.89 (1H, m), 7.96 (1H, s).	Ex. 1
1158		1H-NMR (CDCl3) δ: 1.44-1.82 (12H, m), 2.21-2.29 (2H, m), 3.17 (2H, s), 3.30 (3H, s), 4.58 (2H, s), 7.43 (1H, d, J = 7.6 Hz), 7.48 (1H, t, J = 7.6 Hz), 7.86 (1H, d, J = 7.6 Hz), 7.92 (1H, s).	Ex. 1










Ex. No.	STR	1H-NMR	ref.
1159		1H-NMR (DMSO-d6) δ: 5.78 (1H, s), 6.07 (1H, s), 7.17-7.34 (3H, m), 7.38-7.43 (2H, m), 7.50-7.53 (2H, m), 7.67-7.74 (1H, m), 7.96 (1H, s).	Ex. 1
1160		1H-NMR (CDCl3) δ: 3.20-3.24 (4H, m), 7.45 (1H, d, J = 7.8 Hz), 7.51 (1H, t, J = 7.8 Hz), 7.69-7.72 (1H, m), 7.75 (1H, s), 7.87 (1H, d, J = 5.1 Hz), 9.13 (1H, d, J = 5.1 Hz).	Ex. 2
1161		1H-NMR (DMSO-d6) δ: 4.29 (4H, s), 7.50-7.61 (5H, m), 7.72-7.75 (2H, m).	Ex. 2
1162		1H-NMR (DMSO-d6) δ: 3.07 (3H, s), 4.65 (2H, s), 6.61 (1H, t, J = 7.3 Hz), 6.73 (2H, d, J = 8.3 Hz), 7.13-7.16 (2H, m), 7.40 (1H, d, J = 7.6 Hz), 7.56 (1H, t, J = 8.3 Hz), 7.75-7.76 (2H, m).	Ex. 2
1163		1H-NMR (DMSO-d6) δ: 4.48 (2H, s), 7.51-7.63 (6H, m), 7.76-7.78 (1H, m), 7.96 (1H, s).	Ex. 2
1164		1H-NMR (CDCl3) δ: 4.75 (2H, s), 4.84 (2H, s), 7.54-7.56 (2H, m), 7.66 (1H, d, J = 8.1 Hz), 7.78 (1H, d, J = 8.1 Hz), 7.93-7.97 (1H, m), 8.00 (1H, s), 8.07 (1H, s).	Ex. 2
1165		1H-NMR (DMSO-d6) δ: 3.10 (3H, s), 4.71 (2H, s), 6.70 (1H, dd, J = 3.0, 9.1 Hz), 6.88 (1H, d, J = 3.0 Hz), 7.31 (1H, d, J = 9.1 Hz), 7.39 (1H, d, J = 7.9 Hz), 7.58 (1H, t, J = 7.9 Hz), 7.71 (1H, s), 7.77 (1H, d, J = 7.9 Hz).	Ex. 2









[0817]









Ex. No.	STR	1H-NMR	ref.
1166		1H-NMR (DMSO-d6) δ: 3.17 (3H, s), 4.77 (2H, s), 6.83 (2H, d, J = 8.9 Hz), 7.40 (1H, d, J = 7.7 Hz), 7.44 (2H, d, J = 8.9 Hz), 7.58 (1H, t, J = 7.7 Hz), 7.74-7.78 (2H, m).	Ex. 2
1167		1H-NMR (DMSO-d6) δ: 3.13 (2H, t, J = 7.5 Hz), 3.27-3.31 (2H, m), 7.24-7.33 (3H, m), 7.47-7.54 (2H, m), 7.70-7.73 (2H, m), 7.83-7.82 (2H, m).	Ex. 2
1168		1H-NMR (DMSO-d6) δ: 3.86 (2H, s), 3.98 (2H, s), 7.40 (1H, d, J = 7.7 Hz), 7.46 (1H, t, J = 7.7 Hz), 7.66-7.69 (1H, m), 7.71 (1H, s), 7.81 (1H, s), 7.88 (2H, s).	Ex. 2
1169		1H-NMR (DMSO-d6) δ: 1.26 (9H, s), 3.67 (2H, s), 3.77 (2H, s), 7.20-7.23 (2H, m), 7.30-7.34 (2H, m), 7.48 (1H, d, J = 7.7 Hz), 7.56 (1H, t, J = 7.7 Hz), 7.76 (1H, d, J = 7.7 Hz), 7.83 (1H, s).	Ex. 2
1170		1H-NMR (DMSO-d6) δ: 3.00 (2H, t, J = 6.4 Hz), 3.79 (2H, t, J = 6.4 Hz), 4.69 (2H, s), 7.46 (1H, d, J = 7.7 Hz), 7.53 (1H, t, J = 7.7 Hz), 7.74 (1H, d, J = 7.7 Hz), 7.80 (1H, s), 7.88 (2H, s), 7.97 (1H, s).	Ex. 2
1171		1H-NMR (DMSO-d6) δ: 4.21 (2H, s), 7.63 (1H, s), 7.74 (1H, s), 7.76 (1H, t, J = 1.8 Hz), 7.83 (1H, d, J = 8.0 Hz), 7.95-8.01 (1H, m), 8.76 (1H, d, J = 1.8 Hz).	Ex. 1
1172		1H-NMR (DMSO-d6) δ: 4.11 (2H, s), 7.33-7.39 (1H, m), 7.57-7.59 (1H, m), 7.70-7.78 (3H, m), 8.43-8.49 (1H, m), 8.56-8.61 (1H, m).	Ex. 1
1173		1H-NMR (DMSO-d6) δ: 4.31 (2H, s), 7.37-7.42 (1H, m), 7.49-7.61 (3H, m), 7.72-7.77 (1H, m), 7.84 (1H, s), 7.88 (1H, d, J = 2.0 Hz), 8.03 (1H, d, J = 3.9 Hz).	Ex. 1
1174		1H-NMR (DMSO-d6) δ: 2.35 (3H, s), 7.27-7.32 (2H, m), 7.32-7.37 (2H, m), 7.39-7.44 (2H, m), 7.77-7.83 (2H, m).	Ex. 1
1175		1H-NMR (CDCl3) δ: 2.41 (3H, s), 7.33 (2H, d, J = 8.0 Hz), 7.86 (2H, d, J = 8.0 Hz), 8.03-8.09 (2H, m), 8.09-8.15 (2H, m).	Ex. 1
1176		1H-NMR (DMSO-d6) δ: 4.19 (2H, s), 7.55 (2H, d, J = 7.8 Hz), 7.83 (2H, d, J = 7.8 Hz), 8.15 (1H, s), 8.84 (1H, s), 8.87 (1H, s).	Ex. 1
1178		1H-NMR (CDCl3) δ: 6.81-6.84 (1H, m), 7.19-7.21 (1H, m), 7.33-7.35 (1H, m), 7.72 (1H, d, J = 7.7 Hz), 7.82-7.85 (2H, m).	Ex. 1
1179		1H-NMR (CDCl3) δ: 6.17 (1H, s), 7.38-7.45 (2H, m), 7.68 (1H, d, J = 8.7 Hz), 7.81-7.84 (2H, m).	Ex. 1
1180		1H-NMR (DMSO-d6) δ: 7.48 (1H, d, J = 15.9 Hz), 7.65 (1H, d, J = 15.9 Hz), 7.71-7.78 (3H, m), 7.88 (1H, d, J = 8.0 Hz), 8.07-8.14 (2H, m).	Ex. 2
1181		1H-NMR (DMSO-d6) δ: 7.77 (2H, d, J = 8.2 Hz), 8.15-8.18 (3H, m).	Ex. 1










[08818]

Ex. No.	STR	1H-NMR	ref.
1182		1H-NMR (DMSO-d6) δ: 0.99 (3H, t, J = 7.3 Hz), 1.68-1.81 (2H m), 3.24 (2H, t, J = 7.5 Hz), 7.92 (2H, d, J = 8.3 Hz), 8.19 (2H, d, J = 8.3 Hz).	Ex. 1
1183		1H-NMR (DMSO-d6) δ: 7.48-7.53 (1H, m), 7.71 (1H, dd, J = 2.6, 8.8 Hz), 8.23 (1H, s), 8.43 (1H, dd, J = 6.3, 8.8 Hz).	Ex. 125
1184		1H-NMR (DMSO-d6) δ: 7.65 (1H, d, J = 8.9 Hz), 7.86 (1H, d, J = 8.9 Hz), 7.97 (1H, s), 8.42 (1H, s).	Ex. 125
1185		1H-NMR (DMSO-d6) δ: 2.81 (3H, s), 7.57-7.60 (1H, m), 7.74-7.77 (1H, m), 7.86 (1H, t, J = 1.4 Hz).	Ex. 125
1186		1H-NMR (DMSO-d6) δ: 1.32 (3H, t, J = 7.5 Hz), 3.30 (2H, q, J = 7.5 Hz), 7.57-7.61 (1H, m), 7.75-7.79 (1H, m), 7.88 (1H, s).	Ex. 125
1187		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.5 Hz), 3.27 (2H, q, J = 7.5 Hz), 7.41-7.47 (1H, m), 7.65-7.72 (2H, m).	Ex. 125
1188		1H-NMR (DMSO-d6) δ: 7.46-7.52 (1H, m), 7.74-7.80 (2H, m), 8.44 (1H, s).	Ex. 125
1189		1H-NMR (DMSO-d6) δ: 7.94 (2H, d, J = 8.2 Hz), 8.18 (2H, d, J = 8.1 Hz).	Ex. 108
1190		1H-NMR (DMSO-d6) δ: 7.76 (1H, t, J = 9.7 Hz), 8.38-8.43 (3H, m).	Ex. 1
1191		1H-NMR (DMSO-d6) δ: 8.09 (1H, s), 8.35 (1H, s), 8.41 (1H, s), 8.48 (1H, s).	Ex. 1







Ex. No.	STR	1H-NMR	ref.
1192		1H-NMR (DMSO-d6) δ: 3.95 (3H, s), 7.44 (1H,s), 7.86 (1H, s), 7.94 (1H, s), 8.43 (1H, s).	Ex. 1
1193		1H-NMR (DMSO-d6) δ: 4.00 (3H, s), 7.47 (1H, d, J = 9.5 Hz), 8.27-8.30 (2H, m), 8.33 (1H, s).	Ex. 1
1194		1H-NMR (DMSO-d6) δ: 7.63-7.72 (1H, m), 7.91-7.96 (1H, m), 8.06-8.13 (1H, m), 8.39 (1H, s).	Ex. 1
1195		1H-NMR (DMSO-d6) δ: 8.32 (1H, brs), 8.52 (1H, s), 8.67 (2H, brs).	Ex. 1
1196		1H-NMR (DMSO-d6) δ: 7.40-7.46 (2H, m), 8.09-8.14 (2H, m), 8.34 (1H, s).	Ex. 1
1197		1H-NMR (DMSO-d6) δ: 3.85 (3H, s), 7.10-7.15 (2H, m), 7.97-8.02 (2H, m), 8.24 (1H, s).	Ex. 1
1198		1H-NMR (DMSO-d6) δ: 3.86 (3H, s), 7.12-7.15 (1H, m), 7.46-7.51 (1H, m), 7.60-7.63 (2H, m), 8.34 (1H, s).	Ex. 1
1199		1H-NMR (DMSO-d6) δ: 2.39 (3H, s), 7.38 (2H, d, J = 8.0 Hz), 7.95 (2H, d, J = 8.1 Hz), 8.30 (1H, s).	Ex. 1
1200		1H-NMR (DMSO-d6) δ: 7.58-7.65 (2H, m), 7.99-8.03 (1H, m), 8.10-8.11 (1H, m), 8.40 (1H, s).	Ex. 1







Ex. No.	STR	1H-NMR	ref.
1201		1H-NMR (DMSO-d6) δ: 7.86 (1H, d, J = 8.4 Hz), 8.03 (1H, dd, J = 2.1, 8.4 Hz), 8.28 (1H, d, J = 2.0 Hz), 8.42 (1H, s).	Ex. 1
1202		1H-NMR (DMSO-d6) δ: 7.83 (1H, t, J = 1.8 Hz), 8.09 (2H, d, J = 1.8 Hz), 8.45 (1H, s).	Ex. 1
1203		1H-NMR (DMSO-d6) δ: 8.12 (1H, d, J = 8.3 Hz), 8.26-8.29 (2H, m), 8.58 (1H, s).	Ex. 1
1204		1H-NMR (DMSO-d6) δ: 7.80-7.88 (3H, m), 7.98 (1H, d, J = 7.4 Hz), 8.52 (1H, s).	Ex. 1
1205		1H-NMR (DMSO-d6) δ: 8.05-8.08 (2H, m), 8.22-8.25 (2H, m), 8.48 (1H, s).	Ex. 1
1206		1H-NMR (DMSO-d6) δ: 7.80 (1H, t, J = 7.8 Hz), 8.03 (1H, dt, J = 7.8, 1.3 Hz), 8.36-8.39 (1H, m), 8.44 (1H, s), 8.48 (1H, t, J = 1.5 Hz).	Ex. 1
1207		1H-NMR (DMSO-d6) δ: 7.83 (1H, t, J = 7.9 Hz), 7.93 (1H, dd, J = 2.1, 8.5 Hz), 8.06 (1H, dd, J =2.0, 10.0 Hz), 8.42 (1H, s).	Ex. 1
1208		1H-NMR (DMSO-d6) δ: 7.64-7.68 (2H, m), 7.98-8.03 (2H, m).	Ex. 108

Ex. No.	STR	1H-NMR	ref.
1209		1H-NMR (DMSO-d6) δ: 7.57-7.61 (1H, m), 7.72 (1H, t, J = 8.2 Hz), 7.99-8.01 (2H, m).	Ex. 1208
1210		1H-NMR (DMSO-d6) δ: 8.19-8.27 (3H, m), 8.59 (1H, s).	Ex. 1
1211		1H-NMR (DMSO-d6) δ: 2.80 (3H, s), 7.51-7.55 (1H, m), 7.69 (1H, t, J =8.2 Hz), 7.95-7.98 (2H, m).	Ex. 1
1212		1H-NMR (DMSO-d6) δ: 2.79 (3H, s), 7.82 (1H, d, J = 11.2 Hz), 7.92 (1H, dd, J = 2.8, 11.2 Hz), 8.18 (1H, d, J = 2.7 Hz).	Ex. 1
1213		1H-NMR (DMSO-d6) δ: 2.87 (6H, s), 4.75 (2H, s), 7.62-7.67 (2H, m), 8.02-8.06 (2H m).	Ex. 1
1214		1H-NMR (DMSO-d6) δ: 2.88 (6H, s), 7.55-7.60 (2H, m), 7.89-7.93 (2H, m).	Ex. 1
1215		1H-NMR (DMSO-d6) δ: 1.49 (3H, t, J = 7.0 Hz), 4.42 (2H, q, J = 6.9 Hz), 7.59-7.64 (2H, m), 7.91-7.95 (2H, m).	Ex. 1
1216		1H-NMR (DMSO-d6) δ: 4.22 (3H, s), 7.92 (2H, d, J = 8.5 Hz), 8.12 (2H, d, J = 8.2 Hz).	Ex. 1


Ex. No.	STR	1H-NMR	ref.
1217		1H-NMR (DMSO-d6) δ: 4.22 (3H, s), 7.76-7.81 (1H, m), 7.87 (1H, d, J = 8.1 Hz), 8.18 (1H, d, J = 7.6 Hz), 8.27 (1H, s).	Ex. 1
1218		1H-NMR (DMSO-d6) δ: 4.21 (3H, s), 7.50-7.52 (1H, m), 7.65-7.71 (1H, m), 7.90-7.92 (2H, m).	Ex. 1
1219		1H-NMR (DMSO-d6) δ: 4.20 (3H, s), 7.81 (1H, d, J = 8.4 Hz), 7.87 (1H, dd, J = 2.0, 8.4 Hz), 8.15 (1H, d, J = 2.0 Hz).	Ex. 1
1220		1H-NMR (DMSO-d6) δ: 7.66 (1H, t, J = 8.9 Hz), 7.99-8.04 (1H, m), 8.20 (1H, dd, J = 2.2, 7.0 Hz).	Ex. 108
1222		1H-NMR (DMSO-d6) δ: 1.37 (6H, d, J = 6.8 Hz), 3.96-4.07 (1H, m), 7.61-7.65 (2H, m), 7.99-8.04 (2H, m).	Ex. 1
1223		1H-NMR (DMSO-d6) δ: 1.44 (18H, s), 7.63 (1H, s), 7.83 (2H, s), 8.20 (1H, s).	Ex. 1
1224		1H-NMR (DMSO-d6) δ: 2.12 (3H, s), 5.35 (1H, s), 5.43 (1H, s), 7.62-7.65 (2H, m), 7.99-8.04 (2H, m).	Ex. 1
1225		1H-NMR (DMSO-d6) δ: 1.37 (6H, d, J = 6.8 Hz), 3.97-4.06 (1H, m), 7.61 (1H, t, J = 8.9 Hz), 7.96-8.01 (1H, m), 8.18 (1H, dd, J = 2.0, 7.1 Hz).	Ex. 1
1226		1H-NMR (DMSO-d6) δ: 7.70-7.75 (2H, m), 8.10-8.15 (2H, m).	Ex. 1


[0820]


Ex. No.	STR	1H-NMR	ref.
1227		1H-NMR (DMSO-d6) δ: 0.99 (3H, t, J = 7.3 Hz), 1.68-1.80 (2H m), 3.24 (2H, t, J = 7.6 Hz), 7.52 (1H, d, J = 8.4 Hz), 7.69 (1H, t, J = 8.3 Hz), 7.97-8.00 (2H m).	Ex. 1
1228		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.4 Hz), 3.22-3.30 (2H, m), 7.81 (1H, d, J = 8.5 Hz), 7.91-7.94 (1H, m), 8.19 (1H, s).	Ex. 1
1229		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.4 Hz), 3.23-3.30 (2H, m), 7.57-7.59 (2H, m), 7.91-7.94 (1H, m), 8.03-8.05 (1H, m).	Ex. 1
1230		1H-NMR (DMSO-d6) δ: 1.35 (3H, t, J = 7.4 Hz), 3.24-3.31 (2H, m), 7.92 (2H, d, J = 8.3 Hz), 8.19 (2H, d, J = 8.2 Hz).	Ex. 1
1231		1H-NMR (DMSO-d6) δ: 1.32 (3H, t, J = 7.4 Hz), 2.37 (3H, s), 3.19-3.27 (2H, m), 7.35 (2H, d, J = 8.0 Hz), 7.88 (2H, d, J = 8.1 Hz).	Ex. 1
1232		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.4 Hz), 3.21-3.28 (2H, m), 7.37-7.43 (2H, m), 8.02-8.06 (2H, m).	Ex. 1
1233		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.4 Hz), 3.22-3.30 (2H, m), 7.62 (1H, t, J = 8.9 Hz), 7.96-8.01 (1H, m), 8.16-8.19 (1H, m).	Ex. 1
1234		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.4 Hz), 3.22-3.30 (2H, m), 7.82 (1H, d, J = 8.4 Hz), 7.93 (1H, dd, J = 2.1, 8.4 Hz), 8.20 (1H, d, J = 2.0 Hz).	Ex. 1
1235		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.4 Hz), 3.22-3.30 (2H, m), 7.76 (1H, t, J = 1.9 Hz), 7.97 (2H, d, J = 1.9 Hz).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1236		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.4 Hz), 3.24-3.31 (2H, m), 7.51-7.54 (1H, m), 7.69 (1H, t, J = 8.3 Hz), 7.97-7.99 (2H, m).	Ex. 1
1237		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.4 Hz), 3.21-3.31 (2H, m), 7.69-7.75 (1H, m), 8.27-8.36 (2H, m)	Ex. 1
1238		1H-NMR (DMSO-d6) δ: 0.98 (3H, t, J = 7.3 Hz), 1.68-1.77 (2H, m), 3.19-3.23 (2H, m), 7.59-7.64 (1H, m), 7.95-8.00 (1H, m), 8.15-8.19 (1H, m).	Ex. 1
1239		1H-NMR (DMSO-d6) δ: 0.08-0.11 (2H, m), 0.39-0.44 (2H, m), 0.75-0.82 (1H, m), 1.58-1.63 (2H, m), 3.31-3.34 (2H, m), 7.61 (1H, t, J = 8.9 Hz), 7.95-7.99 (1H, m), 8.16 (1H, dd, J = 2.1, 7.0 Hz).	Ex. 1
1240		1H-NMR (DMSO-d6) δ: 0.08-0.11 (2H, m), 0.39-0.43 (2H, m), 0.75-0.82 (1H, m), 1.58-1.63 (2H, m), 3.31-3.34 (2H, m), 7.61-7.64 (2H, m), 7.98-8.00 (2H, m).	Ex. 1
1241		1H-NMR (DMSO-d6) δ: 0.97 (9H, s), 1.58-1.61 (2H, m), 3.21-3.25 (2H, m), 7.63 (2H, d, J = 8.6 Hz), 7.99 (2H, d, J = 8.5 Hz).	Ex. 1
1242		1H-NMR (DMSO-d6) δ: 2.75 (3H, s), 3.84 (3H, s), 7.08-7.12 (2H, m), 7.90-7.93 (2H, m).	Ex. 1
1243		1H-NMR (DMSO-d6) δ: 1.32 (3H, t, J = 7.4 Hz), 3.22 (2H, q, J = 7.4 Hz), 3.84 (3H, s), 7.03-7.12 (2H, m), 7.91-7.95 (2H, m).	Ex. 1

[0821]

Ex. No.	STR	1H-NMR	ref.
1244		1H-NMR (DMSO-d6) δ: 2.81 (3H, s), 7.45-7.50 (1H, m), 7.67-7.69 (1H, m), 8.42 (1H, dd, J = 6.6, 8.7 Hz).	Ex. 125
1245		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.5 Hz), 3.27-3.33 (2H, m), 7.46-7.51 (1H, m), 7.70 (1H, dd, J = 2.6, 8.9 Hz), 8.42 (1H, dd, J = 6.3, 8.9 Hz).	Ex. 125
1246		1H-NMR (DMSO-d6) δ: 2.82 (3H, s), 7.63 (1H, dd, J = 2.2, 8.6 Hz), 7.83 (1H, d, J = 2.2 Hz), 8.41 (1H, d, J = 8.6 Hz).	Ex. 125
1247		1H-NMR (DMSO-d6) δ: 7.58 (1H, dd, J = 2.0, 8.5 Hz), 7.75 (1H, dd, J = 2.0, 11.3 Hz), 8.31-8.40 (2H, m).	Ex. 125
1248		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.5 Hz), 3.24-3.30 (2H, m), 7.55 (1H, dd, J = 2.0, 8.5 Hz), 7.73 (1H, dd, J = 2.0, 11.3 Hz), 8.28 (1H, t, J = 8.5 Hz).	Ex. 125
1249		1H-NMR (DMSO-d6) δ: 7.60 (1H, t, J = 8.6 Hz), 8.08-8.13 (1H, m), 8.36-8.38 (2H, m).	Ex. 125
1250		1H-NMR (DMSO-d6) δ: 2.79 (3H, s), 7.58 (1H, t, J = 8.6 Hz), 7.98-8.02 (1H, m), 8.29 (1H, dd, J = 2.2, 6.6 Hz).	Ex. 125
1251		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.5 Hz), 3.27 (2H, q, J = 7.5 Hz), 7.58 (1H, t, J = 8.7 Hz), 8.00-8.04 (1H, m), 8.30 (1H, dd, J = 2.2, 6.6 Hz).	Ex. 125
1252		1H-NMR (DMSO-d6) δ: 2.80 (3H, s), 7.56 (1H, dd, J = 2.0, 8.5 Hz), 7.74 (1H, dd, J = 2.0, 11.3 Hz), 8.28 (1H, t, J = 8.5 Hz).	Ex. 125

Ex. No.	STR	1H-NMR	ref.
1253		1H-NMR (DMSO-d6) δ: 2.80 (3H, s), 7.39-7.45 (1H, m), 7.63-7.69 (2H, m).	Ex. 125
1255		1H-NMR (DMSO-d6) δ: 2.65 (3H, s), 7.90 (2H, d, J = 8.3 Hz), 8.21 (2H, d, J = 8.1 Hz).	Ex. 1
1256		1H-NMR (DMSO-d6) δ: 7.92 (2H, d, J = 8.2 Hz), 8.26 (2H, d, J = 8.2 Hz), 8.50 (1H, s).	Ex. 1
1257		1H-NMR (DMSO-d6) δ: 7.60-7.65 (2H, m), 8.04-8.08 (2H, m), 8.42 (1H, s).	Ex. 1
1258		1H-NMR (DMSO-d6) δ: 7.54 (2H, d, J = 8.0 Hz), 8.13-8.18 (2H, m), 8.43 (1H, s).	Ex. 1
1259		1H-NMR (DMSO-d6) δ: 7.62 (1H, t, J = 8.9 Hz), 8.04-8.09 (1H, m), 8.24 (1H, dd, J = 2.2, 7.0 Hz), 8.43 (1H, s).	Ex. 1
1260		1H-NMR (DMSO-d6) δ: 7.66 (2H, d, J = 8.6 Hz), 8.08 (2H, d, J =8.6 Hz).	Ex. 1
1261		1H-NMR (DMSO-d6) δ: 7.82 (1H, t, J = 7.8 Hz), 7.97 (1H, d, J = 8.6 Hz), 8.29-8.34 (2H, m).	Ex. 1
1262		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.5 Hz), 2.99 (2H, q, J = 7.5 Hz), 7.91 (2H, d, J = 8.3 Hz), 8.22 (2H, d, J = 8.3 Hz).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1263		1H-NMR (CDCl3-DMSO-d6) δ: 1.04-1.13 (2H, m), 1.15-1.26 (2H, m), 2.48-2.59 (1H, br.), 7.41 (2H, d, J = 8.5 Hz), 7.87 (2H, d, J = 8.5 Hz), 15.6 (1H, br.).	Ex. 1
1264		1H-NMR (DMSO-d6) δ: 1.05-1.15 (4H, m), 2.39-2.47 (1H, br.), 7.57 (1H, t, J = 8.9 Hz), 7.92-7.99 (1H, m), 8.13 (1H, dd, J = 2.1, 7.0 Hz).	Ref. Ex. 63, Ex. 1
1265		1H-NMR (DMSO-d6) δ: 7.55 (1H, t, J = 8.9 Hz), 7.60-7.65 (1H, m), 7.66-7.70 (2H, m), 7.93 (1H, dd, J = 2.1, 7.1 Hz), 8.05-8.09 (2H, m).	Ex. 1
1266		1H-NMR (DMSO-d6) δ: 2.79 (3H, s), 7.67 (2H, d, J = 10.9 Hz), 7.80 (2H, d, J = 11.0 Hz).	Ex. 1
1267		1H-NMR (DMSO-d6) δ: 4.64 (2H, s), 7.35-7.41 (4H, m), 7.57-7.62 (2H, m), 7.96-8.00 (2H, m).	Ex. 1
1268		1H-NMR (DMSO-d6) δ: 4.76 (2H, s), 7.55-7.62 (4H, m), 7.70 (2H, d, J = 8.1 Hz), 7.97-8.00 (2H, m).	Ex. 1
1269		1H-NMR (CDCl3) δ: 7.54 (2H, d, J = 8.1 Hz), 7.72 (2H, d, J = 8.1 Hz).	Ex. 125







Ex. No.	STR	1H-NMR	ref.
1270		1H-NMR (DMSO-d6) δ: 8.15 (1H, d, J = 8.3 Hz), 8.54 (1H, s), 8.68 (1H, dd, J = 2.1, 7.8 Hz), 9.41 (1H, d, J = 2.0 Hz).	Ex. 1
1271		1H-NMR (DMSO-d6) δ: 2.83 (3H, s), 8.11 (1H, d, J = 8.2 Hz), 8.57 (1H, dd, J = 1.7, 8.2 Hz), 9.33 (1H, d, J = 1.7 Hz).	Ex. 1
1272		1H-NMR (DMSO-d6) δ: 2.82 (3H, s), 8.42 (1H, t, J = 2.1 Hz), 8.77 (1H, d, J = 2.1 Hz), 9.13 (1H, d, J = 2.1 Hz).	Ex. 1
1273		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.5 Hz), 3.29 (2H, q, J = 7.5 Hz), 8.42 (1H, t, J = 2.1 Hz), 8.76 (1H, d, J = 2.1 Hz), 9.13 (1H, d, J = 2.1 Hz).	Ex. 1
1274		1H-NMR (DMSO-d6) δ: 2.81 (3H, s), 7.74 (1H, dd, J = 0.6, 8.4 Hz), 8.36 (1H, dd, J = 2.5, 8.4 Hz), 8.99 (1H, dd, J = 0.6, 2.5 Hz).	Ex. 125
1275		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.4 Hz), 3.28 (2H, q, J = 7.4 Hz), 7.74 (1H, dd, J = 0.6, 8.4 Hz), 8.37 (1H, dd, J = 2.5, 8.4 Hz), 9.00 (1H, dd, J = 0.6, 2.5 Hz).	Ex. 125
1276		1H-NMR (DMSO-d6) δ: 7.72 (1H, d, J = 8.3 Hz), 7.95 (1H, s), 8.40 (1H, dd, J = 2.4, 8.3 Hz), 9.02 (1H, d, J = 2.3 Hz).	Ex. 125
1277		1H-NMR (DMSO-d6) δ: 2.80 (3H, s), 7.64-7.68 (1H, m), 8.09-8.14 (2H, m).	Ex. 125
1278		1H-NMR (DMSO-d6) δ: 8.09 (1H, dd, J = 1.3, 7.4 Hz), 8.37-8.45 (2H, m), 8.50 (1H, s).	Ex. 1
1279		1H-NMR (DMSO-d6) δ: 8.35 (1H, d, J = 6.6 Hz), 8.52 (1H, s), 8.54 (1H, d, J =1.4 Hz), 9.11 (1H, s).	Ex. 1


Ex. No.	STR	1H-NMR	ref.
1280		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.5 Hz), 3.25-3.31 (2H, m), 8.02 (1H, d, J = 6.7 Hz), 8.32-8.40 (2H, m).	Ex. 1
1281		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.5 Hz), 3.26 (2H, q, J = 7.5 Hz), 8.13 (1H, dd, J = 0.5, 8.5 Hz), 8.21 (1H, dd, J = 2.4, 8.5 Hz), 8.73 (1H, dd, J = 0.5, 2.4 Hz).	Ex. 1
1282		1H-NMR (DMSO-d6) δ: 2.79 (3H, s), 7.96-8.04 (1H, m), 8.18 (1H, dd, J = 4.6, 8.8 Hz), 8.67 (1H, d, J = 2.8 Hz).	Ex. 1
1283		1H-NMR (DMSO-d6) δ: 1.31 (3H, t, J = 7.4 Hz), 3.41-3.44 (2H, m), 7.95-8.00 (1H, m), 8.18 (1H, dd, J = 4.6, 8.9 Hz), 8.65 (1H, d, J = 2.8 Hz).	Ex. 1
1284		1H-NMR (DMSO-d6) δ: 2.84 (3H, s), 7.92-7.93 (1H, m), 8.00 (1H, s), 8.59 (1H, d, J = 5.2 Hz).	Ex. 1
1285		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.4 Hz), 3.20-3.50 (2H, m), 7.93 (1H, d, J = 5.1 Hz), 8.01 (1H, s), 8.59 (1H, d, J = 5.1 Hz).	Ex. 1
1286		1H-NMR (DMSO-d6) δ: 7.57 (4H, s), 7.84 (1H, s).	Ex. 1
1287		1H-NMR (DMSO-d6) δ: 7.49-7.52 (2H, m), 7.64-7.68 (2H, m), 7.85 (1H, s).	Ex. 1
1288		1H-NMR (DMSO-d6) δ: 7.52-7.58 (2H, m), 7.84 (1H, s), 7.90-7.93 (1H, m).	Ex. 1
1289		1H-NMR (DMSO-d6) δ: 7.53-7.60 (4H, m).	Ex. 1











[0823]









Ex. No.	STR	1H-NMR	ref.
1290		1H-NMR (DMSO-d6) δ: 7.72-7.77 (2H, m), 7.86-7.89 (1H, m), 7.94 (1H, s).	Ex. 1
1291		1H-NMR (DMSO-d6) δ: 2.63 (3H, s), 7.69-7.87 (4H, m).	Ex. 1
1292		1H-NMR (DMSO-d6) δ: 2.63 (3H, s), 7.67-7.74 (2H, m), 7.84-7.87 (2H, m).	Ex. 1
1293		1H-NMR (DMSO-d6) δ: 7.61 (1H, t, J = 9.0 Hz), 7.81-7.86 (1H, m), 8.11 (1H, dd, J = 2.3, 6.9 Hz), 8.21 (1H, s).	Ex. 1
1294		1H-NMR (DMSO-d6) δ: 7.77 (1H, t, J = 7.8 Hz), 7.92 (1H, d, J = 7.9 Hz), 8.09 (1H, J = 8.1 Hz), 8.13 (1H, s), 8.25 (1H, s).	Ex. 1
1295		1H-NMR (DMSO-d6) δ: 2.62 (3H, s), 7.56-7.61 (2H, m), 7.74-7.78 (2H, m).	Ex. 1
1296		1H-NMR (DMSO-d6) δ: 2.63 (3H, s), 7.57 (1H, t, J = 9.0 Hz), 7.76-7.81 (1H, m), 8.05 (1H, dd, J = 2.3, 6.9 Hz).	Ex. 1
1297		1H-NMR (DMSO-d6) δ: 7.76-7.80 (4H, m), 7.98 (2H, d, J = 8.1 Hz), 8.39 (1H, s).	Ex. 1
1298		1H-NMR (DMSO-d6) δ: 7.90 (2H, d, J = 8.3 Hz), 8.29 (2H, d, J = 8.1 Hz), 8.64 (1H, s).	Ex. 1
1299		1H-NMR (DMSO-d6) δ: 7.58-7.62 (2H, m), 8.07-8.12 (2H, m), 8.46 (1H, s).	Ex. 1








Ex. No.	STR	1H-NMR	ref.
1300		1H-NMR (DMSO-d6) δ: 7.61 (1H, t, J = 9.0 Hz), 8.07-8.12 (1H, m), 8.29 (1H, dd, J = 2.2, 7.2 Hz), 8.53 (1H, s).	Ex. 1
1301		1H-NMR (DMSO-d6) δ: 1.62 (6H, brs), 3.50 (4H, brs), 7.40 (1H, s).	Ex. 1
1302		1H-NMR (DMSO-d6) δ: 3.48 (4H, t, J = 4.9 Hz), 3.74 (4H, t, J = 4.9 Hz), 7.49 (1H, s).	Ex. 1
1303		1H-NMR (DMSO-d6) δ: 5.55 (2H, s), 7.13-7.19 (2H, m), 7.35-7.41 (2H, m), 8.34 (1H, s).	Ex. 1
1304		1H-NMR (DMSO-d6) δ: 5.57 (2H, s), 7.21-7.26 (2H, m), 7.32-7.36 (2H, m), 8.35 (1H, s).	Ex. 1
1305		1H-NMR (DMSO-d6) δ: 5.65 (2H, s), 7.37 (1H, d, J = 7.5 Hz), 7.44-7.47 (2H, m), 7.56-7.61 (1H, m), 8.35 (1H, s).	Ex. 1
1306		1H-NMR (DMSO-d6) δ: 3.57 (3H, s), 7.44-7.47 (3H, m), 7.73-7.78 (2H, m).	Ex. 1
1307		1H-NMR (DMSO-d6) δ: 7.26 (2H, d, J = 8.6 Hz), 7.58 (1H, s), 7.94-7.99 (2H, m), 10.71 (1H, s).	Ex. 1
1308		1H-NMR (DMSO-d6) δ: 7.30 (2H, d, J = 8.8 Hz), 7.57 (1H, s), 7.88 (2H, d, J = 8.8 Hz) 10.64 (1H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1309		1H-NMR (DMSO-d6) δ: 7.67 (1H, dd, J = 1.3, 5.1 Hz), 7.79 (1H, dd, J = 2.9, 5.1 Hz), 8.27-8.28 (2H, m).	Ex. 1
1310		1H-NMR (DMSO-d6) δ: 4.57 (2H, s), 7.66 (2H, d, J = 8.2 Hz), 7.74 (2H, d, J = 8.3 Hz), 8.19 (1H, s).	Ex. 1
1311		1H-NMR (DMSO-d6) δ: 4.45 (2H, s), 7.41-7.48 (4H, m), 8.17 (1H, s).	Ex. 1
1312		1H-NMR (DMSO-d6) δ: 1.24 (3H, t, J = 7.1 Hz), 4.05 (2H, q, J = 7.1 Hz), 7.38 (1H, s), 7.50 (2H, d, J = 8.2 Hz), 7.67-7.71 (2H, m).	Ex. 1
1313		1H-NMR (DMSO-d6) δ: 3.24 (2H t, J = 7.8 Hz), 3.45 (2H, t, J = 7.8 Hz), 7.54 (2H, d, J = 8.1 Hz), 7.65 (2H, d, J = 8.0 Hz), 8.14 (1H, s).	Ex. 1
1314		1H-NMR (DMSO-d6) δ: 3.09 (3H, s), 4.77 (2H, s), 7.34-7.41 (5H, m).	Ex. 1









Ex. No.	STR	m.p.	ref.
1315		248-249	Ex. 1








Ex. No.	STR	1H-NMR	ref.
1316		1H-NMR (DMSO-d6) δ: 6.99 (1H, dd, J = 0.8, 1.8 Hz), 7.89 (1H, t, J = 1.7 Hz), 8.24 (1H, s), 8.46-8.48 (1H, m).	Ex. 1
1317		1H-NMR (DMSO-d6) δ: 3.48-3.52 (4H, m), 3.65-3.68 (4H, m), 7.15 (2H, d, J = 8.7 Hz), 7.50 (1H, s), 7.54 (2H, d, J = 8.8 Hz).	Ex. 1
1318		1H-NMR (DMSO-d6) δ: 1.68-1.82 (2H, m), 1.89-1.93 (2H, m), 2.78-2.86 (1H, m), 3.18-3.27 (2H, m), 4.09-4.13 (2H, m), 7.18-7.34 (5H, m), 7.44 (1H, s).	Ex. 1
1319		1H-NMR (DMSO-d6) δ: 3.30-3.34 (4H, m), 3.63-3.66 (4H, m), 7.01-7.06 (2H, m), 7.24-7.29 (2H, m), 7.49 (1H, s).	Ex. 1
1320		1H-NMR (DMSO-d6) δ: 1.45 (9H, s), 8.15 (1H, s).	Ex. 1
1321		1H-NMR (DMSO-d6) δ: 1.24-1.82 (8H, m), 2.10-2.14 (2H, m), 3.04-3.11 (1H, m), 8.16 (1H, s).	Ex. 1
1322		1H-NMR (DMSO-d6) δ: 4.94 (2H, s), 5.16 (2H, s), 7.66 (1H, t, J =7.7 Hz), 7.76-7.84 (3H, m), 8.38 (1H, s).	Ex. 1
1323		1H-NMR (DMSO-d6) δ: 1.87-2.03 (2H, m), 2.15-2.25 (2H, m), 2.49-2.86 (4H, m), 3.18-3.27 (1H, m), 4.02 (2H, s), 7.45-7.52 (4H, m), 7.88 (1H, s).	Ex. 1
1324		1H-NMR (DMSO-d6) δ: 1.85-1.98 (2H, m), 2.14-2.21 (2H, m), 2.49-2.74 (4H, m), 3.15-3.20 (1H, m), 4.01 (2H, s), 7.66 (2H, d, J = 8.1 Hz), 7.79 (2H, d, J = 8.1 Hz), 7.95 (1H, s).	Ex. 1
1325		1H-NMR (DMSO-d6) δ: 1.79-1.94 (2H, m), 2.17-2.22 (2H, m), 2.85-2.94 (2H, m), 3.24-3.28 (1H, m), 3.76-3.81 (2H, m), 7.00 (2H, d, J = 8.8 Hz), 7.23 (2H, d, J = 8.6 Hz), 8.19 (1H, s).	Ex. 1








Ex. No.	STR	1H-NMR	ref.
1326		1H-NMR (DMSO-d6) δ: 1.77-1.91 (2H, m), 2.18-2.22 (2H, m), 3.00-3.10 (2H, m), 3.25-3.28 (1H, m), 3.95-4.00 (2H, m), 7.12 (2H, d, J = 8.6 Hz), 7.50 (2H, d, J = 8.9 Hz), 8.19 (1H, s).	Ex. 1
1327		1H-NMR (DMSO-d6) δ: 4.75 (2H, s), 4.95 (2H, s), 7.38 (2H, d, J = 8.0 Hz), 7.54 (2H, d, J = 8.6 Hz), 8.30 (1H, s).	Ex. 1
1328		1H-NMR (DMSO-d6) δ: 4.71 (2H, s), 4.93 (2H, s), 7.45 (4H, s), 8.30 (1H, s).	Ex. 1
1329		1H-NMR (DMSO-d6) δ: 4.84 (2H, s), 4.98 (2H, s), 7.64 (2H, d, J = 8.1 Hz), 7.76 (2H, d, J = 8.2 Hz), 8.32 (1H, s).	Ex. 1
1330		1H-NMR (DMSO-d6) δ: 1.37 (18H, s), 4.29 (2H, s), 6.90 (1H, s), 7.14 (2H, s), 8.11 (1H, s).	Ex. 1
1331		1H-NMR (DMSO-d6) δ: 7.16-7.27 (2H, m), 7.48-7.51 (1H, m), 8.10 (1H, s), 8.21 (1H, d, J = 2.9 Hz), 8.55 (1H, d, J = 7.1 Hz), 11.83 (1H, brs).	Ex. 1
1332		1H-NMR (DMSO-d6) δ: 2.59 (3H, s), 7.62-7.64 (2H, m), 8.10-8.13 (2H, m), 12.79 (1H, s).	Ex. 125
1333		1H-NMR (DMSO-d6) δ: 2.47 (3H, s), 4.48 (2H, d, J = 6.0 Hz), 7.37-7.43 (4H, m), 8.18 (1H, t, J = 6.0 Hz).	Ex. 125

Ex. No.	STR	1H-NMR	ref.
1334		1H-NMR (DMSO-d6) δ: 2.48 (3H, s), 4.59 (2H, d, J = 6.0 Hz), 7.61 (2H, d, J = 8.0 Hz), 7.69 (2H, d, J = 8.0 Hz), 8.27 (1H, t, J = 6.0 Hz).	Ex. 125
1335		1H-NMR (DMSO-d6) δ: 1.17 (3H, t, J = 7.8 Hz), 2.96 (2H, q, J = 7.8 Hz), 4.60 (2H, d, J = 6.0 Hz), 7.61 (2H, d, J = 8.1 Hz), 7.69 (2H, d, J = 8.1 Hz), 8.30 (1H, t, J = 6.0 Hz).	Ex. 125
1336		1H-NMR (DMSO-d6) δ: 1.20 (3H, t, J = 7.5 Hz), 2.64 (2H, q, J = 7.5 Hz), 3.69 (3H, s), 7.54-7.58 (2H, m), 8.22-8.26 (2H, m).	Ex. 125
1337		1H-NMR (DMSO-d6) δ: 3.33-3.35 (4H, m), 3.67-3.69 (4H, m), 7.02-7.06 (2H, m), 7.26-7.30 (2H, m), 7.63 (2H, d, J = 8.1 Hz), 7.74 (2H, d, J = 8.1 Hz).	Ex. 125
1339		1H-NMR (DMSO-d6) δ: 7.70 (1H, t, J = 8.7 Hz), 7.82 (1H, t, J = 53.7 Hz), 8.10-8.15 (1H, m), 8.31 (1H, dd, J = 2.2, 7.0 Hz).	Ex. 125
1340		1H-NMR (DMSO-d6) δ: 7.71 (1H, t, J = 8.9 Hz), 8.13-8.17 (1H, m), 8.34 (1H, dd, J = 2.3, 7.0 Hz).	Ex. 125
1342		1H-NMR (DMSO-d6) δ: 7.81 (1H, t, J = 53.8 Hz), 7.68-7.71 (2H, m), 8.09-8.13 (2H, m).	Ex. 125

[0826]

Ex. No.	STR	m.p.	ref.
1341		247.4–248.8	Ex. 125
1343		211-212	Ex. 2
1344		229.3-231.4	Ex. 2
1345		271.2-271.6	Ex. 2
1346		201.8-203.4	Ex. 2
1347		241.1-243.0	Ex. 2
1348		147.6-151.6	Ex. 2
1349		236.1-239.0	Ex. 2

Ex. No.	STR	m.p.	ref.
1350		266.9-269.1	Ex. 2
1351		228.3-230.3	Ex. 2
1352		216.6-220.0	Ex. 2
1353		205.5-207.8	Ex. 2
1354		193-196	Ex. 1
1355		148-167	Ex. 1
1356		151-169	Ex. 1

Ex. No.	STR	m.p.	ref.
1357		209-215	Ex. 1
1358		190-204	Ex. 1
1359		176-188	Ex. 1
1360		176–181	Ex. 1
1361		188–193	Ex. 1
1362		169-170	Ex. 125
1363		176-182	Ex. 125

[08271]

Ex. No.	STR	1H-NMR	ref.
1364		1H-NMR (DMSO-d6) δ: 7.88 (1H, t, J = 7.8 Hz), 8.00 (1H, d, J = 8.2 Hz), 8.29 (1H, s), 8.35 (1H, d, J = 7.9 Hz), 8.93 (1H, s).	Ex. 1
1365		1H-NMR (DMSO-d6) δ: 7.67-7.72 (2H, m), 8.04-8.08 (2H, m), 8.88 (1H, s).	Ex. 1
1366		1H-NMR (DMSO-d6) δ: 1.28 (3H, t, J = 7.5 Hz), 3.01 (2H, q, J = 7.5 Hz), 7.69-7.74 (2H, m), 7.98-8.03 (2H, m).	Ex. 2
1367		1H-NMR (DMSO-d6) δ: 1.42 (9H, s), 7.65-7.68 (2H, m), 8.00-8.03 (2H, m).	Ex. 2
1368		1H-NMR (DMSO-d6) δ: 1.35 (6H, d, J = 6.8 Hz), 3.63-3.70 (1H, m), 7.66 (1H, t, J = 9.2 Hz), 8.00-8.04 (1H, m), 8.14 (1H, dd, J = 2.2, 7.0 Hz).	Ex. 2
1369		1H-NMR (DMSO-d6) δ: 1.36 (6H, d, J = 7.0 Hz), 3.64-3.71 (1H, m), 7.88 (1H, d, J = 8.5 Hz), 7.98 (1H, dd, J = 2.0, 8.5 Hz), 8.16 (1H, d, J = 2.0 Hz).	Ex. 2
1370		1H-NMR (DMSO-d6) δ: 0.98 (3H, t, J = 7.5 Hz), 1.76-1.82 (2H, m), 3.09 (2H, t, J = 7.5 Hz), 7.86 (1H, t, J = 7.9 Hz), 7.96 (1H, d, J = 7.9 Hz), 8.24 (1H, s), 8.30 (1H, d, J = 7.9 Hz).	Ex. 2
1371		1H-NMR (DMSO-d6) δ: 0.97 (3H, t, J = 7.4 Hz), 1.75-1.80 (2H, m), 3.07 (2H, t, J = 7.4 Hz), 7.65 (1H, t, J = 9.1 Hz), 7.99-8.03 (1H, m), 8.12 (1H, dd, J = 2.1, 7.0 Hz).	Ex. 2

Ex. No.	STR	1H-NMR	ref.
1372		1H-NMR (DMSO-d6) δ: 1.35 (6H, d, J = 6.9 Hz), 3.62-3.69 (1H, m), 7.65-7.72 (1H, m), 7.86-7.90 (1H, m), 7.96-8.01 (1H, m).	Ex. 2
1373		1H-NMR (DMSO-d6) δ: 1.12-1.22 (4H, m), 2.58-2.63 (1H, m), 7.63-7.65 (2H, m), 7.96-7.98 (2H, m).	Ex. 2
1374		1H-NMR (DMSO-d6) δ: 0.91 (3H, t, J = 7.4 Hz), 1.34-1.43 (2H, m), 1.69-1.77 (2H, m), 3.10 (2H, t, J = 7.4 Hz), 7.67 (2H, d, J = 8.6 Hz), 8.00 (2H, d, J = 8.6 Hz).	Ex. 2
1375		1H-NMR (DMSO-d6) δ: 1.37 (6H, d, J = 6.9 Hz), 3.66-3.73 (1H, m), 7.97 (2H, d, J = 8.3 Hz), 8.22 (2H, d, J = 8.3 Hz).	Ex. 2
1376		1H-NMR (DMSO-d6) δ: 3.34 (3H, s), 4.85 (2H, s), 7.90 (1H, d, J = 8.5 Hz), 8.00 (1H, dd, J = 2.0, 8.5 Hz), 8.17 (1H, d, J = 2.0 Hz).	Ex. 2
1377		1H-NMR (DMSO-d6) δ: 3.34 (3H, s), 4.85 (2H, s), 7.69 (2H, d, J = 8.6 Hz), 8.05 (2H, d, J = 8.6 Hz).	Ex. 2
1378		1H-NMR (CDCl3) δ: 1.46 (9H, s), 7.62 (1H, t, J = 7.5 Hz), 7.73 (1H, d, J = 7.5 Hz), 8.27-8.30 (2H, m).	Ex. 2
1379		1H-NMR (DMSO-d6) δ: 1.09-1.24 (10H, m), 2.54-2.61 (1H, m), 2.93-3.00 (1H, m), 7.43 (2H, d, J = 8.1 Hz), 7.88 (2H, d, J = 8.1 Hz).	Ex. 2

Ex. No.	STR	1H-NMR	ref.
1380		1H-NMR (DMSO-d6) δ: 1.11-1.26 (4H, m), 2.62-2.68 (1H, m), 7.79 (1H, d, J = 8.1 Hz), 7.94 (1H, d, J = 10.0 Hz), 8.22 (1H, t, J = 7.7 Hz).	Ex. 2
1381		1H-NMR (DMSO-d6) δ: 1.05-1.09 (2H, m), 1.19-1.25 (2H, m), 2.65-2.72 (1H, m), 7.63-7.69 (1H, m), 7.90-7.94 (1H, m), 8.03-8.07 (1H, m).	Ex. 1
1382		1H-NMR (DMSO-d6) δ: 1.18-1.25 (4H, m), 2.60-2.67 (1H, m), 7.93 (1H, d, J = 8.6 Hz), 8.03-8.07 (2H, m).	Ex. 1
1383		1H-NMR (DMSO-d6) δ: 1.10-1.21 (4H, m), 2.38 (3H, s), 2.55-2.61 (1H, m), 7.37 (2H, d, J = 8.0 Hz), 7.86 (2H, d, J = 8.0 Hz).	Ex. 1
1384		1H-NMR (DMSO-d6) δ: 1.30-1.44 (3H, m), 1.64-1.96 (8H, m), 7.61-7.67 (2H, m), 7.96-8.00 (2H, m).	Ex. 1
1385		1H-NMR (DMSO-d6) δ: 1.30-1.45 (3H, m), 1.66-1.97 (8H, m), 7.85 (1H, t, J = 7.9 Hz), 7.96 (1H, d, J = 7.9 Hz), 8.25 (1H, s), 8.31 (1H, d, J = 7.9 Hz).	Ex. 1
1386		1H-NMR (DMSO-d6) δ: 1.66-1.74 (2H, m), 1.80-1.90 (4H, m), 2.02-2.12 (2H, m), 3.72-3.78 (1H, m), 7.66 (1H, t, J = 9.0 Hz), 7.99-8.03 (1H, m), 8.12-8.15 (1H, m).	Ex. 1

[08228]

Ex. No.	STR	1H-NMR	ref.
1387		1H-NMR (DMSO-d6) δ: 1.90-2.10 (2H, m), 2.31-2.40 (2H, m), 2.42-2.48 (2H, m), 4.13-4.21 (1H, m), 7.67 (1H, t, J = 8.9 Hz), 8.04-8.08 (1H, m), 8.20 (1H, dd, J = 2.0, 7.0 Hz).	Ex. 125
1388		1H-NMR (DMSO-d6) δ: 1.29-1.44 (3H, m), 1.65-1.75 (3H, m), 1.80-1.94 (4H, m), 3.40-3.50 (1H, m), 7.63-7.68 (1H, m), 7.99-8.04 (1H, m), 8.13-8.16 (1H, m).	Ex. 125
1389		1H-NMR (DMSO-d6) δ: 1.19-1.27 (4H, m), 2.62-2.70 (1H, m), 8.33 (1H, s), 8.50 (2H, s).	Ex. 125
1390		1H-NMR (DMSO-d6) δ: 1.67-1.74 (2H, m), 1.80-1.90 (4H, m), 2.02-2.10 (2H, m), 3.71-3.78 (1H, m), 7.64-7.71 (1H, m), 7.84-7.89 (1H, m), 7.94-7.99 (1H, m).	Ex. 125
1391		1H-NMR (DMSO-d6) δ: 0.96 (6H, t, J = 6.7 Hz), 2.12-2.20 (1H, m), 3.00 (2H, d, J = 6.7 Hz), 7.66 (1H, t, J = 8.9 Hz), 7.98-8.03 (1H, m), 8.11 (1H, dd, J = 1.9, 7.1 Hz).	Ex. 125
1392		1H-NMR (CDCl3) δ: 2.77 (3H, s), 7.63 (1H, t, J = 8.0 Hz), 7.74 (1H, d, J = 8.0 Hz), 8.27-8.37 (2H, m), 12.4 (1H, br.).	Ex. 125
1393		1H-NMR (DMSO-d6) δ: 2.70 (3H, s), 7.61-7.67 (2H, m), 7.94-7.98 (2H, m).	Ref. Ex. 63, Ex. 125
1394		1H-NMR (DMSO-d6) δ: 1.42 (9H, s), 7.66 (1H, d, J = 8.9 Hz), 7.99-8.04 (1H, m), 8.12-8.16 (1H, m).	Ex. 125

Ex. No.	STR	1H-NMR	ref.
1395		1H-NMR (DMSO-d6) δ: 1.41 (9H, s), 7.64-7.71 (1H, m), 7.85-7.89 (1H, m), 7.96-8.01 (1H, m).	Ex. 125
1396		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.5 Hz), 3.12 (2H, q, J = 7.5 Hz), 7.86 (1H, t, J = 7.8 Hz), 7.97 (1H, d, J = 7.9 Hz), 8.25 (1H, s), 8.30 (1H, d, J = 7.8 Hz).	Ex. 125
1397		1H-NMR (DMSO-d6) δ: 4.38 (2H, q, J = 10.5 Hz), 7.90 (1H, t, J = 7.9 Hz), 8.02 (1H, d, J = 7.9 Hz), 8.24 (1H, s), 8.32 (1H, d, J = 7.9 Hz).	Ex. 125
1398		1H-NMR (DMSO-d6) δ: 4.35 (2H, q, J = 10.5 Hz), 7.70-7.72 (2H, m), 8.01-8.04 (2H, m).	Ex. 125
1399		1H-NMR (DMSO-d6) δ: 4.35 (2H, q, J = 10.6 Hz), 7.70 (1H, t, J = 9.0 Hz), 8.01-8.04 (1H, m), 8.10-8.13 (1H, m).	Ex. 125
1400		1H-NMR (DMSO-d6) δ: 4.34 (2H, q, J = 10.5 Hz), 7.69-7.78 (1H, m), 7.86-7.91 (1H, m), 7.93-8.00 (1H, m).	Ex. 125
1401		1H-NMR (DMSO-d6) δ: 1.32 (3H, t, J = 7.6 Hz), 3.10 (2H, q, J = 7.6 Hz), 7.67 (1H, t, J = 8.9 Hz), 7.99-8.03 (1H, m), 8.13 (1H, dd, J = 2.1, 7.0 Hz).	Ex. 125
1402		1H-NMR (DMSO-d6) δ: 2.70 (3H, s), 7.66 (1H, t, J = 8.8 Hz), 7.98-8.02 (1H, m), 8.11 (1H, dd, J = 2.1, 7.0 Hz).	Ex. 125

Ex. No.	STR	1H-NMR	ref.
1403		1H-NMR (DMSO-d6) δ: 1.33 (3H, t, J = 7.5 Hz), 3.13 (2H, q, J = 7.5 Hz), 7.97 (2H, d, J = 8.3 Hz), 8.21 (2H, d, J = 8.3 Hz).	Ex. 125
1404		1H-NMR (DMSO-d6) δ: 2.73 (3H, s), 7.97 (2H, d, J = 8.5 Hz), 8.20 (2H, d, J = 8.5 Hz).	Ex. 125
1405		1H-NMR (DMSO-d6) δ: 2.70 (3H, s), 7.88 (1H, d, J = 8.4 Hz), 7.95 (1H, dd, J = 2.0, 8.4 Hz), 8.12 (1H, d, J = 2.0 Hz).	Ex. 125
1406		1H-NMR (DMSO-d6) δ: 1.32 (3H, t, J = 7.5 Hz), 3.11 (2H, q, J = 7.5 Hz), 7.88 (1H, d, J = 8.5 Hz), 7.97 (1H, dd, J = 2.0, 8.5 Hz), 8.15 (1H, d, J = 2.0 Hz).	Ex. 125
1407		1H-NMR (DMSO-d6) δ: 2.69 (3H, s), 7.41-7.47 (2H, m), 8.03-8.07 (2H, m).	Ex. 125
1408		1H-NMR (DMSO-d6) δ: 1.31 (3H, t, J = 7.6 Hz), 3.11 (2H, q, J = 7.6 Hz), 7.62-7.65 (2H, m), 7.96-7.99 (2H, m).	Ex. 125
1409		1H-NMR (DMSO-d6) δ: 2.70 (3H, s), 7.60 (2H, d, J = 8.5 Hz), 8.12 (2H, d, J = 8.5 Hz).	Ex. 125
1410		1H-NMR (DMSO-d6) δ: 1.32 (3H, t, J = 7.5 Hz), 3.10 (2H, q, J = 7.5 Hz), 7.60 (2H, d, J = 8.2 Hz), 8.13 (2H, d, J = 8.2 Hz).	Ex. 125









Ex. No.	STR	1H-NMR	ref.
1411		1H-NMR (DMSO-d6) δ: 8.00 (2H, d, J = 7.2 Hz), 8.26 (2H, d, J = 8.7 Hz), 8.93 (1H, s).	Ex. 125
1412		1H-NMR (DMSO-d6) δ: 1.32 (3H, t, J = 7.5 Hz), 3.11 (2H, q, J = 7.5 Hz), 7.60 (1H, d, J = 7.8 Hz), 7.75 (1H, t, J = 8.0 Hz), 7.90 (1H, s), 8.05 (1H, d, J = 7.8 Hz).	Ex. 125
1413		1H-NMR (CDCl3) δ: 6.61 (1H, t, J = 73.0 Hz), 7.26-7.28 (2H, m), 8.14 (2H, d, J = 8.8 Hz), 8.41 (1H, s).	Ex. 125
1414		1H-NMR (DMSO-d6) δ: 7.40-7.44 (2H, m), 7.70-7.72 (2H, m), 8.13-8.21 (4H, m).	Ex. 2
1415		1H-NMR (DMSO-d6) δ: 7.62-7.73 (4H, m), 8.13-8.18 (4H, m).	Ex. 2
1416		1H-NMR (DMSO-d6) δ: 7.51-7.73 (5H, m), 7.79 (1H, dd, J = 1.7, 7.6 Hz), 8.08-8.11 (2H, m).	Ex. 2
1417		1H-NMR (DMSO-d6) δ: 6.80 (1H, s), 7.59 (1H, s), 7.64-7.72 (2H, m), 8.00 (1H, s), 8.03-8.07 (2H, m).	Ex. 125








Ex. No.	STR	m.p.	ref.
1418		183.9－186.7	Ex. 125






Ex. No.	STR	1H-NMR	ref.
1419		1H-NMR (DMSO-d6) δ: 7.56-7.59 (2H, m), 7.92 (1H, s), 8.14 (1H, s), 8.79 (1H, s).	Ex. 125
1420		1H-NMR (DMSO-d6) δ: 7.61 (1H, t, J = 8.9 Hz), 7.98-8.04 (1H, m), 8.32-8.38 (1H, m), 8.76 (1H, s).	Ex. 125
1421		1H-NMR (CDCl3) δ: 1.46 (3H, t, J = 7.6 Hz), 2.94 (2H, q, J = 7.6 Hz), 7.40 (2H, d, J = 5.1 Hz), 7.76 (1H, brs), 7.93 (1H, brs).	Ex. 125
1422		1H-NMR (CDCl3) δ: 1.47 (3H, t, J = 7.6 Hz), 2.96 (2H, q, J = 7.6 Hz), 7.59 (1H, t, J = 7.8 Hz), 7.67 (1H, d, J = 7.8 Hz), 8.09 (1H, d, J = 7.8 Hz), 8.27 (1H, m).	Ex. 125
1423		1H-NMR (DMSO-d6) δ: 5.49 (2H, s), 7.36-7.43 (3H, m), 7.55-7.60 (1H, m), 8.78 (1H, s).	Ex. 1
1424		1H-NMR (DMSO-d6) δ: 1.10-1.20 (4H, m), 2.56 (1H, m), 6.14 (2H, s), 7.09 (1H, d, J = 8.2 Hz), 7.42 (1H, d, J = 1.6 Hz), 7.51 (1H, dd, J = 1.6, 8.2 Hz).	Ex. 1
1425		1H-NMR (DMSO-d6) δ: 1.15-1.21 (4H, m), 2.56-2.62 (1H, m), 7.61 (1H, d, J = 8.5 Hz), 7.85 (1H, dd, J = 1.5, 8.5 Hz), 7.93 (1H, d, J = 1.5 Hz).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1426		1H-NMR (DMSO-d6) δ: 1.36 (6H, d, J = 7.0 Hz), 3.61-3.70 (1H, m), 7.64 (1H, d, J = 8.4 Hz), 7.90 (1H, d, J = 8.4 Hz), 7.96 (1H, s).	Ex. 1
1427		1H-NMR (DMSO-d6) δ: 1.17-1.26 (4H, m), 2.62-2.70 (1H, m), 8.09-8.15 (1H, m), 8.55-8.59 (1H, m), 9.29 (1H, s).	Ex. 1
1428		1H-NMR (DMSO-d6) δ: 1.20-1.27 (4H, m), 2.65-2.73 (1H, m), 7.62-7.69 (3H, m), 8.04-8.07 (1H, m), 8.14 (1H, d, J = 8.3 Hz), 8.22-8.25 (1H, m), 9.50-9.54 (1H, m).	Ex. 1
1429		1H-NMR (DMSO-d6) δ: 1.14-1.27 (4H, m), 2.62-2.68 (1H, m), 7.75-7.78 (1H, m), 8.18-8.21 (2H, m), 8.63 (1H, s).	Ex. 1
1430		1H-NMR (CDCl3) δ: 1.13-1.29 (4H, m), 2.50-2.56 (1H, m), 7.11-7.15 (1H, m), 7.46-7.49 (1H, m), 7.65-7.69 (1H, m).	Ex. 1
1431		1H-NMR (DMSO-d6) δ: 1.08-1.19 (4H, m), 2.57 (1H, m), 3.25-3.30 (2H, m), 4.63 (2H, t, J = 8.7 Hz), 6.92 (1H, d, J = 8.4 Hz), 7.72-7.75 (1H, m), 7.82 (1H, s).	Ex. 1
1432		1H-NMR (DMSO-d6) δ: 1.94-2.14 (2H, m), 2.34-2.50 (4H, m), 4.15-4.23 (1H, m), 8.15 (1H, t, J = 8.3 Hz), 8.65 (1H, d, J = 8.3 Hz), 8.37 (1H, s).	Ex. 125
1433		1H-NMR (DMSO-d6) δ: 1.12-1.28 (4H, m), 2.65-2.72 (1H, m), 8.26 (1H, d, J = 8.3 Hz), 8.45 (1H, dd, J = 2.1, 8.3 Hz), 9.13 (1H, s).	Ex. 125









[0830]







Ex. No.	STR	1H-NMR	ref.
1434		1H-NMR (DMSO-d6) δ: 0.97 (6H, d, J = 6.7 Hz), 2.11-2.19 (1H, m), 3.06 (2H, d, J = 7.2 Hz), 8.29 (1H, d, J = 8.3 Hz), 8.46-8.49 (1H, m), 9.15 (1H, s).	Ex. 125
1435		1H-NMR (DMSO-d6) δ: 1.92-2.13 (2H, m), 2.32-2.54 (4H, m), 4.20 (1H, m), 8.68 (1H, s), 8.19 (1H, s), 9.49 (1H, d, J = 1.6 Hz).	Ex. 125
1436		1H-NMR (DMSO-d6) δ: 1.93-2.13 (2H, m), 2.35-2.47 (4H, m), 4.16-4.24 (1H, m), 7.48-7.52 (1H, m), 8.08 (1H, s), 8.23-8.27 (2H, m).	Ex. 125
1437		1H-NMR (DMSO-d6) δ: 1.34 (3H, t, J = 7.6 Hz), 3.14 (2H, t, J = 7.6 Hz), 8.15 (1H, d, J = 8.2 Hz), 8.59-8.63 (1H, m), 9.32-9.34 (1H, m).	Ex. 125
1438		1H-NMR (DMSO-d6) δ: 2.69 (3H, s), 7.64 (1H, d, J = 8.4 Hz), 7.86-7.89 (1H, m), 7.91-8.93 (1H, m).	Ex. 125
1439		1H-NMR (DMSO-d6) δ: 2.74 (3H, s), 8.14 (1H, d, J = 8.3 Hz), 8.60 (1H, dd, J = 1.8, 8.2 Hz), 9.31 (1H, d, J = 1.8 Hz).	Ex. 125
1440		1H-NMR (DMSO-d6) δ: 1.93-2.01 (1H, m), 2.05-2.12 (1H, m), 2.35-2.47 (4H, m), 4.17-4.23 (1H, m), 7.52-7.57 (1H, m), 7.78-7.81 (1H, m), 8.28 (1H, d, J = 3.3 Hz).	Ex. 125
1441		1H-NMR (DMSO-d6) δ: 7.67 (1H, d, J = 8.4 Hz), 7.93-7.96 (1H, m), 7.99-8.01 (1H, m), 8.86 (1H, s).	Ex. 125








Ex. No.	STR	1H-NMR	ref.
1442		1H-NMR (DMSO-d6) δ: 8.15-8.18 (1H, m), 8.64-8.67 (1H, m), 9.02 (1H, s), 9.36-9.38 (1H, m).	Ex. 125
1444		1H-NMR (DMSO-d6) δ: 1.00-1.05 (2H, m), 1.09-1.15 (2H, m), 2.20-2.27 (1H, m), 8.54 (1H, s).	Ex. 1
1445		1H-NMR (CDCl3) δ: 1.41 (3H, t, J = 7.6 Hz), 2.95 (2H, q, J = 7.6 Hz), 8.33 (1H, s).	Ex. 125
1448		1H-NMR (DMSO-d6) δ: 2.51 (3H, s), 7.86 (1H, t, J = 7.8 Hz), 7.97 (1H, d, J = 7.8 Hz), 8.26-8.29 (2H, m).	Ex. 125
1449		1H-NMR (DMSO-d6) δ: 8.04 (2H, d, J = 8.3 Hz), 8.30 (2H, d, J = 8.3 Hz).	Ex. 125
1450		1H-NMR (DMSO-d6) δ: 7.62 (1H, t, J = 51.4 Hz), 8.02 (2H, d, J = 8.3 Hz), 8.30 (2H, d, J = 8.3 Hz).	Ex. 125
1452		1H-NMR (DMSO-d6) δ: 7.70-7.76 (3H, m), 7.87 (1H, d, J = 3.9 Hz), 8.04 (1H, d, J = 7.7 Hz), 8.06 (1H, s).	Ex. 1








Ex. No.	STR	m.p.	ref.
1443		127-131	Ex. 1
1447		192.8-192.9	Ex. 2
1451		205	Ex. 1
1453		143-146	Ex. 1
1454		162-164	Ex. 1

[0831]








Ex. No.	STR	1H-NMR	ref.
1455		1H-NMR (DMSO-d6) δ: 7.28 (1H, d, J = 4.0 Hz), 7.31 (1H, d, J = 4.0 Hz), 7.45 (1H, d, J = 4.0 Hz), 7.63 (1H, d, J = 4.0 Hz).	Ex. 1
1456		1H-NMR (DMSO-d6) δ: 7.49-7.52 (4H, m), 7.60 (1H, d, J = 3.8 Hz), 7.67 (1H, d, J = 3.8 Hz), 7.73 (2H, d, J = 8.4 Hz).	Ex. 1
1457		1H-NMR (DMSO-d6) δ: 7.51-7.58 (2H, m), 7.70-7.73 (2H, m), 7.85-7.95 (1H, m).	Ex. 1
1458		1H-NMR (DMSO-d6) δ: 5.38 (2H, s), 7.17 (2H, d, J = 8.8 Hz), 7.58 (1H, d, J = 3.9 Hz), 7.68-7.73 (3H, m), 8.11 (1H, s), 8.20 (2H, s).	Ex. 1
1459		1H-NMR (DMSO-d6) δ: 5.16 (2H, s), 7.11 (2H, d, J = 6.9 Hz), 7.13-7.56 (4H, m), 7.67-7.70 (3H, m).	Ex. 1
1460		1H-NMR (DMSO-d6) δ: 5.39 (2H, s), 7.15 (2H, d, J = 8.9 Hz), 7.57 (1H, d, J = 3.9 Hz), 7.67-7.73 (3H, m), 8.00-8.10 (2H, m), 8.19 (1H, s).	Ex. 1
1461		1H-NMR (DMSO-d6) δ: 5.42 (2H, s), 7.07-7.10 (1H, m), 7.35-7.46 (3H, m), 7.70-7.73 (2H, m), 8.00-8.10 (2H, m), 8.22 (1H, s).	Ex. 1
1462		1H-NMR (DMSO-d6) δ: 5.41 (2H, s), 7.09-7.12 (1H, m), 7.34-7.46 (3H, m), 7.72 (2H, s), 8.11 (1H, s), 8.11 (1H, s), 8.22 (1H, s).	Ex. 1
1463		1H-NMR (DMSO-d6) δ: 5.09 (2H, s), 6.92-7.02 (3H, m), 7.20 (1H, d, J = 5.1 Hz), 7.31-7.39 (3H, m), 7.47 (1H, s), 7.59 (1H, d, J = 5.1 Hz).	Ex. 1
1464		1H-NMR (DMSO-d6) δ: 5.31 (2H, s), 6.82 (1H, d, J = 7.6 Hz), 7.01 (1H, s), 7.04 (1H, d, J = 8.5 Hz), 7.31 (1H, t, J = 7.0 Hz), 7.40 (1H, d, J = 3.9 Hz), 7.94 (1H, s), 8.09 (1H, s), 8.13 (2H, s).	Ex. 1
1465		1H-NMR (DMSO-d6) δ: 7.75 (1H, d, J = 3.9 Hz), 8.06 (1H, d, J = 3.9 Hz), 8.10 (1H, s), 8.37 (2H, s).	Ex. 1
1466		1H-NMR (DMSO-d6) δ: 8.07 (1H, s), 8.30 (1H, s), 8.45 (2H, s), 8.58 (1H, s).	Ex. 1
1467		1H-NMR (DMSO-d6) δ: 7.50 (1H, d, J = 8.4 Hz), 7.56-7.59 (1H, m), 7.66-7.73 (2H, m), 7.89 (1H, d, J = 1.8 Hz).	Ex. 1
1468		1H-NMR (DMSO-d6) δ: 7.75-7.86 (4H, m), 7.97 (2H, d, J = 8.0 Hz).	Ex. 1
1469		1H-NMR (DMSO-d6) δ: 7.35-7.40 (1H, m), 7.57-7.64 (1H, m), 7.69-7.82 (4H, m).	Ex. 1
1470		1H-NMR (DMSO-d6) δ: 7.47 (2H, d, J = 8.6 Hz), 7.72 (2H, s), 7.88 (2H, d, J = 8.6 Hz).	Ex. 1
1471		1H-NMR (DMSO-d6) δ: 3.88 (3H, s), 7.74 (1H, d, J = 3.9 Hz), 7.84 (1H, d, J = 3.9 Hz), 7.90 (2H, d, J = 8.4 Hz), 8.03 (2H, d, J = 8.4 Hz).	Ex. 1
1472		1H-NMR (DMSO-d6) δ: 2.61 (3H, s), 7.74 (1H, d, J = 4.0 Hz), 7.85 (1H, d, J = 4.0 Hz), 7.90 (2H, d, J = 8.5 Hz), 8.03 (2H, d, J = 8.6 Hz).	Ex. 1
1474		1H-NMR (DMSO-d6) δ: 2.38 (3H, s), 7.63 (1H, s), 8.18 (3H, s).	Ex. 1








Ex. No.	STR	1H-NMR	ref.
1475		1H-NMR (DMSO-d6) δ: 7.34 (1H, d, J = 16.3 Hz), 7.44 (1H, d, J = 3.8 Hz), 7.69 (1H, d, J = 3.8 Hz), 7.94-7.98 (2H, m), 8.36 (2H, s).	Ex. 1
1476		1H-NMR (DMSO-d6) δ: 2.42 (3H, s), 7.11 (1H, d, J = 16.2 Hz), 7.60-7.62 (3H, m), 7.67 (1H, d, J = 16.2 Hz), 8.00-8.02 (1H, m), 8.09 (1H, s).	Ex. 1
1477		1H-NMR (DMSO-d6) δ: 7.21 (1H, d, J = 16.3 Hz), 7.44 (1H, d, J = 3.9 Hz), 7.67 (1H, d, J = 3.9 Hz), 7.68-7.75 (4H, m), 7.85 (1H, d, J = 8.2 Hz).	Ex. 1
1478		1H-NMR (DMSO-d6) δ: 7.24 (1H, d, J = 16.5 Hz), 7.50 (1H, d, J = 16.5 Hz), 7.73 (2H, d, J = 8.4 Hz), 7.82 (2H, d, J = 8.4 Hz), 7.94 (1H, s), 7.99 (1H, s),	Ex. 1
1479		1H-NMR (DMSO-d6) δ: 0.56-0.60 (2H, m), 0.80-0.85 (2H, m), 1.56-1.61 (1H, m), 5.78 (1H, dd, J = 9.1, 15.7 Hz), 6.71 (1H, d, J = 15.7 Hz), 7.08 (1H, d, J = 3.8 Hz), 7.56 (1H, d, J = 3.8 Hz).	Ex. 1
1480		1H-NMR (DMSO-d6) δ: 7.13 (1H, d, J = 16.1 Hz), 7.23 (2H, t, J = 8.8 Hz), 7.35 (1H, d, J = 8.8 Hz), 7.49 (1H, d, J = 16.1 Hz), 7.64-7.71 (3H, m).	Ex. 1







Ex. No.	STR	1H-NMR	ref.
1481		1H-NMR (DMSO-d6) δ: 7.43 (1H, d, J = 16.3 Hz), 7.57 (1H, d, J = 16.3 Hz), 7.72-7.81 (5H, m), 7.90 (1H, d, J = 5.3 Hz).	Ex. 1
1482		1H-NMR (DMSO-d6) δ: 7.14 (1H, d, J = 16.2 Hz), 7.30 (1H, d, J = 3.9 Hz), 7.35 (1H, d, J = 16.2 Hz), 7.50-7.52 (1H, m), 7.58-7.68 (3H, m).	Ex. 1
1483		1H-NMR (DMSO-d6) δ: 2.38 (3H, s), 7.00 (1H, d, J = 16.1 Hz), 7.22 (2H, d, J = 8.9 Hz), 7.44 (1H, d, J = 16.1 Hz), 7.49 (1H, s), 7.72-7.77 (2H, m).	Ex. 1
1484		1H-NMR (DMSO-d6) δ: 7.66 (1H, d, J = 4.0 Hz), 7.66-7.71 (1H, m), 7.73 (1H, d, J = 4.0 Hz), 7.94 (1H, s), 8.23-8. 28 (2H, m).	Ex. 1
1485		1H-NMR (DMSO-d6) δ: 7.53 (2H, d, J = 8.5 Hz), 7.70-7.74 (2H, m), 7.79 (2H, d, J = 8.5 Hz).	Ex. 1
1486		1H-NMR (DMSO-d6) δ: 7.25-7.33 (1H, m), 7.63 (1H, d, J = 3.9 Hz), 7.66-7.74 (2H, m), 7.80 (1H, s), 8.01-8.08 (1H, m).	Ex. 1
1489		1H-NMR (DMSO-d6) δ: 7.79 (1H, d, J = 3.9 Hz), 7.94-8.01 (2H, m), 8.38-8.45 (1H, m), 9.19 (1H, s).	Ex. 1

Ex. No.	STR	m.p.	ref.
1487		210-211	Ex. 1
1488		219-223	Ex. 1
1490		251	Ex. 1
1491		256-259	Ex. 1
1492		207	Ex. 1
1493		261-264	Ex. 1
1495		208-209	Ex. 1







[0833]










Ex. No.	STR	1H-NMR	ref.
1494		1H-NMR (DMSO-d6) δ: 8.17 (1H, d, J = 8.6 Hz), 8.31 (1H, dd, J = 2.4, 8.6 Hz), 8.38 (1H, d, J = 1.2 Hz), 8.65 (1H, d, J = 1.2 Hz), 9.04 (1H, s).	Ex. 1
1496		1H-NMR (DMSO-d6) δ: 4.18 (2H, s), 7.58 (2H, s), 7.86 (1H, d, J = 8.0 Hz), 7.95-8.00 (1H, m), 8.74 (1H, s).	Ref. Ex. 91, Ex. 1
1497		1H-NMR (DMSO-d6) δ: 7.75 (1H, d, J = 3.9 Hz), 7.90 (1H, d, J = 3.9 Hz), 8.17-8.20 (1H, m), 8.59 (1H, d, J = 2.6 Hz), 8.86-8.87 (1H, m).	Ex. 1
1498		1H-NMR (DMSO-d6) δ: 7.29 (2H, d, J = 8.5 Hz), 7.40 (1H, d, J = 5.2 Hz), 7.45 (2H, d, J = 8.5 Hz), 7.95 (1H, d, J = 5.2 Hz).	Ex. 1
1499		1H-NMR (DMSO-d6) δ: 7.40 (2H, d, J = 8.1 Hz), 7.75 (2H, d, J = 8.1 Hz), 7.97 (1H, d, J = 3.1 Hz), 8.15 (1H, d, J = 3.1 Hz).	Ex. 1
1500		1H-NMR (DMSO-d6) δ: 7.27-7.32 (4H, m), 7.88 (1H, s), 8.10 (1H, s).	Ex. 1
1501		1H-NMR (CDCl3) δ: 7.84 (2H, d, J = 8.3 Hz), 7.94 (2H, d, J = 8.3 Hz), 8.06 (1H, d, J = 1.4 Hz), 8.25 (1H, d, J = 1.4 Hz).	Ex. 125










Ex. No.	STR	1H-NMR	ref.
1503		1H-NMR (DMSO-d6) δ: 5.27 (1H, d, J = 3.7 Hz), 7.70 (1H, d, J = 3.7 Hz), 8.08 (1H, s), 8.47 (2H, s).	Ex. 1
1504		1H-NMR (DMSO-d6) δ: 6.91 (1H, d, J = 3.6 Hz), 7.20 (1H, d, J = 3.6 Hz), 7.30 (1H, d, J = 16.4 Hz), 6.69 (1H, d, J = 16.4 Hz), 7.99 (1H, s), 8.30 (2H, s).	Ex. 1
1505		1H-NMR (DMSO-d6) δ: 6.80 (1H, d, J = 3.6 Hz), 7.13-7.27 (5H, m), 7.62-7.67 (2H, m).	Ex. 1
1506		1H-NMR (DMSO-d6) δ: 6.90 (1H, d, J = 3.6 Hz), 7.19 (1H, d, J = 3.6 Hz), 7.22 (1H, d, J = 15.9 Hz), 7.43 (1H, d, J = 15.9 Hz), 7.73-7.82 (4H, m).	Ex. 1
1507		1H-NMR (DMSO-d6) δ: 6.89 (1H, d, J = 3.6 Hz), 7.19 (1H, d, J = 3.6 Hz), 7.21 (1H, d, J = 16.3 Hz), 7.53 (1H, d, J = 16.3 Hz), 7.59 (1H, d, J = 8.8 Hz), 7.79-7.85 (2H, m).	Ex. 1
1508		1H-NMR (DMSO-d6) δ: 6.81 (1H, d, J = 3.6 Hz), 7.14-7.34 (3H, m), 7.36-7.45 (2H, m), 7.78 (1H, s).	Ex. 1
1509		1H-NMR (DMSO-d6) δ: 6.81 (1H, d, J = 3.6 Hz), 7.16 (1H, d, J = 2.7 Hz), 7.19 (2H, d, J = 10.0 Hz), 7.23-7.34 (1H, m), 7.41 (2H, t, J = 7.1 Hz), 7.59 (2H, d, J = 7.1 Hz).	Ex. 1

Ex. No.	STR	m.p.	ref.
1502		209-212	Ex. 125
1510		198	Ex. 1
1511		257(dec.)	Ex. 1
1512		182(dec.)	Ex. 1
1513		209-211	Ex. 1
1514		205-208	Ex. 1

[0834]

Ex. No.	STR	m.p.	ref.
1515		306-307	Ex. 1
1516		275-277	Ex. 1
1517		197-199	Ex. 1
1518		241-242	Ex. 1
1519		236-238	Ex. 1
1521		175.3-176.1	Ex. 2










Ex. No.	STR	1H-NMR	ref.
1520		1H-NMR (DMSO-d6) δ: 7.30 (1H, d, J = 3.7 Hz), 7.61 (1H, d, J = 3.7 Hz), 8.07 (1H, d, J = 8.0 Hz), 8.42 (1H, d, J = 8.0 Hz), 8.23 (1H, s).	Ex. 1
1522		1H-NMR (DMSO-d6) δ: 5.52 (2H, s), 6.28-6.31 (1H, m), 6.78 (1H, s), 6.96 (2H, d, J = 7.0 Hz), 7.18-7.22 (2H, m), 7.24-7.28 (2H, m), 16.2 (1H, br.).	Ex. 1
1523		1H-NMR (DMSO-d6) δ: 5.61 (2H, s), 6.33-6.35 (1H, m), 6.80-6.82 (1H, m), 7.23-7.26 (2H, m), 7.30 (1H, s), 7.52 (1H. t, J = 7.7 Hz), 7.58 (1H, d. J = 7.9 Hz).	Ex. 1
1524		1H-NMR (CDCl3) δ: 5.79 (2H, s), 6.45 (1H, dd, J = 2.7, 4.0 Hz), 6.67 (1H, s), 6.89 (1H, dd, J = 1.7, 2.7 Hz), 7.20-7.23 (1H, m), 7.61 (1H, d, J = 8.0 Hz), 7.81 (1H, d, J = 8.0 Hz), 11.6 (1H, br.).	Ex. 1
1525		1H-NMR (DMSO-d6) δ: 5.52 (2H, s). 6.29 (1H, dd, J = 2.8, 3.7 Hz), 6.77 (1H, dd, J = 1.6, 3.7 Hz), 6.98-7.01 (2H, m), 7.18 (1H, dd, J = 1.6, 2.8 Hz), 7.32-7.35 (2H, m).	Ex. 1
1526		1H-NMR (DMSO-d6) δ: 5.52 (2H, s), 6.32 (1H, dd, J = 2.8, 3.7 Hz), 6.81 (1H, s), 6.92 (1H, d, J = 8.3 Hz), 7.23 (1H, s), 7.25 (1H, s), 7.55 (1H, d, J = 8.3 Hz).	Ex. 1
1527		1H-NMR (CDCl3) δ: 5.57 (2H, s), 6.40-6.43 (2H, m), 6.87-6.89 (1H, m), 7.15-7.22 (2H, m), 7.31 (1H, d, J = 8.5 Hz), 11.6 (1H, br.).	Ex. 1
1528		1H-NMR (DMSO-d6) δ: 5.52 (2H, s), 6.34 (1H, dd, J = 2.8, 3.7 Hz), 6.81-6.83 (1H, m), 6.99 (2H, s), 7.24-7.26 (1H, m), 7.47-7.49 (1H, m), 16.0 (1H, br).	Ex. 1
1529		1H-NMR (DMSO-d6) δ: 5.68 (2H, s), 6.37 (1H, dd, J = 2.7, 3.7 Hz), 6.81-6.83 (1H, m), 7.31 (1H, dd, J = 1.7, 2.7 Hz), 7.61 (2H, s), 7.99 (1H, s).	Ex. 1









Ex. No.	STR	1H-NMR	ref.
1530		1H-NMR (DMSO-d6) δ: 5.50 (2H, s), 6.34 (1H, dd, J = 2.9, 3.5 Hz), 6.81-6.83 (1H, m), 7.17 (2H, s), 7.24-7.25 (1H, m), 7.69-7.71 (1H, m), 16.1 (1H, br).	Ex. 1
1531		1H-NMR (CDCl3) δ: 5.61 (2H, s), 6.37-7.39 (1H, m), 6.90 (1H, s), 7.08 (2H, d. J = 8.0 Hz), 7.16 (1H, s), 7.53 (2H, d, J = 8.0 Hz), 11.8 (1H, br.).	Ex. 1
1532		1H-NMR (CDCl3) δ: 5.57 (2H, s), 6.34 (1H, d, J = 8.3 Hz), 6.38-7.40 (1H, m), 6.86-6.88 (1H, m), 7.09 (1H, dd, J = 4.0, 8.3 Hz), 7.17 (1H, s), 7.39 (1H, d, J = 2.0 Hz), 11.8 (1H, br.).	Ex. 1
1533		1H-NMR (CDCl3) δ: 5.62 (2H, s), 6.26 (1H, d, J = 7.7 Hz), 6.40 (1H, t, J = 3.3 Hz), 6.88 (1H, t, J = 1.9 Hz), 7.04 (1H, t, J = 7.9 Hz), 7.17 (1H, d, J = 2.7 Hz), 7.34 (1H, d, J = 8.1 Hz), 11.8 (1H, br.).	Ex. 1
1534		1H-NMR (CDCl3) δ: 2.25 (6H, s), 5.43 (2H, s), 6.34-6.36 (1H, m), 6.63 (2H, s), 6.89 (2H, s), 7.07 (1H, s), 11.8 (1H, br.).	Ex. 1
1535		1H-NMR (CDCl3) δ: 5.55 (2H, s), 6.37 (1H, dd, J = 2.7, 3.9 Hz), 6.86-6.91 (3H, m), 7.05-7.14 (2H, m), 7.26-7.32 (1H, m), 11.8 (1H, br.).	Ex. 1
1536		1H-NMR (CDCl3) δ: 5.54 (2H, s), 5.87 (1H, tt, J = 2.9, 53 Hz), 6.37 (1H, dd, J = 2.8, 3.9 Hz), 6.84-6.91 (3H, m), 7.05-7.14 (2H, m), 7.26-7.32 (1H, m), 11.8 (1H, br.).	Ex. 1
1537		1H-NMR (CDCl3) δ: 5.54 (2H, s), 6.36 (1H, dd, J = 2.8, 3.9 Hz), 6.87-6.89 (1H, m), 7.02 (2H, d, J = 8.8 Hz), 7.10-7.15 (3H, m), 11.8 (1H, br.).	Ex. 1
1538		1H-NMR (CDCl3) δ: 1.28 (9H, s), 5.49 (2H, s), 6.32-6.35 (1H, m), 6.89 (1H, s), 6.95 (2H, d, J = 8.2 Hz), 7.07 (1H, s), 7.32 (2H, d, J = 8.2 Hz), 11.8 (1H, br.).	Ex. 1

[0835]




Ex. No.	STR	1H-NMR	ref.
1539		1H-NMR (CDCl3) δ: 5.02 (2H, s), 5.44 (2H, s), 6.31-6.34 (1H, m), 6.85-6.92 (3H, m), 6.97 (2H, d, J = 8.8 Hz), 7.06 (1H, s), 7.30-7.42 (5H, m), 11.7 (1H, br.).	Ex. 1
1540		1H-NMR (CDCl3) δ: 5.57 (2H, s), 6.37 (1H, dd, J = 2.8, 3.9 Hz), 6.92-6.95 (1H, m), 7.08 (2H, d, J = 8.4 Hz), 7.10-7.13 (1H, m), 7.30-7.36 (1H, m), 7.37-7.45 (2H, m), 7.49-7.56 (4H, m), 11.7 (1H, br.).	Ex. 1
1541		1H-NMR (CDCl3) δ: 3.01 (2H, t, J = 7.2 Hz), 4.48 (2H, br.s), 6.23-6.27 (1H, m), 6.76 (1H, s), 6.89-7.08 (3H, m), 7.20-7.29 (3H, m), 11.6 (1H, br.).	Ex. 1
1542		1H-NMR (CDCl3) δ: 4.30 (2H, q, J = 8.0 Hz), 5.47 (2H, s), 6.34 (1H, dd, J = 2.8, 3.9 Hz), 6.82-6.89 (3H, m), 6.95-7.00 (2H, m), 7.06-7.10 (1H, m), 11.6 (1H, br.).	Ex. 1
1543		1H-NMR (CDCl3) δ: 1.97-2.07 (2H, m), 2.20-2.37 (2H, m), 3.97 (2H, t, J = 6.0 Hz), 5.44 (2H, s), 6.31-6.35 (1H, m), 6.80 (2H, d, J = 8.7 Hz), 6.88 (1H, s), 6.96 (2H, d, J = 8.7 Hz), 7.07 (1H, s), 11.6 (1H, br.).	Ex. 1
1544		1H-NMR (DMSO-d6) δ: 3.76 (3H, s), 6.40 (1H, d, J = 4.0 Hz), 6.77 (1H, d, J = 4.0 Hz), 7.36-7.39 (1H, m), 7.51-7.67 (2H, m).	Ex. 2
1545		1H-NMR (DMSO-d6) δ: 3.82 (3H, s), 6.19-6.21 (1H, m), 6.68-6.70 (1H, m), 7.05-7.06 (1H, m).	Ex. 2
1546		1H-NMR (DMSO-d6) δ: 3.77 (3H, s), 6.45 (1H, d, J = 3.9 Hz), 6.79 (1H, d, J = 3.9 Hz), 7.48 (2H, d, J = 7.9 Hz), 7.64-7.67 (2H, m).	Ex. 2
1547		1H-NMR (DMSO-d6) δ: 3.74 (3H, s), 6.38 (1H, d, J = 3.9 Hz), 6.77 (1H, d, J = 3.9 Hz), 7.30-7.35 (2H, m), 7.54-7.58 (2H, m).	Ex. 2
1548		1H-NMR (DMSO-d6) δ: 3.54 (3H, s), 6.30 (1H, d, J = 3.9 Hz), 6.80 (1H, d, J = 3.9 Hz), 7.53-7.59 (2H, m), 7.97-8.00 (1H, m).	Ex. 2




Ex. No.	STR	1H-NMR	ref.
1549		1H-NMR (DMSO-d6) δ: 3.79 (3H, s), 6.49 (1H, d, J = 4.0 Hz), 6.78 (1H, d, J = 4.0 Hz), 7.39-7.41 (1H, m), 7.51 (1H, bs), 7.56-7.65 (2H, m).	Ex. 2
1550		1H-NMR (DMSO-d6) δ: 6.80-6.81 (1H, m), 7.55 (2H, d, J = 8.4 Hz), 7.64-7.65 (1H, m), 7.78-7.81 (2H, m), 7.93-7.94 (1H, m).	Ex. 2
1551		1H-NMR (DMSO-d6) δ: 3.94 (3H, s), 6.79-6.80 (1H, m), 7.24 (1H, s), 7.54-7.55 (1H, m), 7.60 (1H, s), 7.78-7.79 (1H, m), 8.07-8.08 (1H, m).	Ex. 2
1552		1H-NMR (DMSO-d6) δ: 6.78-6.79 (1H, m), 7.23-7.24 (1H, m), 7.58 (1H, s), 7.65 (1H, d, J = 7.7 Hz), 7.76 (1H, t, J = 7.7 Hz), 7.85-7.89 (1H, m), 7.96-7.98 (1H, m).	Ex. 2
1553		1H-NMR (DMSO-d6) δ: 6.79-6.80 (1H, m), 7.59-7.63 (3H, m), 7.70 (2H, d, J = 8.9 Hz), 7.92-7.93 (1H, m).	Ex. 2
1554		1H-NMR (DMSO-d6) δ: 4.00 (2H, s), 6.76-6.77 (1H, m), 7.18-7.33 (5H, m), 7.37-7.40 (2H, m), 7.54-7.56 (3H, m), 7.85-7.86 (1H, m), 16.31 (1H, bs).	Ex. 2
1555		1H-NMR (DMSO-d6) δ: 6.85-6.86 (1H, m), 7.58-7.62 (2H, m), 7.69-7.73 (1H, m), 7.77-7.79 (3H, m), 7.86-7.93 (4H, m), 8.06-8.07 (1H, m), 16.31 (1H, bs).	Ex. 2
1556		1H-NMR (DMSO-d6) δ: 6.77-6.78 (1H, m), 7.06-7.09 (2H, m), 7.15-7.20 (3H, m), 7.41-7.45 (2H, m), 7.55-7.56 (1H, m), 7.64-7.67 (2H, m), 7.85-7.86 (1H, m).	Ex. 2
1557		1H-NMR (DMSO-d6) δ: 6.80-6.81 (1H, m), 7.84-7.85 (1H, m), 7.95 (1H, s), 8.11 (1H, s), 8.15-8.16 (1H, m), 8.32 (1H, s).	Ex. 2
1558		1H-NMR (DMSO-d6) δ: 5.26 (2H, s), 6.59-6.60 (1H, m), 7.11-7.12 (1H, m), 7.22-7.25 (1H, m), 7.36-7.43 (3H, m), 7.54-7.55 (1H, m), 16.08 (1H, bs).	Ex. 2




Ex. No.	STR	1H-NMR	ref.
1559		1H-NMR (DMSO-d6) δ: 5.35 (2H, s), 6.62 (1H, s), 7.10 (2H, s), 7.34-7.38 (2H, m), 7.51-7.53 (2H, m), 16.13 (1H, bs).	Ex. 2
1560		1H-NMR (DMSO-d6) δ: 5.24 (2H, s), 6.58-6.59 (1H, m), 7.08-7.09 (1H, m), 7.28-7.30 (2H, m), 7.43-7.45 (2H, m), 7.50-7.51 (1H, m).	Ex. 2
1561		1H-NMR (DMSO-d6) δ: 4.03 (2H, s), 6.77-6.78 (1H, m), 7.18-7.23 (2H, m), 7.29-7.33 (4H, m), 7.42-7.48 (2H, m), 7.56-7.59 (2H, m), 7.88-7.89 (1H, m).	Ex. 2
1562		1H-NMR (DMSO-d6) δ: 2.95 (2H, t, J = 7.3 Hz), 4.19 (2H, t, J = 7.3 Hz), 5.96 (2H, s), 6.51-6.52 (1H, m), 6.63 (1H, dd, J = 1.7, 7.9 Hz), 6.79 (1H, d, J = 7.9 Hz), 6.83 (1H, d, J = 1.7 Hz), 6.97-6.98 (1H, m), 7.37-7.38 (1H, m).	Ex. 2
1563		1H-NMR (DMSO-d6) δ: 3.06 (2H, t, J = 7.3 Hz), 4.29 (2H, t, J = 7.3 Hz), 6.52 (1H, s), 6.98 (1H, bs), 7.18 (1H, dd, J = 2.0, 8.2 Hz), 7.39 (1H, s), 7.50 (1H, d, J = 2.0 Hz), 7.53 (1H, d, J = 8.2 Hz).	Ex. 2
1564		1H-NMR (DMSO-d6) δ: 2.15-2.20 (1H, m), 2.66-2.70 (1H, m), 2.93-2.97 (1H, m), 3.08-3.14 (1H, m), 5.84 (1H, t, J = 7.1 Hz), 6.59-6.60 (1H, m), 7.01 (1H, t, J = 2.5 Hz), 7.09 (1H, d, J = 7.5 Hz), 7.23 (1H, t, J = 7.2 Hz), 7.32 (1H, t, J = 7.2 Hz), 7.38-7.42 (2H, m).	Ex. 2
1565		1H-NMR (DMSO-d6) δ: 3.17 (2H, dd, J = 6.2, 16.0 Hz), 3.47 (2H, dd, J = 7.4, 16.0 Hz), 5.01-5.15 (1H, m), 6.55-6.56 (1H, m), 7.06-7.07 (1H, m), 7.21-7.24 (2H, m), 7.28-7.31 (2H, m), 7.45-7.46 (1H, m).	Ex. 2
1566		1H-NMR (DMSO-d6) δ: 2.15 (3H, s), 2.27 (3H, s), 5.19 (2H, s), 6.25 (1H, bs), 6.96 (2H, d, J = 8.5 Hz), 7.42 (2H, d, J = 8.5 Hz).	Ex. 2
1567		1H-NMR (CDCl3) δ: 2.19 (3H, s), 2.38 (3H, s), 5.21 (2H, s), 6.47 (1H, s), 7.36 (2H, s), 7.82 (1H, s).	Ex. 2








Ex. No.	STR	1H-NMR	ref.
1568		1H-NMR (DMSO-d6) δ: 7.57-7.64 (1H, m), 8.01 (1H, dd, J = 0.9, 7.7 Hz), 8.14 (1H, t, J = 7.7 Hz), 8.17-8.23 (2H, m), 8.42-8.48 (1H, m).	Ex. 1
1569		1H-NMR (DMSO-d6) δ: 8.10 (1H, d, J = 7.6 Hz), 8.18-8.24 (2H, m). 8.51 (1H, d, J = 7.6 Hz), 9.02 (2H, s).	Ex. 1
1570		1H-NMR (DMSO-d6) δ: 7.58-7.71 (4H, m), 7.90-8.02 (2H, m), 8.05 (1H, t, J = 7.8 Hz), 8.10-8.16 (2H, m).	Ex. 1
1571		1H-NMR (DMSO-d6) δ: 7.61 (1H, d, J = 7.7 Hz), 7.82 (1H, d, J = 15.9 Hz), 7.79-7.99 (1H, m), 8.03-8.09 (2H, m), 8.16 (1H, d, J = 15.9 Hz), 8.23 (2H, s).	Ex. 1
1572		1H-NMR (DMSO-d6) δ: 7.55-7.64 (2H, m), 7.78-7.82 (4H, m), 7.92 (1H, d, J = 7.3 Hz), 8.03-8.15 (2H, m).	Ex. 1
1575		1H-NMR (DMSO-d6) δ: 7.39-7.46 (2H, m), 7.89-8.05 (3H, m), 8.12 (1H, t, J = 7.8 Hz), 8.22 (1H, d, J = 8.0 Hz), 8.32 (1H, s).	Ex. 1
1577		1H-NMR (DMSO-d6) δ: 7.24-7.32 (1H, m), 7.69-7.75 (2H, m), 7.82 (1H, s), 7.93 (1H, s), 8.04-8.10 (2H, m).	Ex. 1
1578		1H-NMR (DMSO-d6) δ: 7.43-7.45 (1H, m), 7.99-8.01 (2H, m), 8.07 (1H, d, J = 8.6 Hz), 8.15 (1H, t, J = 7.8 Hz), 8.23-8.24 (1H, m), 8.27 (1H, s).	Ex. 1




[0837]




Ex. No.	STR	1H-NMR	ref.
1579		1H-NMR (DMSO-d6) δ: 2.70 (3H, s), 7.29-7.37 (1H, m), 7.77 (1H, dd, J = 2.4, 10.2 Hz), 7.96-8.07 (3H, m), 8.18 (1H, t, J = 7.9 Hz).	Ref. Ex. 91, Ex. 1
1580		1H-NMR (DMSO-d6) δ: 7.27-7.35 (1H, m), 7.72 (1H, dd, J = 2.5, 9.7 Hz), 7.98-8.02 (1H, m), 8.04-8.18 (2H, m), 8.22-8.26 (1H, m), 8.29 (1H, s).	Ex. 1
1582		1H-NMR (DMSO-d6) δ: 7.29-7.44 (2H, m), 7.67-7.77 (3H, m), 8.15 (1H, d, J = 8.1 Hz), 8.49 (1H, dd, J = 1.9, 8.3 Hz), 9.34 (1H, d, J = 1.9 Hz).	Ex. 1









Ex. No.	STR	m.p.	ref.
1573		230-233	Ex. 1
1574		236-239	Ex. 1
1576		260-261	Ex. 1






Ex. No.	STR	m.p.	ref.
1581		297	Ex. 1
1583		272-275	Ex. 1
1584		288	Ex. 1



Ex. No.	STR	1H-NMR	ref.
1585		1H-NMR (DMSO-d6) δ: 4.80 (2H, s), 4.90 (2H, s), 7.64 (1H, d, J = 7.7 Hz), 7.93 (1H, d, J = 7.3 Hz), 8.03-8.08 (4H, m).	Ex. 2
1586		1H-NMR (DMSO-d6) δ: 4.76 (2H, s), 4.81 (2H, s), 7.64-7.74 (5H, m), 7.94 (1H, d, J = 7.4 Hz), 8.07 (1H, t, J = 7.8 Hz).	Ex. 2
1587		1H-NMR (DMSO-d6) δ: 4.70 (2H, s), 4.74 (2H, s), 7.54-7.68 (3H, m), 7.93 (1H, d, J = 7.4 Hz), 8.06 (1H, t, J = 7.7 Hz).	Ex. 2
1588		1H-NMR (CDCl3) δ: 1.65 (3H, d, J = 6.6 Hz), 4.62-4.85 (3H, m), 7.59 (1H, d, J = 7.8 Hz), 7.80 (3H, s), 7.95 (1H, t, J = 7.8 Hz), 8.06 (1H, d, J = 7.8 Hz).	Ex. 2
1589		1H-NMR (DMSO-d6) δ: 4.82 (2H, s), 4.96 (2H, s), 7.65 (1H, d, J = 7.6 Hz), 7.95 (1H, d, J = 7.6 Hz), 8.04-8.11 (4H, m).	Ex. 2
1590		1H-NMR (DMSO-d6) δ: 4.84 (2H, s), 4.95 (2H, s), 7.61 (1H, d, J = 7.8 Hz), 7.92-7.95 (2H, m), 8.00 (1H, d, J = 8.0 Hz), 8.07 (1H, t, J = 8.0 Hz), 8.13 (1H, s).	Ex. 2
1591		1H-NMR (DMSO-d6) δ: 1.57 (3H, d, J = 6.5 Hz), 4.61-4.77 (3H, m), 7.60 (2H, d, J = 8.1 Hz), 7.66 (1H, d, J = 7.4 Hz), 7.71 (2H, d, J = 8.1 Hz), 7.92-7.94 (1H, m), 8.07 (1H, t, J = 7.4 Hz).	Ex. 2

Ex. No.	STR	1H-NMR	ref.
1592		1H-NMR (DMSO-d6) δ: 8.10 (2H, d, J = 7.8 Hz), 8.27 (1H, t, J = 7.8 Hz).	Ex. 125
1593		1H-NMR (DMSO-d6) δ: 7.50-7.53 (1H, m), 8.02 (1H, dt, J = 1.8, 7.8 Hz), 8.09 (1H, dd, J = 1.0, 7.8 Hz), 8.18 (1H, t, J = 7.8 Hz), 8.53 (1H, dd, J = 1.0, 7.8 Hz), 8.70 (1H, dt, J = 1.0, 7.8 Hz), 8.73-8.75 (1H, m).	Ex. 125
1595		1H-NMR (DMSO-d6) δ: 7.30-7.45 (2H, m), 7.68-7.78 (3H, m), 8.70 (1H, s), 9.07 (1H, s), 9.32 (1H, s).	Ex. 1

Ex. No.	STR	m.p.	ref.
1594		268	Ex. 1
1596		242	Ex. 1
1597		280-281	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1598		1H-NMR (CDCl3) δ: 5.80 (2H, s), 6.98 (2H, d, J = 7.3 Hz), 7.18-7.34 (6H, m), 7.46 (1H, s), 7.75 (1H, d, J = 8.0 Hz).	Ex. 1
1599		1H-NMR (CDCl3) δ: 5.85 (2H, s), 7.01 (1H, d, J = 7.7 Hz), 7.20-7.24 (1H, m), 7.26-7.35 (3H, m), 7.43 (1H, s), 7.48 (1H, d, J = 7.7 Hz), 7.51 (1H, s), 7.77 (1H, d, J = 8.0 Hz), 11.8 (1H, br.).	Ex. 1
1600		1H-NMR (CDCl3) δ: 6.00 (2H, s), 6.73 (1H, s), 7.17 (1H, d, J = 8.3 Hz), 7.21-7.33 (2H, m), 7.58 (1H, s), 7.60 (1H, d, J = 8.1 Hz), 7.80 (1H, d, J = 8.0 Hz), 7.87 (1H, d, J = 8.1 Hz), 11.8 (1H, br.).	Ex. 1
1601		1H-NMR (CDCl3) δ: 5.77 (2H, s), 6.92 (2H, d. J = 8.2 Hz), 7.19-7.22 (3H, m), 7.27-7.30 (2H, m), 7.48 (1H, s), 7.74 (1H, dd, J = 0.7, 7.9 Hz), 11.9 (1H, br.).	Ex. 1
1602		1H-NMR (CDCl3) δ: 5.75 (2H, s), 6.77 (1H, dd, J = 1.4, 8.2 Hz), 7.17 (1H, d, J = 1.4 Hz), 7.22 (1H, t, J = 7.3 Hz), 7.26-7.33 (3H, m), 7.50 (1H, s), 7.77 (1H, d, J = 7.9 Hz), 11.9 (1H, br.).	Ex. 1
1603		1H-NMR (CDCl3) δ: 5.78 (2H, s), 6.93-6.97 (2H, m), 7.20-7.28 (5H, m), 7.37 (1H, s), 7.70-7.72 (1H, m), 12.1 (1H, br.).	Ex. 1
1604		1H-NMR (CDCl3) δ: 7.33-7.38 (2H, m), 7.45-7.48 (1H, m), 7.55-7.60 (5H, m), 8.16 (1H, s), 8.3 (1H, br.), 11.9 (1H, br.).	Ex. 1
1605		1H-NMR (CDCl3) δ: 7.34-7.38 (2H, m), 7.48-7.57 (5H, m), 8.11 (1H, s), 8.25 (1H, s), 12.0 (1H, br.).	Ex. 1


Ex. No.	STR	1H-NMR	ref.
1606		1H-NMR (CDCl3) δ: 5.43 (2H, s), 7.17 (2H, d, J = 7.2 Hz), 7.26-7.39 (6H, m), 8.00 (1H, s.), 8.18 (1H, br.), 11.9 (1H, br.).	Ex. 1
1607		1H-NMR (CDCl3) δ: 5.40 (2H, s), 7.09 (2H, d, J = 8.5 Hz), 7.26-7.34 (5H, m), 7.99 (1H, s.), 8.18 (1H, br.), 12.0 (1H, br.).	Ex. 1
1608		1H-NMR (CDCl3) δ: 5.57 (2H, s), 6.95-6.97 (1H, m), 7.01-7.02 (1H, m), 7.24-7.26 (1H, m), 7.26-7.36 (2H, m), 7.46-7.50 (1H, m), 8.00 (1H, s), 8.20 (1H, s), 12.0 (1H, br.).	Ex. 1
1609		1H-NMR (CDCl3) δ: 0.43-0.47 (2H, m), 0.69-0.74 (2H, m), 1.33-1.37 (1H, m), 4.08 (2H, d, J = 7.0 Hz), 7.26-7.37 (2H, m), 7.47 (1H, d, J = 8.2 Hz), 8.09 (1H, s), 8.10 (1H, br.), 12.0 (1H, br.).	Ex. 1
1610		1H-NMR (DMSO-d6) δ: 2.53 (3H, s), 7.05-7.14 (2H, m), 7.74-7.88 (1H, br), 7.96 (1H, d, J = 2.9 Hz), 11.89 (1H, brs)	Ex. 1


Ex. No.	STR	m.p.	ref.
1611		227-228	Ex. 1
1612		162-164	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1621		1H-NMR (CDCl3-CD3OD) δ: 6.78 (1H, dd, J = 0.7, 3.3 Hz), 6.82-6.91 (1H, m), 7.09-7.19 (2H, m), 7.44 (1H, d, J = 3.3 Hz), 7.75-7.84 (2H, m), 8.19-8.23 (1H, m).	Ex. 1
1622		1H-NMR (DMSO-d6) δ: 7.00 (1H, d, J = 2.7 Hz), 7.43 (1H, t, J = 7.8 Hz), 7.49-7.57 (1H, m), 7.58-7.78 (3H, m), 7.80-7.91 (2H, m).	Ex. 1
1623		1H-NMR (CDCl3) δ: 5.38 (2H, s), 6.60-6.71 (1H, m), 6.95-7.07 (2H, m), 7.31 (1H, d, J = 3.3 Hz), 7.33-7.39 (1H, m), 7.45 (1H, d, J = 8.2 Hz), 7.71-7.80 (1H, m), 12.3 (1H, br.).	Ex. 1
1624		1H-NMR (DMSO-d6) δ: 7.36 (1H, d, J = 7.3 Hz), 7.47 (1H, t, J = 8.3 Hz), 7.52-7.60 (1H, m), 7.69 (1H, dd, J = 8.9, 10.4 Hz), 7.79 (1H, d, J = 8.3 Hz), 7.86-7.94 (1H, m), 8.07 (1H, s).	Ex. 1
1625		1H-NMR (CDCl3) δ: 7.15-7.19 (1H, m), 7.40 (1H, dd, J = 7.5, 8.3 Hz), 7.49 (1H, d, J = 3.3 Hz), 7.63-7.75 (4H, m), 7.76-7.82 (2H, m).	Ex. 1
1626		1H-NMR (CDCl3) δ: 5.38 (2H, s), 6.64 (1H, dd, J = 0.7, 3.2 Hz), 6.73-6.83 (1H, m), 6.94-7.04 (1H, m), 7.29 (1H, d, J = 3.2 Hz), 7.66-7.72 (1H, m.), 7.78 (1H, d, J = 8.2 Hz), 7.95 (1H, s), 12.5 (1H, br.).	Ex. 1
1627		1H-NMR (CDCl3-DMSO-d6) δ: 6.73 (1H, dd, J = 0.8, 3.2 Hz), 7.23-7.29 (2H, m), 7.42 (1H, d, J = 3.2 Hz), 7.49-7.57 (2H, m), 7.71-7.82 (2H, m), 8.12 (1H, s).	Ex. 1
1628		1H-NMR (CDCl3-DMSO-d6) δ: 6.75 (1H, dd, J = 0.8, 3.2 Hz), 7.07-7.15 (1H, m), 7.29-7.41 (2H, m), 7.45 (1H, d, J = 3.2 Hz), 7.50-7.59 (1H, m), 7.79 (2H, s), 8.22 (1H, s).	Ex. 1



Ex. No.	STR	1H-NMR	ref.
1613		1H-NMR (CDCl3) δ: 6.78-6.82 (1H, m), 7.49 (1H, d, J = 3.3 Hz), 7.65-7.87 (6H, m), 8.12 (1H, s).	Ex. 1
1614		1H-NMR (CDCl3) δ: 6.81 (1H, dd, J = 0.7, 3.3 Hz), 7.26-7.31 (1H, m), 7.32-7.42 (3H, m), 7.60 (1H, d, J = 8.7 Hz), 7.78-7.84 (1H, m), 8.31 (1H, s), 12.0 (1H, br.).	Ex. 1
1615		1H-NMR (CDCl3) δ: 6.85 (1H, dd, J = 0.7, 3.3 Hz), 7.44 (1H, d, J = 3.3 Hz), 7.62-7.84 (6H, m), 8.32 (1H, d, J = 1.3 Hz), 12.0 (1H, br.).	Ex. 1
1616		1H-NMR (CDCl3) δ: 5.35 (2H, s), 6.64 (1H, dd, J = 0.8, 3.2 Hz), 6.90-6.99 (2H, m), 7.07-7.17 (1H, m), 7.26-7.30 (1H, m), 7.69 (1H, br.), 7.78 (1H, d, J = 8.2 Hz), 7.90 (1H, s), 12.0 (1H, br.).	Ex. 1
1617		1H-NMR (CDCl3): δ 5.45 (2H, s), 6.66 (1H, dd, J = 0.8, 3.2 Hz), 7.26–7.34 (2H, m), 7.41-7.49 (2H, m), 7.52-7.57 (1H, m), 7.70 (1H, br.), 7.79 (1H, d, J = 8.2 Hz), 7.92 (1H, s), 12.0 (1H, br.).	Ex. 1
1618		1H-NMR (DMSO-d6) δ: 3.85 (3H, s), 6.78 (1H, dd, J = 0.7, 3.2 Hz), 7.13-7.20 (2H, m), 7.53-7.59 (2H, m), 7.65 (1H, dd, J = 1.5, 8.2 Hz), 7.78 (1H, d, J = 3.2 Hz), 7.88 (1H, d, J = 8.2 Hz), 8.01-8.05 (1H, m).	Ex. 1
1619		1H-NMR (DMSO-d6) δ: 6.16 (2H, s), 6.78 (1H, d, J = 3.2 Hz), 7.06-7.14 (2H, m), 7.26 (1H, d, J = 1.9 Hz), 7.64 (1H, dd, J = 1.4, 8.3 Hz), 7.77 (1H, d, J = 3.2 Hz), 7.86 (1H, d, J = 8.3 Hz), 8.05 (1H, s).	Ex. 1
1620		1H-NMR (DMSO-d6) δ: 6.85 (1H, d, J = 3.3 Hz), 7.64-7.74 (5H, m), 7.86-7.92 (2H, m), 8.12 (1H, s).	Ex. 1



[0840]





Ex. No.	STR	1H-NMR	ref.
1629		1H-NMR (CDCl3) δ: 6.79-6.82 (1H, m), 7.50 (1H, d, J = 3.2 Hz), 7.76-7.88 (6H, m), 8.23 (1H, s).	Ex. 1
1630		1H-NMR (CDCl3-DMSO-d6) δ: 5.61 (2H, s), 6.67 (1H, dd, J = 0.8, 3.2 Hz), 6.85 (1H, s), 7.20 (1H, d, J = 3.2 Hz), 7.62 (1H, d, J = 8.4 Hz), 7.74-7.77 (2H, m), 7.80-7.83 (1H, m), 7.87 (1H, d, J = 8.2 Hz).	Ex. 1
1631		1H-NMR (CDCl3) δ: 2.44 (3H, s), 6.73 (1H, dd, J = 0.7, 3.2 Hz), 7.33-7.39 (2H, m), 7.40-7.45 (2H, m), 7.46 (1H, d, J = 3.2 Hz), 7.66-7.72 (1H, m), 7.80 (1H, d, J = 8.3 Hz), 8.12 (1H, s).	Ex. 1
1632		1H-NMR (CDCl3) δ: 5.52 (2H, s), 6.70 (1H, dd, J = 0.8, 3.2 Hz), 7.28 (1H, d, J = 3.2 Hz), 7.59 (2H, s), 7.68-7.79 (1H, m), 7.79-7.85 (2H, m), 7.91 (1H, s).	Ex. 1
1633		1H-NMR (CDCl3) δ: 6.78 (1H, d, J = 3.2 Hz), 7.05-7.17 (2H, m), 7.36-7.39 (1H, m), 7.49-7.59 (1H, m), 7.74 (1H, dd, J = 1.3, 8.3 Hz), 7.83 (1H, d, J = 8.3 Hz), 7.86 (1H, s), 12.0 (1H, br.).	Ex. 1
1634		1H-NMR (CDCl3) δ: 6.79 (1H, d, J = 3.3 Hz), 7.09-7.18 (1H, m), 7.27-7.38 (2H, m), 7.39-7.43 (1H, m), 7.73-7.85 (2H, m), 7.94 (1H, s), 12.0 (1H, br.).	Ex. 1
1635		1H-NMR (CDCl3) δ: 5.47 (2H, s), 6.65 (1H, dd, J = 0.7, 3.1 Hz), 7.23-7.32 (3H, m), 7.57 (2H, d, J = 8.1 Hz), 7.64-7.71 (1H, m), 7.79 (1H, d, J = 8.2 Hz), 7.91 (1H, s), 12.4 (1H, br.).	Ex. 1
1636		1H-NMR (CDCl3) δ: 0.94-1.11 (2H, m), 1.11-1.31 (3H, m), 1.56-1.77 (5H, m), 1.81-1.98 (1H, m), 4.02 (2H, d, J = 7.2 Hz), 6.54 (1H, dd, J = 0.7, 3.1 Hz), 7.21 (1H, d, J = 3.1 Hz), 7.51-7.70 (1H, m), 7.75 (1H, d, J = 8.2 Hz), 7.97 (1H, s), 12.5 (1H, br.).	Ex. 1






Ex. No.	STR	1H-NMR	ref.
1637		1H-NMR (CDCl3) δ: 1.75-1.98 (4H, m), 2.00-2.16 (2H, m), 2.80-2.96 (1H, m), 4.22 (2H, d, J = 7.2 Hz), 6.55 (1H, dd, J = 0.7, 3.1 Hz), 7.24 (1H, d, J = 3.1 Hz), 7.55-7.67 (1H, m), 7.75 (1H, d, J = 8.2 Hz), 8.03 (1H, s).	Ex. 1
1638		1H-NMR (CDCl3) δ: 0.38-0.47 (2H, m), 0.62-0.72 (2H, m), 1.23-1.40 (1H, m), 4.08 (2H, d, J = 6.8 Hz), 6.58 (1H, d, J = 3.1 Hz), 7.39 (1H, d, J = 3.1 Hz), 7.59-7.67 (1H, m), 7.77 (1H, d, J = 8.3 Hz), 8.03 (1H, s).	Ex. 1
1639		1H-NMR (CDCl3) δ: 0.00-0.08 (2H, m), 0.38-0.47 (2H, m), 0.54-0.69 (1H, m), 1.76 (2H, q, J = 6.8 Hz), 4.29 (2H, t, J = 6.8 Hz), 6.55 (1H, d, J = 3.1 Hz), 7.27 (1H, d, J = 3.1 Hz), 7.61 (1H, dd, J = 1.5, 8.3 Hz), 7.75 (1H, d, J = 8.3 Hz), 8.01 (1H, s).	Ex. 1
1640		1H-NMR (CDCl3) δ: 1.97 (3H, d, J = 7.1 Hz), 5.72 (1H, q, J = 7.1 Hz), 6.94 (1H, d, J = 3.2 Hz), 7.10-7.16 (2H, m), 7.22-7.35 (4H, m), 7.40 (1H, d, J = 8.4 Hz), 7.47 (1H, d, J = 3.2 Hz), 7.67 (1H, d = 7.1 Hz).	Ex. 1
1641		1H-NMR (CDCl3) δ: 1.97 (3H, d, J = 7.0 Hz), 5.76 (1H, q, J = 7.0 Hz), 6.63 (1H, dd, J = 0.7, 3.2 Hz), 7.17-7.35 (5H, m), 7.46 (1H, d, J = 3.2 Hz), 7.56-7.63 (1H, m), 7.75 (1H, d, J = 8.3 Hz), 7.88 (1H, s).	Ex. 1
1642		1H-NMR (CDCl3) δ: 1.59-1.98 (3H, m), 2.02-2.17 (1H, m), 3.77-3.94 (2H, m), 4.18-4.45 (3H, m), 6.54 (1H, dd, J = 0.7, 3.1 Hz), 7.30 (1H, d, J = 3.1 Hz), 7.55 (1H, br.), 7.68 (1H, d, J = 8.2 Hz), 7.98 (1H, s).	Ex. 1
1643		1H-NMR (DMSO-d6) δ: 7.55-7.61 (2H, m), 7.73 (1H, d, J = 8.8 Hz), 8.05 (1H, d, J = 2.0 Hz).	Ex. 1





[0841]

Ex. No.	STR	1H-NMR	ref.
1644		1H-NMR (DMSO-d6) δ: 7.41 (1H, d, J = 16.4 Hz), 7.56-7.63 (6H, m), 7.77 (1H, s), 7.93-8.04 (2H, m).	Ex. 1
1645		1H-NMR (DMSO-d6) δ: 7.60 (1H, s), 7.74-7.84 (4H, m), 8.04-8.07 (2H, m), 8.20 (1H, s).	Ex. 1






Ex. No.	STR	m.p.	ref.
1646		255-256	Ex. 1
1647		176-179	Ex. 1



Ex. No.	STR	m.p.	ref.
1648		242-245	Ex. 1
1649		257-259	Ex. 1
1650		265-267	Ex. 1
1651		232	Ex. 1




Ex. No.	STR	m.p.	ref.
1652		273-276	Ex. 1
1654		216-217	Ex. 1
1655		197-200	Ex. 1
1656		259	Ex. 1
1657		226-228	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1653		1H-NMR (DMSO-d6) δ: 7.49 (2H, d, J = 8.0 Hz), 7.60 (1H, d, J = 0.7 Hz), 7.75 (1H, dd, J = 1.9, 8.7 Hz), 7.81-7.87 (3H, m), 8.11 (1H, d, J = 1.9 Hz).	Ref. Ex. 260, Ex. 1
1658		1H-NMR (DMSO-d6) δ: 2.57 (3H, s), 7.31 (2H, t, J = 8.9 Hz), 7.65-7, 70 (1H, m), 7.80-7.88 (3H, m), 7.92-7.94 (1H, m).	Ex. 1
1659		1H-NMR (DMSO-d6) δ: 7.53-7.61 (3H, m), 7.67-7.72 (1H, m), 7.81-7.92 (3H, m), 8.04 (1H, s).	Ex. 1
1662		1H-NMR (DMSO-d6) δ: 7.34 (2H, t, J = 8.8 Hz), 7.76 (1H, dd, J = 1.5, 8.4 Hz), 7.81-7.87 (2H, m), 8.07 (1H, s), 8.11 (1H, d, J = 8.4 Hz), 8.41 (1H, s).	Ex. 1

[0842]


Ex. No.	STR	m.p.	ref.
1660		269-272	Ex. 1
1661		248-250	Ex. 1
1663		222	Ex. 1
1664		231	Ex. 1
1665		189-191	Ex. 1
1666		301	Ex. 1


Ex. No.	STR	m.p.	ref.
1667		154-157	Ex. 1
1670		248-250	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1668		1H-NMR (DMSO-d6) δ: 7.50-7.63 (3H, m), 8.14 (2H, s), 8.20-8.26 (2H, m).	Ex. 1
1669		1H-NMR (DMSO-d6) δ: 7.76 (1H, dd, J = 1.5, 8.6 Hz), 8.21 (1H, s), 8.35 (1H, d, J = 8.6 Hz), 8.53 (1H, s).	Ex. 1
1671		1H-NMR (DMSO-d6) δ: 7.91-7.96 (1H, m), 8.04 (1H, d, J = 8.0 Hz), 8.11 (1H, s), 8.21 (1H, d, J = 8.0 Hz), 8.47-8.52 (1H, m), 8.63 (1H, s), 9.21-9.23 (1H, m).	Ex. 1
1672		1H-NMR (DMSO-d6) δ: 1.63-1.69 (6H, m), 3.80-3.82 (4H, m), 7.24 (1H, s), 7.48-7.52 (3H, m), 8.50-8.55 (2H, m).	Ex. 2

Ex. No.	STR	1H-NMR	ref.
1673		1H-NMR (DMSO-d6) δ: 7.54-7.61 (3H, m), 7.96 (1H, d, J = 5.1 Hz), 8.59-8.62 (2H, m), 9.12 (1H, d, J = 5.1 Hz).	Ex. 2
1674		1H-NMR (DMSO-d6) δ: 2.65 (3H, s), 7.55 (1H, d, J = 15.6 Hz), 7.77-7.80 (2H, m), 7.90 (1H, s), 7.95-8.01 (3H, m).	Ex. 2
1675		1H-NMR (DMSO-d6) δ: 2.60 (3H, s), 7.22-7.28 (2H, m), 7.33 (1H, d, J = 16.0 Hz), 7.80-7.84 (3H, m), 7.90 (1H, d, J = 16.0 Hz).	Ex. 2
1676		1H-NMR (CDCl3) δ: 2.61 (4H, brs), 3.49 (2H, brs), 3.82 (2H, brs), 6.92 (1H, s), 7.48-7.52 (3H, m), 8.45 (2H, d, J = 3.6 Hz).	Ex. 2
1677		1H-NMR (DMSO-d6) δ: 1.98-2.05 (4H, m), 3.48-3.49 (2H, m), 3.72-3.73 (2H, m), 6.99 (1H, s), 7.88 (2H, d, J = 8.2 Hz), 8.70 (2H, d, J = 8.2 Hz).	Ex. 2
1678		1H-NMR (DMSO-d6) δ: 3.95-4.00 (8H, m), 7.27 (1H, s), 7.48-7.55 (3H, m), 8.51-8.57 (2H, m).	Ex. 1
1679		1H-NMR (DMSO-d6) δ: 1.90-1.99 (4H, m), 3.54 (2H, brs), 3.60 (2H, brs), 3.91 (3H, s), 6.52 (1H, s).	Ex. 2
1680		1H-NMR (DMSO-d6) δ: 8.04 (2H, d, J = 8.3 Hz), 8.40 (2H, d, J = 8.3 Hz), 8.74 (1H, s).	Ex. 1


[0843]

Ex. No.	STR	1H-NMR	ref.
1681		1H-NMR (CDCl3) δ: 1.71-1.72 (4H, m), 1.74-1.83 (2H, m), 3.82 (4H, brs), 7.33 (1H, s).	Ex. 1
1682		1H-NMR (CDCl3) δ: 2.10 (2H, brs), 2.14 (2H, brs), 3.53 (2H, brs), 3.85 (2H, brs), 7.00 (1H, s), 7.97 (1H, s), 9.00 (2H, s).	Ex. 1
1683		1H-NMR (DMSO-d6) δ: 7.95 (2H, d, J = 8.4 Hz), 7.98 (2H, d, J = 8.4 Hz), 8.49 (1H, s), 8.61 (2H, d, J = 8.1 Hz), 8.89 (2H, d, J = 8.1 Hz).	Ex. 1
1684		1H-NMR (DMSO-d6) δ: 7.90-7.92 (3H, m), 8.76 (2H, d, J = 8.1 Hz), 8.95 (1H, d, J = 5.2 Hz).	Ex. 1
1685		1H-NMR (DMSO-d6) δ: 2.00 (4H, brs), 3.68 (4H, t, J = 6.5 Hz), 7.90 (1H, s), 8.30 (1H, s), 8.80 (2H, s).	Ex. 1
1686		1H-NMR (DMSO-d6) δ: 1.99 (4H, t, J = 6.5 Hz), 3.66 (4H, t, J = 6.5 Hz), 7.68 (1H, s), 7.90 (2H, d, J = 8.3 Hz), 8.37 (2H, d, J = 8.3 Hz).	Ex. 1

























Ex. No.	STR	1H-NMR	ref.
1687		1H-NMR (DMSO-d6) δ: 3.96 (3H, s), 5.62 (2H, s), 7.30 (1H, dd, J = 2.5, 9.1 Hz), 7.34 (1H, d, J = 2.5 Hz), 7.58 (1H, s), 7.83 (4H, s), 8.17 (1H, d, J = 9.1 Hz).	Ex. 2
1688		1H-NMR (DMSO-d6) δ: 7.69-7.73 (1H, m), 7.86-7.90 (1H, m), 8.07 (1H, s), 8.09 (1H, d, J = 0.8 Hz), 8.14 (1H, d, J = 8.5 Hz), 8.61 (1H, d, J = 8.5 Hz).	Ex. 1
1689		1H-NMR (DMSO-d6) δ: 4.00 (3H, s), 7.35 (1H, dd, J = 2.6, 9.3 Hz), 7.48 (1H, d, J = 2.6 Hz), 7.70-7.78 (1H, m), 7.84-7.86 (2H, m), 7.92 (1H, s), 7.98-8.00 (2H, m).	Ex. 1
1690		1H-NMR (DMSO-d6) δ: 3.99 (3H, s), 7.35 (1H, dd, J = 2.6, 9.2 Hz), 7.44-7.48 (3H, m), 7.65-7.69 (2H, m), 7.79 (1H, d, J = 9.2 Hz), 7.88 (1H, s).	Ex. 1
1691		1H-NMR (DMSO-d6) δ: 3.99 (3H, s), 7.36 (1H, dd, J = 2.6, 9.3 Hz), 7.45 (1H, d, J = 2.6 Hz), 7.50 (1H, dd, J = 1.3, 4.9 Hz), 7.86 (1H, dd, J = 2.9, 4.9 Hz), 7.95 (1H, s), 8.01 (1H, dd, J = 1.3, 2.9 Hz), 8.03 (1H, d, J = 9.3 Hz).	Ex. 125
1692		1H-NMR (DMSO-d6) δ: 3.99 (3H, s), 7.35 (1H, dd, J = 2.6, 9.3 Hz), 7.47 (1H, d, J = 2.6 Hz), 7.63-7.65 (2H, m), 7.68-7.70 (2H, m), 7.79 (1H, d, J = 9.3 Hz), 7.88 (1H, s).	Ex. 1

Ex. No.	STR	1H-NMR	ref.
1693		1H-NMR (DMSO-d6) δ: 1.80-1.83 (4H, m), 3.16 (4H, t, J = 6.5 Hz), 7.28-7.32 (1H, m), 7.63-7.70 (2H, m), 7.81 (1H, d, J = 7.9 Hz), 8.27 (1H, s).	Ex. 1
1694		1H-NMR (DMSO-d6) δ: 7.63 (2H, d, J = 8.2 Hz), 7.74-7.80 (3H, m), 7.93-7.99 (1H, m), 8.19 (2H, d, J = 8.2 Hz), 8.82 (1H, s).	Ex. 1
1695		1H-NMR (CDCl3) δ: 3.37 (2H, t, J = 8.5 Hz), 3.98 (2H, t, J = 8.5 Hz), 6.90-6.99 (1H, m), 7.02-7.27 (5H, m), 12.2 (1H, br.).	Ex. 1
1696		1H-NMR (CDCl3) δ: 3.40 (2H, t, J = 8.4 Hz), 4.07 (2H, t, J = 8.4 Hz), 7.20-7.35 (4H, m), 7.40-7.52 (3H, m), 12.3 (1H, br.).	Ex. 1
1697		1H-NMR (DMSO-d6) δ: 3.20 (2H, t, J = 8.5 Hz), 3.4 (2H, t, J = 8.5 Hz), 4.45 (2H, s), 6.99 (1H, d, J = 1.4 Hz), 7.12 (1H, dd, J = 1.4, 7.6 Hz), 7.26 (1H, d, J = 7.6 Hz), 7.57-7.74 (4H, m).	Ex. 1
1698		1H-NMR (CDCl3) δ: 3.08 (2H, t, J = 8.4 Hz), 3.48 (2H, t, J = 8.4 Hz), 4.33 (2H, s), 6.90-7.01 (2H, m), 7.15-7.31 (3H, m).	Ex. 1
1699		1H-NMR (CDCl3) δ: 3.20 (2H, t, J = 8.5 Hz), 3.99 (2H, t, J = 8.5 Hz), 7.07-7.14 (2H, m), 7.22-7.31 (4H, m), 7.40-7.49 (1H, m), 12.4 (1H, br.).	Ex. 1
1700		1H-NMR (CDCl3) δ: 3.24 (2H, t, J = 8.4 Hz), 4.08 (2H, t, J = 8.4 Hz), 7.22-7.26 (1H, m), 7.29-7.42 (3H, m), 7.46-7.53 (1H, m), 7.54-7.59 (1H, m), 7.63-7.68 (1H, m), 12.4 (1H, br.).	Ex. 1







[0844]





Ex. No.	STR	1H-NMR	ref.
1701		1H-NMR (CDCl3) δ: 3.24 (2H, t, J = 8.5 Hz), 4.02 (2H, t, J = 8.5 Hz), 6.75-6.85 (1H, m), 7.07-7.18 (3H, m), 7.30 (1H, d, J = 7.5 Hz), 7.34-7.41 (1H, m), 12.3 (1H, br.).	Ex. 1
1702		1H-NMR (CDCl3) δ: 1.48 (9H, s), 1.6-1.9 (2H, m), 1.9-2.03 (2H, m), 2.82-2.99 (2H, m), 3.01-3.17 (1H, m), 4.11-4.31 (2H, s), 12.9 (1H, br.).	Ex. 1
1703		1H-NMR (CDCl3) δ: 1.72-1.95 (2H, br.), 1.95-2.06 (2H, m), 2.91-3.17 (3H, m), 4.22-4.37 (2H, m), 5.16 (2H, s), 7.30-7.37 (5H, m), 12.7 (1H, br.).	Ex. 1
1704		1H-NMR (CDCl3) δ: 1.98-2.10 (4H, m), 2.25-2.38 (2H, m), 2.91-3.17 (3H, m), 3.75 (2H, s), 7.47 (1H, t, J = 7.6 Hz), 7.52-7.63 (3H, m).	Ex. 1
1705		1H-NMR (CDCl3-CD3OD) δ: 1.71-2.26 (4H, m), 2.96-3.12 (1H, m), 3.17-3.31 (2H, m), 3.72-3.87 (1H, m), 4.71-4.85 (1H, m), 7.55 (2H, d, J = 8.0 Hz), 7.72 (2H, d, J = 8.0 Hz).	Ex. 1
1706		1H-NMR (CDCl3-CD3OD) δ: 1.69-2.22 (4H, m), 2.92-3.11 (1H, m), 3.14-3.30 (2H, m), 3.81-3.99 (1H, m), 4.68-4.85 (1H, m), 7.38-7.47 (5H, m).	Ex. 1
1707		1H-NMR (CDCl3) δ: 1.94-2.12 (4H, m), 2.37-2.49 (2H, m), 2.47 (3H, s), 2.78-2.93 (1H, m), 3.85-3.96 (2H, m), 7.37 (2H, d, J = 8.0 Hz), 7.68 (2H, d, J = 8.0 Hz).	Ex. 1
1708		1H-NMR (CDCl3) δ: 2.02-2.21 (4H, m), 2.74-2.89 (2H, m), 3.01-3.15 (1H, m), 3.41-3.53 (2H, m), 6.75-6.87 (1H, m), 6.87-6.99 (1H, m), 12.4 (1H, br.).	Ex. 1
1709		1H-NMR (CDCl3) δ: 1.95-2.21 (4H, m), 2.81-2.94 (2H, m), 3.01-3.15 (1H, m), 3.68-3.78 (2H, m), 6.85-6.94 (2H, m), 7.19-7.26 (2H, m).	Ex. 1
1710		1H-NMR (CD3OD) δ: 1.77-1.98 (2H, m), 2.04-2.17 (2H, m), 3.05-3.40 (3H, m), 4.21-4.34 (1H, m), 4.37-4.49 (1H, m), 7.08-7.15 (2H, m), 7.20-7.27 (1H, m), 7.35-7.44 (2H, m).	Ex. 1
1711		1H-NMR (CDCl3-CD3OD) δ: 1.49-1.65 (1H, m), 1.66-1.83 (1H, m), 1.91-2.09 (2H, m), 2.74-2.87 (1H, m), 3.09-3.25 (2H, m), 3.75 (2H, s), 3.93-4.04 (1H, m), 4.62-4.73 (1H, m), 6.99-7.08 (2H, m), 7.18-7.26 (2H, m).	Ex. 1
1712		1H-NMR (DMSO-d6) δ: 1.53-1.93 (3H, m), 2.10-2.22 (1H, m), 2.90-3.81 (4H, m), 4.32-4.48 (0.4H, m), 4.58-4.74 (0.6H, m), 7.56-7.69 (2H, m), 7.74-7.88 (2H, m), 16.0 (1H, br.).	Ex. 1
1713		1H-NMR (DMSO-d6) δ: 1.64-1.90 (3H, m), 2.04-2.16 (1H, m), 2.77-2.87 (1H, m), 2.92-3.04 (1H, m), 3.16-3.31 (1H, m), 3.63-3.74 (1H, m), 3.84-3.94 (1H, m), 7.01-7.09 (2H, m), 7.22-7.30 (2H, m).	Ex. 1
1714		1H-NMR (CDCl3) δ: 1.79-2.08 (2H, m), 2.20-2.37 (1H, m), 2.37-2.56 (1H, m), 3.40-3.60 (2H, m), 3.60-3.81 (2H, m), 3.91-4.07 (1H, m), 7.07-7.21 (1H, m), 7.91-8.18 (1H, m).	Ex. 1
1715		1H-NMR (DMSO-d6) δ: 7.42-7.45 (1H, m), 7.50-7.54 (2H, m), 7.86 (1H, s), 8.02-8.04 (2H, m), 13.23 (1H, brs).	Ex. 1
1716		1H-NMR (DMSO-d6) δ: 2.21 (3H, s), 5.47 (2H, s), 7.19 (2H, d, J = 8.1 Hz), 7.64 (2H, d, J = 8.1 Hz), 8.60 (1H, brs).	Ex. 1
1717		1H-NMR (CDCl3) δ: 2.49 (3H, s), 5.26 (2H, s), 7.26 (2H, d, J = 8.1 Hz), 7.67 (2H, d, J = 8.1 Hz), 7.94 (1H, s).	Ex. 1
1718		1H-NMR (DMSO-d6) δ: 2.23 (3H, s), 3.65 (3H, s), 7.62 (2H, d, J = 8.6 Hz), 7.78 (2H, d, J = 8.6 Hz).	Ex. 1
1719		1H-NMR (DMSO-d6) δ: 2.26 (3H, s), 3.66 (3H, s), 7.38-7.47 (2H, m), 7.82-7.85 (2H, m).	Ex. 1
1720		1H-NMR (DMSO-d6) δ: 2.26 (3H, s), 3.70 (3H, s), 7.91 (2H, d, J = 8.2 Hz), 8.00 (2H, d, J = 8.2 Hz).	Ex. 1
1721		1H-NMR (CDCl3) δ: 2.59 (3H, s), 3.69 (3H, s), 7.75 (4H, s).	Ex. 1
1722		1H-NMR (CDCl3) δ: 2.56 (3H, s), 3.65 (3H, s), 7.42-7.46 (2H, m), 7.51-7.55 (2H, m).	Ex. 1
1723		1H-NMR (CDCl3) δ: 2.56 (3H, s), 3.64 (3H, s), 7.12-7.20 (2H, m), 7.55-7.60 (2H, m).	Ex. 1
1724		1H-NMR (CDCl3) δ: 1.20 (3H, t, J = 7.5 Hz), 2.43 (3H, s), 2.68 (2H, q, J = 7.5 Hz), 5.12 (2H, s), 6.92 (2H, d, J = 8.5 Hz), 7.35 (2H, d, J = 8.5 Hz).	Ex. 1



[0845]


Ex. No.	STR	1H-NMR	ref.
1725		1H-NMR (CDCl3) δ: 0.87 (3H, t, J = 7.4 Hz), 1.31-1.42 (2H, m), 1.65-1.72 (2H, m), 2.65 (2H, t, J = 7.8 Hz), 5.21 (2H, s), 6.87 (2H, d, J = 8.5 Hz), 7.25-7.32 (2H, m).	Ex. 1
1726		1H-NMR (CDCl3-CD3OD) δ: 7.11 (1H, d, J = 2.6 Hz), 7.59-7.70 (2H, m), 8.02-8.09 (2H, m), 8.18 (1H, d, J = 2.6 Hz).	Ex. 1
1727		1H-NMR (CDCl3-CD3OD) δ: 7.07 (1H, d, J = 2.6 Hz), 7.45-7.51 (2H, m), 7.72-7.80 (2H, m), 8.05 (1H, d = 2.6 Hz).	Ex. 1
1728		1H-NMR (DMSO-d6) δ: 4.09 (3H, s), 7.27 (1H, s), 7.47-7.54 (2H, m), 7.84-7.90 (2H, m).	Ex. 1
1729		1H-NMR (CDCl3) δ: 3.81 (3H, s), 5.32 (2H, s), 6.85-6.91 (2H, m), 6.95 (1H, d, J = 2.4 Hz), 7.16-7.22 (2H, m), 7.50 (1H, d, J = 2.4 Hz).	Ex. 1
1730		1H-NMR (CDCl3) δ: 0.95 (3H, t, J = 7.5 Hz), 1.88-1.98 (2H, m), 4.54 (2H, t, J = 7.4 Hz), 7.38-7.42 (2H, m), 7.77-7.82 (2H, m), 12.8 (1H, br.).	Ref. Ex. 63, Ex. 1
1731		1H-NMR (CDCl3-CD3OD) δ: 0.40-0.44 (2H, m), 0.51-0.56 (2H, m), 1.34-1.44 (1H, m), 4.45 (2H, d, J = 7.1 Hz), 7.20 (1H, s), 7.39-7.42 (2H, m), 7.78-7.81 (2H, m).	Ex. 1
1732		1H-NMR (CDCl3) δ: 0.85 (3H, t, J = 7.4 Hz), 1.82-1.91 (2H, m), 4.15 (2H, t, J = 7.3 Hz), 6.96 (1H, br.), 7.35-7.39 (2H, m), 7.45-7.52 (2H, m), 13.2 (1H, br.).	Ex. 1
1733		1H-NMR (DMSO-d6) δ: 7.68 (2H, d, J = 8.5 Hz), 8.04-8.06 (1H, m), 8.17 (2H, d, J = 8.5 Hz), 8.27 (1H, d, J = 8.5 Hz), 8.69 (1H, s).	Ex. 1
1734		1H-NMR (DMSO-d6) δ: 7.97 (2H, d, J = 8.3 Hz), 8.06-8.09 (1H, m), 8.34 (1H, d, J = 8.7 Hz), 8.36 (2H, d, J = 8.3 Hz), 8.74 (1H, s).	Ex. 1
1735		1H-NMR (DMSO-d6) δ: 8.08-8.11 (1H, m), 8.14 (1H, d, J = 8.3 Hz), 8.38 (1H, d, J = 8.3 Hz), 8.76-8.80 (2H, m), 9.50 (1H, s).	Ex. 1
1736		1H-NMR (DMSO-d6) δ: 7.64 (1H, dd, J = 2.2, 8.8 Hz), 8.15 (1H, d, J = 8.8 Hz), 8.40 (1H, d, J = 2.2 Hz).	Ex. 125
1737		1H-NMR (DMSO-d6) δ: 7.92 (1H, dd, J = 1.7, 8.6 Hz), 8.34 (1H, d, J = 8.6 Hz), 8.77 (1H, d, J =1.7 Hz).	Ex. 125
1738		1H-NMR (DMSO-d6) δ: 7.11-7.14 (2H, m), 7.20-7.24 (1H, m), 7.29 (1H, dd, J = 2.5, 8.9 Hz), 7.43-7.47 (2H, m), 7.84 (1H, d, J = 2.5 Hz), 8.14 (1H, d, J = 8.9 Hz).	Ex. 125
1739		1H-NMR (DMSO-d6) δ: 7.88 (2H, d, J = 8.3 Hz), 7.99 (1H, dd, J = 1.9, 8.6 Hz), 8.03 (2H, d, J = 8.3 Hz), 8.26 (1H, d, J = 8.6 Hz), 8.66 (1H, d, J = 1.9 Hz).	Ex. 125
1740		1H-NMR (DMSO-d6) δ: 4.04 (3H, s), 7.15 (1H, dd, J = 0.6, 8.1 Hz), 7.50 (1H, t, J = 8.1 Hz), 7.76 (1H, d, J = 0.6, 8.1 Hz).	Ex. 125
1741		1H-NMR (DMSO-d6) δ: 3.88 (3H, s), 7.20 (1H, dd, J = 2.6, 9.0 Hz), 7.80 (1H, d, J = 2.6 Hz), 8.03 (1H, d, J = 9.0 Hz).	Ex. 125
1742		1H-NMR (DMSO-d6) δ: 3.90 (3H, s), 7.19 (1H, dd, J = 2.5, 8.8 Hz), 7.66 (1H, d, J = 2.5 Hz), 8.09 (1H, d, J = 8.8 Hz).	Ex. 125
1743		1H-NMR (DMSO-d6) δ: 7.26 (2H, d, J = 8.5 Hz), 7.40 (1H, dd, J = 2.5, 8.9 Hz), 7.79 (2H, d, J = 8.5 Hz), 8.02 (1H, d, J = 2.5 Hz), 8.20 (1H, d, J = 8.9 Hz).	Ex. 125
1744		1H-NMR (DMSO-d6) δ: 7.14-7.18 (2H, m), 7.33 (1H, dd, J = 2.5, 8.8 Hz), 7.47-7.51 (2H, m), 7.88 (1H, d, J = 2.5 Hz), 8.16 (1H, d, J = 8.8 Hz).	Ex. 125
1745		1H-NMR (DMSO-d6) δ: 2.32 (3H, s), 7.01-7.05 (2H, m), 7.25-7.27 (3H, m), 7.77 (1H, d, J = 2.5 Hz), 8.12 (1H, d, J = 8.9 Hz).	Ex. 125
1746		1H-NMR (DMSO-d6) δ: 7.64 (1H, s), 7.66-7.68 (2H, m), 8.02-8.05 (2H, m).	Ex. 2
1747		1H-NMR (DMSO-d6) δ: 7.43-7.47 (2H, m), 7.58 (1H, s), 8.07-8.10 (2H, m).	Ex. 2
1748		1H-NMR (DMSO-d6) δ: 3.40 (2H, t, J = 8.6 Hz), 4.78 (2H, t, J = 8.6 Hz), 7.92 (1H, s), 7.94 (1H, s), 8.00 (1H, d, J = 8.3 Hz), 8.35 (1H, dd, J = 1.9, 8.3 Hz), 9.09 (1H, d, J = 1.9 Hz).	Ex. 1
1751		1H-NMR (DMSO-d6) δ: 7.41-7.43 (2H, m), 7.47-7.50 (2H, m), 9.56 (1H, s).	Ex. 125





[0846]

Ex. No.	STR	1H-NMR	ref.
1752		1H-NMR (DMSO-d6) δ: 7.61 (2H, d, J = 8.6 Hz), 8.10 (2H, d, J = 8.6 Hz), 8.33 (1H, s).	Ex. 125
1753		1H-NMR (DMSO-d6) δ: 7.41 (2H, d, J = 8.3 Hz), 7.54 (2H, d, J = 8.3 Hz), 9.58 (1H, s).	Ex. 125
1754		1H-NMR (DMSO-d6) δ: 7.54 (2H, d, J = 8.4 Hz), 8.21 (2H, d, J = 8.4 Hz), 8.37 (1H, s).	Ex. 125
1756		1H-NMR (DMSO-d6) δ: 7.56-7.59 (2H, m), 8.03-8.07 (1H, m), 8.14 (1H, s), 8.42 (1H, s).	Ex. 125
1757		1H-NMR (DMSO-d6) δ: 7.92 (2H, d, J = 8.3 Hz), 8.30 (2H, d, J = 8.3 Hz), 8.43 (1H, s).	Ex. 125
1758		1H-NMR (DMSO-d6) δ: 7.64 (2H, d, J = 8.1 Hz), 7.79 (2H, d, J = 8.1 Hz), 9.61 (1H, s).	Ex. 125




Ex. No.	STR	m.p.	ref.
1749		186—189	Ex. 1
1750		242-256	Ex. 1
1755		189.1—191.1	Ex. 125
1759		224-226	Ex. 1


Ex. No.	STR	1H-NMR	ref.
1760		1H-NMR (DMSO-d6) δ: 7.67 (1H, d, J = 8.4 Hz), 7.73-7.75 (1H, m), 7.86 (1H, s).	Ex. 1
1761		1H-NMR (DMSO-d6) δ: 1.35 (3H, t, J = 7.0 Hz), 4.52 (2H, q, J = 7.0 Hz), 7.30 (1H, t, J = 7.5 Hz), 7.53-7.56 (1H, m), 7.70 (1H, d, J = 8.2 Hz), 7.87 (1H, d, J = 8.2 Hz), 7.95-7.97 (1H, m), 8.20 (1H, d, J = 7.5 Hz), 8.67 (1H, s).	Ex. 1



Ex. No.	STR	m.p.	ref.
1762		197	Ex. 1







Ex. No.	STR	1H-NMR	ref.
1763		1H-NMR (DMSO-d6) δ: 2.71-2.74 (2H, m), 2.93-2.96 (2H, m), 5.39 (2H, s), 7.18 (1H, d, J = 8.3 Hz), 7.24 (1H, d, J = 8.3 Hz), 7.37 (1H, t, J = 8.3 Hz), 7.95 (2H, s), 8.02 (1H, s).	Ex. 1
1764		1H-NMR (DMSO-d6) δ: 7.25 (1H, d, J = 16.6 Hz), 7.37-7.54 (4H, m), 7.68-7.71 (2H, m).	Ex. 1
1765		1H-NMR (DMSO-d6) δ: 5.41 (2H, s), 7.07-7.60 (6H, m), 8.01-8.10 (2H, m), 8.21 (1H, s).	Ex. 1
1766		1H-NMR (CDCl3) δ: 4.19 (2H, s), 7.26-7.38 (5H, m).	Ex. 2
1767		1H-NMR (CDCl3) δ: 1.28 (9H, s).	Ex. 2




[0847]

Ex. No.	STR	1H-NMR	ref.
1768		1H-NMR (DMSO-d6) δ: 7.02 (1H, brs), 7.95 (2H, d, J = 8.4 Hz), 8.56-8.58 (2H, m), 13.17 (1H, brs).	Ex. 1
1769		1H-NMR (CDCl3) δ: 1.44-1.47 (2H, m), 1.60-1.63 (2H, m), 7.33 (4H, s).	Ex. 2
1770		1H-NMR (CDCl3) δ: 4.16 (2H, s), 6.90-6.92 (2H, m), 6.98-7.02 (3H, m), 7.10-7.14 (1H, m), 7.28-7.36 (3H, m).	Ex. 2




Ex. No.	STR	m.p.	ref.
1771		125.6-125.8	Ex. 2


Ex. No.	STR	1H-NMR	ref.
1772		1H-NMR (DMSO-d6) δ: 2.93 (2H, t, J = 7.5 Hz), 3.09 (2H, t, J = 7.5 Hz), 5.18 (2H, s), 6.92-6.95 (2H, m), 7.07-7.10 (2H, m), 7.65 (2H, d, J = 8.1 Hz), 7.75 (2H, d, J = 8.1 Hz).	Ex. 2
1773		1H-NMR (DMSO-d6) δ: 4.13 (2H, s), 5.21 (2H, s), 6.99-7.01 (2H, m), 7.10-7.12 (2H, m), 7.65 (2H, d, J = 8.0 Hz), 7.75 (2H, d, J = 8.0 Hz).	Ex. 2



Ex. No.	STR	1H-NMR	ref.
1774		1H-NMR (CDCl3) δ: 4.33 (2H, s), 7.77 (1H, s), 7.82 (2H, s).	Ex. 2
1775		1H-NMR (CDCl3) δ: 3.04 (2H, t, J = 7.5 Hz), 3.18 (2H, t, J = 7.5 Hz), 5.11 (2H, s), 6.79-6.85 (3H, m), 7.22 (1H, d, J = 8.3 Hz), 7.54 (2H, d, J = 8.1 Hz), 7.65 (2H, d, J = 8.1 Hz).	Ex. 2
1776		1H-NMR (DMSO-d6) δ: 5.39 (2H, s), 7.22-7.25 (2H, m), 7.71 (2H, d, J = 8.2 Hz), 7.79 (2H, d, J = 8.2 Hz), 8.25-8.28 (2H, m).	Ex. 2
1777		1H-NMR (DMSO-d6) δ: 4.16 (2H, s), 7.27-7.30 (1H, m), 7.37-7.41 (3H, m), 7.50 (1H, s), 7.58 (1H, d, J = 7.7 Hz), 7.64 (1H, t, J = 7.7 Hz), 7.72 (1H, d, J = 7.7 Hz).	Ex. 2
1778		1H-NMR (DMSO-d6) δ: 4.18 (2H, s), 5.21 (2H, s), 6.84 (1H, d, J = 7.7 Hz), 6.93-6.95 (2H, m), 7.26-7.30 (1H, m), 7.75 (2H, d, J = 8.0 Hz), 7.66 (2H, d, J = 8.0 Hz).	Ex. 2
1780		1H-NMR (DMSO-d6) δ: 3.03 (2H, t, J = 7.2 Hz), 3.14 (2H, t, J = 7.2 Hz), 5.24 (2H, s), 6.87 (1H, t, J = 7.6 Hz), 7.02-7.07 (2H, m), 7.18-7.22 (1H, m), 7.69 (2H, d, J = 8.0 Hz), 7.77 (2H, d, J = 8.0 Hz).	Ex. 2








Ex. No.	STR	1H-NMR	ref.
1781		1H-NMR (DMSO-d6) δ: 4.19 (2H, s), 5.23 (2H, s), 6.95 (1H, t, J = 7.3 Hz), 7.04 (1H, d, J = 8.2 Hz), 7.25-7.27 (2H, m), 7.49-7.51 (2H, m), 7.70 (2H, d, J = 8.1 Hz).	Ex. 2
1782		1H-NMR (DMSO-d6) δ: 2.84-2.95 (4H, m), 7.19-7.21 (1H, m), 7.29-7.38 (3H, m), 7.55-7.58 (2H, m), 7.67 (1H, t, J = 7.7 Hz), 7.74 (1H, d, J = 7.7 Hz).	Ex. 2
1783		1H-NMR (DMSO-d6) δ: 1.37-1.45 (4H, m), 5.21 (2H, s), 6.97-7.00 (2H, m), 7.22-7.25 (2H, m), 7.65 (2H, d, J = 8.0 Hz), 7.75 (2H, d, J = 8.0 Hz).	Ex. 2
1784		1H-NMR (DMSO-d6) δ: 3.08 (2H, t, J = 7.2 Hz), 3.21 (2H, t, J = 7.2 Hz), 7.21 (1H, d, J = 7.5 Hz), 7.40 (1H, t, J = 8.0 Hz), 7.57-7.59 (2H, m), 7.68-7.75 (2H, m), 7.93-7.96 (2H, m).	Ex. 2
1785		1H-NMR (DMSO-d6) δ: 7.42 (1H, dd, J = 1.7, 7.1 Hz), 7.83 (2H, d, J = 8.2 Hz), 8.15 (1H, s), 8.23 (2H, t, J = 8.2 Hz), 8.73 (1H, s), 8.77 (1H, d, J = 7.1 Hz).	Ex. 2
1786		1H-NMR (DMSO-d6) δ: 7.18 (1H, t, J = 7.1 Hz), 7.81-7.85 (3H, m), 8.35 (2H, d, J = 8.2 Hz), 8.75 (1H, s), 8.77 (1H, d, J = 6.8 Hz).	Ex. 2





[0848]


Ex. No.	STR	1H-NMR	ref.
1787		1H-NMR (CDCl3) δ: 1.53-1.71 (4H, m), 2.05-2.28 (4H, m), 2.90-3.05 (1H, m), 3.43-3.50 (1H, m), 4.61-4.66 (2H, m), 7.46-7.50 (2H, m), 7.59-7.62 (2H, m).	Ex. 2
1788		1H-NMR (DMSO-d6) δ: 8.06 (2H, d, J = 8.2 Hz), 8.25 (2H, d, J = 8.2 Hz).	Ref. Ex. 159, Ex. 1
1789		1H-NMR (DMSO-d6) δ: 6.26 (2H, s), 7.47 (1H, d, J = 1.4 Hz), 7.79 (1H, d, J = 1.4 Hz), 8.10 (1H, d, J = 8.3 Hz), 8.45 (1H, dd, J = 1.9, 8.3 Hz), 9.16 (1H, d, J = 1.9 Hz).	Ex. 1

Ex. No.	STR	m.p.	ref.
1790		205.4-210.8	Ex. 125

Ex. No.	STR	1H-NMR	ref.
1791		1H-NMR (DMSO-d6) δ: 5.75 (2H, s), 7.33-7.43 (5H, m), 8.80 (1H, s).	Ex. 125
1792		1H-NMR (DMSO-d6) δ: 7.68-7.71 (2H, m), 8.28-8.31 (2H, m).	Ex. 125

Ex. No.	STR	1H-NMR	ref.
1793		1H-NMR (DMSO-d6) δ: 7.39-7.43 (1H, m), 7.49-7.53 (2H, m), 7.77-7.80 (2H, m), 7.82 (1H, dd, J = 1.9, 8.6 Hz), 7.96 (1H, d, J = 8.6 Hz), 8.20 (1H, d, J = 1.9 Hz).	Ex. 125
1794		1H-NMR (DMSO-d6) δ: 7.53 (1H, dd, J = 2.0, 8.6 Hz), 7.93 (1H, d, J = 8.6 Hz), 8.11 (1H, d, J = 2.0 Hz).	Ex. 125
1795		1H-NMR (DMSO-d6) δ: 3.87 (3H, s), 7.09 (1H, dd, J = 2.4, 8.8 Hz), 7.51 (1H, d, J = 2.4 Hz), 7.81 (1H, d, J = 8.8 Hz).	Ex. 125
1796		1H-NMR (DMSO-d6) δ: 2.47 (3H, s), 7.35 (1H, dd, J = 1.1, 8.4 Hz), 7.73-7.74 (1H, m), 7.76 (1H, d, J = 8.4 Hz).	Ex. 125
1797		1H-NMR (DMSO-d6) δ: 7.85 (1H, d, J = 8.4 Hz), 7.91 (1H, dd, J = 2.3, 8.4 Hz), 8.31 (1H, d, J = 1.9 Hz), 8.49 (1H, d, J = 2.3 Hz), 9.29 (1H, d, J = 1.9 Hz).	Ex. 125
1798		1H-NMR (DMSO-d6) δ: 7.66-7.70 (2H, m), 8.10-8.14 (2H, m).	Ex. 125
1799		1H-NMR (DMSO-d6) δ: 2.32 (3H, d, J = 0.6 Hz), 7.39-7.40 (1H, m), 7.78 (1H, d, J = 3.2 Hz), 7.95 (1H, s), 8.17 (1H, d, J = 0.6 Hz), 8.23 (1H, s).	Ex. 125

Ex. No.	STR	1H-NMR	ref.
1800		1H-NMR (DMSO-d6) δ: 2.43 (3H, s), 2.49 (3H, s), 6.98 (1H, d, J = 1.0 Hz), 7.89 (1H, s), 8.13 (1H, s), 8.19 (1H, s).	Ex. 125
1801		1H-NMR (DMSO-d6) δ: 8.17 (1H, d, J = 0.3 Hz), 8.50 (1H, d, J = 0.3 Hz), 8.58 (1H, d, J = 1.8 Hz), 8.85 (1H, s), 9.32 (1H, d, J = 1.8 Hz).	Ex. 125
1803		1H-NMR (DMSO-d6) δ: 2.01 (3H, d, J = 0.5 Hz), 2.19 (3H, s), 7.32 (1H, dd, J = 1.1, 3.2 Hz), 7.37 (1H, d, J = 7.9 Hz), 7.41 (1H, d, J = 3.2 Hz), 7.75 (1H, dd, J = 1.7, 7.9 Hz), 7.83 (1H, d, J = 1.1 Hz).	Ex. 125
1804		1H-NMR (CDCl3) δ: 2.00-2.21 (4H, m), 4.27 (2H, t, J = 6.7 Hz), 6.65 (1H, dd, J = 0.7, 3.1 Hz), 7.18 (1H, d, J = 3.1 Hz), 7.45 (1H, d, J = 8.6 Hz), 7.68-7.85 (1H, m), 8.24 (1H, s), 12.2 (1H, br.).	Ex. 1


Ex. No.	STR	m.p.	ref.
1805		200.2-203.1	Ex. 125

[0849]

Example 1806

Synthesis of 3-(1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0850]



[0851]

4N HCl in AcOEt (6.02 ml, 24.08 mmol) was added to 3-(1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester (316 mg, 0.48 mmol) at 0°C. The reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by silica gel flash column chromatography (hexane:AcOEt = 95:5-35:65) to give the title compound (255 mg, 88%) as a white amorphous.

^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.01 (3H, d, J = 6.3 Hz), 4.19 (1H, d, J = 10.6 Hz), 4.30 (1H, d, J = 10.6 Hz), 5.36 (2H, s), 6.99 (1H, q, J = 6.3 Hz), 7.11 (1H, dd, J = 8.3 Hz, 2.5 Hz), 7.46 (1H, t, J = 8.0 Hz), 7.63 (1H, t, J = 2.3 Hz), 7.67 (1H, d, J = 7.8 Hz), 7.72 (1H, d, J = 8.2 Hz), 7.85 (1H, d, J = 8.2 Hz), 8.09 (1H, s).


[0852]

Example 1807

Synthesis of 3-{1-[4-(5-chloro-4'-trifluoromethoxy-biphenyl-3-

yl)-5-cyano-2H-[1,2,3]triazol-2-yl]-ethoxycarbonyloxy}-2,2-dimethyl-propionic acid

[0853]



[0854]

To a stirred solution of 3-{1-[4-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-5-cyano-2H-[1,2,3]triazol-2-yl]-ethoxycarbonyloxy}-2,2-dimethyl-propionic acid benzyl ester (483 mg, 0.751 mmol) in ethanol (5 ml) were added, under nitrogen, 10% Pd-C (483 mg) followed by 1,4-cyclohexadiene (0.711 ml, 7.51 mmol). The suspension was stirred at room temperature for 30 min. The catalyst was removed by filtration through Celite, and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel flash column chromatography (hexane:AcOEt =100:0-55:45) to give the title compound (188 mg, 45%) as a white amorphous.


^{1}H-NMR (DMSO-d_6) δ: 1.11 (3H, s), 1.12 (3H, s), 1.92 (3H, d, J = 6.1 Hz), 4.14 (1H, d, J = 10.2 Hz), 4.18 (1H, d, J = 10.2 Hz), 7.10 (1H, q, J = 6.1 Hz), 7.54 (2H, d, J = 8.5 Hz), 7.91 (2H, d, J = 8.5 Hz), 7.93 (1H, t, J = 1.6 Hz), 8.00 (1H, t, J = 1.6 Hz), 8.13 (1H, t, J = 1.4 Hz).

[0855]

Example 1808

Synthesis of 3-(1-{4-[3-chloro-5-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0856]



[0857]

The title compound was obtained using 3-(1-{4-[3-chloro-5-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester in the same manner as in Example 1806.

white amorphous


^{1}H-NMR ($CDCl_3$) δ: 1.27 (6H, s), 2.02 (3H, d, J = 6.3 Hz), 4.20 (1H, d, J = 10.5 Hz), 4.30 (1H, d, J = 10.5 Hz), 7.00 (1H, q, J = 6.3 Hz), 7.17 (1H, d, J = 8.1 Hz), 7.30-7.34 (2H, m), 7.61 (1H, t, J = 1.7 Hz), 7.97 (1H, t, J = 1.7 Hz), 8.03 (1H, t, J = 1.6 Hz).

[0858]

Example 1809

Synthesis of 3-(1-{4-cyano-5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0859]



[0860]

The title compound was obtained using 3-(1-{4-cyano-5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1807.

white amorphous

^{1}H-NMR (DMSO-d_6) δ: 1.11 (3H, s), 1.12 (3H, s), 1.93 (3H, d, J


= 6.1 Hz), 2.54 (3H, s), 4.15 (1H, d, J = 10.2 Hz), 4.19 (1H, d, J = 10.2 Hz), 7.10 (1H, q, J = 6.1 Hz), 7.97 (1H, s), 8.04 (1H, d, J = 5.0 Hz), 8.41 (1H, s), 8.83 (1H, s), 9.34 (1H, d, J = 4.9 Hz).

[0861]

Example 1810

Synthesis of 3-(1-{4-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0862]



[0863]

The title compound was obtained using 3-(1-{4-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester in the same manner as in Example 1806.

white amorphous


^{1}H-NMR ($CDCl_3$) δ: 1.27 (3H, s), 1.29 (3H, s), 2.03 (3H, d, J = 6.2 Hz), 4.23 (1H, d, J = 10.5 Hz), 4.29 (1H, d, J = 10.5 Hz), 7.00 (1H, q, J = 6.2 Hz), 7.62 (1H, d, J = 5.0 Hz), 8.15 (1H, t, J = 1.8 Hz), 8.62 (1H, t, J = 1.8 Hz), 9.02 (1H, t, J = 1.5 Hz), 9.17 (1H, d, J = 5.0 Hz).

[0864]

Example 1811

Synthesis of 3-[1-(4-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-5-cyano-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid

[0865]



[0866]

The title compound was obtained using 3-[1-(4-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-5-cyano-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid *tert*-butyl ester in the same manner as in Example 1806.

white amorphous


^{1}H-NMR ($CDCl_3$) δ: 1.27 (6H, s), 2.02 (3H, d, J = 6.2 Hz), 4.21 (1H, d, J = 10.5 Hz), 4.30 (1H, d, J = 10.5 Hz), 7.00 (1H, q, J = 6.2 Hz), 7.15 (1H, d, J = 16.3 Hz), 7.22 (1H, d, J = 16.3 Hz), 7.50 (1H, t, J = 7.7 Hz), 7.56 (1H, d, J = 7.8 Hz), 7.62 (1H, s), 7.70 (1H, d, J = 7.7 Hz), 7.78 (1H, s), 7.90 (1H, t, J = 1.5 Hz), 8.03 (1H, s).

[0867]

Example 1812

Synthesis of 3-(1-{4-cyano-5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0868]



[0869]

The title compound was obtained using 3-(1-{4-cyano-5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1814.

colorless powder


1H-NMR ($CDCl_3$) δ: 1.26 (3H, s), 1.34 (3H, s), 2.00 (3H, d, J = 6.2 Hz), 3.98 (3H, s), 4.00 (1H, d, J = 10.3 Hz), 4.52 (1H, d, J = 10.3 Hz), 6.89 (1H, q, J = 6.2 Hz), 7.48-7.52 (1H, m), 7.57-7.59 (1H, m), 7.71-7.72 (1H, m), 7.97 (1H, s), 8.25 (1H, t, J = 1.5 Hz), 9.11 (1H, d, J = 5.2 Hz).

[0870]

Example 1813

Synthesis of 3-[1-(4-cyano-5-{3-trifluoromethyl-5-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid

[0871]



[0872]

The title compound was obtained using 3-[1-(4-cyano-5-{3-trifluoromethyl-5-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1815.

white powder


^{1}H-NMR ($CDCl_3$) δ:1.27 (3H, s), 1.29 (3H, s), 2.03 (3H, d, J =6.2 Hz), 4.26 (2H, s), 7.01 (1H, q, J = 6.2 H), 7.39 (1H, d, d = 16.1 Hz), 7.59 (1H, d, J = 7.7 Hz), 7.64 (1H, J = 8.0 Hz), 7.81 (1H, d, J = 16.1 Hz), 7.90 (1H, t, J = 7.8 Hz), 7.94 (1H, s), 8.21 (1H, s), 8.42 (1H, s).

[0873]

Example 1814

Synthesis of 3-(1-{4-[2-(4-chloro-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0874]



[0875]

To a solution of 3-(1-{4-[2-(4-chloro-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester (325.3 mg, 0.575 mmol) in AcOEt (15 ml) under nitrogen was added 10% Pd/C (dry) (150 mg). The reaction mixture was stirred at room temperature for 3 hr under hydrogen. After filtration, 10% Pd/C (dry) (150 mg) was added to the filtrate. The reaction mixture was stirred at room temperature for 2 hr under hydrogen. After filtration, the filtrate was concentrated *in vacuo*. The residue was purified by silica gel flash column chromatography (AcOEt/hexane = 0% to 40%). The obtained oil was precipitated with hexane, and recrystallized from AcOEt/hexane (Recrystallization was repeated twice) to give the title compound (75 mg, 27%) as colorless prisms.


^{1}H-NMR ($CDCl_3$) δ: 1.26 (3H, s), 1.27 (3H, s), 2.02 (3H, d, J = 6.2 Hz), 4.21 (1H, d, J = 10.5 Hz), 4.32 (1H, d, J = 10.5 Hz), 6.99 (1H, q, J = 6.2 Hz), 7.43-7.47 (2H, m), 7.92-8.02 (3H, m).

[0876]

Example 1815

Synthesis of 3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid

[0877]



[0878]

To a solution of 3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid allyl ester (207.8 mg, 0.365 mmol) in THF (4 ml) were added AcOH (0.418 ml, 7.30 mmol), triphenylphosphine (9.57 mg, 0.036 mmol) and $Pd(Ph_3P)_4$ (21.08 mg, 0.018 mmol) in argon, and the reaction mixture was stirred for 2.5 hr at room temperature. The reaction mixture was concentrated *in vacuo*. The residue was purified by silica gel flash column chromatography (hexane/AcOEt = 0% to 50%), and recrystallized (AcOEt-hexane) to give the title compound (136 mg, 70%) as a white powder.


^{1}H-NMR ($CDCl_3$) δ: 1.27 (3H, s), 1.41 (3H, s), 1.99 (3H, d, J = 6.2 Hz), 3.90 (1H, d, J = 10.4 Hz), 4.63 (1H, d, J = 10.4 Hz), 6.89 (1H, q, J = 6.2 Hz), 7.43-7.46 (1H, m), 7.52-7.57 (2H, m), 7.58 (1H, d, J = 16.5 Hz), 7.75 (1H, d, J = 16.5 Hz), 7.89 (1H, s), 7.97-8.00 (1H, m), 8.44 (1H, s), 8.79 (1H, d, J = 5.0 Hz).

[0879]

Example 1816

Synthesis of 3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid

[0880]



[0881]

The title compound was obtained using 3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1815.

colorless powder


^{1}H-NMR ($CDCl_3$) δ: 1.27 (3H, s), 1.35 (3H, s), 2.00 (3H, d, J = 6.2 Hz), 4.07 (1H, d, J = 10.4 Hz), 4.46 (1H, d, J = 10.4 Hz), 6.94 (1H, q, J = 6.2 Hz), 7.49 (1H, d, J = 5.0 Hz), 7.56 (1H, t, J = 7.8 Hz), 7.62 (1H, d, J = 15.9 Hz), 7.68 (1H, d, J = 7.8 Hz), 8.00-8.03 (1H, m), 8.17 (1H, d, J = 15.9 Hz), 8.38 (1H, s), 8.95 (1H, d, J = 5.0 Hz).

[0882]

Example 1817

Synthesis of 3-(1-{4-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0883]



[0884]

The title compound was obtained using 3-(1-{4-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1815.

pale brown powder


^{1}H-NMR (DMSO-d_6) δ: 1.11 (3H, s), 1.12 (3H, s), 1.93 (3H, d, J = 6.1 Hz), 4.15 (1H, d, J = 10.3 Hz), 4.19 (1H, d, J = 10.3 Hz), 7.10 (1H, q, J = 6.2 Hz), 7.83 (1H, t, J = 7.8 Hz), 7.95 (1H, d, J = 7.8 Hz), 8.27 (1H, d, J = 7.8 Hz), 8.35 (1H, s), 12.52 (1H, brs).

[0885]

Example 1818

Synthesis of 3-(1-{4-cyano-5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0886]



[0887]

The title compound was obtained using 3-(1-{4-cyano-5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1814.

colorless powder


^{1}H-NMR (DMSO-d_6) δ: 1.11 (6H, s), 1.92 (3H, d, J = 6.1 Hz), 4.15 (1H, d, J = 10.3 Hz), 4.18 (1H, d, J = 10.3 Hz), 7.08 (1H, q, J = 6.1 Hz), 7.56-7.58 (1H, m), 7.72 (1H, t, J = 8.0 Hz), 8.04-8.08 (2H, m), 8.49 (1H, s).

[0888]

Example 1819

Synthesis of 3-(1-{4-cyano-5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0889]



[0890]

The title compound was obtained using 3-(1-{4-cyano-5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1815.

pale brown powder


^{1}H-NMR (DMSO-d_6) δ: 1.11 (3H, s), 1.12 (3H, s), 1.92 (3H, d, J = 6.1 Hz), 4.14 (1H, d, J = 10.3 Hz), 4.18 (1H, d, J = 10.3 Hz), 7.07 (1H, q, J = 6.1 Hz), 7.86 (1H, d, J = 8.4 Hz), 8.03 (1H, dd, J = 2.1, 8.4 Hz), 8.27 (1H, d, J = 2.1 Hz), 12.54 (1H, brs).

[0891]

Example 1820

Synthesis of 3-(1-{4-cyano-5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0892]



[0893]

The title compound was obtained using 3-(1-{4-cyano-5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1814.

white powder


^{1}H-NMR ($CDCl_3$) δ: 1.26 (3H, s), 1.27 (3H, s), 2.03 (3H, d, J = 6.2 Hz), 2.81 (3H, s), 4.22 (1H, d, J = 10.6 Hz), 4.27 (1H, d, J = 10.6 Hz), 7.01 (1H, q, J = 6.2 Hz), 7.72 (2H, d, J = 8.3 Hz), 7.85 (2H, d, J = 8.3 Hz).

[0894]

Example 1821

Synthesis of 3-(1-{4-cyano-5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0895]



[0896]

The title compound was obtained using 3-(1-{4-cyano-5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1815.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (3H, s), 1.27 (3H, s), 2.01 (3H, d, J = 6.2 Hz), 4.23 (1H, d, J = 10.5 Hz), 4.27 (1H, d, J = 10.5 Hz), 5.50 (2H, s), 6.98 (1H, q, J = 6.2 Hz), 7.06-7.07 (1H, m), 7.10-7.11 (1H, m), 7.52 (1H, t, J = 7.6 Hz), 7.56-7.58 (1H, m), 7.96-7.98 (1H, m), 8.11 (1H, s), 8.35 (1H, d, J = 5.3 Hz).

[0897]

Example 1822

Synthesis of 3-(1-{4-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0898]



[0899]

The title compound was obtained using 3-(1-{4-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1807.

white powder


^{1}H-NMR (DMSO-d_6) δ: 1.10 (3H, s), 1.11 (3H, s), 1.35 (3H, d, J = 2.0 Hz), 1.36 (3H, d, J = 2.0 Hz), 1.91 (3H, d, J = 6.1 Hz), 3.61-3.68 (1H, m), 4.11-4.19 (2H, m), 7.07 (1H, q, J = 6.1 Hz), 7.68 (2H, d, J = 8.6 Hz), 8.03 (2H, d, J = 8.6 Hz).

[0900]

Example 1823

Synthesis of 3-(1-{4-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0901]



[0902]

The title compound was obtained using 3-(1-{4-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1814.

colorless powder


^{1}H-NMR (DMSO-d_6) δ: 1.11 (3H, s), 1.12 (3H, s), 1.93 (3H, d, J = 6.1 Hz), 2.79 (3H, s), 4.15 (1H, d, J = 10.3 Hz), 4.18 (1H, d, J = 10.3 Hz), 7.08 (1H, q, J = 6.1 Hz), 7.63 (1H, t, J = 8.9 Hz), 7.96-7.99 (1H, m), 8.16 (1H, dd, J = 2.2, 7.0 Hz), 12.54 (1H, brs).

[0903]

Example 1824

Synthesis of 3-(1-{4-cyano-5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0904]



[0905]

The title compound was obtained using 3-(1-{4-cyano-5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1814.

colorless powder


^{1}H-NMR (DMSO-d_6) δ: 1.09 (3H, s), 1.10 (3H, s), 1.22 - 1.25 (4H, m), 1.92 (3H, d, J = 6.1 Hz), 2.59-2.64 (1H, m), 4.14 (1H, d, J = 10.2 Hz), 4.16 (1H, d, J = 10.2 Hz), 7.06 (1H, q, J = 6.1 Hz), 7.83 (1H, t, J = 7.8 Hz), 7.94 (1H, d, J = 7.8 Hz), 8.21 (1H, s), 8.26 (1H, d, J = 7.8 Hz).

[0906]

Example 1825

Synthesis of 3-(1-{4-cyano-5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0907]



[0908]

The title compound was obtained using 3-(1-{4-cyano-5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic

acid benzyl ester in the same manner as in Example 1807.

white amorphous


^{1}H-NMR ($CDCl_3$) δ: 1.26 (3H, s), 1.27 (3H, s), 2.02 (3H, d, J = 6.3 Hz), 2.54 (3H, s), 4.25 (2H, s), 7.00 (1H, q, J = 6.2 Hz), 7.53 (1H, s), 7.79 (1H, d, J = 8.1 Hz), 7.90 (1H, s), 8.04 (1H, s), 8.11 (1H, dd, J = 8.1, 2.0 Hz), 9.03 (1H, d, J = 1.8 Hz).

[0909]

Example 1826

Synthesis of 3-(1-{4-cyano-5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid

[0910]



[0911]

The title compound was obtained using 3-(1-{4-cyano-5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1814.

colorless powder


1H-NMR ($CDCl_3$) δ: 1.27 (6H, s), 1.42 (3H, t, J = 7.5 Hz), 2.03 (3H, d, J = 6.2 Hz), 3.30 (2H, q, J = 7.5 Hz), 4.21 (1H, d, J = 10.5 Hz), 4.29 (1H, d, J = 10.5 Hz), 7.02 (1H, q, J = 6.2 Hz), 8.04-8.06 (1H, m), 8.44 (1H, d, J = 8.2 Hz), 8.84 (1H, s).

[0912]

Example 1827

Synthesis of 3-(1-{4-[3-(2,5-bis-trifluoromethylbenzyloxy)phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}ethoxycarbonyloxy)-3-methylbutyric acid

[0913]



[0914]

The title compound was obtained using 3-(1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-3-methyl-butyric acid benzyl ester in the same manner as in Example 1814.

colorless powder

Melting point 90.1-94.2°C


^{1}H-NMR ($CDCl_3$) δ: 1.59 (6H, s), 1.99 (3H, d, J = 6.2 Hz), 2.91 (1H, d, J = 14.6 Hz), 2.96 (1H, d, J = 14.6 Hz), 5.36 (2H, s), 6.95 (1H, q, J = 6.2 Hz), 7.09-7.12 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.63-7.64 (1H, m), 7.67-7.69 (1H, m), 7.72 (1H, d, J = 8.3 Hz), 7.85 (1H, d, J = 8.3 Hz), 8.09 (1H, s).

[0915]

Example 1828

Synthesis of carbonic acid 1-{4-[3-(2,5-bis-trifluoromethylbenzyloxy)phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}ethyl ester 2-hydroxyethyl ester

[0916]



[0917]

To a solution of carbonic acid 1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethyl ester 2-(tetrahydro-pyran-2-yloxy)-ethyl ester (0.79 g, 1.257 mmol) in THF (8 ml) was added 1N HCl (3.77 ml, 3.77 mmol). The reaction mixture was stirred at room temperature overnight. The organic solution was concentrated. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed

with brine, dried over magnesium sulfate, and concentrated *in vacuo*. The residue was purified by silica gel flash column chromatography (8%-66% AcOEt/hexane) to give colorless oil. The oil was dissolved in AcOEt and precipitated with hexane then recrystallized from AcOEt/hexane to give the title compound (0.35 g, 51%) as a colorless powder.

Melting point 70.1-73.0°C


^{1}H-NMR ($CDCl_3$) δ: 1.81 (1H, t, J = 6.2 Hz), 3.02 (3H, d, J = 6.2 Hz), 3.85-3.89 (2H, m), 4.26-4.38 (2H, m), 5.37 (2H, s), 7.01 (1H, q, J = 6.2 Hz), 7.10-7.13 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.63-7.64 (1H, m), 7.67-7.69 (1H, m), 7.72 (1H, d, J = 8.0 Hz), 7.85 (1H, d, J = 8.0 Hz), 8.09 (1H, s).

[0918]

Example 1829

Synthesis of acetic acid 4-cyano-5-[3-methyl-5-(4-trifluoromethylpyrimidin-2-yl)phenyl]-2H-[1,2,3]triazol-2-ylmethyl ester

[0919]



[0920]

To a stirred solution of 5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (250 mg, 0.757 mmol) in DMF (10 ml) was added NaH (36.3 mg, 0.833 mmol) at 0°C. After the reaction mixture was stirred at the same temperature for 15 minutes, chloromethyl acetate (123 mg, 1.135 mmol) was added thereto, and the mixture was stirred at room temperature for 5 hr. Saturated NH_4Cl solution was added to the reaction mixture at 0°C, and the precipitate was collected by filtration, washed with water, and dried at 60°C. The crude product was purified by recrystallization from CH_3CN to give the title compound (205 mg,

67%) as a colorless powder.


^{1}H-NMR (DMSO-d_6) δ: 2.15 (3H, s), 2.54 (3H, s), 6.48 (2H, s), 7.97 (1H, s), 8.04 (1H, d, J = 5.0 Hz), 8.41 (1H, s), 8.83 (1H, s), 9.34 (1H, d, J = 5.0 Hz).

[0921]

Example 1830

Synthesis of acetic acid 4-{3-chloro-5-[(E)-2-(3-trifluoromethylphenyl)vinyl]phenyl}-5-cyano-2H-[1,2,3]triazol-2-ylmethyl ester

[0922]



[0923]

The title compound was obtained using 5-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile and chloromethyl acetate in the same manner as in Example 1829.

white powder


^{1}H-NMR (DMSO-d_6) δ: 2.15 (3H, s), 6.47 (2H, s), 7.60 (2H, s),7.64-7.69 (2H, m), 7.83 (1H, t, J = 1.6 Hz), 7.96 (1H, d, J = 7.1 Hz), 8.00 (1H, t, J = 1.6 Hz), 8.04 (1H, s), 8.04-8.06 (1H, m).

[0924]

Example 1831

Synthesis of butyric acid 4-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-5-cyano-2H-[1,2,3]triazol-2-ylmethyl ester

[0925]



[0926]

The title compound was obtained using 5-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile and chloromethyl butyrate in the same manner as in Example 1829.

white powder


^{1}H-NMR (DMSO-d_6) δ: 0.88 (3H, t, J = 7.4 Hz), 1.53-1.61 (2H, m), 2.42 (2H, t, J = 7.3 Hz), 6.49 (2H, s), 7.59 (2H, s), 7.62-7.69 (2H, m), 7.82-7.83 (1H, m), 7.96 (1H, d, J = 6.7 Hz), 7.98-8.00 (1H, m), 8.03 (1H, s), 8.04-8.06 (1H, m).

[0927]

Example 1832

Synthesis of butyric acid 4-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-ylmethyl ester

[0928]



[0929]

The title compound was obtained using 5-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile and chloromethyl butyrate in the same manner as in Example 1829.

white powder

^{1}H-NMR (DMSO-d_6) δ: 0.88 (3H, t, J = 7.4 Hz), 1.53-1.61 (2H, m),


2.42 (2H, t, J = 7.3 Hz), 6.52 (2H, s), 8.10 (1H, d, J = 5.0 Hz), 8.15-8.17 (1H, m), 8.51-8.53 (1H, m), 8.91-8.93 (1H, m), 9.37 (1H, d, J = 5.0 Hz).

[0930]

Example 1833

Synthesis of butyric acid 1-{4-cyano-5-[3-methyl-5-(4-trifluoromethylpyrimidin-2-yl)phenyl]-2H-[1,2,3]triazol-2-yl}ethyl ester

[0931]



[0932]

To a stirred solution of 5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (350 mg, 1.060 mmol) in DMF (8 ml) were added K_2CO_3 (439 mg, 3.18 mmol) and 1-iodoethyl butyrate (641 mg, 2.65 mmol). The reaction mixture was stirred at 80°C overnight. Water was added to the reaction mixture at 0°C, and the precipitate was collected by filtration, washed with water, and dried at 60°C. The crude product was purified by silica gel flash column chromatography (hexane:AcOEt = 100:0-75:25) and recrystallization from CH_3CN to give the title compound (187 mg, 40%) as a white powder.

^{1}H-NMR ($CDCl_3$) δ: 0.95 (3H, t, J = 7.5 Hz), 1.65-1.72 (2H, m), 1.97 (3H, d, J = 6.2 Hz), 2.38 (2H, t, J = 7.4 Hz), 2.55 (3H, s), 7.17 (1H, q, J = 6.2 Hz), 7.56 (1H, d, J = 4.9 Hz), 7.97 (1H, s), 8.45 (1H, s), 8.95 (1H, s), 9.09 (1H, d, J = 4.9 Hz).


[0933]

Example 1834

Synthesis of isobutyric acid 1-(4-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-5-cyano-2H-

[1,2,3]triazol-2-yl)-ethyl ester

[0934]



[0935]

The title compound was obtained using 5-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile and 1-chloroethyl isobutyrate in the same manner as in Example 1833.

white powder


^{1}H-NMR (DMSO-d_6) δ: 1.07 (3H, d, J = 7.0 Hz), 1.12 (3H, d, J = 7.0 Hz), 1.90 (3H, d, J = 6.2 Hz), 2.60-2.66 (1H, m), 7.18 (1H, q, J = 6.2 Hz), 7.59 (2H, s), 7.63-7.69 (2H, m), 7.83 (1H, t, J = 1.6 Hz), 7.96 (1H, d, J = 7.0 Hz), 7.99-8.00 (1H, m), 8.03 (1H, s), 8.04-8.06 (1H, m).

[0936]

Example 1835

Synthesis of isobutyric acid 1-{4-cyano-5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethyl ester

[0937]



[0938]

The title compound was obtained using 5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 1-chloroethyl isobutyrate in the same manner as in Example 1833.

white powder


^{1}H-NMR (DMSO-d_6) δ: 1.07 (3H, d, J = 6.9 Hz), 1.11 (3H, d, J = 6.9 Hz), 1.20-1.25 (4H, m), 1.89 (3H, d, J = 6.2 Hz), 2.59-2.66 (2H, m), 7.17 (1H, q, J = 6.2 Hz), 7.83 (1H, t, J = 7.9 Hz), 7.94 (1H, d, J = 7.9 Hz), 8.21 (1H, s), 8.26 (1H, d, J = 7.9 Hz).

[0939]

Example 1836

Synthesis of 3-(1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester

[0940]



[0941]

To a solution of 5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (500 mg, 1.213 mmol) in DMF (2.5 ml) were added sodium bicarbonate (408 mg, 4.85 mmol) and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester (375 mg, 1.334 mmol). The reaction mixture was stirred at 60°C overnight. Water was added to the reaction mixture, and the mixture was extracted twice with AcOEt. The combined organic layers were washed with water, brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by silica gel flash column chromatography (hexane:AcOEt = 100:0-75:25) to give the title compound (316 mg, 40%) as a colorless oil.

^{1}H-NMR ($CDCl_3$) δ: 1.18 (3H, s), 1.19 (3H, s), 1.39 (9H, s), 2.01 (3H, d, J = 6.2 Hz), 4.20 (2H, s), 5.36 (2H, s), 7.00 (1H, q, J = 6.2 Hz), 7.11 (1H, dd, J = 8.3 Hz, 2.5 Hz), 7.46 (1H, t, J = 8.0 Hz), 7.63 (1H, t, J = 2.3 Hz), 7.68 (1H, d, J = 7.8 Hz), 7.72 (1H, d, J = 8.2 Hz), 7.86 (1H, d, J = 8.2 Hz), 8.09


(1H, s).

[0942]

Example 1837

Synthesis of 3-{1-[4-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-5-cyano-2H-[1,2,3]triazol-2-yl]-ethoxycarbonyloxy}-2,2-dimethyl-propionic acid benzyl ester

[0943]



[0944]

The title compound was obtained using 5-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.00 (3H, d, J = 6.2 Hz), 4.22 (1H, d, J = 10.5 Hz), 4.31 (1H, d, J = 10.5 Hz), 5.10 (1H, d, J = 12.4 Hz), 5.13 (1H, d, J = 12.4 Hz), 6.96 (1H, q, J = 6.2 Hz), 7.27-7.36 (7H, m), 7.62-7.67 (3H, m), 7.97 (1H, t, J = 1.5 Hz), 8.07 (1H, t, J = 1.5 Hz).

[0945]

Example 1838

Synthesis of 3-(1-{4-[3-chloro-5-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester

[0946]



[0947]

The title compound was obtained using 5-[3-chloro-5-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.18 (3H, s), 1.19 (3H, s), 1.40 (9H, s), 2.02 (3H, d, J = 6.3 Hz), 4.21 (2H, s), 7.00 (1H, q, J = 6.3 Hz), 7.17 (1H, d, J = 8.1 Hz), 7.31-7.35 (2H, m), 7.60-7.62 (1H, m), 7.96-7.98 (1H, m), 8.02-8.04 (1H, m).

[0948]

Example 1839

Synthesis of 3-(1-{4-cyano-5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[0949]



[0950]

The title compound was obtained using 5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example

1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.25 (3H, s), 1.26 (3H, s), 2.01 (3H, d, J = 6.3 Hz), 2.55 (3H, s), 4.22 (1H, d, J = 10.6 Hz), 4.32 (1H, d, J = 10.6 Hz), 5.10 (1H, d, J = 12.5 Hz), 5.14 (1H, d, J = 12.5 Hz), 6.98 (1H, q, J = 6.3 Hz), 7.27-7.36 (5H, m), 7.55 (1H, d, J = 5.0 Hz), 7.96 (1H, s), 8.45 (1H, s), 8.95 (1H, s), 9.08 (1H, d, J = 5.0 Hz).

[0951]

Example 1840

Synthesis of 3-(1-{4-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester

[0952]



[0953]

The title compound was obtained using 5-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.18 (3H, s), 1.19 (3H, s), 1.40 (9H, s), 2.03 (3H, d, J = 6.2 Hz), 4.21 (2H, s), 7.03 (1H, q, J = 6.2 Hz), 7.61 (1H, d, J = 5.0 Hz), 8.14 (1H, t, J = 1.9 Hz), 8.63 (1H, d, J = 1.9 Hz), 9.07-9.08 (1H, m), 9.12 (1H, d, J = 4.9 Hz).

[0954]

Example 1841

Synthesis of 3-[1-(4-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-5-cyano-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid *tert*-butyl ester

[0955]



[0956]

The title compound was obtained using 5-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid *tert*-butyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.18 (3H, s), 1.19 (3H, s), 1.40 (9H, s), 2.02 (3H, d, J = 6.2 Hz), 4.21 (2H, s), 7.01 (1H, q, J = 6.2 Hz), 7.16 (1H, d, J = 16.3 Hz), 7.23 (1H, d, J = 16.3 Hz), 7.51 (1H, t, J = 7.8 Hz), 7.56 (1H, d, J = 7.9 Hz), 7.63 (1H, s), 7.71 (1H, d, J = 7.6 Hz), 7.79 (1H, s), 7.91 (1H, t, J = 1.5 Hz), 8.04 (1H, s).

[0957]

Example 1842

Synthesis of 3-(1-{4-cyano-5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[0958]



[0959]

The title compound was obtained using 5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.00 (3H, d, J = 6.3 Hz), 2.81 (3H, s), 4.21 (1H, d, J = 10.4 Hz), 4.31 (1H, d, J = 10.4 Hz), 5.11 (1H, d, J = 12.6 Hz), 5.14 (1H, d, J = 12.6 Hz), 6.98 (1H, q, J = 6.3 Hz), 7.27-7.36 (5H, m), 7.71 (2H, d, J = 8.3 Hz), 8.11 (2H, d, J = 8.3 Hz).

[0960]

Example 1843

Synthesis of 3-(1-{4-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[0961]



[0962]

The title compound was obtained using 5-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil

^{1}H-NMR ($CDCl_3$) δ: 1.25 (3H, s), 1.26 (3H, s), 1.37 (3H, d, J = 1.8 Hz), 1.38 (3H, d, J = 1.8 Hz), 1.98 (3H, d, J = 6.3 Hz), 3.62-3.70 (1H, m), 4.20 (1H, d, J = 10.4 Hz), 4.32 (1H, d, J = 10.4 Hz), 5.11-5.15 (2H, m), 6.96 (1H, q, J = 6.3 Hz), 7.28-


7.37 (5H, m), 7.45 (2H, d, J = 8.6 Hz), 8.03 (2H, d, J = 8.6 Hz).

[0963]

Example 1844

Synthesis of 3-(1-{4-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[0964]



[0965]

The title compound was obtained using 5-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.00 (3H, d, J = 6.2 Hz), 2.78 (3H, s), 4.21 (1H, d, J = 10.4 Hz), 4.31 (1H, d, J = 10.4 Hz), 5.10 (1H, d, J = 12.5 Hz), 5.15 (1H, d, J = 12.5 Hz), 6.98 (1H, q, J = 6.2 Hz), 7.23 (1H, t, J = 8.6 Hz), 7.27-7.37 (5H, m), 7.90-7.94 (1H, m), 8.00 (1H, dd, J = 2.2, 6.9 Hz).

[0966]

Example 1845

Synthesis of 3-(1-{4-cyano-5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[0967]



[0968]

The title compound was obtained using 5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.16-1.22 (4H, m), 1.24 (6H, s), 1.99 (3H, d, J = 6.2 Hz), 2.59-2.65 (1H, m), 4.22 (1H, d, J = 10.4 Hz), 4.31 (1H, d, J = 10.4 Hz), 5.11 (1H, d, J = 12.5 Hz), 5.15 (1H, d, J = 12.5 Hz), 6.97 (1H, q, J = 6.2 Hz), 7.28-7.37 (5H, m), 7.59 (1H, t, J = 7.8 Hz), 7.69 (1H, d, J = 7.8 Hz), 8.19 (1H, s), 8.26 (1H, d, J = 7.8 Hz).

[0969]

Example 1846

Synthesis of 3-(1-{4-cyano-5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[0970]



[0971]

The title compound was obtained using 5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-

propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.00 (3H, d, J = 6.2 Hz), 2.54 (3H, s), 4.22 (1H, d, J = 10.5 Hz), 4.30 (1H, d, J = 10.5 Hz), 5.11 (2H, d, J = 4.0 Hz), 6.97 (1H, q, J = 6.2 Hz), 7.27-7.37 (5H, m), 7.53 (1H, s), 7.78 (1H, d, J = 8.1 Hz), 7.90 (1H, s), 8.01 (1H, s), 8.09 (1H, dd, J = 8.1, 2.1 Hz), 8.98 (1H, d, J = 1.9 Hz).

[0972]

Example 1847

Synthesis of 3-(1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-3-methyl-butyric acid benzyl ester

[0973]



[0974]

The title compound was obtained using 5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-3-methyl-butyric acid benzyl ester in the same manner as in Example 1836.

colorless oil

^{1}H-NMR ($CDCl_3$) δ: 1.56 (3H, s), 1.57 (3H, s), 1.92 (3H, d, J = 6.3 Hz), 2.89 (1H, d, J = 14.4 Hz), 3.02 (1H, d, J = 14.4 Hz), 5.09 (2H, s), 5.35 (2H, s), 6.90 (1H, q, J = 6.3 Hz), 7.10 (1H, dd, J = 2.3, 8.0 Hz), 7.27-7.36 (5H, m), 7.45 (1H, t, J = 8.0 Hz), 7.63 (1H, t, J = 2.3 Hz), 7.66 (1H, d, J = 8.1 Hz), 7.72 (1H, d, J = 8.1 Hz), 7.85 (1H, d, J = 8.1 Hz), 8.09 (1H, s).


[0975]

Example 1848

Synthesis of carbonic acid 1-{4-[3-(2,5-bis-trifluoromethyl-

benzyloxy)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethyl ester 2-(tetrahydro-pyran-2-yloxy)-ethyl ester

[0976]



[0977]

The title compound was obtained using 5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile and carbonic acid 1-chloro-ethyl ester 2-(tetrahydro-2H-pyran-2-yloxy)-ethyl ester in the same manner as in Example 1836.

pale yellow oil


^{1}H-NMR ($CDCl_3$) δ: 1.48-1.52 (2H, m), 1.53-1.63 (2H, m), 1.64-1.73 (1H, m), 1.74-1.82 (1H, m), 2.01 (3H, d, J = 6.2 Hz), 3.47-3.51 (1H, m), 3.64-3.69 (1H, m), 3.79-3.83 (1H, m), 3.89-3.96 (1H, m), 4.32-4.43 (2H, m), 4.61-4.63 (1H, m), 5.36 (2H, s), 7.01 (1H, q, J = 6.2 Hz), 7.10-7.13 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.63-7.64 (1H, m), 7.67-7.69 (1H, m), 7.72 (1H, d, J = 8.1 Hz), 7.85 (1H, d, J = 8.1 Hz), 8.09 (1H, s).

[0978]

Example 1849

Synthesis of 3-[1-(4-cyano-5-{3-trifluoromethyl-5-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid allyl ester

[0979]



[0980]

The title compound was obtained using 5-{3-trifluoromethyl-5-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.04 (3H, d, J = 6.2 Hz), 4.24 (1H, d, J = 10.5 Hz), 4.30 (1H, d, J = 10.5 Hz), 4.56-4.60 (2H, m), 5.19-5.23 (1H, m), 5.25-5.31 (1H, m), 5.82-5.93 (1H, m), 7.01 (1H, q, J = 6.2 Hz), 7.36 (1H, d, J = 16.1 Hz), 7.59 (1H, d, J = 7.7 Hz), 7.62 (1H, J = 7.8 Hz), 7.83 (1H, d, J = 16.1 Hz), 7.89 (1H, t, J = 7.8 Hz), 7.96 (1H, s), 8.20 (1H, s), 8.41 (1H, s).

[0981]

Example 1850

Synthesis of 3-(1-{4-[2-(4-chloro-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[0982]



[0983]

The title compound was obtained using 5-[2-(4-chloro-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 1.99 (3H, d, J = 6.2 Hz), 4.22 (1H, d, J = 10.5 Hz), 4.30 (1H, d, J = 10.5 Hz), 5.10 (1H, d, J = 12.5 Hz), 5.14 (1H, d, J = 12.5 Hz), 6.97 (1H, q, J = 6.2 Hz), 7.26-7.36 (5H, m), 7.43-7.47 (2H, m), 7.49 (1H, s), 7.99-8.02 (2H, m).

[0984]

Example 1851

Synthesis of 3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid allyl ester

[0985]



[0986]

The title compound was obtained using 5-{3-[(E)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.03 (3H, d, J = 6.2 Hz), 4.23 (1H, d, J = 10.5 Hz), 4.30 (1H, d, J = 10.5 Hz), 4.56-4.60 (2H, m), 5.17-5.22 (1H, m), 5.25-5.31 (1H, m), 5.82-5.91 (1H, m), 7.00 (1H, q, J = 6.2 Hz), 7.31 (1H, d, J = 16.1 Hz), 7.38-7.40 (1H, m), 7.55 (1H, t, J = 7.8 Hz), 7.62 (1H, s), 7.69-7.72 (1H, m), 7.81 (1H, d, J = 16.1 Hz), 7.96-8.00 (1H, m), 8.24 (1H, s), 8.79 (1H, d, J = 5.0 Hz).

[0987]

Example 1852

Synthesis of 3-(1-{4-cyano-5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester

[0988]



[0989]

The title compound was obtained using 5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.25 (6H, s), 2.02 (3H, d, J = 6.2 Hz), 4.22 (1H, d, J = 10.4 Hz), 4.29 (1H, d, J = 10.4 Hz), 4.57-4.59 (2H, m), 5.19-5.23 (1H, m), 5.26-5.31 (1H, m), 5.82-5.92 (1H, m), 7.00 (1H, q, J = 6.2 Hz), 7.56 (1H, d, J = 8.4 Hz), 7.93 (1H, dd, J = 2.1, 8.4 Hz), 7.99 (1H, s), 8.12 (1H, d, J = 2.1 Hz).

[0990]

Example 1853

Synthesis of 3-(1-{4-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester

[0991]



[0992]

The title compound was obtained using 5-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1836.

colorless oil

^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.04 (3H, d, J = 6.2 Hz), 4.22


(1H, d, J = 10.4 Hz), 4.30 (1H, d, J = 10.4 Hz), 4.58-4.60 (2H, m), 5.20-5.23 (1H, m), 5.26-5.32 (1H, m), 5.83-5.93 (1H, m), 7.04 (1H, q, J = 6.2 Hz), 7.63 (1H, t, J = 7.8 Hz), 7.74 (1H, d, J = 7.8 Hz), 8.14 (1H, s), 8.23 (1H, d, J = 7.8 Hz).

[0993]

Example 1854

Synthesis of 3-(1-{4-cyano-5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[0994]



[0995]

The title compound was obtained using 5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.00 (3H, d, J = 6.2 Hz), 3.97 (3H, s), 4.23 (1H, d, J = 10.5 Hz), 4.32 (1H, d, J = 10.5 Hz), 5.10 (1H, d, J = 12.4 Hz), 5.14 (1H, d, J = 12.4 Hz), 6.98 (1H, q, J = 6.2 Hz), 7.28-7.36 (5H, m), 7.51 (1H, dd, J = 0.7, 5.0 Hz), 7.64 (1H, dd, J = 1.5, 2.4 Hz), 7.74 (1H, dd, J = 1.5, 2.4 Hz), 7.98 (1H, s), 8.22 (1H, t, J = 1.5 Hz), 8.90 (1H, d, J = 5.0 Hz).

[0996]

Example 1855

Synthesis of 3-(1-{4-cyano-5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[0997]



[0998]

The title compound was obtained using 5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.59 (6H, s), 2.00 (3H, d, J = 6.2 Hz), 4.22 (1H, d, J = 10.5 Hz), 4.31 (1H, d, J = 10.5 Hz), 5.12 (2H, d, J = 2.5 Hz), 6.97 (1H, q, J = 6.2 Hz), 7.28-7.40 (6H, m), 7.52 (1H, t, J = 8.0 Hz), 7.91 (1H, s), 7.98 (1H, s), 8.00-8.03 (1H, m).

[0999]

Example 1856

Synthesis of 3-(1-{4-cyano-5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester

[1000]



[1001]

The title compound was obtained using 5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1836.

colorless oil

^{1}H-NMR ($CDCl_3$) δ: 1.25 (6H, s), 2.00 (3H, d, J = 6.2 Hz), 4.22


(1H, d, J = 10.5 Hz), 4.29 (1H, d, J = 10.5 Hz), 4.57 (1H, t, J = 1.4 Hz), 4.58 (1H, t, J = 1.4 Hz), 5.18-5.23 (1H, m), 5.25-5.33 (1H, m), 5.50 (2H, s), 5.81-5.93 (1H, m), 6.99 (1H, q, J = 6.2 Hz), 7.07-7.08 (1H, m), 7.10-7.11 (1H, m), 7.49-7.55 (1H, m), 7.57-7.59 (1H, m), 7.96-7.99 (1H, m), 8.11-8.12 (1H, m), 8.34 (1H, d, J = 5.3 Hz).

[1002]

Example 1857

Synthesis of 3-(1-{4-cyano-5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester

[1003]



[1004]

The title compound was obtained using 5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid benzyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 1.42 (3H, t, J = 7.5 Hz), 2.00 (3H, d, J = 6.2 Hz), 3.30 (2H, q, J = 7.5 Hz), 4.21 (1H, d, J = 10.4 Hz), 4.32 (1H, d, J = 10.4 Hz), 5.13 (2H, d, J = 2.4 Hz), 6.99 (1H, q, J = 6.2 Hz), 7.28-7.36 (5H, m), 8.05 (1H, dd, J = 1.9, 8.4 Hz), 8.45 (1H, d, J = 8.4 Hz), 8.84-8.85 (1H, m).

[1005]

Example 1858

Synthesis of 3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid allyl ester

[1006]



[1007]

The title compound was obtained using 5-{3-[(E)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile and 3-(1-chloro-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid allyl ester in the same manner as in Example 1836.

colorless oil


^{1}H-NMR ($CDCl_3$) δ: 1.26 (6H, s), 2.03 (3H, d, J = 6.2 Hz), 4.23 (1H, d, J = 10.5 Hz), 4.30 (1H, d, J = 10.5 Hz), 4.57 (1H, t, J = 1.4 Hz), 4.59 (1H, t, J = 1.4 Hz), 5.18-5.22 (1H, m), 5.25-5.31 (1H, m), 5.82-5.92 (1H, m), 7.00 (1H, q, J = 6.2 Hz), 7.40 (1H, d, J = 16.0 Hz), 7.46 (1H, d, J = 4.9 Hz), 7.57 (1H, t, J = 7.8 Hz), 7.77 (1H, d, J = 7.8 Hz), 7.99-8.03 (1H, m), 8.16 (1H, d, J = 16.0 Hz), 8.27 (1H, s), 8.97 (1H, d, J = 4.9 Hz).

[1008]

Example 1859

Synthesis of carbonic acid 1-[4-cyano-5-(3-(thiophen-3-yl)-5-trifluoromethylphenyl)-2H-[1,2,3]triazol-2-yl]ethyl ester ethyl ester

[1009]



[1010]

To a solution of 5-(3-(thiophen-3-yl)-5-trifluoromethyl-

phenyl)-3H-[1,2,3]triazole-4-carbonitrile (0.19 g, 0.593 mmol) in DMF (1 ml) was added 1-chloroethyl ethyl carbonate (0.120 ml, 0.890 mmol) and sodium bicarbonate (0.150 g, 1.780 mmol). The reaction mixture was stirred at 50°C for 6h. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated *in vacuo*. The residue was purified by flash column chromatography (3%-30% AcOEt/hexane) to give colorless oil. The oil was precipitated with hexane and recrystallized from hexane to give the title compound (40 mg, 15%) as a colorless powder.

Melting point 79.7-83.3°C


^{1}H-NMR ($CDCl_3$) δ: 1.34 (3H, t, J = 7.1 Hz), 2.03 (3H, d, J = 6.2 Hz), 4.20-4.34 (2H, m), 7.03 (1H, q, J = 6.2 Hz), 7.48 (2H, d, J = 2.2 Hz), 7.65 (1H, t, J = 2.2 Hz), 7.93-7.94 (1H, m), 8.16-8.17 (1H, m), 8.43-8.44 (1H, m).

[1011]

Example 1860

Synthesis of carbonic acid 1-[4-cyano-5-(3-(thiophen-3-yl)-5-trifluoromethylphenyl)-2H-[1,2,3]triazol-2-yl]ethyl ester 2-hydroxyethyl ester

[1012]



[1013]

To a solution of carbonic acid 1-[4-cyano-5-(3-(thiophen-3-yl)-5-trifluoromethyl-phenyl)-2H-[1,2,3]triazol-2-yl]-ethyl ester 2-(tetrahydro-pyran-2-yloxy)-ethyl ester (0.20 g, 0.373 mmol) in THF (2ml) was added 1N HCl aqueous (1.118 ml, 1.118 mmol). The reaction mixture was stirred at room temperature overnight. The organic solution was concentrated. Water was

added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated *in vacuo*. The residue was purified by flash column chromatography (8%-66% AcOEt/hexane) to give colorless oil. The oil was dissolved in AcOEt, precipitated with hexane, and recrystallised from AcOEt/hexane to give the title compound (60 mg, 36%) as a colorless powder.

Melting point 101.0-104.9°C


^{1}H-NMR ($CDCl_3$) δ: 1.81 (1H, s), 2.05 (3H, d, J = 6.2 Hz), 3.89 (2H, d, J = 3.6 Hz), 4.27-4.41 (2H, m), 7.04 (1H, q, J = 6.2 Hz), 7.48 (2H, d, J = 2.2 Hz), 7.65 (1H, t, J = 2.2 Hz), 7.94 (1H, d, J = 0.6 Hz), 8.16 (1H, d, J = 0.6 Hz), 8.42-8.44 (1H, m).

[1014]

Example 1863

Synthesis of acetic acid 4-cyano-5-(3-(thiophen-3-yl)-5-trifluoromethylphenyl)-2H-[1,2,3]triazol-2-ylmethyl ester

[1015]



[1016]

To a solution of 5-(3-(thiophen-3-yl)-5-trifluoromethyl-phenyl)-3H-[1,2,3]triazole-4-carbonitrile (300 mg, 0.937 mmol) in DMF (3 ml) was added NaH (49.0 mg, 1.124 mmol) at 0°C. The reaction mixture was stirred at 0°C for 0.5 hr. The reaction mixture was added chloromethyl acetate (0.278 ml, 2.81 mmol) at 0°C, and stirred at room temperature overnight. Water was added to the reaction mixture, and the resulting suspension was filtered. The obtained solid was purified by flash column chromatography (3%-30% AcOEt/hexane) to give a colorless solid.

The solid was recrystalized from AcOEt/hexane to give the title compound (0.15 g, 41%) as a colorless powder.

Melting point 126.4-127.9°C


^{1}H-NMR ($CDCl_3$) δ: 2.20 (3H, s), 6.37 (2H, s), 7.48 (2H, d, J = 2.2 Hz), 7.65 (1H, t, J = 2.2 Hz), 7.94-7.95 (1H, m), 8.16-8.17 (1H, m), 8.44 (1H, brs).

[1017]

Example 1864

Synthesis of {1-[4-cyano-5-(3-(thiophen-3-yl)-5-trifluoromethylphenyl)-2H-[1,2,3]triazol-2-yl]ethoxycarbonylamino}acetic acid ethyl ester

[1018]



[1019]

To a solution of glycine ethyl ester hydrochloride (0.351 g, 2.52 mmol) in CH_2Cl_2 (6 ml) were added Et_3N (0.702 ml, 5.04 mmol) and 1-chloro ethyl chloroformate (0.228 ml, 2.098 mmol) at 0°C. The reaction mixture was stirred at 0°C for 1.5 hr. To the reaction mixture were added 5-(3-(thiophen-3-yl)-5-trifluoromethyl-phenyl)-3H-[1,2,3]triazole-4-carbonitrile (0.470 g, 1.469 mmol), DMF (3 ml) and sodium bicarbonate (0.370 g, 4.41 mmol) at 0°C, and the reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated *in vacuo*. The residue was purified by flash column chromatography (6%-30% AcOEt/hexane), and then purified by thin layer chromatography (AcOEt:Hexane = 1:3, twice) to give the title compound (40 mg, 4%) as a pale yellow solid.


^{1}H-NMR ($CDCl_3$) δ: 1.28 (3H, t, J = 7.1 Hz), 1.98 (3H, d, J = 6.2 Hz), 3.89-4.06 (2H, m), 4.22 (2H, q, J = 7.1 Hz), 5.42 (1H, t, J = 5.1 Hz), 7.13 (1H, q, J = 6.2 Hz), 7.46-7.49 (2H, m), 7.64-7.66 (1H, m), 7.92-7.93 (1H, m), 8.16-8.17 (1H, m), 8.43 (1H, s).

[1020]

Example 1889

Synthesis of carbonic acid 1-{4-[3-(2,5-bis-trifluoromethylbenzyloxy)phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}ethyl ester ethyl ester

[1021]



[1022]

To a solution of 5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile (1 g, 2.425 mmol) in DMF (3 ml) were added 1-chloroethyl ethyl carbonate (0.652 ml, 4.85 mmol) and sodium bicarbonate (0.611 g, 7.28 mmol). The reaction mixture was stirred at 60°C for 4 hr. After cooling to room temperature, the precipitate was filtered and washed with 20% AcOEt/Hex. The obtained solid was recrystallized from IPA to give carbonic acid 1-{4-[3-(2,5-bis-trifluoromethylbenzyloxy)phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}ethyl ester ethyl ester (0.48 g, 37 %) as a colorless powder.

The filtrate of the reaction mixture was concentrated *in vacuo*. The obtained residue was purified by flash column chromatography (3%-28% AcOEt/hexane) to give carbonic acid 1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-1H-[1,2,3]triazol-1-yl}-ethyl ester ethyl ester (0.10 g, 8 %) as a colorless powder and carbonic acid 1-{5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-4-cyano-1H-[1,2,3]triazol-

1-yl}-ethyl ester ethyl ester (71 mg, 6 %) as a colorless oil.

carbonic acid 1-{4-[3-(2,5-bis-trifluoromethylbenzyloxy)phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}ethyl ester ethyl ester

^{1}H-NMR ($CDCl_3$) δ: 1.33 (3H, t, J = 7.1 Hz), 2.01 (3H, d, J = 6.2 Hz), 4.21-4.31 (2H, m), 5.36 (2H, s), 7.00 (1H, q, J = 6.2 Hz), 7.10-7.13 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.63-7.64 (1H, m), 7.67-7.69 (1H, m), 7.72 (1H, d, J = 8.3 Hz), 7.85 (1H, d, J = 8.3 Hz), 8.09 (1H, s).

carbonic acid 1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-1H-[1,2,3]triazol-1-yl}-ethyl ester ethyl ester

^{1}H-NMR ($CDCl_3$) δ: 1.33 (3H, t, J = 7.2 Hz), 2.10 (3H, d, J = 6.3 Hz), 4.20-4.33 (2H, m), 5.37 (2H, s), 7.04 (1H, q, J = 6.3 Hz), 7.11-7.16 (1H, m), 7.47 (1H, t, J = 8.0 Hz), 7.71-7.72 (1H, m), 7.73-7.75 (2H, m), 7.86 (1H, d, J = 8.2 Hz), 8.09 (1H, s).

carbonic acid 1-{5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-4-cyano-1H-[1,2,3]triazol-1-yl}-ethyl ester ethyl ester


^{1}H-NMR ($CDCl_3$) δ: 1.27 (3H, t, J = 7.1 Hz), 1.93 (3H, d, J = 6.3 Hz), 4.14-4.24 (2H, m), 5.37 2H, s), 6.74 (1H, q, J = 6.3 Hz), 7.14-7.17 (1H, m), 7.20-7.21 (1H, m), 7.23-7.26 (1H, m), 7.56 (1H, t, J = 8.0 Hz), 7.74 (1H, d, J = 8.2 Hz), 7.87 (1H, d, J = 8.2 Hz), 8.09 (1H, s).

[1023]

Example 1899

Synthesis of 3-(1-{4-cyano-5-[4-(4-trifluoromethylpyrimidin-2-yl)phenyl]-2H-[1,2,3]triazol-2-yl}ethoxycarbonyloxy)-3-methylbutyric acid

[1024]



[1025]

To a solution of 5-[4-(4-trifluoromethylpyrimidin-2-yl)phenyl]-3H-[1,2,3]triazole-4-carbonitrile (0.30 g, 0.949 mmol) in DMF (1.5 ml) were added 3-(1-chloroethoxycarbonyloxy)-3-methylbutyric acid benzyl ester (0.448 g, 1.423 mmol) and sodium bicarbonate (0.239 g, 2.85 mmol). The reaction mixture was stirred at 60°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with AcOEt. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated *in vacuo*. The residue was purified by flash column chromatography (3%-30% AcOEt/hexane) to give 3-(1-{4-cyano-5-[4-(4-trifluoromethylpyrimidin-2-yl)phenyl]-2H-[1,2,3]triazol-2-yl}ethoxycarbonyloxy)-3-methylbutyric acid benzyl ester (0.36 g, 64%) as a colorless oil.

To a solution of 3-(1-{4-cyano-5-[4-(4-trifluoromethylpyrimidin-2-yl)phenyl]-2H-[1,2,3]triazol-2-yl}ethoxycarbonyloxy)-3-methylbutyric acid benzyl ester (0.35 g, 0.589 mmol) in AcOEt (4 ml) under N_2 was added 10% Pd/C (dry) (70 mg). The reaction mixture was stirred at room temperature for 2 hr under hydrogen. After filtration, the filtrate was concentrated to give pale yellow oil. The oil was dissolved in AcOEt, precipitated with hexane, and recrystallized from AcOEt/hexane to give the title compound (0.21 g, 71%) as a pale yellow powder.

Melting point 119.3-127.1°C

^{1}H-NMR ($CDCl_3$) δ: 1.59 (3H, s), 1.60 (3H, s), 2.01 (3H, d, J = 6.2 Hz), 2.94 (2H, s), 6.98 (1H, q, J = 6.2 Hz), 7.56 (1H, d,

J = 5.0 Hz), 8.15-8.18 (2H, m), 8.62-8.67 (2H, m), 9.09 (1H, d, J = 5.0 Hz).


[1026]





The following compounds were synthesized in the same manner as in the above-mentioned Examples. The structures and physical property thereof (melting point, ^{1}H-NMR data, mass spectrum etc.) are shown in the following Table 5. The "ref." in Table 5 means "Example No." or "Reference Example No." which the compound was synthesized in reference to.

[1027]


Table 5

[1028]







Ex. No.	STR	1H-NMR	ref.
1861		1H-NMR (CDCl3) δ: 1.28 (3H, t, J = 7.2 Hz), 2.08 (3H, d, J = 6.2 Hz), 4.19-4.31 (2H, m), 4.64 (1H, d, J = 15.9 Hz), 4.71 (1H, d, J = 15.9 Hz), 7.05 (1H, q, J = 6.2 Hz), 7.45-7.49 (2H, m), 7.66 (1H, t, J = 2.2 Hz), 7.94 (1H, brs), 8.17 (1H, brs), 8.44 (1H, brs).	Ex. 1859
1862		1H-NMR (CDCl3) δ: 2.03 (3H, d, J = 6.2 Hz), 3.38 (3H, s), 3.63 (2H, t, J = 4.6 Hz), 4.29-4.43 (2H, m), 7.03 (1H, q, J = 6.2 Hz), 7.48 (2H, d, J = 2.2 Hz), 7.65 (1H, t, J = 2.2 Hz), 7.94 (1H, d, J = 0.7 Hz), 8.16 (1H, d, J = 0.7 Hz), 8.43 (1H, s).	Ex. 1859
1865		1H-NMR (DMSO-d6) δ: 1.22 (3H, t, J = 7.1 Hz), 1.92 (3H, d, J = 6.1 Hz), 2.51 (3H, s), 4.15-4.22 (2H, m), 7.09 (1H, q, J = 6.2 Hz), 7.82 (1H, s), 7.87 (1H, s), 8.06 (1H, d, J = 8.2 Hz), 8.09 (1H, s), 8.41 (1H, dd, J = 8.3, 2.1 Hz), 9.13 (1H, d, J = 2.1 Hz).	Ex. 1859
1866		1H-NMR (CDCl3) δ: 1.20-1.60 (6H, m), 1.69-1.80 (2H, m), 1.87-1.99 (2H, m), 2.02 (3H, d, J = 6.2 Hz), 2.54 (3H, s), 4.65-4.70 (1H, m), 7.00 (1H, q, J = 6.1 Hz), 7.53 (1H, s), 7.79 (1H, d, J = 8.2 Hz), 7.91 (1H, s), 8.02 (1H, s), 8.10 (1H, dd, J = 8.1, 2.1 Hz), 8.98 (1H, d, J = 1.8 Hz).	Ex. 1859
1867		1H-NMR (DMSO-d6) δ: 3.14 (3H, s), 5.09 (1H, dd, J = 10.4, 7.3 Hz), 5.17 (1H, dd, J = 10.4, 2.9 Hz), 7.27 (1H, dd, J = 7.3, 2.8 Hz), 7.84 (1H, s), 7.90 (1H, s), 8.07 (1H, d, J = 8.2 Hz), 8.12 (1H, s), 8.42 (1H, dd, J = 8.1 Hz, 2.0 Hz), 9.14 (1H, d, J = 2.0 Hz).	Ex. 1863
1868		1H-NMR (CDCl3) δ: 2.54 (3H, s), 6.61 (2H, s), 7.45-7.50 (2H, m), 7.54 (1H, s), 7.60-7.65 (1H, m), 7.79 (1H, d, J = 8.0 Hz), 7.91 (1H, d, J = 0.6 Hz), 8.03 (1H, s), 8.08-8.11 (3H, m), 8.98 (1H, d, J = 2.0 Hz).	Ex. 1863
1869		1H-NMR (DMSO-d6) δ: 1.22 (3H, t, J = 7.1 Hz), 1.92 (3H, d, J = 6.1 Hz), 4.16-4.23 (2H, m), 7.11 (1H, q, J = 6.1 Hz), 7.85 (1 H, t, J = 7.8 Hz), 8.05 (1H, d, J = 5.3 Hz), 8.15-8.18 (1H, m), 8.57-8.60 (1H, m), 9.01 (1H, t, J = 1.6 Hz), 9.36 (1H, d, J = 5.1 Hz).	Ex. 1859







Ex. No.	STR	1H-NMR	ref.
1870		1H-NMR (DMSO-d6) δ: 1.93 (3H, d, J = 6.1 Hz), 3.23 (3H, s), 3.53 (2H, t, J = 4.5 Hz), 4.22-4.30 (2H, m), 7.12 (1H, q, J = 6.1 Hz), 7.85 (1H, t, J = 7.9 Hz), 8.05 (1H, d, J = 5.1 Hz), 8.15-8.18 (1H, m), 8.58-8.60 (1H, m), 9.00-9.02 (1H, m), 9.36 (1H, d, J = 5.1 Hz).	Ex. 1859
1871		1H-NMR (DMSO-d6) δ: 1.17-1.49 (6H, m), 1.58-1.69 (2H, m), 1.77-1.90 (2H, m), 1.92 (3H, d, J = 6.1 Hz), 4.57-4.63 (1H, m), 7.10 (1H, q, J = 6.1 Hz), 7.85 (1H, t, J = 7.9 Hz), 8.05 (1H, d, J = 5.1 Hz), 8.15-8.18 (1H, m), 8.57-8.61 (1H, m), 9.01 (1H, t, J = 1.6 Hz), 9.35 (1H, d, J = 5.0 Hz).	Ex. 1859
1872		1H-NMR (DMSO-d6) δ: 2.15 (3H, s), 6.49 (2H, s), 7.85 (1H, t, J = 7.9 Hz), 8.05 (1H, d, J = 5.0 Hz), 8.15-8.18 (1H, m), 8.57-8.60 (1H, m), 9.01 (1H, t, J = 1.7 Hz), 9.35 (1H, d, J = 5.0 Hz).	Ex. 1863
1873		1H-NMR (DMSO-d6) δ: 1.18 (9H, s), 6.52 (2H, s), 7.85 (1H, t, J = 7.7 Hz), 8.15-8.18 (1H, m), 8.05 (1H, d, J = 5.0 Hz), 8.58-8.60 (1H, m), 9.01 (1H, t, J = 1.7 Hz), 9.35 (1H, d, J = 5.0 Hz).	Ex. 1863
1874		1H-NMR (DMSO-d6) δ: 0.88 (3H, t, J = 7.4 Hz), 1.53-1.61 (2H, m), 2.42 (2H, t, J = 7.2 Hz), 6.52 (2H, s), 7.85 (1H, t, J = 7.9 Hz), 8.05 (1H, d, J = 5.1 Hz), 8.14-8.18 (1H, m), 8.59 (1H, dt, J = 8.1, 1.4 Hz), 9.01 (1H, t, J = 1.7 Hz), 9.35 (1H, d, J = 5.0 Hz).	Ex. 1863
1875		1H-NMR (DMSO-d6) δ: 1.22 (3H, t, J = 7.1 Hz), 1.92 (3H, d, J = 6.2 Hz), 2.54 (3H, s), 4.14-4.24 (2H, m), 7.10 (1H, q, J = 6.2 Hz), 7.97 (1H, s), 8.04 (1H, d, J = 4.9 Hz), 8.41 (1H, s), 8.83 (1H, s), 9.34 (1H, d, J = 4.9 Hz).	Ex. 1859
1876		1H-NMR (DMSO-d6) δ: 1.16-1.50 (6H, m), 1.58-1.69 (2H, m), 1.77-1.90 (2H, m), 1.92 (3H, d, J = 6.2 Hz), 2.54 (3H, s), 4.57-4.64 (1H, m), 7.09 (1H, q, J = 6.2 Hz), 7.97 (1H, s), 8.04 (1H, d, J = 5.0 Hz), 8.41 (1H, s), 8.83 (1H, s), 9.34 (1H, d, J = 4.9 Hz).	Ex. 1859

[1029]







Ex. No.	STR	1H-NMR	ref.
1877		1H-NMR (DMSO-d6) δ: 2.55 (3H, s), 5.09 (1H, dd, J = 10.4, 7.1 Hz), 5.16 (1H, dd, J = 10.4, 2.8 Hz), 7.30 (1H, dd, J = 7.1, 2.8 Hz), 7.98 (1H, s), 8.04 (1H, d, J = 5.0 Hz), 8.43 (1H, s), 8.84 (1H, s), 9.34 (1H, d, J = 5.0 Hz).	Ex. 1863
1878		1H-NMR (DMSO-d6) δ: 2.15 (3H, s), 2.54 (3H, s), 6.48 (2H, s), 7.97 (1H, s), 8.04 (1H, d, J = 5.0 Hz), 8.41 (1H, s), 8.83 (1H, s), 9.34 (1H, d, J = 5.0 Hz).	Ex. 1863
1880		1H-NMR (CDCl3) δ: 1.33 (3H, t, J = 7.1 Hz), 1.99 (3H, d, J = 6.3 Hz), 4.04 (2H, s), 4.21-4.31 (2H, m), 6.97-7.04 (3H, m), 7.12 (1H, s), 7.15-7.19 (2H, m), 7.70 (1H, s), 7.76 (1H, s).	Ex. 1859
1881		1H-NMR (CDCl3) δ: 1.21-1.58 (6H, m), 1.70-1.80 (2H, m), 1.86-1.97 (2H, m), 1.99 (3H, d, J = 6.3 Hz), 4.04 (2H, s), 4.63-4.70 (1H, m), 6.94-7.04 (3H, m), 7.12 (1H, s), 7.15-7.19 (2H, m), 7.70 (1H, s), 7.77 (1H, s).	Ex. 1859
1882		1H-NMR (CDCl3) δ: 4.04 (2H, s), 6.58 (2H, s), 7.01 (2H, t, J = 8.7 Hz), 7.13 (1H, s), 7.14-7.18 (1H, m), 7.44-7.50 (3H, m), 7.62 (1H, t, J = 7.5 Hz), 7.71 (1H, s), 7.77 (1H, s), 8.05-8.09 (2H, m).	Ex. 1863
1883		1H-NMR (CDCl3) δ: 0.95 (3H, t, J = 7.4 Hz), 1.65-1.72 (2H, m), 2.40 (2H, t, J = 7.4 Hz), 4.04 (2H, s), 6.33 (2H, s), 7.02 (2H, t, J = 8.6 Hz), 7.13 (1H, s), 7.15-7.19 (2H, m), 7.70 (1H, s), 7.76 (1H, s).	Ex. 1863
1884		1H-NMR (DMSO-d6) δ: 1.22 (3H, t, J = 7.0 Hz), 1.92 (3H, d, J = 6.1 Hz), 4.14-4.24 (2H, m), 7.08 (1H, q, J = 6.1 Hz), 7.60 (2H, s), 7.63-7.68 (2H, m), 7.84 (1H, t, J = 1.6 Hz), 7.96 (1H, d, J = 7.1 Hz), 8.00 (1H, t, J = 1.6 Hz), 8.03-8.06 (2H, m).	Ex. 1859
1885		1H-NMR (DMSO-d6) δ: 1.17-1.50 (6H, m), 1.59-1.69 (2H, m), 1.77-1.90 (2H, m), 1.92 (3H, d, J = 6.1 Hz), 4.57-4.64 (1H, m), 7.07 (1H, q, J = 6.1 Hz), 7.59 (2H, s), 7.62-7.69 (2H, m), 7.83 (1H, t, J = 1.6 Hz), 7.96 (1H, d, J = 6.9 Hz), 8.00 (1H, t, J = 1.6 Hz), 8.03 (1H, s), 8.05 (1H, t, J = 1.4 Hz).	Ex. 1859
1886		1H-NMR (DMSO-d6) δ: 5.10 (1H, dd, J = 10.3, 7.3 Hz), 5.17 (1H, dd, J = 10.3, 2.9 Hz), 7.27 (1H, dd, J = 7.2, 2.8 Hz), 7.60 (2H, s), 7.63-7.70 (2H, m), 7.85-7.87 (1H, m), 7.96 (1H, d, J = 6.9 Hz), 8.02-8.07 (3H, m).	Ex. 1863
1887		1H-NMR (DMSO-d6) δ: 2.15 (3H, s), 6.47 (2H, s), 7.60 (2H, s), 7.64-7.69 (2H, m), 7.83 (1H, t, J = 1.6 Hz), 7.96 (1H, d, J = 7.1 Hz), 8.00 (1H, t, J = 1.6 Hz), 8.04 (1H, s), 8.04-8.06 (1H, m).	Ex. 1863
1888		1H-NMR (DMSO-d6) δ: 6.76 (2H, s), 7.57 (2H, d, J = 7.7 Hz), 7.59 (2H, s), 7.62-7.69 (2H, m), 7.73 (1H, t, J = 7.4 Hz), 7.84 (1H, s), 7.96 (1H, d, J = 6.8 Hz), 8.00 (1H, s), 8.01-8.05 (3H, m), 8.06 (1H, s).	Ex. 1863
1892		1H-NMR (CDCl3) δ: 2.02 (3H, d, J = 6.2 Hz), 2.50 (4H, brs), 2.86 (2H, brs), 3.69 (4H, brs), 4.33 (2H, brs), 5.36 (2H, s), 7.00 (1H, q, J = 6.2 Hz), 7.10-7.13 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.63-7.64 (1H, m), 7.66-7.69 (1H, m), 7.73 (1H, d, J = 8.0 Hz), 7.86 (1H, d, J = 8.0 Hz), 8.09 (1H, s).	Ex. 1864
1893		1H-NMR (CDCl3) δ: 1.27 (3H, t, J = 7.1 Hz), 2.05 (3H, d, J = 6.2 Hz), 4.24 (2H, q, J = 7.1 Hz), 4.62 (1H, d, J = 15.8 Hz), 4.72 (1H, d, J = 15.8 Hz), 5.37 (2H, s), 7.02 (1H, q, J = 6.2 Hz), 7.10-7.13 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.64 (1H, t, J = 1.6 Hz), 7.67-7.69 (1H, m), 7.72-7.74 (1H, m), 7.85 (1H, d, J = 8.2 Hz), 8.09 (1H, s).	Ex. 1859
1894		1H-NMR (CDCl3) δ: 2.02 (3H, d, J = 6.2 Hz), 3.38 (3H, s), 3.62 (2H, t, J = 4.6 Hz), 4.26-4.42 (2H, m), 5.36 (2H, s), 7.00 (1H, q, J = 6.2 Hz), 7.10-7.13 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.62-7.63 (1H, m), 7.67-7.69 (1H, m), 7.73 (1H, d, J = 8.4 Hz), 7.86 (1H, d, J = 8.4 Hz), 8.09 (1H, s).	Ex. 1859








[1030]

Ex. No.	STR	1H-NMR	ref.
1895		1H-NMR (CDCl3) δ: 2.28 (1H, t, J = 6.3 Hz), 4.21-4.29 (2H, m), 4.64-4.71 (2H, m), 5.36 (2H, s), 7.09-7.12 (1H, m), 7.46 (1H, t, J = 8.0 Hz), 7.60-7.61 (1H, m), 7.65-7.67 (1H, m), 7.72 (1H, d, J = 8.2 Hz), 7.85 (1H, d, J = 8.2 Hz), 8.09 (1H, s).	Ex. 1863
1896		1H-NMR (CDCl3) δ: 4.31 (3H, s), 5.36 (2H, s), 7.09-7.11 (1H, m), 7.46 (1H, t, J = 8.1 Hz), 7.61 (1H, s), 7.65 (1H, d, J = 7.7 Hz), 7.73 (1H, d, J = 7.7 Hz), 7.86 (1H, d, J = 8.1 Hz), 8.10 (1H, s).	Ex. 1863
1897		1H-NMR (CDCl3) δ: 1.34 (3H, t, J = 7.1 Hz), 2.02 (3H, d, J = 6.2 Hz), 4.21-4.31 (2H, m), 7.03 (1H, q, J = 6.2 Hz), 7.56 (1H, d, J = 5.0 Hz), 8.16-8.19 (2H, m), 8.64-8.68 (2H, m), 9.09 (1H, d, J = 5.0 Hz).	Ex. 1859
1898		1H-NMR (CDCl3) δ: 1.27 (6H, s), 2.03 (3H, d, J = 6.2 Hz), 4.21 (1H, d, J = 10.5 Hz), 4.31 (1H, d, J = 10.5 Hz), 7.01 (1H, q, J = 6.2 Hz), 7.57 (1H, d, J = 5.0 Hz), 8.15-8.18 (2H, m), 8.64-8.68 (2H, m), 9.09 (1H, d, J = 5.0 Hz).	Ex. 1899
1900		1H-NMR (CDCl3) δ: 4.34 (3H, s), 7.56 (1H, d, J = 5.0 Hz), 8.08-8.22 (2H, m), 8.58-8.71 (2H, m), 9.08 (1H, d, J = 5.0 Hz).	Ex. 1863
1901		1H-NMR (CDCl3) δ: 2.20 (3H, s), 6.36 (2H, s), 7.57 (1H, d, J = 5.0 Hz), 8.16-8.19 (2H, m), 8.66-8.69 (2H, m), 9.10 (1H, d, J = 5.0 Hz).	Ex. 1863
1902		1H-NMR (CDCl3) δ: 1.33 (3H, t, J = 7.1 Hz), 2.02 (3H, d, J = 6.2 Hz), 2.83 (3H, s), 4.22-4.32 (2H, m), 7.03 (1H, q, J = 6.2 Hz), 7.71 (2H, d, J = 8.2 Hz), 8.11 (2H, d, J = 8.2 Hz).	Ex. 1859







Ex. No.	STR	1H-NMR	ref.
1903		1H-NMR (CDCl3) δ: 1.26 (3H, s), 1.27 (3H, s), 2.03 (3H, d, J = 6.2 Hz), 2.81 (3H, s), 4.22 (1H, d, J = 10.6 Hz), 4.27 (1H, d, J = 10.6 Hz), 7.01 (1H, q, J = 6.3 Hz), 7.72 (2H, d, J = 8.3 Hz), 7.85 (2H, d, J = 8.3 Hz).	Ex. 1899
1904		1H-NMR (CDCl3) δ: 1.16 (3H, t, J = 7.3 Hz), 1.94 (3H, d, J = 6.2 Hz), 3.19-3.33 (2H, m), 4.84 (1H, s), 7.12 (1H, q, J = 6.2 Hz), 7.56 (1H, d, J = 5.0 Hz), 8.16-8.18 (2H, m), 8.64-8.67 (2H, m), 9.09 (1H, d, J = 5.0 Hz).	Ex. 1864
1905		1H-NMR (DMSO-d6) δ: 1.12-1.43 (6H, m), 1.50-1.68 (3H, m), 1.74-1.86 (2H, m), 1.89 (3H, d, J = 6.1 Hz), 2.81 (3H, s), 7.19 (1H, q, J = 6.1 Hz), 7.94 (2H, d, J = 8.2 Hz), 8.19 (2H, d, J = 8.2 Hz).	Ex. 1859
1906		1H-NMR (DMSO-d6) δ: 2.15 (3H, s), 2.82 (3H, s), 6.47 (2H, s), 7.94 (2H, d, J = 8.3 Hz), 8.19 (2H, d, J = 8.3 Hz).	Ex. 1863
1907		1H-NMR (DMSO-d6) δ: 0.87 (3H, t, J = 7.5 Hz), 1.52-1.60 (2H, m), 2.42 (2H, t, J = 7.2 Hz), 2.81 (3H, s), 6.50 (2H, s), 7.94 (2H, d, J = 8.4 Hz), 8.19 (2H, d, J = 8.4 Hz).	Ex. 1863
1908		1H-NMR (DMSO-d6) δ: 1.19-1.25 (7H, m), 1.91 (3H, d, J = 6.2 Hz), 2.58-2.65 (1H, m), 4.14-4.23 (2H, m), 7.06 (1H, q, J = 6.2 Hz), 7.58-7.65 (2H, m), 7.91-7.97 (2H, m).	Ex. 1859
1909		1H-NMR (DMSO-d6) δ: 1.16-1.50 (10H, m), 1.58-1.69 (2H, m), 1.75-1.89 (2H, m), 1.90 (3H, d, J = 6.1 Hz), 2.57-2.65 (1H, m), 4.56-4.63 (1H, m), 7.05 (1H, q, J = 6.1 Hz), 7.59-7.65 (2H, m), 7.91-7.97 (2H, m).	Ex. 1859
1910		1H-NMR (DMSO-d6) δ: 1.19-1.26 (4H, m), 2.14 (3H, s), 2.57-2.65 (1H, m), 6.44 (2H, s), 7.59-7.65 (2H, m), 7.91-7.96 (2H, m).	Ex. 1863







[1031]

Ex. No.	STR	1H-NMR	ref.
1911		1H-NMR (DMSO-d6) δ: 1.18-1.24 (4H, m), 2.58-2.65 (1H, m), 6.73 (2H, s), 7.54-7.65 (4H, m), 7.71-7.76 (1H, m), 7.91-7.97 (2H, m), 8.00-8.05 (2H, m).	Ex. 1863
1912		1H-NMR (DMSO-d6) δ: 1.12-1.42 (9H, m), 1.51-1.69 (3H, m), 1.74-1.85 (2H, m), 1.88 (3H, d, J = 6.1 Hz), 2.35-2.46 (1H, m), 2.56-2.65 (1H, m), 7.14-7.19 (1H, m), 7.59-7.66 (2H, m), 7.90-7.97 (2H, m).	Ex. 1859
1913		1H-NMR (DMSO-d6) δ: 1.20 (3H, t, J = 7.1 Hz), 1.75 (3H, d, J = 6.2 Hz), 4.09-4.19 (2H, m), 6.94 (1H, q, J = 6.2 Hz), 7.58 (1H, d, J = 5.2 Hz), 8.03-8.06 (3H, m), 8.12 (1H, s).	Ex. 1859
1914		1H-NMR (DMSO-d6) δ: 1.16-1.50 (6H, m), 1.58-1.67 (2H, m), 1.75 (3H, d, J = 6.1 Hz), 1.77-1.87 (2H, m), 4.52-4.58 (1H, m), 6.94 (1H, q, J = 6.1 Hz), 7.59 (1H, d, J = 5.2 Hz), 8.02-8.06 (3H, m), 8.12 (1H, s).	Ex. 1859
1915		1H-NMR (DMSO-d6) δ: 1.12 (9H, s), 6.40 (2H, s), 7.60 (1H, d, J = 5.2 Hz), 8.00 (2H, s), 8.06 (1H, d, J = 5.2 Hz), 8.13 (1H, s).	Ex. 1863
1916		1H-NMR (DMSO-d6) δ: 0.85 (3H, t, J = 7.4 Hz), 1.49-1.56 (2H, m), 2.35 (2H, t, J = 7.3 Hz), 6.38 (2H, s), 7.59 (1H, d, J = 7.1 Hz), 8.03 (2H, s), 8.05 (1H, d, J = 5.0 Hz), 8.12 (1H, s).	Ex. 1863

Ex. No.	STR	1H-NMR	ref.
1917		1H-NMR (CDCl3) δ: 0.92 (3H, t, J = 7.4 Hz), 1.59-1.67 (2H, m), 1.82 (3H, d, J = 6.2 Hz), 2.29-2.33 (2H, m), 7.03 (1H, q, J = 6.2 Hz), 7.27 (1H, d, J = 5.2 Hz), 7.64 (1H, d, J = 5.2 Hz), 7.82 (2H, s), 7.86 (1H, s).	Ex. 1859
1918		1H-NMR (DMSO-d6) δ: 1.22 (3H, t, J = 7.1 Hz), 1.89 (3H, d, J = 6.2 Hz), 4.15-4.22 (2H, m), 7.05 (1H, q, J = 6.2 Hz), 7.30 (1H, d, J = 3.6 Hz), 7.32 (1H, d, J = 3.6 Hz), 7.58 (2H, d, J = 8.6 Hz), 7.85 (2H, d, J = 8.6 Hz).	Ex. 1859
1919		1H-NMR (DMSO-d6) δ: 1.18-1.50 (6H, m), 1.58-1.68 (2H, m), 1.76-1.87 (2H, m), 1.88 (3H, d, J = 6.2 Hz), 4.56-4.62 (1H, m), 7.03 (1H, q, J = 6.2 Hz), 7.29 (1H, d, J = 3.7 Hz), 7.33 (1H, d, J = 3.7 Hz), 7.58 (2H, d, J = 8.6 Hz), 7.85 (2H, d, J = 8.6 Hz).	Ex. 1859
1920		1H-NMR (DMSO-d6) δ: 1.16 (9H, s), 6.47 (2H, s), 7.29 (1H, d, J = 3.6 Hz), 7.33 (1H, d, J = 3.6 Hz), 7.59 (2H, d, J = 8.5 Hz), 7.85 (2H, d, J = 8.5 Hz).	Ex. 1863
1921		1H-NMR (DMSO-d6) δ: 0.87 (3H, t, J = 7.4 Hz), 1.52-1.59 (2H, m), 2.41 (2H, t, J = 7.2 Hz), 6.46 (2H, s), 7.29 (1H, d, J = 3.6 Hz), 7.33 (1H, d, J = 3.6 Hz), 7.59 (2H, d, J = 8.6 Hz), 7.86 (2H, d, J = 8.6 Hz).	Ex. 1863
1922		1H-NMR (CDCl3) δ: 2.20 (1H, brs), 4.26 (2H, t, J = 5.0 Hz), 4.67-4.74 (2H, m), 7.47 (2H, d, J = 2.2 Hz), 7.64 (1H, t, J = 2.2 Hz), 7.90-7.93 (1H, m), 8.13-8.14 (1H, m), 8.41-8.43 (1H, m).	Ex. 1863
1923		1H-NMR (CDCl3) δ: 1.16 (3H, t, J = 7.3 Hz), 1.94 (3H, d, J = 6.2 Hz), 3.18-3.33 (2H, m), 4.85 (1H, s), 7.12 (1H, q, J = 6.2 Hz), 7.48 (2H, d, J = 2.2 Hz), 7.64 (1H, t, J = 2.2 Hz), 7.93 (1H, s), 8.13-8.16 (1H, m), 8.43 (1H, s).	Ex. 1864

[1032]

Ex. No.	STR	1H-NMR	ref.
1924		1H-NMR (CDCl3) δ: 2.31 (1H, brs), 4.25 (2H, t, J = 4.8 Hz), 4.66-4.75 (2H, m), 7.57 (1H, d, J = 4.9 Hz), 8.10-8.16 (2H, m), 8.65-8.68 (2H, m), 9.09 (1H, d, J = 4.9 Hz).	Ex. 1863
1925		1H-NMR (DMSO) δ: 2.80 (3H, s), 4.37 (3H, s), 7.92 (2H, d, J = 8.3 Hz), 8.16 (2H, d, J = 8.3 Hz).	Ex. 1863
1926		1H-NMR (CDCl3) δ: 1.57 (3H, s), 1.58 (3H, s), 1.95 (3H, d, J = 6.2 Hz), 2.90 (1H, d, J = 14.4 Hz), 3.03 (1H, d, J = 14.4 Hz), 5.10 (2H, s), 6.93 (1H, q, J = 6.2 Hz), 7.30-7.38 (5H, m), 7.56 (1H, d, J = 5.0 Hz), 8.13-8.18 (2H, m), 8.64-8.68 (2H, m), 9.09 (1H, d, J = 5.0 Hz).	Ex. 1859
1927		1H-NMR (CDCl3) δ: 1.26 (6H, s), 2.00 (3H, d, J = 6.2 Hz), 4.22 (1H, d, J = 10.4 Hz), 4.32 (1H, d, J = 10.4 Hz), 5.13 (2H, d, J = 2.3 Hz), 6.98 (1H, q, J = 6.2 Hz), 7.28-7.44 (5H, m), 7.57 (1H, d, J = 4.9 Hz), 8.15-8.18 (2H, m), 8.64-8.68 (2H, m), 9.09 (1H, d, J = 4.9 Hz).	Ex. 1859
1928		1H-NMR (CDCl3) δ: 1.42-1.52 (2H, m), 1.53-1.59 (2H, m), 1.66-1.86 (2H, m), 2.04 (3H, d, J = 6.2 Hz), 3.47-3.52 (1H, m), 3.63-3.75 (1H, m), 3.76-3.84 (1H, m), 3.88-.3.99 (1H, m), 4.32-4.47 (2H, m), 4.61-4.63 (1H, m), 7.04 (1H, q, J = 6.2 Hz), 7.45-7.50 (2H, m), 7.65 (1H, t, J = 2.2 Hz), 7.94 (1H, s), 8.16 (1H, d, J = 0.4 Hz), 8.44 (1H, s).	Ex. 1859
1929		1H-NMR (CDCl3) δ: 4.13 (2H, s), 7.07-7.17 (7H, m), 7.26-7.44 (13H, m), 7.81-7.86 (2H, m).	Ex. 1833

Ex. No.	STR	1H-NMR	ref.
1930		1H-NMR (CDCl3) δ: 5.36 (2H, s), 5.76 (2H, s), 7.10-7.13 (1H, m), 7.46 (1H, t, J = 8.2 Hz), 7.58 (1H, s), 7.64-7.73 (2H, m), 7.84-7.92 (4H, m), 8.08 (1H, s).	Ex. 1829
1931		1H-NMR (CDCl3) δ: 5.93 (1H, bs), 7.13-7.16 (7H, m), 7.28-7.39 (9H, m), 7.61 (1H, s), 7.75 (1H, s).	Ex. 1859
1932		1H-NMR (CDCl3) δ: 5.20 (2H, s), 7.11-7.14 (6H, m), 7.26-7.39 (10H, m), 7.53-7.57 (2H, m), 7.64-7.67 (2H, m), 7.72 (1H, s), 7.78 (1H, s).	Ex. 1859
1933		1H-NMR (CDCl3) δ: 7.12-7.17 (6H, m), 7.26-7.40 (9H, m), 7.62-7.67 (1H, m), 7.95-8.00 (1H, m), 8.20-8.25 (1H, m), 8.40 (1H, s), 10.06 (1H, s).	Ex. 1859
1934		1H-NMR (CDCl3) δ: 1.77 (1H, br.s), 4.75 (2H, br.s), 7.10-7.18 (6H, m), 7.29-7.39 (9H, m), 7.44-7.49 (2H, m), 7.85-7.93 (2H, m).	Ref. Ex. 19
1935		1H-NMR (CDCl3) δ: 2.99 (3H, s), 5.28 (2H, s), 7.11-7.16 (6H, m), 7.32-7.42 (9H, m), 7.48-7.54 (2H, m), 7.95 (1H, s), 7.96-7.99 (1H, m).	Ref. Ex. 103

[1033]

Ex. No.	STR	1H-NMR	ref.
1936		1H NMR (CDCl3) δ: 3.23 (2H, d, J = 16.8 Hz), 3.47 (2H, dd, J = 6.1, 16.8 Hz), 5.26 (1H, bs), 7.15-7.43 (20H, m), 7.70 (1H, s), 7.76 (1H, s).	Ref. Ex. 80
1937		1H-NMR (CDCl3) δ: 2.21-2.32 (1H, m), 2.60-2.72 (1H, m), 2.98-3.07 (1H, m), 3.18-3.28 (1H, m), 5.87-5.91 (1H, m), 7.16-7.19 (6H, m), 7.33-7.40 (14H, m), 7.81 (2H, s).	Ref. Ex. 80
1938		1H-NMR (CDCl3) δ: 1.05 (3H, s), 1.36-1.55 (10H, m), 3.72 (2H, s), 7.12-7.20 (7H, m), 7.33-7.39 (9H, m), 7.64 (1H, s), 7.71 (1H, s).	Ref. Ex. 80
1939		1H-NMR (CDCl3) δ: 0.97-1.05 (4H, m), 4.06 (2H, s), 7.11-7.14 (7H, m), 7.24-7.40 (13H, m), 7.57 (1H, s), 7.67 (1H, s).	Ref. Ex. 80
1940		1H-NMR (CDCl3) δ: 1.04 (4H, s), 4.12 (2H, s), 7.12-7.15 (8H, m), 7.30-7.42 (13H, m), 7.60 (1H, s), 7.71 (1H, s).	Ref. Ex. 80

Ex. No.	STR	1H-NMR	ref.
1941		1H NMR (CDCl3) δ: 1.80-1.89 (1H, m), 2.02-2.20 (3H, m), 2.82-2.92 (2H, m), 5.46-5.49 (1H, m), 7.13-7.38 (20H, m), 7.78 (2H, s).	Ref. Ex. 80
1942		1H NMR (CDCl3) δ: 1.07-1.31 (11H, m), 1.68-1.93 (3H, m), 4.18-4.26 (1H, m), 7.13-7.16 (7H, m), 7.26-7.37 (9H, m), 7.61 (1H, s), 7.69 (1H, s).	Ref. Ex. 80
1943		1H-NMR (CDCl3) δ: 1.07 (9H, s), 3.69 (2H, s), 7.14-7.17 (7H, m), 7.30-7.40 (9H, m), 7.68 (1H, s), 7.74 (1H, s).	Ref. Ex. 80
1944		1H-NMR (CDCl3) δ: 0.47-0.57 (4H, m), 1.27 (3H, s), 3.81 (2H, s), 7.13-7.16 (7H, m), 7.33-7.39 (9H, m), 7.65 (1H, s), 7.73 (1H, s).	Ref. Ex. 80
1945		1H-NMR (CDCl3) δ: 1.13-1.22 (4H, m), 4.15 (2H, s), 7.13-7.16 (7H, m), 7.30-7.40 (9H, m), 7.64 (1H, s), 7.78 (1H, s).	Ref. Ex. 80

[1034]

The following compounds were synthesized in the same manner as in the above-mentioned Examples. The structures and physical property thereof (melting point, ^{1}H-NMR data, mass spectrum etc.) are shown in the following Table 6. The "ref." in Table 6 means "Example No." or "Reference Example No." which the compound was synthesized in reference to.

[1035]

Table 6

[1036]

The compounds of Examples in Table 6 are shown as one tautomer, which are not limited, and the other two tautomers are also encompassed therein.








Ex. No.	STR	MS (M+H)
1946		185
1947		189
1948		263
1949		277








Ex. No.	STR	MS (M+H)
1950		221
1951		217
1952		293
1953		224
1954		201










Ex. No.	STR	MS (M+H)
1955		231
1956		215
1957		229
1958		213
1959		227
1960		279
1961		215
1962		259
1963		242









Ex. No.	STR	MS (M+H)
1964		272
1965		205
1966		189
1967		239
1968		199
1969		199
1970		199
1971		231
1972		185

[1037]









Ex. No.	STR	MS (M+H)
1973		199
1974		199
1975		261
1976		261
1977		307
1978		383
1979		383










Ex. No.	STR	MS (M+H)
1980		277
1981		307
1982		344
1983		311
1984		300
1985		327
1986		339










Ex. No.	STR	MS (M+H)
1987		199
1988		187
1989		191
1990		172
1991		172
1992		177
1993		191
1994		222
1995		259









Ex. No.	STR	MS (M+H)
1996		205
1997		240
1998		269
1999		205
2000		213
2001		250
2002		228
2003		240

[1038]










Ex. No.	STR	MS (M+H)
2030		285
2031		286
2032		338
2033		210
2034		287
2035		314
2036		325
2037		209









Ex. No.	STR	MS (M+H)
2021		330
2022		270
2023		189
2024		241
2025		271
2026		305
2027		339
2028		225
2029		177








Ex. No.	STR	MS (M+H)
2012		224
2013		237
2014		314
2015		352
2016		224
2017		364
2018		306
2019		211
2020		254










Ex. No.	STR	MS (M+H)
2004		311
2005		297
2006		222
2007		160
2008		161
2009		175
2010		210
2011		211

[1039]










Ex. No.	STR	MS (M+H)
2038		242
2039		278
2040		260
2041		314
2042		260
2043		260
2044		227
2045		227
2046		264










Ex. No.	STR	MS (M+H)
2047		302
2048		306
2049		465
2050		223
2051		279
2052		196
2053		172
2054		239









Ex. No.	STR	MS (M+H)
2055		255
2056		357
2057		297
2058		331
2059		293
2060		277
2061		281









Ex. No.	STR	MS (M+H)
2062		255
2063		200
2064		265
2065		331
2066		307
2067		265
2068		265
2069		315
2070		261

[1040]










Ex. No.	STR	MS (M+H)
2071		261
2072		281
2073		289
2074		303
2075		277
2076		289
2077		353
2078		272
2079		292









Ex. No.	STR	MS (M+H)
2080		383
2081		315
2082		315
2083		315
2084		299
2085		323
2086		303
2087		293
2088		293







Ex. No.	STR	MS (M+H)
2089		277
2090		339
2091		295
2092		275
2093		291
2094		305
2095		301
2096		277
2097		277




Ex. No.	STR	MS (M+H)
2098		277
2099		325
2100		291
2101		298
2102		289
2103		299
2104		298
2105		298
2106		289

[1041]








Ex. No.	STR	MS (M+H)
2107		298
2108		280
2109		284
2110		261
2111		289
2112		287
2113		305
2114		303
2115		300







Ex. No.	STR	MS (M+H)
2116		318
2117		298
2118		337
2119		290
2120		249
2121		332
2122		298
2123		265







Ex. No.	STR	MS (M+H)
2124		331
2125		283
2126		261
2127		307
2128		253
2129		265
2130		265








Ex. No.	STR	MS (M+H)
2131		261
2132		281
2133		289
2134		303
2135		277
2136		289
2137		353

[1042]









Ex. No.	STR	MS (M+H)
2138		272
2139		325
2140		292
2141		315
2142		315
2143		315
2144		275








Ex. No.	STR	MS (M+H)
2145		297
2146		303
2147		293
2148		293
2149		295
2150		275










Ex. No.	STR	MS (M+H)
2151		291
2152		305
2153		305
2154		305
2155		277
2156		277









Ex. No.	STR	MS (M+H)
2157		277
2158		248
2159		291
2160		298
2161		289
2162		299
2163		298

[1043]










Ex. No.	STR	MS (M+H)
2164		298
2165		289
2166		298
2167		345
2168		280
2169		261
2170		289
2171		287









Ex. No.	STR	MS (M+H)
2172		305
2173		303
2174		300
2175		318
2176		298
2177		337
2178		339








Ex. No.	STR	MS (M+H)
2179		290
2180		249
2181		332
2182		298
2183		315
2184		237
2185		261
2186		315
2187		275








Ex. No.	STR	MS (M+H)
2188		286
2189		297
2190		339
2191		266
2192		282
2193		308
2194		332
2195		290
2196		340
2197		331

[1044]









Ex. No.	STR	MS (M+H)
2198		272
2199		262
2200		311
2201		327
2202		340
2203		237
2204		315
2205		261
2206		315









Ex. No.	STR	MS (M+H)
2207		299
2208		286
2209		277
2210		266
2211		282
2212		308
2213		332
2214		340









Ex. No.	STR	MS (M+H)
2215		262
2216		311
2217		327
2218		340
2219		381
2220		396
2221		413









Ex. No.	STR	MS (M+H)
2222		423
2223		429
2224		397
2225		366
2226		437
2227		469
2228		427

[1045]































Ex. No.	STR	MS (M+H)
2229		371
2230		327
2231		395
2232		399
2233		399
2234		496
2235		425
2236		462

Ex. No.	STR	MS (M+H)
2237		363
2238		337
2239		429
2240		409
2241		451
2242		379
2243		385
2244		414










Ex. No.	STR	MS (M+H)
2245		485
2246		435
2247		435
2248		364
2249		399
2250		418
2251		412
2252		363










Ex. No.	STR	MS (M+H)
2253		459
2254		427
2255		431
2256		431
2257		363
2258		426
2259		410
2260		442









[1046]










Ex. No.	STR	MS (M+H)
2261		425
2262		427
2263		423
2264		434
2265		425
2266		428
2267		445
2268		413
2269		415
2270		426
2271		510
2272		509
2273		481
2274		439
2275		443
2276		443
2277		453
2278		493
2279		427
2280		481
2281		415
2282		425
2283		427
2284		490
2285		427
2286		410
2287		442
2288		498
2289		403
2290		393

[1047]









Ex. No.	STR	MS (M+H)
2291		307
2292		307
2293		307
2294		337
2295		321
2296		291
2297		291
2298		291
2299		305









Ex. No.	STR	MS (M+H)
2300		305
2301		295
2302		295
2303		313
2304		313
2305		327
2306		327
2307		361
2308		361









Ex. No.	STR	MS (M+H)
2309		361
2310		334
2311		344
2312		335
2313		373
2314		309
2315		319
2316		348









Ex. No.	STR	MS (M+H)
2317		319
2318		343
2319		347
2320		331
2321		318
2322		317
2323		342
2324		345
2325		343

[1048]




































Ex. No.	STR	MS (M+H)
2326		343
2327		361
2328		374
2329		361
2330		360
2331		346
2332		350
2333		376

Ex. No.	STR	MS (M+H)
2334		348
2335		362
2336		360
2337		346
2338		346
2339		374
2340		347
2341		378










Ex. No.	STR	MS (M+H)
2342		325
2343		331
2344		320
2345		342
2346		306
2347		403
2348		347
2349		360









Ex. No.	STR	MS (M+H)
2350		339
2351		374
2352		317
2353		360
2354		335
2355		360
2356		360
2357		360








[1049]










Ex. No.	STR	MS (M+H)
2358		376
2359		325
2360		391
2361		379
2362		331
2363		329
2364		335
2365		303
2366		243
2367		255
2368		311
2369		257
2370		239
2371		297
2372		343
2373		408
2374		342
2375		345
2376		379
2377		417
2378		414
2379		371
2380		387
2381		321
2382		297
2383		297
2384		283
2385		303
2386		229
2387		394
2388		364
2389		428
2390		271
2391		320
2392		298

[1050]










Ex. No.	STR	MS (M+H)
2393		312
2394		321
2395		325
2396		325
2397		241
2398		333
2399		333
2400		333
2401		281










Ex. No.	STR	MS (M+H)
2402		354
2403		343
2404		331
2405		343
2406		335
2407		357
2408		358
2409		357










Ex. No.	STR	MS (M+H)
2410		358
2411		357
2412		360
2413		378
2414		378
2415		355
2416		378









Ex. No.	STR	MS (M+H)
2417		312
2418		271
2419		317
2420		297
2421		309
2422		273
2423		309
2424		309
2425		297

[1051]







































Ex. No.	STR	MS (M+H)
2426		255
2427		295
2428		285
2429		296
2430		295
2431		279
2432		284
2433		295
2434		282

Ex. No.	STR	MS (M+H)
2435		312
2436		330
2437		388
2438		402
2439		399
2440		373
2441		360
2442		355
2443		404










Ex. No.	STR	MS (M+H)
2444		302
2445		241
2446		379
2447		360
2448		359
2449		298
2450		317
2451		333
2452		342










Ex. No.	STR	MS (M+H)
2453		374
2454		296
2455		360
2456		331
2457		330
2458		281
2459		425
2460		442











[1052]










Ex. No.	STR	MS (M+H)
2461		347
2462		357
2463		341
2464		341
2465		325
2466		302
2467		284
2468		284
2469		268
2470		328
2471		298
2472		323
2473		358
2474		357
2475		355
2476		339
2477		292
2478		337
2479		267
2480		278
2481		379
2482		254
2483		297
2484		304
2485		304
2486		295
2487		293
2488		311
2489		306
2490		325
2491		304
2492		296
2493		255
2494		304
2495		338
2496		346
2497		278
2498		346

[1053]








Ex. No.	STR	MS (M+H)
2499		335
2500		347
2501		372
2502		285
2503		313
2504		360
2505		324
2506		333
2507		310











Ex. No.	STR	MS (M+H)
2508		337
2509		346
2510		307
2511		257
2512		268
2513		268
2514		268
2515		331
2516		271

Ex. No.	STR	MS (M+H)
2517		306
2518		257
2519		309
2520		339
2521		271
2522		272
2523		259
2524		320
2525		335
2526		353

Ex. No.	STR	MS (M+H)
2527		335
2528		293
2529		268
2530		340
2531		268
2532		279
2533		325
2534		299
2535		322

[1054]

Ex. No.	Ex. No.	MS (M+H)
2546		215
2547		225
2548		193
2549		267
2550		203
2551		169
2552		193

Ex. No.	STR	MS (M+H)
2536		297
2537		322
2538		268
2539		256
2540		165
2541		149
2542		199
2543		151
2544		151
2545		165

[1055]

Experimental Example 1

Effects on type 2 diabetes: Meal load test

To evaluate whether a cyanotriazol compound improves diabetes or not, especially related to postprandial blood glucose, meal load test was performed using one of type 2 diabetic model rats, the Zucker Diabetic Fatty (ZDF) rat (Charles river, Japan). About 24 animals fasted overnight (17h) were taken blood samples from the tail veins, and measured blood glucose levels (Pre BG) and body weights (BW). Proper animals were selected and divided into two groups (n = 6) based on the Pre BG and BW using SAS Statistical Analysis System (SAS institute Japan Ltd. Release 9.1). The compounds to be tested (10 or 30 mg/kg body weight in 5 % Arabia gum) or Arabia gum solution only (vehicle group) were orally administrated via gavage two hours prior to or just before meal loading (50 kcal/kg body weight). The meal suspension was prepared by mixing purified AIN-93G (Norsan Corp, Yokohama, Japan) and distilled water (2:3, w/v). One-hour after meal loading, blood glucose (BG1h) of each animal was measured. Effectiveness of each compound was shown by ⊿BG1h (BG1h difference between compound group and vehicle group). Although a set of 24 animals was used several times (from 13 weeks to 21 weeks of age), at least a one-week interval was placed from one to another test. The results are shown in Table 7.

[1056]

Table 7-1

Example No.	Dose (mg/kg)	⊿BG1h		Example No.	Dose (mg/kg)	⊿BG1h
11	10	-93.2		423	10	-87.6
14	10	-79.2		504	10	-69.1
15	10	-50.5		600	10	-74.0
21	10	-95.7		607	10	-106.8
22	10	-108.5		610	10	-86.8
23	10	-137.0		613	10	-138.8
29	10	-37.3		617	10	-113.3
41	10	-158.0		620	10	-159.7
47	10	-89.7		623	10	-111.2
49	10	-78.7		627	10	-85.2
50	10	-120.0		639	10	-58.5
51	10	-79.0		640	10	-62.0
52	10	-120.4		644	10	-131.0
55	10	-110.2		645	10	-121.6
60	10	-132.0		646	10	-89.3
70	10	-137.2		649	10	-99.4
75	10	-83.2		657	10	-120.5
77	10	-61.3		659	10	-161.2
78	10	-93.7		663	10	-149.5
79	10	-51.0		718	10	-147.5
90	10	-119.0		790	10	-61.5
92	10	-69.2		807	10	-94.5
98	10	-87.9		931	10	-76.4
100	10	-100.5		934	10	-87.2
108	10	-101.9		944	10	-125.1
120	10	-114.3		989	10	-116.0
122	10	-75.5		1004	10	-89.8
137	10	-162.6		1017	10	-124.6
146	10	-94.9		1018	10	-59.2
147	10	-80.5		1248	10	-82.2
220	10	-85.6		1505	10	-123.5
275	10	-83.3		1573	10	-132.7
276	10	-71.4		1672	10	-94.8
298	10	-62.8		1676	10	-49.5

[1057]

Table 7-2

Example No.	Dose (mg/kg)	⊿BG1h
1806	30	-86.3
1808	30	-76.0
1810	30	-53.2
1811	30	-84.5
1812	30	-111.8
1813	30	-73.0
1814	30	-108.7
1815	30	-63.2
1816	30	-45.5
1817	30	-106.5
1818	30	-33.0
1819	30	-54.3
1820	30	-77.0
1822	30	-36.0
1823	30	-63.3
1824	30	-70.5
1825	30	-48.3
1826	30	-91.3
1827	30	-82.5
1828	30	-69.3
1829	30	-93.7
1830	30	-52.5
1831	30	-61.0

[1058]

Experimental Example 2

Assay of the citric acid cycle activation

(1) Construction of the human NaCT expression vector pME-NaCT

The human NaCT (also called SLC13A5 or NAC2; GenBank accession No. NM_177550) cDNA was inserted into the EcoRI-NotI site of the mammalian expression vector pME18S (GenBank accession No. AB009864) and purified by Qiagen Plasmid Maxi Kit (Qiagen).

[1059]

(2) Establishment of NaCT stably expressed CHO cells

The pME-NaCT vector and the pcDNA™3.1 vector containing the neomycin resistance gene (Life Technologies) were co-transfected into CHO-K1 cells (ATCC) by Lipofectamine 2000 reagent (Life Technologies). The next day the cells were subcultured in Nutrient Mixture F-12 Ham (Sigma-Aldrich) with

10% FBS (Biological Industries), and Geneticin (Life Technologies) was added (final concentration 350 μg/mL) in the following day. CHO cell clones stably expressing NaCT were given by neomycin resistant cell screening and limiting dilution method. Established cell lines (named NaCT-CHO) were also maintained in culture medium (Nutrient Mixture F-12 Ham) with 10% FBS and 350 μg/mL Geneticin. For control cells (named pME-CHO) preparation, the naive pME18S were also transfected instead of pME-NaCT into CHO-K1 cells.

[1060]

(3) Assay of the citric acid cycle activation

NaCT-CHO and pME-CHO were plated at 20,000 cells/well into white CulturPlate™-96 (PerkinElmer) two days before the assay. Prior to assay incubation, the cultured plates were washed twice with washing buffer, 10 mM HEPES-Tris(pH7.4) containing 140 mM choline chloride, 2 mM KCl, 1 mM $CaCl_2$, 1 mM $MgCl_2$. The compounds to be tested were dissolved and diluted in DMSO (Wako Pure Chemical industries) to 1,000 times of a final concentration, and further diluted to two times as high as the final concentration in assay buffer, 10 mM HEPES-Tris(pH7.4) containing 140 mM NaCl, 2 mM KCl, 1 mM $CaCl_2$, 1 mM $MgCl_2$. The range of final concentrations was properly determined based on the test compounds activity. Each 25 μL compound solution was added to well and subsequently 25 μL radio-labeled substrate solution containing 0.4 mM (0.4MBq/mL) [1,5-^{14}C]-citric acid (PerkinElmer) in the assay buffer was added. After 1 hour incubation at 37°C, the reaction mixture was discarded and washed three times with pre-chilled washing buffer and then 0.1 mL MicroScint 20 (PerkinElmer) was added to well. The plate was sealed with TopSeal-A (PerkinElmer) and the radioactivity was measured using a TopCount (PerkinElmer). Non-specific activity (NS cpm) and total radio activity (Total cpm) were determined by counting of pME-CHO plated wells and NaCT-CHO plated wells without compounds, respectively. Diffusion of [^{14}C]-CO_2 was able to be estimated from residual

radioactivity (R cpm) by an equation (Total - R) / (Total - NS) × 100 (%). The difference of Total and R was disappeared in the presence of 0.1 μM antimycin A. EC_{50} values were calculated by regression analysis using SAS Statistical Analysis System (SAS institute Japan Ltd. Release 9.1). The results are shown in Table 8.

[1061]

Table 8-1

Ex. No.	EC50 (μM)		Ex. No.	EC50 (μM)
1	0.5		51	0.76
2	0.28		52	0.58
3	0.26		53	0.48
4	0.24		54	0.43
5	0.2		55	0.65
6	0.4		56	0.73
7	0.17		57	0.48
8	0.29		58	0.72
9	0.23		59	0.50
10	0.07		60	0.30
11	0.67		61	0.44
12	0.69		62	0.6
13	0.87		63	0.96
14	0.5		64	0.24
15	0.49		65	0.79
16	0.67		66	0.66
17	0.52		67	0.49
18	0.57		68	0.46
19	0.53		69	0.53
20	1.62		70	0.51
21	0.77		71	0.59
22	0.65		72	0.3
23	0.45		73	0.73
24	0.48		74	2.91
25	0.54		75	0.88
26	0.69		76	0.59
27	0.89		77	0.91
28	0.37		78	0.51
29	0.68		79	0.62
30	0.64		80	0.87
31	0.38		81	0.99
32	0.74		82	0.76
33	0.27		83	1.08
34	0.46		84	1.5
35	0.34		85	0.69
36	0.45		86	0.67
37	0.12		87	0.90
38	0.42		88	0.62
39	0.71		89	0.76
40	0.55		90	0.56
41	0.39		91	0.7
42	0.59		92	0.82
43	0.67		93	0.58
44	0.69		94	0.79
45	0.91		95	0.74
46	0.98		96	0.67
47	1.07		97	0.50
48	0.43		98	0.59
49	0.48		99	0.54
50	0.44		100	0.54

[1062]

Table 8-2

Ex. No.	EC50 (μM)	Ex. No.	EC50 (μM)
101	0.85	220	0.35
102	0.36	275	1.04
103	0.23	276	0.85
104	0.70	298	0.74
105	1.91	423	0.92
106	0.84	504	1.47
107	2.56	600	0.43
108	0.42	607	0.45
109	0.67	610	1.74
110	3.23	613	0.43
111	0.75	617	0.48
112	0.79	620	1.45
113	0.79	623	0.69
114	0.45	627	0.74
115	0.65	639	1.21
116	4.13	640	0.67
117	1.59	644	2.35
118	4.06	645	1.09
119	0.71	646	0.62
120	0.89	649	2.47
121	0.99	657	1.16
122	0.51	659	0.81
123	0.68	663	1.25
124	0.92	718	1.51
125	0.54	790	0.98
126	0.26	807	1.1
127	0.74	931	0.69
128	0.56	934	0.51
129	0.44	944	1.01
130	0.73	989	0.80
131	0.44	1004	1.80
132	0.32	1017	1.00
133	0.19	1018	1.17
134	0.085	1248	3.05
135	1.57	1505	0.42
136	0.68	1573	1.03
137	0.57	1672	1.29
138	0.062	1676	2.22
139	0.21		
140	0.8		
141	0.71		
142	0.58		
143	1.02		
144	0.79		
145	0.37		
146	0.41		
147	1.66		
148	0.92		
149	0.7		
150	0.86		

[1063]

Experimental Example 3

Measurement of carbon dioxide evolution rate and oxygen consumption rate

Carbon dioxide evolution rate (CDER) and oxygen consumption rate (OCR) were measured using an extracellular flux analyzer (XF24-3; Seahorse Bioscience). Measurements were conducted in Krebs-Henseleit HEPES Buffer (KHHB) containing 111 mM NaCl, 4.7 mM KCl, 2 mM $MgSO_4$, 1.2 mM Na_2HPO_4, 25 mM glucose, 1 mM sodium pyruvate, 20 mM HEPES (pH7.1). NaCT-CHO was maintained in culture medium (Nutrient Mixture F-12 Ham with 10% FBS and 350 μg/mL geneticin). The day before XF24 assay, the cells in a 100 μL volume of culture medium were seeded at 100,000 cells/well in an XF24 cell culture microplate (Seahorse Bioscience), allowed to attach for 4-5 hours, and then 150 μL of culture medium was added to each well. XF24-3 assay cartridge sensors (Seahorse Bioscience) were hydrated with XF Calibration solution (Seahorse Bioscience) and were incubated at 37°C for overnight. Next day the plate was incubated at 37°C for 1 hour prior to assay. After washing the plate twice with KHHB, 675 μL of KHHB was added to each well and then the plate was incubated for another 30 min. The compounds to be tested were first dissolved in DMSO (Wako Pure Chemical industries) at 1,000 times as high as a final concentration required for the assay and followed by further dilution with KHHB to 10 times of the final concentration. Injection port was loaded with the 75 μL of KHHB containing compounds. After a 13-min equilibration periods, a round of measurement which consisted of a 6.5-min mixing periods, a 0.5-min waiting period and a 4-min measuring periods, was repeated twice for basal measurement, and followed by the compounds injection. After the injection, a 5-round measurement was conducted for evaluating compound efficacy on CDER and OCR. CDER and OCR raw data were transformed using the "(LEVEL) Curve Fit" algorithm and

"(LEVEL) Direct (AKOS)" algorithm, respectively, which are components of the Seahorse XF24 1.8.0.14 software package. The results are shown in Figures 1 and 2.

Industrial Applicability

[1064]


Since Compound (1) stimulates the citric acid cycle activity and/or improves hyperglycemia, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

[1065]

This application is based on provisional patent application Nos. 61/847,268, 61/885,254 and 61/928,267 filed in USA, the contents of which are encompassed in full herein.

CLAIMS

1. A cyanotriazole compound represented by the formula (1):



(1)

wherein

R^1 is a phenyl group, a thiazolyl group, a thienyl group, a pyridyl group or a quinolyl group, each of which is substituted (provided that the phenyl group is substituted with a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halogen atom, a phenoxy group or a carboxy group, then the the phenyl group is substituted with additional one or more substituents); or

an oxazolyl group, a furyl group, a pyrrolyl group, a piperidyl group, an indolyl group, a benzofuryl group, a benzothienyl group, a phenyl lower alkyl group, a pyrimidinyl group, a 2,3-dihydroindolyl group, an imidazolyl group, a benzothiazolyl group, an isoxazolyl group, a 2,3-dihydrobenzofuryl group, an isothiazolyl group, a dibenzofuryl group, a benzo[1,3]dioxolyl group, a carbazolyl group, a naphthyl group, a 2-oxo-1,2,3,4-tetrahydroquinolyl group, a 6-oxo-1,6-dihydropyrimidinyl group, an imidazo[1,2-a]pyridyl group, an oxadiazolyl group, a thiadiazolyl group, a benzoxazolyl group, a styryl group, a benzoyl group, a cycloalkyl group, a higher alkyl group, a 2-oxo-1,2-dihydroquinolyl group, a benzimidazolyl group, a 2,3-dihydro[1,4]benzodioxinyl group, a fluorenyl group, a bicyclo[2,2,1]hept-2-enyl group, a thieno[3,2-b]pyridyl group, an imidazo[1,2-a]benzimidazolyl group, a 3,4-dihydro-2H-[1,4]benzoxazinyl group, a 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl group or an amino group, each of which is optionally substituted; and

R^2 is

(1) a hydrogen atom,

(2) a lower alkyl group optionally substituted with one or more substituents excluding an oxo group, or

(3) a heterocyclyl group optionally substituted with one or more substituents;

provided that

5-(4-styrylphenyl)-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3,4,5-trimethoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

methyl 4-[4-(4-cyano-1,2,3-triazol-5-yl)styryl]benzoate;

5-[4-(4-cyanostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-{4-[4-(*N*,*N*-dimethylamino)styryl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(biphenyl-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[4-(2-oxo-2*H*-chromen-3-yl)styryl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[4-(benzo[d]oxazol-2-yl)styryl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(2-methoxynaphthalen-1-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(4-methoxynaphthalen-1-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(pyridin-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(thiophen-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(benzofuran-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-[4-(4-formylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(4'-formylbiphenyl-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
4-(2,3-dimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3,4-dimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3,4,5-trimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3-fluoro-4-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(4-fluoro-3-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(4-fluoro-3-methoxyphenyl)-1,2,3-triazole-5-carbonitrile;
(5-(5-cyano-1,2,3-triazol-4-yl)furan-2-yl)methyl acetate;
2-[4-(4'-benzoxazole-2-yl-stilbene-4-yl)-5-cyano-1,2,3-triazole-N-yl]acetic acid methyl ester;
4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-N-trityl-1,2,3-triazole-5-carbonitrile;
2-(4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-5-cyano-1,2,3-triazol-N-yl)acetamide;
2-(4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-5-cyano-1,2,3-triazol-N-yl)acetic acid;
4-(4-(4-(1H-benzo[d]imidazol-2-yl)styryl)phenyl)-N-(2-oxo-2-phenylethyl)-1,2,3-triazole-5-carbonitrile; and
4-(4'-benzoxazole-2-yl-stilbene-4-yl)-5-cyano-N-acetamide-1,2,3-triazole;
are excluded,
or a salt thereof.

2. The compound or salt according to claim 1, wherein R^1 is a group represented by formula:

-A-L1-B

wherein

A is a divalent group selected from (A1) to (A45):

(A1) a phenylene group,
(A2) a thiazolediyl group,
(A3) an oxazolediyl group,
(A4) a thiophenediyl group,
(A5) a furandiyl group,
(A6) a pyrrolediyl group,

(A7) a pyridinediyl group,

(A8) a piperidinediyl group,

(A9) an indolediyl group,

(A10) a benzofurandiyl group,

(A11) a benzothiophenediyl group,

(A12) -lower alkylene-phenylene-,

(A13) a pyrimidinediyl group,

(A14) a quinolinediyl group,

(A15) a 2,3-dihydroindolediyl group,

(A16) an imidazolediyl group,

(A17) a benzothiazolediyl group,

(A18) an isoxazolediyl group,

(A19) a 2,3-dihydrobenzofurandiyl group,

(A20) an isothiazolediyl group,

(A21) a dibenzofurandiyl group,

(A22) a benzo[1,3]dioxolediyl group,

(A23) a carbazolediyl group,

(A24) a naphthalenediyl group,

(A25) a 2-oxo-1,2,3,4-tetrahydroquinolinediyl group,

(A26) a 6-oxo-1,6-dihydropyrimidinediyl group,

(A27) an imidazo[1,2-a]pyridinediyl group,

(A28) a [1,3,4]oxadiazolediyl group,

(A29) a [1,2,4]thiadiazolediyl group,

(A30) a benzoxazolediyl group,

(A31) a [1,3,4]thiadiazolediyl group,

(A32) a styrenediyl group,

(A33) -CO-phenylene-,

(A34) a cycloalkanediyl group,

(A35) a higher alkylene group,

(A36) a 2-oxo-1,2-dihydroquinolinediyl group,

(A37) a benzimidazolediyl group,

(A38) a 2,3-dihydro[1,4]benzodioxinediyl group,

(A39) a fluorenediyl group,

(A40) a bicyclo[2,2,1]hept-2-enediyl group,

(A41) a thieno[3,2-b]pyridinediyl group,

(A42) an imidazo[1,2-a]benzimidazolediyl group,

(A43) a 3,4-dihydro-2H-[1,4]benzoxazinediyl group,

(A44) a 3,4-dihydro-2H-benzo[b][1,4]dioxepinediyl group, and

(A45) -NH-,

each of (A1) to (A45) is optionally substituted with one or more members selected from the group consisting of

a halogen atom;

a lower alkyl group optionally substituted with one or more halogen atoms;

a lower alkenyl group;

a hydroxy group;

a lower alkoxy group optionally substituted with one or more halogen atoms;

a lower alkenyloxy group;

a lower alkynyloxy group;

a cyano group;

an amino group optionally mono- or di-substituted with members selected from the group consisting of a lower alkyl group, a lower alkyl-carbonyl group, a lower alkoxy-carbonyl group, and a lower alkylsulfonyl group;

a N,N-di-lower alkylamino lower alkyl group;

a N,N-di-lower alkylamino lower alkoxy group;

a cycloalkyl group optionally substituted with one or more halogen atoms;

a cycloalkoxy group optionally substituted with one or more halogen atoms;

a cycloalkyl lower alkyl group optionally substituted with one or more halogen atoms;

a cycloalkyl lower alkoxy group optionally substituted with one or more halogen atoms;

a lower alkoxy lower alkyl group optionally substituted with one or more halogen atoms;

a lower alkoxy lower alkoxy group optionally substituted with one or more halogen atoms;

a lower alkylthio group;

a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;

a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;

a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;

a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;

a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;

a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;

a phenoxy lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;

a thienyl group;
an oxetanyl lower alkoxy group optionally substituted with one or more lower alkyl groups;
a furyl group;
a piperidyl group;
a pyrrolidinyl group; and
a morpholinyl group;

L1 is

a bond,
lower alkylene, lower alkenylene,
-O-, -O-lower alkylene, lower alkylene-O-, -O-lower alkenylene, lower alkenylene-O-,
-O-lower alkylene-CO-, -CO-lower alkylene-O-,
-O-lower alkylene-O-, -O-lower alkenylene-O-, lower alkylene-O-lower alkylene, lower alkylene-C(OH)-lower alkylene,
-CO-, -CO-lower alkylene, lower alkylene-CO-,
-NH-, -NH-lower alkylene, lower alkylene-NH-, -N(phenyl)-, -N(lower alkyl)-, -N(lower alkyl)-lower alkylene, lower alkylene-N(lower alkyl)-,
-CONH-, -CONH-lower alkylene, lower alkylene-CONH-, -CO-N(lower alkyl)-, -CO-N(lower alkyl)-lower alkylene, lower alkylene-CO-N(lower alkyl)-,
-NHCO-, -N(lower alkyl)-CO-, -NHCO-lower alkylene, lower alkylene-NHCO-, -N(lower alkyl)-CO-lower alkylene, lower alkylene -N(lower alkyl)-CO-,
-CO_2-, -CO_2-lower alkylene, lower alkylene-CO_2-,
-OCO-, -OCO-lower alkylene, lower alkylene-OCO-,
-$NHCO_2$-lower alkylene, lower alkylene-$NHCO_2$-, -N(lower alkyl)-CO_2-lower alkylene, lower alkylene-N(lower alkyl)-CO_2-,
-OCONH-lower alkylene, lower alkylene-OCONH-, -OCO-N(lower alkyl)-lower alkylene, lower alkylene-OCO-N(lower alkyl)-,
-S-, lower alkylene-S-, -S-lower alkylene, lower alkylene-S-lower alkylene,
-SO_2-, lower alkylene-SO_2-, -SO_2-lower alkylene, lower alkylene-SO_2-lower alkylene,

-$NHSO_2$-lower alkylene, lower alkylene-$NHSO_2$-, -N(lower alkyl)-SO_2-lower alkylene, lower alkylene-N(lower alkyl)-SO_2-, -SO_2NH-lower alkylene, lower alkylene-SO_2NH-, -SO_2-N(lower alkyl) -lower alkylene, or lower alkylene-SO_2-N(lower alkyl)-; and

B is a group or an atom selected from (B1) to (B65):

(B1) a phenyl group,

(B2) a naphthyl group,

(B3) a tetrahydronaphthyl group,

(B4) an imidazolyl group,

(B5) a [1,2,3]triazolyl group,

(B6) a thiazolyl group,

(B7) a pyrazolyl group,

(B8) a thienyl group,

(B9) a furyl group,

(B10) a tetrahydrofuryl group,

(B11) a pyrrolyl group,

(B12) a pyridyl group,

(B13) an imidazo[1,2-a]pyridyl group,

(B14) a pyrimidinyl group,

(B15) a pyridazyl group,

(B16) a pyrazyl group,

(B17) a pyrrolo[2,3-b]pyridyl group,

(B18) a pyrazolo[3,4-b]pyridyl group,

(B19) a piperidyl group,

(B20) a piperazinyl group,

(B21) a morpholinyl group,

(B22) a pyrrolidinyl group,

(B23) a quinolyl group,

(B24) an isoquinolyl group,

(B25) a 1,2,3,4-tetrahydroquinolyl group,

(B26) a 1,2,3,4-tetrahydroisoquinolyl group,

(B27) a 2-oxo-1,2,3,4-tetrahydroquinolyl group,

(B28) an indolyl group,

(B29) a 2,3-dihydroindolyl group,

(B30) an indanyl group,

(B31) a benzofuryl group,

(B32) a 2,3-dihydrobenzofuryl group,

(B33) a benzothienyl group,

(B34) a benzothiazolyl group,

(B35) a benzo[1,3]dioxolyl group,

(B36) a cycloalkyl group,

(B37) a cycloalkenyl group,

(B38) a tetrahydropyranyl group,

(B39) an oxetanyl group,

(B40) an oxiranyl group,

(B41) a 2,3-dihydro[1,4]benzodioxinyl group,

(B42) a 3,4-dihydro-2H-benzo[1,4]oxazinyl group,

(B43) a dibenzofuryl group,

(B44) a 4H-benzo[1,3]dioxinyl group,

(B45) a 1,2,4-oxadiazolyl group,

(B46) a 1,3,4-oxadiazolyl group,

(B47) an indazolyl group,

(B48) an isoxazolyl group,

(B49) a benzoisoxazolyl group,

(B50) a 2-oxo-1,2-dihydro-1H-benzimidazolyl group,

(B51) a 2-oxo-2,3-dihydro-3H-benzothiazolyl group,

(B52) a 2,3,4,5-tetrahydrobenzo[1,4]oxazepinyl group,

(B53) an isoindolinyl group,

(B54) a 2,4-dihydro-1H-benzo[1,3]oxazinyl group,

(B55) a 1,2,3,4-tetrahydrobenzo[1,4]oxazepinyl group,

(B56) a 2,3,4,5-tetrahydro-1H-benzoazepinyl group,

(B57) a tetrazolyl group,

(B58) a 2-oxo-1,2-dihydroquinolyl group,

(B59) a 3,4-dihydro-2H-benzodioxepinyl group,

(B60) a 3,6-dihydropyranyl group,

(B61) a 2-oxo-benzoxazolyl group,

(B62) an oxazolyl group,

(B63) a benzoxazolyl group,

(B64) a triphenylphosphonium group, and

(B65) a hydrogen atom,

each of (B1) to (B64) is optionally substituted on the ring(s) with one or more members selected from the group consisting of a halogen atom;

an oxo group;

a lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, and a hydroxy group;

a higher alkyl group;

a hydroxy group;

a lower alkoxy group optionally substituted with one or more halogen atoms;

a cyano group;

a nitro group;

an amino group optionally mono- or di-substituted with lower alkyl groups;

a lower alkylsulfonylamino group;

a N,N-di-lower alkylamino-carbonyl group;

a N,N-di-lower alkylamino lower alkoxy group;

an acetylamino lower alkyl group;

a formyl group;

a lower alkyl-carbonyl group;

a lower alkylsulfonyl group;

a lower alkoxy-carbonyl group optionally substituted with one or more halogen atoms;


a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, a lower alkoxy group optionally substituted with one or more halogen atoms, and a phenoxy group;

a phenoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;

a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a phenoxy lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms;
a benzoyl group;
a lower alkylthio group optionally substituted with one or more halogen atoms;
a morpholinyl group;
a piperazinyl group optionally substituted with one or more lower alkyl groups;
a thienyl group;
a pyrrolyl group;
a pyrimidinyl group;
a pyrazolyl group optionally substituted with one or more

lower alkyl groups optionally substituted with one or more halogen atoms;
a thiazolyl group optionally substituted with one or more lower alkyl groups;
a tetrahydropyranyloxy group;
a furyl group;
a pyrazinyl group optionally substituted with one or more lower alkyl groups;
a [1,2,4]oxadiazolyl group optionally substituted with one or more lower alkyl groups;
a [1,3,4]oxadiazolyl group optionally substituted with one or more lower alkyl groups;
a pyrrolidinyl group;
a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms;
an isoxazolyl group;
an imidazolyl group;
a cycloalkyl group;
a 2-oxo-pyrrolidinyl group; and
a [1,2,3]triazolyl group optionally substituted with one or more cyano groups.

3. A cyanotriazole compound represented by the formula (1aa):



(1aa)

wherein

R^{1a} is one of the following (1-1) to (1-34):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-108):

(1-1-1) a lower alkyl group optionally substituted with one

or more halogen atoms,
(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-3) a lower alkoxy lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atoms; and a cycloalkyl group,
(1-1-4) a cycloalkyl group,
(1-1-5) a cycloalkoxy group optionally substituted with one or more halogen atoms,
(1-1-6) a cycloalkyl lower alkyl group,
(1-1-7) a cycloalkyl lower alkoxy group optionally substituted on the cycloalkyl group with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group optionally substituted with one or more halogen atoms,
(1-1-8) a cycloalkyl lower alkoxy lower alkyl group optionally substituted on the cycloalkyl group with one or more members selected from the group consisting of a hydroxy; and a lower alkoxy group,
(1-1-9) a halogen atom,
(1-1-10) a cyano group,
(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkoxy-carbonyl group; a lower alkylsulfonyl group; a phenyl group; a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom and a lower alkyl group optionally substituted with one or more halogen atoms; a phenoxy group; and a cyano group,
(1-1-12) a phenyl lower alkyl group optionally substituted with one or more members selected from the group consisting

of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; and a hydroxy group,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; a halogen atom; and a 5-cyano-1H-1,2,3-triazol-4-yl group,

(1-1-14) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; and a cyano group,

(1-1-17) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atoms; and a lower alkyl group,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; and a lower alkyl group optionally substituted with one or more

halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a cyano group,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-25) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group,

(1-1-28) a benzoxazolyl group optionally substituted with one or more halogen atoms,

(1-1-29) a benzofuryl group optionally substituted with one or more halogen atoms,

(1-1-30) a benzofuryl lower alkoxy group optionally substituted on the benzofuran ring with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkyl-carbonyl group; and a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-32) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-34) an indolinyl lower alkyl group,

(1-1-35) a benzothienylvinyl group,

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-1-37) a lower alkoxy lower alkoxy group,

(1-1-38) a cycloalkoxy lower alkyl group optionally substituted on the cycloalkyl group with one or more lower alkyl groups,

(1-1-39) a cycloalkyl lower alkenyl group,

(1-1-40) a cycloalkenyloxy group,

(1-1-41) a cycloalkenylvinyl group,

(1-1-42) an oxiranyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-43) an oxetanyl lower alkoxy group optionally substituted on the oxetane ring with one or more lower alkyl groups,

(1-1-44) a tetrahydropyranyl lower alkoxy group,

(1-1-45) a hydroxy group,

(1-1-46) a phenyl lower alkoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkylthio group optionally substituted with one or more halogen atoms,

(1-1-47) a phenyl lower alkenyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-48) a benzoyl group optionally substituted with one or more halogen atoms,

(1-1-49) a phenylthio lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atoms; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-50) a phenylsulfonyl group optionally substituted with one or more lower alkyl groups,

(1-1-51) a phenylsulfonyl lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-52) a naphthyl group optionally substituted with one or more halogen atoms,

(1-1-53) a naphthylvinyl group optionally substituted on

the naphthyl ring with one or more halogen atoms,
(1-1-54) a tetrahydronaphthyloxy group,
(1-1-55) an indanyloxy group,
(1-1-56) an amino group optionally mono- or di-substituted with members selected from the group consisting of a lower alkyl group; a lower alkyl-carbonyl group; a lower alkoxy-carbonyl group; and a lower alkylsulfonyl group;
(1-1-57) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-58) an aminocarbonyl group optionally substituted with one or more members selected from the group consisting of a lower alkyl group; a cycloalkyl group; a cycloalkyl lower alkyl group; and a phenyl group optionally substituted with one or more halogen atoms,
(1-1-59) a pyridyl lower alkoxy group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-60) a pyridyloxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-61) a pyrrolo[2,3-b]pyridyl group optionally substituted with one or more lower alkyl groups,
(1-1-62) a pyrazolo[3,4-b]pyridyl group optionally substituted with one or more lower alkyl groups,
(1-1-63) an imidazo[1,2-a]pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-64) a pyrimidinyl lower alkyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-65) a pyrimidinyl lower alkoxy group optionally substituted on the pyrimidine ring with one or more members selected from the group consisting of a lower alkoxy group; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group,

(1-1-66) a pyrimidinyloxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-67) a pyrimidinyloxy lower alkyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-68) a pyrazinyl group optionally substituted with one or more lower alkyl groups,

(1-1-69) a pyridazinyl group optionally substituted with one or more members selected from the group consisting of a lower alkyl group; and a lower alkoxy group,

(1-1-70) a piperidyl lower alkyl group,

(1-1-71) a piperidylcarbonyl group,

(1-1-72) a piperazinyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-1-73) an imidazolyl group,

(1-1-74) a pyrazolyl group optionally substituted with one or more lower alkyl groups,

(1-1-75) a pyrrolyl lower alkyl group,

(1-1-76) a thiazolyl group,

(1-1-77) a thiazolyl lower alkoxy group optionally substituted on the thiazole ring with one or more lower alkyl groups,

(1-1-78) a benzothiazolyl group optionally substituted with one or more halogen atoms,

(1-1-79) a furyl group,

(1-1-80) a furylvinyl group optionally substituted on the furan ring with one or more lower alkyl groups,

(1-1-81) a benzofurylvinyl group,
(1-1-82) a 2,3-dihydrobenzofuryl group,
(1-1-83) a thienyl lower alkoxy group,
(1-1-84) a thienylvinyl group optionally substituted on the thiophene ring with one or more halogen atoms,
(1-1-85) a benzothienyl lower alkyl group optionally substituted on the benzothiophene ring with one or more halogen atoms,
(1-1-86) a benzothienyl lower alkoxy group optionally substituted on the benzothiophene ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-87) a benzo[1,3]dioxolyl lower alkyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,
(1-1-88) a benzo[1,3]dioxolyl lower alkoxy group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,
(1-1-89) a 4H-benzo[1,3]dioxinyl group optionally substituted with one or more halogen atoms,
(1-1-90) a 4H-benzo[1,3]dioxinylvinyl group optionally substituted on the benzo[1,3]dioxine ring with one or more halogen atoms,
(1-1-91) a quinolyl group,
(1-1-92) a quinolyl lower alkoxy group,
(1-1-93) a quinolylvinyl group,
(1-1-94) a 3,4-dihydro-2H-quinolyl group,
(1-1-95) a 3,4-dihydro-2H-quinolyl lower alkyl group,
(1-1-96) a 2-oxo-1,2,3,4-tetrahydroquinolyl group,
(1-1-97) a 2-oxo-1,2,3,4-tetrahydroquinolyl lower alkoxy group,
(1-1-98) a 2-oxo-1,2,3,4-tetrahydroquinolyloxy group optionally substituted with one or more lower alkyl groups,
(1-1-99) an isoquinolyl group,

(1-1-100) a 3,4-dihydro-1H-isoquinolyl group,
(1-1-101) a 3,4-dihydro-1H-isoquinolyl lower alkyl group,
(1-1-102) an indolyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group; and a lower alkoxy-carbonyl group,
(1-1-103) an indolyl lower alkyl group,
(1-1-104) an indolylvinyl group optionally substituted on the indole ring with one or more lower alkyl groups,
(1-1-105) an indolinyl group,
(1-1-106) an indolinylcarbonyl group,
(1-1-107) a 1H-1,2,3-triazolyl group optionally substituted with one or more cyano groups, and
(1-1-108) a triphenylphosphonium lower alkyl group,
(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-26):
(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,
(1-2-2) a lower alkoxy group,
(1-2-3) a cycloalkyl group,
(1-2-4) a halogen atom,
(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a hydroxy group; and a cyano group,
(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group

optionally substituted with one or more halogen atoms,
(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,
(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-2-10) an amino group optionally mono- or di-substituted with members selected from the group consisting of a lower alkyl group; a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms; a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms; and a benzoyl group optionally substituted with one or more halogen atoms,
(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-2-12) a lower alkenyl group,
(1-2-13) a cycloalkyl lower alkyl group,
(1-2-14) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a hydroxy group,
(1-2-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or

more halogen atoms,

(1-2-16) a phenyl lower alkoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group optionally substituted with one or more halogen atoms; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-17) a phenyl lower alkylsulfonyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-18) a mono- or di-N-lower alkyl amino lower alkyl group;

(1-2-19) a piperidyl group optionally substituted with one or more members selected from the group consisting of a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-20) a piperazinyl group optionally substituted with one or more phenyl groups optionally substituted with one or more members selected from the group consisting of a halogen atom, and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-21) an indolyl group,

(1-2-22) a morpholinyl group,

(1-2-23) a thienyl group,

(1-2-24) a benzothienyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-25) a furyl group, and

(1-2-26) a cyano group,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-12):

(1-3-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3-2) a cycloalkyl group,

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-3-4) a lower alkoxy lower alkyl group,

(1-3-5) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-3-6) a naphthyl group,

(1-3-7) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-3-8) a furyl group,

(1-3-9) a dihydrobenzofuryl group,

(1-3-10) a thienyl group,

(1-3-11) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-3-12) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-14):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more members selected from the group consisting of a halogen atom and a hydroxy group; a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl-carbonyl group; a lower alkoxy-carbonyl group; and a benzyloxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms, and a halogen atom,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a halogen atom,

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-6) a cycloalkyl lower alkenyl group,

(1-4-7) a halogen atom,

(1-4-8) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-9) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-10) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-11) a thienyl group optionally substituted with one or more members selected from the group consisting of a

halogen atom; and a phenyl group optionally substituted with one or more halogen atoms,

(1-4-12) a thienylvinyl group,

(1-4-13) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-4-14) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-8):

(1-5-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a phenyl group,

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,

(1-5-3) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-5-4) a naphthyl group,

(1-5-5) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5-6) a quinolyl group,

(1-5-7) a benzothienyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-5-8) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more

members selected from the group consisting of the following (1-6-1) to (1-6-5):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a phenoxy group; a benzyl group; and a benzoyl group,

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; a lower alkoxy group optionally substituted with one or more halogen atoms; a phenyl group; and a phenyl lower alkoxy group,

(1-6-4) an indanyl group, and

(1-6-5) a benzo[1,3]dioxolyl lower alkyl group,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-9):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7-3) a benzofuryl group,

(1-7-4) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7-5) a naphthyl group,

(1-7-6) a halogen atom,

(1-7-7) a pyridyl group,

(1-7-8) a benzothienyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-7-9) a [1,2,3]triazolyl group optionally substituted with one or more cyano groups,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-8):

(1-8-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-8-3) a lower alkoxy-carbonyl group,

(1-8-4) a benzoyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-8-5) a phenyl lower alkyl-carbonyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-8-6) a phenyl lower alkoxy-carbonyl group,

(1-8-7) a phenoxycarbonyl group, and

(1-8-8) a phenylsulfonyl group optionally substituted with one or more lower alkyl groups,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-8):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-9-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group,
(1-9-3) a cycloalkyl lower alkyl group,
(1-9-4) a halogen atom,
(1-9-5) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-9-6) a thienyl lower alkyl group,
(1-9-7) a tetrahydrofuryl lower alkyl group, and
(1-9-8) a benzo[1,3]dioxolyl group,
(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of the following (1-10-1) to (1-10-7):
(1-10-1) a halogen atom,
(1-10-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-10-3) a lower alkyl group,
(1-10-4) a benzyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-10-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-10-6) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms, and
(1-10-7) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-11) a benzothienyl group optionally substituted with one or

more members selected from the group consisting of the following (1-11-1) to (1-11-7):

(1-11-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-11-2) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-11-3) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-11-4) a halogen atom,

(1-11-5) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-11-6) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-11-7) a thienyl group,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-4):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-12-3) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-12-4) a phenoxy group,

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-7):

(1-13-1) a phenyl group optionally substituted with one or

more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-13-2) a pyrrolidyl group,

(1-13-3) a piperidyl group,

(1-13-4) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-13-5) a lower alkoxy group,

(1-13-6) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-13-7) a morpholinyl group,

(1-14) a quinolyl group substituted with one or more members selected from the group consisting of the following (1-14-1) to (1-14-5):

(1-14-1) a lower alkoxy group,

(1-14-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-14-3) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-14-4) a pyrrolidyl group, and

(1-14-5) a thienyl group,

(1-15) a 2,3-dihydro-1H-indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-15-1) to (1-15-2):

(1-15-1) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-15-2) a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group

optionally substituted with one or more halogen atoms,

(1-16) an imidazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-16-1) to (1-16-4):

(1-16-1) a lower alkyl group,

(1-16-2) a halogen atom,

(1-16-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-16-4) a benzyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-17) a benzothiazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-17-1) to (1-17-6):

(1-17-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-17-2) a lower alkoxy group,

(1-17-3) a halogen atom,

(1-17-4) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-17-5) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-17-6) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-18) an isoxazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-19) a 2,3-dihydrobenzofuryl group optionally substituted with one or more members selected from the group consisting of the following (1-19-1) to (1-19-3):

(1-19-1) a halogen atom,

(1-19-2) a phenyl group optionally substituted with one or more halogen atoms, and

(1-19-3) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-20) an isothiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more members selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted with one or more halogen atoms, and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-21) a dibenzofuryl group,

(1-22) a benzo[1,3]dioxolyl group optionally substituted with one or more members selected from the group consisting of the following (1-22-1) to (1-22-2):

(1-22-1) a halogen atom, and

(1-22-2) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-23) a carbazolyl group optionally substituted with one or more lower alkyl groups,

(1-24) a naphthyl group optionally substituted with one or more benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-25) a 2-oxo-1,2,3,4-tetrahydroquinolyl group optionally substituted with one or more benzyl groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-26) a 6-oxo-1,6-dihydropyrimidinyl group optionally substituted with one or more phenyl groups optionally

substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-27) an imidazo[1,2-a]pyridyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-28) a [1,3,4]oxadiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-29) a [1,2,4]thiadiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-30) a benzoxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-30-1) to (1-30-4):

(1-30-1) a lower alkyl group,

(1-30-2) a lower alkoxy group,

(1-30-3) a halogen atom, and

(1-30-4) a phenyl group,

(1-31) a [1,3,4]thiadiazolyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms;

(1-32) a styryl group optionally substituted on the phenyl ring with one or more benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-33) a benzoyl group optionally substituted with one or more benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-34) a cycloalkyl group optionally substituted with one or more members selected from the group consisting of a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom and a benzyloxy

group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and a benzyloxy groups optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms; provided that

5-(4-styrylphenyl)-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3,4,5-trimethoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-cyanostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(pyridin-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(thiophen-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(benzofuran-2-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

4-(4-methylphenyl)-5-cyano-1,2,3-triazole;

4-(4-isopropylphenyl)-5-cyano-1,2,3-triazole;

4-(4-methoxyphenyl)-5-cyano-1,2,3-triazole;

4-(2,3-dimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3,4-dimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3,4,5-trimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(4-fluorophenyl)-5-cyano-1,2,3-triazole;

4-(4-chlorophenyl)-5-cyano-1,2,3-triazole;

4-(4-bromophenyl)-5-cyano-1,2,3-triazole;

4-(4-phenoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3-fluoro-4-phenoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3-phenoxyphenyl)-5-cyano-1,2,3-triazole;

4-(4-fluoro-3-phenoxyphenyl)-5-cyano-1,2,3-triazole;

4-(2-fluorophenyl)-1,2,3-triazole-5-carbonitrile; and

4-(4-fluoro-3-methoxyphenyl)-1,2,3-triazole-5-carbonitrile;

are excluded,
or a salt thereof.

4. The compound or salt according to claim 3, wherein R^{1a} is one of the following (1-1) to (1-13):
(1-1) a phenyl group substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-36):
(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-3) a lower alkoxy lower alkyl group,
(1-1-4) a cycloalkyl group,
(1-1-5) a cycloalkoxy group,
(1-1-6) a cycloalkyl lower alkyl group,
(1-1-7) a cycloalkyl lower alkoxy group,
(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,
(1-1-9) a halogen atom,
(1-1-10) a cyano group,
(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom,

(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower

alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-29) a benzofuryl group,

(1-1-30) a benzofuryl lower alkoxy group,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-34) an indolinyl lower alkyl group,

(1-1-35) a benzothienylvinyl group, and

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a

halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-3):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-3) a benzofuryl group,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or

more members selected from the group consisting of the following (1-10-1) to (1-10-2):

(1-10-1) a halogen atom, and

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and


(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidinyl group, and

(1-13-3) a piperidyl group.

5. A cyanotriazole compound represented by the formula (1aa):



(1aa)

wherein

R^{1a} is the following (1-1):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-36):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-3) a lower alkoxy lower alkyl group,
(1-1-4) a cycloalkyl group,
(1-1-5) a cycloalkoxy group,
(1-1-6) a cycloalkyl lower alkyl group,
(1-1-7) a cycloalkyl lower alkoxy group,
(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,
(1-1-9) a halogen atom,
(1-1-10) a cyano group,
(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom,
(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more

halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,

(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,


(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,
(1-1-29) a benzofuryl group,
(1-1-30) a benzofuryl lower alkoxy group,
(1-1-31) a thienyl group,
(1-1-32) a benzothienyl group,
(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,
(1-1-34) an indolinyl lower alkyl group,
(1-1-35) a benzothienylvinyl group, and
(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms;

provided that
5-(4-styrylphenyl)-1,2,3-triazole-4-carbonitrile;
5-[4-(4-methylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(4-methoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(3,4,5-trimethoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(4-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(3-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-[4-(4-cyanostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;
5-{4-[2-(pyridin-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;
4-(4-methylphenyl)-5-cyano-1,2,3-triazole;
4-(4-isopropylphenyl)-5-cyano-1,2,3-triazole;
4-(4-methoxyphenyl)-5-cyano-1,2,3-triazole;
4-(2,3-dimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3,4-dimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3,4,5-trimethoxyphenyl)-5-cyano-1,2,3-triazole;
4-(4-fluorophenyl)-5-cyano-1,2,3-triazole;
4-(4-chlorophenyl)-5-cyano-1,2,3-triazole;
4-(4-bromophenyl)-5-cyano-1,2,3-triazole;
4-(4-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3-fluoro-4-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(3-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(4-fluoro-3-phenoxyphenyl)-5-cyano-1,2,3-triazole;
4-(2-fluorophenyl)-1,2,3-triazole-5-carbonitrile; and
4-(4-fluoro-3-methoxyphenyl)-1,2,3-triazole-5-carbonitrile;
are excluded,
or a salt thereof.

6. A cyanotriazole compound represented by the formula (1aa):



(1aa)

wherein

R^{1a} is one of the following (1-2) to (1-13):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl

ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a phenyl lower alkyl group optionally substituted

on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-3):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-3) a benzofuryl group,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of the following (1-10-1) to (1-10-2):

(1-10-1) a halogen atom, and

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or

more phenyl groups optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms; and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidinyl group, and

(1-13-3) a piperidyl group,

or a salt thereof.

7. The compound or salt according to claim 3 or 4, wherein R^{1a} is one of the following (1-1) to (1-7), (1-9), (1-10), (1-12) and (1-13):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-9) a halogen atom,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted

on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom,

(1-1-14) a phenoxy group,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups

optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-1-35) a benzothienylvinyl group, and

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms,

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members

selected from the group consisting of

(1-4-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of

(1-6-1) a lower alkyl group, and

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of

(1-7-3) a benzofuryl group,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally

substituted with one or more halogen atoms, and


(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group.

8. A cyanotriazole compound represented by the formula (1aa):



(1aa)

wherein

R^{1a} is the following (1-1):

(1-1) a phenyl group substituted with one or more members selected from the group consisting of

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-9) a halogen atom,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group optionally substituted with one or more halogen atoms; a lower alkyl

group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom,

(1-1-14) a phenoxy group,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted

with one or more halogen atoms,

(1-1-35) a benzothienylvinyl group, and

(1-1-36) a benzo[1,3]dioxolylvinyl group optionally substituted on the benzo[1,3]dioxole ring with one or more halogen atoms;

provided that

5-(4-styrylphenyl)-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methylstyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-methoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3,4,5-trimethoxystyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(3-chlorostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-[4-(4-cyanostyryl)phenyl]-1,2,3-triazole-4-carbonitrile;

5-{4-[2-(pyridin-4-yl)vinyl]phenyl}-1,2,3-triazole-4-carbonitrile;

4-(4-methylphenyl)-5-cyano-1,2,3-triazole;

4-(4-isopropylphenyl)-5-cyano-1,2,3-triazole;

4-(4-methoxyphenyl)-5-cyano-1,2,3-triazole;

4-(2,3-dimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3,4-dimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3,4,5-trimethoxyphenyl)-5-cyano-1,2,3-triazole;

4-(4-fluorophenyl)-5-cyano-1,2,3-triazole;

4-(4-chlorophenyl)-5-cyano-1,2,3-triazole;

4-(4-bromophenyl)-5-cyano-1,2,3-triazole;

4-(4-phenoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3-fluoro-4-phenoxyphenyl)-5-cyano-1,2,3-triazole;

4-(3-phenoxyphenyl)-5-cyano-1,2,3-triazole; and

4-(4-fluoro-3-phenoxyphenyl)-5-cyano-1,2,3-triazole;


4-(2-fluorophenyl)-1,2,3-triazole-5-carbonitrile; and

4-(4-fluoro-3-methoxyphenyl)-1,2,3-triazole-5-carbonitrile;

are excluded,

or a salt thereof.

9. A cyanotriazole compound represented by the formula (1aa):



(1aa)

wherein

R^{1a} is one of the following (1-2) to (1-7), (1-9), (1-10), (1-12) and (1-13):

(1-2) a thiazolyl group substituted with one or more members selected from the group consisting of

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group substituted with one or more members selected from the group consisting of

(1-4-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more members selected from the group consisting of

(1-6-1) a lower alkyl group, and

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group substituted with one or more members selected from the group consisting of

(1-7-3) a benzofuryl group,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more members selected from the group consisting of

(1-10-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of


(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and

(1-13-3) a piperidyl group,

or a salt thereof.

10. A cyanotriazole compound represented by the formula (1bb):



(1bb)

wherein

R^{1b} is one of the following (1-1) to (1-13):

(1-1) a phenyl group optionally substituted with one or more members selected from the group consisting of the following (1-1-1) to (1-1-34):

(1-1-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-3) a lower alkoxy lower alkyl group,

(1-1-4) a cycloalkyl group,

(1-1-5) a cycloalkoxy group,

(1-1-6) a cycloalkyl lower alkyl group,

(1-1-7) a cycloalkyl lower alkoxy group,

(1-1-8) a cycloalkyl lower alkoxy lower alkyl group,

(1-1-9) a halogen atom,

(1-1-10) a cyano group,

(1-1-11) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl

group optionally substituted with one or more halogen atoms,
(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkoxy group; a lower alkyl group optionally substituted with one or more halogen atoms; a cyano group; and a halogen atom,
(1-1-14) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-15) a phenoxy lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,
(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; a lower alkoxy group; and a lower alkyl group optionally substituted with one or more halogen atoms,
(1-1-17) a phenylthio group optionally substituted with one or more halogen atoms,
(1-1-18) a benzylthio lower alkyl group optionally substituted on the phenyl ring with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,
(1-1-19) an N-lower alkyl-N-phenyl amino lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,
(1-1-20) an N-benzyl-N-lower alkyl amino group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,
(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or

more halogen atoms,

(1-1-22) a pyridyl lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-27) a piperidyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-28) a benzoxazolyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-29) a benzofuryl group,

(1-1-30) a benzofuryl lower alkoxy group,

(1-1-31) a thienyl group,

(1-1-32) a benzothienyl group,

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms, and

(1-1-34) an indolinyl lower alkyl group,

(1-2) a thiazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-2-1) to (1-2-11):

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-2) a lower alkoxy group,

(1-2-3) a cycloalkyl group,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-6) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-2-7) a phenoxy group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-2-8) a benzyloxy group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-2-9) a phenylthio group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-10) an N-lower alkyl-N-phenyl amino group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from the group consisting of the following (1-3-1) to (1-3-3):

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group optionally substituted with one or more members selected from the group consisting of the following (1-4-1) to (1-4-5):

(1-4-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-4-3) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-4-4) a phenoxy group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-4-5) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-5) a furyl group optionally substituted with one or more members selected from the group consisting of the following (1-5-1) to (1-5-2):

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms, and

(1-5-2) a styryl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-6) a pyrrolyl group optionally substituted with one or more

members selected from the group consisting of the following (1-6-1) to (1-6-3):

(1-6-1) a lower alkyl group,

(1-6-2) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-6-3) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-7) a pyridyl group optionally substituted with one or more members selected from the group consisting of the following (1-7-1) to (1-7-2):

(1-7-1) a benzyloxy lower alkyl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-7-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-8) a piperidyl group optionally substituted with one or more members selected from the group consisting of the following (1-8-1) to (1-8-2):

(1-8-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-8-2) a benzyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-9) an indolyl group optionally substituted with one or more members selected from the group consisting of the following (1-9-1) to (1-9-2):

(1-9-1) a lower alkyl group optionally substituted with one or more halogen atoms, and

(1-9-2) a phenyl group optionally substituted with one or more halogen atoms,

(1-10) a benzofuryl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-11) a benzothienyl group optionally substituted with one or more phenyl groups optionally substituted with one or more halogen atoms,

(1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more members selected from the group consisting of the following (1-12-1) to (1-12-2):

(1-12-1) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-12-2) a benzyloxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-13) a pyrimidinyl group optionally substituted with one or more members selected from the group consisting of the following (1-13-1) to (1-13-3):

(1-13-1) a phenyl group,

(1-13-2) a pyrrolidyl group, and


(1-13-3) a piperidyl group; and

R^{2a} is one of the following (2-1) to (2-3):

(2-1) a lower alkyl group optionally substituted with one or more members selected from the group consisting of a hydroxy group; and a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(2-2) a 2-oxo-1,3-dioxolanyl group, and

(2-3) a group represented by the formula:



wherein

* is a bonding site;

R^{2A} is one of the following (2A-1) to (2A-2):

(2A-1) a hydrogen atom, or

(2A-2) a lower alkyl group; and

R^{2B} is one of the following (2B-1) to (2B-6):

(2B-1) a lower alkoxy group optionally substituted with one or more members selected from the group consisting of a lower alkoxy group; a carboxy group; a lower alkoxy-carbonyl group; a hydroxy group; a phenyl lower alkoxy-carbonyl group; a lower alkenyloxy-carbonyl group; a morpholinyl group; a benzyloxycarbonyl group; and a tetrahydropyran-2-yloxy group,

(2B-2) a lower alkyl group;

(2B-3) a lower alkylamino group optionally substituted with one or more lower alkoxy-carbonyl groups;


(2B-4) a cycloalkyl group;

(2B-5) a cycloalkoxy group; and

(2B-6) a phenyl group;

or a salt thereof.

11. The cyanotriazole compound or salt according to claim 10, which is a compound represented by the formula (1bbA):



(1bbA)

wherein each symbol is as defined in claim 10,

or a salt thereof.

12. The cyanotriazole compound or salt according to claim 10 or 11, wherein

R^{1b} is one of the following (1-1) to (1-5):

(1-1) a phenyl group optionally substituted with one or more members selected from:

(1-1-1) a lower alkyl group optionally substituted with one

or more halogen atoms,

(1-1-2) a lower alkoxy group optionally substituted with one or more halogen atoms,

(1-1-9) a halogen atom,

(1-1-11) a phenyl group optionally substituted with one or more lower alkoxy groups optionally substituted with one or more halogen atoms,

(1-1-12) a phenyl lower alkyl group optionally substituted on the phenyl ring with one or more halogen atoms,

(1-1-13) a styryl group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-16) a phenyl lower alkoxy group optionally substituted on the phenyl ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-21) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-23) a pyridyloxy lower alkyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-24) a pyridylvinyl group optionally substituted on the pyridine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-25) a pyrimidinyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-26) a pyrimidinylvinyl group optionally substituted on the pyrimidine ring with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-1-31) a thienyl group, and

(1-1-33) a benzo[1,3]dioxolyl group optionally substituted with one or more halogen atoms,

(1-2) a thiazolyl group optionally substituted with one or

more members selected from:

(1-2-1) a lower alkyl group optionally substituted with one or more halogen atoms,

(1-2-4) a halogen atom,

(1-2-5) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; a lower alkyl group optionally substituted with one or more halogen atoms; and a lower alkoxy group optionally substituted with one or more halogen atoms, and

(1-2-11) a pyridyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms,

(1-3) an oxazolyl group optionally substituted with one or more members selected from:

(1-3-1) a lower alkyl group,

(1-3-2) a cycloalkyl group, and

(1-3-3) a phenyl group optionally substituted with one or more members selected from the group consisting of a halogen atom; and a lower alkyl group optionally substituted with one or more halogen atoms,

(1-4) a thienyl group optionally substituted with one or more members selected from:

(1-4-2) a phenyl group optionally substituted with one or more lower alkyl groups optionally substituted with one or more halogen atoms, and

(1-5) a furyl group optionally substituted with one or more members selected from:

(1-5-1) a phenyl group optionally substituted with one or more halogen atoms; and

R^{2a} is one of the following groups:

a 1-(((2-carboxy-2,2-dimethylethoxy)carbonyl)oxy)ethyl group;

a 1-(((2-carboxy-1,1-dimethylethoxy)carbonyl)oxy)ethyl group;

a 1-(((2-hydroxyethoxy)carbonyl)oxy)ethyl group;

a 1-(butyryloxy)ethyl group;

a 1-(isobutyryloxy)ethyl group;

an acetoxymethyl group; and
a butyryloxymethyl group.

13. A cyanotriazole compound selected from the group consisting of following compounds:
5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-trifluoromethyl-5-(6-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-trifluoromethyl-5-(6-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-trifluoromethyl-5-(6-trifluoromethyl-pyridin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,

5-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-4'-trifluoromethoxy-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-cyano-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-cyano-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-cyano-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(5-trifluoromethyl-pyridin-3-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(5-trifluoromethyl-pyridin-3-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(5-trifluoromethyl-pyridin-3-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-

1H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(*E*)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(*E*)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(*E*)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(*E*)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyridin-2-yloxymethyl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,

5-[2-(4-chloro-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-ethyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-ethyl-thiazol-4-yl]-2H-

[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-ethyl-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-yl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-yl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(*E*)-2-(3-trifluoromethyl-phenyl)-vinyl]-furan-2-yl}-1H-[1,2,3]triazole-4-carbonitrile,
5-[1-(4,4,4-trifluoro-butyl)-1H-indol-6-yl]-3H-[1,2,3]triazole-4-carbonitrile,

5-[1-(4,4,4-trifluoro-butyl)-1H-indol-6-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[1-(4,4,4-trifluoro-butyl)-1H-indol-6-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[6-(4-fluoro-phenyl)-benzofuran-2-yl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[6-(4-fluoro-phenyl)-benzofuran-2-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[6-(4-fluoro-phenyl)-benzofuran-2-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-(5'-fluoro-3'-trifluoromethyl-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile,
5-(5'-fluoro-3'-trifluoromethyl-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(5'-fluoro-3'-trifluoromethyl-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3',5'-bis-trifluoromethyl-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3',5'-bis-trifluoromethyl-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3',5'-bis-trifluoromethyl-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3'-fluoro-4'-trifluoromethoxy-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3'-fluoro-4'-trifluoromethoxy-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(5-chloro-3'-fluoro-4'-trifluoromethoxy-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(3'-fluoro-5,4'-bis-trifluoromethoxy-biphenyl-3-yl)-3H-[1,2,3]triazole-4-carbonitrile,
5-(3'-fluoro-5,4'-bis-trifluoromethoxy-biphenyl-3-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(3'-fluoro-5,4'-bis-trifluoromethoxy-biphenyl-3-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(3,4-bis-trifluoromethyl-benzyloxy)-phenyl]-3H-

[1,2,3]triazole-4-carbonitrile,
5-[3-(3,4-bis-trifluoromethyl-benzyloxy)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(3,4-bis-trifluoromethyl-benzyloxy)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethoxy-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethoxy-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,5-bis-trifluoromethyl-benzyloxy)-5-trifluoromethoxy-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-methyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-methyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-methyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-5-chloro-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-5-chloro-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-5-chloro-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,

5-{3-[(E)-2-(4-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-trifluoromethyl-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-methyl-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-methyl-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-methyl-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-trifluoromethoxy-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-trifluoromethoxy-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-5-trifluoromethoxy-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-phenyl)-vinyl]-phenyl}-1H-

[1,2,3]triazole-4-carbonitrile,
5-{3-ethoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-ethoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-ethoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-5-trifluoromethyl-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-5-trifluoromethyl-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-5-trifluoromethyl-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,4-difluoro-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(3-trifluoromethoxy-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(3-trifluoromethoxy-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-chloro-5-[(E)-2-(3-trifluoromethoxy-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-methoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-methoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-methoxy-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,

5-{3-[(E)-2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-(3-benzo[b]thiophen-2-yl-5-chloro-phenyl)-3H-[1,2,3]triazole-4-carbonitrile,
5-(3-benzo[b]thiophen-2-yl-5-chloro-phenyl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(3-benzo[b]thiophen-2-yl-5-chloro-phenyl)-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-5-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-5-trifluoromethoxy-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-5-trifluoromethoxy-

phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-5-trifluoromethoxy-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-ethoxy-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-ethoxy-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-ethoxy-5-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-methyl-4-(4-trifluoromethyl-pyrimidin-2-yl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-[3-((E)-2-benzo[b]thiophen-2-yl-vinyl)-phenyl]-3H-[1,2,3]triazole-4-carbonitrile,
5-[3-((E)-2-benzo[b]thiophen-2-yl-vinyl)-phenyl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[3-((E)-2-benzo[b]thiophen-2-yl-vinyl)-phenyl]-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{3-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-1H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-2-fluoro-phenyl)-5-ethyl-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile,

5-[2-(4-chloro-2-fluoro-phenyl)-5-ethyl-thiazol-4-yl]-2H-[1,2,3]triazole-4-carbonitrile,
5-[2-(4-chloro-2-fluoro-phenyl)-5-ethyl-thiazol-4-yl]-1H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(E)-2-(4-fluoro-phenyl)-vinyl]-furan-2-yl}-3H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(E)-2-(4-fluoro-phenyl)-vinyl]-furan-2-yl}-2H-[1,2,3]triazole-4-carbonitrile,
5-{5-[(E)-2-(4-fluoro-phenyl)-vinyl]-furan-2-yl}-1H-[1,2,3]triazole-4-carbonitrile,
5-(6-(benzofuran-2-yl)-pyridin-2-yl)-3H-[1,2,3]triazole-4-carbonitrile,
5-(6-(benzofuran-2-yl)-pyridin-2-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(6-(benzofuran-2-yl)-pyridin-2-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(piperidin-1-yl)-pyrimidin-4-yl)-3H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(piperidin-1-yl)-pyrimidin-4-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(piperidin-1-yl)-pyrimidin-4-yl)-1H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(pyrrolidin-1-yl)-pyrimidin-4-yl)-3H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(pyrrolidin-1-yl)-pyrimidin-4-yl)-2H-[1,2,3]triazole-4-carbonitrile,
5-(2-phenyl-6-(pyrrolidin-1-yl)-pyrimidin-4-yl)-1H-[1,2,3]triazole-4-carbonitrile,
3-(1-{4-[3-(2,5-bis-trifluoromethyl-benzyloxy)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-[3-chloro-5-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-[3-chloro-5-(4-trifluoromethyl-pyrimidin-2-yl)-

phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid ,
3-[1-(4-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-5-cyano-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid,
3-(1-{4-cyano-5-[3-methoxy-5-(4-trifluoromethyl-pyridin-2-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-[1-(4-cyano-5-{3-trifluoromethyl-5-[(E)-2-(6-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid,
3-(1-{4-[2-(4-chloro-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyridin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid,
3-[1-(4-cyano-5-{3-[(E)-2-(4-trifluoromethyl-pyrimidin-2-yl)-vinyl]-phenyl}-2H-[1,2,3]triazol-2-yl)-ethoxycarbonyloxy]-2,2-dimethyl-propionic acid,
3-(1-{4-[5-chloro-2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-cyano-5-[2-(3-trifluoromethoxy-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-cyano-5-[2-(3,4-dichloro-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-cyano-5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-[2-(4-chloro-phenyl)-5-isopropyl-oxazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-

propionic acid,
3-(1-{4-[2-(3-chloro-4-fluoro-phenyl)-5-methyl-thiazol-4-yl]-5-cyano-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-cyano-5-[5-cyclopropyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-cyano-5-[3-methyl-5-(6-trifluoromethyl-pyridin-3-yl)-phenyl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-cyano-5-[5-ethyl-2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl]-2H-[1,2,3]triazol-2-yl}-ethoxycarbonyloxy)-2,2-dimethyl-propionic acid,
3-(1-{4-[3-(2,5-bis-trifluoromethylbenzyloxy)phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}ethoxycarbonyloxy)-3-methylbutyric acid,
carbonic acid 1-{4-[3-(2,5-bis-trifluoromethylbenzyloxy) phenyl]-5-cyano-2H-[1,2,3]triazol-2-yl}ethyl ester -2-hydroxyethyl ester,
acetic acid 4-cyano-5-[3-methyl-5- (4-trifluoromethylpyrimidin-2-yl)phenyl]-2H-[1,2,3]triazol-2-ylmethyl ester,
acetic acid 4-{3-chloro-5-[(E)-2-(3-trifluoromethylphenyl) vinyl]phenyl}-5-cyano-2H-[1,2,3]triazol-2-ylmethyl ester, and
butyric acid 4-{3-chloro-5-[(E)-2-(3-trifluoromethyl-phenyl)-vinyl]-phenyl}-5-cyano-2H-[1,2,3]triazol-2-ylmethyl ester,
or a salt thereof.

14. A prophylactic and/or therapeutic agent for a disease or a disorder on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, comprising, as an active ingredient, the cyanotriazole compound or salt according to claim 1.

15. The prophylactic and/or therapeutic agent according to claim 14, wherein the disease or disorder on which citric acid

cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect is selected from the group consisting of diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, athrosclerosis and cardiovascular disease.

16. The cyanotriazole compound or salt according to claim 1 for use as a prophylactic and/or therapeutic agent for a disease or a disorder on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect.

17. Use of the cyanotriazole compound or salt according to claim 1 for manufacturing a prophylactic and/or therapeutic agent for a disease or a disorder on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect.

18. A method for preventing and/or treating a disease or a disorder on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, comprising administering an effective amount of the cyanotriazole compound or salt according to claim 1 to a patient.